nct_id,brief_title,official_title,overall_status,start_date,completion_date,last_update,study_type,phase,enrollment,enrollment_type,allocation,intervention_model,primary_purpose,masking,condition,intervention_name,intervention_type,primary_outcome_count,secondary_outcome_count,min_age,max_age,sex,healthy_volunteers,lead_sponsor_name,lead_sponsor_class,collaborator_count,location_count,countries,trial_success,is_phase1,is_phase2,is_phase3,is_phase4,is_combined_phase,phase_numeric,is_oncology,is_autoimmune,is_cns,is_cardiovascular,condition_count,log_enrollment,enrollment_size,is_small_trial,is_actual_enrollment,is_industry_sponsor,is_academic_sponsor,is_big_pharma,has_collaborators,is_multisite,is_international,is_us_trial,is_europe_trial,is_randomized,is_blinded,is_treatment_purpose,is_parallel,total_outcome_count,has_secondary_outcomes,is_drug,is_biological,is_device,intervention_count,has_multiple_interventions,start_date_dt,completion_date_dt,study_duration_days,start_year,is_recent_trial,complexity_score,is_complex_trial
NCT02137239,Regimen Optimization Study,"Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression",COMPLETED,2015-12-31,2019-05-02,2021-06-22,INTERVENTIONAL,PHASE2,58.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Kidney Transplantation,Thymoglobulin|Belatacept|mycophenolate mofetil(MMF)|Corticosteroids|Everolimus(EVL)|Tacrolimus(TAC),DRUG,1,27,18 Years,75 Years,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,20,Argentina|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.07753744390572,medium,1,1,1,0,1,0,1,1,1,0,1,0,1,1,28,1,1,0,0,6,1,2015-12-31,2019-05-02,1218.0,2015.0,1,3,1
NCT04427072,Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation,"A Phase III, Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib Versus SoC Docetaxel Chemotherapy in Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (METΔex14).",TERMINATED,2020-09-25,2023-11-06,2025-05-16,INTERVENTIONAL,PHASE3,22.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Carcinoma, Non-Small-Cell Lung",Capmatinib|Docetaxel,DRUG,1,20,18 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,43,Russia|Malaysia|Bulgaria|Hungary|Brazil|Vietnam|Portugal|South Korea|Lithuania|Thailand|France|South Africa|Spain|Germany|Netherlands|Belgium|Italy|India,0.0,0,0,1,0,0,3.0,1,0,0,0,1,3.1354942159291497,small,1,1,1,0,1,0,1,1,0,1,1,0,1,0,21,1,1,0,0,2,1,2020-09-25,2023-11-06,1137.0,2020.0,1,3,1
NCT02593175,Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC,"Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy",COMPLETED,2016-11-03,2025-04-03,2025-11-06,INTERVENTIONAL,PHASE2,43.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma,Carboplatin|Paclitaxel|Panitumumab,DRUG|BIOLOGICAL,1,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,11,3.784189633918261,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,3,1,2016-11-03,2025-04-03,3073.0,2016.0,1,2,0
NCT03019575,Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043),"A Phase III, Multi-Center, Open Label, Single-Group Trial to Investigate the Efficacy and Safety of MK-8962 (Corifollitropin Alfa) in Combination With Human Chorionic Gonadotropin (hCG) for Initiation or Restoration of Puberty as Assessed by Increased Testicular Volume in Adolescent Males 14 to <18 Years Old With Hypogonadotropic Hypogonadism (MK-8962-043)",COMPLETED,2017-02-02,2020-05-05,2024-05-23,INTERVENTIONAL,PHASE3,17.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hypogonadotropic Hypogonadism,Corifollitropin alfa|hCG,DRUG,4,13,14 Years,17 Years,MALE,False,Organon and Co,INDUSTRY,0,15,Russia|Denmark|Brazil|South Africa|Mexico|Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,2.8903717578961645,small,1,1,1,0,0,0,1,1,0,1,0,0,1,0,17,1,1,0,0,2,1,2017-02-02,2020-05-05,1188.0,2017.0,1,3,1
NCT04779957,Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy,Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy ; a Pilot Phase II Study.,COMPLETED,2021-10-01,2024-08-09,2025-12-31,INTERVENTIONAL,PHASE2,18.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Kidney Transplantation|Graft Failure,Tocilizumab,DRUG,1,2,18 Years,,ALL,False,"University Hospital, Toulouse",OTHER,0,1,France,1.0,0,1,0,0,0,2.0,0,0,0,0,2,2.9444389791664403,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,3,1,1,0,0,1,0,2021-10-01,2024-08-09,1043.0,2021.0,1,1,0
NCT02465801,Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein,Efficacy and Safety Phase II Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Patients,COMPLETED,2014-12-16,2016-04-26,2017-07-18,INTERVENTIONAL,PHASE2,216.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Chemotherapy-induced Neutropenia,HSA-GCSF 1.2 mg|HSA-GCSF 1.5 mg|GCSF,DRUG,1,5,18 Years,65 Years,FEMALE,False,Tianjin SinoBiotech Ltd.,INDUSTRY,0,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.37989735354046,large,0,1,1,0,0,0,0,0,0,0,1,0,0,1,6,1,1,0,0,3,1,2014-12-16,2016-04-26,497.0,2014.0,0,2,0
NCT03802201,Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia,A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects With Chronic Anemia,COMPLETED,2018-12-19,2020-07-31,2021-07-16,INTERVENTIONAL,PHASE2,63.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,β-thalassemia|Ineffective Erythropoiesis|Chronic Anemia,PTG-300,DRUG,2,0,12 Years,65 Years,ALL,False,"Protagonist Therapeutics, Inc.",INDUSTRY,0,33,United Kingdom|Turkey (Türkiye)|Malaysia|United States|Thailand|Lebanon|Greece|Tunisia|Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,3,4.1588830833596715,medium,1,1,1,0,0,0,1,1,1,1,0,0,1,0,2,0,1,0,0,1,0,2018-12-19,2020-07-31,590.0,2018.0,1,2,0
NCT00316212,Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass,"Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel Group Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Graft Surgery Involving Cardiopulmonary Bypass",TERMINATED,2006-04,,2016-11-18,INTERVENTIONAL,PHASE2,160.0,,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Coronary Disease,INS50589 Intravenous Infusion,DRUG,1,2,18 Years,75 Years,ALL,,Merck Sharp & Dohme LLC,INDUSTRY,0,27,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,5.081404364984463,medium,0,0,1,0,1,0,1,0,1,0,1,1,0,1,3,1,1,0,0,1,0,,,,,0,0,0
NCT03401112,A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia),"A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)",COMPLETED,2018-01-26,2020-08-28,2025-05-15,INTERVENTIONAL,PHASE2,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Sickle Cell Disease,IMR-687|Placebo,DRUG,1,6,18 Years,55 Years,ALL,False,"Cardurion Pharmaceuticals, Inc.",INDUSTRY,1,13,United Kingdom|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.61512051684126,medium,0,1,1,0,0,1,1,1,1,1,1,1,1,1,7,1,1,0,0,2,1,2018-01-26,2020-08-28,945.0,2018.0,1,3,1
NCT01511081,Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT),"Randomized Phase II Study Comparing Stereotactic Body Radiotherapy (SBRT) With Stereotactic Body Proton Therapy (SBPT) for Centrally Located Stage I, Selected Stage II and Recurrent Non-Small Cell Lung Cancer",TERMINATED,2012-08,2016-10,2017-12-07,INTERVENTIONAL,PHASE2,21.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Non-small-cell Lung Cancer,SBRT (stereotactic body radiotherapy)|SBPT (stereotactic body proton therapy),RADIATION,1,1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,2,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.091042453358316,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,2,1,0,0,0,2,1,,,,,0,1,0
NCT04592419,"A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)","A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)",COMPLETED,2020-09-25,2023-01-19,2024-06-26,INTERVENTIONAL,PHASE3,568.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Macular Edema|Retinal Vein Occlusion,KSI-301|Aflibercept|Sham Procedure,DRUG|OTHER,2,8,18 Years,,ALL,False,Kodiak Sciences Inc,INDUSTRY,0,141,United States|Puerto Rico|Hungary|Slovakia|Latvia|France|Spain|Czechia|Italy|Germany|Poland|Israel,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.343880434126331,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,10,1,1,0,0,3,1,2020-09-25,2023-01-19,846.0,2020.0,1,4,1
NCT00107419,S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma,Phase II Trial of Pemetrexed for Advanced Chondrosarcomas,COMPLETED,2005-09,2009-08,2012-01-18,INTERVENTIONAL,PHASE2,75.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Sarcoma,pemetrexed disodium,DRUG,1,2,18 Years,,ALL,False,SWOG Cancer Research Network,NETWORK,1,58,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.330733340286331,medium,1,1,0,0,0,1,1,0,1,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT02353728,Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy,"Detection, Monitoring, and Molecular Characterization of Leukemic Stem Cells From Patients With Chronic Myeloid Leukemia (CML) Undergoing Therapy With Nilotinib",COMPLETED,2015-01,2021-02,2022-03-25,INTERVENTIONAL,PHASE2,16.0,ACTUAL,,SINGLE_GROUP,BASIC_SCIENCE,NONE,Chronic Myeloid Leukemia,Nilotinib,DRUG,1,0,18 Years,,ALL,False,Weill Medical College of Cornell University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.833213344056216,small,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT03513328,Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation,"PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders",COMPLETED,2018-06-15,2023-02-19,2023-09-15,INTERVENTIONAL,PHASE1|PHASE2,6.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Bone Marrow Failure Syndrome|Thalassemia|Sickle Cell Disease|Diamond Blackfan Anemia|Acquired Neutropenia in Newborn|Acquired Anemia Hemolytic|Acquired Thrombocytopenia|Hemophagocytic Lymphohistiocytoses|Wiskott-Aldrich Syndrome|Chronic Granulomatous Disease|Common Variable Immunodeficiency|X-linked Lymphoproliferative Disease|Severe Combined Immunodeficiency|Hurler Syndrome|Mannosidosis|Adrenoleukodystrophy,Thiotepa--single daily dose|Thiotepa--escalated dose,DRUG,1,7,3 Months,39 Years,ALL,False,University of Florida,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,16,1.9459101490553132,small,1,1,0,1,0,1,0,0,1,0,1,0,1,0,8,1,1,0,0,2,1,2018-06-15,2023-02-19,1710.0,2018.0,1,4,1
NCT05181865,Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors,"A Phase 1/2a, First-In-Human, Open Label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FL-301 in Patients With Advanced Solid Tumors",WITHDRAWN,2022-01,2022-01-18,2022-02-07,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Pancreas Cancer|Gastric Cancer|Solid Tumor,"1 mg/kg IV FL-301|3 mg/kg IV FL-301|10 mg/kg IV FL-301|20 mg/kg IV FL-301|30 mg/kg IV FL-301|RP2D, IV FL-301|RP2D, IV FL-301|RP2D, IV FL-301",DRUG,2,8,18 Years,,ALL,False,Flame Biosciences,INDUSTRY,0,0,,0.0,1,1,0,0,1,1.5,1,0,0,0,3,0.0,,1,1,1,0,0,0,0,0,0,0,0,0,1,0,10,1,1,0,0,8,1,,2022-01-18,,,0,4,1
NCT00877500,Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy,A Phase II Randomized Study of Ixabepilone vs. Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2/Neu-Negative Breast Cancer,ACTIVE_NOT_RECRUITING,2009-03-30,2026-12-31,2025-11-10,INTERVENTIONAL,PHASE2,116.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Bilateral Breast Carcinoma|HER2/Neu Negative|Invasive Breast Carcinoma,Best Practice|Ixabepilone,DRUG|OTHER,2,2,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,3,United States,,0,1,0,0,0,2.0,1,0,0,0,3,4.762173934797756,medium,0,0,0,1,0,1,1,0,1,0,1,0,1,1,4,1,1,0,0,2,1,2009-03-30,2026-12-31,6485.0,2009.0,0,2,0
NCT02239692,A Trial Comparing the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy,"A Randomised, Assessor-blinded, Multi-centre Trial Comparing the Efficacy, Safety and Tolerability of the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy",COMPLETED,2014-11,2015-06,2016-06-23,INTERVENTIONAL,PHASE3,204.0,ACTUAL,RANDOMIZED,PARALLEL,,SINGLE,Bowel Cleansing,PICOPREP,DRUG,2,4,18 Years,,ALL,False,Ferring Pharmaceuticals,INDUSTRY,0,3,Germany|France|Netherlands,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.3230099791384085,large,0,1,1,0,0,0,1,1,0,1,1,0,0,1,6,1,1,0,0,1,0,,,,,0,2,0
NCT03101111,Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area,Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in a Previously Epidemic Area,COMPLETED,2017-08-09,2019-04-02,2021-07-19,INTERVENTIONAL,PHASE2,34.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Chikungunya,MV-CHIK|MMR-vaccine,BIOLOGICAL,1,1,21 Years,50 Years,ALL,True,Themis Bioscience GmbH,INDUSTRY,1,1,Puerto Rico,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.5553480614894135,small,1,1,1,0,0,1,0,0,0,0,1,1,0,1,2,1,0,1,0,2,1,2017-08-09,2019-04-02,601.0,2017.0,1,1,0
NCT04765371,"Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, with CoViD-19","Comparison Between Prednisolone and Dexamethasone on D28 Mortality in Patients on Oxygen Therapy, with CoViD-19: Multicenter, Randomized, Open-label Non-inferiority Study",COMPLETED,2021-03-03,2022-02-10,2024-09-19,INTERVENTIONAL,PHASE3,89.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Coronavirus Infection,DEXAMETHASONE|PREDNISOLONE,DRUG,1,5,18 Years,,ALL,False,Hôpital NOVO,OTHER,0,8,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.499809670330265,medium,1,1,0,1,0,0,1,0,0,1,1,0,1,1,6,1,1,0,0,2,1,2021-03-03,2022-02-10,344.0,2021.0,1,2,0
NCT04756271,Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection,Safety and Immunogenicity of Oxford AstraZeneca Vaccine in Zagazig University Hospital Health-care Workers,COMPLETED,2021-02-11,2021-12-22,2022-02-09,INTERVENTIONAL,PHASE3,246.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Vaccine Adverse Reaction|Seroconversion,SARS-Cov-2 neutralizing antibody titer,BIOLOGICAL,2,0,18 Years,,ALL,True,Zagazig University,OTHER_GOV,0,1,Egypt,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.5093883366279774,large,0,1,0,1,0,0,0,0,0,0,0,0,0,0,2,0,0,1,0,1,0,2021-02-11,2021-12-22,314.0,2021.0,1,1,0
NCT01828034,"First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma","A Phase I/II Study of First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma",COMPLETED,2013-04,2019-05-30,2020-11-17,INTERVENTIONAL,PHASE1|PHASE2,42.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Biliary Tract Carcinoma,Gemcitabine|Cisplatin|MEK162,DRUG,3,3,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.7612001156935624,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,6,1,1,0,0,3,1,,2019-05-30,,,0,3,1
NCT04618744,A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH),"A Double-Blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)",COMPLETED,2020-11-24,2022-06-27,2024-08-07,INTERVENTIONAL,PHASE2,32.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Diabetes Mellitus, Type 2|NASH - Nonalcoholic Steatohepatitis",ORMD-0801 (Insulin) capsule 8 mg BD|Placebo,DRUG|OTHER,1,20,18 Years,70 Years,ALL,False,"Oramed, Ltd.",INDUSTRY,1,3,Israel|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.4965075614664802,small,1,1,1,0,0,1,1,1,1,0,1,1,1,1,21,1,1,0,0,2,1,2020-11-24,2022-06-27,580.0,2020.0,1,4,1
NCT00653744,Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES),"A 6-Week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects. (ARIES)",COMPLETED,2002-03,2004-03,2009-03-16,INTERVENTIONAL,PHASE3,1700.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hypercholesterolemia|Dyslipidaemia,Rosuvastatin|Atorvastatin,DRUG,1,2,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,2,7.438971592395862,xlarge,0,0,1,0,1,0,0,0,0,0,1,0,1,1,3,1,1,0,0,2,1,,,,,0,2,0
NCT03031444,Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis,A Multicenter Study of Prognosis and the Efficacy Comparison of Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Patients(Clinical Risk Score≥3) of Resectable Colorectal Liver Metastasis,COMPLETED,2016-01,2020-12-30,2021-02-01,INTERVENTIONAL,PHASE2|PHASE3,135.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Cancer Stage IV|Metastasis,Cetuximab plus FOLFIRI/FOLFOX|FOLFIRI/FOLFOX/CapeOX,DRUG,1,2,18 Years,80 Years,ALL,False,Peking University Cancer Hospital & Institute,OTHER,4,4,China,1.0,0,1,1,0,1,2.5,1,0,0,0,2,4.912654885736052,medium,0,1,0,1,0,1,1,0,0,0,0,0,1,1,3,1,1,0,0,2,1,,2020-12-30,,,0,3,1
NCT00811434,Study of Lactulose in Children With Chronic Liver Disease,Improvement of Cognitive Function and Healthcare -Related Quality of Life After Lactulose Treatment in Children With Chronic Liver Disease,TERMINATED,2009-01,2010-11,2014-02-10,INTERVENTIONAL,PHASE2,16.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Minimal Hepatic Encephalopathy,Lactulose|placebo,DRUG,1,2,5 Years,18 Years,ALL,False,Indiana University,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.833213344056216,small,1,1,0,1,0,0,0,0,1,0,1,1,1,0,3,1,1,0,0,2,1,,,,,0,1,0
NCT03037164,INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections,"Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections and Treatment Use Open-Label Extension Study",ACTIVE_NOT_RECRUITING,2017-05-11,2026-12-30,2025-11-10,INTERVENTIONAL,PHASE3,692.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Anemia,INTERCEPT Blood System for Red Blood Cells|Conventional (Control),DEVICE,3,8,4 Years,,ALL,False,Cerus Corporation,INDUSTRY,0,16,Puerto Rico|Turkey (Türkiye)|United States,,0,0,1,0,0,3.0,0,0,0,0,1,6.541029999189903,xlarge,0,1,1,0,0,0,1,1,1,0,1,1,1,1,11,1,0,0,1,2,1,2017-05-11,2026-12-30,3520.0,2017.0,1,3,1
NCT03830164,"Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer","Pentoxifylline, Atorvastatin, and Vitamin E (PAVE) as Treatment for Radiation-Induced Erectile Dysfunction",COMPLETED,2019-11-20,2022-11-02,2023-10-17,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Male Erectile Disorder|Prostate Adenocarcinoma|Erectile Dysfunction, CTCAE|Impotence",Atorvastatin|Pentoxifylline|Vitamin E Compound,DRUG|DIETARY_SUPPLEMENT,1,2,18 Years,,MALE,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,2.70805020110221,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,3,1,1,0,0,3,1,2019-11-20,2022-11-02,1078.0,2019.0,1,2,0
NCT04476199,Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT,Phase II Study on Venetoclax (VEN) Plus Decitabine (DEC) (VEN-DEC) for Elderly (≥60 <75years) Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation (allo-SCT),ACTIVE_NOT_RECRUITING,2019-12-09,2025-06-30,2025-01-06,INTERVENTIONAL,PHASE2,100.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Myeloid Leukemia,Venetoclax and Decitabine,COMBINATION_PRODUCT,7,0,60 Years,75 Years,ALL,False,Gruppo Italiano Trapianto di Midollo Osseo,OTHER,0,25,Italy,,0,1,0,0,0,2.0,1,0,0,0,1,4.61512051684126,medium,0,1,0,1,0,0,1,0,0,1,0,0,1,0,7,0,0,0,0,1,0,2019-12-09,2025-06-30,2030.0,2019.0,1,1,0
NCT00398099,To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052),"Clinical Evaluation for the Efficacy, Safety, Tolerability & Medical Resource Utilization of Invanz (Ertapenem Sodium) Therapy",COMPLETED,2005-07,2006-01,2017-02-17,INTERVENTIONAL,PHASE3,30.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Infection|Pneumonia|Urinary Tract Infection,"MK0826, ertapenem sodium / Duration of Treatment: 14 Days",DRUG,1,1,20 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,3,3.4339872044851463,small,1,0,1,0,1,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT03970109,HLAB-002 of ANS-6637 for Alcohol Use Disorder,Human Laboratory Study of ANS-6637 for Alcohol Use Disorder,TERMINATED,2019-10-08,2020-05-22,2024-10-29,INTERVENTIONAL,PHASE2,43.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alcohol Use Disorder,ANS-6637|Placebo oral tablet,DRUG,1,16,21 Years,,ALL,False,National Institute on Alcohol Abuse and Alcoholism (NIAAA),NIH,0,3,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.784189633918261,small,1,1,0,1,0,0,1,0,1,0,1,1,1,1,17,1,1,0,0,2,1,2019-10-08,2020-05-22,227.0,2019.0,1,2,0
NCT01276509,Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease,"A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-00547659 In Subjects With Crohn's Disease (Opera)",COMPLETED,2011-04-06,2015-10-09,2021-06-03,INTERVENTIONAL,PHASE2,265.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Crohn's Disease,PF-00547659 SC injection|PF-00547659 SC injection|PF-00547659 SC injection|PF-00547659 SC injection,DRUG,1,12,18 Years,75 Years,ALL,False,Shire,INDUSTRY,0,137,Serbia|Bulgaria|United States|Canada|Slovakia|Netherlands|Austria|Poland|France|South Africa|Spain|Germany|Japan|Belgium|South Korea|Norway,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.583496308781699,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,13,1,1,0,0,4,1,2011-04-06,2015-10-09,1647.0,2011.0,0,3,1
NCT00274963,Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,Treatment of Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL) WITH Bendamustine / Mitoxantrone (BM),COMPLETED,2004-10,2009-10,2018-05-11,INTERVENTIONAL,PHASE2,60.0,ESTIMATED,NON_RANDOMIZED,,TREATMENT,,Chronic Lymphocytic Leukemia,bendamustine hydrochloride|mitoxantrone hydrochloride,DRUG,1,3,18 Years,,ALL,False,German CLL Study Group,OTHER,0,12,Germany,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.110873864173311,medium,1,0,0,1,0,0,1,0,0,1,0,0,1,0,4,1,1,0,0,2,1,,,,,0,1,0
NCT03199963,Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue,"A Randomized, Double-blind, Placebo Controlled Trial of 4-Hydroxytamoxifen Gel for Reducing Breast Tissue Density in Women With BI-RADS Breast Density Categories C or D",TERMINATED,2017-08-21,2019-04-23,2022-07-26,INTERVENTIONAL,PHASE3,223.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Mammographic Breast Density,4-OH tamoxifen|Placebo,DRUG,1,6,35 Years,75 Years,FEMALE,False,"BHR Pharma, LLC",INDUSTRY,0,19,Germany|Spain|United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.4116460518550396,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,7,1,1,0,0,2,1,2017-08-21,2019-04-23,610.0,2017.0,1,3,1
NCT00997087,"A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder","Phase IIa A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder.",TERMINATED,2009-10,2012-12,2014-04-22,INTERVENTIONAL,PHASE2,11.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Obsessive Compulsive Disorder,Flumazenil,DRUG,1,1,19 Years,60 Years,ALL,False,Parkway Medical Center,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.4849066497880004,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT02176187,Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease,"A Randomised Open Label, Four Way, Cross-over Scintigraphic Evaluation of the Respimat® Inhaler vs a Metered Dose Inhaler (HFA-MDI) Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Poor MDI Technique",TERMINATED,2003-04,,2014-07-14,INTERVENTIONAL,PHASE3,3.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Pulmonary Disease, Chronic Obstructive",Berodual® Respimat® inhaler|Berodual® metered dose inhaler,DRUG,1,5,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,1.3862943611198906,small,1,1,1,0,0,0,0,0,0,0,1,0,1,0,6,1,1,0,0,2,1,,,,,0,2,0
NCT00737893,Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy,Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy: a Prospective Randomized Controlled Trial (ERECT),COMPLETED,2017-07-01,2019-12-31,2021-04-08,INTERVENTIONAL,PHASE2,56.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Prostate Cancer|Erectile Dysfunction,Placebo|Erythropoietin (EPO),DRUG,1,21,40 Years,65 Years,MALE,False,Johns Hopkins University,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.04305126783455,medium,1,1,0,1,0,0,0,0,1,0,1,1,1,1,22,1,1,0,0,2,1,2017-07-01,2019-12-31,913.0,2017.0,1,3,1
NCT05008393,Efficacy of PJS-539 for Adult Patients With COVID-19.,"Efficacy of PJS-539 for Adult Patients With SARS-CoV-2: Multicentre, Phase 2, Randomized, Double-blind, Placebo-controlled Clinical Trial.",COMPLETED,2021-09-25,2022-03-04,2022-04-12,INTERVENTIONAL,PHASE2,153.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Covid19|COVID-19 Pneumonia,PJS-539 Dose 1|PJS-539 Dose 2|Placebo,DRUG,1,6,18 Years,,ALL,False,Hospital do Coracao,OTHER,1,1,Brazil,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.0369526024136295,medium,0,1,0,1,0,1,0,0,0,0,1,1,1,1,7,1,1,0,0,3,1,2021-09-25,2022-03-04,160.0,2021.0,1,3,1
NCT00004014,Liposomal Doxorubicin in Treating Patients With Prostate Cancer,"Liposome-Encapsulated Doxorubicin (LED) in Hormone Refractory Prostate Carcinoma, Phase II",COMPLETED,1999-04,2001-11,2010-08-16,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,pegylated liposomal doxorubicin hydrochloride,DRUG,1,0,,,MALE,False,Case Comprehensive Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT00064714,Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes,Effect of AC 2993 (Synthetic Exendin-4) - Administered Alone or in Combination With Daclizumab - on Islet Function in Patients With Type I Diabetes,COMPLETED,2003-07,2008-03,2015-03-11,INTERVENTIONAL,PHASE2,47.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Diabetes Mellitus,AC2993 (exenatide)|daclizumab (immunosuppressive),DRUG,1,0,18 Years,60 Years,ALL,False,AstraZeneca,INDUSTRY,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.871201010907891,small,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,2,1,,,,,0,1,0
NCT04435314,Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19,"Prospective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day for Post Exposure Prophylaxis of COVID-19 in Subjects From Vulnerable Communities",WITHDRAWN,2020-06,2020-08,2022-10-28,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,covid19,Nitazoxanide|Placebo,DRUG,1,6,18 Years,,ALL,True,Azidus Brasil,INDUSTRY,1,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,1,0,0,1,0,0,0,0,1,1,0,1,7,1,1,0,0,2,1,,,,,0,2,0
NCT00241514,Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs,Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs,COMPLETED,2001-02,2003-02,2011-01-21,INTERVENTIONAL,PHASE3,334.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,GERD,Esomeprazole,DRUG,4,1,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,113,United States|Hungary|France|Spain|Germany|Belgium,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.814130531825066,large,0,0,1,0,1,0,1,1,1,1,1,1,1,1,5,1,1,0,0,1,0,,,,,0,1,0
NCT04204616,A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN),"A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis",ACTIVE_NOT_RECRUITING,2021-01-11,2026-10-26,2025-11-12,INTERVENTIONAL,PHASE3,500.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Prurigo Nodularis,Nemolizumab,DRUG,1,25,18 Years,,ALL,False,Galderma R&D,INDUSTRY,0,164,United Kingdom|Denmark|United States|Sweden|Canada|Hungary|Poland|Austria|South Korea|France|Spain|Switzerland|Germany|Netherlands|Belgium|Italy,,0,0,1,0,0,3.0,0,0,0,0,1,6.2166061010848646,large,0,0,1,0,0,0,1,1,1,1,0,0,1,0,26,1,1,0,0,1,0,2021-01-11,2026-10-26,2114.0,2021.0,1,2,0
NCT01493206,A Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer,A Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer,COMPLETED,2004-07,2011-08,2025-05-31,INTERVENTIONAL,PHASE2,32.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Malignant Rectal Neoplasm|Recurrent Tumor,intraoperative radiotherapy,RADIATION,1,1,18 Years,,ALL,False,"Peter MacCallum Cancer Centre, Australia",OTHER,0,1,Australia,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.4965075614664802,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,0,0,0,1,0,,,,,0,1,0
NCT01762904,Residual Effect of Chlorhexidine-alcohol Compared to Triclosan-alcohol,Residual Effect of Chlorhexidine 2% / Isopropyl Alcohol 70% Compared to Triclosan 1% / Isopropyl Alcohol 70%,COMPLETED,2013-01,2013-10,2014-07-02,INTERVENTIONAL,PHASE3,135.0,ACTUAL,,SINGLE_GROUP,PREVENTION,SINGLE,Infectious Diseases,Bacterial culture of the prepared skin's areas with two antiseptics and two controls|Preparing skin's areas to be tested with two antiseptics and two controls,OTHER,3,1,18 Years,,ALL,True,Universidad de Guanajuato,OTHER,1,1,Mexico,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.912654885736052,medium,0,1,0,1,0,1,0,0,0,0,0,0,0,0,4,1,0,0,0,2,1,,,,,0,1,0
NCT00659204,Efficacy of Silver Nanoparticle Gel Versus a Common Antibacterial Hand Gel,A Randomized Controlled Trial of the Efficacy of a Novel Silver Nanoparticle Gel Versus a Common Antibacterial Hand Gel Against Bacterial Hand Flora,TERMINATED,2008-01,2008-08,2026-01-23,INTERVENTIONAL,PHASE3,22.0,ACTUAL,RANDOMIZED,PARALLEL,SCREENING,TRIPLE,Healthy,Silver Nanoparticle Gel|alcohol-based hand gel,DRUG,3,1,19 Years,,ALL,True,Madigan Army Medical Center,FED,0,1,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.1354942159291497,small,1,1,0,0,0,0,0,0,1,0,1,1,0,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00462904,Pharmacokinetic Response to BPI in Burns,Phase IIa Trial to Evaluate the Pharmacokinetic Response to Bactericidal/Permeability-increasing Protein (rBPI21) for the Treatment of Patients With Burn Injury.,TERMINATED,2006-04,2007-11,2019-11-20,INTERVENTIONAL,PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Burns,BPI,DRUG,1,1,13 Years,60 Years,ALL,False,University of Texas Southwestern Medical Center,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.6094379124341003,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT03136484,Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes,Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes,COMPLETED,2017-03-15,2018-11-16,2020-01-21,INTERVENTIONAL,PHASE3,788.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes|Diabetes Mellitus, Type 2",Semaglutide|Canagliflozin|Placebo (canagliflozin)|Placebo (semaglutide),DRUG,1,60,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,119,United Kingdom|Argentina|Malaysia|United States|Sweden|Canada|Brazil|Ireland|Lebanon|Mexico|Italy|India,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.670766320845874,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,61,1,1,0,0,4,1,2017-03-15,2018-11-16,611.0,2017.0,1,4,1
NCT00801684,ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD,"Efficacy, Safety, Tolerability, and Pharmacokinetics of Trospium Inhalation Powder (TrIP) Administered to Subjects With Chronic Obstructive Pulmonary Disease (COPD)",COMPLETED,2009-02,2009-07,2011-08-19,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Chronic Obstructive Pulmonary Disease (COPD),Placebo|TrIP-2D|TrIP-2SS|TrIP-2D|TrIP-2SS + Foradil,DRUG,1,2,40 Years,80 Years,ALL,False,"Alkermes, Inc.",INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.2188758248682006,small,1,1,1,0,0,0,0,0,1,0,1,1,1,0,3,1,1,0,0,5,1,,,,,0,1,0
NCT00370084,Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia,"Effects of Itopride Hydrochloride on Gastric Emptying, Glycaemia and ""Meal-related"" Symptoms in Patients With Type 1 and Type 2 Diabetes Mellitus",COMPLETED,2005-03,2006-07,2017-02-09,INTERVENTIONAL,PHASE1|PHASE2,25.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Gastroparesis,Itopride|Placebo,DRUG|OTHER,1,1,18 Years,65 Years,ALL,False,Forest Laboratories,INDUSTRY,0,1,Australia,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.258096538021482,small,1,1,1,0,0,0,0,0,0,0,1,1,1,0,2,1,1,0,0,2,1,,,,,0,2,0
NCT04224584,A Mechanism Based Proof of Concept Study of the Effects of Duloxetine in the Treatment of Patients With Osteoarthritic Knee Pain,A Mechanism Based Proof of Concept Study of the Effects of Duloxetine in the Treatment of Patients With Osteoarthritic Knee Pain,COMPLETED,2020-01-01,2021-07-01,2022-02-16,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,TRIPLE,"Osteoarthritis, Knee",Duloxetine|Placebo oral tablet,DRUG,1,0,40 Years,75 Years,ALL,False,Kristian Kjær Petersen,OTHER,2,1,Denmark,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.713572066704308,small,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,2,1,2020-01-01,2021-07-01,547.0,2020.0,1,1,0
NCT02542514,Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma,Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma,COMPLETED,2015-09,2021-12-01,2022-04-14,INTERVENTIONAL,PHASE2,52.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Primary Central Nervous Lymphoma|Intraocular Lymphoma,Ibrutinib,DRUG,1,7,18 Years,,ALL,False,The Lymphoma Academic Research Organisation,OTHER,0,10,France,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.970291913552122,medium,1,1,0,1,0,0,1,0,0,1,0,0,1,0,8,1,1,0,0,1,0,,2021-12-01,,,0,2,0
NCT02349516,Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME),"A Randomized, Controlled Study of the Safety and Efficacy of Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema",WITHDRAWN,2015-02,2015-09,2016-06-01,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Diabetic Retinopathy,Squalamine Lactate Ophthalmic Solution 0.2%,DRUG,1,3,18 Years,,ALL,False,Starr Muscle,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,1,0,1,1,1,1,4,1,1,0,0,1,0,,,,,0,0,0
NCT01839916,Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies,Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies,COMPLETED,2013-04-04,2018-08,2019-08-07,INTERVENTIONAL,PHASE2,77.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia,therapeutic allogeneic lymphocytes|laboratory biomarker analysis,OTHER|BIOLOGICAL,1,5,14 Years,75 Years,ALL,False,University of Chicago,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,64,4.356708826689592,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,6,1,0,1,0,2,1,2013-04-04,,,2013.0,0,3,1
NCT02379806,The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study,Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study,COMPLETED,2015-09-03,2020-12-29,2022-07-05,INTERVENTIONAL,PHASE3,2560.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Venous Thromboembolism,Enoxaparin|Placebo,DRUG,1,1,70 Years,,ALL,False,"University Hospital, Brest",OTHER,0,46,France|Switzerland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.848153086199526,xlarge,0,1,0,1,0,0,1,1,0,1,1,1,0,1,2,1,1,0,0,2,1,2015-09-03,2020-12-29,1944.0,2015.0,1,2,0
NCT06022406,Fecal Microbiota Translantation (FMT) to Reduce Inflammation in PLWH: The Gutsy Pilot Study,Fecal Microbiota Transplantation to Reduce Immune Activation in ART-treated People Living With HIV With Low CD4/CD8 Ratio: The Gutsy Study,COMPLETED,2024-07-31,2025-08-13,2025-09-03,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,HIV-1-infection,FMT capsules|Placebo capsules,BIOLOGICAL,1,17,18 Years,,ALL,False,Jean-Pierre Routy,OTHER,1,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,18,1,0,1,0,2,1,2024-07-31,2025-08-13,378.0,2024.0,1,2,0
NCT00789633,Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer,"A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer",COMPLETED,2008-11-25,2012-08-31,2018-12-17,INTERVENTIONAL,PHASE3,353.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Pancreatic Cancer,Masitinib|Placebo|Gemcitabine,DRUG,1,2,18 Years,,ALL,False,AB Science,INDUSTRY,0,68,United States|France|Lebanon|Czechia|Romania,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.869296913133774,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,3,1,1,0,0,3,1,2008-11-25,2012-08-31,1375.0,2008.0,0,2,0
NCT02639533,Brain Response to Single Dose of Pregabalin in Fibromyalgia,"Pregabalin Acute Effects on Cortical Excitability, Psychophysical Parameters, and Serum Markers of Neuroplastic Processes in Fibromyalgia: a Placebo Controlled, Double Blinded, Randomized, Crossover Clinical Trial",COMPLETED,2014-12,2017-01,2018-02-08,INTERVENTIONAL,PHASE2|PHASE3,27.0,ACTUAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,QUADRUPLE,Fibromyalgia,Pregabalin|Placebo,DRUG|OTHER,2,7,18 Years,65 Years,FEMALE,True,Hospital de Clinicas de Porto Alegre,OTHER,3,0,,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.332204510175204,small,1,1,0,1,0,1,0,0,0,0,1,1,0,0,9,1,1,0,0,2,1,,,,,0,3,1
NCT02834052,Pembrolizumab + Poly-ICLC in MRP Colon Cancer,A Phase I/II Trial of Pembrolizumab (MK-3475) and Poly-ICLC in Patients With Metastatic Mismatch Repair-proficient (MRP) Colon Cancer,COMPLETED,2018-01-10,2022-07-29,2024-06-07,INTERVENTIONAL,PHASE1|PHASE2,42.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Metastatic Colon Cancer|Solid Tumor,pembrolizumab|Poly-ICLC,DRUG,3,3,18 Years,,ALL,False,Asha Nayak,OTHER,2,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,2,3.7612001156935624,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,6,1,1,0,0,2,1,2018-01-10,2022-07-29,1661.0,2018.0,1,4,1
NCT05601752,ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer (SURPASS-3),"A Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in Subjects with Recurrent Ovarian Cancers",ACTIVE_NOT_RECRUITING,2023-06-26,2026-08-12,2024-12-19,INTERVENTIONAL,PHASE2,66.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Ovarian Cancer,Autologous genetically modified ADP-A2M4CD8 cells|Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab,GENETIC|COMBINATION_PRODUCT,1,12,18 Years,75 Years,FEMALE,False,Adaptimmune,INDUSTRY,1,23,United Kingdom|United States|Canada|France|Spain,,0,1,0,0,0,2.0,1,0,0,0,1,4.204692619390966,medium,1,0,1,0,0,1,1,1,1,1,1,0,1,1,13,1,0,0,0,2,1,2023-06-26,2026-08-12,1143.0,2023.0,1,3,1
NCT02931175,ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study),"An Open-label, Multi-center, Randomized, Phase II Study of the Safety,Efficacy and Bioactivity of Two Dose Regimens of Subcutaneous Injections of ACTH Gel in Patients With Non-infectious Uveitis",COMPLETED,2017-11-10,2021-10-28,2025-12-17,INTERVENTIONAL,PHASE2,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Uveitis,ACTH gel,DRUG,2,16,18 Years,,ALL,False,Quan Dong Nguyen,OTHER,1,7,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.367295829986474,small,1,1,0,1,0,1,1,0,1,0,1,0,1,1,18,1,1,0,0,1,0,2017-11-10,2021-10-28,1448.0,2017.0,1,1,0
NCT00457457,"Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.","A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Proof of Concept and Dose Ranging Study With an Active Control to Assess the Efficacy and Safety/Tolerability of UK-369,003 Immediate Release (IR) and Modified Release (MR) in the Treatment of Men With Lower Urinary Tract Symptoms (LUTS) With and Without Erectile Dysfunction (ED)",COMPLETED,2007-05,2008-04,2018-12-19,INTERVENTIONAL,PHASE2,609.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Prostatic Hyperplasia,"Tamsulosin|UK-369,003",DRUG,1,5,40 Years,,MALE,False,Pfizer,INDUSTRY,0,46,United Kingdom|Chile|Finland|Denmark|Australia|Colombia|Canada|Slovakia|Poland|Lithuania|Latvia|Spain|Greece|Belgium|Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.413458957167357,xlarge,0,1,1,0,1,0,1,1,0,1,1,1,1,1,6,1,1,0,0,2,1,,,,,0,3,1
NCT02846857,Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes,"An Open-label, Randomized, Multicenter Study to Assess the Efficacy of Single-hormone Closed-loop Strategy, Dual-hormone Closed-loop Strategy and Sensor-augmented Pump Therapy in Regulating Glucose Levels for 15 Weeks in Free-living Outpatient Conditions in Adolescents and Adults With Type 1 Diabetes",WITHDRAWN,,,2019-07-23,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 1 Diabetes,15-week intervention with sensor-augmented pump|15-week intervention with single-hormone closed-loop|15-week intervention with dual-hormone closed-loop|Insulin pump|Continuous glucose monitoring system|Insulin|Glucagon,DRUG|OTHER|DEVICE,1,21,12 Years,,ALL,False,Institut de Recherches Cliniques de Montreal,OTHER,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,0,1,0,22,1,1,0,1,7,1,,,,,0,2,0
NCT02581657,"Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM","Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus",COMPLETED,2015-10,2016-11,2018-04-10,INTERVENTIONAL,PHASE2,37.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,PE0139 Injection|Placebo Injection,DRUG,1,14,18 Years,80 Years,ALL,False,PhaseBio Pharmaceuticals Inc.,INDUSTRY,0,6,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6375861597263857,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,15,1,1,0,0,2,1,,,,,0,2,0
NCT04601857,Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma,A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma,TERMINATED,2021-01-07,2025-09-16,2025-12-31,INTERVENTIONAL,PHASE2,43.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Advanced and Metastatic Urothelial Cancer,Futibatinib|Pembrolizumab,DRUG,1,5,18 Years,,ALL,False,"Taiho Oncology, Inc.",INDUSTRY,1,18,France|Spain|United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.784189633918261,small,1,1,1,0,0,1,1,1,1,1,0,0,1,1,6,1,1,0,0,2,1,2021-01-07,2025-09-16,1713.0,2021.0,1,3,1
NCT05746481,Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases,A Phase II Clinical Trial of Tiragolumab in Combination With Atezolizumab in Patients With Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases.,TERMINATED,2023-08-10,2025-11-08,2026-01-22,INTERVENTIONAL,PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-small Cell Lung Cancer,Tiragolumab|Atezolizumab|Pemetrexed|Carboplatin,DRUG,1,10,18 Years,,ALL,False,"Liza Villaruz, MD",OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.3862943611198906,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,11,1,1,0,0,4,1,2023-08-10,2025-11-08,821.0,2023.0,1,2,0
NCT03519230,Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer",ACTIVE_NOT_RECRUITING,2018-05-14,2027-01-30,2026-01-05,INTERVENTIONAL,PHASE3,224.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ovarian Cancer,Pamiparib capsule|Placebo capsule,DRUG,1,6,18 Years,,FEMALE,False,BeiGene,INDUSTRY,0,28,China,,0,0,1,0,0,3.0,1,0,0,0,1,5.41610040220442,large,0,1,1,0,0,0,1,0,0,0,1,1,1,1,7,1,1,0,0,2,1,2018-05-14,2027-01-30,3183.0,2018.0,1,2,0
NCT02257528,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer","A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer",ACTIVE_NOT_RECRUITING,2015-05-18,2026-03-17,2025-09-08,INTERVENTIONAL,PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Recurrent Cervical Carcinoma|Stage IV Cervical Cancer AJCC v6 and v7|Stage IVA Cervical Cancer AJCC v6 and v7|Stage IVB Cervical Cancer AJCC v6 and v7,Laboratory Biomarker Analysis|Nivolumab,OTHER|BIOLOGICAL,2,2,18 Years,,FEMALE,False,National Cancer Institute (NCI),NIH,1,333,United States,,0,1,0,0,0,2.0,1,0,0,0,6,3.295836866004329,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,0,1,0,2,1,2015-05-18,2026-03-17,3956.0,2015.0,1,2,0
NCT00535665,Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine,"The Clinical Trial of Pandemic Influenza Vaccine (Whole-Virion， Inactivated, Adjuvanted) on Healthy Adults by Randomized and Double-Blind Design: a Phase II Study",COMPLETED,2007-09,2007-11,2007-11-09,INTERVENTIONAL,PHASE2,402.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Pandemic Influenza|Prevention,pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14),BIOLOGICAL,1,1,18 Years,60 Years,ALL,True,"Sinovac Biotech Co., Ltd",INDUSTRY,1,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.998936561946683,large,0,1,1,0,0,1,0,0,0,0,1,1,0,1,2,1,0,1,0,4,1,,,,,0,2,0
NCT00648167,A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD),A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD),COMPLETED,2008-03,2009-01,2017-04-04,INTERVENTIONAL,PHASE2,55.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hyperphosphatemia|End-stage Renal Disease,ferric citrate,DRUG,1,0,19 Years,,ALL,False,Keryx Biopharmaceuticals,INDUSTRY,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.02535169073515,medium,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,1,0
NCT00004767,"Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders",,COMPLETED,1985-01,,2005-06-24,INTERVENTIONAL,PHASE2,20.0,,,,TREATMENT,,"Amino Acid Metabolism, Inborn Errors",Sodium Benzoate|Sodium Phenylacetate|Sodium Phenylbutyrate|Dietary Intervention,DRUG|BEHAVIORAL,0,0,18 Years,65 Years,ALL,False,National Center for Research Resources (NCRR),NIH,1,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,4,1,,,,,0,1,0
NCT01323400,Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST),"A Phase II Randomized Multicentre Study Evaluating the Efficacy of Pazopanib+Best Supportive Care (BSC) Versus BSC Alone in Metastatic and/or Locally Advanced Unresectable GIST, Resistant to Imatinib and Sunitinib",COMPLETED,2011-03,2016-02,2016-02-25,INTERVENTIONAL,PHASE2,81.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,GIST,Pazopanib|Best supportive care,DRUG|OTHER,1,8,18 Years,90 Years,ALL,False,Centre Leon Berard,OTHER,1,13,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.406719247264253,medium,1,1,0,1,0,1,1,0,0,1,1,0,1,1,9,1,1,0,0,2,1,,,,,0,2,0
NCT02949700,Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma,A Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma,COMPLETED,2017-01-26,2022-07-07,2023-06-29,INTERVENTIONAL,PHASE1|PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Head and Neck Squamous Cell Carcinoma,Metformin,DRUG,2,2,18 Years,,ALL,False,Baylor College of Medicine,OTHER,0,3,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.295836866004329,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2017-01-26,2022-07-07,1988.0,2017.0,1,1,0
NCT01025700,Nabilone & Marijuana Addiction,A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal,COMPLETED,2009-06,2010-10,2011-02-17,INTERVENTIONAL,PHASE2|PHASE3,35.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Marijuana Smoking,Cesemat,DRUG,1,1,19 Years,65 Years,ALL,False,University of British Columbia,OTHER,0,1,Canada,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.58351893845611,small,1,0,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,1,0
NCT01994707,Remote Ischemic Preconditioning of Human Myocardium,Remote Ischemic Preconditioning of Human Myocardium,COMPLETED,2013-08,2016-04-27,2018-01-12,INTERVENTIONAL,PHASE2,134.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,Coronary Artery Bypass Graft Triple Vessel|Apoptotic DNA Damage,Remote ischemic preconditioning|Placebo,PROCEDURE,1,5,18 Years,80 Years,ALL,False,Medical University of Silesia,OTHER,1,1,Poland,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.90527477843843,medium,0,1,0,1,0,1,0,0,0,0,1,1,0,1,6,1,0,0,0,2,1,,2016-04-27,,,0,3,1
NCT02592707,Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs,"An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)",TERMINATED,2017-03-06,2022-02-22,2023-07-19,INTERVENTIONAL,PHASE1|PHASE2,40.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,Neuroendocrine Tumors,Satoreotide tetraxetan|Amino acid solution|Antiemetic,DRUG|OTHER,2,23,18 Years,,ALL,False,Ipsen,INDUSTRY,0,9,United Kingdom|Denmark|Australia|United States|Canada|Austria|France|Switzerland,0.0,1,1,0,0,1,1.5,1,0,0,0,1,3.713572066704308,small,1,1,1,0,0,0,1,1,1,1,0,0,1,0,25,1,1,0,0,3,1,2017-03-06,2022-02-22,1814.0,2017.0,1,4,1
NCT03108911,Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy,Gluten Free Diet for AML Patients Undergoing Induction Chemotherapy,TERMINATED,2017-07-27,2017-11-14,2017-11-17,INTERVENTIONAL,PHASE2,1.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Acute Myeloid Leukemia,Best Practice|Biospecimen Collection|Dietary Intervention|Laboratory Biomarker Analysis,PROCEDURE|OTHER,3,0,18 Years,,ALL,False,"Rutgers, The State University of New Jersey",OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.6931471805599453,small,1,1,0,1,0,1,0,0,1,0,1,0,0,1,3,0,0,0,0,4,1,2017-07-27,2017-11-14,110.0,2017.0,1,1,0
NCT00117871,Study With a Topical Gel to Treat Common Warts in Adults,"A Two-Stage, Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Adults",COMPLETED,2004-10,,2007-02-19,INTERVENTIONAL,PHASE2,48.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Warts,Resiquimod,DRUG,1,1,18 Years,,ALL,False,"Graceway Pharmaceuticals, LLC",INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8918202981106265,small,1,0,1,0,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT03569371,A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa,"A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa",COMPLETED,2018-07-17,2019-04-22,2022-09-26,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hidradenitis Suppurativa,INCB054707,DRUG,1,15,18 Years,75 Years,ALL,False,Incyte Corporation,INDUSTRY,0,4,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,16,1,1,0,0,1,0,2018-07-17,2019-04-22,279.0,2018.0,1,1,0
NCT00867334,New Individualized Therapy Trial for Metastatic Colorectal Cancer,A Phase I/II Study of Gleevec® Combined With Panitumumab (Vectibix®) in Patients Prescreened for C-kit/PDGFr Activated Pathways Using a Proteomic Based Assay,COMPLETED,2009-06,2011-08,2020-06-30,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Neoplasm|Colorectal Cancer,Imatinib mesylate and panitumumab|Standard-of-care treatment with panitumumab,DRUG,1,1,18 Years,,ALL,False,Inova Health Care Services,OTHER,1,2,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,2,2.3978952727983707,small,1,1,0,1,0,1,1,0,1,0,0,0,1,1,2,1,1,0,0,2,1,,,,,0,3,1
NCT02409264,The Effect of Individualised Homeopathic Treatment of Insomnia Disorder in Females,The Effect of Individualised Homeopathic Treatment of Insomnia Disorder in Females,COMPLETED,2015-01,2015-08,2016-05-17,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Insomnia Disorder,Individualised Homeopathic Remedy,OTHER,1,1,18 Years,45 Years,FEMALE,True,University of Johannesburg,OTHER,0,1,South Africa,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,0,0,0,1,0,,,,,0,0,0
NCT02131064,A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,"A Randomized, Multicenter, Open-Label, Two-Arm, Phase III Neoadjuvant Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Breast Cancer",COMPLETED,2014-06-25,2018-05-29,2019-07-02,INTERVENTIONAL,PHASE3,444.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Neoplasms,Carboplatin|Docetaxel|Pertuzumab|Trastuzumab|Trastuzumab Emtansine,DRUG,1,21,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,79,Russia|Ukraine|United States|Canada|Taiwan|France|Spain|Germany|Belgium|South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.09807428216624,large,0,1,1,0,1,0,1,1,1,1,1,0,1,1,22,1,1,0,0,5,1,2014-06-25,2018-05-29,1434.0,2014.0,0,3,1
NCT04336332,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,TERMINATED,2020-04-01,2020-10-14,2023-02-28,INTERVENTIONAL,PHASE2,75.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,SARS-CoV-2|COVID-19,Hydroxychloroquine Sulfate + Azithromycin|Hydroxychloroquine Sulfate,DRUG|COMBINATION_PRODUCT,1,0,18 Years,,ALL,False,"Rutgers, The State University of New Jersey",OTHER,0,5,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,4.330733340286331,medium,1,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,2,1,2020-04-01,2020-10-14,196.0,2020.0,1,2,0
NCT00594932,Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis,Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis,COMPLETED,2006-11,2009-04,2020-10-09,INTERVENTIONAL,PHASE1|PHASE2,27.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Systemic Lupus Erythematosus|Arthritis,mycophenolate mofetil|placebo,DRUG|OTHER,1,2,14 Years,70 Years,ALL,False,Oklahoma Medical Research Foundation,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,1,0,0,2,3.332204510175204,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,3,1,1,0,0,2,1,,,,,0,3,1
NCT01614132,Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults,Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults (NOA-07),COMPLETED,2009-01,2018-10,2020-03-31,INTERVENTIONAL,PHASE1|PHASE2,33.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Medulloblastoma,"maintenance chemotherapy (vincristin, cisplatin and CCNU)|Radiotherapy",DRUG|RADIATION,1,5,18 Years,65 Years,ALL,False,University of Regensburg,OTHER,0,15,Germany,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.5263605246161616,small,1,1,0,1,0,0,1,0,0,1,0,0,1,0,6,1,1,0,0,2,1,,,,,0,3,1
NCT01309932,Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin,"A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda (BMS-914143) Administered With Ribavirin Plus a Single Direct Antiviral Agent (BMS-790052 or BMS-650032) Versus Pegasys Administered With Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) Administered With or Without Ribavirin Plus 2 Direct Antiviral Agents (BMS-790052 and BMS-650032) (Part B) in Chronic Hepatitis C Genotype-1 Treatment naïve Subjects",COMPLETED,2011-03,2014-09,2015-10-09,INTERVENTIONAL,PHASE2,165.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hepatitis C,Pegylated Interferon Lambda (pegIFNλ)|BMS-790052 (NS5A Inhibitor)|Ribavirin (RBV)|BMS-650032 (NS3 Protease Inhibitor)|Pegylated Interferon Alfa-2a (pegIFNα-2a)|Pegylated Interferon Lambda (pegIFNλ)|Ribavirin (RBV)|Pegylated Interferon Lambda (pegIFNλ)|Ribavirin (RBV)|BMS-790052 (NS5A Inhibitor)|BMS-650032 (NS3 Protease Inhibitor)|Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)|Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)|Placebo for Ribavirin (RBV)|Placebo for Ribavirin (RBV),DRUG|BIOLOGICAL,3,14,18 Years,70 Years,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,40,Australia|United States|Puerto Rico|New Zealand|France|Spain|Germany|Japan|Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.111987788356544,medium,0,1,1,0,1,0,1,1,1,1,1,1,1,1,17,1,1,1,0,15,1,,,,,0,3,1
NCT00909532,Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects With Cystic Fibrosis and the G551D Mutation",COMPLETED,2009-06,2012-11,2013-01-18,INTERVENTIONAL,PHASE3,167.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cystic Fibrosis,Ivacaftor|Placebo,DRUG,1,5,12 Years,,ALL,False,Vertex Pharmaceuticals Incorporated,INDUSTRY,1,65,United Kingdom|Australia|United States|Canada|Ireland|France|Czechia|Germany,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.123963979403259,medium,0,1,1,0,0,1,1,1,1,1,1,1,1,1,6,1,1,0,0,2,1,,,,,0,3,1
NCT00416598,Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia,Phase II Study of Maintenance Therapy With Decitabine (NSC #127716) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML &lt; 60 Years,COMPLETED,2006-11-15,2016-12-01,2019-02-19,INTERVENTIONAL,PHASE2,546.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Myeloid Leukemia|Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A|Untreated Adult Acute Myeloid Leukemia,Autologous Bone Marrow Transplantation|Autologous Hematopoietic Stem Cell Transplantation|Busulfan|Cytarabine|Daunorubicin Hydrochloride|Decitabine|Etoposide|Filgrastim|Laboratory Biomarker Analysis|Pharmacological Study,PROCEDURE|DRUG|OTHER|BIOLOGICAL,2,0,15 Years,59 Years,ALL,False,National Cancer Institute (NCI),NIH,0,46,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,7,6.304448802421981,xlarge,0,1,0,1,0,0,1,0,1,0,0,0,1,0,2,0,1,1,0,10,1,2006-11-15,2016-12-01,3669.0,2006.0,0,2,0
NCT00010998,Yoga: Effect on Attention in Aging & Multiple Sclerosis,Yoga: Effect on Attention in Aging & Multiple Sclerosis,COMPLETED,1999-09,2004-12,2006-08-18,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Multiple Sclerosis,Yoga,PROCEDURE,0,0,65 Years,85 Years,ALL,True,National Center for Complementary and Integrative Health (NCCIH),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,0.0,,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,,,,,0,0,0
NCT04666298,Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C,"A Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Effect of Different Doses of Inclisiran Given as Subcutaneous Injections in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C",COMPLETED,2021-01-29,2022-10-19,2024-06-20,INTERVENTIONAL,PHASE2,312.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hypercholesterolemia|Heterozygous Familial Hypercholesterolemia,Inclisiran sodium|Placebo,DRUG,1,15,20 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,42,Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.746203190540153,large,0,1,1,0,1,0,1,0,0,0,1,1,1,1,16,1,1,0,0,2,1,2021-01-29,2022-10-19,628.0,2021.0,1,3,1
NCT02276898,A Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance Index,A Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance Index as a Short-term Pharmacodynamic Biomarker in Patients With Cystic Fibrosis.,COMPLETED,2011-11,2014-09,2015-05-22,INTERVENTIONAL,PHASE2,24.0,ESTIMATED,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Cystic Fibrosis,Hypertonic Saline 7%|Isotonic Saline 0.9% (Placebo),DRUG,1,3,6 Years,18 Years,ALL,False,The Hospital for Sick Children,OTHER,0,2,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.2188758248682006,small,1,0,0,1,0,0,1,0,0,0,1,1,1,0,4,1,1,0,0,2,1,,,,,0,1,0
NCT01200498,Study of SB939 in Subjects With Myelofibrosis,"A Phase 2, Prospective, Open-Label Study to Determine the Safety and Efficacy of SB939, A Histone Deacetylase Inhibitor, in Subjects With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (PMF; Post-Polycythemia Vera (PV) Myelofibrosis (MF), Or Post- Essential Thrombosis (ET) MF",COMPLETED,2010-11,2012-11,2014-01-30,INTERVENTIONAL,PHASE2,23.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Myeloproliferative Disorders,SB939,DRUG,1,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.1780538303479458,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT00731198,Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP),"Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During ERCP: a Prospective, Multicenter Randomized Controlled Trial",COMPLETED,2008-08,2009-07,2010-09-08,INTERVENTIONAL,PHASE3,650.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,ERCP|Pancreatic Diseases|Bile Duct Diseases,Drotaverine hydrochloride|Hyoscine-N-butylbromide,DRUG,1,4,18 Years,90 Years,ALL,False,Changhai Hospital,OTHER,0,4,China,1.0,0,0,1,0,0,3.0,0,0,0,0,3,6.478509642208569,xlarge,0,1,0,1,0,0,1,0,0,0,1,0,0,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00008398,Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer,A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated With Curative Radiation Therapy in Head and Neck Cancer Patients,COMPLETED,2000-10,,2013-11-19,INTERVENTIONAL,PHASE3,,,RANDOMIZED,,SUPPORTIVE_CARE,DOUBLE,Head and Neck Cancer|Oral Complications|Radiation Toxicity,sargramostim|quality-of-life assessment|radiation therapy,PROCEDURE|RADIATION|BIOLOGICAL,0,0,,,ALL,False,Radiation Therapy Oncology Group,NETWORK,1,236,Canada|United States,1.0,0,0,1,0,0,3.0,1,0,0,0,3,0.0,,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,3,1,,,,,0,3,1
NCT03518398,Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction,Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction,COMPLETED,2018-07-03,2019-04-02,2019-06-19,INTERVENTIONAL,PHASE3,114.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Meibomian Gland Dysfunction (Disorder)|Dry Eye Syndromes,Intense Pulsed Light|Standard treatment,COMBINATION_PRODUCT|DEVICE,1,10,18 Years,80 Years,ALL,True,Chulalongkorn University,OTHER,0,1,Thailand,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.74493212836325,medium,0,1,0,1,0,0,0,0,0,0,1,1,1,1,11,1,0,0,1,2,1,2018-07-03,2019-04-02,273.0,2018.0,1,3,1
NCT01210898,Immunogenicity and Safety of V70P5 Revaccination Subjects,"A Phase IIIB, Observer-Blind, Randomized, Parallel Groups, Extension Study to Evaluate the Immunogenicity and Safety Following a Single Intramuscular Dose of a Sub-unit Adjuvanted or a Non-adjuvanted Influenza Vaccines in Healthy Children Previously Vaccinated in the V70P5 Study",COMPLETED,2010-09,2011-12,2016-12-01,INTERVENTIONAL,PHASE3,197.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Influenza,Adjuvanted seasonal influenza vaccine,BIOLOGICAL,4,2,18 Months,96 Months,ALL,True,Novartis Vaccines,INDUSTRY,0,16,Finland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.288267030694535,medium,0,1,1,0,1,0,1,0,0,0,1,0,0,1,6,1,0,1,0,1,0,,,,,0,1,0
NCT01821963,Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC),Telaprevir in Combination With Standard of Care in Hepatitis C Genotype 1 Infection in Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation,TERMINATED,2013-04,2014-02,2020-09-24,INTERVENTIONAL,PHASE3,1.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Infection,Pegylated Interferon Alfa 2a|Ribavirin|Telaprevir,DRUG,1,1,18 Years,69 Years,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.6931471805599453,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,0,0,3,1,,,,,0,1,0
NCT00066963,Fluoride Varnish Randomized Clinical Trial,Comprehensive Oral Health Center for Discovery: New Strategies for Enhancing Tissue Integrity and Repair Early Childhood Caries: Prevention and Treatment Outcomes,COMPLETED,2002-10,2006-12,2022-03-09,INTERVENTIONAL,PHASE3,376.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Dental Caries,Fluoride Varnish,DEVICE,1,0,6 Months,36 Months,ALL,True,"University of California, San Francisco",OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.932245187448011,large,0,1,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,,,,,0,0,0
NCT04261387,LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients,"A Two-Part (Open-Label Followed by Randomized, Double-Blind, Placebo-Controlled) Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of Topically Administered LUT014 for the Treatment of Radiation-Induced Dermatitis in Breast Cancer Patients",COMPLETED,2021-01-30,2022-07-15,2022-07-27,INTERVENTIONAL,PHASE1|PHASE2,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Radiation Dermatitis,LUT014 Gel|Placebo for LUT014 Gel,DRUG,2,4,18 Years,,FEMALE,False,Lutris Pharma Ltd.,INDUSTRY,0,2,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.367295829986474,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,6,1,1,0,0,2,1,2021-01-30,2022-07-15,531.0,2021.0,1,3,1
NCT00276887,Cognitive Behavior Therapy for Somatization Disorder,Cognitive Behavior Therapy for Somatization Disorder,COMPLETED,1999-09,2004-04,2014-02-20,INTERVENTIONAL,PHASE2,84.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Somatoform Disorders,Cognitive Behavior Therapy|Psychiatric Consultation Letter,BEHAVIORAL,2,2,18 Years,70 Years,ALL,False,University of Medicine and Dentistry of New Jersey,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.442651256490317,medium,1,1,0,1,0,1,0,0,1,0,1,0,1,1,4,1,0,0,0,2,1,,,,,0,1,0
NCT00464087,Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI,Switching From Arixtra (Fondaparinux) to Angiomax (Bivalirudin) or Unfractionated Heparin in Patients With Acute Coronary Syndromes (ACS) Without ST-segment Elevation Undergoing Percutaneous Coronary Intervention (PCI): SWITCH III,COMPLETED,2007-06,2010-11,2013-08-01,INTERVENTIONAL,PHASE3,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Coronary Syndromes,Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin,DRUG,3,1,18 Years,,ALL,False,Medstar Health Research Institute,OTHER,1,7,Canada|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.61512051684126,medium,0,1,0,1,0,1,1,1,1,0,1,0,1,1,4,1,1,0,0,1,0,,,,,0,1,0
NCT01113593,A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease,"A Randomized, Multiple-Dose, Crossover Study Characterizing the Pharmacodynamic Profiles of Formoterol Fumarate Inhalation Solution and Formoterol Dry Powder Inhaler in Subjects With Stable Chronic Obstructive Pulmonary Disease",COMPLETED,2010-05,,2013-05-27,INTERVENTIONAL,PHASE2,45.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Chronic Obstructive Pulmonary Disease (COPD),Formoterol Fumarate|Formoterol Fumarate|Formoterol Fumarate|Foradil Aerolizer|Foradil Aerolizer,DRUG,1,0,40 Years,,ALL,False,Dey,INDUSTRY,0,4,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.828641396489095,small,1,1,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,0,0,5,1,,,,,0,1,0
NCT03795116,Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention,Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention,COMPLETED,2019-03-18,2020-10-26,2022-06-01,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Fibrosis|Skin Scarring|Skin Wound|Hypertrophic Scar|Scar|Keloid,LED-RL phototherapy|Mock irradiation,DEVICE,2,10,,,ALL,True,State University of New York - Downstate Medical Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,6,3.4339872044851463,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,12,1,0,0,1,2,1,2019-03-18,2020-10-26,588.0,2019.0,1,3,1
NCT03081416,"""THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department""","""THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department""",COMPLETED,2016-05,2017-10,2018-01-18,INTERVENTIONAL,PHASE3,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Headache|Intranasal Ketamine,Ketamine|Normal saline|Metoclopramide|Ketorolac|Dexamethasone|Benadryl,DRUG,1,6,18 Years,65 Years,ALL,True,Brooke Army Medical Center,FED,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.394449154672439,medium,1,1,0,0,0,0,0,0,1,0,1,0,1,1,7,1,1,0,0,6,1,,,,,0,3,1
NCT01652716,Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes,"A Randomized, Open-Label, Long-Term, Parallel-Group, Comparator-Controlled, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Exenatide Twice Daily in Subjects With Type 2 Diabetes Mellitus",COMPLETED,2013-01,2014-08,2018-07-03,INTERVENTIONAL,PHASE3,377.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",Exenatide once weekly suspension|Exenatide twice daily,DRUG,1,4,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,58,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.934894195619588,large,0,1,1,0,1,0,1,0,1,0,1,0,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT02394106,Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome,"Ofatumumab in Children With Steroid- and Calcineurin-inhibitor-resistant Nephrotic Syndrome: a Double-blind Randomized, Controlled, Superiority Trial",TERMINATED,2015-07,2019-06,2020-07-29,INTERVENTIONAL,PHASE2,13.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Nephrotic Syndrome,Ofatumumab|Placebo,DRUG|OTHER,1,3,2 Years,18 Years,ALL,False,Istituto Giannina Gaslini,OTHER,0,1,Italy,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.6390573296152584,small,1,1,0,1,0,0,0,0,0,1,1,1,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00002684,Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer,"Phase II Trial of Paclitaxel, Cisplatin and Ifosfamide in Patients With Advanced Urothelial Tumors",COMPLETED,1995-05,2007-10,2013-07-03,INTERVENTIONAL,PHASE2,40.0,ESTIMATED,,,TREATMENT,,Bladder Cancer|Urethral Cancer,cisplatin|ifosfamide|paclitaxel,DRUG,1,0,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.713572066704308,small,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,3,1,,,,,0,2,0
NCT06428084,Comparative Efficacy of Dexamethasone - Ondansetron Versus Dexamethasone - Haloperidol in Reducing PONV,Comparative Efficacy of Dexamethasone - Ondansetron Versus Dexamethasone - Haloperidol in Reducing Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized Controlled Trial,COMPLETED,2023-11-01,2024-02-28,2024-05-24,INTERVENTIONAL,PHASE2,38.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Laparoscopic Cholecystectomy,Ondansetron|Haloperidol,DRUG,1,0,18 Years,65 Years,ALL,False,Universitas Padjadjaran,OTHER,0,1,Indonesia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6635616461296463,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,2023-11-01,2024-02-28,119.0,2023.0,1,1,0
NCT00176384,Impact of Exercise Training on Exercise Capacity in Patients With Severe Chronic Heart Failure,Impact of Three Months of Aerobic Exercise Training on Exercise Capacity and Peripheral Maladaptations in Patients With Severe Chronic Heart Failure (NYHA III b),COMPLETED,2003-03,2006-12,2007-08-01,INTERVENTIONAL,PHASE2,36.0,,RANDOMIZED,SINGLE_GROUP,,NONE,Heart Failure,Aerobic endurance exercise training (ergometer),BEHAVIORAL,1,3,18 Years,75 Years,MALE,False,University of Leipzig,OTHER,1,1,Germany,1.0,0,1,0,0,0,2.0,0,0,0,1,1,3.6109179126442243,small,1,0,0,1,0,1,0,0,0,1,1,0,0,0,4,1,0,0,0,1,0,,,,,0,0,0
NCT00207233,Use of MCT Oil for Enhancement of Weight Loss and Glycemic Control in Obese Diabetic Patients,Use of MCT Oil for Enhancement of Weight Loss and Glycemic Control in Obese Diabetic Patients 2002-292G,COMPLETED,2004-07,2009-07,2011-01-25,INTERVENTIONAL,PHASE1|PHASE2,42.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Obesity|Type 2 Diabetes Mellitus,MCT oil hypocaloric liquid diet|LCT hypocaloric liquid diet|Subcutaneous abdominal adipose tissue biopsy,PROCEDURE|BEHAVIORAL,4,0,18 Years,65 Years,ALL,False,Boston Medical Center,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,2,3.7612001156935624,small,1,0,0,1,0,0,0,0,1,0,1,1,1,1,4,0,0,0,0,3,1,,,,,0,3,1
NCT00286377,Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of Prosaptide Over 6 Weeks of Treatment for the Relief of Neuropathic Pain Associated With HIV-1",TERMINATED,2003-09,2004-12,2006-02-03,INTERVENTIONAL,PHASE2,350.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,HIV|Peripheral Nervous System Disorders,prosaptide,DRUG,1,2,18 Years,,ALL,False,Savient Pharmaceuticals,INDUSTRY,1,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,2,5.860786223465865,large,0,0,1,0,0,1,0,0,0,0,1,1,1,1,3,1,1,0,0,1,0,,,,,0,1,0
NCT01052077,Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPDC-34712 (1 to 3 mg/Day) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder.",COMPLETED,2010-03,2011-11,2015-11-02,INTERVENTIONAL,PHASE2,773.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Major Depressive Disorder,OPC-34712|Placebo|ADT,DRUG,1,9,18 Years,65 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,0,43,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.651571873589727,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,1,1,10,1,1,0,0,3,1,,,,,0,2,0
NCT00767975,"Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison","Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison",COMPLETED,2008-01,2010-11,2010-11-29,INTERVENTIONAL,PHASE3,2384.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Tuberculosis,"isoniazid , randomized, open label|rifampin, randomized, open label",DRUG,1,1,,,MALE,False,National Taiwan University Hospital,OTHER,0,1,Taiwan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.776954403322442,xlarge,0,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT04856475,Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer,An Open Label Phase II Study to Evaluate Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer,WITHDRAWN,2021-11-24,2021-11-24,2022-03-02,INTERVENTIONAL,PHASE2,0.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer|Brain Metastases,Neratinib,DRUG,3,15,18 Years,,FEMALE,False,Jules Bordet Institute,OTHER,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,2,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,1,18,1,1,0,0,1,0,2021-11-24,2021-11-24,0.0,2021.0,1,2,0
NCT01072175,"Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212","An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination With the MEK Inhibitor GSK1120212 in Subjects With BRAF Mutant Metastatic Melanoma",COMPLETED,2010-03-26,2018-02-27,2019-07-05,INTERVENTIONAL,PHASE2,430.0,ACTUAL,NON_RANDOMIZED,,TREATMENT,NONE,Cancer,GSK2118436|GSK1120212,DRUG,30,27,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,15,Australia|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,6.066108090103747,large,0,1,1,0,1,0,1,1,1,0,0,0,1,0,57,1,1,0,0,2,1,2010-03-26,2018-02-27,2895.0,2010.0,0,3,1
NCT02948101,"PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",Pilot Study of the Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer,WITHDRAWN,2018-12-31,2019-02-06,2019-03-12,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma,Anti-CSF1 Monoclonal Antibody PD-0360324|Cyclophosphamide|Laboratory Biomarker Analysis,DRUG|OTHER|BIOLOGICAL,5,0,18 Years,,FEMALE,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,3,0.0,,1,1,0,1,0,1,0,0,1,0,0,0,1,0,5,0,1,1,0,3,1,2018-12-31,2019-02-06,37.0,2018.0,1,2,0
NCT01065701,Comparison of Two Doses of Intranasal Dexmedetomidine as Premedication in Children,Comparison of Two Doses of Intranasal Dexmedetomidine as Premedication in Children - a Double-blinded Randomized Controlled Trial,COMPLETED,2009-07,2010-08,2017-10-26,INTERVENTIONAL,PHASE3,104.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Patient Between 1-8 Years Old Undergoing Elective Surgery at Queen Mary Hospital,Dexmedetomidine,DRUG,1,1,1 Year,8 Years,ALL,False,The University of Hong Kong,OTHER,0,1,Hong Kong,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.653960350157523,medium,0,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT01402401,Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients,"An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer",TERMINATED,2011-11,2013-06,2020-12-10,INTERVENTIONAL,PHASE2,21.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Gastric Cancer,AUY922|Trastuzumab,DRUG,1,0,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,15,United States|South Korea|France|Spain|Germany|Japan|Belgium|Italy,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.091042453358316,small,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,0,1,0,0,2,1,,,,,0,2,0
NCT00068601,S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer,"Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer",COMPLETED,2003-10,2016-09,2019-12-30,INTERVENTIONAL,PHASE3,257.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Breast Cancer|Infertility|Menopausal Symptoms,cyclophosphamide|goserelin acetate,DRUG,1,2,18 Years,49 Years,FEMALE,False,SWOG Cancer Research Network,NETWORK,4,34,Australia|New Zealand|Switzerland|Hungary|Belgium|Italy,1.0,0,0,1,0,0,3.0,1,0,0,0,3,5.552959584921617,large,0,1,0,0,0,1,1,1,0,1,1,0,0,1,3,1,1,0,0,2,1,,,,,0,3,1
NCT01189812,Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms,"A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Assess the Safety and Efficacy of Citalopram in Combination With Lithium or Placebo in the Treatment of Symptoms in Patients With Depressive Mood Disorders",COMPLETED,2010-03,2011-01,2011-08-24,INTERVENTIONAL,PHASE2,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Major Depressive Disorder|Dysthymia|Depression Not Otherwise Specified|Borderline Personality Disorder,Lithium Carbonate|Placebo|Citalopram,DRUG,1,2,18 Years,75 Years,ALL,False,Columbia Northwest Pharmaceuticals,INDUSTRY,0,2,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,4,4.394449154672439,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,1,3,1,1,0,0,3,1,,,,,0,2,0
NCT00764881,Effects of SH T00658ID on Libido,"Multi-center, Double-blind, Randomized Study to Investigate the Impact of a Sequential Oral Contraceptive Containing Estradiol Valerate and Dienogest (SH T00658ID) Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (Microgynon) Over 6 Treatment Cycles on Alleviating Complaints of Reduced Libido in Women With Acquired Female Sexual Dysfunction (FSD) Associated With Oral Contraceptive Use",COMPLETED,2009-01,2010-07,2014-12-30,INTERVENTIONAL,PHASE3,217.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Contraception|Libido,"EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|Microgynon|Placebo",DRUG,2,108,18 Years,50 Years,FEMALE,False,Bayer,INDUSTRY,0,32,Australia|Austria|Thailand|Spain|Germany|Belgium|Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.384495062789089,large,0,1,1,0,0,0,1,1,0,1,1,1,1,1,110,1,1,0,0,3,1,,,,,0,4,1
NCT02013830,A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer,"A Single-arm, Open-label Study of Avastin Plus Xeloda on Objective Treatment Response in Patients With Advanced or Metastatic Liver Cancer Who Have Had no Previous Cytotoxic Chemotherapy",COMPLETED,2005-05,2008-03,2014-06-06,INTERVENTIONAL,PHASE2,45.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Liver Cancer,bevacizumab [Avastin]|capecitabine [Xeloda],DRUG,1,7,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,7,Singapore|Hong Kong|Australia|Taiwan,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.828641396489095,small,1,1,1,0,1,0,1,1,0,0,0,0,1,0,8,1,1,0,0,2,1,,,,,0,3,1
NCT06067230,A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults,"A Phase 3 Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-Risk Adults",ACTIVE_NOT_RECRUITING,2023-10-06,2026-07-30,2025-08-08,INTERVENTIONAL,PHASE3,1153.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Respiratory Syncytial Virus,mRNA-1345,BIOLOGICAL,6,21,18 Years,,ALL,False,"ModernaTX, Inc.",INDUSTRY,0,44,Puerto Rico|Canada|United Kingdom|United States,,0,0,1,0,0,3.0,0,0,0,0,1,7.050989447068045,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,0,1,27,1,0,1,0,1,0,2023-10-06,2026-07-30,1028.0,2023.0,1,2,0
NCT01775930,Carfilzomib in Refractory Renal Cell Carcinoma (RCC),Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma,COMPLETED,2013-10,2019-01-18,2020-03-04,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Kidney Cancer,Carfilzomib,DRUG,1,4,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,5,1,1,0,0,1,0,,2019-01-18,,,0,0,0
NCT03071965,Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel),Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel),COMPLETED,2017-05-12,2021-05-11,2025-05-09,INTERVENTIONAL,PHASE2,70.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,SINGLE,MacTel (Macular Telangiectasia) Type 2,Ciliary neurotrophic factor (CNTF)|Surgery|Surgery,PROCEDURE|BIOLOGICAL,2,4,21 Years,80 Years,ALL,False,Neurotech Pharmaceuticals,INDUSTRY,0,11,Australia|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.2626798770413155,medium,1,1,1,0,0,0,1,1,1,0,0,0,1,1,6,1,0,1,0,3,1,2017-05-12,2021-05-11,1460.0,2017.0,1,3,1
NCT00950365,Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer,A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) vs Single Agent Pemetrexed (Alimta®) in Patients With Progressive or Recurrent Non-small Cell Lung Cancer (NSCLC),COMPLETED,2006-04,2017-11-17,2020-09-16,INTERVENTIONAL,PHASE2,79.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Bronchioloalveolar Carcinoma|Large Cell Lung Carcinoma|Lung Adenocarcinoma|Recurrent Non-Small Cell Lung Carcinoma|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,Erlotinib Hydrochloride|Laboratory Biomarker Analysis|Pemetrexed Disodium,DRUG|OTHER,1,2,18 Years,,ALL,False,Albert Einstein College of Medicine,OTHER,3,5,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,6,4.382026634673881,medium,1,1,0,1,0,1,1,0,1,0,1,0,1,1,3,1,1,0,0,3,1,,2017-11-17,,,0,2,0
NCT01621867,Repeated Application of Gene Therapy in CF Patients,"A Randomised, Double-blind, Placebo-controlled Phase 2B Clinical Trial of Repeated Application of Gene Therapy in Patients With Cystic Fibrosis",COMPLETED,2012-05,2014-05,2015-10-22,INTERVENTIONAL,PHASE2,130.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Cystic Fibrosis,pGM169/GL67A|Placebo,DRUG,1,3,12 Years,,ALL,False,Imperial College London,OTHER,3,3,United Kingdom,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.875197323201151,medium,0,1,0,1,0,1,1,0,0,1,1,1,1,0,4,1,1,0,0,2,1,,,,,0,1,0
NCT01761500,Improve the Survival Rate of Chinese Children and Adolescents With Non-Hodgkin's Lymphoma,,COMPLETED,1998-03,2011-12,2013-01-04,INTERVENTIONAL,PHASE2,200.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Childhood Non-Hodgkin's Lymphoma,Modified BFM-90 protocol,OTHER,1,1,6 Months,20 Years,ALL,False,Sun Yat-sen University,OTHER,0,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.303304908059076,medium,0,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,0,0,0,1,0,,,,,0,0,0
NCT06692907,Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults,"A Phase 2b, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Intramuscularly Administered CssBA+dmLT Against Moderate-severe Diarrhea in a Controlled Human Infection Model With Enterotoxigenic Escherichia Coli (ETEC) Strain B7A in Healthy Adults",ACTIVE_NOT_RECRUITING,2025-03-31,2026-08-20,2026-01-30,INTERVENTIONAL,PHASE2,72.0,ESTIMATED,RANDOMIZED,SEQUENTIAL,PREVENTION,DOUBLE,Escherichia Infection,B7A (ETEC challenge strain)|CssBA|dmLT|Placebo,OTHER|BIOLOGICAL,6,11,18 Years,49 Years,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,2,United States,,0,1,0,0,0,2.0,0,0,0,0,1,4.290459441148391,medium,1,0,0,1,0,0,1,0,1,0,1,1,0,0,17,1,0,1,0,4,1,2025-03-31,2026-08-20,507.0,2025.0,1,2,0
NCT00092807,Sitosterolemia Extension Study (0653-003)(COMPLETED),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia - 1 Year Open-Label Extension",COMPLETED,2001-02-12,2004-11-30,2024-08-15,INTERVENTIONAL,PHASE3,37.0,ACTUAL,,,TREATMENT,,"Lipid Metabolism, Inborn Errors|Heart Disease","MK0653, ezetimibe|Comparator: placebo",DRUG,1,1,10 Years,,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,1,2,3.6375861597263857,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,2,1,2001-02-12,2004-11-30,1387.0,2001.0,0,2,0
NCT01657292,Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Healing of Grade 2a Partial-Thickness Burn Wounds",COMPLETED,2012-08,2014-07,2015-09-28,INTERVENTIONAL,PHASE3,61.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Burns,Oleogel-S10 ointment|Octenilin® wound gel,DRUG|DEVICE,1,10,18 Years,,ALL,False,Birken AG,INDUSTRY,0,9,Germany|United Kingdom|Switzerland|Sweden,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.127134385045092,medium,1,1,1,0,0,0,1,1,0,1,1,0,1,0,11,1,1,0,1,2,1,,,,,0,3,1
NCT00363636,A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL),"A Phase III, Randomized, Double-Blind Study of Galiximab in Combination With Rituximab Compared With Rituximab in Combination With Placebo for the Treatment of Subjects With Relapsed or Refractory, Follicular Non-Hodgkin's Lymphoma",TERMINATED,2006-09,2010-04,2015-10-02,INTERVENTIONAL,PHASE3,340.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Lymphoma, Non-Hodgkin's",Galiximab in combination with rituximab|Rituximab in combination with placebo,DRUG,1,4,18 Years,,ALL,False,Biogen,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,1,0,0,0,1,5.831882477283517,large,0,1,1,0,1,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT00656136,BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1),"Phase IIb/III Randomized, Double-blind Trial of BIBW 2992 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-Lung 1)",COMPLETED,2008-04,2013-10,2016-07-26,INTERVENTIONAL,PHASE3,585.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Carcinoma, Non-Small-Cell Lung",placebo|BIBW 2992,DRUG,1,2,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,90,United Kingdom|United States|Canada|South Korea|Taiwan|Thailand|France|Spain|China|Singapore|Germany|Netherlands|Belgium|Italy|Hong Kong,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.373319789577012,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,3,1,1,0,0,2,1,,,,,0,2,0
NCT00473811,Diabetic Educational Eating Plan,Applicability of a Low Glycemic Index Diet in Diabetes,COMPLETED,2005-08,2012-08,2012-08-30,INTERVENTIONAL,PHASE1|PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Low-GI Dietary Education|ADA Dietary Education,Low GI|ADA diet,BEHAVIORAL,1,0,21 Years,,ALL,False,"University of Massachusetts, Worcester",OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,2,3.713572066704308,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,2,1,,,,,0,3,1
NCT00137111,Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,COMPLETED,2000-07-08,2014-04,2020-09-11,INTERVENTIONAL,PHASE3,501.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Lymphoblastic Leukemia, Acute","Prednisone, Dexamethasone, Vincristine, Daunorubicin|Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase|Methotrexate, Cyclophosphamide, Cytarabine, Etoposide|Mercaptopurine, Imatinib|chemotherapy, intrathecal chemotherapy|steroid therapy, hematopoietic stem cell transplantation",DRUG|PROCEDURE,2,3,12 Months,18 Years,ALL,False,St. Jude Children's Research Hospital,OTHER,1,2,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.218600119691729,xlarge,0,1,0,1,0,1,1,0,1,0,1,0,1,1,5,1,1,0,0,6,1,2000-07-08,,,2000.0,0,1,0
NCT00163111,"A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.","A Randomized, Open Label, Comparative Multicenter Study Of Voriconazole Versus Conventional Amphotericin B Followed By Fluconazole In The Treatment Of Candidaemia In Non Neutropenic Subjects.",COMPLETED,1998-09,2003-05,2011-04-26,INTERVENTIONAL,PHASE3,412.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Candidiasis,"VFENDÂ® I.V., Oral|Conventional amphotericin B|Diflucan IV, oral",DRUG,1,1,18 Years,70 Years,ALL,False,Pfizer,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.023447592961033,large,0,1,1,0,1,0,0,0,0,0,1,0,1,1,2,1,1,0,0,3,1,,,,,0,1,0
NCT05397171,A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours,"A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours",TERMINATED,2022-06-07,2023-06-06,2024-10-01,INTERVENTIONAL,PHASE1|PHASE2,17.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,"Urinary Bladder Neoplasms|Colorectal Cancer|Carcinoma, Non-Small-Cell Lung",AZD8853|Zirconium-89 crefmirlimab berdoxam,DRUG,2,13,18 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,1,6,Canada|United States,0.0,1,1,0,0,1,1.5,1,0,0,0,3,2.8903717578961645,small,1,1,1,0,1,1,1,1,1,0,0,0,1,0,15,1,1,0,0,2,1,2022-06-07,2023-06-06,364.0,2022.0,1,5,1
NCT01628471,"MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer",A Phase I/IIa Dose-Escalation Study of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) Subjects,COMPLETED,2012-11,2015-09,2015-09-23,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non Small Cell Lung Cancer,decitabine in combination with genistein,DRUG,1,2,18 Years,75 Years,ALL,False,Uman Pharma,INDUSTRY,3,1,Canada,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.044522437723423,small,1,1,1,0,0,1,0,0,0,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,1,0
NCT02874144,Anti-Inflammatory Agent in Sinusitis,"A Phase 2A, Single-Center, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy of an Anti-Inflammatory Agent in Patients With Sinusitis",COMPLETED,2016-06-20,2020-08-10,2022-05-25,INTERVENTIONAL,PHASE2,43.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Nasal Polyps,AZ compound|Collection of Biological Specimens|Intranasal corticosteroid|Placebo,DRUG|OTHER,3,2,18 Years,70 Years,ALL,False,Northwestern University,OTHER,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.784189633918261,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,4,1,2016-06-20,2020-08-10,1512.0,2016.0,1,1,0
NCT00716534,Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),"A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination With ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment",COMPLETED,2008-06,2012-04,2013-04-29,INTERVENTIONAL,PHASE2,145.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Advanced or Metastatic Non-Small Cell Lung Cancer,ABT-869|Placebo for ABT-869|ABT-869|Carboplatin|Paclitaxel,DRUG,1,2,18 Years,,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,1,37,Russia|Australia|United States|Brazil|Czechia|Singapore,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.983606621708336,medium,0,1,1,0,1,1,1,1,1,0,1,1,1,1,3,1,1,0,0,5,1,,,,,0,2,0
NCT00161564,A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone,"A Randomized Trial Comparing Higher Doses of Rituximab (Rituxan) With Standard Doses of Rituxan in Combination With CVP (Cyclophosphamide, Vincristine,and Prednisone) in Subjects With Chronic ITP Who Have Failed/Relapsed After Rituxan Treatment",WITHDRAWN,2004-02,,2018-07-17,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Idiopathic Thrombocytopenic Purpura (ITP),Rituximab,DRUG,0,0,12 Years,,ALL,False,Weill Medical College of Cornell University,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,,,,,0,0,0
NCT00093964,Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor),"A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.",COMPLETED,2004-10-13,2010-10-21,2019-04-16,INTERVENTIONAL,PHASE2,81.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Glioblastoma Multiforme,Cilengitide 500 mg|Cilengitide 2000 mg,DRUG,1,14,18 Years,,ALL,False,EMD Serono,INDUSTRY,0,17,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.406719247264253,medium,1,1,1,0,0,0,1,0,1,0,1,0,1,1,15,1,1,0,0,2,1,2004-10-13,2010-10-21,2199.0,2004.0,0,2,0
NCT02362464,Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139,A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccine in Previously Vaccinated Men on NCI 09-C-0139.,COMPLETED,2015-05-12,2022-03-25,2024-12-10,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostatic Neoplasms|Neoplasms of Prostate|Prostate Cancer|Cancer Of Prostate|Stage D0 Prostate Cancer,Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine,BIOLOGICAL,1,4,18 Years,,MALE,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,5,2.70805020110221,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,5,1,0,1,0,1,0,2015-05-12,2022-03-25,2509.0,2015.0,1,1,0
NCT00752609,Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.,A Phase 2 Study of the Safety and Efficacy of Hematide Injection for the Maintenance Treatment of Anemia in Subjects With Chronic Renal Failure Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa,COMPLETED,2008-09,2009-12,2012-07-27,INTERVENTIONAL,PHASE2,102.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Anemia,Peginesatide,DRUG,1,6,18 Years,90 Years,ALL,False,Takeda,INDUSTRY,1,10,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.634728988229636,medium,0,1,1,0,1,1,1,0,1,0,0,0,1,0,7,1,1,0,0,1,0,,,,,0,1,0
NCT04901299,Fulvestrant + Neratinib In Breast Cancer,"An Open-Label Phase II Trial of Fulvestrant And Neratinib in Previously Treated HRPositive, HER2-Negative Metastatic Breast Cancer Subjects Assessed With a Test Measuring Live Cell HER2 Signaling Function",WITHDRAWN,2023-07,2025-07-01,2023-08-01,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Stage IV (Metastatic) Breast Cancer|Metastatic Breast Cancer|ER Positive Breast Cancer|PR-Positive Breast Cancer|HER2-negative Breast Cancer|Invasive Breast Cancer,NERATINIB|FULVESTRANT,DRUG,1,10,18 Years,,ALL,False,Massachusetts General Hospital,OTHER,2,2,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,6,0.0,,1,1,0,1,0,1,1,0,1,0,0,0,1,0,11,1,1,0,0,2,1,,2025-07-01,,,0,3,1
NCT05263999,A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR),"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease",TERMINATED,2022-04-29,2025-05-12,2025-06-17,INTERVENTIONAL,PHASE3,158.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Graft Versus Host Disease|GVHD|Acute-graft-versus-host Disease|Acute GVHD|aGVHD,Itolizumab|EQ001 Placebo,DRUG|BIOLOGICAL,1,2,12 Years,,ALL,False,Equillium,INDUSTRY,1,118,Australia|United States|Canada|Portugal|South Korea|New Zealand|France|Spain|Italy|Germany|Belgium|Israel,0.0,0,0,1,0,0,3.0,0,0,0,0,5,5.0689042022202315,medium,0,1,1,0,0,1,1,1,1,1,1,1,1,1,3,1,1,1,0,2,1,2022-04-29,2025-05-12,1109.0,2022.0,1,3,1
NCT04346199,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",COMPLETED,2020-06-12,2020-11-17,2021-09-17,INTERVENTIONAL,PHASE2,177.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,COVID-19,Acalabrutinib,DRUG,1,18,18 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,1,50,Argentina|Chile|Russia|Mexico|Turkey (Türkiye)|Brazil|Poland|France|South Africa|Germany|Japan|Italy|India|Peru,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.181783550292085,medium,0,1,1,0,1,1,1,1,0,1,1,0,1,1,19,1,1,0,0,1,0,2020-06-12,2020-11-17,158.0,2020.0,1,2,0
NCT00496132,A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,"An Open-Label, Multicenter, Phase I/II Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Who Have Been Treated With a Purine Nucleoside Analogue-Containing Regimen",TERMINATED,2007-08-27,2009-06-17,2017-07-02,INTERVENTIONAL,PHASE1|PHASE2,16.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Lymphocytic Leukemia,PRO131921,DRUG,1,2,18 Years,,ALL,False,"Genentech, Inc.",INDUSTRY,0,0,,0.0,1,1,0,0,1,1.5,1,0,0,0,1,2.833213344056216,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,3,1,1,0,0,1,0,2007-08-27,2009-06-17,660.0,2007.0,0,1,0
NCT03100032,Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis,"A Prospective Multi-centre, Randomised, Controlled Study to Evaluate the Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis by Interbody Fusion (L1 - S1)",COMPLETED,2017-01,2021-06,2021-08-13,INTERVENTIONAL,PHASE1|PHASE2,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Spondylolisthesis,NVD-001|Standard of Care,PROCEDURE|BIOLOGICAL,8,8,18 Years,,ALL,False,Novadip Biosciences,INDUSTRY,0,12,Poland|Belgium|Czechia,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.8918202981106265,small,1,1,1,0,0,0,1,1,0,0,1,0,1,1,16,1,0,1,0,2,1,,,,,0,4,1
NCT03172598,"Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy","A Phase IIa, Multi-Centre, Randomised, Double-Blind, Cross-Over, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy Incorporating an Open Label Pilot Arm",COMPLETED,2017-07-25,2018-08-08,2025-12-22,INTERVENTIONAL,PHASE2,61.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Painful Diabetic Peripheral Neuropathy,MT-8554 low dose|MT-8554 middle dose|MT-8554 high dose|Placebo,DRUG,2,2,18 Years,,ALL,False,Tanabe Pharma Corporation,INDUSTRY,0,3,Germany|Hungary|Poland,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.127134385045092,medium,1,1,1,0,0,0,1,1,0,1,1,1,1,0,4,1,1,0,0,4,1,2017-07-25,2018-08-08,379.0,2017.0,1,2,0
NCT00345163,A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN),"A Phase II, Multicenter, Randomized, Non-Comparative Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme in First or Second Relapse",COMPLETED,2006-07,2007-09,2017-05-16,INTERVENTIONAL,PHASE2,167.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Glioblastoma,bevacizumab|irinotecan,DRUG,2,3,18 Years,,ALL,False,"Genentech, Inc.",INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.123963979403259,medium,0,1,1,0,0,0,0,0,0,0,1,0,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT02740387,Open Label Study of OTO-104 in Subjects With Meniere's Disease,"A 1-Year, Phase 2, Open-Label Safety Study of OTO-104 Given at 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease",TERMINATED,2016-06,2017-09,2017-09-15,INTERVENTIONAL,PHASE2,34.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Meniere's Disease,OTO-104,DRUG,1,3,18 Years,80 Years,ALL,False,"Otonomy, Inc.",INDUSTRY,0,1,Canada,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.5553480614894135,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT03333187,Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability,Ruxolitinib Versus Allogeneic Stem Cell Transplantation for Patients With Myelofibrosis According to Donor Availability: A Prospective Phase II Trial (MMM 02 Study),ACTIVE_NOT_RECRUITING,2016-12-21,2025-10-07,2025-03-30,INTERVENTIONAL,PHASE2,87.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Bone Marrow Fibrosis,Allogeneic stem cell transplantation|Ruxolitinib continuous therapy,PROCEDURE|DRUG,1,20,18 Years,70 Years,ALL,False,Universitätsklinikum Hamburg-Eppendorf,OTHER,2,14,Germany,,0,1,0,0,0,2.0,0,0,0,0,1,4.477336814478207,medium,1,1,0,1,0,1,1,0,0,1,0,0,1,1,21,1,1,0,0,2,1,2016-12-21,2025-10-07,3212.0,2016.0,1,2,0
NCT00268593,Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer,A Randomised Phase II Study of Two Dose Schedules of PI-88 in Combination With Docetaxel in Patients With Androgen-independent Prostate Cancer,COMPLETED,2005-08,2008-02,2011-06-15,INTERVENTIONAL,PHASE2,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,PI-88|docetaxel|prednisone,DRUG,1,7,18 Years,,MALE,False,Progen Pharmaceuticals,INDUSTRY,2,8,Australia,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.8918202981106265,small,1,1,1,0,0,1,1,0,0,0,1,0,1,1,8,1,1,0,0,3,1,,,,,0,2,0
NCT00314314,The Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder,"A Randomized, Double-Blind Controlled Trial Evaluating the Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder",COMPLETED,2006-05,2009-03,2009-07-13,INTERVENTIONAL,PHASE3,60.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Bipolar Disorder,Intranasal Insulin|Diluent,DRUG,1,1,18 Years,60 Years,ALL,False,"University Health Network, Toronto",OTHER,1,1,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.110873864173311,medium,1,0,0,1,0,1,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT01952314,Medical Expulsive Therapy for Ureter Stone Using Naftopidil,"Medical Expulsive Therapy for Ureter Stone Using Naftopidil: Multicenter, Randomized, Double-blind, Placebo Controlled Study",COMPLETED,2014-05,2015-08,2015-12-10,INTERVENTIONAL,PHASE3,150.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ureter Stones,Naftopidil 75mg|Placebo for Naftopidil|Standard treatment,DRUG,1,4,20 Years,,ALL,False,Seoul National University Hospital,OTHER,1,6,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.017279836814924,medium,0,1,0,1,0,1,1,0,0,0,1,1,1,1,5,1,1,0,0,3,1,,,,,0,1,0
NCT01767116,A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection,"A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)",COMPLETED,2012-12,2014-08,2021-07-12,INTERVENTIONAL,PHASE3,419.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Hepatitis C Infection,"ABT-450/r/ABT-267, ABT-333|Ribavirin|Placebo for ribavirin",DRUG,1,5,18 Years,70 Years,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.040254711277414,large,0,1,1,0,1,0,0,0,0,0,1,1,1,1,6,1,1,0,0,3,1,,,,,0,2,0
NCT00827216,The Effect of Intravenous Erythromycin on Gastric Emptying in Non-fasted Patients Before Emergency Total Anesthesia,"The Effect of Intravenous Erythromycin on Gastric Emptying in Patients Undergoing Rapid Sequence Intubation for Full Stomach - A Randomised, Placebo-controlled, Double-blind Study",COMPLETED,2009-01,2013-04,2015-06-23,INTERVENTIONAL,PHASE2,132.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,Aspiration of Gastric Contents|Gastric Emptying,Placebo|Erythromycin,DRUG,1,6,18 Years,,ALL,False,"University Hospital, Geneva",OTHER,0,1,Switzerland,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.890349128221754,medium,0,1,0,1,0,0,0,0,0,0,1,1,1,0,7,1,1,0,0,2,1,,,,,0,3,1
NCT02976116,A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer,"Fruquintinib in Combination With Gefitinib as First-line Therapy in Patients With Advanced Non-squamous Non-small-cell Lung Cancer Harboring Activating EGFR Mutations : a Single-arm, Multicenter, Phase II Study",COMPLETED,2016-12,2019-06-28,2019-11-15,INTERVENTIONAL,PHASE2,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,NSCLC,Fruquintinib|Gefitinib,DRUG,2,4,18 Years,,ALL,False,Hutchison Medipharma Limited,INDUSTRY,0,2,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.9318256327243257,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,6,1,1,0,0,2,1,,2019-06-28,,,0,2,0
NCT04191304,A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES),"A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-Week Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)",ACTIVE_NOT_RECRUITING,2020-07-20,2026-12-30,2025-11-26,INTERVENTIONAL,PHASE3,134.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hypereosinophilic Syndrome,Benralizumab|Placebo,BIOLOGICAL,1,13,12 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,0,51,United Kingdom|Argentina|Denmark|United States|Netherlands|Austria|Poland|South Korea|France|Spain|Italy|China|Germany|Japan|Belgium|Israel|India,,0,0,1,0,0,3.0,0,0,0,0,1,4.90527477843843,medium,0,1,1,0,1,0,1,1,1,1,1,1,1,1,14,1,0,1,0,2,1,2020-07-20,2026-12-30,2354.0,2020.0,1,3,1
NCT03667404,Resistant Maltodextrin for Gut Microbiome in Parkinson's Disease: Safety and Tolerability Study,Gut Microbial Remodeling with Resistant Maltodextrin for Motor and Non-motor Symptoms in Parkinson's Disease: Safety and Tolerability Study,ACTIVE_NOT_RECRUITING,2018-11-06,2026-03-31,2025-02-19,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Parkinson Disease|Intestinal Bacteria Flora Disturbance|Dietary Modification,Resistant maltodextrin|maltodextrin,DIETARY_SUPPLEMENT,1,1,60 Years,,ALL,False,Northwestern University,OTHER,1,1,United States,,0,1,0,0,0,2.0,0,0,1,0,3,3.4339872044851463,small,1,0,0,1,0,1,0,0,1,0,1,1,1,1,2,1,0,0,0,2,1,2018-11-06,2026-03-31,2702.0,2018.0,1,2,0
NCT00940784,Clopidogrel and Aspirin for the Treatment of Polycythemia Vera,"MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera",WITHDRAWN,2009-06,2011-01,2014-11-26,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,DOUBLE,Polycythemia Vera,Clopidogrel (Plavix)|Placebo|Aspirin,DRUG,1,0,18 Years,81 Years,ALL,False,Ronald Hoffman,OTHER,2,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,0,0,3,1,,,,,0,1,0
NCT02678533,Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor,Pilot Study Assessing the Feasibility of CD34+ Cells Mobilization and Collection After Treatment With G-CSF and Plerixafor in Patients With Fanconi Anemia for Subsequent Treatment by Gene Therapy,COMPLETED,2017-02-10,2019-05-03,2025-09-11,INTERVENTIONAL,PHASE1|PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Fanconi Anemia,G-CSF|Plerixafor,DRUG,1,1,2 Years,17 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,2,1,France,1.0,1,1,0,0,1,1.5,0,0,0,0,1,1.6094379124341003,small,1,1,0,1,0,1,0,0,0,1,0,0,1,0,2,1,1,0,0,2,1,2017-02-10,2019-05-03,812.0,2017.0,1,2,0
NCT04190433,"Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial",AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment (ATACAR) Trial,WITHDRAWN,2020-09-01,2023-04-18,2023-05-24,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,DOUBLE,Breast Carcinoma|Hematopoietic and Lymphoid Cell Neoplasm|Lymphoma|Sarcoma,Carvedilol|Lisinopril|Pravastatin|Spironolactone,DRUG,1,2,18 Years,,ALL,False,Mayo Clinic,OTHER,1,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,4,0.0,,1,1,0,1,0,1,0,0,0,0,1,1,0,1,3,1,1,0,0,4,1,2020-09-01,2023-04-18,959.0,2020.0,1,2,0
NCT05796752,Behavioral Treatment and Memantine in Body Focused Repetitive Behaviors,Single-Group Crossover Trial Comparing Behavioral Treatment to Memantine in Body Focused Repetitive Behaviors,ACTIVE_NOT_RECRUITING,2023-08-02,2026-06,2025-12-03,INTERVENTIONAL,PHASE2|PHASE3,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Skin-Picking|Trichotillomania (Hair-Pulling Disorder),Memantine|ComB Behavioral Therapy,DRUG|BEHAVIORAL,1,8,18 Years,,ALL,False,University of Chicago,OTHER,0,1,United States,,0,1,1,0,1,2.5,0,0,0,0,2,3.295836866004329,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,9,1,1,0,0,2,1,2023-08-02,,,2023.0,1,4,1
NCT04633447,A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis,"A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis",TERMINATED,2020-12-10,2024-05-22,2025-07-01,INTERVENTIONAL,PHASE2,53.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Giant Cell Arteritis,Guselkumab|Placebo,DRUG,1,14,50 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,30,United States|Canada|France|Spain|Italy|Germany|Poland|Belgium|Israel,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.9889840465642745,medium,1,1,1,0,0,0,1,1,1,1,1,1,1,1,15,1,1,0,0,2,1,2020-12-10,2024-05-22,1259.0,2020.0,1,3,1
NCT00001038,A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients,"A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (< 100 CD4+ Lymphocytes)",COMPLETED,,,2011-03-01,INTERVENTIONAL,PHASE3,1200.0,,,,TREATMENT,,Cytomegalovirus Infections|HIV Infections,Valacyclovir hydrochloride|Acyclovir,DRUG,0,0,13 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,1,35,United Kingdom|Denmark|Australia|United States|Sweden|Canada|France|Switzerland|Germany|Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,2,7.0909098220799835,xlarge,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,0,2,1,,,,,0,3,1
NCT01230138,Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis,"A Randomised, Double Blind, Placebo Controlled Efficacy and Safety Trial of Different Doses/Dose Regimens of FP187 Compared to Placebo in Moderate to Severe Plaque Psoriasis (Pivotal Registration Study)",COMPLETED,2010-09,2012-05,2012-12-11,INTERVENTIONAL,PHASE2,252.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Plaque Psoriasis,Placebo|FP187|FP187|FP187|FP187,DRUG,1,9,18 Years,90 Years,ALL,False,Forward-Pharma GmbH,INDUSTRY,0,2,Germany,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.53338948872752,large,0,1,1,0,0,0,1,0,0,1,1,1,1,1,10,1,1,0,0,5,1,,,,,0,2,0
NCT01716377,Healing With Venlafaxine After Injury (HELP),Healing With Venlafaxine After Injury: A Randomized Clinical Trial of Venlafaxine Following Motor Vehicle Collision,COMPLETED,2012-10,2016-09,2017-04-13,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Neck Pain,Venlafaxine,DRUG,1,1,18 Years,50 Years,ALL,False,Rhode Island Hospital,OTHER,4,3,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,1,1,0,1,0,1,1,0,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT03189745,A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).,"A PHASE IIIB, OPEN STUDY TO EVALUATE THE IMMUNOGENICITY, REACTOGENICITY AND SAFETY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER HEALTHY SUBJECTS AGED 11-17 YEARS RECEIVED EITHER MENACWY-TT VACCINE (NIMENRIX(REGISTERED)) OR MENCEVAX ACWY(REGISTERED).",COMPLETED,2017-08-01,2018-04-11,2020-10-12,INTERVENTIONAL,PHASE3,229.0,ACTUAL,,PARALLEL,PREVENTION,NONE,Meningococcal ACWY Disease,MenACWY-TT,BIOLOGICAL,1,8,20 Years,28 Years,ALL,True,Pfizer,INDUSTRY,0,1,Philippines,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.438079308923196,large,0,1,1,0,1,0,0,0,0,0,0,0,0,1,9,1,0,1,0,1,0,2017-08-01,2018-04-11,253.0,2017.0,1,1,0
NCT01809977,Comparison of Partial Removal and Total Removal of the Corneal Epithelium on Keratoconus,Study of Surgical Methods for Keratoconus,COMPLETED,2012-07,2012-12,2013-03-13,INTERVENTIONAL,PHASE2,22.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Keratoconus,collagen cross-linking procedure (total removal)|collagen cross-linking procedure (partial removal),PROCEDURE,1,1,16 Years,40 Years,ALL,True,Isfahan University of Medical Sciences,OTHER,0,1,Iran,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.1354942159291497,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,0,0,0,2,1,,,,,0,1,0
NCT02344472,Detect V / CHEVENDO (Chemo vs. Endo),"DETECT V / CHEVENDO A Multicenter, Randomized Phase III Study to Compare Chemo- Versus Endocrine Therapy in Combination With Dual HER2-targeted Therapy of Herceptin® (Trastuzumab) and Perjeta® (Pertuzumab) Plus Kisqali® (Ribociclib) in Patients With HER2 Positive and Hormone-receptor Positive Metastatic Breast Cancer.",ACTIVE_NOT_RECRUITING,2015-09,2025-01-31,2024-06-04,INTERVENTIONAL,PHASE3,271.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Breast Cancer,pertuzumab|Trastuzumab|Capecitabine|Paclitaxel|Vinorelbine|Docetaxel|Exemestane|Letrozole|Anastrozole|Fulvestrant|Ribociclib|nab-Paclitaxel|eribulin|leuprorelin|goserelin,DRUG,1,9,18 Years,,FEMALE,False,Prof. Wolfgang Janni,OTHER,4,1,Germany,,0,0,1,0,0,3.0,1,0,0,0,1,5.605802066295998,large,0,1,0,1,0,1,0,0,0,1,1,0,1,1,10,1,1,0,0,15,1,,2025-01-31,,,0,2,0
NCT02785172,Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis,"A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis",COMPLETED,2016-04,2017-01,2020-08-20,INTERVENTIONAL,PHASE2,154.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Psoriasis,IDP-118 Vehicle Lotion|IDP-118 Vehicle Cream|IDP-118 Lotion|Ultravate Cream,DRUG,1,0,18 Years,,ALL,True,"Bausch Health Americas, Inc.",INDUSTRY,0,14,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.043425116919247,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,4,1,,,,,0,1,0
NCT00850772,Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer,Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer,COMPLETED,2009-01,2013-08,2014-06-12,INTERVENTIONAL,PHASE3,109.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Epithelial Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer,Early post-operative enteral feeding,DIETARY_SUPPLEMENT,1,5,18 Years,,FEMALE,False,Queensland Centre for Gynaecological Cancer,OTHER_GOV,2,6,Australia,1.0,0,0,1,0,0,3.0,1,0,0,0,3,4.700480365792417,medium,0,1,0,1,0,1,1,0,0,0,1,0,0,1,6,1,0,0,0,1,0,,,,,0,2,0
NCT01256372,An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery,"An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery",COMPLETED,2010-10,2011-08,2012-03-15,INTERVENTIONAL,PHASE2,77.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Cardiac Surgery|Coronary Artery Bypass|Aortic Aneurysm|Valve Surgery|Kidney Diseases,AP214|Placebo,DRUG,2,1,18 Years,,ALL,False,Action Pharma A/S,INDUSTRY,0,1,Denmark,1.0,0,1,0,0,0,2.0,0,0,0,1,5,4.356708826689592,medium,1,1,1,0,0,0,0,0,0,0,1,1,0,1,3,1,1,0,0,2,1,,,,,0,2,0
NCT01213095,Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL),R-CVP Followed by Rituximab Maintenance Therapy for Patients With Advanced Marginal Zone B-cell Lymphoma,COMPLETED,2010-09,2015-09,2016-04-11,INTERVENTIONAL,PHASE2,48.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lymphoma,rituximab,DRUG,1,2,20 Years,,ALL,False,Dong-A University Hospital,OTHER,0,1,South Korea,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.8918202981106265,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT03876795,Evaluation of Effectiveness of Combined Intra-articular and Intra-osseus Injection VS a Single Intra-articular Injection of Bone Marrow Concentrate,"Evaluation of Effectiveness of Combined Intra-articular and Intra-osseus Injection VS a Single Intra-articular Injection of Bone Marrow Concentrate for the Treatment of Osteoarthritis in the Knee. (INTERFACE) Double Blind, Randomized Clinical Trial",COMPLETED,2019-11-08,2023-03-01,2023-04-19,INTERVENTIONAL,PHASE3,86.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Osteoarthritis, Knee",Bone Marrow Concentrate,BIOLOGICAL,1,1,40 Years,70 Years,ALL,False,Istituto Ortopedico Rizzoli,OTHER,0,1,Italy,1.0,0,0,1,0,0,3.0,0,1,0,0,1,4.465908118654584,medium,1,1,0,1,0,0,0,0,0,1,1,1,1,1,2,1,0,1,0,1,0,2019-11-08,2023-03-01,1209.0,2019.0,1,0,0
NCT06002295,A Comparative Analysis of 4% Chlorhexidine Versus Methylated Spirit as Prophylaxis of Omphalitis and Sepsis in Newborns,A Comparative Analysis of 4% Chlorhexidine Versus Methylated Spirit as Prophylaxis of Omphalitis and Sepsis in Newborns,COMPLETED,2020-09-12,2021-11-19,2023-08-23,INTERVENTIONAL,PHASE2,300.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Neonatal Sepsis|Omphalitis,Chlorhexidine Topical Cream|Methylated Spirit,DRUG,1,1,1 Day,10 Days,ALL,True,Sheikh Zayed Federal Postgraduate Medical Institute,OTHER,0,1,Pakistan,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.707110264748875,large,0,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,2,1,2020-09-12,2021-11-19,433.0,2020.0,1,2,0
NCT00002395,Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML),"An Open, Comparative Phase II Study of Immediate Versus Delayed Treatment With Topotecan HCl Given as a Continuous 21-Day Infusion Every 28 Days to Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy",COMPLETED,,,2005-06-24,INTERVENTIONAL,PHASE2,54.0,,,,TREATMENT,NONE,"HIV Infections|Leukoencephalopathy, Progressive Multifocal",Topotecan,DRUG,0,0,18 Years,,ALL,False,SmithKline Beecham,INDUSTRY,0,5,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.007333185232471,medium,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,1,0
NCT02645175,Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease Fatigue,"A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Safety Profile and Ability of TW1025 to Decrease Fatigue",TERMINATED,2016-01,2018-12,2016-10-21,INTERVENTIONAL,PHASE2,3.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Metastatic Breast Cancer|Fatigue,TW1025|Placebo,DIETARY_SUPPLEMENT,1,1,18 Years,80 Years,FEMALE,False,Meriyana Bio Inc.,INDUSTRY,1,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,2,1.3862943611198906,small,1,1,1,0,0,1,0,0,0,0,1,1,1,1,2,1,0,0,0,2,1,,,,,0,2,0
NCT00020657,Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer,Treatment of Delayed Nausea: What Works Best?,COMPLETED,2001-07,2004-10,2015-10-15,INTERVENTIONAL,PHASE3,,,RANDOMIZED,,SUPPORTIVE_CARE,,"Nausea and Vomiting|Unspecified Adult Solid Tumor, Protocol Specific",dolasetron mesylate|granisetron hydrochloride|ondansetron|prochlorperazine|quality-of-life assessment,DRUG|PROCEDURE,0,0,18 Years,120 Years,ALL,False,Gary Morrow,OTHER,1,15,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,2,0.0,,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,5,1,,,,,0,2,0
NCT02975557,Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD),"A Phase I/II Randomized, Placebo-Controlled, Double-Blind, Single-Center, Tolerability And Preliminary Efficacy Study Of Use of Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)",TERMINATED,2016-05,2017-04-13,2019-11-08,INTERVENTIONAL,PHASE1|PHASE2,15.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dry Eye|Ocular Graft vs Host Disease|Meibomian Gland Dysfunction,Brimonidine 0.15%|Brimonidine 0.075%|Placebo,DRUG,1,0,18 Years,,ALL,False,"Sandeep Jain, MD",OTHER,1,2,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,3,2.772588722239781,small,1,1,0,1,0,1,1,0,1,0,1,1,1,1,1,0,1,0,0,3,1,,2017-04-13,,,0,3,1
NCT02767557,Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients,"A Multinational, Randomized, Phase II Study of the Combination of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab, an IL-6R Inhibitor, as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer.",COMPLETED,2017-01-26,2023-01-01,2023-09-22,INTERVENTIONAL,PHASE2,147.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Unresectable Pancreatic Carcinoma,Tocilizumab|Gemcitabine|nab-Paclitaxel,DRUG,1,8,18 Years,,ALL,False,Herlev Hospital,OTHER,1,2,Norway|Denmark,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.997212273764115,medium,0,1,0,1,0,1,1,1,0,0,1,0,1,1,9,1,1,0,0,3,1,2017-01-26,2023-01-01,2166.0,2017.0,1,3,1
NCT03170401,Supplemental Enteral Protein in Critical Illness,Protein-enhanced Enteral Nutrition and Metabolomics in Critically Ill Trauma and Surgical Patients,COMPLETED,2016-11,2022-12,2024-06-05,INTERVENTIONAL,PHASE3,500.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Nutrition Disorder|Trauma|Critical Illness,Protein supplementation|Standard enteral nutrition,OTHER|DIETARY_SUPPLEMENT,1,2,18 Years,,ALL,False,University of Washington,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,3,6.2166061010848646,large,0,1,0,1,0,1,0,0,1,0,1,1,0,1,3,1,0,0,0,2,1,,,,,0,2,0
NCT04610801,Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2,A Randomized Placebo Control Trial to Evaluate the Efficacy of Xylitol Nasal Spray vs. Placebo for Acute COVID-19 Infection,WITHDRAWN,2021-12-08,2022-08-08,2023-10-16,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Covid19,Nasal Spray,DRUG,1,1,18 Years,90 Years,ALL,True,Larkin Community Hospital,OTHER,2,2,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,1,0,1,0,1,0,1,0,2,1,1,0,0,1,0,2021-12-08,2022-08-08,243.0,2021.0,1,0,0
NCT02485301,A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults,Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Adults in Africa,COMPLETED,2015-07-15,2016-12-23,2018-01-04,INTERVENTIONAL,PHASE2,3024.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Virus Diseases,GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|Placebo,DRUG|BIOLOGICAL,21,2,18 Years,,ALL,True,GlaxoSmithKline,INDUSTRY,0,5,Senegal|Mali|Nigeria|Cameroon,1.0,0,1,0,0,0,2.0,0,0,0,0,1,8.014666370464942,xlarge,0,1,1,0,0,0,1,1,0,0,1,1,0,1,23,1,1,1,0,2,1,2015-07-15,2016-12-23,527.0,2015.0,1,3,1
NCT06414512,Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis,Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis,COMPLETED,2024-04-09,2024-10-02,2025-08-27,INTERVENTIONAL,PHASE2,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cryptococcal Meningitis,AMBITION trial control|Flucytosine,DRUG,1,2,18 Years,,ALL,False,University of Minnesota,OTHER,3,2,Uganda,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8918202981106265,small,1,1,0,1,0,1,1,0,0,0,1,0,1,1,3,1,1,0,0,2,1,2024-04-09,2024-10-02,176.0,2024.0,1,1,0
NCT04461119,"Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia","A Phase II, Randomized, 4-Week, Double-Blind, Placebo-Controlled, Multiple-Dose Study, Designed to Determine the Safety, Tolerability, EEG Effects and Preliminary Efficacy of Fixed Oral Doses of 7.5 and 15 MG BID of Evenamide in Patients With Chronic Schizophrenia Who Are Symptomatic on Their Current Second-Generation Antipsychotic Medication",COMPLETED,2020-06-16,2021-03-13,2021-05-20,INTERVENTIONAL,PHASE2,138.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia,Evenamide|Placebo,DRUG,2,6,18 Years,,ALL,False,Newron Pharmaceuticals SPA,INDUSTRY,0,14,India|United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,4.9344739331306915,medium,0,1,1,0,0,0,1,1,1,0,1,1,1,1,8,1,1,0,0,2,1,2020-06-16,2021-03-13,270.0,2020.0,1,3,1
NCT00895830,Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV),"Randomised, Double-blind, Placebo-controlled, Phase II Study to Assess the Safety and Efficacy of Different Doses of Intravenous APD405 for the Prevention of Post-operative Nausea and Vomiting",COMPLETED,2009-05,2009-11,2011-03-29,INTERVENTIONAL,PHASE2,257.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Postoperative Nausea and Vomiting,APD405|Placebo,DRUG,1,0,18 Years,,ALL,False,Acacia Pharma Ltd,INDUSTRY,0,18,Germany|France|Switzerland|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.552959584921617,large,0,1,1,0,0,0,1,1,1,1,1,1,0,1,1,0,1,0,0,2,1,,,,,0,2,0
NCT02137330,Obalon in Children With Severe Obesity,Tolerance and Efficacy of the Swallowable Obalon® Gastric Balloons System in Children With Severe Obesity,COMPLETED,2014-01,2014-06,2015-07-22,INTERVENTIONAL,PHASE3,10.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Severe Pediatric Obesity (BMI > 97° pc -According to Centers for Disease Control and Prevention BMI Charts-)|Altered Liver Function Tests|Glycemic Intolerance,Swallowable Obalon® Gastric Balloon,DEVICE,1,1,9 Years,17 Years,ALL,False,Bambino Gesù Hospital and Research Institute,OTHER,0,1,Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,3,2.3978952727983707,small,1,1,0,1,0,0,0,0,0,1,0,0,1,1,2,1,0,0,1,1,0,,,,,0,1,0
NCT02542930,Abscopal Effect for Metastatic Non-small Cell Lung Cancer.,"A Phase II Study of Radiotherapy and ZADAXIN's® (Thymalfasin) Induced Abscopal Effect in Patients With Heavily Pretreated, Metastatic Non-small Cell Lung Cancer.",WITHDRAWN,2016-01,2019-12,2019-03-26,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-small Cell Lung Cancer|Metastatic Non-small Cell Lung Cancer|Radiotherapy|Thymalfasin,Radiotherapy|Thymalfasin,DRUG|RADIATION,1,2,19 Years,,ALL,False,Zhejiang Provincial People's Hospital,OTHER,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,4,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,3,1,1,0,0,2,1,,,,,0,2,0
NCT05508867,"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)","A Phase 2 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)",COMPLETED,2022-10-18,2026-01-08,2026-01-20,INTERVENTIONAL,PHASE2,203.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hodgkin Lymphoma,favezelimab/pembrolizumab|bendamustine|gemcitabine,DRUG|BIOLOGICAL,1,5,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,105,Canada|China|Argentina|Australia|Spain|Belgium|Israel|Chile|United States|Sweden|France|Czechia|South Korea|Germany|Poland|United Kingdom|Turkey (Türkiye)|Brazil|Switzerland|Mexico,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.318119993844216,large,0,1,1,0,1,0,1,1,1,1,1,0,1,1,6,1,1,1,0,3,1,2022-10-18,2026-01-08,1178.0,2022.0,1,3,1
NCT00630500,Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB),"A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies",COMPLETED,2006-02,2009-03,2015-07-28,INTERVENTIONAL,PHASE2,75.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dementia Associated With Parkinson's Disease|Dementia With Lewy Bodies,Memantine|Placebo,DRUG,1,7,,,ALL,False,Helse Stavanger HF,OTHER_GOV,2,4,Sweden|Norway|United Kingdom,1.0,0,1,0,0,0,2.0,0,0,1,0,2,4.330733340286331,medium,1,1,0,1,0,1,1,1,0,1,1,1,1,1,8,1,1,0,0,2,1,,,,,0,4,1
NCT02230800,PPALM-Palm Oil and Pentoxifylline Against Late Morbidity,Randomised Double-blind Placebo Controlled Phase II Trial of Tocovid SupraBio in Combination With Pentoxifylline (PTX) in Patients Suffering Long-term Adverse Effects of Radiotherapy for Pelvic Cancer,COMPLETED,2014-11-25,2019-12-20,2019-12-23,INTERVENTIONAL,PHASE2,62.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Long-term Adverse Effects of Radiotherapy for Pelvic Cancer,Tocovid SupraBio plus pentoxifylline|Matching placebos,DRUG,1,7,18 Years,,ALL,False,Royal Marsden NHS Foundation Trust,OTHER,1,1,United Kingdom,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.143134726391533,medium,1,1,0,1,0,1,0,0,0,1,1,1,1,1,8,1,1,0,0,2,1,2014-11-25,2019-12-20,1851.0,2014.0,0,2,0
NCT03338400,Dexamethasone Administration To Improve Patient Recovery In Ambulatory Vaginal Prolapse Surgery: Is There A Role?,Dexamethasone Administration To Improve Patient Recovery In Ambulatory Vaginal Reconstructive Surgery: Is There A Role?,COMPLETED,2017-05-01,2018-08-21,2021-04-14,INTERVENTIONAL,PHASE2,51.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Quality of Recovery|Same Day Surgery|Nausea and Vomiting, Postoperative|Vaginal Prolapse",Dexamethasone|Normal saline,DRUG,1,4,18 Years,,FEMALE,False,The Cleveland Clinic,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,4,3.9512437185814275,medium,1,1,0,1,0,0,0,0,1,0,1,0,1,1,5,1,1,0,0,2,1,2017-05-01,2018-08-21,477.0,2017.0,1,2,0
NCT01540292,Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders,Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders,TERMINATED,2013-02-01,2015-12-31,2021-05-12,INTERVENTIONAL,PHASE1|PHASE2,13.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Crohn's Disease,Mesenchymal Stem Cells (MSC),BIOLOGICAL,1,7,18 Years,75 Years,ALL,False,University of Liege,OTHER,0,1,Belgium,0.0,1,1,0,0,1,1.5,0,1,0,0,1,2.6390573296152584,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,8,1,0,1,0,1,0,2013-02-01,2015-12-31,1063.0,2013.0,0,2,0
NCT02131636,Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea,,COMPLETED,2014-05,2014-12,2019-11-18,INTERVENTIONAL,PHASE3,440.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Erythema|Rosacea,AGN-199201|Vehicle to AGN-199201,DRUG,1,5,18 Years,,ALL,False,Allergan,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.089044875446846,large,0,1,1,0,0,0,0,0,1,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,3,1
NCT01122511,Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration,,TERMINATED,2010-08,2011-05,2012-09-05,INTERVENTIONAL,PHASE2,4.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Subfoveal Choroidal Neovascularization|Age-Related Maculopathy,700 ug dexamethasone|ranibizumab|sham,DRUG|OTHER|BIOLOGICAL,1,3,50 Years,,ALL,False,Allergan,INDUSTRY,0,2,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,1.6094379124341003,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,4,1,1,1,0,3,1,,,,,0,2,0
NCT00054171,Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia,"A Pilot Study of Short (1-2.5 h), Medium (4-6 h) and Long (18-24 h) Applications of 20% Topical ALA-PDT for Photodynamic Therapy of Cutaneous T and B Cell Lymphomas and Cutaneous Infiltrates of Early CLL",COMPLETED,1999-02,,2013-01-31,INTERVENTIONAL,PHASE2,1.0,ACTUAL,RANDOMIZED,,TREATMENT,,Leukemia|Lymphoma,aminolevulinic acid hydrochloride,DRUG,6,0,,,ALL,False,Roswell Park Cancer Institute,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,0.6931471805599453,small,1,1,0,1,0,1,0,0,1,0,1,0,1,0,6,0,1,0,0,1,0,,,,,0,2,0
NCT01573871,Tolerance and Compliance of Infants Fed an Hydrolyzed Infant Formula,Tolerance and Compliance of Infants Fed an Extensively Hydrolyzed Infant Formula,COMPLETED,2012-02,2012-09,2013-02-15,INTERVENTIONAL,PHASE3,25.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Infant|Gastrointestinal Intolerance,Experimental Hydrolyzed infant formula,OTHER,1,1,,180 Days,ALL,False,Abbott Nutrition,INDUSTRY,0,3,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,3.258096538021482,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,2,1,0,0,0,1,0,,,,,0,1,0
NCT04762771,Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19),Open-label (Unblinded) Randomization to Treatment of Colchicine Plus Current Care Per Institution Treating Physicians vs. Current Care Per Institution Treating Physicians (Control Arm),TERMINATED,2020-12-23,2021-09-20,2022-07-25,INTERVENTIONAL,PHASE1|PHASE2,2.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Covid19,Colchicine,DRUG,3,7,18 Years,99 Years,ALL,False,Baptist Health South Florida,OTHER,1,1,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,10,1,1,0,0,1,0,2020-12-23,2021-09-20,271.0,2020.0,1,2,0
NCT03089944,A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis,"A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis",COMPLETED,2017-04-28,2019-11-08,2020-07-13,INTERVENTIONAL,PHASE3,343.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatitis C Virus (HCV),Glecaprevir/Pibrentasvir,DRUG,2,6,18 Years,,ALL,False,AbbVie,INDUSTRY,0,113,Canada|Ireland|Hungary|Russia|Bulgaria|Portugal|Spain|Romania|Italy|Israel|United States|Vietnam|France|Czechia|Poland|Greece|United Kingdom|Puerto Rico|Taiwan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.840641657373398,large,0,1,1,0,1,0,1,1,1,1,0,0,1,0,8,1,1,0,0,1,0,2017-04-28,2019-11-08,924.0,2017.0,1,2,0
NCT05466344,the Condylar Response of Mini-plate Anchored Rigid Fixed Functional Appliance Versus Dentally Anchored Semi-rigid One,Assessment of the Condylar Response of Mini-plate Anchored Rigid Fixed Functional Appliance Versus Dentally Anchored Semi-rigid One; A Randomized Clinical Trial,COMPLETED,2020-06-15,2022-04-15,2022-07-21,INTERVENTIONAL,PHASE2|PHASE3,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Class II Malocclusion,Herbst Group|TFBC Group,DEVICE,1,1,18 Years,20 Years,ALL,True,Al-Azhar University,OTHER,0,1,Egypt,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,0,0,1,2,1,2020-06-15,2022-04-15,669.0,2020.0,1,2,0
NCT02111044,Phase II Study With ITF2984 in Acromegalic Patients,"A Randomized, Multicenter, Phase II Study to Investigate Efficacy and Safety of ITF2984 in Acromegalic Patients",COMPLETED,2014-04,2016-02,2016-06-16,INTERVENTIONAL,PHASE2,48.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Acromegaly,Octreotide|ITF2984 500 mcg|ITF2984 1000 mcg|ITF2984 2000 mcg,DRUG,1,6,18 Years,80 Years,ALL,False,Italfarmaco,INDUSTRY,0,26,Poland|France|Spain|Czechia|Hungary|Netherlands|Romania|Italy|Serbia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8918202981106265,small,1,1,1,0,0,0,1,1,0,1,1,0,1,0,7,1,1,0,0,4,1,,,,,0,3,1
NCT00333164,Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis,Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis (CATHARSIS),COMPLETED,2006-05,2012-03,2017-12-19,INTERVENTIONAL,PHASE3,200.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cerebrovascular Disease,"Asprin, Cilostazol",DRUG,1,3,45 Years,85 Years,ALL,False,"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",OTHER,7,1,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.303304908059076,medium,0,0,0,1,0,1,0,0,0,0,1,0,1,1,4,1,1,0,0,1,0,,,,,0,0,0
NCT05326464,Tofacitinib in Recurrent GBM Patients,Tofacitinib: Suppressing Tumor Invasion in Recurrent GBM Patients,ACTIVE_NOT_RECRUITING,2022-10-07,2027-06-01,2025-12-15,INTERVENTIONAL,PHASE3,17.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Glioblastoma,Tofacitinib 10mg,DRUG,1,3,18 Years,,ALL,False,University of Texas Southwestern Medical Center,OTHER,1,1,United States,,0,0,1,0,0,3.0,0,0,0,0,1,2.8903717578961645,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2022-10-07,2027-06-01,1698.0,2022.0,1,0,0
NCT01891864,Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel,"A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Etanercept (GP2015) and Enbrel® in Patients With Moderate to Severe Chronic Plaque-type Psoriasis",COMPLETED,2013-06,2015-03,2017-03-27,INTERVENTIONAL,PHASE3,531.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Stable Plaque Psoriasis,GP2015 Etanercept|Enbrel,DRUG,1,4,18 Years,,ALL,False,Sandoz,INDUSTRY,1,74,United Kingdom|Estonia|Russia|Ukraine|Bulgaria|Hungary|Slovakia|South Africa|Czechia|Germany|Poland|Romania,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.2766434893416445,xlarge,0,1,1,0,0,1,1,1,0,1,1,1,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00597909,Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Two Doses of AMMONUL® (Sodium Phenylacetate and Sodium Benzoate) Injection 10% / 10% in Subjects With Grade 3 or 4 Hepatic Encephalopathy",TERMINATED,2007-12,2008-09,2024-12-17,INTERVENTIONAL,PHASE2,1.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hepatic Encephalopathy,sodium phenylacetate and sodium benzoate injection 10% / 10%|sodium phenylacetate and sodium benzoate injection 10% / 10%|placebo solution (10% dextrose),DRUG,1,8,18 Years,75 Years,ALL,False,Amgen,INDUSTRY,0,3,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.6931471805599453,small,1,1,1,0,1,0,1,0,1,0,1,1,1,1,9,1,1,0,0,3,1,,,,,0,2,0
NCT00002899,Adjuvant Radiation Therapy in Treating Patients With Brain Metastases,Phase III Trial on Convergent Beam Irradiation of Cerebral Metastases,TERMINATED,1996-11,,2012-07-02,INTERVENTIONAL,PHASE3,340.0,ESTIMATED,RANDOMIZED,,TREATMENT,,Metastatic Cancer,adjuvant therapy|radiation therapy|stereotactic radiosurgery,PROCEDURE|RADIATION,1,6,18 Years,,ALL,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,0,33,United Kingdom|Turkey (Türkiye)|Finland|Portugal|Latvia|France|Spain|Italy|Switzerland|Germany|Netherlands|Belgium|Israel,0.0,0,0,1,0,0,3.0,1,0,0,0,1,5.831882477283517,large,0,0,0,0,0,0,1,1,0,1,1,0,1,0,7,1,0,0,0,3,1,,,,,0,3,1
NCT04417699,SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer,"SHORT: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer, a Phase II Trial",COMPLETED,2022-07-05,2024-02-21,2025-12-10,INTERVENTIONAL,PHASE2,13.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Rectal Cancer,TAS 102|Oxaliplatin,DRUG,1,1,18 Years,,ALL,False,Providence Health & Services,OTHER,1,4,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.6390573296152584,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,2,1,1,0,0,2,1,2022-07-05,2024-02-21,596.0,2022.0,1,1,0
NCT01335932,Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure,A Randomized Double-Blind Placebo-Controlled Trial of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure (The GRAIL Study),COMPLETED,2011-03-10,2016-10-28,2018-08-21,INTERVENTIONAL,PHASE2,160.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Acute Lung Injury|Acute Respiratory Distress Syndrome|Respiratory Failure,IV Ganciclovir|Placebo,DRUG,1,66,18 Years,,ALL,False,Fred Hutchinson Cancer Center,OTHER,2,14,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,5.081404364984463,medium,0,1,0,1,0,1,1,0,1,0,1,1,0,1,67,1,1,0,0,2,1,2011-03-10,2016-10-28,2059.0,2011.0,0,3,1
NCT00442832,TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection,"A Phase 2, Randomized, Double Blind, Study of Intravenous TD 1792 Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections",COMPLETED,2006-12,2007-05,2021-01-20,INTERVENTIONAL,PHASE2,203.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Staphylococcal Skin Infection,TD-1792|Vancomycin,DRUG,1,0,18 Years,65 Years,ALL,False,Theravance Biopharma,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.318119993844216,large,0,1,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT02538198,Lenalidomide Maintenance in Plasma Cell Myeloma,Lenalidomide Maintenance in Plasma Cell Myeloma,ACTIVE_NOT_RECRUITING,2015-08-31,2026-08,2025-07-03,INTERVENTIONAL,PHASE2,108.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Plasma Cell Myeloma,Lenalidomide,DRUG,1,0,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,0,6,United States,,0,1,0,0,0,2.0,1,0,0,0,1,4.6913478822291435,medium,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,0,2015-08-31,,,2015.0,1,0,0
NCT00984763,"A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria","A Phase I/IIa Study of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria",COMPLETED,2010-01,2010-09,2015-05-28,INTERVENTIONAL,PHASE1|PHASE2,8.0,ACTUAL,NON_RANDOMIZED,PARALLEL,PREVENTION,NONE,Malaria,AMA1-C1/Alhydrogel® + CPG 7909,BIOLOGICAL,1,1,18 Years,50 Years,ALL,True,University of Oxford,OTHER,1,1,United Kingdom,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.1972245773362196,small,1,1,0,1,0,1,0,0,0,1,0,0,0,1,2,1,0,1,0,1,0,,,,,0,1,0
NCT01385293,BKM120 in Metastatic Castration-resistant Prostate Cancer,Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer,TERMINATED,2011-08,2016-02,2017-05-19,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer|Metastatic (Spread to Other Areas of the Body),BKM120,DRUG,1,6,18 Years,,MALE,False,"Andrew J. Armstrong, MD",OTHER,1,3,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,2,3.4339872044851463,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,7,1,1,0,0,1,0,,,,,0,2,0
NCT03436121,Single-dose Ketamine for the Reduction of Pain and Depression in the Emergency Department,"Single-dose Ketamine to Reduce Pain Severity, Depressive Symptoms and the Need for Opiates Both During and After Emergency Department Care",WITHDRAWN,2019-12,2020-02-05,2020-02-11,INTERVENTIONAL,PHASE2|PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Pain|Depression,Ketamine|Midazolam|Placebo,DRUG,1,1,18 Years,65 Years,ALL,False,Maria Pacella,OTHER,1,0,,0.0,0,1,1,0,1,2.5,0,0,1,0,2,0.0,,1,1,0,1,0,1,0,0,0,0,1,1,1,1,2,1,1,0,0,3,1,,2020-02-05,,,0,3,1
NCT05687721,Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer,A Phase II Trial With Copanlisib Plus Avelumab as a Maintenance Therapy for Metastatic Bladder Cancer After Platinum-based Chemotherapy,WITHDRAWN,2025-06-02,2025-06-02,2025-06-15,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Urothelial Carcinoma,copanlisib|Avelumab,DRUG,1,4,18 Years,,ALL,False,VA Office of Research and Development,FED,1,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,0.0,,1,1,0,0,0,1,0,0,1,0,0,0,1,0,5,1,1,0,0,2,1,2025-06-02,2025-06-02,0.0,2025.0,1,2,0
NCT02325414,Prevention of Bone Loss After Acute SCI by Zoledronic Acid,"Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy",COMPLETED,2015-02,2020-08-25,2025-12-02,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Spinal Cord Injury|Acute Spinal Cord Injury|Bone Loss|Osteoporosis,Zoledronic acid|Placebo,DRUG,2,2,18 Years,,ALL,False,Northwestern University,OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,4,4.110873864173311,medium,1,1,0,1,0,1,1,0,1,0,1,1,0,1,4,1,1,0,0,2,1,,2020-08-25,,,0,2,0
NCT00000506,Cardiovascular System in Obesity: Effect of Treatment,,COMPLETED,1983-05,1988-04,2013-11-26,INTERVENTIONAL,PHASE2,,,RANDOMIZED,PARALLEL,TREATMENT,,Heart Diseases|Obesity|Vascular Diseases,fenfluramine|phentermine,DRUG,0,0,18 Years,60 Years,ALL,False,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,1,3,0.0,,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,2,1,,,,,0,2,0
NCT01527006,"Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs","An Open-label Pilot Study With an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, and Efficacy of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Pediatric Subjects From 2 to Less Than 12 Years of Age With Epilepsy",COMPLETED,2012-01,2015-04,2016-07-12,INTERVENTIONAL,PHASE2,63.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Central Nervous System,perampanel,DRUG,2,13,2 Years,11 Years,ALL,False,Eisai Inc.,INDUSTRY,0,23,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.1588830833596715,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,0,15,1,1,0,0,1,0,,,,,0,1,0
NCT02933684,D-Cycloserine and Virtual Reality Exposure Therapy,D-Cycloserine and Virtual Reality Exposure Therapy Delivered on an iPad: Increasing Access to Treatment for Social Anxiety Disorder,WITHDRAWN,2015-01-01,2016-12-31,2018-04-13,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Social Anxiety Disorder,Seromycin|Virtual Reality Exposure Therapy|Placebo,DRUG|BEHAVIORAL,3,5,18 Years,,ALL,False,Georgia State University,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,1,0,1,0.0,,1,1,0,1,0,1,0,0,1,0,1,1,1,1,8,1,1,0,0,3,1,2015-01-01,2016-12-31,730.0,2015.0,1,2,0
NCT01345084,Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab,"A Phase III Study Evaluating the Standard Radiation Therapy and Chemotherapy Regimen, With or Without Nimotuzumab, in Unresectable, Locally Advanced Epidermoid Carcinoma of the Head and Neck",WITHDRAWN,2013-11,2017-11,2025-03-28,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Carcinoma|Head and Neck Cancer,Radiation Therapy|Nimotuzumab|Cisplatin,DRUG|RADIATION,1,1,18 Years,75 Years,ALL,False,Eurofarma Laboratorios S.A.,INDUSTRY,0,8,Brazil,0.0,0,0,1,0,0,3.0,1,0,0,0,2,0.0,,1,1,1,0,0,0,1,0,0,0,1,0,1,1,2,1,1,0,0,3,1,,,,,0,2,0
NCT00609284,Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux,Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux,COMPLETED,2008-02-15,2019-03-26,2020-04-15,INTERVENTIONAL,PHASE3,406.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,HNSCC,"cetuximab|Carboplatin, 5FU concomitant|Radiotherapy",DRUG|RADIATION,1,1,18 Years,70 Years,ALL,False,Groupe Oncologie Radiotherapie Tete et Cou,OTHER,0,5,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.008813185442595,large,0,1,0,1,0,0,1,0,0,1,1,0,1,1,2,1,1,0,0,3,1,2008-02-15,2019-03-26,4057.0,2008.0,0,1,0
NCT01621633,A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers,"A Single-dose, Open-label Parallel-group Study to Assess the Pharmacokinetics of LCZ696 in Subjects With Hepatic Impairment Compared to Matched Healthy Subjects",COMPLETED,2012-09,2013-01,2015-08-10,INTERVENTIONAL,PHASE2,32.0,ACTUAL,NON_RANDOMIZED,PARALLEL,,NONE,Hepatic Impairment,LCZ696,DRUG,3,1,18 Years,75 Years,ALL,True,Novartis Pharmaceuticals,INDUSTRY,0,1,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4965075614664802,small,1,1,1,0,1,0,0,0,0,1,0,0,0,1,4,1,1,0,0,1,0,,,,,0,0,0
NCT01997333,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer","A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)",COMPLETED,2013-11,2018-08-07,2019-03-08,INTERVENTIONAL,PHASE2,327.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic gpNMB Over-expressing Triple Negative Breast Cancer,CDX-011|Capecitabine,DRUG,1,5,18 Years,,ALL,False,Celldex Therapeutics,INDUSTRY,0,140,United Kingdom|Australia|United States|Canada|France|Spain|Germany|Belgium|Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.793013608384144,large,0,1,1,0,0,0,1,1,1,1,1,0,1,1,6,1,1,0,0,2,1,,2018-08-07,,,0,3,1
NCT00006052,STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia,A Study to Determine the Efficacy and Safety of STI571 in Patients With Chronic Myeloid Leukemia in Accelerated Phase,COMPLETED,2000-06,,2014-01-31,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Leukemia,imatinib mesylate,DRUG,0,0,18 Years,,ALL,False,Novartis,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT00318747,Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug,Asthma Immunotherapy With a Ragweed Allergen Immunostimulatory Sequence Conjugate,TERMINATED,2006-04,2006-11,2013-02-05,INTERVENTIONAL,PHASE2,140.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Asthma|Allergy|Allergic Rhinitis|Rhinitis, Allergic, Seasonal",Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC),DRUG,1,3,18 Years,65 Years,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,1,4,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,4,4.948759890378168,medium,0,0,0,1,0,1,1,0,1,0,1,1,1,1,4,1,1,0,0,1,0,,,,,0,1,0
NCT05171647,A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma,"A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma",ACTIVE_NOT_RECRUITING,2022-04-25,2027-02-28,2025-11-12,INTERVENTIONAL,PHASE3,242.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non-Hodgkin Lymphoma,Mosunetuzumab|Polatuzumab vedotin|Tocilizumab|Rituximab|Gemcitabine|Oxaliplatin,DRUG,2,16,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,51,Argentina|Turkey (Türkiye)|United States|Canada|Brazil|South Korea|Thailand|New Zealand|China|Mexico|Japan|Israel|Peru,,0,0,1,0,0,3.0,1,0,0,0,1,5.493061443340548,large,0,1,1,0,1,0,1,1,1,0,1,0,1,1,18,1,1,0,0,6,1,2022-04-25,2027-02-28,1770.0,2022.0,1,3,1
NCT01605747,Study of Culturelle in the Prophylaxis of Infection and Diarrhea,A Blinded Placebo Controlled Clinical Outcomes Study of Culturelle® in the Prophylaxis of Infection and Diarrhea,TERMINATED,2011-01,2015-12,2013-11-13,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Pediatric Burns,Culturelle|Placebo,DIETARY_SUPPLEMENT,1,1,6 Months,18 Years,ALL,False,Shriners Hospitals for Children,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,0,0,0,1,0,1,1,0,1,2,1,0,0,0,2,1,,,,,0,1,0
NCT05925647,The Effects of Mesenchymal Stem Cell Secretome in Rheumatoid Arthritis Patients,The Effects of Mesenchymal Stem Cell Secretome in Rheumatoid Arthritis Patients,COMPLETED,2022-08-01,2023-03-09,2023-06-29,INTERVENTIONAL,PHASE1|PHASE2,15.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Rheumatoid Arthritis,Messenchymal stem cell secretome|Placebo,DRUG,1,0,18 Years,60 Years,ALL,False,Universitas Sebelas Maret,OTHER,0,1,Indonesia,1.0,1,1,0,0,1,1.5,0,1,0,0,1,2.772588722239781,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,2022-08-01,2023-03-09,220.0,2022.0,1,2,0
NCT00001047,Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS,"An Open-Label, Randomized Trial of Four Treatment Regimens for Patients With Disseminated Mycobacterium Avium Complex Disease and Acquired Immunodeficiency Syndrome (AIDS)",COMPLETED,,1996-08,2021-11-04,INTERVENTIONAL,PHASE3,400.0,,,,TREATMENT,,Mycobacterium Avium-intracellulare Infection|HIV Infections,Ethambutol hydrochloride|Clarithromycin|Clofazimine|Rifabutin,DRUG,0,0,13 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,16,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.993961427306569,large,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,4,1,,,,,0,2,0
NCT01151449,"Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer","A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Carcinoma",TERMINATED,2010-06,2015-08,2017-04-11,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Male Breast Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-negative Breast Cancer,gamma-secretase/Notch signalling pathway inhibitor RO4929097|laboratory biomarker analysis,DRUG|OTHER,2,3,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,2,Canada,0.0,0,1,0,0,0,2.0,1,0,0,0,10,1.9459101490553132,small,1,1,0,1,0,0,1,0,0,0,0,0,1,0,5,1,1,0,0,2,1,,,,,0,2,0
NCT06780449,A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity,Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With Obesity,ACTIVE_NOT_RECRUITING,2025-02-10,2028-10-31,2026-01-20,INTERVENTIONAL,PHASE3,400.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Obesity,Cagrilintide|Semaglutide|Placebo cagrilintide|Placebo semaglutide,DRUG,1,59,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,36,United Kingdom|Denmark|United States|Canada|Portugal|Belgium,,0,0,1,0,0,3.0,0,0,0,0,1,5.993961427306569,large,0,0,1,0,0,0,1,1,1,1,1,1,1,1,60,1,1,0,0,4,1,2025-02-10,2028-10-31,1359.0,2025.0,1,3,1
NCT01231438,Treatment of Early Stage Renal Failure With Active Vitamin D or a Phosphate Binder.,"An Open, Randomized, Crossover Phase 2 Pilot Study of Treatment of Stage 3B Renal Failure With Active Vitamin D or a Phosphate Binder to Evaluate the Effect on the FGF23 and PTH Levels.",COMPLETED,2010-10,2011-03,2012-11-09,INTERVENTIONAL,PHASE2,21.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Kidney Failure,Renvela|Etalpha,DRUG,1,5,18 Years,,ALL,False,Helse Stavanger HF,OTHER_GOV,1,2,Norway,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.091042453358316,small,1,1,0,1,0,1,1,0,0,0,1,0,1,0,6,1,1,0,0,2,1,,,,,0,2,0
NCT01955512,Effect of Clopidogrel on Allergen Challenge in Asthma,Effect of Clopidogrel on Allergen Challenge in Asthma,COMPLETED,2013-05,2014-05,2023-05-22,INTERVENTIONAL,PHASE2,24.0,ESTIMATED,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Asthma,Clopidogrel|Placebo,DRUG,1,7,18 Years,50 Years,ALL,False,University of Southampton,OTHER,0,1,United Kingdom,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.2188758248682006,small,1,0,0,1,0,0,0,0,0,1,1,1,0,1,8,1,1,0,0,2,1,,,,,0,2,0
NCT00160212,Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension,"A Randomized, Placebo-Controlled, Double-Blind, Six-Arm, Dose Escalation, Multi-Center Study to Evaluate the Efficacy and Safety of SLV306: 150, 300, 600 mg Once Daily, 150-300 mg Twice Daily and Amlodipine 5-10 mg Once Daily in Subjects With Hypertension",COMPLETED,2004-12,,2009-01-30,INTERVENTIONAL,PHASE2,,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hypertension,Daglutril,DRUG,0,0,18 Years,,ALL,False,Solvay Pharmaceuticals,INDUSTRY,0,130,United Kingdom|Estonia|Denmark|Australia|Bulgaria|Hungary|Slovakia|Lithuania|Latvia|Germany|Israel,1.0,0,1,0,0,0,2.0,0,0,0,1,1,0.0,,0,0,1,0,0,0,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,,,,,0,1,0
NCT02630381,Shock Wave Therapy for Osteoporosis,Treatment of Osteoporosis With Unfocused Extracorporeal Shock Wave Therapy: Pilot Study,COMPLETED,2015-05-18,2016-09-19,2017-10-12,INTERVENTIONAL,PHASE2,12.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Osteoporosis,Unfocused extracoporeal shock wave therapy,DEVICE,2,2,50 Years,80 Years,FEMALE,False,UMC Utrecht,OTHER,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.5649493574615367,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,4,1,0,0,1,1,0,2015-05-18,2016-09-19,490.0,2015.0,1,0,0
NCT02648581,"Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease","A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease",COMPLETED,2017-06-14,2019-11-19,2025-09-08,INTERVENTIONAL,PHASE2,16.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Behçet Disease,Subcutaneous Ustekinumab,DRUG,2,40,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,1,1,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.833213344056216,small,1,1,0,1,0,1,0,0,0,1,0,0,1,0,42,1,1,0,0,1,0,2017-06-14,2019-11-19,888.0,2017.0,1,1,0
NCT00992719,Novartis H1N1 Vaccine in Pregnant Women,A Phase II Study In Pregnant Women to Assess the Safety and Immunogenicity of an Unadjuvanted Novartis H1N1 Inactivated Influenza Vaccine Administered at Two Dose Levels,COMPLETED,2009-11,2011-02,2013-08-07,INTERVENTIONAL,PHASE2,84.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Influenza,Inactivated H1N1 Vaccine,BIOLOGICAL,9,2,18 Years,39 Years,FEMALE,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,6,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.442651256490317,medium,1,1,0,1,0,0,1,0,1,0,1,0,0,1,11,1,0,1,0,1,0,,,,,0,1,0
NCT00483119,Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus,Phase 2 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus,TERMINATED,2007-04,2011-02,2016-02-18,INTERVENTIONAL,PHASE2,9.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Pemphigus Vulgaris,intravenous immunoglobulin|cyclophosphamide,DRUG,2,2,18 Years,85 Years,ALL,True,NYU Langone Health,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.302585092994046,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00383630,Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure,The Effect of Intramyocardial Injection of Immunoselected Bone Marrow Cells on Myocardial Function in LVAD Bridge to Transplant Patients,TERMINATED,2007-09,2008-12,2019-04-17,INTERVENTIONAL,PHASE2,1.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Heart Failure, Congestive",Intramyocardial injection of bone marrow mononuclear cells|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells|LVAD alone,DEVICE|BIOLOGICAL,1,2,18 Years,,ALL,False,Columbia University,OTHER,1,7,United States,0.0,0,1,0,0,0,2.0,0,0,0,1,1,0.6931471805599453,small,1,1,0,1,0,1,1,0,1,0,1,0,1,1,3,1,0,1,1,3,1,,,,,0,1,0
NCT05376930,Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.,"A Multi-center, Open-label, Extension Study to Evaluate the Long-term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus",COMPLETED,2021-09-16,2022-05-31,2022-10-25,INTERVENTIONAL,PHASE3,63.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,T2DM (Type 2 Diabetes Mellitus),DWP16001 Amg,DRUG,1,3,19 Years,80 Years,ALL,False,Daewoong Pharmaceutical Co. LTD.,INDUSTRY,0,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.1588830833596715,medium,1,1,1,0,0,0,0,0,0,0,0,0,1,0,4,1,1,0,0,1,0,2021-09-16,2022-05-31,257.0,2021.0,1,0,0
NCT00508430,ASP 8825 - Study in Patients With Painful Diabetic Polyneuropathy,"ASP 8825 Phase II Study-A Double- Blind, Placebo- Controlled Study in Patients With Painful Diabetic Polyneuropathy",TERMINATED,2007-07,2008-11,2008-12-05,INTERVENTIONAL,PHASE2,199.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetic Neuropathies,ASP8825|Placebo,DRUG,1,4,20 Years,79 Years,ALL,False,Astellas Pharma Inc,INDUSTRY,0,8,Japan,0.0,0,1,0,0,0,2.0,0,0,0,0,1,5.298317366548036,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT02119728,Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity,A Randomized Multicenter Phase II Study Using HPPH With PDT Versus Standard of Care Surgery for Patients With T1/T2 Squamous Cell Carcinoma of the Oral Cavity,WITHDRAWN,,,2016-04-21,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage I Squamous Cell Carcinoma of the Oropharynx|Stage I Verrucous Carcinoma of the Oral Cavity|Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage II Squamous Cell Carcinoma of the Oropharynx|Stage II Verrucous Carcinoma of the Oral Cavity|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Verrucous Carcinoma of the Oral Cavity,HPPH|Light Infusion Therapy™|therapeutic conventional surgery,DRUG|PROCEDURE|DEVICE,2,1,18 Years,,ALL,False,Roswell Park Cancer Institute,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,21,0.0,,1,1,0,1,0,1,0,0,1,0,1,0,1,1,3,1,1,0,1,3,1,,,,,0,2,0
NCT01688128,Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART),"An Open-label, Controlled, Cross-over Trial of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART) in Mild Cognitive Impairment",COMPLETED,2012-08,2015-12,2016-04-20,INTERVENTIONAL,PHASE3,50.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Mild Cognitive Impairment,Phase I U-SMART (4 wks)|Washout (2 wks)|Phase II U-SMART (4 wks),OTHER|DEVICE,1,3,55 Years,90 Years,ALL,False,Seoul National University Bundang Hospital,OTHER,1,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,1,0,0,0,0,1,0,1,0,4,1,0,0,1,3,1,,,,,0,1,0
NCT00163267,Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel,Follow-up Management of Peripheral Arterial Intervention With Clopidogrel MIRROR-Study,COMPLETED,2005-09,2011-04,2011-08-09,INTERVENTIONAL,PHASE2|PHASE3,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Peripheral Vascular Diseases,clopidogrel,DRUG,1,4,18 Years,90 Years,ALL,False,University Hospital Tuebingen,OTHER,0,1,Germany,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.394449154672439,medium,1,1,0,1,0,0,0,0,0,1,1,1,1,1,5,1,1,0,0,1,0,,,,,0,1,0
NCT02945800,Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma,Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults,COMPLETED,2016-10-25,2025-02-17,2026-01-26,INTERVENTIONAL,PHASE2,59.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Soft Tissue Sarcoma,nab-Paclitaxel|Gemcitabine,DRUG,2,1,3 Years,30 Years,ALL,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,14,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,4.0943445622221,medium,1,1,0,1,0,1,1,0,1,0,0,0,1,0,3,1,1,0,0,2,1,2016-10-25,2025-02-17,3037.0,2016.0,1,2,0
NCT00361907,Effect of Pulsatile IV Insulin on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes,Effect of Pulsatile IV Insulin Delivery on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes,TERMINATED,2005-02,2009-08,2016-08-09,INTERVENTIONAL,PHASE2|PHASE3,105.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Diabetes Mellitus,Effect of Pulsatile IV insulin on diabetic pt blood markers|Effect of Pulsatile IV Insulin on blood markers|Effect of Pulsatile IV insulin on diabetic pt blood markers,PROCEDURE,1,0,21 Years,85 Years,ALL,False,Florida Atlantic University,OTHER,1,1,United States,0.0,0,1,1,0,1,2.5,0,0,0,0,1,4.663439094112067,medium,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,3,1,,,,,0,2,0
NCT02209792,Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease,"A Randomised, Double-blind, Placebo-controlled, Five* Parallel Groups, Dose Finding Study of BIRB 796 BS (10, 20, 30, and 60 mg*) Administered Twice a Day Orally Over 8 Weeks in Patients With Moderate to Severe Crohn's Disease Followed by a 18 Weeks Treatment Extension in Patients With Clinical Remission or Clinical Response After 8 Weeks Treatment With the Respective Dose of BIRB 796 BS - Extension Phase. * Subsequent to Amendment 4 (Dated 11 Jun 2002) a 60 mg b.i.d. Group Was Included.",TERMINATED,2001-10,,2014-08-06,INTERVENTIONAL,PHASE2,284.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Crohn Disease,"Placebo|BIBR 796 BS, 5 mg|BIBR 796 BS, 20 mg",DRUG,1,22,18 Years,65 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,1,0,0,1,5.652489180268651,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,23,1,1,0,0,3,1,,,,,0,2,0
NCT02834936,A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation,A Phase 2 Clinica Study: Efficacy and Safety of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation,COMPLETED,2016-10-20,2019-06-20,2025-08-28,INTERVENTIONAL,PHASE2,60.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non Small Cell Lung,pyrotinib,DRUG,1,2,18 Years,75 Years,ALL,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,11,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.110873864173311,medium,1,1,1,0,0,0,1,0,0,0,0,0,1,0,3,1,1,0,0,1,0,2016-10-20,2019-06-20,973.0,2016.0,1,0,0
NCT04004611,A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC),"A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis",COMPLETED,2020-05-18,2023-03-15,2024-03-26,INTERVENTIONAL,PHASE2,26.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Ulcerative Colitis,Mirikizumab,DRUG,1,12,2 Years,17 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,37,United States|Canada|South Korea|Japan|Israel,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.295836866004329,small,1,1,1,0,1,0,1,1,1,0,0,0,1,1,13,1,1,0,0,1,0,2020-05-18,2023-03-15,1031.0,2020.0,1,2,0
NCT05277571,"A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)","A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)",COMPLETED,2022-03-07,2025-09-19,2025-10-20,INTERVENTIONAL,PHASE1|PHASE2,273.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,Atopic Dermatitis,UCB1381|Placebo,DRUG|BIOLOGICAL,5,12,18 Years,65 Years,ALL,True,UCB Biopharma SRL,INDUSTRY,0,16,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,5.6131281063880705,large,0,1,1,0,0,0,1,0,1,0,1,1,0,1,17,1,1,1,0,2,1,2022-03-07,2025-09-19,1292.0,2022.0,1,3,1
NCT03302871,Integrated Management Enhances Functional Gains in Children With Cerebral Palsy Treated by BoNT-A,Integrated Management With Brain Stimulation and Hybrid Training Enhances Functional Gains in Children With Cerebral Palsy Treated by Botulinum Toxin A,COMPLETED,2016-01-18,2020-01-30,2020-04-24,INTERVENTIONAL,PHASE3,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Cerebral Palsy,Botulinum toxin type A|transcranial direct current stimulation|hybrid training model of CIMT and BIT|usual care,DRUG|OTHER|DEVICE,1,1,5 Years,16 Years,ALL,False,Kocaeli University,OTHER,0,1,Turkey (Türkiye),1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.713572066704308,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,1,0,1,4,1,2016-01-18,2020-01-30,1473.0,2016.0,1,1,0
NCT03151434,Comparison of Three Different Pain Blocks for Subjects Undergoing VATS (Video Assisted Thoracoscopic Surgery) Procedure.,"Randomized Prospective Study Comparing Paravertebral Catheters, Single Shot Paravertebral Block, Thoracic Epidural, for Postoperative Analgesia Following Video-assisted Thoracoscopic Surgery",COMPLETED,2017-02-07,2018-07-30,2021-01-27,INTERVENTIONAL,PHASE3,147.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Video Assisted Thoracoscopic Surgery|Pain, Postoperative|Pain, Acute",US Guided Single Shot Paravertebral Block (0.2% ropivicaine infusion)|US Guided Paravertebral Catheter (0.2% ropivicaine bolus)|Thoracic Epidural (0.125% bupivicaine/hydromorphone),DRUG,2,1,18 Years,,ALL,False,Indiana University,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,3,4.997212273764115,medium,0,1,0,1,0,0,0,0,1,0,1,0,1,1,3,1,1,0,0,3,1,2017-02-07,2018-07-30,538.0,2017.0,1,2,0
NCT05178134,A Phase 2 Bridging Study to Assess the New Formulation of ETVAX,"A Phase 2 Immunological Bridging Study Assessing the Non-inferiority of a New Formulation of ETVAX®. A Prospective Double-blind, Randomized Study in Healthy Volunteers.",COMPLETED,2021-11-08,2022-10-20,2025-08-19,INTERVENTIONAL,PHASE2,280.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,"Healty Volunteers|Preventable Disease, Vaccine",Etvax|Etvax,BIOLOGICAL,1,1,18 Years,50 Years,ALL,True,Scandinavian Biopharma AB,INDUSTRY,3,1,Sweden,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.638354669333745,large,0,1,1,0,0,1,0,0,0,0,1,1,0,1,2,1,0,1,0,2,1,2021-11-08,2022-10-20,346.0,2021.0,1,2,0
NCT00164164,HalfLytely Bowel Prep System for Colonoscopy,HalfLytely Bowel Prep System for Colonoscopy,COMPLETED,1999-08,,2013-02-07,INTERVENTIONAL,PHASE3,200.0,,RANDOMIZED,PARALLEL,,SINGLE,Colonoscopy,HalfLytely|NuLytely,DRUG,1,1,18 Years,,ALL,,Braintree Laboratories,INDUSTRY,0,2,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.303304908059076,medium,0,0,1,0,0,0,1,0,1,0,1,0,0,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT03616964,A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II),"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus",COMPLETED,2018-08-02,2021-10-20,2022-11-23,INTERVENTIONAL,PHASE3,778.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Systemic Lupus Erythematosus,Baricitinib|Placebo,DRUG,1,11,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,1,159,Argentina|Chile|United States|Colombia|Philippines|Poland|South Korea|France|South Africa|Spain|Romania|Japan|Italy|India|Serbia,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.658011045870748,xlarge,0,1,1,0,1,1,1,1,1,1,1,1,1,1,12,1,1,0,0,2,1,2018-08-02,2021-10-20,1175.0,2018.0,1,3,1
NCT00050609,Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Study of IC351 (LY450190) in Patients With Diabetic Gastroparesis",COMPLETED,2003-02,2003-09,2007-11-20,INTERVENTIONAL,PHASE2,2.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Gastroparesis,tadalafil|tadalafil|placebo,DRUG,1,2,18 Years,69 Years,ALL,False,Eli Lilly and Company,INDUSTRY,1,12,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,1.0986122886681098,small,1,1,1,0,1,1,1,0,0,0,1,1,1,1,3,1,1,0,0,3,1,,,,,0,1,0
NCT01258309,Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis,,COMPLETED,2010-12,2011-01,2012-01-25,INTERVENTIONAL,PHASE3,129.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Rhinitis, Allergic, Seasonal|Conjunctivitis, Allergic",olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution|olopatadine hydrochloride 0.1% ophthalmic solution,DRUG,1,3,18 Years,,ALL,False,Allergan,INDUSTRY,0,1,India,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.867534450455582,medium,0,1,1,0,0,0,0,0,0,0,1,0,1,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT00132899,COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial),"A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Evaluate the Safety and Efficacy of Infliximab in Combination With Methotrexate for the Long-term Treatment of Crohn's Disease (CD)",COMPLETED,2005-12,2008-07,2013-12-11,INTERVENTIONAL,PHASE3,128.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Crohn's Disease,Methotrexate|Placebo,DRUG,1,3,18 Years,,ALL,False,"University of Western Ontario, Canada",OTHER,1,1,Canada,1.0,0,0,1,0,0,3.0,0,1,0,0,1,4.859812404361672,medium,0,1,0,1,0,1,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT01621399,Safety and Efficacy Study to Treat Bacterial Vaginosis,"A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis",COMPLETED,2012-05,2012-12,2013-08-21,INTERVENTIONAL,PHASE3,651.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Bacterial Vaginosis,Product 55394|Placebo Vehicle (non-treatment),DRUG,1,1,18 Years,,FEMALE,False,Medicis Global Service Corporation,INDUSTRY,0,37,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.480044561926653,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT02739698,Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia,Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia,COMPLETED,2012-07,2017-03,2017-08-01,INTERVENTIONAL,PHASE2,32.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Peritoneal Carcinomatosis,Paclitaxel|Radical surgery-peritonectomy,DRUG|PROCEDURE,1,0,18 Years,75 Years,FEMALE,False,Maimónides Biomedical Research Institute of Córdoba,OTHER,0,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4965075614664802,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT05516498,"Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)","A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants With Cirrhosis With Features of Portal Hypertension",TERMINATED,2022-10-31,2025-07-17,2025-08-15,INTERVENTIONAL,PHASE2,205.0,ACTUAL,RANDOMIZED,PARALLEL,SCREENING,TRIPLE,Liver Cirrhosis,Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|Part A: zibotentan (dose B) + dapagliflozin|Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)|Part B: placebo (matching zibotentan capsule) + dapagliflozin|Part B: zibotentan (dose A) + dapagliflozin|Part B: zibotentan (dose B) + dapagliflozin|Part B: zibotentan (dose C) + dapagliflozin,DRUG,2,12,18 Years,80 Years,ALL,False,AstraZeneca,INDUSTRY,0,50,United Kingdom|Denmark|Australia|United States|Austria|Taiwan|France|Spain|Czechia|China|Switzerland|Germany|Netherlands|Belgium|Romania,0.0,0,1,0,0,0,2.0,0,0,0,0,1,5.327876168789581,large,0,1,1,0,1,0,1,1,1,1,1,1,0,1,14,1,1,0,0,7,1,2022-10-31,2025-07-17,990.0,2022.0,1,3,1
NCT02039063,A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease,A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease,COMPLETED,2014-04-05,2017-11-27,2023-01-30,INTERVENTIONAL,PHASE1|PHASE2,28.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,,Crohn's Disease,E6011 2 mg/kg|E6011 5 mg/kg|E6011 10 mg/kg|E6011 15 mg/kg,DRUG,6,2,20 Years,64 Years,ALL,False,"EA Pharma Co., Ltd.",INDUSTRY,0,17,Japan,1.0,1,1,0,0,1,1.5,0,1,0,0,1,3.367295829986474,small,1,1,1,0,0,0,1,0,0,0,0,0,1,1,8,1,1,0,0,4,1,2014-04-05,2017-11-27,1332.0,2014.0,0,3,1
NCT00252187,Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure,Cardiac Hormone Replacement With BNP in Heart Failure: A Novel Therapeutic Strategy,COMPLETED,2000-01,2010-06,2012-12-20,INTERVENTIONAL,PHASE1|PHASE2,45.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Congestive Heart Failure|Cardiomyopathy,B-type Natriuretic Peptide (BNP)|Placebo,DRUG|OTHER,2,6,18 Years,,ALL,False,Horng Chen,OTHER,4,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,1,2,3.828641396489095,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,8,1,1,0,0,2,1,,,,,0,4,1
NCT00045487,Erlotinib in Treating Patients With Advanced Kidney Cancer,"A Phase II, Pharmacokinetic And Biologic Correlative Study of OSI-774, An EGFR Tyrosine Kinase Inhibitor, In Patients With Advanced Renal Cell Carcinoma",COMPLETED,2002-06,2008-05,2014-01-27,INTERVENTIONAL,PHASE2,41.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Kidney Cancer,OSI-774,DRUG,1,0,18 Years,,ALL,False,The University of Texas Health Science Center at San Antonio,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.7376696182833684,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT00248287,PhII ICb With/Without Erbitux in MBC Pts,Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,2005-07-28,2026-12,2025-01-29,INTERVENTIONAL,PHASE2,154.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Breast Cancer,Irinotecan + Carboplatin|irinotecan + Carboplatin + erbitux,DRUG,1,3,18 Years,,ALL,False,US Oncology Research,INDUSTRY,2,59,United States,,0,1,0,0,0,2.0,1,0,0,0,1,5.043425116919247,medium,0,1,1,0,0,1,1,0,1,0,1,0,1,1,4,1,1,0,0,2,1,2005-07-28,,,2005.0,0,1,0
NCT02247193,Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair,Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair,COMPLETED,2015-12,2020-01-13,2021-11-03,INTERVENTIONAL,PHASE1|PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cleft Lip|Scarring|Cleft Palate,Botulinum Toxin Type A|Normal Saline Injection,DRUG,8,0,,6 Months,ALL,True,"The University of Texas Health Science Center, Houston",OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,3,3.4339872044851463,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,8,0,1,0,0,2,1,,2020-01-13,,,0,4,1
NCT00343421,Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers,"Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Infanrix®-IPV+Hib When Both Vaccines Are Co-Administered With Prevenar® to Infants and Toddlers at 2, 3, 4 and 12-18 Months of Age",COMPLETED,2006-07,2009-06,2016-06-03,INTERVENTIONAL,PHASE3,588.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Diphtheria|Tetanus|Pertussis|Poliomyelitis|Haemophilus Influenzae Type b,PEDIACEL® and Prevenar®|Infanrix®-IPV+Hib and Prevenar®,BIOLOGICAL,1,1,55 Days,75 Days,ALL,True,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,0,2,France|Poland,1.0,0,0,1,0,0,3.0,0,0,0,0,5,6.3784261836515865,xlarge,0,1,1,0,1,0,1,1,0,1,1,0,0,1,2,1,0,1,0,2,1,,,,,0,3,1
NCT03318614,Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster,Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster,COMPLETED,2015-09,2015-12,2017-10-24,INTERVENTIONAL,PHASE2|PHASE3,53.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Irritable Bowel Syndrome|Abdominal Pain|Small Intestinal Bacterial Overgrowth,Probiotics M-63|Control group,OTHER|DIETARY_SUPPLEMENT,1,4,18 Years,,ALL,True,Universiti Sains Malaysia,OTHER,1,0,,1.0,0,1,1,0,1,2.5,0,0,0,0,3,3.9889840465642745,medium,1,1,0,1,0,1,0,0,0,0,0,0,1,1,5,1,0,0,0,2,1,,,,,0,3,1
NCT00000214,IV Cocaine Abuse: A Laboratory Model - 3,IV Cocaine Abuse: A Laboratory Model,COMPLETED,1992-01,1993-01,2015-08-31,INTERVENTIONAL,PHASE2,0.0,,,,TREATMENT,,Cocaine-Related Disorders,Buprenorphine,DRUG,4,0,18 Years,45 Years,ALL,False,New York State Psychiatric Institute,OTHER,2,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,0,0,1,0,1,0,0,1,0,0,0,1,0,4,0,1,0,0,1,0,,,,,0,0,0
NCT02473016,Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia,"A Placebo-Controlled, Single-Blind Study Evaluating the Safety and Efficacy of Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia",COMPLETED,2015-09,2017-04,2017-11-17,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,CROSSOVER,TREATMENT,SINGLE,Trigeminal Neuralgia,Carbon Dioxide Drug Delivery System (CDDS),DRUG,1,10,18 Years,,ALL,False,"Capnia, Inc.",INDUSTRY,0,6,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4339872044851463,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,11,1,1,0,0,1,0,,,,,0,1,0
NCT00551616,Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception,,COMPLETED,2007-04,2009-04,2022-05-03,INTERVENTIONAL,PHASE3,2221.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Contraception,CDB-2914|Levonorgestrel,DRUG,1,2,16 Years,,FEMALE,False,HRA Pharma,INDUSTRY,0,33,United Kingdom|Ireland|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.706162970199576,xlarge,0,1,1,0,0,0,1,1,1,1,1,0,1,1,3,1,1,0,0,2,1,,,,,0,2,0
NCT00004106,Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome,Phase II Trial of Temozolomide for the Treatment of Mycosis Fungoides and the Sezary Syndrome,TERMINATED,1998-05,2006-04,2012-06-06,INTERVENTIONAL,PHASE2,29.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Lymphoma,temozolomide,DRUG,1,0,18 Years,,ALL,False,Northwestern University,OTHER,1,3,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4011973816621555,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT03959384,Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age,"Efficacy and Safety of Curosurf® in Patients Under 12 Months of Age Requiring Invasive Mechanical Ventilation for Acute Respiratory Distress Syndrome in the Course of Bronchiolitis: A Randomized, Double-blind, Placebo-controlled Trial",TERMINATED,2019-01-09,2021-04-09,2021-04-15,INTERVENTIONAL,PHASE3,9.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Bronchiolitis, Viral",Curosurf 80Mg/Ml Intratracheal Suspension|Ambient Air,DRUG|OTHER,1,11,40 Weeks,12 Months,ALL,False,Azienda Ospedaliera Universitaria Integrata Verona,OTHER,0,1,Italy,0.0,0,0,1,0,0,3.0,0,0,0,0,1,2.302585092994046,small,1,1,0,1,0,0,0,0,0,1,1,1,1,1,12,1,1,0,0,2,1,2019-01-09,2021-04-09,821.0,2019.0,1,2,0
NCT02960204,"Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension",COMPLETED,2016-10-17,2019-04-08,2022-02-11,INTERVENTIONAL,PHASE2,263.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Cirrhosis|Portal Hypertension|Non-alcoholic Steatohepatitis,Emricasan|Placebo,DRUG,1,3,18 Years,,ALL,False,Histogen,INDUSTRY,0,37,Germany|Spain|United States,1.0,0,1,0,0,0,2.0,0,0,0,1,3,5.575949103146316,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,4,1,1,0,0,2,1,2016-10-17,2019-04-08,903.0,2016.0,1,3,1
NCT01693484,Application of Indocyanine Green Angiography for Closed Operative Calcaneus Fractures,Application of Indocyanine Green Angiography for Closed Operative Calcaneus Fractures Requiring Extensile Lateral Incision,TERMINATED,2013-04,2015-03,2017-06-20,INTERVENTIONAL,PHASE2|PHASE3,13.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,"Fractures, Comminuted|Surgical Wound Dehiscence|Necrosis",ICG (Indocyanine Green),DRUG,1,0,18 Years,65 Years,ALL,False,Louisiana State University Health Sciences Center Shreveport,OTHER,0,1,United States,0.0,0,1,1,0,1,2.5,0,0,0,0,3,2.6390573296152584,small,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,,,,,0,2,0
NCT00563433,MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers,MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers,COMPLETED,1994-08,1996-07,2020-09-03,INTERVENTIONAL,PHASE3,342.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetic Foot Ulcers,ofloxacin|MSI-78,DRUG,1,5,18 Years,,ALL,False,"Abeona Therapeutics, Inc",INDUSTRY,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.8377304471659395,large,0,1,1,0,0,1,0,0,1,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT03806933,Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines,"A Prospective, Randomized, Double-blind, Multicenter Study to Investigate the Safety and Duration of Effect of Different NT 201 Dose Groups Following the Treatment of Glabellar Frown Lines",COMPLETED,2019-01-23,2020-10-08,2023-11-15,INTERVENTIONAL,PHASE2,241.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Moderate to Severe Glabellar Frown Lines,NT 201,DRUG,6,6,18 Years,,ALL,False,Merz Aesthetics GmbH,INDUSTRY,1,9,Germany|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.488937726156687,large,0,1,1,0,0,1,1,1,1,1,1,1,1,1,12,1,1,0,0,1,0,2019-01-23,2020-10-08,624.0,2019.0,1,2,0
NCT02757352,A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis,"A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis",COMPLETED,2016-08-02,2019-05-07,2020-03-13,INTERVENTIONAL,PHASE3,303.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Axial Spondyloarthritis,Ixekizumab|Placebo,DRUG,2,27,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,109,Argentina|Finland|Russia|Mexico|United States|Puerto Rico|Canada|Brazil|Netherlands|Austria|Poland|Czechia|Germany|Japan|Romania|South Korea,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.717027701406222,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,29,1,1,0,0,2,1,2016-08-02,2019-05-07,1008.0,2016.0,1,3,1
NCT00836147,Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids,"A Single-centre, Double Blind, Randomised, Exploratory Study to Explore the Efficacy and Safety of Juvista 250ng/100µL/Linear cm When Administered Following Excision of Ear Lobe Keloids.",COMPLETED,2009-02,2010-06,2010-09-28,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,Keloid,Avotermin (Juvista)|Placebo,DRUG,1,1,18 Years,85 Years,ALL,False,Renovo,INDUSTRY,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.044522437723423,small,1,1,1,0,0,0,0,0,1,0,1,1,1,0,2,1,1,0,0,2,1,,,,,0,2,0
NCT02181738,Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational),"Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects",COMPLETED,2014-08-12,2022-12-27,2023-11-28,INTERVENTIONAL,PHASE2,294.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hodgkin Disease,Nivolumab|Doxorubicin|Vinblastine|Dacarbazine,DRUG,2,19,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,38,United Kingdom|United States|Canada|Austria|Spain|Czechia|Germany|Netherlands|Belgium|Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.68697535633982,large,0,1,1,0,1,0,1,1,1,1,0,0,1,0,21,1,1,0,0,4,1,2014-08-12,2022-12-27,3059.0,2014.0,0,3,1
NCT02193958,Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies,"A Phase 1/2a, Dose Escalation Study of FF-10501-01 for the Treatment of Advanced Hematologic Malignancies",COMPLETED,2014-07,2019-10-15,2025-03-19,INTERVENTIONAL,PHASE1|PHASE2,55.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,AML|CMML|MDS,FF-10501-01,DRUG,1,1,18 Years,,ALL,False,"Fujifilm Pharmaceuticals U.S.A., Inc.",INDUSTRY,0,2,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,3,4.02535169073515,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,2019-10-15,,,0,2,0
NCT07001748,Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity,Protocol EA2234: A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis - STOPGAP II,ACTIVE_NOT_RECRUITING,2025-08-19,2030-05-30,2026-01-26,INTERVENTIONAL,PHASE2|PHASE3,148.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Peritoneal Carcinomatosis,Standard of Care Chemotherapy|Biospecimen Collection|Computed Tomography|Diagnostic Laparoscopy|Intraperitoneal Port Placement|Magnetic Resonance Imaging|Intraperitoneal Paclitaxel,DRUG|PROCEDURE,2,1,18 Years,,ALL,False,ECOG-ACRIN Cancer Research Group,NETWORK,1,10,United States,,0,1,1,0,1,2.5,1,0,0,0,3,5.003946305945459,medium,0,0,0,0,0,1,1,0,1,0,1,0,1,1,3,1,1,0,0,7,1,2025-08-19,2030-05-30,1745.0,2025.0,1,3,1
NCT03360448,AC6 Gene Transfer in Patients With Reduced Left Ventricular Ejection Fraction Heart Failure,"Randomized, Phase 3, Placebo-Controlled Double-Blind, Multicenter Trial of a One Time Intracoronary Administration of Ad5.hAC6 Gene Transfer for Patients With Reduced Left Ventricular Heart Failure",WITHDRAWN,2019-06,2023-06,2019-06-07,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Heart Failure,Ad5.hAC6|Placebo,DRUG,1,4,18 Years,80 Years,ALL,False,Renova Therapeutics,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,1,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT02988648,A Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer That Overexpresses Functional Na/I Symporter,A Phase I/II Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer That Overexpresses Functional Na/I Symporter,WITHDRAWN,2016-12,2018-01,2018-08-22,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,Radioiodide (131I-),RADIATION,1,0,18 Years,70 Years,FEMALE,False,Yale University,OTHER,0,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,,,,,0,1,0
NCT03685448,ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB),A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802),COMPLETED,2019-04-11,2025-06-04,2025-08-08,INTERVENTIONAL,PHASE2,35.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Renal Cell Carcinoma|Papillary Renal Cell Carcinoma Type 1|Papillary Renal Cell Carcinoma Type 2|Chromophobe Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Xp11.2 Translocation-Related Renal Cell Carcinoma,Cabozantinib,DRUG,1,3,18 Years,,ALL,False,Australian and New Zealand Urogenital and Prostate Cancer Trials Group,OTHER,0,11,Australia,1.0,0,1,0,0,0,2.0,1,0,0,0,6,3.58351893845611,small,1,1,0,1,0,0,1,0,0,0,0,0,1,0,4,1,1,0,0,1,0,2019-04-11,2025-06-04,2246.0,2019.0,1,1,0
NCT00050375,Clinical Trial for Ovarian Cancer (OvaRex®),"A Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of Intravenous OvaRex® MAb-B43.13 as Post Chemotherapy Consolidation for Epithelial Carcinoma of Ovarian, Tubal or Peritoneal Origin",TERMINATED,2002-12,2007-12,2007-12-18,INTERVENTIONAL,PHASE3,354.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Ovarian Cancer,oregovomab,DRUG,0,0,18 Years,,FEMALE,False,Unither Pharmaceuticals,INDUSTRY,0,62,United States,0.0,0,0,1,0,0,3.0,1,0,0,0,1,5.872117789475416,large,0,0,1,0,0,0,1,0,1,0,1,1,1,1,0,0,1,0,0,1,0,,,,,0,0,0
NCT03379675,"A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus","A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Subjects Infected With Respiratory Syncytial Virus",COMPLETED,2018-02-06,2019-12-26,2025-02-04,INTERVENTIONAL,PHASE2,72.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Respiratory Syncytial Virus Infections,JNJ-53718678 500 mg|JNJ-53718678 80 mg|Placebo,DRUG,21,19,18 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,124,Canada|South Africa|Argentina|Russia|Australia|Bulgaria|Spain|Belgium|Ukraine|United States|Sweden|France|Germany|Poland|South Korea|Brazil|Taiwan|Mexico|Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.290459441148391,medium,1,1,1,0,0,0,1,1,1,1,1,1,1,1,40,1,1,0,0,3,1,2018-02-06,2019-12-26,688.0,2018.0,1,3,1
NCT02049957,Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer,A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant,COMPLETED,2014-02-13,2018-06-29,2023-02-08,INTERVENTIONAL,PHASE2,118.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,Sapanisertib|Fulvestrant|Exemestane,DRUG,2,10,18 Years,,FEMALE,False,"Calithera Biosciences, Inc",INDUSTRY,0,40,France|Belgium|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.77912349311153,medium,0,1,1,0,0,0,1,1,1,1,0,0,1,1,12,1,1,0,0,3,1,2014-02-13,2018-06-29,1597.0,2014.0,0,3,1
NCT03403712,A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer,"A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Phase 3b Study to Assess the Safety and to Describe the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination (IV NEPA FDC) Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination (Akynzeo®) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Initial and Repeated Cycles of Anthracycline-cyclophosphamide (AC) Chemotherapy in Women With Breast Cancer",COMPLETED,2018-03-16,2018-09-19,2020-06-01,INTERVENTIONAL,PHASE3,404.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Chemotherapy-induced Nausea and Vomiting,fosnetupitant/ palonosetron|netupitant/palonosetron|dexamethasone,DRUG,4,4,18 Years,,FEMALE,False,Helsinn Healthcare SA,INDUSTRY,2,40,Georgia|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.003887067106539,large,0,1,1,0,0,1,1,1,1,0,1,1,0,1,8,1,1,0,0,3,1,2018-03-16,2018-09-19,187.0,2018.0,1,3,1
NCT02688712,ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer,Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma,ACTIVE_NOT_RECRUITING,2016-03-24,2025-12,2025-03-10,INTERVENTIONAL,PHASE2,50.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Rectal Adenocarcinoma,LY2157299|Capecitabine|Fluorouracil|Tumor specific mesorectal excision,DRUG|PROCEDURE,1,3,18 Years,,ALL,False,Providence Health & Services,OTHER,1,1,United States,,0,1,0,0,0,2.0,1,0,0,0,1,3.9318256327243257,small,1,0,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,0,0,4,1,2016-03-24,,,2016.0,1,1,0
NCT04856865,ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults,"A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Harmony Study)",COMPLETED,2021-04-20,2022-12-13,2024-05-16,INTERVENTIONAL,PHASE1|PHASE2,73.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Food Allergy,Low dose ADP101|High dose ADP101|Pooled Placebo,BIOLOGICAL,1,3,4 Years,55 Years,ALL,False,"Alladapt Immunotherapeutics, Inc.",INDUSTRY,0,15,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.30406509320417,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,1,4,1,0,1,0,3,1,2021-04-20,2022-12-13,602.0,2021.0,1,2,0
NCT02694328,A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study),A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults With Schizophrenia,COMPLETED,2016-03-02,2018-11-07,2020-02-10,INTERVENTIONAL,PHASE3,561.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia,ALKS 3831|Olanzapine,DRUG,2,2,18 Years,55 Years,ALL,False,"Alkermes, Inc.",INDUSTRY,0,54,Puerto Rico|United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,6.331501849893691,xlarge,0,1,1,0,0,0,1,1,1,0,1,1,1,1,4,1,1,0,0,2,1,2016-03-02,2018-11-07,980.0,2016.0,1,2,0
NCT00038428,Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer,,COMPLETED,2001-06,2005-07,2011-07-25,INTERVENTIONAL,PHASE2,40.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Ovarian Neoplasms,TLK286,DRUG,0,0,18 Years,,FEMALE,False,Telik,INDUSTRY,0,3,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.713572066704308,small,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT02316028,Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC),A Phase I Clinical Trial on Decitabine (5-aza-2'-Deoxycytidine) Administered by Hepatic Arterial Infusion in Patients With Unresectable Liver-predominant Metastases From Colorectal Cancer,COMPLETED,2014-03,2017-07,2017-10-27,INTERVENTIONAL,PHASE1|PHASE2,11.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Liver Metastasis|Colorectal Cancer,Decitabine,DRUG,1,5,18 Years,,ALL,False,Universitair Ziekenhuis Brussel,OTHER,1,2,Belgium,1.0,1,1,0,0,1,1.5,1,0,0,0,2,2.4849066497880004,small,1,1,0,1,0,1,1,0,0,0,0,0,1,0,6,1,1,0,0,1,0,,,,,0,3,1
NCT00985465,Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali,"Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine GSK1024850A, Given Either as a Booster Dose or as a 2-dose Catch-up Immunization in Healthy Malian Children",COMPLETED,2009-11-12,2010-07-26,2018-12-14,INTERVENTIONAL,PHASE3,218.0,ACTUAL,NON_RANDOMIZED,PARALLEL,PREVENTION,NONE,"Infections, Streptococcal",Pneumococcal vaccine GSK1024850A,BIOLOGICAL,1,11,15 Months,21 Months,ALL,True,GlaxoSmithKline,INDUSTRY,0,1,Mali,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.389071729816501,large,0,1,1,0,0,0,0,0,0,0,0,0,0,1,12,1,0,1,0,1,0,2009-11-12,2010-07-26,256.0,2009.0,0,1,0
NCT04479267,Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma,"A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Double and Triple Hit Lymphoma, Double Expressor Lymphoma and High-Grade B Cell Lymphoma",ACTIVE_NOT_RECRUITING,2020-08-21,2026-07-19,2025-09-29,INTERVENTIONAL,PHASE2,8.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements|Double Expressor Lymphoma|High-grade B-cell Lymphoma",Prednisone|Prednisolone|Methylprednisolone|Rituximab|Polatuzumab Vedotin|Cyclophosphamide|Doxorubicin Hydrochloride,DRUG|BIOLOGICAL,1,4,18 Years,,ALL,False,Barbara Ann Karmanos Cancer Institute,OTHER,1,1,United States,,0,1,0,0,0,2.0,1,0,0,0,5,2.1972245773362196,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,5,1,1,1,0,7,1,2020-08-21,2026-07-19,2158.0,2020.0,1,2,0
NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery,Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754),ACTIVE_NOT_RECRUITING,2014-07-11,2025-12-23,2025-12-01,INTERVENTIONAL,PHASE2|PHASE3,140.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Alveolar Soft Part Sarcoma|Angiomatoid Fibrous Histiocytoma|Atypical Fibroxanthoma|Clear Cell Sarcoma of Soft Tissue|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Epithelioid Sarcoma|Extraskeletal Myxoid Chondrosarcoma|Extraskeletal Osteosarcoma|Fibrohistiocytic Neoplasm|Fibrosarcoma|Inflammatory Myofibroblastic Tumor|Intimal Sarcoma|Leiomyosarcoma|Liposarcoma|Liver Embryonal Sarcoma|Low Grade Fibromyxoid Sarcoma|Low Grade Myofibroblastic Sarcoma|Malignant Peripheral Nerve Sheath Tumor|Malignant Skin Granular Cell Tumor|Malignant Triton Tumor|Mesenchymal Chondrosarcoma|Myxofibrosarcoma|Myxoid Chondrosarcoma|Myxoinflammatory Fibroblastic Sarcoma|Nerve Sheath Neoplasm|PEComa|Pericytic Neoplasm|Plexiform Fibrohistiocytic Tumor|Sclerosing Epithelioid Fibrosarcoma|Skin Glomus Tumor|Stage IB Soft Tissue Sarcoma AJCC v7|Stage IIB Soft Tissue Sarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Synovial Sarcoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone,Doxorubicin|Doxorubicin Hydrochloride|Ifosfamide|Pazopanib|Pazopanib Hydrochloride|Radiation Therapy|Therapeutic Conventional Surgery,DRUG|PROCEDURE|RADIATION,5,4,2 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,381,Puerto Rico|Canada|United States,,0,1,1,0,1,2.5,1,1,0,0,36,4.948759890378168,medium,0,1,0,1,0,0,1,1,1,0,1,0,1,1,9,1,1,0,0,7,1,2014-07-11,2025-12-23,4183.0,2014.0,0,5,1
NCT01206907,"Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects","AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER EFFECTIVENESS, SAFETY AND TOLERABILITY STUDY OF OXYMORPHONE HCl IMMEDIATE-RELEASE ORAL LIQUID IN OPIOID-TOLERANT PEDIATRIC SUBJECTS WITH CHRONIC PAIN REQUIRING AN AROUND THE CLOCK OPIOID",WITHDRAWN,2010-10,2013-12,2012-08-17,INTERVENTIONAL,PHASE3,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Pain,oxymorphone IR,DRUG,2,2,2 Years,6 Years,ALL,False,Endo Pharmaceuticals,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT00211107,A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation.,"A Placebo-Controlled, Double-Blind, Randomized, Parallel Study Of The Efficacy And Safety Of Dapoxetine HCl In The Treatment Of Rapid Ejaculation",COMPLETED,2003-06,2004-06,2011-05-19,INTERVENTIONAL,PHASE3,1294.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Ejaculation,Dapoxetine,DRUG,1,1,18 Years,,MALE,False,"Alza Corporation, DE, USA",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.166265974133638,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT00677807,"Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)","A 26-week Extension to a 26-week Treatment, Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess Safety, Tolerability and Efficacy of Two Doses of Indacaterol (150 and 300 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease",COMPLETED,2008-05,2009-03,2011-08-22,INTERVENTIONAL,PHASE3,415.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,COPD,Indacaterol|Placebo,DRUG,6,2,40 Years,,ALL,False,Novartis,INDUSTRY,0,190,Argentina|Turkey (Türkiye)|United States|Sweden|Canada|Spain|Germany|Italy|India,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.030685260261263,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,8,1,1,0,0,2,1,,,,,0,3,1
NCT04140292,Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses,Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses,COMPLETED,2020-01-13,2021-05-27,2022-06-24,INTERVENTIONAL,PHASE2,75.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Actinic Keratosis,Photodynamic therapy (PDT)|Vitamin D3,DRUG,1,4,18 Years,,ALL,False,Case Comprehensive Cancer Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.330733340286331,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,5,1,1,0,0,2,1,2020-01-13,2021-05-27,500.0,2020.0,1,1,0
NCT03938792,Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B,An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis,COMPLETED,2020-03-09,2025-04-29,2025-06-10,INTERVENTIONAL,PHASE3,189.0,ACTUAL,,CROSSOVER,TREATMENT,NONE,Hemophilia A|Hemophilia B,PF-06741086,DRUG,12,11,12 Years,74 Years,MALE,False,Pfizer,INDUSTRY,0,62,Oman|Canada|South Africa|China|Saudi Arabia|Hong Kong|Russia|Bulgaria|Spain|Italy|United States|France|South Korea|India|Croatia|Turkey (Türkiye)|Taiwan|Mexico|Japan|Serbia,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.247024072160486,medium,0,1,1,0,1,0,1,1,1,1,0,0,1,0,23,1,1,0,0,1,0,2020-03-09,2025-04-29,1877.0,2020.0,1,3,1
NCT00401011,Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients,An Open-Label Phase I/II Study of the Safety and Efficacy of Perifosine and Bortezomib With or Without Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Bortezomib,COMPLETED,2006-08,2011-07,2018-02-23,INTERVENTIONAL,PHASE1|PHASE2,84.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Multiple Myeloma|Multiple Myeloma in Relapse,Perifosine|Bortezomib|Dexamethasone,DRUG,1,2,18 Years,,ALL,False,AEterna Zentaris,INDUSTRY,0,0,,1.0,1,1,0,0,1,1.5,1,0,0,0,2,4.442651256490317,medium,1,1,1,0,0,0,0,0,0,0,0,0,1,0,3,1,1,0,0,3,1,,,,,0,3,1
NCT02188771,"A Phase I, Prospective, Randomized, Open-label, Active-Controlled Clinical Trial for Safety Evaluation of Intra-articular Injection of RegenoGel-SP for the Treatment of Moderate to Severe Osteoarthritis",,COMPLETED,2014-02,2015-10,2017-04-27,INTERVENTIONAL,PHASE1|PHASE2,11.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Osteoarthritis,intra-articular administration of RegenoGel-SP or hyaluronic acid (HA),DEVICE,1,1,45 Years,75 Years,ALL,False,ProCore Ltd.,INDUSTRY,0,1,Israel,1.0,1,1,0,0,1,1.5,0,1,0,0,1,2.4849066497880004,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,2,1,0,0,1,1,0,,,,,0,1,0
NCT02169271,Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules,A Randomized Phase II Trial of Low Dose Aspirin Versus Placebo in High-Risk Individuals With CT-Detected Subsolid Lung Nodules,COMPLETED,2014-11-21,2020-02-14,2020-05-21,INTERVENTIONAL,PHASE2,109.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Current Smoker|Former Smoker|Multiple Pulmonary Nodules|Tobacco Use Disorder,Aspirin|Laboratory Biomarker Analysis|Placebo,DRUG|OTHER,1,8,50 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,2,Italy|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,4,4.700480365792417,medium,0,1,0,1,0,0,1,1,1,1,1,1,0,1,9,1,1,0,0,3,1,2014-11-21,2020-02-14,1911.0,2014.0,0,4,1
NCT02101034,PD 0332991 and Cetuximab in Patients With Incurable SCCHN,Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN,COMPLETED,2014-06-17,2023-11-10,2023-12-21,INTERVENTIONAL,PHASE1|PHASE2,96.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,"Carcinoma, Squamous Cell of Head and Neck",Cetuximab|PD 0332991,DRUG|BIOLOGICAL,2,7,18 Years,,ALL,False,Washington University School of Medicine,OTHER,1,5,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.574710978503383,medium,1,1,0,1,0,1,1,0,1,0,0,0,1,0,9,1,1,1,0,2,1,2014-06-17,2023-11-10,3433.0,2014.0,0,3,1
NCT01328444,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A,An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A,COMPLETED,2011-03-01,2012-06-14,2017-10-11,INTERVENTIONAL,PHASE3,349.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Pulmonary Disease, Chronic Obstructive",GSK 573719 +GW642444 125/25|GSK573719 + GW642444 62.5/25|GSK 573719 125|GSK 573719 62.5|GW642444 25|Plb,DRUG,2,4,40 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,31,United Kingdom|Estonia|Russia|Bulgaria|United States|Germany,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.857933154483459,large,0,1,1,0,0,0,1,1,1,1,1,1,1,0,6,1,1,0,0,6,1,2011-03-01,2012-06-14,471.0,2011.0,0,3,1
NCT01648634,Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy,"A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Examine the Effect of Nebivolol, a Beta-Blockade Drug, for the Prevention of Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy",COMPLETED,2012-02-13,2021-07-20,2025-11-20,INTERVENTIONAL,PHASE3,51.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Duchenne Muscular Dystrophy|Cardiomyopathy|Heart Failure,Nebivolol|Placebo,DRUG,1,5,10 Years,15 Years,MALE,False,Assistance Publique - Hôpitaux de Paris,OTHER,2,1,France,1.0,0,0,1,0,0,3.0,0,0,0,1,3,3.9512437185814275,medium,1,1,0,1,0,1,0,0,0,1,1,1,0,1,6,1,1,0,0,2,1,2012-02-13,2021-07-20,3445.0,2012.0,0,3,1
NCT04770064,Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE),Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE),WITHDRAWN,2023-06,2024-05-31,2022-07-29,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Osteoarthritis, Knee",High-dose/short-duration Fisetin|Low-dose/sustained-duration Fisetin|Oral placebo capsule,DRUG|OTHER,3,5,35 Years,80 Years,ALL,False,Austin V Stone,OTHER,1,2,United States,0.0,1,1,0,0,1,1.5,0,1,0,0,1,0.0,,1,1,0,1,0,1,1,0,1,0,1,1,1,1,8,1,1,0,0,3,1,,2024-05-31,,,0,3,1
NCT02534909,"Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria","An Open-label Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316, an Anti-C5 Monoclonal Antibody in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)",COMPLETED,2015-09-09,2022-05-24,2025-05-16,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Paroxysmal Nocturnal Hemoglobinuria,LFG316|LNP023,DRUG|BIOLOGICAL,2,4,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,7,Japan|Czechia|Lithuania,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,1,0,1,0,1,1,0,0,0,0,1,0,6,1,1,1,0,2,1,2015-09-09,2022-05-24,2449.0,2015.0,1,3,1
NCT03961009,"Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients","A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients",COMPLETED,2019-04-30,2020-12-21,2025-04-13,INTERVENTIONAL,PHASE3,47.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Primary Immunodeficiency Disease,Kedrion IVIG 10%,BIOLOGICAL,1,78,2 Years,70 Years,ALL,False,Kedrion S.p.A.,INDUSTRY,0,11,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.871201010907891,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,79,1,0,1,0,1,0,2019-04-30,2020-12-21,601.0,2019.0,1,1,0
NCT04052932,A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout,"A Phase3, Multicentre, Randomized, Double-Blind, Allopurinol and Placebo-Controlled Study to Evaluate the Efficacy and Safety of SHR4640 Monotherapy in Subjects With Gout",COMPLETED,2019-07-16,2021-07-14,2022-06-13,INTERVENTIONAL,PHASE3,594.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Gout,SHR4640 dose1|SHR4640 dose2|Placebo oral tablet|Allopurinol 300 MG,DRUG,1,4,18 Years,75 Years,ALL,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.38856140554563,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,4,1,2019-07-16,2021-07-14,729.0,2019.0,1,1,0
NCT00407563,Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer,"A Phase 2 Study of Bevacizumab With Abraxane in Patients With Recurrent, Platinum-Resistant Primary Epithelial Ovarian or Primary Peritoneal Carcinoma",COMPLETED,2007-01,2011-02,2012-04-05,INTERVENTIONAL,PHASE2,48.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Epithelial Ovarian Cancer|Primary Peritoneal Carcinoma,Bevacizumab|Abraxane,DRUG,1,4,18 Years,,FEMALE,False,Accelerated Community Oncology Research Network,OTHER,2,11,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.8918202981106265,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,5,1,1,0,0,2,1,,,,,0,2,0
NCT02820987,"PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock","Pharmacokinetics and Pharmacodynamic (PK/PD) of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock",COMPLETED,2016-09-27,2018-10-04,2025-01-16,INTERVENTIONAL,PHASE3,119.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Septic Shock,MEROPENEM|PIPERACILLIN-TAZOBACTAM|CEFEPIME,DRUG,1,1,18 Years,,ALL,False,Centre Hospitalier Universitaire de Besancon,OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.787491742782046,medium,0,1,0,1,0,0,0,0,0,1,0,0,1,1,2,1,1,0,0,3,1,2016-09-27,2018-10-04,737.0,2016.0,1,1,0
NCT02163187,Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation,Randomized Crossover Study of the Efficacy of Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation,TERMINATED,2014-06-10,2016-12-19,2018-02-05,INTERVENTIONAL,PHASE2|PHASE3,4.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Rectal Cancer|for Bowel Dysfunction Following Surgery for Rectal Cancers,Implantation of the InterStimTM|MSK BFI questionnaires|The Low Anterior Resection Score (LARS) questionnaires|The EuroQOL5D questionnaires|The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires,BEHAVIORAL|DEVICE,1,1,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,2,United States,0.0,0,1,1,0,1,2.5,1,0,0,0,2,1.6094379124341003,small,1,1,0,1,0,1,1,0,1,0,1,0,1,0,2,1,0,0,1,5,1,2014-06-10,2016-12-19,923.0,2014.0,0,3,1
NCT01576887,"A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis",,WITHDRAWN,2012-07-31,2012-10-31,2025-05-29,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,End-Stage Renal Disease|Type 2 Diabetes Mellitus,Bardoxolone Methyl 20 mg|Placebo,DRUG,1,6,18 Years,,ALL,False,Biogen,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,2,0.0,,1,1,1,0,1,0,0,0,0,0,1,1,1,1,7,1,1,0,0,2,1,2012-07-31,2012-10-31,92.0,2012.0,0,3,1
NCT06999993,Efficacy and Safety of Sodium Hyaluronate Gel Combined With Sodium Bicarbonate Versus Sodium Bicarbonate Alone in Prevention of Failed Back Surgery Syndrome,Efficacy and Safety of Sodium Hyaluronate Gel Combined With Sodium Bicarbonate Versus Sodium Bicarbonate Alone in Prevention of Failed Back Surgery Syndrome (FBSS),ACTIVE_NOT_RECRUITING,2025-06-20,2026-05-31,2025-07-29,INTERVENTIONAL,PHASE2|PHASE3,60.0,ESTIMATED,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Postdiscectomy Epidural Fibrosis|Pain,Sodium hyaluronate jell|Sodium Bicarbonate|Saline,DRUG,1,3,18 Years,70 Years,ALL,False,Misr University for Science and Technology,OTHER,0,1,Egypt,,0,1,1,0,1,2.5,0,0,0,0,2,4.110873864173311,medium,1,0,0,1,0,0,0,0,0,0,1,1,0,1,4,1,1,0,0,3,1,2025-06-20,2026-05-31,345.0,2025.0,1,3,1
NCT00002593,S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed,Phase III Randomized Trial of 5-FU/Leucovorin/Levamisole Versus 5-FU Continuous Infusion/Levamisole as Adjuvant Therapy for High-Risk Resectable Colon Cancer,COMPLETED,1994-12,2005-03,2013-01-03,INTERVENTIONAL,PHASE3,1135.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Cancer,fluorouracil|leucovorin calcium|levamisole hydrochloride,DRUG,1,1,18 Years,,ALL,False,SWOG Cancer Research Network,NETWORK,4,60,Puerto Rico|Canada|South Africa|United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,7.035268599281097,xlarge,0,1,0,0,0,1,1,1,1,0,1,0,1,1,2,1,1,0,0,3,1,,,,,0,2,0
NCT01536314,Prophylaxis of Neuropathic Pain by mémantine,Preventing the Development of Neuropathic Pain Post-mastectomy/Tumorectomy by Pre-emptive or Post-operative Memantine Administration,COMPLETED,2012-02,2013-11,2014-07-01,INTERVENTIONAL,PHASE3,43.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Neuropathic Pain,Memantine EBIXA®|Placebo : lactose,DRUG,1,3,18 Years,,FEMALE,False,"University Hospital, Clermont-Ferrand",OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.784189633918261,small,1,1,0,1,0,0,0,0,0,1,0,0,0,0,4,1,1,0,0,2,1,,,,,0,1,0
NCT00003914,Dolastatin 10 in Treating Patients With Advanced Kidney Cancer,Phase II Study of Dolastatin-10 in Patients With Advanced Renal Cell Carcinoma,COMPLETED,1999-08,2009-05,2011-05-11,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,,,TREATMENT,,Kidney Cancer,dolastatin 10,DRUG,0,0,18 Years,,ALL,False,Mayo Clinic,OTHER,1,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4339872044851463,small,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT00420914,Strategies for Transfusion of Platelets (SToP),"Strategies for Transfusion of Platelets (SToP) [Formerly Titled ""Evaluation of the Hemostatic Efficacy and Platelet Utilization Rates of Low Versus Standard Dose Platelet Therapy""]",TERMINATED,2003-10,,2008-05-28,INTERVENTIONAL,PHASE3,130.0,ACTUAL,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,DOUBLE,Thrombocytopenia,low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9),PROCEDURE,1,19,17 Years,,ALL,False,Hamilton Health Sciences Corporation,OTHER,5,6,Canada|Norway|United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,4.875197323201151,medium,0,1,0,1,0,1,1,1,1,0,1,1,0,1,20,1,0,0,0,1,0,,,,,0,2,0
NCT01332916,Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging,Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging,TERMINATED,2010-12,2014-04,2014-04-25,INTERVENTIONAL,PHASE2,60.0,ESTIMATED,NON_RANDOMIZED,PARALLEL,,NONE,Breast Cancer|Healthy,cognitive tests and cerebral IRM|cognitive tests and cerebral IRM,PROCEDURE,1,1,45 Years,,FEMALE,True,Centre Francois Baclesse,OTHER,0,2,France,0.0,0,1,0,0,0,2.0,1,0,0,0,2,4.110873864173311,medium,1,0,0,1,0,0,1,0,0,1,0,0,0,1,2,1,0,0,0,2,1,,,,,0,2,0
NCT02164916,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,Randomized Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,COMPLETED,2014-11,2020-11-19,2020-12-30,INTERVENTIONAL,PHASE2,106.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Colorectal Cancer,cetuximab|irinotecan hydrochloride|vemurafenib,DRUG|BIOLOGICAL,1,1,18 Years,,ALL,False,SWOG Cancer Research Network,NETWORK,2,763,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.672828834461906,medium,0,1,0,0,0,1,1,0,1,0,1,0,1,0,2,1,1,1,0,3,1,,2020-11-19,,,0,1,0
NCT01970306,Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material,A Prospective Phase II Trial to Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material,COMPLETED,2013-10-18,2023-02-24,2023-11-03,INTERVENTIONAL,PHASE2,78.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Esophageal Adenocarcinoma,MatriStem PSM,DEVICE,1,2,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,4,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.3694478524670215,medium,1,1,0,1,0,1,1,0,1,0,0,0,1,0,3,1,0,0,1,1,0,2013-10-18,2023-02-24,3416.0,2013.0,0,0,0
NCT01240304,A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas,A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemotherapy With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas,TERMINATED,2010-11,2019-10,2019-12-10,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pancreatic Cancer,Gemcitabine|Radiation therapy|pancreaticoduodenectomy,DRUG|PROCEDURE|RADIATION,1,0,18 Years,,ALL,False,University of Arkansas,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,3,1,,,,,0,1,0
NCT02412852,A Phase 2a Study to Assess Safety & Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain,"A Randomized, Double-blinded, Phase 2a Study to Assess the Safety and Pharmacokinetics of a Sustained Release Formulation of Sodium Nitrite (TV1001sr) in Patients With Diabetic Neuropathic Pain (DNP)",COMPLETED,2015-04-28,2017-04-03,2020-04-24,INTERVENTIONAL,PHASE2,26.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetes,Sodium nitrite|Placebo,DRUG,1,6,18 Years,,ALL,False,TheraVasc Inc.,INDUSTRY,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.295836866004329,small,1,1,1,0,0,1,0,0,1,0,1,1,1,1,7,1,1,0,0,2,1,2015-04-28,2017-04-03,706.0,2015.0,1,2,0
NCT00782652,The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients,The Effects of Nitric Oxide for Inhalation on Survival or the Need for Dialysis or a Right Ventricular Assistance Device (RVAD) in Right Ventricular Infarction Patients,TERMINATED,2006-03,2007-02,2016-09-09,INTERVENTIONAL,PHASE2,3.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Right Ventricular Infarction,inhaled nitric oxide|nitrogen gas,DRUG,1,12,18 Years,,ALL,False,Mallinckrodt,INDUSTRY,0,6,United States|Canada|Spain|Poland|Belgium,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.3862943611198906,small,1,1,1,0,0,0,1,1,1,1,1,1,1,1,13,1,1,0,0,2,1,,,,,0,3,1
NCT00988247,Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 mcg in Allergic Rhinitis,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Long-term Efficacy and Safety of BDP HFA Nasal Aerosol (320 mcg, Once Daily) in Adult and Adolescent Subjects (12 Years of Age and Older) With Perennial Allergic Rhinitis (PAR)",COMPLETED,2009-10-31,2011-02-28,2021-12-03,INTERVENTIONAL,PHASE3,529.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Rhinitis, Allergic, Perennial",Beclomethasone dipropionate|Placebo Nasal Aerosol,DRUG,1,5,12 Years,,ALL,False,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,0,34,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.272877006546167,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,1,1,6,1,1,0,0,2,1,2009-10-31,2011-02-28,485.0,2009.0,0,2,0
NCT03039049,GNRH Agonist Trigger and Modified Luteal Phase Adding a Bolus of GnRHa at the Time of Implantation: a RCT,"GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Mid-luteal Bolus of GnRHa: a Randomised Controlled Trial.",COMPLETED,2014-03,2017-03,2017-07-07,INTERVENTIONAL,PHASE3,328.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Infertility,Triptorelin 0.1 mg,DRUG,1,4,18 Years,40 Years,FEMALE,False,Centre Hospitalier Universitaire Ibn Rochd,OTHER,0,2,Algeria,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.796057750765372,large,0,1,0,1,0,0,1,0,0,0,1,1,1,1,5,1,1,0,0,1,0,,,,,0,0,0
NCT00933049,Cotrimoxazole Versus Amoxicillin in the Treatment of Community Acquired Pneumonia in Children Aged 2-59 Months,Clinical Efficacy of Cotrimoxazole Versus Amoxicillin in the Treatment of Community Acquired Pneumonia in Children Aged 2-59 Months Attending Mulago Hospital: A Randomized Clinical Trial.,COMPLETED,2007-07,2008-01,2009-07-07,INTERVENTIONAL,PHASE3,505.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Childhood Pneumonia,Amoxicillin|Cotrimoxazole|Amoxicillin placebo|Cotrimoxazole placebo,DRUG,1,1,2 Months,59 Months,ALL,False,Makerere University,OTHER,0,1,Uganda,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.226536669287466,xlarge,0,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,4,1,,,,,0,1,0
NCT01594749,Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031),"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy",COMPLETED,2012-09-24,2014-11-03,2018-09-04,INTERVENTIONAL,PHASE3,1015.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Chemotherapy-Induced Nausea and Vomiting (CINV),Fosaprepitant dimeglumine|Fosaprepitant Placebo|Dexamethasone|Ondansetron|Dexamethasone Placebo|Ondansetron Placebo|Rescue Therapy,DRUG,3,3,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.923628628138427,xlarge,0,1,1,0,1,0,0,0,0,0,1,1,0,1,6,1,1,0,0,7,1,2012-09-24,2014-11-03,770.0,2012.0,0,2,0
NCT05087849,Intralesional HPV Vaccine for Condylomata,Therapeutic Intralesional Nonavalent HPV Vaccine for Genital Condylomata in Adults: an Open Label Pilot Study,COMPLETED,2022-04-15,2024-07-01,2025-10-02,INTERVENTIONAL,PHASE1|PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Human Papilloma Virus|Warts|Warts, Genital|Condyloma|Condylomata Acuminata",nonavalent human papillomavirus vaccine,BIOLOGICAL,2,2,18 Years,,ALL,False,"University of California, San Francisco",OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,5,1.0986122886681098,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,4,1,0,1,0,1,0,2022-04-15,2024-07-01,808.0,2022.0,1,2,0
NCT05991349,"A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","A Phase 1/2 Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors",COMPLETED,2024-03-12,2025-05-31,2025-11-25,INTERVENTIONAL,PHASE1|PHASE2,180.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Solid Tumor,IBI129,DRUG,4,13,18 Years,,ALL,False,Innovent Biologics (Suzhou) Co. Ltd.,INDUSTRY,0,7,Australia|China,1.0,1,1,0,0,1,1.5,1,0,0,0,1,5.198497031265826,medium,0,1,1,0,0,0,1,1,0,0,0,0,1,0,17,1,1,0,0,1,0,2024-03-12,2025-05-31,445.0,2024.0,1,3,1
NCT00003911,S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases,A Phase II Pilot Study of Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases,TERMINATED,1999-07,2007-08,2013-01-31,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Melanoma (Skin)|Metastatic Cancer,stereotactic radiosurgery,RADIATION,0,0,,,ALL,False,SWOG Cancer Research Network,NETWORK,1,86,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,2,1.0986122886681098,small,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,,,,,0,1,0
NCT01217671,"International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema","A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema",COMPLETED,2009-12,2015-06,2019-11-29,INTERVENTIONAL,PHASE2|PHASE3,168.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Emphysema,Kamada AAT for inhalation|Placebo,OTHER|BIOLOGICAL,1,6,18 Years,,ALL,False,"Kamada, Ltd.",INDUSTRY,0,12,United Kingdom|Denmark|Sweden|Canada|Ireland|Germany|Netherlands,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.1298987149230735,medium,0,1,1,0,0,0,1,1,0,1,1,1,1,1,7,1,0,1,0,2,1,,,,,0,4,1
NCT03613571,"A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis","A Single-centre, Open Single-arm Study Where the Safety, Tolerability and Efficacy of Subcutaneously Administered ILB Will be Evaluated in Patients With Amyotrophic Lateral Sclerosis",TERMINATED,2018-08-15,2019-08-20,2023-06-12,INTERVENTIONAL,PHASE2,13.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Amyotrophic Lateral Sclerosis,ILB,DRUG,17,9,18 Years,80 Years,ALL,False,TikoMed AB,INDUSTRY,0,1,Sweden,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.6390573296152584,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,26,1,1,0,0,1,0,2018-08-15,2019-08-20,370.0,2018.0,1,1,0
NCT00366171,Open Label Extension Study of Bifeprunox,An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients With Schizophrenia.,COMPLETED,2006-11,2007-10,2007-12-27,INTERVENTIONAL,PHASE3,120.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Schizophrenia,Bifeprunox,DRUG,1,1,18 Years,66 Years,ALL,False,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,83,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,4.795790545596741,medium,0,0,1,0,1,0,1,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT03503344,Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer,"A Randomized, Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on PSMA-PET Imaging",COMPLETED,2019-12-17,2025-10-31,2026-01-21,INTERVENTIONAL,PHASE2,26.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|PSA Progression|Stage IV Prostate Adenocarcinoma AJCC v7,Apalutamide|Stereotactic Body Radiation Therapy,DRUG|RADIATION,1,2,18 Years,,MALE,False,"University of California, San Francisco",OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,3.295836866004329,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,3,1,1,0,0,2,1,2019-12-17,2025-10-31,2145.0,2019.0,1,2,0
NCT00960544,Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism,Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism Using a Limited Pharmacokinetic Sampling Plan,WITHDRAWN,2019-01,2021-01,2019-06-14,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,Capecitabine,DRUG,1,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT00317044,Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma,"A 6-month Randomized, Double-blind, Parallel-group, Multicentre, Placebo-controlled Phase II Study to Compare Anti-asthmatic Effect and Safety of Esomeprazole (Nexium®) 40 mg Twice Daily or 40 mg Once Daily With Placebo in Adults With Asthma",COMPLETED,2006-04,2008-07,2014-06-09,INTERVENTIONAL,PHASE2,961.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Asthma|GERD,Esomeprazole|Esomeprazole|Placebo,DRUG,1,12,18 Years,70 Years,ALL,False,AstraZeneca,INDUSTRY,0,130,Argentina|Mexico|Bulgaria|United States|Canada|Hungary|Slovakia|Portugal|France|Czechia|Switzerland|Germany|Poland|Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,2,6.8690144506657065,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,13,1,1,0,0,3,1,,,,,0,4,1
NCT03169244,Buproprion for Binge Drinking,Efficacy and Safety of the Melanocortin Activator Bupropion in Treating Binge Drinking,COMPLETED,2017-09-04,2019-09-17,2020-08-26,INTERVENTIONAL,PHASE2,42.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alcohol Abuse,Bupropion|Placebo Oral Tablet,DRUG,2,1,21 Years,44 Years,ALL,False,"University of North Carolina, Chapel Hill",OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.7612001156935624,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,3,1,1,0,0,2,1,2017-09-04,2019-09-17,743.0,2017.0,1,1,0
NCT00368264,TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ),"A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNF-alpha Chimeric Monoclonal Antibody (Infliximab) and Azathioprine in Patients Suffering From Systemic Lupus Erythematosus (SLE) With WHO Class V Glomerulonephritis",TERMINATED,2006-09,2009-06,2009-10-05,INTERVENTIONAL,PHASE2|PHASE3,1.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Lupus Erythematosus, Systemic|Lupus Nephritis",infliximab|placebo,DRUG,1,8,18 Years,,ALL,False,Medical University of Vienna,OTHER,8,9,Germany|Netherlands|Austria,0.0,0,1,1,0,1,2.5,0,1,0,0,2,0.6931471805599453,small,1,1,0,1,0,1,1,1,0,1,1,1,1,1,9,1,1,0,0,2,1,,,,,0,5,1
NCT00018564,Novel Therapies for Essential Tremor,Novel Therapies for Essential Tremor,COMPLETED,2000-10,2003-09,2009-01-21,INTERVENTIONAL,PHASE3,,,RANDOMIZED,,TREATMENT,DOUBLE,Essential Tremor,treatments for essential tremor,DRUG,0,0,18 Years,,ALL,False,US Department of Veterans Affairs,FED,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT00023764,Bortezomib in Treating Patients With Lymphoproliferative Disorders,Phase II Study of PS-341 in Low Grade Lymphoproliferative Disorders,COMPLETED,2001-06,2009-03,2015-12-08,INTERVENTIONAL,PHASE2,103.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma,bortezomib,DRUG,1,0,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,4.6443908991413725,medium,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,1,0
NCT01829464,TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes",TERMINATED,2013-05,2014-03,2016-06-01,INTERVENTIONAL,PHASE3,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetes,Placebo|TAK-875|TAK-875,DRUG,1,2,18 Years,,ALL,False,Takeda,INDUSTRY,0,86,Argentina|Peru|United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,4.51085950651685,medium,1,1,1,0,1,0,1,1,1,0,1,1,1,1,3,1,1,0,0,3,1,,,,,0,2,0
NCT01426698,18 Month Follow Up of Preterm Infants Enrolled in the Cord Clamping Study,18 Month Follow Up of Preterm Infants Enrolled in the Cord Clamping Study,COMPLETED,2011-08,2014-12,2014-12-05,INTERVENTIONAL,PHASE2,208.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,SINGLE,Developmental Delay,delayed cord clamping,PROCEDURE,1,1,24 Weeks,31 Weeks,ALL,False,University of Rhode Island,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.342334251964811,large,0,1,0,1,0,1,0,0,1,0,1,0,0,1,2,1,0,0,0,1,0,,,,,0,0,0
NCT05383898,Study to Evaluate D-1553 in Subjects With Lung Cancer,"A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors",COMPLETED,2021-03-16,2024-05-17,2024-10-15,INTERVENTIONAL,PHASE1|PHASE2,225.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,NSCLC,D-1553,DRUG,3,1,18 Years,,ALL,False,"InventisBio Co., Ltd",INDUSTRY,0,2,China,1.0,1,1,0,0,1,1.5,0,0,0,0,1,5.420534999272286,large,0,1,1,0,0,0,1,0,0,0,0,0,1,0,4,1,1,0,0,1,0,2021-03-16,2024-05-17,1158.0,2021.0,1,1,0
NCT03701763,Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis,"A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN PEDIATRIC SUBJECTS FROM 6 THROUGH 17 YEARS WITH MODERATE TO SEVERE PLAQUE PSORIASIS",COMPLETED,2018-12-19,2023-03-27,2024-12-16,INTERVENTIONAL,PHASE3,245.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Psoriasis,Apremilast (CC-10004)|Placebo,DRUG|OTHER,1,29,6 Years,17 Years,ALL,False,Amgen,INDUSTRY,0,99,Russia|United States|Canada|France|Spain|Czechia|Italy|Netherlands|Belgium|Israel,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.5053315359323625,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,30,1,1,0,0,2,1,2018-12-19,2023-03-27,1559.0,2018.0,1,3,1
NCT05384587,"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia","A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)",ACTIVE_NOT_RECRUITING,2022-11-11,2027-10-17,2025-10-14,INTERVENTIONAL,PHASE2,34.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Myelogenous Leukemia - Chronic Phase,asciminib,DRUG,1,15,18 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,80,United States,,0,1,0,0,0,2.0,1,0,0,0,1,3.5553480614894135,small,1,1,1,0,1,0,1,0,1,0,0,0,1,0,16,1,1,0,0,1,0,2022-11-11,2027-10-17,1801.0,2022.0,1,1,0
NCT04717193,Laparoscopically Guided Rectus Sheath Block in Pediatric Appendicitis,Laparoscopically Guided Rectus Sheath Block in Pediatric Appendicitis - a Randomized Control Trial,COMPLETED,2021-05-28,2023-04-17,2024-03-12,INTERVENTIONAL,PHASE2,42.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Appendicitis Acute,Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine|Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine,DRUG|PROCEDURE,1,4,8 Years,17 Years,ALL,False,University of Alberta,OTHER,0,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.7612001156935624,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,2021-05-28,2023-04-17,689.0,2021.0,1,1,0
NCT00067093,Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT),,COMPLETED,2003-05,2005-09,2011-04-06,INTERVENTIONAL,PHASE3,1452.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Deep Vein Thrombosis,SanOrg34006|LMW heparin|Unfractionated heparin|Vitamin K antagonist (VKA),DRUG,1,1,18 Years,,ALL,False,Sanofi,INDUSTRY,0,24,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.2813856635702825,xlarge,0,1,1,0,1,0,1,0,1,0,1,0,1,1,2,1,1,0,0,4,1,,,,,0,1,0
NCT01807221,Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone,"A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone",COMPLETED,2013-06-17,2014-12-09,2021-07-06,INTERVENTIONAL,PHASE2,1066.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Heart Failure,Finerenone (BAY94-8862)|Placebo|Inspra (eplerenone),DRUG,1,7,18 Years,,ALL,False,Bayer,INDUSTRY,0,172,Canada|Austria|Lithuania|South Africa|Hungary|Australia|Bulgaria|Portugal|Spain|Norway|Italy|Israel|Finland|United States|Sweden|France|Czechia|Germany|Netherlands|Poland|Greece|South Korea|Turkey (Türkiye)|Denmark|Taiwan,1.0,0,1,0,0,0,2.0,0,0,0,1,1,6.9726062513017535,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,8,1,1,0,0,3,1,2013-06-17,2014-12-09,540.0,2013.0,0,3,1
NCT02093221,Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus,"A Multicenter, Randomized, Partial-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus",TERMINATED,2014-03,2017-06,2018-09-05,INTERVENTIONAL,PHASE2,76.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 1 Diabetes Mellitus,180 mg/kg Alpha1-PI|90 mg/kg Alpha1-PI|Placebo,BIOLOGICAL,1,5,6 Years,35 Years,ALL,False,Grifols Therapeutics LLC,INDUSTRY,0,36,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.343805421853684,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,1,6,1,0,1,0,3,1,,,,,0,2,0
NCT05370521,A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens,"A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects With Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens",TERMINATED,2022-05-15,2023-08-31,2025-10-09,INTERVENTIONAL,PHASE2,27.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Polycystic Ovary Syndrome,Tildacerfont|Placebo,DRUG,1,3,18 Years,40 Years,FEMALE,False,Spruce Biosciences,INDUSTRY,0,21,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.332204510175204,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,4,1,1,0,0,2,1,2022-05-15,2023-08-31,473.0,2022.0,1,1,0
NCT04046614,Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology,Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology - An AIO Phase Ib Trial,COMPLETED,2018-05-25,2023-09-15,2024-02-06,INTERVENTIONAL,PHASE1|PHASE2,56.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Adenocarcinoma of the Lung,nintedanib-nivolumab combination therapy,DRUG,3,7,18 Years,,ALL,False,AIO-Studien-gGmbH,OTHER,0,1,Germany,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.04305126783455,medium,1,1,0,1,0,0,0,0,0,1,0,0,1,0,10,1,1,0,0,1,0,2018-05-25,2023-09-15,1939.0,2018.0,1,2,0
NCT07186114,A Prospective Study on the Therapeutic Outcomes of Mebo and Tantum Verde in Patients With Oral Mucositis,A Prospective Study on the Therapeutic Outcomes of Mebo and Tantum Verde in Patients With Oral Mucositis,COMPLETED,2023-03-01,2024-12-14,2025-09-22,INTERVENTIONAL,PHASE3,36.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Oral Mucositis (Ulcerative) Due to Radiation,MEBO Wound Ointment (MEBO)|Tantum Verde® mouthwash,DRUG,1,0,18 Years,,ALL,False,Cairo University,OTHER,0,2,Egypt,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.6109179126442243,small,1,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,2,1,2023-03-01,2024-12-14,654.0,2023.0,1,1,0
NCT03345914,Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD),"A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis",COMPLETED,2017-11-17,2019-09-10,2020-08-13,INTERVENTIONAL,PHASE3,367.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Dermatitis, Atopic",Dupilumab|Matching Placebo|Background Treatment: Topical Corticosteroids|Background Treatment: Moisturizers,DRUG|OTHER,1,21,6 Years,11 Years,ALL,False,Regeneron Pharmaceuticals,INDUSTRY,1,61,United Kingdom|United States|Canada|Czechia|Germany|Poland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.908082938168931,large,0,1,1,0,0,1,1,1,1,1,1,1,1,1,22,1,1,0,0,4,1,2017-11-17,2019-09-10,662.0,2017.0,1,3,1
NCT02157506,A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure,"A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure",COMPLETED,2014-06-30,2015-07-31,2019-07-31,INTERVENTIONAL,PHASE2,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Heart Failure|Decompensated Heart Failure|Acute Heart Failure,CXL-1427|Placebo,DRUG,4,6,18 Years,85 Years,ALL,False,Bristol-Myers Squibb,INDUSTRY,1,35,Russia|Jordan|United States|Germany|Poland,1.0,0,1,0,0,0,2.0,0,0,0,1,3,4.2626798770413155,medium,1,1,1,0,1,1,1,1,1,1,1,1,1,1,10,1,1,0,0,2,1,2014-06-30,2015-07-31,396.0,2014.0,0,4,1
NCT04229706,A Study of Xiangjurupining Capsule in the Treatment of Hyperplasia of Breast (Liver Stagnation and Phlegm Coagulation),"A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Xiangjurupining Capsule in the Treatment of Hyperplasia of Breast (Liver Stagnation and Phlegm Coagulation)",COMPLETED,2019-12-31,2022-01-15,2024-09-05,INTERVENTIONAL,PHASE2,180.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hyperplasia of Breast,High dose Xiang Ju Ru Pi Ning capsule|Low dose Xiang Ju Ru Pi Ning capsule|Xiang Ju Ru Pi Ning capsule placebo,DRUG,5,0,18 Years,50 Years,FEMALE,False,"Tasly Pharmaceutical Group Co., Ltd",INDUSTRY,0,8,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.198497031265826,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,5,0,1,0,0,3,1,2019-12-31,2022-01-15,746.0,2019.0,1,1,0
NCT02647684,Triple P for Parents of Children With a Diagnosis of Cancer,Triple P for Parents of Children With a Diagnosis of Cancer,COMPLETED,2016-01,2016-08,2016-10-25,INTERVENTIONAL,PHASE1|PHASE2,4.0,ACTUAL,,SINGLE_GROUP,SUPPORTIVE_CARE,NONE,Cancer,Self-Directed Triple P,BEHAVIORAL,1,4,18 Years,100 Years,ALL,False,University of Manchester,OTHER,1,1,United Kingdom,1.0,1,1,0,0,1,1.5,1,0,0,0,1,1.6094379124341003,small,1,1,0,1,0,1,0,0,0,1,0,0,0,0,5,1,0,0,0,1,0,,,,,0,1,0
NCT00398684,Nevirapine Plus Zidovudine to Prevent Perinatal HIV in Thailand,,COMPLETED,2001-01,2004-06,2008-05-07,INTERVENTIONAL,PHASE3,1792.0,,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,HIV Infections|Pregnancy,Single dose nevirapine to the mother and to the child|Single dose nevirapine to the mother and placebo to the child|Single dose placebo to the mother and to the child,DRUG,1,1,,,FEMALE,False,Institut de Recherche pour le Developpement,OTHER_GOV,3,1,Thailand,1.0,0,0,1,0,0,3.0,0,0,0,0,2,7.491645473605133,xlarge,0,0,0,1,0,1,0,0,0,0,1,1,0,1,2,1,1,0,0,3,1,,,,,0,2,0
NCT05351684,Effect of Dolutegravir Intensification on HIV-1 Reservoirs,Effect of Dolutegravir Intensification on Blood and Tissue Latent HIV-1 Reservoirs and on Residual Viremia Despite ART,COMPLETED,2019-01-01,2022-12-13,2022-12-15,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,HIV-1-infection,Dolutegravir 50 MG,DRUG,1,5,18 Years,,ALL,False,University of Liege,OTHER,0,1,Belgium,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,6,1,1,0,0,1,0,2019-01-01,2022-12-13,1442.0,2019.0,1,1,0
NCT00918333,"Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma",A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma,COMPLETED,2009-06,2019-07-16,2020-03-10,INTERVENTIONAL,PHASE1|PHASE2,124.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|B-cell Adult Acute Lymphoblastic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Splenic Marginal Zone Lymphoma|T-cell Adult Acute Lymphoblastic Leukemia|Waldenström Macroglobulinemia,panobinostat|everolimus|laboratory biomarker analysis|pharmacological study,DRUG|OTHER,2,3,18 Years,,ALL,False,Mayo Clinic,OTHER,1,3,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,28,4.8283137373023015,medium,0,1,0,1,0,1,1,0,1,0,0,0,1,0,5,1,1,0,0,4,1,,2019-07-16,,,0,3,1
NCT07235033,Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2),"A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Participants With Uncomplicated Plasmodium Falciparum Malaria",COMPLETED,2024-01-23,2025-03-19,2025-11-19,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Uncomplicated Plasmodium Falciparum Malaria,Cipargamin|SoC (Coartem)|KLU156,DRUG,1,10,12 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,6,Ghana|Kenya|Côte d’Ivoire|Burkina Faso|Gabon|Uganda,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.110873864173311,medium,1,1,1,0,1,0,1,1,0,0,1,0,1,1,11,1,1,0,0,3,1,2024-01-23,2025-03-19,421.0,2024.0,1,3,1
NCT02515552,Web-Based Program for Symptom Management in Fibromyalgia,Web-Based Program for Symptom Management in Fibromyalgia,COMPLETED,2008-09,2011-08,2015-08-04,INTERVENTIONAL,PHASE2,883.0,ACTUAL,,SINGLE_GROUP,,NONE,Fibromyalgia,The Fibromyalgia Wellness Project,BEHAVIORAL,1,4,21 Years,,ALL,False,"Collinge and Associates, Inc.",OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.784457062637643,xlarge,0,1,0,1,0,0,0,0,1,0,0,0,0,0,5,1,0,0,0,1,0,,,,,0,0,0
NCT01220752,Treatment of Malignant Sinonasal Tumours With Intensity-modulated Radiotherapy (IMRT) and Carbon Ion Boost (C12),Treatment of Malignant Sinonasal Tumours With Intensity-modulated Radiotherapy (IMRT) and Carbon Ion Boost (C12),COMPLETED,2011-06-17,2021-12-19,2022-09-01,INTERVENTIONAL,PHASE2,36.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Sinonasal Malignancies|Adenocarcinoma and Squamous Cell Carcinoma of the Paranasal Sinuses,carbon ion boost,RADIATION,1,5,18 Years,80 Years,ALL,False,Heidelberg University,OTHER,0,1,Germany,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.6109179126442243,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,6,1,0,0,0,1,0,2011-06-17,2021-12-19,3838.0,2011.0,0,2,0
NCT01180647,Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail,Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail,COMPLETED,2010-05,2013-07,2016-04-07,INTERVENTIONAL,PHASE3,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Opiate Dependence,Extended-Release Naltrexone|Motivational Enhancement Counseling,DRUG|BEHAVIORAL,1,5,18 Years,60 Years,ALL,False,NYU Langone Health,OTHER,2,2,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.8918202981106265,small,1,1,0,1,0,1,1,0,1,0,1,0,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT01965158,Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy",COMPLETED,2013-08-29,2015-01-22,2017-05-30,INTERVENTIONAL,PHASE3,547.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Opioid-induced Constipation,Naldemedine|Placebo,DRUG,1,4,18 Years,80 Years,ALL,False,Shionogi,INDUSTRY,0,65,United Kingdom|United States|Austria|Spain|Czechia|Germany|Poland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.306275286948016,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,5,1,1,0,0,2,1,2013-08-29,2015-01-22,511.0,2013.0,0,2,0
NCT02375048,Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI,Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: Adjuvant Hypofractionated Whole Breast Irradiation (WBI) Versus Accelerated Partial Breast Irradiation (APBI),TERMINATED,2015-01-19,2018-02-01,2018-10-24,INTERVENTIONAL,PHASE2,179.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cancer of Breast,Hypofractionated WBI|Accelerated Partial Breast Irradiation,RADIATION,2,4,55 Years,70 Years,FEMALE,False,Istituto Clinico Humanitas,OTHER,0,1,Italy,0.0,0,1,0,0,0,2.0,1,0,0,0,1,5.19295685089021,medium,0,1,0,1,0,0,0,0,0,1,1,0,1,1,6,1,0,0,0,2,1,2015-01-19,2018-02-01,1109.0,2015.0,1,2,0
NCT02559648,Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis,"Evaluation of Efficacy of Denosumab in Patients With Thalassemia Major and Osteoporosis: A Randomized, Placebo-controlled, Single-site, Double Blind Phase 2b Clinical Trial",COMPLETED,2014-09,2017-12,2019-08-26,INTERVENTIONAL,PHASE2,63.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Thalassemia Major|Osteoporosis,Denosumab|Placebo,DRUG,1,3,30 Years,,ALL,False,Ersi Voskaridou,OTHER,0,1,Greece,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.1588830833596715,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT02458248,Sodium Intake in Chronic Kidney Disease (STICK),Sodium Intake in Chronic Kidney Disease (STICK): A Randomised Controlled Trial,COMPLETED,2016-03,2020-08,2021-04-28,INTERVENTIONAL,PHASE2,105.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Kidney Diseases|Renal Insufficiency, Chronic|Renal Insufficiency",Sodium Reduction,BEHAVIORAL,1,9,18 Years,,ALL,False,University College Hospital Galway,OTHER,2,1,Ireland,1.0,0,1,0,0,0,2.0,0,0,0,0,3,4.663439094112067,medium,0,1,0,1,0,1,0,0,0,0,1,0,1,1,10,1,0,0,0,1,0,,,,,0,2,0
NCT00333138,Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis,"Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Safety, Tolerability and Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients With Relapsing Multiple Sclerosis Including 18 Month Extension Phase",COMPLETED,2003-05,2011-04,2017-09-15,INTERVENTIONAL,PHASE2,281.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Multiple Sclerosis,FTY720|Placebo,DRUG,4,7,18 Years,60 Years,ALL,False,Novartis,INDUSTRY,0,26,United Kingdom|Finland|Denmark|Canada|Portugal|France|Spain|Switzerland|Germany|Poland|Italy,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.641907070938114,large,0,1,1,0,1,0,1,1,0,1,1,1,1,1,11,1,1,0,0,2,1,,,,,0,3,1
NCT00496158,Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus,"A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepatitis B Virus",TERMINATED,2007-08,,2009-04-27,INTERVENTIONAL,PHASE3,,,RANDOMIZED,,TREATMENT,DOUBLE,Chronic Hepatitis|Hepatitis B,Clevudine|Adefovir,DRUG,0,0,16 Years,,ALL,False,Pharmasset,INDUSTRY,0,119,United Kingdom|Argentina|Australia|United States|Puerto Rico|Canada|Taiwan|Thailand|Spain|China|Greece,0.0,0,0,1,0,0,3.0,0,0,0,0,2,0.0,,0,0,1,0,0,0,1,1,1,1,1,1,1,0,0,0,1,0,0,2,1,,,,,0,3,1
NCT05454358,Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP,Letrozole as Maintenance Therapy Versus Observation After Adjuvant Treatment on the Prognosis for Post-surgical Endometrial Cancer Patients With Non-specific Molecular Profile: a Superiority Randomized Controlled Trial,TERMINATED,2022-08-02,2025-12-01,2025-12-15,INTERVENTIONAL,PHASE2|PHASE3,12.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Endometrial Cancer,Letrozole 2.5mg,DRUG,1,5,18 Years,80 Years,FEMALE,False,Fudan University,OTHER,1,1,China,0.0,0,1,1,0,1,2.5,1,0,0,0,1,2.5649493574615367,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,6,1,1,0,0,1,0,2022-08-02,2025-12-01,1217.0,2022.0,1,2,0
NCT06949358,A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France,A Long-Term Follow-up Study to Evaluate Safety and Tolerability of Olipudase Alfa in Patients Who Completed the DFI12712 or the LTS13632 Study in France,COMPLETED,2021-11-18,2025-04-08,2025-04-29,INTERVENTIONAL,PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Niemann-Pick Disease,Olipudase alfa,DRUG,1,0,,,ALL,False,Sanofi,INDUSTRY,0,2,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,1.3862943611198906,small,1,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,2021-11-18,2025-04-08,1237.0,2021.0,1,0,0
NCT01981655,0.5M Na Lactate Solution in Acute Heart Failure (AHF),"A Phase 2, Randomised, Single-Blind, Placebo-controlled Study of Half Molar Sodium Lactate Solution in the Treatment of Subjects With Acute Heart Failure",COMPLETED,2009-12,2013-08,2013-11-13,INTERVENTIONAL,PHASE2,41.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Acute Heart Failure,0.5M Sodium lactate|Hartmann's solution,DRUG,1,3,18 Years,,ALL,False,Nepean Blue Mountains Local Health District,OTHER,1,1,Australia,1.0,0,1,0,0,0,2.0,0,0,0,1,1,3.7376696182833684,small,1,1,0,1,0,1,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00329355,Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA),"A Randomized, Double-blind, Single Migraine Attack, Placebo-controlled, Parallel-group Multicenter Study to Evaluate the Efficacy and Tolerability of Trexima (Sumatriptan Succinate.Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pain Phase of Menstrual Migraine in Women With Dysmenorrhea",COMPLETED,2006-05,2006-11,2017-01-23,INTERVENTIONAL,PHASE3,351.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Migraine|Migraine Disorders,sumatriptan succinate/naproxen sodium,DRUG,1,1,18 Years,65 Years,FEMALE,False,GlaxoSmithKline,INDUSTRY,0,35,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,2,5.863631175598097,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,1,0
NCT02037555,Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass,"A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiac Surgery With Cardiopulmonary Bypass",COMPLETED,2014-06-26,2018-01-25,2019-03-15,INTERVENTIONAL,PHASE2,425.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cardiac Surgery|Cardiopulmonary Bypass,AT-III (Human)|Placebo,OTHER|BIOLOGICAL,1,0,18 Years,,ALL,False,Grifols Therapeutics LLC,INDUSTRY,2,41,United States,1.0,0,1,0,0,0,2.0,0,0,0,1,2,6.054439346269371,large,0,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,0,2,1,2014-06-26,2018-01-25,1309.0,2014.0,0,2,0
NCT04287855,Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma,Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,2020-08-28,2026-04-15,2023-01-10,INTERVENTIONAL,PHASE2,82.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Multiple Myeloma in Relapse|Multiple Myeloma, Refractory",Isatuximab|Carfilzomib|Pomalidomide|Dexamethasone,DRUG,1,3,18 Years,,ALL,False,Poitiers University Hospital,OTHER,4,1,France,,0,1,0,0,0,2.0,1,0,0,0,2,4.418840607796598,medium,1,1,0,1,0,1,0,0,0,1,0,0,1,0,4,1,1,0,0,4,1,2020-08-28,2026-04-15,2056.0,2020.0,1,2,0
NCT06684626,The Role of Butirprost® in Combination With Antibiotics in Chronic Bacterial Prostatitis (CBP) Treatment,The Role of Butirprost® as an Adjuvant in Enhancing the Effect of Antibiotics in Patients Affected by Chronic Bacterial Prostatitis: A Randomized Prospective Trial,COMPLETED,2024-03-01,2024-09-01,2024-11-18,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Prostate Inflammation|Prostate Disease|Chronic Bacterial Prostatitis,Sodium Hyaluronate|Levofloxacin 500mg,DRUG,4,0,18 Years,50 Years,MALE,False,Federico II University,OTHER,0,1,Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,3,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,1,1,0,1,1,4,0,1,0,0,2,1,2024-03-01,2024-09-01,184.0,2024.0,1,2,0
NCT01773109,Etirinotecan Pegol (NKTR-102) in NSCLC,Phase 2 Study of Etirinotecan Pegol (NKTR-102) in the Treatment of Patients With Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of 2nd Line Treatment,COMPLETED,2013-01,2017-03-15,2020-04-03,INTERVENTIONAL,PHASE2,40.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Non Small Cell Lung Cancer|Recurrent Non Small Cell Lung Cancer,Etirinotecan pegol (NKTR-102),DRUG,1,0,18 Years,,ALL,False,Abramson Cancer Center at Penn Medicine,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.713572066704308,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,2017-03-15,,,0,1,0
NCT00140309,TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment,"TBTC Study 27: An Evaluation of the Activity and Tolerability of Moxifloxacin During the First Two Months of Treatment for Pulmonary Tuberculosis--A Double-Blind, Randomized, Multicenter Study by the Tuberculosis Trials Consortium",COMPLETED,2003-07,2005-12,2007-03-19,INTERVENTIONAL,PHASE2,350.0,,RANDOMIZED,FACTORIAL,TREATMENT,DOUBLE,"Tuberculosis, Pulmonary","moxifloxacin (with isoniazid, rifampin, pyrazinamide)",DRUG,2,0,18 Years,,ALL,False,Centers for Disease Control and Prevention,FED,0,23,Uganda|Canada|South Africa|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.860786223465865,large,0,0,0,0,0,0,1,1,1,0,1,1,1,0,2,0,1,0,0,1,0,,,,,0,1,0
NCT00084409,Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease,A Randomized Phase II Chemoprevention Study of Iloprost Versus Placebo in Patients at High Risk for Lung Cancer,COMPLETED,2001-11,2009-01,2020-05-14,INTERVENTIONAL,PHASE2,152.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Lung Cancer|Precancerous Condition,iloprost|placebo,DRUG|OTHER,1,10,18 Years,85 Years,ALL,False,"University of Colorado, Denver",OTHER,1,6,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,5.030437921392435,medium,0,1,0,1,0,1,1,0,1,0,1,1,0,1,11,1,1,0,0,2,1,,,,,0,3,1
NCT00354432,Soy Protein/Effexor Hormone Therapy for Prostate Cancer,Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer,TERMINATED,2007-02-01,2010-08-01,2021-09-28,INTERVENTIONAL,PHASE3,120.0,ACTUAL,RANDOMIZED,FACTORIAL,SUPPORTIVE_CARE,QUADRUPLE,Hot Flashes|Prostate Cancer,oral soy protein/isoflavones powder|Venlafaxine|Placebo Powder|Placebo Pill,DRUG|DIETARY_SUPPLEMENT,1,1,21 Years,,MALE,False,Wake Forest University Health Sciences,OTHER,1,20,United States,0.0,0,0,1,0,0,3.0,1,0,0,0,2,4.795790545596741,medium,0,1,0,1,0,1,1,0,1,0,1,1,0,0,2,1,1,0,0,4,1,2007-02-01,2010-08-01,1277.0,2007.0,0,2,0
NCT00433732,To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches,"A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study to Evaluate the Safety and Efficacy Opf Trexima in the Acute Treatment of Migraine Headaches",COMPLETED,2004-08,2005-04,2007-02-12,INTERVENTIONAL,PHASE3,1400.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Migraine Headaches,sumatriptan|naproxen sodium,DRUG,1,1,18 Years,65 Years,ALL,False,POZEN,INDUSTRY,0,2,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,7.244941546337007,xlarge,0,0,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT00896363,Safety and Efficacy Study in Patients With Major Depressive Disorder,"A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of GSK163090 in Subjects With Major Depressive Disorder",COMPLETED,2009-04-23,2010-02-09,2018-03-19,INTERVENTIONAL,PHASE2,99.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Depressive Disorder,GSK163090 1 mg|GSK163090 Placebo|GSK163090 3 mg,DRUG,13,4,18 Years,64 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,15,Russia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.605170185988092,medium,1,1,1,0,0,0,1,0,0,0,1,1,1,1,17,1,1,0,0,3,1,2009-04-23,2010-02-09,292.0,2009.0,0,2,0
NCT04585893,Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi,"LCCC 1950 - Rituximab for Multicentric Castleman Disease in Malawi, A Single-Arm Phase II Safety/Efficacy Trial",ACTIVE_NOT_RECRUITING,2021-06-22,2026-06-07,2025-09-11,INTERVENTIONAL,PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multicentric Castleman Disease,Rituximab|Etoposide,DRUG,1,13,18 Years,,ALL,False,UNC Lineberger Comprehensive Cancer Center,OTHER,1,1,Malawi,,0,1,0,0,0,2.0,0,0,0,0,1,2.772588722239781,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,14,1,1,0,0,2,1,2021-06-22,2026-06-07,1811.0,2021.0,1,2,0
NCT01979393,"IRCI Gynae Sarcomas, High Grade Uterine Sarcoma",A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Uterine Sarcoma (HGUtS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment,COMPLETED,2015-02-02,2024-01-15,2025-08-01,INTERVENTIONAL,PHASE2,58.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Uterine Sarcoma,Cabozantinib|Placebo,DRUG,1,7,18 Years,,FEMALE,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,2,15,United Kingdom|France|Spain|Netherlands|Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.07753744390572,medium,1,1,0,0,0,1,1,1,0,1,1,1,1,1,8,1,1,0,0,2,1,2015-02-02,2024-01-15,3269.0,2015.0,1,3,1
NCT01784393,Chemoradiation for Bone Metastasis,Chemoradiation With Capecitabine for Palliation of Pain From Bone Metastasis,COMPLETED,2004-05,2007-04,2013-02-05,INTERVENTIONAL,PHASE2,29.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer|Bone Metastasis|Pain,chemoradiation,RADIATION,1,1,18 Years,,FEMALE,False,Rabin Medical Center,OTHER,1,1,Israel,1.0,0,1,0,0,0,2.0,1,0,0,0,3,3.4011973816621555,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,2,1,0,0,0,1,0,,,,,0,1,0
NCT00503321,Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma,Randomized Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Unresectable Advanced Gastric Carcinoma and Recurrent Gastric Carcinoma,TERMINATED,2006-10,2011-08,2009-01-23,INTERVENTIONAL,PHASE2|PHASE3,13.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Gastric Cancer,"Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)|Tegafur/gimeracil/oteracil potassium (S-1)",DRUG,1,1,20 Years,,ALL,False,"Eastern Network of Cancer Immunological Therapy, Japan",OTHER,0,1,Japan,0.0,0,1,1,0,1,2.5,1,0,0,0,1,2.6390573296152584,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT01950221,Pomegranate Extract and Memory,"12-Month, Double-blind, Placebo-Controlled Study of Pomegranate Extract",COMPLETED,2011-10,2015-10,2020-03-02,INTERVENTIONAL,PHASE2,212.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Healthy Volunteers,POMx|Placebo,OTHER|DIETARY_SUPPLEMENT,1,1,50 Years,75 Years,ALL,True,"University of California, Los Angeles",OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.3612921657094255,large,0,1,0,1,0,1,0,0,1,0,1,1,1,1,2,1,0,0,0,2,1,,,,,0,1,0
NCT00466921,Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome,"Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma",COMPLETED,2005-04-19,2013-05-17,2020-12-01,INTERVENTIONAL,PHASE2,33.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lymphoma,lenalidomide,DRUG,3,1,18 Years,120 Years,ALL,False,Northwestern University,OTHER,1,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.5263605246161616,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2005-04-19,2013-05-17,2950.0,2005.0,0,0,0
NCT02090621,Extracorporeal Photopheresis After Liver Transplant,Extracorporeal Photopheresis After Liver Transplant. Phase II Clinical Trial on Safety and Efficacy in Patients With Progressive Withdrawal of Immunosuppression,COMPLETED,2012-10,2015-03,2015-03-12,INTERVENTIONAL,PHASE2,10.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Hepatic Insufficiency,Extracorporeal photopheresis,PROCEDURE,3,5,18 Years,,ALL,False,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,OTHER,0,1,Spain,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,0,0,1,0,0,0,0,0,1,0,0,1,0,8,1,0,0,0,1,0,,,,,0,1,0
NCT03741621,Viscosity of Fibre Predicts Cholesterol-lowering in Healthy Individuals,Viscosity Rather Than Quality of Dietary Fibre Predicts Cholesterol-lowering Effect in Healthy Individuals,COMPLETED,1992-01,2010-07,2018-11-15,INTERVENTIONAL,PHASE2,23.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Lipidemia|Healthy,Viscous Fibre Blend|Psyllium|Wheat Bran,DIETARY_SUPPLEMENT,1,5,18 Years,70 Years,ALL,True,Unity Health Toronto,OTHER,2,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.1780538303479458,small,1,1,0,1,0,1,0,0,0,0,1,1,1,0,6,1,0,0,0,3,1,,,,,0,3,1
NCT00383214,Study of Epratuzumab in Systemic Lupus Erythematosus (SLE),"A Phase III, Randomized, Double Blind, Placebo Controlled, Multi-Center Study of Epratuzumab in Patients With Active Systemic Lupus Erythematosus.",TERMINATED,2005-05,2007-03,2012-06-07,INTERVENTIONAL,PHASE3,54.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Systemic Lupus Erythematosus,Epratuzumab|Placebo,DRUG|OTHER,1,8,18 Years,,ALL,False,UCB Pharma,INDUSTRY,0,60,United Kingdom|United States|Canada|Brazil|France|Spain|Czechia|Germany|Netherlands|Belgium|Italy,0.0,0,0,1,0,0,3.0,0,1,0,0,1,4.007333185232471,medium,1,1,1,0,0,0,1,1,1,1,1,1,1,1,9,1,1,0,0,2,1,,,,,0,3,1
NCT02910414,TARGET BP I Clinical Trial,"A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects With Hypertension",ACTIVE_NOT_RECRUITING,2019-07-22,2026-05,2023-10-03,INTERVENTIONAL,PHASE3,300.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Hypertension,Dehydrated alcohol|Peregrine System Kit (Sham Procedure),DRUG|DEVICE,1,23,18 Years,80 Years,ALL,False,"Ablative Solutions, Inc.",INDUSTRY,0,5,United States,,0,0,1,0,0,3.0,0,0,0,1,1,5.707110264748875,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,24,1,1,0,1,2,1,2019-07-22,,,2019.0,1,2,0
NCT03063606,Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment,Behavioral and Pharmacologic Treatment of Binge Eating and Obesity,COMPLETED,2017-09-05,2022-12-16,2024-02-01,INTERVENTIONAL,PHASE2|PHASE3,31.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Binge-Eating Disorder|Obesity,Cognitive-Behavioral Therapy (CBT)|NB Medication (on-going from acute treatment),DRUG|BEHAVIORAL,2,2,18 Years,70 Years,ALL,False,Yale University,OTHER,1,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,2,3.4657359027997265,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,4,1,1,0,0,2,1,2017-09-05,2022-12-16,1928.0,2017.0,1,3,1
NCT00515216,Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors,Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal (GEJ) Tumors: A Phase II Study,COMPLETED,2007-08,2013-11,2016-01-07,INTERVENTIONAL,PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Stomach Neoplasms|Esophageal Neoplasms,5-fluorouracil|Oxaliplatin|Leucovorin,DRUG,1,18,18 Years,,ALL,False,Vanderbilt University,OTHER,4,4,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.295836866004329,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,19,1,1,0,0,3,1,,,,,0,3,1
NCT02628704,"Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma","Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Selinexor (KPT-330), Carfilzomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With a Proteasome Inhibitor and an Immunomodulatory Drug",WITHDRAWN,2015-12,2018-06,2023-01-26,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Multiple Myeloma,Selinexor|Placebo (for selinexor)|carfilzomib|Dexamethasone,DRUG,1,1,18 Years,,ALL,False,Karyopharm Therapeutics Inc,INDUSTRY,0,2,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,4,1,,,,,0,1,0
NCT02141204,"Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants","Immunogenicity and Safety Study of Two Different Formulations of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, Rotarix in Healthy Infants",COMPLETED,2019-02-20,2019-12-28,2020-12-09,INTERVENTIONAL,PHASE3,451.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Rotavirus,HRV Liquid|HRV Lyophilized,BIOLOGICAL,1,4,6 Weeks,10 Weeks,ALL,True,GlaxoSmithKline,INDUSTRY,0,8,India,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.113682179832232,large,0,1,1,0,0,0,1,0,0,0,1,0,0,1,5,1,0,1,0,2,1,2019-02-20,2019-12-28,311.0,2019.0,1,1,0
NCT02762084,"Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients","Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients",COMPLETED,2016-06-06,2017-04-24,2020-07-23,INTERVENTIONAL,PHASE2,17.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Basal Cell Nevus Syndrome,Patidegib|Vehicle gel,DRUG,4,7,18 Years,85 Years,ALL,False,"PellePharm, Inc.",INDUSTRY,0,2,United Kingdom,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.8903717578961645,small,1,1,1,0,0,0,1,0,0,1,1,1,1,1,11,1,1,0,0,2,1,2016-06-06,2017-04-24,322.0,2016.0,1,2,0
NCT02330133,Mid-life Women: Preventing Unintended Pregnancy and STIs,Mid-life Women: Preventing Unintended Pregnancy and STIs,COMPLETED,2008-05,2009-09,2015-01-01,INTERVENTIONAL,PHASE2,333.0,ACTUAL,RANDOMIZED,PARALLEL,,NONE,Reproductive Health,Women's Reproductive Health|Online sexual health content,BEHAVIORAL,1,3,25 Years,55 Years,FEMALE,True,"Oregon Center for Applied Science, Inc.",INDUSTRY,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.811140992976701,large,0,1,1,0,0,1,0,0,1,0,1,0,0,1,4,1,0,0,0,2,1,,,,,0,1,0
NCT02255552,Study of Eteplirsen in DMD Patients,"An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy",COMPLETED,2014-11-17,2019-06-14,2021-01-25,INTERVENTIONAL,PHASE3,109.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Duchenne Muscular Dystrophy (DMD),eteplirsen,DRUG,1,6,7 Years,16 Years,MALE,False,"Sarepta Therapeutics, Inc.",INDUSTRY,0,37,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.700480365792417,medium,0,1,1,0,0,0,1,0,1,0,0,0,1,1,7,1,1,0,0,1,0,2014-11-17,2019-06-14,1670.0,2014.0,0,1,0
NCT03343652,A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma,A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab and Bendamustine Combination (NB) in Patients With Relapsed or Refractory Hodgkin's Lymphoma,COMPLETED,2017-05-27,2020-03-27,2020-05-28,INTERVENTIONAL,PHASE1|PHASE2,30.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hodgkin's Lymphoma,Nivolumab|Bendamustine Hydrochloride,DRUG,1,5,18 Years,70 Years,ALL,False,St. Petersburg State Pavlov Medical University,OTHER,0,1,Russia,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,2,1,2017-05-27,2020-03-27,1035.0,2017.0,1,3,1
NCT04246047,"Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma",ACTIVE_NOT_RECRUITING,2020-05-07,2026-06-19,2024-10-24,INTERVENTIONAL,PHASE3,494.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,Belantamab mafodotin|Daratumumab|Bortezomib|Dexamethasone,DRUG,1,22,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,144,Canada|China|Russia|Australia|Spain|Belgium|Italy|Israel|United States|France|Czechia|South Korea|Netherlands|Poland|Germany|Greece|United Kingdom|Brazil|New Zealand|Japan,,0,0,1,0,0,3.0,1,0,0,0,1,6.20455776256869,large,0,1,1,0,0,0,1,1,1,1,1,0,1,1,23,1,1,0,0,4,1,2020-05-07,2026-06-19,2234.0,2020.0,1,3,1
NCT00808249,AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD),"A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Efficacy and Safety Study of AZD7325 in the Treatment of Generalized Anxiety Disorder (GAD)",COMPLETED,2008-12,2009-05,2011-06-20,INTERVENTIONAL,PHASE2,725.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Anxiety Disorders,AZD7325|AZD7325|AZD7325|Placebo,DRUG,1,4,18 Years,65 Years,ALL,False,AstraZeneca,INDUSTRY,0,52,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,6.587550014824796,xlarge,0,1,1,0,1,0,1,0,1,0,1,1,1,1,5,1,1,0,0,4,1,,,,,0,1,0
NCT01583738,Effect of V0251 in Acute Vertigo,,COMPLETED,2012-04,2013-04,2014-10-30,INTERVENTIONAL,PHASE2,132.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Vertigo,V0251|placebo,DRUG,1,2,18 Years,70 Years,ALL,False,Pierre Fabre Medicament,INDUSTRY,0,40,Hungary|France|Spain|Czechia|Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.890349128221754,medium,0,1,1,0,0,0,1,1,0,1,1,1,1,1,3,1,1,0,0,2,1,,,,,0,2,0
NCT01728558,Early Goal-Directed Sedation Compared With Standard Care in Mechanically Ventilated Critically Ill Patients,Early Goal-Directed Sedation Compared With Standard Care in Mechanically Ventilated Critically Ill Patients: a Prospective Multicentre Randomised Controlled Trial,COMPLETED,2013-11,2018-12,2019-08-20,INTERVENTIONAL,PHASE3,4000.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Critical Illness and Mechanical Ventilation,Early goal Directed Sedation|Standard care sedation,OTHER,1,15,18 Years,,ALL,False,Australian and New Zealand Intensive Care Research Centre,OTHER,1,74,United Kingdom|Malaysia|Australia|Ireland|New Zealand|Switzerland|Saudi Arabia|Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,8.294299608857235,xlarge,0,1,0,1,0,1,1,1,0,1,1,0,1,1,16,1,0,0,0,2,1,,,,,0,3,1
NCT01628848,A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients,A Placebo-controlled Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa,COMPLETED,2006-08,2008-04,2014-03-19,INTERVENTIONAL,PHASE2,174.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Parkinson's Disease,SPM 962|Placebo,DRUG,1,11,30 Years,79 Years,ALL,False,"Otsuka Pharmaceutical Co., Ltd.",INDUSTRY,0,7,Japan,1.0,0,1,0,0,0,2.0,0,0,1,0,1,5.1647859739235145,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,12,1,1,0,0,2,1,,,,,0,2,0
NCT00110955,Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy,"A Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy",COMPLETED,2004-02,2005-04,2010-01-15,INTERVENTIONAL,PHASE3,391.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Anemia|Non-Myeloid Malignancies,Darbepoetin alfa|Placebo,DRUG,1,13,18 Years,,ALL,False,Amgen,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.971261839790462,large,0,1,1,0,1,0,0,0,0,0,1,1,1,1,14,1,1,0,0,2,1,,,,,0,3,1
NCT00291655,Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).,"A Multicenter, Open-label, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam, for Patients Suffering From Epilepsy and Coming From the Study N01175 (NCT00175903).",COMPLETED,2006-06,2008-04,2015-05-18,INTERVENTIONAL,PHASE3,130.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Epilepsy,Levetiracetam,DRUG,1,1,16 Years,,ALL,False,UCB Pharma,INDUSTRY,0,35,Finland|Bulgaria|France|Switzerland|Poland|Belgium,1.0,0,0,1,0,0,3.0,0,0,1,0,1,4.875197323201151,medium,0,1,1,0,0,0,1,1,0,1,0,0,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT00088855,Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma,Phase II Study of Bortezomib (PS-341) and Pegylated Liposomal Doxorubicin as Initial Therapy for Adult Patients With Symptomatic Multiple Myeloma,COMPLETED,2004-06-15,2008-01-08,2019-09-23,INTERVENTIONAL,PHASE2,55.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,DS Stage I Plasma Cell Myeloma|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma,Bortezomib|Laboratory Biomarker Analysis|Pegylated Liposomal Doxorubicin Hydrochloride,DRUG|OTHER,1,6,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,25,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,4.02535169073515,medium,1,1,0,1,0,0,1,0,1,0,0,0,1,0,7,1,1,0,0,3,1,2004-06-15,2008-01-08,1302.0,2004.0,0,3,1
NCT00445848,S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer,A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (RHUMAB VEGF; NSC 704865) in Never-Smokers With Stage IIIB and IV Primary NSCLC Adenocarcinomas,COMPLETED,2007-07,2014-01,2020-03-05,INTERVENTIONAL,PHASE2,89.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lung Cancer,bevacizumab|erlotinib hydrochloride,DRUG|BIOLOGICAL,1,3,18 Years,120 Years,ALL,False,SWOG Cancer Research Network,NETWORK,1,153,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.499809670330265,medium,1,1,0,0,0,1,1,0,1,0,0,0,1,0,4,1,1,1,0,2,1,,,,,0,1,0
NCT02380755,Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism,Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism: Metabolic and Cardiovascular Effects.,COMPLETED,2015-04,2017-01,2017-12-27,INTERVENTIONAL,PHASE2,78.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Obesity|Hypoandrogenism,Clomiphene Citrate|Placebo,DRUG,2,0,18 Years,50 Years,MALE,False,University of Sao Paulo,OTHER,1,1,Brazil,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.3694478524670215,medium,1,1,0,1,0,1,0,0,0,0,1,1,1,1,2,0,1,0,0,2,1,,,,,0,2,0
NCT00281255,Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy,Allopurinol and Cardiac Function Pilot Study in Idiopathic Dilated Cardiomyopathy,WITHDRAWN,2003-06,2013-06,2013-06-19,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,"Cardiovascular Diseases|Cardiomyopathy, Dilated|Heart Diseases|Heart Failure, Congestive",Allopurinol|Dobutamine,DRUG,1,0,18 Years,,ALL,False,University of Pennsylvania,OTHER,1,1,United States,0.0,1,1,0,0,1,1.5,0,0,0,1,4,0.0,,1,1,0,1,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,2,1,,,,,0,3,1
NCT01543555,Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose,Multicenter Randomized Controlled Trial of Loading Dose Statins for the Prevention of Cardiovascular Complications in High-Risk Non-Cardiac Surgery,COMPLETED,2012-11,2015-06,2015-12-31,INTERVENTIONAL,PHASE3,648.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Myocardial Infarction|Peripheral Vascular Disease|Aortic Aneurism,Atorvastatin|Placebo,DRUG,1,9,40 Years,,ALL,False,Hospital do Coracao,OTHER,0,1,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,1,3,6.47543271670409,xlarge,0,1,0,1,0,0,0,0,0,0,1,1,0,1,10,1,1,0,0,2,1,,,,,0,3,1
NCT00504426,Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis,Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis,COMPLETED,2007-07,2009-05,2014-01-30,INTERVENTIONAL,PHASE2,101.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Pain Due to Osteoporosis,OPC-249,DRUG,1,1,46 Years,79 Years,FEMALE,False,"Otsuka Pharmaceutical Co., Ltd.",INDUSTRY,0,5,Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.624972813284271,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT04971226,A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP,"A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase",ACTIVE_NOT_RECRUITING,2021-10-06,2028-01-18,2025-11-21,INTERVENTIONAL,PHASE3,406.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive,Imatinib|Nilotinib|Bosutinib|Dasatinib|Asciminib,DRUG,2,31,18 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,110,Canada|Austria|China|Hungary|Australia|Bulgaria|Portugal|Spain|Norway|Belgium|Italy|Israel|Finland|United States|Sweden|France|Czechia|Singapore|Germany|Netherlands|South Korea|India|United Kingdom|Denmark|Malaysia|Slovakia|Taiwan|Switzerland|Japan,,0,0,1,0,0,3.0,1,0,0,0,1,6.008813185442595,large,0,1,1,0,1,0,1,1,1,1,1,0,1,1,33,1,1,0,0,5,1,2021-10-06,2028-01-18,2295.0,2021.0,1,3,1
NCT01437878,Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD),"A Phase 2, Multi-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Inhaled Iloprost on Endurance Time During Cardiopulmonary Exercise Testing in Patients With Pulmonary Hypertension Secondary to Chronic Obstructive Pulmonary Disease",TERMINATED,2012-03,2012-11,2015-11-20,INTERVENTIONAL,PHASE2,2.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Chronic Obstructive Pulmonary Disease|Pulmonary Hypertension,Iloprost|Placebo,DRUG,1,17,40 Years,75 Years,ALL,False,Actelion,INDUSTRY,0,11,France|Spain|United States,0.0,0,1,0,0,0,2.0,0,0,0,1,2,1.0986122886681098,small,1,1,1,0,0,0,1,1,1,1,1,1,1,1,18,1,1,0,0,2,1,,,,,0,4,1
NCT00000485,Hypertension Detection and Follow-up Program (HDFP),,COMPLETED,1971-05,1982-05,2016-07-12,INTERVENTIONAL,PHASE3,,,RANDOMIZED,,PREVENTION,,Cardiovascular Diseases|Heart Diseases|Hypertension|Vascular Diseases,diuretics|antihypertensive agents,DRUG,0,0,30 Years,69 Years,ALL,False,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,1,4,0.0,,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,2,1,,,,,0,2,0
NCT05331885,A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Efficacy and Safety of Suvratoxumab in Mechanically Ventilated Adults and Adolescents for the Prevention of Nosocomial Pneumonia",TERMINATED,2022-09-02,2024-07-08,2025-03-24,INTERVENTIONAL,PHASE3,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ventilator Associated Pneumonia|Staphylococcus Aureus,Suvratoxumab|Placebo,DRUG|BIOLOGICAL,1,9,12 Years,65 Years,ALL,False,"Aridis Pharmaceuticals, Inc.",INDUSTRY,0,27,Netherlands|France|Spain|Greece|Belgium|Israel,0.0,0,0,1,0,0,3.0,0,0,0,0,2,3.2188758248682006,small,1,1,1,0,0,0,1,1,0,1,1,1,1,1,10,1,1,1,0,2,1,2022-09-02,2024-07-08,675.0,2022.0,1,4,1
NCT02872285,An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis,"A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis",COMPLETED,2016-12-05,2017-06-22,2019-04-10,INTERVENTIONAL,PHASE2,33.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Psoriasis,Drug: LYC-30937-EC|Placebo,DRUG,1,4,18 Years,75 Years,ALL,False,Lycera Corp.,INDUSTRY,0,7,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.5263605246161616,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,5,1,1,0,0,2,1,2016-12-05,2017-06-22,199.0,2016.0,1,1,0
NCT02545036,Combined Western and Traditional Chinese Medicine Daycare for CKD Patients,Clinical Study of Combined Western Medicine and Traditional Chinese Medicine Daycare Model for Chronic Kidney Disease Patients,COMPLETED,2015-06,2017-09-20,2021-08-02,INTERVENTIONAL,PHASE3,58.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Chronic Kidney Disease,Traditional Chinese Medicine (TCM) daycare model,OTHER,2,9,20 Years,,ALL,False,China Medical University Hospital,OTHER,1,1,Taiwan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.07753744390572,medium,1,1,0,1,0,1,0,0,0,0,0,0,1,1,11,1,0,0,0,1,0,,2017-09-20,,,0,1,0
NCT00550836,Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer,"Randomized Phase II Trial of Panitumumab, Erlotinib and Gemcitabine vs. Erlotinib and Gemcitabine in Patients With Untreated, Metastatic Pancreatic Adenocarcinoma",COMPLETED,2009-03,2013-05,2017-04-05,INTERVENTIONAL,PHASE2,104.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Pancreatic Cancer,panitumumab|erlotinib hydrochloride|gemcitabine hydrochloride,DRUG|BIOLOGICAL,1,4,18 Years,,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,1,262,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.653960350157523,medium,0,1,0,1,0,1,1,0,1,0,1,0,1,1,5,1,1,1,0,3,1,,,,,0,1,0
NCT00952471,Reduction in Clinical Variance Using Targeted Design Changes in Computerized Provider Order Entry Order (CPOE) Sets,Reduction in Clinical Variance Using Targeted Design Changes in Computerized Provider Order Entry Order (CPOE) Sets,COMPLETED,2004-09,2006-12,2015-05-21,INTERVENTIONAL,PHASE3,458.0,ACTUAL,NON_RANDOMIZED,FACTORIAL,HEALTH_SERVICES_RESEARCH,NONE,Asthma Exacerbation,Evidence Based Intervention to order set,OTHER,1,0,,,ALL,False,Brian Jacobs,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.129050210060545,large,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,,,,,0,0,0
NCT00217971,Dronabinol Treatment for Marijuana Addiction,"A Randomized, Double-Blind, Placebo-Controlled Study of Dronabinol in the Treatment of Marijuana Addiction",COMPLETED,2005-03,2009-12,2019-04-24,INTERVENTIONAL,PHASE2,156.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Marijuana Abuse,Dronabinol|Placebo,DRUG,1,0,18 Years,60 Years,ALL,True,New York State Psychiatric Institute,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.056245805348308,medium,0,1,0,1,0,1,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT01103271,Pilot Study of Open-label Placebo to Treat Major Depressive Disorder,Harnessing the Placebo Effect in Major Depressive Disorder,COMPLETED,2010-05,2011-05,2013-01-14,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Major Depressive Disorder,Open-label Placebo,OTHER,1,1,18 Years,60 Years,ALL,False,Massachusetts General Hospital,OTHER,2,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,1,0,0,1,0,1,0,1,0,2,1,0,0,0,1,0,,,,,0,0,0
NCT00974571,Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246),"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis",COMPLETED,2001-11,2002-05,2022-02-03,INTERVENTIONAL,PHASE3,1365.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Perennial Allergic Rhinitis,montelukast sodium|Comparator: cetirizine|Comparator: placebo,DRUG,1,4,15 Years,85 Years,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.2196420401307355,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,3,1,,,,,0,1,0
NCT05908734,A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer,A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,2023-05-18,2027-03-31,2026-01-16,INTERVENTIONAL,PHASE1|PHASE2,71.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,"Carcinoma, Non-Small-Cell Lung",Cetrelimab|Amivantamab,DRUG,3,6,18 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,44,United Kingdom|Turkey (Türkiye)|Malaysia|United States|Brazil|Spain|South Korea|Poland|Italy,,1,1,0,0,1,1.5,1,0,0,0,1,4.276666119016055,medium,1,1,1,0,0,0,1,1,1,1,0,0,1,0,9,1,1,0,0,2,1,2023-05-18,2027-03-31,1413.0,2023.0,1,4,1
NCT01288534,Hypofractionated Stereotactic Body Radiation Therapy (SBRT),A Study of Hypofractionated Stereotactic Body Radiation Therapy (SBRT) Using Continuous Real-time Evaluation of Prostate Motion,COMPLETED,2011-01,2016-01,2017-10-24,INTERVENTIONAL,PHASE2,68.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,Radiation Therapy,RADIATION,1,4,18 Years,,ALL,False,University of Michigan Rogel Cancer Center,OTHER,3,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.23410650459726,medium,1,1,0,1,0,1,1,0,1,0,0,0,1,0,5,1,0,0,0,1,0,,,,,0,0,0
NCT01540864,A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects,"A 26 Week Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety and Efficacy of Various Doses of HPP404 on Weight Loss in Overweight or Obese Subjects",TERMINATED,2012-05,2013-05,2015-09-04,INTERVENTIONAL,PHASE2,126.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Obesity|Overweight,HPP404|Placebo,DRUG,1,2,18 Years,65 Years,ALL,False,"High Point Pharmaceuticals, LLC.",INDUSTRY,0,10,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,4.844187086458591,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,3,1,1,0,0,2,1,,,,,0,2,0
NCT04880109,A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.,"A Phase 2, Double-blind, Placebo-controlled, Efficacy, and Safety Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.",TERMINATED,2021-10-20,2022-04-28,2024-01-18,INTERVENTIONAL,PHASE2,16.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,COVID-19,APX-115|Placebo,DRUG,1,15,18 Years,80 Years,ALL,False,"Aptabio Therapeutics, Inc.",INDIV,1,3,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.833213344056216,small,1,1,0,0,0,1,1,0,1,0,1,1,1,1,16,1,1,0,0,2,1,2021-10-20,2022-04-28,190.0,2021.0,1,2,0
NCT00197132,Study In Patients With Insulin Resistance,"A Single-centre, Randomised, Double-blind, Placebo Controlled, Two 12 Week Period, Cross-over Phase III Study to Investigate the Effect of Rosiglitazone 4mg bd on the Vasodilator Response to Hyperinsulinaemia in Obese Insulin Resistant Subjects.",COMPLETED,2002-10,2003-08,2016-12-05,INTERVENTIONAL,PHASE3,18.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Insulin Resistance,Avandia,DRUG,1,1,30 Years,65 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,1,Netherlands,1.0,0,0,1,0,0,3.0,0,0,0,0,1,2.9444389791664403,small,1,1,1,0,0,0,0,0,0,0,1,1,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT04669132,"Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer","Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer",COMPLETED,2020-12-17,2022-01-17,2022-02-23,INTERVENTIONAL,PHASE2,50.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Nausea Post Chemotherapy,Olanzapine|Netupitant|Palonesetron,DRUG,1,2,18 Years,,FEMALE,False,Instituto Brasileiro de Controle do Cancer,OTHER,0,1,Brazil,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,0,0,0,0,0,0,0,0,0,3,1,1,0,0,3,1,2020-12-17,2022-01-17,396.0,2020.0,1,1,0
NCT05239598,Povidone-Iodine Oral Rinse Study,"A Phase II, Randomized Trial to Test the Effect of Povidone-iodine 0.5% as Mouthwash/Gargle on SARS-CoV-2 Load (COVID 19) as an Adjuvant Infection Control Measure in Dental Practice",COMPLETED,2022-02-07,2022-07-13,2023-08-14,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,COVID-19,Mouth rinse,DRUG,1,1,18 Years,,ALL,False,University of Pennsylvania,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.713572066704308,small,1,1,0,1,0,1,0,0,1,0,1,1,0,1,2,1,1,0,0,1,0,2022-02-07,2022-07-13,156.0,2022.0,1,0,0
NCT00260598,LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer,LIFE-Lung Fluorescence Endoscopic Surveillance in Patients at High Risk For Developing Lung Cancer,TERMINATED,1998-08,2017-03,2018-09-13,INTERVENTIONAL,PHASE2,142.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,SCREENING,NONE,"Non-Small-Cell Lung Carcinoma|Head and Neck Squamous Cell Cancer|Pulmonary Disease, Chronic Obstructive",LIFE Bronchoscopy,PROCEDURE,1,1,18 Years,85 Years,ALL,False,University of Pittsburgh,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,3,4.962844630259907,medium,0,1,0,1,0,1,0,0,1,0,0,0,0,0,2,1,0,0,0,1,0,,,,,0,1,0
NCT02058563,"Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older",Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Seven Years and Older (209762),COMPLETED,2014-07-01,2015-09-17,2018-06-06,INTERVENTIONAL,PHASE3,996.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Rubella|Mumps|Measles,"Priorix®|Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine",BIOLOGICAL,3,13,7 Years,,ALL,True,GlaxoSmithKline,INDUSTRY,1,17,Estonia|Slovakia|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,3,6.904750769961838,xlarge,0,1,1,0,0,1,1,1,1,0,1,1,0,1,16,1,0,1,0,2,1,2014-07-01,2015-09-17,443.0,2014.0,0,4,1
NCT04544787,A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates,"A Phase 2, Partial Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of Two Novel Live Attenuated Serotype 2 Oral Poliovirus Vaccines Candidates, in Healthy Adults Previously Vaccinated With Oral Polio Vaccine (OPV) or Inactivated Polio Vaccine (IPV), Compared With Historical Controls Given Sabin OPV2 or Placebo",COMPLETED,2018-10-22,2019-05-08,2021-10-15,INTERVENTIONAL,PHASE2,250.0,ACTUAL,RANDOMIZED,SEQUENTIAL,PREVENTION,QUADRUPLE,Poliomyelitis,Novel OPV2 candidate 1|Novel OPV2 candidate 2|Placebo,BIOLOGICAL,2,11,18 Years,50 Years,ALL,True,Pierre Van Damme,OTHER,4,2,Belgium,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.5254529391317835,large,0,1,0,1,0,1,1,0,0,0,1,1,0,0,13,1,0,1,0,3,1,2018-10-22,2019-05-08,198.0,2018.0,1,2,0
NCT02370121,Effect of Gymnema Sylvestre on Metabolic Syndrome and Insulin,"Effect of Gymnema Sylvestre Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion",COMPLETED,2013-02,2015-01,2019-06-18,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Metabolic Syndrome,Placebo|Gymnema Sylvestre,DRUG,9,8,30 Years,60 Years,ALL,False,University of Guadalajara,OTHER,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.2188758248682006,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,17,1,1,0,0,2,1,,,,,0,2,0
NCT01616121,Preemptive Lung Impedance-Guided Therapy in Evolving Acute Heart Failure in Acute Myocardial Infarction Patients,,COMPLETED,2002-06-01,2014-07-01,2020-06-19,INTERVENTIONAL,PHASE3,654.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Heart Failure,Usual treatment of patients with developing acute heart failure|Lung Impedance-Guided Therapy,OTHER|DEVICE,1,1,18 Years,,ALL,False,Hillel Yaffe Medical Center,OTHER_GOV,0,1,Israel,1.0,0,0,1,0,0,3.0,0,0,0,1,1,6.484635235635252,xlarge,0,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,0,0,1,2,1,2002-06-01,2014-07-01,4413.0,2002.0,0,1,0
NCT01219816,Multi-centric Study,"Phase II, Multicenter, Open Label, Prospective to Evaluate Efficacy and Tolerance of a Chemoimmunotherapy With HyperCVAD or Vincristine/Dexamethasone Plus the Anti-CD22 Monovlonal Antobody Epratuzumab for the Treatment of Adult Relapsed/Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients : CHEPRALL Study, a GRAALL Study.",COMPLETED,2010-11,2016-11,2018-02-27,INTERVENTIONAL,PHASE2,57.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,B ALL|CD22+ Expression|Refractory B-ALL,Epratuzumab|Epratuzumab,DRUG,1,5,18 Years,,ALL,False,Nantes University Hospital,OTHER,0,11,France,1.0,0,1,0,0,0,2.0,0,0,0,0,3,4.060443010546419,medium,1,1,0,1,0,0,1,0,0,1,0,0,1,1,6,1,1,0,0,2,1,,,,,0,3,1
NCT03297216,Improving Pregnancy Outcomes With Progesterone,Z 31702 - Improving Pregnancy Outcomes With Progesterone (IPOP): a Trial of 17-Hydroxyprogesterone Caproate to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy,COMPLETED,2018-02-07,2020-08-06,2021-07-22,INTERVENTIONAL,PHASE3,800.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Pre-term Birth|HIV-1-infection,17P|Placebo,DRUG|OTHER,1,13,18 Years,,FEMALE,False,"University of North Carolina, Chapel Hill",OTHER,3,2,Zambia,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.68586094706836,xlarge,0,1,0,1,0,1,1,0,0,0,1,1,0,1,14,1,1,0,0,2,1,2018-02-07,2020-08-06,911.0,2018.0,1,3,1
NCT04462406,"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial",A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop),ACTIVE_NOT_RECRUITING,2021-02-09,2026-08-29,2026-01-28,INTERVENTIONAL,PHASE2,150.0,ESTIMATED,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Advanced Melanoma|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Melanoma of Unknown Primary|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Unresectable Acral Lentiginous Melanoma|Unresectable Melanoma|Unresectable Mucosal Melanoma,Ipilimumab|Nivolumab|Patient Observation|Pembrolizumab,OTHER|BIOLOGICAL,1,5,18 Years,,ALL,False,ECOG-ACRIN Cancer Research Group,NETWORK,1,482,United States,,0,1,0,0,0,2.0,1,0,0,0,11,5.017279836814924,medium,0,0,0,0,0,1,1,0,1,0,0,0,1,0,6,1,0,1,0,4,1,2021-02-09,2026-08-29,2027.0,2021.0,1,3,1
NCT00136604,Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m,"Assess Immunogenicity, Safety & Reactogenicity of a 4th Dose of GSK Biologicals' Tritanrix-HepB/Hib-MenAC at 15-24 m & of a Dose of Mencevax ACWY at 24-30 m in Subjects Primed With 3 Doses of Tritanrix-HepB/Hib-MenAC",COMPLETED,2006-01-22,2006-04-23,2020-02-20,INTERVENTIONAL,PHASE3,617.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Whole Cell Pertussis|Haemophilus Influenzae Type b|Hepatitis B|Diphtheria|Tetanus|Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin,Tritanrix-HepB/Hib-MenAC|Mencevax ACWY|Tritanrix-HepB/Hiberix|Meningitec,BIOLOGICAL,3,22,427 Days,730 Days,ALL,True,GlaxoSmithKline,INDUSTRY,0,3,Thailand,1.0,0,0,1,0,0,3.0,0,0,0,0,6,6.42648845745769,xlarge,0,1,1,0,0,0,1,0,0,0,1,0,0,1,25,1,0,1,0,4,1,2006-01-22,2006-04-23,91.0,2006.0,0,3,1
NCT03494504,ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis,"A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions (0.25% and 0.5%) Compared to Vehicle in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis",COMPLETED,2018-03-30,2018-11-05,2025-02-11,INTERVENTIONAL,PHASE3,318.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Allergic Conjunctivitis,Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.5%)|Vehicle Ophthalmic Solution,DRUG,1,1,18 Years,,ALL,False,"Aldeyra Therapeutics, Inc.",INDUSTRY,0,7,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.765191102784844,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,3,1,2018-03-30,2018-11-05,220.0,2018.0,1,1,0
NCT06344104,A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension,"A Double-Blind, Randomised, Placebo-Controlled, Multicentre Study Evaluating the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension",ACTIVE_NOT_RECRUITING,2024-04-08,2026-04-03,2025-12-22,INTERVENTIONAL,PHASE3,326.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Uncontrolled Hypertension|Resistant Hypertension,Baxdrostat|Placebo,DRUG,1,10,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,93,Argentina|Russia|Turkey (Türkiye)|Australia|Vietnam|Philippines|Japan|China|South Korea|Hong Kong|India,,0,0,1,0,0,3.0,0,0,0,1,2,5.7899601708972535,large,0,1,1,0,1,0,1,1,0,0,1,1,1,1,11,1,1,0,0,2,1,2024-04-08,2026-04-03,725.0,2024.0,1,4,1
NCT00484484,Ketamine Associated With Opioids in Refractory Cancer Pain Treatment,Efficacy of Low Analgesic Doses of Ketamine Associated With Opioids in Refractory Cancer Pain Treatment,COMPLETED,2007-05,2009-09,2011-05-04,INTERVENTIONAL,PHASE3,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Pain,Ketamine,DRUG,1,1,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.61512051684126,medium,0,1,0,1,0,0,0,0,0,1,1,1,1,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT00599833,Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery,Locally Advanced Pancreatic Cancer: Phase II Study of Cetuximab and 3-D Conformal Image Guided Radiotherapy (PACER),COMPLETED,2007-05,2010-10,2013-06-26,INTERVENTIONAL,PHASE2,44.0,ESTIMATED,,,TREATMENT,NONE,Pancreatic Cancer,cetuximab|3-dimensional conformal radiation therapy,RADIATION|BIOLOGICAL,1,3,18 Years,,ALL,False,The Christie NHS Foundation Trust,OTHER,0,2,United Kingdom,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.8066624897703196,small,1,0,0,1,0,0,1,0,0,1,0,0,1,0,4,1,0,1,0,2,1,,,,,0,1,0
NCT00152633,Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension,Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension,WITHDRAWN,2005-09,2006-01,2012-07-06,INTERVENTIONAL,PHASE2|PHASE3,0.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Hypertension,Losartan|Metoprolol|Losartan,DRUG,1,0,18 Years,65 Years,ALL,False,University of Erlangen-Nürnberg Medical School,OTHER,1,1,Germany,0.0,0,1,1,0,1,2.5,0,0,0,1,1,0.0,,1,1,0,1,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,3,1,,,,,0,2,0
NCT00002152,A Study of WF 10 IV Solution in Patients With Advanced HIV Disease,"Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of WF 10 IV Solution ( TCDO ) in the Management of Patients With Advanced HIV Disease",COMPLETED,,,2005-06-24,INTERVENTIONAL,PHASE2,60.0,,,,TREATMENT,DOUBLE,HIV Infections,WF10,DRUG,0,0,18 Years,,ALL,False,Oxo Chemie GmbH,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.110873864173311,medium,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT00004852,Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs,"A Phase II/III 48-Week, Randomized, Double-Blind, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lamivudine 300mg Once Daily Vs. Lamivudine 150mg BID in Combination With Zidovudine 300mg BID and Efavirenz 600mg Once Daily in Antiretroviral-Naive Adults With HIV-1 Infection",COMPLETED,1999-09,,2005-06-24,INTERVENTIONAL,PHASE2,,,,,TREATMENT,DOUBLE,HIV Infections,Efavirenz|Lamivudine|Zidovudine,DRUG,0,0,18 Years,,ALL,False,Glaxo Wellcome,INDUSTRY,0,66,Argentina|United States|Puerto Rico|Canada|Brazil,1.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,1,0,0,3,1,,,,,0,2,0
NCT05185947,"Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer","Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer",ACTIVE_NOT_RECRUITING,2022-10-13,2025-04-04,2025-03-07,INTERVENTIONAL,PHASE2,19.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Gynecologic Cancer|Gynecologic Neoplasms|Peritoneal Carcinomatosis|Peritoneal Neoplasms|Ovarian Cancer|Ovarian Neoplasms|Colorectal Cancer|Colorectal Neoplasms|Appendiceal Cancer|Appendiceal Neoplasms,Paclitaxel|Nilotinib,DRUG,1,6,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,,0,1,0,0,0,2.0,1,0,0,0,10,2.995732273553991,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,7,1,1,0,0,2,1,2022-10-13,2025-04-04,904.0,2022.0,1,3,1
NCT00864838,"Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab","Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection",COMPLETED,2008-06,2009-03,2009-03-19,INTERVENTIONAL,PHASE2,56.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Age Related Macular Degeneration|Diabetic Retinopathy,Acetazolamide|Brimonidine tartarate|Anterior chamber paracentesis,DRUG|PROCEDURE,1,0,18 Years,,ALL,False,University of Sao Paulo,OTHER,1,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.04305126783455,medium,1,1,0,1,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,3,1,,,,,0,2,0
NCT04539938,A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer,"A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer",COMPLETED,2020-12-01,2025-03-07,2025-09-30,INTERVENTIONAL,PHASE2,70.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,HER2 Positive Breast Cancer,tucatinib|trastuzumab deruxtecan,DRUG,1,13,18 Years,,ALL,False,"Seagen, a wholly owned subsidiary of Pfizer",INDUSTRY,0,140,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.2626798770413155,medium,1,1,1,0,1,0,1,0,1,0,0,0,1,0,14,1,1,0,0,2,1,2020-12-01,2025-03-07,1557.0,2020.0,1,2,0
NCT01222338,Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients,"Phase 2 Placebo-controlled, Randomized Study of Oral Immunomodulator in TB and TB/HIV Patients",COMPLETED,2010-01,2011-01,2012-08-03,INTERVENTIONAL,PHASE2,123.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Tuberculosis,V-5 immunitor,BIOLOGICAL,1,4,18 Years,70 Years,ALL,False,Lisichansk Regional Tuberculosis Dispensary,OTHER,2,1,Ukraine,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.820281565605037,medium,0,1,0,1,0,1,0,0,0,0,1,1,1,1,5,1,0,1,0,1,0,,,,,0,0,0
NCT04147858,Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia",COMPLETED,2019-11-12,2022-06-16,2023-04-28,INTERVENTIONAL,PHASE2,310.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Fibromyalgia,NYX-2925|Placebo,DRUG,1,9,18 Years,75 Years,ALL,False,Aptinyx,INDUSTRY,1,42,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.739792912179234,large,0,1,1,0,0,1,1,0,1,0,1,1,1,1,10,1,1,0,0,2,1,2019-11-12,2022-06-16,947.0,2019.0,1,2,0
NCT04896658,"Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma","Belantamab Mafodotin, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma",TERMINATED,2021-12-03,2024-12-01,2025-04-03,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Relapsed/Refractory Multiple Myeloma,"Belantamab Mafodotin, Cyclophosphamide and Dexamethasone",DRUG,2,3,18 Years,,ALL,False,"University of Maryland, Baltimore",OTHER,0,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,5,1,1,0,0,1,0,2021-12-03,2024-12-01,1094.0,2021.0,1,1,0
NCT01833455,Premature Ventricular Contractions (PVCs) and Blood Pressure Control,The Effects of PVC Suppression on Blood Pressure Control in Patients With Frequent PVCs,TERMINATED,2013-02,2016-06,2019-02-22,INTERVENTIONAL,PHASE2,8.0,ACTUAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,QUADRUPLE,Ventricular Premature Complexes|Blood Pressure,PVC Suppression using Flecainide|No PVC Suppression using Placebo,DRUG,1,1,18 Years,65 Years,ALL,False,"University of Wisconsin, Madison",OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,2.1972245773362196,small,1,1,0,1,0,0,0,0,1,0,1,1,0,0,2,1,1,0,0,2,1,,,,,0,2,0
NCT00086255,Tiagabine for the Treatment of Cocaine Dependence - 1,Tiagabine for the Treatment of Cocaine Dependence,COMPLETED,2002-10,2004-06,2017-01-12,INTERVENTIONAL,PHASE2,140.0,,,PARALLEL,TREATMENT,DOUBLE,Cocaine-Related Disorders,Tiagabine,DRUG,4,0,18 Years,99 Years,ALL,False,National Institute on Drug Abuse (NIDA),NIH,1,4,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.948759890378168,medium,0,0,0,1,0,1,1,0,1,0,0,1,1,1,4,0,1,0,0,1,0,,,,,0,0,0
NCT04442048,Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure,"COV-IMMUNO: A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure",COMPLETED,2020-10-01,2025-12-22,2025-12-30,INTERVENTIONAL,PHASE3,195.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cancer|Covid-19,IMM-101|Observation,OTHER|BIOLOGICAL,1,10,18 Years,,ALL,False,Canadian Cancer Trials Group,NETWORK,6,8,Canada,1.0,0,0,1,0,0,3.0,1,0,0,0,2,5.278114659230517,medium,0,1,0,0,0,1,1,0,0,0,1,0,1,1,11,1,0,1,0,2,1,2020-10-01,2025-12-22,1908.0,2020.0,1,3,1
NCT00269048,SB-480848 In Subjects With Coronary Heart Disease,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study of SB-480848, an Oral Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-PLA2 Effects on Circulating Biomarkers Associated With Cardiovascular Risk, Safety and Tolerability Over 12 Weeks",COMPLETED,2005-11,2006-09,2016-08-08,INTERVENTIONAL,PHASE2,969.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Atherosclerosis,SB-480848|placebo,DRUG,1,1,18 Years,80 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,119,Estonia|Argentina|Denmark|Australia|Bulgaria|United States|Canada|Hungary|New Zealand|France|Spain|Pakistan|Germany|Netherlands|Romania|India,1.0,0,1,0,0,0,2.0,0,0,0,1,1,6.877296071497429,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT01739348,An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738),"A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)",TERMINATED,2012-11-30,2017-04-14,2018-10-24,INTERVENTIONAL,PHASE2|PHASE3,2211.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Alzheimer's Disease,Verubecestat (Part I and Part II)|Verubecestat (Part I and Part II)|Verubecestat (Part I and Part II)|Placebo (Part I)|Verubecestat (Part II),DRUG,8,7,55 Years,85 Years,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,0.0,0,1,1,0,1,2.5,0,0,1,0,1,7.701652362642226,xlarge,0,1,1,0,1,0,0,0,0,0,1,1,1,1,15,1,1,0,0,5,1,2012-11-30,2017-04-14,1596.0,2012.0,0,3,1
NCT01305226,A Trial Using Double-Bolus THR-100 Versus Streptokinase,"A Prospective Phase III Parallel, Randomised Controlled Trial Using Double-bolus Recombinant Staphylokinase (THR-100) vs Streptokinase in Patients With Acute Myocardial Infarction",COMPLETED,2010-10,2011-08,2021-02-23,INTERVENTIONAL,PHASE3,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Myocardial Infarction,THR-100|Streptokinase,DRUG,1,1,30 Years,75 Years,ALL,False,Bharat Biotech International Limited,INDUSTRY,0,4,India,1.0,0,0,1,0,0,3.0,0,0,0,1,1,4.795790545596741,medium,0,1,1,0,0,0,1,0,0,0,1,0,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT04765111,Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma,A Phase II Study of Acalabrutinib Plus Rituximab in Previously Untreated Elderly Patients With Mantle Cell Lymphoma,ACTIVE_NOT_RECRUITING,2021-06-30,2026-08-30,2025-11-10,INTERVENTIONAL,PHASE2,53.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Mantle Cell Lymphoma,Acalabrutinib|Rituximab,DRUG|BIOLOGICAL,2,3,65 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,1,United States,,0,1,0,0,0,2.0,1,0,0,0,1,3.9889840465642745,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,5,1,1,1,0,2,1,2021-06-30,2026-08-30,1887.0,2021.0,1,1,0
NCT00997971,"Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein",Phase 3 Safety Study of a Partially Hydrolyzed Rice Protein Formula in Healthy Infants,COMPLETED,2007-09,2009-08,2009-10-20,INTERVENTIONAL,PHASE3,86.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,,NONE,Growth|Allergy,Modilac Rose 1,OTHER,1,2,,1 Month,ALL,False,Sodilac,INDUSTRY,0,9,France,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.465908118654584,medium,1,1,1,0,0,0,1,0,0,1,0,0,0,0,3,1,0,0,0,1,0,,,,,0,1,0
NCT03839771,"A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy","A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy.",ACTIVE_NOT_RECRUITING,2019-03-01,2034-09-19,2024-10-02,INTERVENTIONAL,PHASE3,968.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Acute Myeloid Leukemia|Myelodysplastic Syndrome With Excess Blasts-2,AG-120|Placebo for AG-120|AG-221|Placebo for AG-221,DRUG,1,11,18 Years,,ALL,False,Stichting Hemato-Oncologie voor Volwassenen Nederland,OTHER,1,181,Estonia|Finland|Australia|Sweden|Ireland|Austria|Lithuania|France|Luxembourg|Spain|Switzerland|Germany|Netherlands|Belgium|Norway,,0,0,1,0,0,3.0,1,0,0,0,2,6.876264611890766,xlarge,0,0,0,1,0,1,1,1,0,1,1,1,1,1,12,1,1,0,0,4,1,2019-03-01,2034-09-19,5681.0,2019.0,1,4,1
NCT00000871,A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers,A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers,COMPLETED,,2000-01,2021-11-04,INTERVENTIONAL,PHASE2,420.0,,,,PREVENTION,DOUBLE,HIV Infections,MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|MN rgp120/HIV-1 and A244 rgp120/HIV-1|ALVAC-HIV MN120TMG (vCP205)|rgp120/HIV-1 SF-2,BIOLOGICAL,0,0,18 Years,60 Years,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,18,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.042632833682381,large,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,4,1,,,,,0,1,0
NCT04527471,Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19,"A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19",COMPLETED,2020-09-04,2021-05-01,2022-09-22,INTERVENTIONAL,PHASE2,45.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Coronavirus Infection|Covid-19|SARS-CoV-2,Ensifentrine Dose 1|Placebo pMDI,DRUG,1,0,18 Years,80 Years,ALL,False,Verona Pharma Inc,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,3.828641396489095,small,1,1,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2020-09-04,2021-05-01,239.0,2020.0,1,2,0
NCT02906644,Combination Nicotine Patch / Lorcaserin for Smoking Cessation,Combination Nicotine Patch / Lorcaserin for Smoking Cessation,COMPLETED,2016-11-08,2018-10-18,2019-05-07,INTERVENTIONAL,PHASE2,97.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Nicotine Dependence,lorcaserin|nicotine patch|placebo lorcaserin,DRUG,2,6,18 Years,65 Years,ALL,False,Duke University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.584967478670572,medium,1,1,0,1,0,1,0,0,1,0,1,1,1,1,8,1,1,0,0,3,1,2016-11-08,2018-10-18,709.0,2016.0,1,2,0
NCT01212744,"Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)","A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Dose Levels of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria",COMPLETED,2011-03,2015-04,2019-02-26,INTERVENTIONAL,PHASE2,16.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Phenylketonuria,rAvPAL-PEG,DRUG,1,9,16 Years,70 Years,ALL,False,BioMarin Pharmaceutical,INDUSTRY,0,9,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.833213344056216,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,10,1,1,0,0,1,0,,,,,0,1,0
NCT01184144,Endometriosis: Immunomodulation,Effect of Pioglitazone on Peritoneal Cytokines in Women With Endometriosis,WITHDRAWN,2010-08,2012-05,2015-10-02,INTERVENTIONAL,PHASE2|PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,Endometriosis,Pioglitazone,DRUG,1,0,18 Years,45 Years,FEMALE,False,"University of Wisconsin, Madison",OTHER,0,0,,0.0,0,1,1,0,1,2.5,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,,,,,0,1,0
NCT04381234,Strategies for Asymmetrical Triacetate Dialyzer Heparin-Free Effective Hemodialysis,Strategies for Asymmetrical Triacetate Dialyzer,COMPLETED,2018-01-06,2020-05-05,2020-05-21,INTERVENTIONAL,PHASE2,20.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Hemodialysis Complication,dialyzer|hemodialysis with citrate-containing dialysate|predilution hemodiafiltration,OTHER|COMBINATION_PRODUCT|DEVICE,1,3,18 Years,,ALL,False,Universitaire Ziekenhuizen KU Leuven,OTHER,1,1,Belgium,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,0,1,0,1,0,0,0,0,1,0,1,0,4,1,0,0,1,3,1,2018-01-06,2020-05-05,850.0,2018.0,1,1,0
NCT05533164,Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse,Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse,ACTIVE_NOT_RECRUITING,2023-02-09,2028-01,2026-02-04,INTERVENTIONAL,PHASE3,174.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Polymyalgia Rheumatica,Rituximab|Placebo,DRUG,1,8,50 Years,,ALL,False,Sint Maartenskliniek,OTHER,2,1,Netherlands,,0,0,1,0,0,3.0,0,0,0,0,1,5.1647859739235145,medium,0,0,0,1,0,1,0,0,0,0,1,1,1,1,9,1,1,0,0,2,1,2023-02-09,,,2023.0,1,2,0
NCT01570764,Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease,Intravenous Cyclophosphamide for the Treatment of Systemic Sclerosis Associated Interstitial Lung Disease,COMPLETED,2013-01-14,2018-02-22,2025-09-12,INTERVENTIONAL,PHASE3,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Systemic Sclerosis|Scleroderma|Interstitial Lung Disease|Lung Fibrosis,Cyclophosphamide|Placebo,DRUG,1,9,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,2,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,4,3.713572066704308,small,1,1,0,1,0,1,0,0,0,1,1,1,1,1,10,1,1,0,0,2,1,2013-01-14,2018-02-22,1865.0,2013.0,0,3,1
NCT02914509,Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT,"A Prospective, Multicenter, Randomized, Parallel-Arm, Double Masked, Vehicle Controlled Phase 3A Study Evaluating the Safety and Efficacy of OTX-TP in the Treatment of Subjects With Open-Angle Glaucoma or Ocular Hypertension",COMPLETED,2016-11-07,2019-03-30,2021-10-11,INTERVENTIONAL,PHASE3,565.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Open Angle Glaucoma|Ocular Hypertension,Travoprost|Placebo Vehicle,DRUG|OTHER,3,0,18 Years,,ALL,False,"Ocular Therapeutix, Inc.",INDUSTRY,0,10,United States,1.0,0,0,1,0,0,3.0,0,0,0,1,2,6.338594078203183,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,1,1,3,0,1,0,0,2,1,2016-11-07,2019-03-30,873.0,2016.0,1,2,0
NCT03492099,Assessing the Safety of Buprenorphine in People With Sickle Cell Disease,Assessing the Safety of Buprenorphine in People With Sickle Cell Disease,COMPLETED,2018-08-01,2022-02-28,2022-04-25,INTERVENTIONAL,PHASE2,47.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Sickle Cell Disease,buprenorphine,DRUG,1,3,18 Years,,ALL,False,Johns Hopkins University,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.871201010907891,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2018-08-01,2022-02-28,1307.0,2018.0,1,0,0
NCT03323398,Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies,"A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Efficacy Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection Alone or in Combination With Durvalumab for Patients With Advanced Malignancies",TERMINATED,2017-08-15,2021-08-18,2024-07-31,INTERVENTIONAL,PHASE1|PHASE2,79.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Relapsed/Refractory Solid Tumor Malignancies or Lymphoma|Ovarian Cancer,mRNA-2416|Durvalumab,BIOLOGICAL,3,3,18 Years,,ALL,False,"ModernaTX, Inc.",INDUSTRY,0,9,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,2,4.382026634673881,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,1,6,1,0,1,0,2,1,2017-08-15,2021-08-18,1464.0,2017.0,1,4,1
NCT00683163,PTH & Ibandronate Combination Study (PICS),PTH & Ibandronate Combination Study (PICS): Optimizing the Use of PTH With Boniva (Pilot Randomized Controlled Trial),COMPLETED,2008-05,2011-04,2013-11-05,INTERVENTIONAL,PHASE2|PHASE3,44.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Osteoporosis,PTH(1-84)|Ibandronate|Placebo injection|Placebo pills,DRUG|OTHER,1,1,55 Years,75 Years,FEMALE,False,"University of California, San Francisco",OTHER,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.8066624897703196,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,2,1,1,0,0,4,1,,,,,0,2,0
NCT03645863,Effects of Iron Supplements on the Pharmacokinetics of MT-6548,A Clinical Pharmacological Study to Evaluate the Effects of Iron Supplements on the Pharmacokinetics of MT-6548 in Healthy Male Volunteers,COMPLETED,2018-08-27,2018-09-30,2026-01-07,INTERVENTIONAL,PHASE3,61.0,ACTUAL,RANDOMIZED,CROSSOVER,OTHER,NONE,Healthy,MT-6548|Iron supplement A|Iron supplement B|Iron supplement C|Iron supplement D,DRUG,7,0,20 Years,45 Years,MALE,True,Tanabe Pharma Corporation,INDUSTRY,0,1,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.127134385045092,medium,1,1,1,0,0,0,0,0,0,0,1,0,0,0,7,0,1,0,0,5,1,2018-08-27,2018-09-30,34.0,2018.0,1,2,0
NCT03298087,Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer,Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer,COMPLETED,2018-07-01,2024-03-31,2025-08-01,INTERVENTIONAL,PHASE2,28.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Newly Diagnosed Oligometastatic Prostate Cancer,radical prostatectomy|stereotactic body radiotherapy|Leuprolide|apalutamide|abiraterone,PROCEDURE|DRUG|RADIATION,1,6,18 Years,,MALE,False,VA Office of Research and Development,FED,0,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.367295829986474,small,1,1,0,0,0,0,1,0,1,0,0,0,1,0,7,1,1,0,0,5,1,2018-07-01,2024-03-31,2100.0,2018.0,1,2,0
NCT00548587,Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome,"A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and Its Effects on Clinical Events and Biomarkers in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome",COMPLETED,2007-10,2009-08,2016-02-04,INTERVENTIONAL,PHASE2,600.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Acute Coronary Syndrome,E5555|Placebo,DRUG,1,1,45 Years,80 Years,ALL,False,Eisai Inc.,INDUSTRY,0,2,United Kingdom|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.398594934535208,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT00622193,Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Anamorelin HCl Dose Range Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC",COMPLETED,2008-03,2009-12,2017-04-14,INTERVENTIONAL,PHASE2,228.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Carcinoma, Non-Small-Cell Lung",anamorelin HCl|anamorelin HCl|placebo,DRUG,1,1,18 Years,85 Years,ALL,False,"Helsinn Therapeutics (U.S.), Inc",INDUSTRY,0,33,India|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.43372200355424,large,0,1,1,0,0,0,1,1,1,0,1,1,1,1,2,1,1,0,0,3,1,,,,,0,2,0
NCT01620593,Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer,"Phase II, Randomized, Placebo Controlled, Double Blind, Prospective Study of Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer.",COMPLETED,2011-04,2016-09,2018-05-23,INTERVENTIONAL,PHASE2,41.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Prostate Cancer,Placebo|Metformin,DRUG,2,3,18 Years,,MALE,False,The University of Texas Health Science Center at San Antonio,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.7376696182833684,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT01827293,Promethazine vs. Lorazepam for Treatment of Vertigo,Promethazine vs. Lorazepam for Treatment of Vertigo in the Emergency Department: A Randomized Clinical Trial,COMPLETED,2013-04,2013-06,2013-06-14,INTERVENTIONAL,PHASE3,210.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Peripheral Vertigo.,Promethazine|Lorazepam,DRUG,1,1,18 Years,65 Years,ALL,False,Shahid Beheshti University of Medical Sciences,OTHER,0,1,Iran,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.351858133476067,large,0,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT01421121,Safety and Immunogenicity of an Inactivated EV71 Vaccine in Infants,,COMPLETED,2011-06,2011-12,2012-11-27,INTERVENTIONAL,PHASE2,540.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,"Infection, Viral, Enterovirus",100U EV71 vaccine with adjuvant|200 U EV71 vaccine with adjuvant|400U EV71 vaccine with adjuvant|200U EV71 vaccine without adjuvant|Placebo,BIOLOGICAL,1,1,6 Months,35 Months,ALL,True,"Sinovac Biotech Co., Ltd",INDUSTRY,0,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.293419278846481,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,0,1,2,1,0,1,0,5,1,,,,,0,1,0
NCT01210521,Use of Vitamin D3 for the Treatment of Steroid Resistant Asthmatic Patients,Use of Vitamin D3 for the Treatment of Steroid Resistant Asthmatic Patients,WITHDRAWN,2010-09,2016-02,2016-08-10,INTERVENTIONAL,PHASE2,0.0,ACTUAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,Asthma,Vitamin D,DRUG,1,1,12 Years,70 Years,ALL,False,Florida Atlantic University,OTHER,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT00190216,Assessing Repetitive Transcranial Magnetic Stimulation as a Treatment for Refractory Depression (rTMS),Assessing Repetitive Transcranial Magnetic Stimulation as a Treatment for Refractory Depression,TERMINATED,2001-12,2007-10,2007-11-08,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Depression,Magnetic stimulator,DEVICE,1,2,18 Years,55 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,2,1,France,0.0,0,0,1,0,0,3.0,0,0,1,0,1,4.110873864173311,medium,1,1,0,1,0,1,0,0,0,1,1,1,1,1,3,1,0,0,1,1,0,,,,,0,0,0
NCT01659606,Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita,Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease,ACTIVE_NOT_RECRUITING,2012-07,2034-12,2026-01-09,INTERVENTIONAL,PHASE2,40.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Dyskeratosis Congenita|Hoyeraal Hreidarsson Syndrome|Revesz Syndrome|Aplastic Anemia,alemtuzumab|Fludarabine|Cyclosporins|Mycophenolate mofetil|Tacrolimus,DRUG|BIOLOGICAL,1,10,30 Days,65 Years,ALL,False,Boston Children's Hospital,OTHER,15,14,Sweden|Norway|United States,,0,1,0,0,0,2.0,0,0,0,0,4,3.713572066704308,small,1,0,0,1,0,1,1,1,1,0,0,0,1,0,11,1,1,1,0,5,1,,,,,0,4,1
NCT02275806,Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC,A Phase II Study of Definitive Concurrent Radiation Therapy With Cisplatin and Irinotecan Chemotherapy in Locally Advanced In-operable Non-Small Cell Lung Cancer,TERMINATED,2014-10,2017-09-27,2019-08-21,INTERVENTIONAL,PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Lung Neoplasms, Non-Small Cell Lung Cancer",Irinotecan|Cisplatin,DRUG,2,2,18 Years,,ALL,False,Leo W. Jenkins Cancer Center,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.6094379124341003,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,4,1,1,0,0,2,1,,2017-09-27,,,0,1,0
NCT05815004,An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3,"Guard3: An Open-label, Parallel-arm, Randomized, Controlled, Phase 2/Phase 3 Study Evaluating the Efficacy and Safety of Autologous HSC Gene Therapy, AVR-RD-02, Compared to ERT for Gaucher Disease Type 3 in Participants Aged 2 to 25",WITHDRAWN,2023-10,2027-12,2023-08-09,INTERVENTIONAL,PHASE2|PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Gaucher Disease, Type 3",Gene therapy|Enzyme Replacement Agent,DRUG,1,10,2 Years,25 Years,ALL,False,AVROBIO,INDUSTRY,0,0,,0.0,0,1,1,0,1,2.5,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,1,1,11,1,1,0,0,2,1,,,,,0,3,1
NCT01987804,Dose-relationship of Vaginally Administrated Oxytocin in Postmenopausal Women,"A Double-blind, Placebo Controlled Single Centre Trial to Evaluate the Dose-relationship of the Effects of Vaginally Administered Oxytocin on the Vaginal Mucosal Membrane in Postmenopausal Women With Vaginal Atrophy",COMPLETED,2012-01,2013-01,2020-11-13,INTERVENTIONAL,PHASE2,64.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Vaginal Atrophy,Oxytocin 100 i.u.|Oxytocin 400 i.u.|Placebo,DRUG,1,1,40 Years,,FEMALE,False,PepTonic Medical AB,INDUSTRY,1,1,Sweden,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.174387269895637,medium,1,1,1,0,0,1,0,0,0,0,1,1,1,1,2,1,1,0,0,3,1,,,,,0,1,0
NCT00642304,A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.,"A Single Arm Open Label Study to Assess Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneously C.E.R.A. for the Maintenance of Hemoglobin Levels in Patients With Chronic Renal Anemia Not on Dialysis",COMPLETED,2008-03-27,2009-12-09,2018-06-26,INTERVENTIONAL,PHASE3,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Anemia,methoxy polyethylene glycol-epoetin beta [C.E.R.A.],DRUG,1,5,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,23,Netherlands,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.044522437723423,small,1,1,1,0,1,0,1,0,0,0,0,0,1,0,6,1,1,0,0,1,0,2008-03-27,2009-12-09,622.0,2008.0,0,1,0
NCT04968184,Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD),A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of KBP-5074 Mineralocorticoid Receptor Antagonist in Subjects With Uncontrolled Hypertension and Moderate or Severe (Stage 3b/4) CKD,TERMINATED,2021-11-05,2024-07-10,2025-09-03,INTERVENTIONAL,PHASE3,652.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Kidney Diseases,Placebo|KBP-5074,DRUG,2,11,18 Years,,ALL,False,KBP Biosciences,INDUSTRY,0,215,Canada|Lithuania|Latvia|South Africa|China|Hungary|Hong Kong|Australia|Bulgaria|Spain|Israel|United States|Czechia|Georgia|Germany|Poland|South Korea|Croatia|Malaysia|Bosnia and Herzegovina|Taiwan|Serbia,0.0,0,0,1,0,0,3.0,0,0,0,0,1,6.481577129276431,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,13,1,1,0,0,2,1,2021-11-05,2024-07-10,978.0,2021.0,1,3,1
NCT01876433,Beta 3 Agonist Treatment in Heart Failure,Beta 3 Agonist Treatment in Heart Failure,COMPLETED,2013-09-30,2015-09-30,2020-10-19,INTERVENTIONAL,PHASE2,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Heart Failure With Reduced Ejection Fraction (HFrEF),Mirabegron|Placebo,DRUG,1,10,18 Years,,ALL,False,Henning Bundgaard,OTHER,0,3,Denmark|Australia,1.0,0,1,0,0,0,2.0,0,0,0,1,1,4.2626798770413155,medium,1,1,0,1,0,0,1,1,0,0,1,1,1,1,11,1,1,0,0,2,1,2013-09-30,2015-09-30,730.0,2013.0,0,3,1
NCT01468233,Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa,A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II,COMPLETED,2011-11,2014-04,2021-07-12,INTERVENTIONAL,PHASE3,326.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hidradenitis Suppurativa (HS),adalimumab|placebo,BIOLOGICAL,1,3,18 Years,99 Years,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.7899601708972535,large,0,1,1,0,1,0,0,0,0,0,1,1,1,1,4,1,0,1,0,2,1,,,,,0,1,0
NCT05736952,Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer,Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer：,WITHDRAWN,2023-03-01,2026-02-01,2023-05-11,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Platinum-resistant Ovarian Cancer,Oral Topotecan Combined With Anlotinib,DRUG,1,4,18 Years,,FEMALE,False,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",OTHER,0,1,China,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,5,1,1,0,0,1,0,2023-03-01,2026-02-01,1068.0,2023.0,1,0,0
NCT05324852,AGItated Patients Management: intraNASAL Midazolam vs Intramuscular Loxapine,"AGItated Patients Management: intraNASAL Midazolam vs Intramuscular Loxapine, a Randomized Non Inferiority Trial",TERMINATED,2023-04-09,2024-04-23,2024-05-28,INTERVENTIONAL,PHASE3,1.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Emergence Delirium,Intranasal midazolam|Intramuscular loxapine,DRUG,1,7,18 Years,60 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,1,1,France,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.6931471805599453,small,1,1,0,1,0,1,0,0,0,1,1,0,1,1,8,1,1,0,0,2,1,2023-04-09,2024-04-23,380.0,2023.0,1,2,0
NCT00517738,Effect of Physical Training Program on Health-related Quality of Life in Cirrhosis,Impact and Safety of a Physical Training Program on Health-related Quality of Life in Patients With Cirrhosis and Portal Hypertension,COMPLETED,2007-02,2014-05,2015-10-08,INTERVENTIONAL,PHASE2,29.0,ACTUAL,RANDOMIZED,PARALLEL,,NONE,Cirrhosis,Physical training|Diet intervention,OTHER,2,4,18 Years,70 Years,ALL,False,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,OTHER,1,2,Mexico,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4011973816621555,small,1,1,0,1,0,1,1,0,0,0,1,0,0,1,6,1,0,0,0,2,1,,,,,0,2,0
NCT00024258,Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors,Phase II Study of Arsenic Trioxide in Neuroblastoma and Other Pediatric Solid Tumors,COMPLETED,2001-03,2009-05,2015-11-25,INTERVENTIONAL,PHASE2,22.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Kidney Cancer|Liver Cancer|Neuroblastoma|Ovarian Cancer|Retinoblastoma|Sarcoma,arsenic trioxide,DRUG,1,0,,40 Years,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,9,3.1354942159291497,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,1,0
NCT00087958,"Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment","Phase II Multi-Center, Open-Label, Non-Randomized Study of Intravenous RPR109881 Given Every 3 Weeks in Patients With Metastatic Breast Cancer Progressing After Therapy With Anthracyclines, Taxanes and Capecitabine",COMPLETED,2004-08,2009-04,2009-05-01,INTERVENTIONAL,PHASE2,168.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,XRP9881,DRUG,1,3,18 Years,,ALL,False,Sanofi,INDUSTRY,0,15,Argentina|Turkey (Türkiye)|Denmark|United States|Colombia|Canada|South Korea|France|South Africa|Spain|Switzerland|Germany|Netherlands|Belgium|Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.1298987149230735,medium,0,1,1,0,1,0,1,1,1,1,0,0,1,0,4,1,1,0,0,1,0,,,,,0,1,0
NCT00352248,Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder,Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder,COMPLETED,,,2006-07-14,INTERVENTIONAL,PHASE3,50.0,,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Autistic Disorder|Autism,Tongue Acupuncture (Procedure),PROCEDURE,5,0,3 Years,11 Years,ALL,False,The University of Hong Kong,OTHER,0,1,Hong Kong,1.0,0,0,1,0,0,3.0,0,0,0,0,2,3.9318256327243257,small,1,0,0,1,0,0,0,0,0,0,1,0,1,1,5,0,0,0,0,1,0,,,,,0,1,0
NCT00915655,A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents,"A Phase II, Open-Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Drv/Rtv Once Daily in Treatment-Naive HIV-1 Infected Adolescents Aged Between 12 and < 18 Years",COMPLETED,2009-07,2011-03,2012-09-03,INTERVENTIONAL,PHASE2,12.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,HIV-1 Infection,darunavir|ritonavir|zidovudine|lamivudine|abacavir,DRUG,1,1,12 Years,18 Years,ALL,False,"Tibotec Pharmaceuticals, Ireland",INDUSTRY,1,9,United Kingdom|Ukraine|United States|Ireland|France|Spain,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.5649493574615367,small,1,1,1,0,0,1,1,1,1,1,0,0,1,0,2,1,1,0,0,5,1,,,,,0,2,0
NCT00006255,"Magnetic Resonance Imaging-guided Thermal Radiofrequencey Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases","A Phase II Study of Magnetic Resonance Guided and Monitored Interstitial Thermal Radiofrequency Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases",COMPLETED,2000-04,2005-03,2010-06-11,INTERVENTIONAL,PHASE2,17.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Kidney Cancer|Metastatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific",radiofrequency ablation|thermal ablation therapy,PROCEDURE,1,0,18 Years,,ALL,False,Case Comprehensive Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,2.8903717578961645,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,2,1,,,,,0,2,0
NCT01416155,Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis,"A Long-Term, Open-Label, Multicenter, Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2010-10,2014-12,2016-01-14,INTERVENTIONAL,PHASE2,97.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis,natalizumab,DRUG,2,2,18 Years,65 Years,ALL,False,Biogen,INDUSTRY,0,22,Japan,1.0,0,1,0,0,0,2.0,0,1,0,0,2,4.584967478670572,medium,1,1,1,0,1,0,1,0,0,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,1,0
NCT00507455,Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction,"A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate With 0.4 mg Tamsulosin Hydrochloride OCAS (TOCAS) Using Urodynamics in Male Subjects With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)",COMPLETED,2007-06,2008-08,2014-08-06,INTERVENTIONAL,PHASE2,222.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Lower Urinary Tract Symptoms|Bladder Outlet Obstruction,solifenacin succinate|tamsulosin hydrochloride|Placebo to solifenacin|Placebo to tamsulosin,DRUG,2,16,45 Years,,MALE,False,Astellas Pharma Inc,INDUSTRY,0,33,United States|Hungary|Czechia|Germany|Poland|Belgium,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.407171771460119,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,18,1,1,0,0,4,1,,,,,0,4,1
NCT02114255,Effects of BCG on Influenza Induced Immune Response,The Effects of BCG-vaccination on the Immune Response Induced by Influenza-vaccination in Healthy Volunteers. A Pilot Proof-of-principle Study.,COMPLETED,2014-05,2014-09,2015-11-10,INTERVENTIONAL,PHASE2|PHASE3,40.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Influenza Virus Infection|Trained Immunity,Placebo|BCG,OTHER|BIOLOGICAL,2,7,18 Years,35 Years,MALE,True,Radboud University Medical Center,OTHER,0,1,Netherlands,1.0,0,1,1,0,1,2.5,0,0,0,0,2,3.713572066704308,small,1,1,0,1,0,0,0,0,0,0,1,1,0,1,9,1,0,1,0,2,1,,,,,0,4,1
NCT01339455,Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica,Autologous Hematopoietic Stem Cell Transplant in Patients With Neuromyelitis Optica,TERMINATED,2011-03,2017-03,2018-05-02,INTERVENTIONAL,PHASE1|PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Neuromyelitis Optica,AHSCT,PROCEDURE,1,9,18 Years,65 Years,ALL,False,University of Calgary,OTHER,0,1,Canada,0.0,1,1,0,0,1,1.5,0,0,0,0,1,1.3862943611198906,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,10,1,0,0,0,1,0,,,,,0,2,0
NCT01020955,Metabolic Effects of GH and IGF-I in Growth Hormone Deficient(GHD) and Diabetes and Impaired Glucose Tolerance(IGT),Effects on Insulin Sensitivity and Body Composition of GH and IGF-I in Adult-GHD With Impaired Glucose Tolerance or Diabetes,COMPLETED,2009-10,2011-11,2015-04-07,INTERVENTIONAL,PHASE3,14.0,ACTUAL,RANDOMIZED,PARALLEL,,QUADRUPLE,Diabetes,NutropinAq (GH) and Increlex (IGF-I)|NutropinAq and placebo,DRUG,1,1,18 Years,70 Years,ALL,False,Karolinska University Hospital,OTHER,0,1,Sweden,1.0,0,0,1,0,0,3.0,0,0,0,0,1,2.70805020110221,small,1,1,0,1,0,0,0,0,0,0,1,1,0,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT00004026,CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy,A Phase II Study of CT-2584 Mesylate in Patients With Hormone Refractory Prostate Cancer,TERMINATED,1998-12,2005-01,2020-10-19,INTERVENTIONAL,PHASE2,80.0,ESTIMATED,RANDOMIZED,,TREATMENT,,Prostate Cancer,CT-2584|chemotherapy,DRUG,0,0,18 Years,120 Years,MALE,False,CTI BioPharma,INDUSTRY,0,7,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,4.394449154672439,medium,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,2,1,,,,,0,1,0
NCT04140526,"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)",ACTIVE_NOT_RECRUITING,2020-09-16,2027-12-31,2025-05-23,INTERVENTIONAL,PHASE1|PHASE2,733.0,ESTIMATED,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Non Small Cell Lung Cancer|Advanced Solid Tumor|Metastatic Melanoma|Metastatic Head and Neck Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Colorectal Cancer|Sarcomas|Metastatic Prostate Cancer|Ovarian Cancer|Small Cell Lung Cancer|Metastatic Breast Cancer|Pancreas Cancer|Gastric Cancer|Esophageal Cancer|Gastroesophageal Junction Adenocarcinoma|Cervical Cancer|Adenoid Cystic Carcinoma|Salivary Gland Cancer|Urothelial Carcinoma,ONC-392|Pembrolizumab|Docetaxel,DRUG,4,5,18 Years,,ALL,False,"OncoC4, Inc.",INDUSTRY,1,37,Australia|United States,,1,1,0,0,1,1.5,1,0,0,0,19,6.598509028614515,xlarge,0,0,1,0,0,1,1,1,1,0,0,0,1,0,9,1,1,0,0,3,1,2020-09-16,2027-12-31,2662.0,2020.0,1,5,1
NCT00705146,CMC (Carpometacarpal) OA (Osteoarthritis) Thumb Splint Study,Comparison of Two Carpometacarpal Stabilizing Splints for People With Thumb Osteoarthritis,COMPLETED,2008-04,2009-06,2014-12-11,INTERVENTIONAL,PHASE2,56.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Osteoarthritis,Comfort Cool thumb splint by North Coast Medical|Custom made thermoplastic & neoprene splint,DEVICE,1,1,45 Years,,ALL,False,University of British Columbia,OTHER,1,3,Canada,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.04305126783455,medium,1,1,0,1,0,1,1,0,0,0,1,0,1,0,2,1,0,0,1,2,1,,,,,0,1,0
NCT00957346,Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14-21 Weeks LMP),Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14-21 Weeks LMP): A Randomized-controlled Double-blinded Trial,TERMINATED,2011-02,2012-01,2011-11-08,INTERVENTIONAL,PHASE3,20.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Abortion, Induced",Mifepristone+misoprostol|Placebo+Misoprostol,DRUG,2,5,,,FEMALE,True,Gynuity Health Projects,OTHER,1,1,Puerto Rico,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.044522437723423,small,1,0,0,1,0,1,0,0,0,0,1,1,1,1,7,1,1,0,0,2,1,,,,,0,2,0
NCT04299503,Topical Crisaborole in Patients with Alopecia Areata,Phase 2 Double Blind Randomized Placebo Controlled Trial of Topical Crisaborole in Patients with Mild-to-Moderate Alopecia Areata,WITHDRAWN,2020-03-06,2022-12,2024-10-28,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Alopecia Areata,Crisaborole Topical Ointment|Placebo Topical Ointment,DRUG,2,10,2 Years,,ALL,False,Tufts Medical Center,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,1,0,1,1,1,0,12,1,1,0,0,2,1,2020-03-06,,,2020.0,1,2,0
NCT01023061,Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer,"Phase II Trial of Radiation With Androgen Deprivation: Abiraterone Acetate, Prednisone and Luteinizing Hormone Releasing Hormone Agonist Prior to Radiation Therapy",COMPLETED,2010-03,2015-09,2017-06-06,INTERVENTIONAL,PHASE2,24.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Adenocarcinoma of the Prostate|Stage II Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer,abiraterone acetate|prednisone|leuprolide acetate|laboratory biomarker analysis|external beam radiation therapy|goserelin acetate,DRUG|OTHER|RADIATION,2,1,18 Years,,MALE,False,University of Washington,OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,3.2188758248682006,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,3,1,1,0,0,6,1,,,,,0,2,0
NCT00220961,Actos Now for Prevention of Diabetes (ACT NOW),Actos Now for Prevention of Diabetes (ACT NOW),COMPLETED,2004-01,2010-04,2016-08-11,INTERVENTIONAL,PHASE3,602.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Impaired Glucose Tolerance|Type 2 Diabetes,Pioglitazone|Placebo,DRUG,1,4,18 Years,,ALL,False,The University of Texas Health Science Center at San Antonio,OTHER,2,8,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.401917196727186,xlarge,0,1,0,1,0,1,1,0,1,0,1,1,0,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00425061,Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma,"Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study Conducted Sequentially With 3 Doses Of Ima-638 Administered Sc.",COMPLETED,2007-02,2008-08,2015-01-14,INTERVENTIONAL,PHASE2,159.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Asthma,IMA-638|IMA-638|placebo,OTHER|BIOLOGICAL,2,19,18 Years,80 Years,ALL,False,Pfizer,INDUSTRY,0,82,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.075173815233827,medium,0,1,1,0,1,0,1,1,1,0,1,1,1,1,21,1,0,1,0,3,1,,,,,0,3,1
NCT01641042,Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects,Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Administered to at Risk Subjects From 1 to Less Than 18 Years,COMPLETED,2012-09-10,2015-03-03,2017-10-18,INTERVENTIONAL,PHASE3,86.0,ACTUAL,NON_RANDOMIZED,PARALLEL,PREVENTION,NONE,"Infections, Meningococcal",Meningococcal vaccine GSK134612,BIOLOGICAL,2,19,1 Year,17 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,16,Czechia|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.465908118654584,medium,1,1,1,0,0,0,1,1,1,0,0,0,0,1,21,1,0,1,0,1,0,2012-09-10,2015-03-03,904.0,2012.0,0,2,0
NCT00347386,Therapeutic Zinc in Infant Bacterial Illness,Zinc as an Immunomodulator in the Treatment of Possible Serious Bacterial Infections in Infants 7 Days and up to 4 Months of Age,COMPLETED,2005-07,2008-12,2010-12-07,INTERVENTIONAL,PHASE2|PHASE3,700.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Sepsis|Bacterial Infections|Pneumonia,Drug: Zinc (zinc sulphate)|Placebo,DRUG,1,3,1 Week,4 Months,ALL,False,Centre For International Health,OTHER,1,3,India,1.0,0,1,1,0,1,2.5,0,0,0,0,3,6.55250788703459,xlarge,0,1,0,1,0,1,1,0,0,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,3,1
NCT01124370,Chronic Evaluation of Respicardia Therapy,Safety and Efficacy Evaluation of Respicardia Therapy for Central Sleep Apnea,COMPLETED,2010-05,2014-08,2016-05-16,INTERVENTIONAL,PHASE2,57.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Sleep Disordered Breathing|Cheyne Stokes Respiration|Periodic Breathing|Sleep Apnea|Central Sleep Apnea,remedē (TM) system,DEVICE,1,6,18 Years,,ALL,False,"Respicardia, Inc.",INDUSTRY,0,13,Germany|Poland|Italy|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,5,4.060443010546419,medium,1,1,1,0,0,0,1,1,1,1,0,0,1,0,7,1,0,0,1,1,0,,,,,0,3,1
NCT02968173,A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus,"A Prospective, International, Multicenter, Open-Label, Non-Controlled Study of Safety and Effectiveness of Palivizumab, in Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus",COMPLETED,2016-11-09,2017-07-13,2018-03-13,INTERVENTIONAL,PHASE3,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Respiratory Syncytial Virus (RSV),Palivizumab,DRUG,1,7,,24 Months,ALL,False,AbbVie,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.9318256327243257,small,1,1,1,0,1,0,0,0,0,0,0,0,1,0,8,1,1,0,0,1,0,2016-11-09,2017-07-13,246.0,2016.0,1,1,0
NCT04951869,: Protescal: Prevention of Hypertrophic Scar and Keloid Formation Post Caesarean Section,Assessing the Effectiveness of Protescal In Preventing Post Caesarean Section Hypertrophic Scar and Keloid,COMPLETED,2017-04-26,2017-11-16,2021-07-07,INTERVENTIONAL,PHASE2|PHASE3,90.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Caesarean Wound|Hypertrophic Surgical Scar|Keloid Scar Following Surgery,Protescal gel,DRUG,3,1,18 Years,,FEMALE,True,Universiti Kebangsaan Malaysia Medical Centre,OTHER,0,1,Malaysia,1.0,0,1,1,0,1,2.5,0,0,0,0,3,4.51085950651685,medium,1,1,0,1,0,0,0,0,0,0,1,0,0,1,4,1,1,0,0,1,0,2017-04-26,2017-11-16,204.0,2017.0,1,2,0
NCT06128369,Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery,"A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of OCS-01 Ophthalmic Suspension in the Treatment of Inflammation and Pain Following Cataract Surgery",TERMINATED,2023-12-18,2024-05-09,2024-12-10,INTERVENTIONAL,PHASE3,117.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Inflammation Eye|Pain, Postoperative|Cataract",Dexamethasone Ophthalmic Suspension|Vehicle of OCS-01,DRUG|OTHER,2,0,18 Years,,ALL,False,Oculis,INDUSTRY,1,12,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,3,4.770684624465665,medium,0,1,1,0,0,1,1,0,1,0,1,1,1,1,2,0,1,0,0,2,1,2023-12-18,2024-05-09,143.0,2023.0,1,2,0
NCT00004083,Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer,A Phase II Pilot Study of SPI-77 (Stealth Liposomal Cisplatin) in Patients With Recurrent Platinum-Sensitive Ovarian Cancer,COMPLETED,1999-02,,2011-03-28,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Ovarian Cancer,cisplatin liposomal,DRUG,0,0,18 Years,,FEMALE,False,NYU Langone Health,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT02980341,Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer,"Phase 1/2, Multicenter, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer",COMPLETED,2016-11-28,2023-09-07,2024-10-30,INTERVENTIONAL,PHASE1|PHASE2,182.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Metastatic Breast Cancer,Patritumab Deruxtecan,DRUG,2,18,18 Years,,ALL,False,"Daiichi Sankyo Co., Ltd.",INDUSTRY,2,26,Japan|United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,5.209486152841421,medium,0,1,1,0,0,1,1,1,1,0,1,0,1,0,20,1,1,0,0,1,0,2016-11-28,2023-09-07,2474.0,2016.0,1,3,1
NCT04158141,Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma,Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM),TERMINATED,2020-01-29,2023-11-20,2025-02-19,INTERVENTIONAL,PHASE3,16.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Pleural Biphasic Mesothelioma|Pleural Epithelioid Mesothelioma|Stage I Pleural Malignant Mesothelioma AJCC v8|Stage IA Pleural Malignant Mesothelioma AJCC v8|Stage IB Pleural Malignant Mesothelioma AJCC v8|Stage II Pleural Malignant Mesothelioma AJCC v8|Stage IIIA Pleural Malignant Mesothelioma AJCC v8,Carboplatin|Cisplatin|Decortication|Intensity-Modulated Radiation Therapy|Pemetrexed|Pemetrexed Disodium|Pencil beam scanning proton therapy|Pleurectomy,DRUG|PROCEDURE|RADIATION,1,5,18 Years,80 Years,ALL,False,NRG Oncology,OTHER,1,27,Canada|United States,0.0,0,0,1,0,0,3.0,0,0,0,0,7,2.833213344056216,small,1,1,0,1,0,1,1,1,1,0,1,0,1,1,6,1,1,0,0,8,1,2020-01-29,2023-11-20,1391.0,2020.0,1,4,1
NCT00332241,Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD),"A Multicenter Double-Blind, Randomized, Placebo-Controlled, Flexible-Dosed, Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder (AD)",COMPLETED,2006-06,2008-04,2013-12-02,INTERVENTIONAL,PHASE3,98.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Autistic Disorder,Aripiprazole|Placebo,DRUG,1,7,6 Years,17 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,1,9,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.59511985013459,medium,1,1,1,0,0,1,1,0,1,0,1,1,1,1,8,1,1,0,0,2,1,,,,,0,2,0
NCT00546754,BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333),"BP-EASE-A 12-Week, Multicenter, Open-Label, Randomized, Controlled Trial To Compare The Effectiveness of Losartan 50 mg/HCTZ 12.5 mg Titrated as Needed to Losartan 100 mg/HCTZ 25 mg or Valsartan 160 mg/HCTZ 25 mg, in Patients With Essential Hypertension Who Have Not Achieved Target Blood Pressure With",COMPLETED,2007-05-01,2009-05-01,2024-05-16,INTERVENTIONAL,PHASE3,808.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hypertension,losartan potassium (+) hydrochlorothiazide|Comparator: Valsartan (+) Hydrochlorothiazide,DRUG,2,11,18 Years,75 Years,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,1,1,6.695798917058491,xlarge,0,1,1,0,0,0,0,0,0,0,1,0,1,1,13,1,1,0,0,2,1,2007-05-01,2009-05-01,731.0,2007.0,0,2,0
NCT01796405,Clofarabine for Langerhans in Pedi,Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis,WITHDRAWN,,,2015-08-25,INTERVENTIONAL,PHASE2,0.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Langerhans Cell Histiocytosis,Clofarabine,DRUG,1,3,,,ALL,False,Dana-Farber Cancer Institute,OTHER,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,1,4,1,1,0,0,1,0,,,,,0,0,0
NCT01526694,Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM,"Phase II Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in R/R MM Pts After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs",COMPLETED,2012-07,2017-04-08,2018-07-03,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma,Bendamustine|Thalidomide|Dexamethasone,DRUG,2,3,18 Years,,ALL,False,Azienda Ospedaliera di Bolzano,OTHER,1,19,Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,1,1,0,0,1,0,0,1,0,5,1,1,0,0,3,1,,2017-04-08,,,0,1,0
NCT02976766,Gypenosides Treatment for Optic Neuritis,"Gypenosides Treatment for Optic Neuritis: a Randomised, Double-blind, Placebo-controlled Trial",TERMINATED,2017-02-04,2020-12-31,2025-12-19,INTERVENTIONAL,PHASE2,10.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Optic Neuritis,Gypenosides|Placebo,DRUG,1,5,18 Years,60 Years,ALL,False,First Affiliated Hospital of Guangxi Medical University,OTHER,0,1,China,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,6,1,1,0,0,2,1,2017-02-04,2020-12-31,1426.0,2017.0,1,2,0
NCT03517566,A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis,"A Randomized, Double-blind, Placebo-controlled Multicenter Dose Ranging Study to Assess the Safety and Efficacy of Multiple Oral ZPL389 Doses in Patients With Moderate to Severe Atopic Dermatitis (ZEST Trial)",TERMINATED,2018-11-14,2020-08-06,2021-10-08,INTERVENTIONAL,PHASE2,293.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Atopic Dermatitis,Placebo|ZPL389 3mg|ZPL389 10mg|ZPL389 30mg|ZPL389 50mg,DRUG,1,6,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,89,United Kingdom|Russia|Finland|United States|Canada|Hungary|Slovakia|Netherlands|Austria|Poland|Taiwan|Czechia|Japan|Germany|Iceland|Belgium,0.0,0,1,0,0,0,2.0,0,0,0,0,1,5.683579767338681,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,7,1,1,0,0,5,1,2018-11-14,2020-08-06,631.0,2018.0,1,3,1
NCT00699166,"Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)","A Randomized, Double-Blind, Placebo-Controlled, Multicenter 2-Week Pilot Study to Evaluate the Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) Given Orally in Female Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)",COMPLETED,2004-04,2005-09,2008-06-17,INTERVENTIONAL,PHASE2,135.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Irritable Bowel Syndrome,DNK333,DRUG,1,1,18 Years,,FEMALE,False,Novartis,INDUSTRY,0,29,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.912654885736052,medium,0,1,1,0,1,0,1,0,1,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT00016666,Clinical Trial of Propranolol for Seasonal Affective Disorder,Treatment of Winter Depression With Pharmacological Suppression of Melatonin Secretion,COMPLETED,2001-05-21,2007-01-19,2017-07-02,INTERVENTIONAL,PHASE2,70.0,,,,TREATMENT,,Seasonal Affective Disorder|Healthy,Propranolol,DRUG,0,0,18 Years,50 Years,ALL,True,National Institute of Mental Health (NIMH),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.2626798770413155,medium,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,2001-05-21,2007-01-19,2069.0,2001.0,0,1,0
NCT05591222,Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Investigate the Efficacy and Safety of Daxdilimab Subcutaneous Injection in Reducing Disease Activity in Adult Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus",TERMINATED,2022-12-29,2025-05-08,2025-10-21,INTERVENTIONAL,PHASE2,72.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Discoid Lupus Erythematosus,Placebo|Daxdilimab,DRUG,1,6,18 Years,75 Years,ALL,False,Amgen,INDUSTRY,0,68,Argentina|Denmark|Bulgaria|United States|Canada|Brazil|Poland|France|Czechia|Germany|Greece,0.0,0,1,0,0,0,2.0,0,1,0,0,1,4.290459441148391,medium,1,1,1,0,1,0,1,1,1,1,1,1,1,1,7,1,1,0,0,2,1,2022-12-29,2025-05-08,861.0,2022.0,1,3,1
NCT02300922,Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer,Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer : A Multicentric Phase I/II Study of Fractionated TF2 Plus 90Y-IMP288 (RITCOLON),TERMINATED,2015-01-27,2017-12-20,2022-08-01,INTERVENTIONAL,PHASE1|PHASE2,7.0,ACTUAL,,SINGLE_GROUP,OTHER,NONE,Metastatic Colorectal Cancer,Antibody TF2|90-Y-IMP-288|111-In-IMP-288,DRUG,1,0,18 Years,,ALL,False,Nantes University Hospital,OTHER,0,1,France,0.0,1,1,0,0,1,1.5,1,0,0,0,1,2.0794415416798357,small,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,3,1,2015-01-27,2017-12-20,1058.0,2015.0,1,2,0
NCT02092922,A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM),,COMPLETED,2014-05,2017-09-05,2020-10-19,INTERVENTIONAL,PHASE2,154.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Multiple Myeloma,"Filanesib, KSP (Eg5) inhibitor; intravenous|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous",DRUG,1,7,18 Years,,ALL,False,Pfizer,INDUSTRY,0,60,United Kingdom|United States|Canada|France|Spain|Germany|Greece|Belgium,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.043425116919247,medium,0,1,1,0,1,0,1,1,1,1,0,0,1,0,8,1,1,0,0,2,1,,2017-09-05,,,0,3,1
NCT03555422,Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer [SIENDO],"A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer",ACTIVE_NOT_RECRUITING,2018-01-05,2025-12,2025-01-20,INTERVENTIONAL,PHASE3,263.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Endometrial Cancer,Selinexor|Matching placebo for selinexor,DRUG,1,12,18 Years,,FEMALE,False,Karyopharm Therapeutics Inc,INDUSTRY,7,78,United States|Canada|Spain|Czechia|Italy|China|Germany|Greece|Belgium|Israel,,0,0,1,0,0,3.0,1,0,0,0,1,5.575949103146316,large,0,1,1,0,0,1,1,1,1,1,1,1,1,1,13,1,1,0,0,2,1,2018-01-05,,,2018.0,1,3,1
NCT01321151,Use of Resveratrol to Decrease Acute Secondary Brain Injury Following Sports-Related Concussions in Boxers,"Use of Resveratrol to Decrease Secondary Brain Injury Following Sports-Related Concussions: a Double-Blind, Placebo-Controlled Study",COMPLETED,2011-03,2011-11,2021-02-11,INTERVENTIONAL,PHASE1|PHASE2,12.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Sports Concussion,Resveratrol|Placebo,DRUG,2,4,18 Years,35 Years,ALL,True,University of Texas Southwestern Medical Center,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.5649493574615367,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,3,1
NCT01703351,Prospective Randomized Trial Comparing the Effectiveness of Continuous Paravertebral Infusion of Local Anesthetics Versus Intravenous Patient-controlled Analgesia on Acute and Chronic Neuropathic Pain After VATS Lobectomy,,COMPLETED,2012-10-04,2015-11-06,2019-01-31,INTERVENTIONAL,PHASE2,79.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Lung Neoplasms|Postoperative Pain,0.5% ropivacaine|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg,DRUG,1,1,18 Years,78 Years,ALL,False,Yonsei University,OTHER,0,1,South Korea,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.382026634673881,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,2,1,2012-10-04,2015-11-06,1128.0,2012.0,0,2,0
NCT00201851,Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer,Phase III Randomized Study of Immediate Versus Luteal Phase Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-positive Breast Cancer,COMPLETED,2004-01,2013-05,2015-04-29,INTERVENTIONAL,PHASE3,740.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,Tamoxifen|Surgery: Oophorectomy,DRUG|PROCEDURE,1,0,18 Years,50 Years,FEMALE,False,International Breast Cancer Research Foundation,OTHER,0,9,Vietnam|Philippines|Morocco,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.608000625296087,xlarge,0,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,2,1,,,,,0,2,0
NCT01135329,"Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers","Reduced-intensity, Related-donor Allogeneic BMT With Fludarabine, Busulfan, and High-dose Posttransplantation Cyclophosphamide for Hematologic Malignancies",TERMINATED,2010-08,2012-05,2018-07-03,INTERVENTIONAL,PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lymphoma|Leukemia|Myelodysplastic Syndrome,Fludarabine|Busulfan|Cyclophosphamide|Mycophenolate Mofetil|Tacrolimus,DRUG,2,6,6 Months,75 Years,ALL,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,3,2.772588722239781,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,8,1,1,0,0,5,1,,,,,0,3,1
NCT01215929,Studying Amphetamine Withdrawal in Humans,Amphetamine Withdrawal Paradigm in Humans,COMPLETED,2009-10,2014-05,2014-08-04,INTERVENTIONAL,PHASE2,35.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Methamphetamine Dependence,Dextroamphetamine|Placebo,DRUG,1,0,21 Years,65 Years,ALL,False,University of Arkansas,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.58351893845611,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT01466231,Everolimus in Refractory Testicular Germ Cell Cancer,Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer.,COMPLETED,2011-11,2015-06,2016-01-12,INTERVENTIONAL,PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Germ Cell Tumor,Everolimus,DRUG,1,7,18 Years,,MALE,False,"National Cancer Institute, Slovakia",OTHER_GOV,0,1,Slovakia,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.772588722239781,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,8,1,1,0,0,1,0,,,,,0,1,0
NCT00006231,Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma,A Randomized Study to Assess Whether Radiotherapy Prevents Skin Lumps at Sites Where Needles or Tubes Have Been Inserted in Patients With Malignant Mesothelioma,COMPLETED,1998-02,2002-12,2013-12-19,INTERVENTIONAL,PHASE3,44.0,ESTIMATED,,,TREATMENT,,Malignant Mesothelioma|Perioperative/Postoperative Complications,quality-of-life assessment|standard follow-up care|radiation therapy,PROCEDURE|RADIATION,1,0,,,ALL,False,University of Glasgow,OTHER,0,3,United Kingdom,1.0,0,0,1,0,0,3.0,0,0,0,0,2,3.8066624897703196,small,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,3,1,,,,,0,2,0
NCT00002802,Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma,PHASE III MULTICENTRE TRIAL OF TREATMENT OF NEUROBLASTOMA IN CHILDREN AND ADOLESCENTS,COMPLETED,1990-07,2003-09,2013-12-19,INTERVENTIONAL,PHASE3,500.0,ESTIMATED,NON_RANDOMIZED,,TREATMENT,,Neuroblastoma,carboplatin|cisplatin|cyclophosphamide|dacarbazine|doxorubicin hydrochloride|etoposide|ifosfamide|melphalan|mesna|vincristine sulfate|vindesine|autologous bone marrow transplantation|conventional surgery|low-LET cobalt-60 gamma ray therapy|low-LET electron therapy|low-LET photon therapy|radioisotope therapy,DRUG|PROCEDURE|RADIATION,0,0,,20 Years,ALL,False,"Children's Hospital Medical Center, Cincinnati",OTHER,0,1,Germany,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.2166061010848646,large,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,17,1,,,,,0,1,0
NCT00005053,Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer,Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Pancreatic Cancer,COMPLETED,1999-12,,2012-09-24,INTERVENTIONAL,PHASE2,35.0,ACTUAL,RANDOMIZED,,TREATMENT,,Pancreatic Cancer,glufosfamide,DRUG,0,0,18 Years,,ALL,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,0,15,Denmark|Netherlands|France|Switzerland|Germany|Greece|Israel,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.58351893845611,small,1,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,1,0,,,,,0,1,0
NCT05809453,Intranasal Cocaine and Temperature Regulation During Exercise,Intranasal Cocaine and Temperature Regulation During Exercise,COMPLETED,2023-09-01,2024-08-01,2025-07-14,INTERVENTIONAL,PHASE1|PHASE2,27.0,ACTUAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,SINGLE,Hyperthermia|Cocaine Use|Exercise,Cocaine|Lidocaine,DRUG,1,5,18 Years,50 Years,ALL,True,University of Texas Southwestern Medical Center,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,3,3.332204510175204,small,1,1,0,1,0,0,0,0,1,0,1,0,0,0,6,1,1,0,0,2,1,2023-09-01,2024-08-01,335.0,2023.0,1,4,1
NCT00108953,A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma,A Randomized Controlled Study of BAY43-9006 in Combination With Doxorubicin Versus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma.,COMPLETED,2005-04,2008-04,2014-10-31,INTERVENTIONAL,PHASE2,96.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Carcinoma, Hepatocellular","Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin|Doxorubicin/Placebo",DRUG,1,7,18 Years,,ALL,False,Bayer,INDUSTRY,0,28,United Kingdom|Argentina|Russia|United States|Canada|Hong Kong,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.574710978503383,medium,1,1,1,0,0,0,1,1,1,1,1,1,1,1,8,1,1,0,0,2,1,,,,,0,3,1
NCT01685853,Bowel Cleansing for Colonoscopy: Comparison Between a Same Day Low-Volume Preparation and a Conventional 4L Split One,"Bowel Cleansing for Colonoscopy: Comparison Between a Same Day Low-Volume Preparation and a Conventional 4L Split One. A Randomized, Observer-blind, Parallel Group, Comparative Study.",COMPLETED,2011-04,2012-03,2012-09-19,INTERVENTIONAL,PHASE3,164.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Colonoscopy,Bisacodyl plus PEG-CS|PEG 4 litres split,DRUG,1,6,18 Years,85 Years,ALL,False,European Institute of Oncology,OTHER,0,1,Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.10594547390058,medium,0,1,0,1,0,0,0,0,0,1,1,0,1,1,7,1,1,0,0,2,1,,,,,0,2,0
NCT02205372,"Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy","A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 (Low Dose) in Subjects With Diabetic Nephropathy",COMPLETED,2014-07,2015-08,2015-09-16,INTERVENTIONAL,PHASE1|PHASE2,31.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetic Nephropathy,MT-3995|Placebo,DRUG,1,4,20 Years,75 Years,ALL,False,Tanabe Pharma Corporation,INDUSTRY,0,1,Japan,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.4657359027997265,small,1,1,1,0,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00000937,Study and Treatment of Post Lyme Disease (STOP-LD),Study and Treatment of Post Lyme Disease (STOP-LD),COMPLETED,,2005-11,2010-08-27,INTERVENTIONAL,PHASE3,55.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Lyme Disease,Antibiotics,DRUG,0,0,18 Years,65 Years,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.02535169073515,medium,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,,,,,0,0,0
NCT00432237,Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016),"A Phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK0974 in the Acute Treatment of Migraine With or Without Aura",COMPLETED,2007-03,2007-12,2015-07-03,INTERVENTIONAL,PHASE3,1703.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Migraine,MK0974 50 mg|MK0974 150 mg|MK0974 300 mg|Comparator: Placebo,DRUG,5,3,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,1,0,1,7.440733707389261,xlarge,0,1,1,0,1,0,0,0,0,0,1,1,1,1,8,1,1,0,0,4,1,,,,,0,2,0
NCT05195645,AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS,AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS,ACTIVE_NOT_RECRUITING,2022-10-04,2025-09-15,2024-12-13,INTERVENTIONAL,PHASE2,21.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Myocarditis,Abatacept 250 MG,DRUG,1,52,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,1,France,,0,1,0,0,0,2.0,0,0,0,0,1,3.091042453358316,small,1,1,0,1,0,0,0,0,0,1,1,1,1,1,53,1,1,0,0,1,0,2022-10-04,2025-09-15,1077.0,2022.0,1,1,0
NCT03678545,Dupilumab in Eosinophilic Gastritis,"A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis",COMPLETED,2021-05-15,2024-11-13,2025-11-04,INTERVENTIONAL,PHASE2,41.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Eosinophilic Gastritis|Eosinophilic Gastroenteritis,Dupilumab (blinded)|Placebo (blinded),DRUG,1,0,12 Years,70 Years,ALL,False,"Children's Hospital Medical Center, Cincinnati",OTHER,2,12,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.7376696182833684,small,1,1,0,1,0,1,1,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2021-05-15,2024-11-13,1278.0,2021.0,1,2,0
NCT00237172,Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study),Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study),COMPLETED,2002-09,,2012-05-01,INTERVENTIONAL,PHASE2,72.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Gastrointestinal Stromal Tumors,Imatinib Mesylate,DRUG,1,1,20 Years,74 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.290459441148391,medium,1,1,1,0,1,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT03878095,Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors,A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors,ACTIVE_NOT_RECRUITING,2020-01-30,2026-07-10,2025-11-17,INTERVENTIONAL,PHASE2,24.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Malignant Solid Neoplasm|Refractory Cholangiocarcinoma|Refractory Malignant Solid Neoplasm,Biopsy Procedure|Biospecimen Collection|Bone Marrow Aspiration|Bone Marrow Biopsy|Ceralasertib|Computed Tomography|Magnetic Resonance Imaging|Olaparib,PROCEDURE|DRUG,1,4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,13,United States,,0,1,0,0,0,2.0,1,0,0,0,3,3.2188758248682006,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,5,1,1,0,0,8,1,2020-01-30,2026-07-10,2353.0,2020.0,1,2,0
NCT04356495,Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation,Randomized Trial to Evaluate the Safety and Efficacy of Outpatient Treatments to Reduce the Risk of Worsening in Individuals With COVID-19 With Risk Factors (COVERAGE France),COMPLETED,2020-07-29,2021-10-22,2022-02-04,INTERVENTIONAL,PHASE2|PHASE3,412.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Corona Virus Infection|Sars-CoV2,Vitamins|Telmisartan|Ciclesonide|interferon β-1b,DRUG|DIETARY_SUPPLEMENT,4,12,50 Years,,ALL,False,"University Hospital, Bordeaux",OTHER,1,7,France,1.0,0,1,1,0,1,2.5,0,0,0,0,2,6.023447592961033,large,0,1,0,1,0,1,1,0,0,1,1,0,1,1,16,1,1,0,0,4,1,2020-07-29,2021-10-22,450.0,2020.0,1,4,1
NCT00318695,"Influence of Probiotics on Prevention of Atopy, Atopic Disease and Immunological Responses","Influence of Probiotics on Prevention of Atopy, Atopic Disease and Immunological Responses- A Randomized Double-Blind Placebo Controlled Trial",COMPLETED,2004-05,2009-01,2009-01-22,INTERVENTIONAL,PHASE2,253.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Eczema|Asthma|Allergic Rhinitis,Probiotics|Placebo,OTHER|DIETARY_SUPPLEMENT,1,3,,,ALL,True,"National University Hospital, Singapore",OTHER,2,1,Singapore,1.0,0,1,0,0,0,2.0,0,0,0,0,3,5.537334267018537,large,0,1,0,1,0,1,0,0,0,0,1,1,0,1,4,1,0,0,0,2,1,,,,,0,2,0
NCT04791839,Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer,A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,2021-08-04,2030-06-30,2025-11-05,INTERVENTIONAL,PHASE2,30.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Non Small Cell Lung Cancer|Non-small Cell Carcinoma|Non-small Cell Lung Cancer,Zimberelimab|Domvanalimab|Etrumadenant,DRUG,1,6,18 Years,,ALL,False,Washington University School of Medicine,OTHER,1,1,United States,,0,1,0,0,0,2.0,1,0,0,0,3,3.4339872044851463,small,1,1,0,1,0,1,0,0,1,0,0,0,1,1,7,1,1,0,0,3,1,2021-08-04,2030-06-30,3252.0,2021.0,1,3,1
NCT00630539,A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women,"Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A Phase II Dose Ranging, 12-Week, Randomized , Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 5 mg, 15 mg and 30 mg Daily Doses With Placebo",COMPLETED,2007-08,2008-02,2013-06-28,INTERVENTIONAL,PHASE2,126.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Atrophy|Vaginal Diseases,Placebo|Ospemifene 5 mg|Ospemifene 15 mg|Ospemifene 30 mg,DRUG,3,8,40 Years,80 Years,FEMALE,False,Shionogi,INDUSTRY,2,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.844187086458591,medium,0,1,1,0,0,1,0,0,0,0,1,1,1,1,11,1,1,0,0,4,1,,,,,0,3,1
NCT00430157,Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber,"An 8 Day, Randomised, Double Blinded, Placebo-controlled 2-way Crossover Trial of Repeat Doses of Intranasal GSK256066 and Placebo in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR)",COMPLETED,2007-01,,2012-06-04,INTERVENTIONAL,PHASE2,45.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Rhinitis, Allergic, Seasonal|Seasonal Allergic Rhinitis",GSK256066,DRUG,1,1,18 Years,50 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,1,Austria,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.828641396489095,small,1,1,1,0,0,0,0,0,0,0,1,1,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT01447212,Study to Assess Longer-term Opioid Medication Effectiveness (SALOME),"SALOME: Multi-Centre, Double Blind Randomized Controlled Trial Comparing The Effectiveness Of Diacetylmorphine Vs. Hydromorphone For The Treatment Of Long-Term Injection Opioid Users Who Do Not Benefit From Available Therapies",COMPLETED,2011-12,2016-02,2016-06-07,INTERVENTIONAL,PHASE3,202.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Opioid Dependence|Heroin Dependence,"Hydromorphone, Injectable|Diacetylmorphine, injectable|Hydromorphone, liquid oral|Diacetylmorphine, liquid oral",DRUG,1,0,19 Years,,ALL,False,University of British Columbia,OTHER,3,1,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.313205979041787,large,0,1,0,1,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,4,1,,,,,0,2,0
NCT02045212,Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).,"A Preliminary Double Blind Clinical Study, Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).",COMPLETED,2014-02,2016-12,2020-03-19,INTERVENTIONAL,PHASE2,22.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Non-arteritic Ischemic Optic Neuropathy|Optic Nerve Injuries,RPh201|Placebo,DRUG,3,1,18 Years,,ALL,False,Regenera Pharma Ltd,INDUSTRY,0,1,Israel,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.1354942159291497,small,1,1,1,0,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT05585112,Articaine 4% Versus Lidocaine 2% for Local Anesthesia of MIH-affected Maxillary Molars,Comparative Study of Articaine 4% Versus Lidocaine 2% in Local Anesthesia and Permanent Maxillary First Molars Affected by MIH.,COMPLETED,2022-10-17,2022-12-25,2023-05-03,INTERVENTIONAL,PHASE1|PHASE2,26.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Molar Incisor Hypomineralisation,Lidocaine 2%|Articaine 4%,DRUG,4,0,6 Years,12 Years,ALL,True,Tishreen University,OTHER,0,1,Syria,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.295836866004329,small,1,1,0,1,0,0,0,0,0,0,1,1,1,0,4,0,1,0,0,2,1,2022-10-17,2022-12-25,69.0,2022.0,1,2,0
NCT01754181,Initial Testing of the Diabeloop Algorithm in T1D Patients on Pump Therapy Over the Prandial Period and Physical Activity.,"Development of the Glycemic Control Algorithm, in Prandial and Physical Effort Situations.",COMPLETED,2013-03,2013-07,2014-10-27,INTERVENTIONAL,PHASE3,18.0,ACTUAL,NON_RANDOMIZED,CROSSOVER,HEALTH_SERVICES_RESEARCH,NONE,Type 1 Diabetes,Insulin,DRUG,1,1,18 Years,,ALL,False,Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète,OTHER,0,3,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,2.9444389791664403,small,1,1,0,1,0,0,1,0,0,1,0,0,0,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT00838812,Safety and Efficacy Study of Association Between Tretinoin and Clindamycin on the Treatment of Acne Mild and Moderate,"Monocentric Study, Prospective, Open and Non Controlled for to Evaluate the Effectiveness, and Tolerability the Safety of Association of Clindamycin Phosphate 1.2% and Tretinoin 0,025% in the Treatment of Acne Vulgaris Mild to Moderate, When Used Once Daily for 12 Weeks.",COMPLETED,2009-03,2010-04,2010-05-25,INTERVENTIONAL,PHASE3,154.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Acne Vulgaris,application of the topic gel,DRUG,1,0,12 Years,,ALL,True,Igefarma Laboratorios S.A.,INDUSTRY,0,1,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.043425116919247,medium,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT00256919,Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA),"A Randomised, Placebo-controlled, Parallel Group Single Dose Study of GW856553 in Patients With Active RA to Investigate the C-Reactive Protein (CRP) Dose Response Relationship",COMPLETED,2005-11,2006-11,2012-11-05,INTERVENTIONAL,PHASE2,51.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Arthritis, Rheumatoid",GW856553,DRUG,1,1,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,17,Ukraine|Bulgaria|Sweden|Spain|Germany,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.9512437185814275,medium,1,1,1,0,0,0,1,1,0,1,1,1,1,1,2,1,1,0,0,1,0,,,,,0,1,0
NCT03490019,Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement,Treatment of Infantile and Juvenile Patients With Bardet-Biedl-Syndrome With Metformin. Evaluation of a Visual Improvement as a Side Effect of the Pediatric Treatment of Adipositas - a Prospective Pilot Study Without Control,WITHDRAWN,2018-04-01,2020-08,2019-04-18,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Bardet-Biedl Syndrome|Visual Impairment,Metformin,DRUG,1,11,10 Years,25 Years,ALL,False,University Hospital Tuebingen,OTHER,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,2,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,12,1,1,0,0,1,0,2018-04-01,,,2018.0,1,2,0
NCT02652130,Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD,Safety Follow-up Through 180 Days of Treatment With Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD,COMPLETED,2015-10-28,2018-06-15,2022-03-16,INTERVENTIONAL,PHASE3,32.0,ACTUAL,,SINGLE_GROUP,OTHER,NONE,Grade B Acute Graft Versus Host Disease|Grade C Acute Graft Versus Host Disease|Grade D Acute Graft Versus Host Disease,Remestemcel-L,BIOLOGICAL,1,1,2 Months,17 Years,ALL,False,"Mesoblast, Inc.",INDUSTRY,1,20,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,3,3.4965075614664802,small,1,1,1,0,0,1,1,0,1,0,0,0,0,0,2,1,0,1,0,1,0,2015-10-28,2018-06-15,961.0,2015.0,1,1,0
NCT01185028,A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures,"An Open-Label Safety and Tolerability Study of Nitazoxanide, Pegylated-Interferon Alfa 2a and Ribavirin in HIV/HCV Co-Infected Genotype 1 Prior Treatment Relapsers and Non-Responders",COMPLETED,2010-08,2011-10,2021-10-05,INTERVENTIONAL,PHASE1|PHASE2,8.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatitis C Infection|HIV Infection,Nitazoxanide With Pegylated Interferon And Ribavirin,DRUG,1,2,18 Years,99 Years,ALL,False,National Institutes of Health Clinical Center (CC),NIH,0,4,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,2,2.1972245773362196,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,2,0
NCT06018467,Senolytics to Improve Osteoporosis Therapy,SENolytics to Improve Osteoporosis Therapy: a Randomised Controlled Clinical Trial The SENIOR Trial,ACTIVE_NOT_RECRUITING,2023-09-06,2026-04-30,2026-01-28,INTERVENTIONAL,PHASE2,120.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Osteopenia, Osteoporosis|Age-related Bone Loss",Dasatinib 100 Mg Oral Tablet|Quercetin 1.250 mg (oral)|Nicotinamide Riboside 1g (oral),DRUG|DIETARY_SUPPLEMENT,1,2,60 Years,90 Years,ALL,False,Odense University Hospital,OTHER,2,1,Denmark,,0,1,0,0,0,2.0,0,0,0,0,2,4.795790545596741,medium,0,0,0,1,0,1,0,0,0,0,1,0,1,1,3,1,1,0,0,3,1,2023-09-06,2026-04-30,967.0,2023.0,1,2,0
NCT00131300,A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Shoulder Osteoarthritis,,COMPLETED,2004-04,2006-02,2015-03-18,INTERVENTIONAL,PHASE3,,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Osteoarthritis|Musculoskeletal Diseases,Synvisc (hylan G-F 20),DEVICE,1,0,18 Years,,ALL,False,"Genzyme, a Sanofi Company",INDUSTRY,0,6,Germany|France,1.0,0,0,1,0,0,3.0,0,1,0,0,2,0.0,,0,0,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,,,,,0,2,0
NCT01032200,Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors,A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue,COMPLETED,2010-08-01,2013-01-08,2021-09-28,INTERVENTIONAL,PHASE2,54.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,QUADRUPLE,Brain Tumors|Nervous System Tumors|Cognition Disorders|Fatigue,Armodafinil|placebo,DRUG|OTHER,2,3,18 Years,,ALL,False,Wake Forest University Health Sciences,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,4.007333185232471,medium,1,1,0,1,0,1,0,0,1,0,1,1,0,1,5,1,1,0,0,2,1,2010-08-01,2013-01-08,891.0,2010.0,0,2,0
NCT01573754,Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda,A Prospective Comparison of Low Dose Hydroxychloroquine and Phlebotomy in the Treatment of Porphyria Cutanea Tarda. IRB 02-435,COMPLETED,2006-03-21,2021-07-06,2023-02-17,INTERVENTIONAL,PHASE2,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Porphyria Cutanea Tarda,Hydroxychloroquine|Phlebotomy,DRUG|PROCEDURE,1,3,18 Years,100 Years,ALL,False,"The University of Texas Medical Branch, Galveston",OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8918202981106265,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,4,1,1,0,0,2,1,2006-03-21,2021-07-06,5586.0,2006.0,0,1,0
NCT00445705,Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome,,TERMINATED,2007-03,2008-01,2015-09-07,INTERVENTIONAL,PHASE2,211.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Fibromyalgia,placebo|AGN 203818|AGN 203818|AGN 203818,DRUG,1,3,18 Years,75 Years,FEMALE,False,Allergan,INDUSTRY,0,3,United Kingdom|Switzerland|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,5.356586274672012,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,4,1,1,0,0,4,1,,,,,0,2,0
NCT00441766,Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain,,TERMINATED,2007-03,2008-02,2012-01-20,INTERVENTIONAL,PHASE2,213.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Irritable Bowel Syndrome,AGN 203818|AGN 203818|AGN 203818|placebo,DRUG,1,3,18 Years,,FEMALE,False,Allergan,INDUSTRY,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,5.365976015021851,large,0,1,1,0,0,0,0,0,1,0,1,1,1,1,4,1,1,0,0,4,1,,,,,0,1,0
NCT00102466,Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes,Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes,COMPLETED,2005-01,2009-01,2020-12-17,INTERVENTIONAL,PHASE3,1007.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2",vildagliptin|Gliclazide|Metformin,DRUG,1,5,18 Years,78 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,2,Germany|Switzerland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.915723448631314,xlarge,0,1,1,0,1,0,1,1,0,1,1,1,1,1,6,1,1,0,0,3,1,,,,,0,3,1
NCT03470922,A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma,"A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma",ACTIVE_NOT_RECRUITING,2018-04-11,2030-12-15,2025-09-09,INTERVENTIONAL,PHASE2|PHASE3,714.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Melanoma,Relatlimab|Nivolumab,BIOLOGICAL,1,2,12 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,127,Canada|Austria|Argentina|Russia|Australia|Spain|Romania|Norway|Belgium|Italy|Israel|Chile|Finland|United States|Sweden|Colombia|France|Germany|Greece|Poland|United Kingdom|Denmark|Brazil|New Zealand|Mexico,,0,1,1,0,1,2.5,1,0,0,0,1,6.5722825426940075,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,3,1,0,1,0,2,1,2018-04-11,2030-12-15,4631.0,2018.0,1,3,1
NCT00164151,A Comparison of the Efficacy and Safety of HalfLytely Vs Visicol Prior To Colonoscopy.,"A Comparison of the Efficacy and Safety of Two Bowel Preparations: HalfLytely® (2L NuLYTELY and 20 mg Bisacodyl), and Visicol™ Prior To Colonoscopy.",COMPLETED,2001-06,,2013-02-07,INTERVENTIONAL,PHASE3,60.0,,RANDOMIZED,FACTORIAL,,SINGLE,Colonoscopy,HalfLytely|Visicol,DRUG,1,2,18 Years,,ALL,,Braintree Laboratories,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.110873864173311,medium,1,0,1,0,0,0,0,0,1,0,1,0,0,0,3,1,1,0,0,2,1,,,,,0,1,0
NCT02152631,A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer,JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy,ACTIVE_NOT_RECRUITING,2014-10-03,2025-12,2025-04-22,INTERVENTIONAL,PHASE3,453.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non Small Cell Lung Cancer,Abemaciclib|Erlotinib,DRUG,1,6,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,231,Canada|Austria|China|Argentina|Russia|Spain|Romania|Italy|Israel|Ukraine|United States|France|South Korea|Poland|Germany|Greece|Turkey (Türkiye)|Puerto Rico|Brazil|Taiwan|Japan,,0,0,1,0,0,3.0,1,0,0,0,1,6.118097198041348,large,0,1,1,0,1,0,1,1,1,1,1,0,1,1,7,1,1,0,0,2,1,2014-10-03,,,2014.0,0,3,1
NCT00696631,European Trial of Dronedarone in Moderate to Severe Congestive Heart Failure,Antiarrhythmic Trial With Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease,TERMINATED,2002-06,2003-08,2010-02-15,INTERVENTIONAL,PHASE3,653.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Congestive Heart Failure,Dronedarone (SR33589)|Placebo,DRUG,1,0,18 Years,,ALL,False,Sanofi,INDUSTRY,0,6,Denmark|Sweden|Poland|Hungary|Netherlands|Norway,0.0,0,0,1,0,0,3.0,0,0,0,1,1,6.483107351457199,xlarge,0,1,1,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,2,0
NCT01454531,An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy,An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy,COMPLETED,2011-06,2012-04,2015-03-06,INTERVENTIONAL,PHASE2|PHASE3,199.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Allergic Rhinoconjunctivitis,AVANZ Phleum pratense,DRUG,1,5,18 Years,65 Years,ALL,False,ALK-Abelló A/S,INDUSTRY,0,20,Spain,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.298317366548036,medium,0,1,1,0,0,0,1,0,0,1,0,0,1,0,6,1,1,0,0,1,0,,,,,0,2,0
NCT02287831,Umbilical Cord Mesenchymal Stem Cells Injection for Peripheral Arterial Disease,Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Injection for Peripheral Arterial Disease,COMPLETED,2014-02,2022-12-26,2023-02-08,INTERVENTIONAL,PHASE1|PHASE2,28.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Peripheral Arterial Disease,umbilical cord mesenchymal stem cells,BIOLOGICAL,1,1,18 Years,75 Years,ALL,False,"Institute of Hematology & Blood Diseases Hospital, China",OTHER,0,0,,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.367295829986474,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,0,1,0,1,0,,2022-12-26,,,0,1,0
NCT01138722,Predicting Cell Death by Radiation Therapy in Early Stage Non-small Cell Lung Cancer: a Prospective Translational Trial,Pathologic Effects of Neoadjuvant Radiation Therapy in Operable Early Stage Lung Cancer,TERMINATED,2010-05,2011-08,2021-07-08,INTERVENTIONAL,PHASE2,1.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Early Stage Non-small Cell Lung Cancer,hypofractionated radiation therapy followed by surgery,RADIATION,1,7,18 Years,,ALL,False,"University Hospital, Ghent",OTHER,1,2,Belgium,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.6931471805599453,small,1,1,0,1,0,1,1,0,0,0,0,0,1,0,8,1,0,0,0,1,0,,,,,0,1,0
NCT01613651,Robotic Assisted Laparoscopic Prostatectomy With or Without Pelvic Drain Placement in Reducing Adverse Events After Surgery in Patients With Prostate Cancer,A Prospective Randomized Trial of Pelvic Drain Placement Versus no Pelvic Drain Placement After Robotic Assisted Laparoscopic Prostatectomy (RALP) in Patients With Prostate Cancer,COMPLETED,2012-08-24,2017-09-11,2017-09-14,INTERVENTIONAL,PHASE3,191.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,SINGLE,Perioperative/Postoperative Complications|Prostate Cancer,robot-assisted laparoscopic surgery|questionnaire administration|intraoperative complication management/prevention,PROCEDURE|OTHER,1,3,18 Years,,MALE,False,City of Hope Medical Center,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,2,5.2574953720277815,medium,0,1,0,1,0,1,0,0,1,0,1,0,0,1,4,1,0,0,0,3,1,2012-08-24,2017-09-11,1844.0,2012.0,0,2,0
NCT00593151,"Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C","An Open-Label, 3-Panel, Dose-Escalation Study to Assess the Safety and Tolerability, Pharmacokinetics, and Viral Kinetics of Two Doses of LocteronTM (Poly ActiveTM - Interferon Alpha 2b) Given Every 2 Weeks for 4-12 Weeks in Comparison With PEG-Intron Given Weekly for 4-12 Weeks in Patients With Chronic Hepatitis C",COMPLETED,2008-01,2009-03,2012-02-03,INTERVENTIONAL,PHASE1|PHASE2,32.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hepatitis C,Locteron (controlled-release interferon alpha 2b)|pegylated IFNa2b,OTHER|BIOLOGICAL,1,1,18 Years,,ALL,False,"Biolex Therapeutics, Inc.",INDUSTRY,0,5,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.4965075614664802,small,1,1,1,0,0,0,1,0,1,0,1,0,1,1,2,1,0,1,0,2,1,,,,,0,2,0
NCT01825551,The Effect of GCSF in the Treatment of ALS Patients,The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013,COMPLETED,2012-11,2013-11,2013-11-13,INTERVENTIONAL,PHASE2|PHASE3,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Amyotrophic Lateral Sclerosis,Granulocyte Colony Stimulating Factor|Placebo,DRUG,1,4,18 Years,85 Years,ALL,False,Tehran University of Medical Sciences,OTHER,0,1,Iran,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.713572066704308,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT02033629,Low Remifentanil Target Controlled Infusions for Cardiac Surgery,Early Extubation After Cardiac Surgery: What Is the Appropriate Target Remifentanil Effect-Site Concentration?,COMPLETED,2014-05,2019-05-15,2019-07-18,INTERVENTIONAL,PHASE3,75.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Cardiac Surgery,Ce 1 ng/ml|Ce 2 ng/ml|Ce 3 ng/ml,DRUG,1,7,18 Years,,ALL,False,Imam Abdulrahman Bin Faisal University,OTHER,0,1,Saudi Arabia,1.0,0,0,1,0,0,3.0,0,0,0,1,1,4.330733340286331,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,8,1,1,0,0,3,1,,2019-05-15,,,0,2,0
NCT00894829,Efficacy and Safety of Sodium Heparin (Eurofarma),Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass,COMPLETED,2009-06,2011-12,2013-02-25,INTERVENTIONAL,PHASE3,104.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Cardiac Surgery,heparin sodium - Eurofarma|heparin sodium - APP,BIOLOGICAL,2,1,18 Years,,ALL,False,Azidus Brasil,INDUSTRY,0,1,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,1,1,4.653960350157523,medium,0,1,1,0,0,0,0,0,0,0,1,0,0,1,3,1,0,1,0,2,1,,,,,0,1,0
NCT00941031,AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis,"A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis",COMPLETED,2009-07,2010-12,2015-08-20,INTERVENTIONAL,PHASE2,404.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Plaque-type Psoriasis,AIN457|AIN457A|AIN457A|Placebo,DRUG,1,2,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,62,United States|France|Germany|Japan|Iceland|Israel|Norway,1.0,0,1,0,0,0,2.0,0,1,0,0,1,6.003887067106539,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,3,1,1,0,0,4,1,,,,,0,2,0
NCT02740231,A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis,"A Two-stage 6-month Multicentre, Randomised, Double-blind, Controlled Study on the Safety and Efficacy Intra-articular Administration of JTA-004 in Patients With Symptomatic Knee Osteoarthritis",COMPLETED,2016-02,2018-04-27,2021-12-06,INTERVENTIONAL,PHASE2|PHASE3,173.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Knee Osteoarthritis,JTA-004 intra-articular injection|Reference product intra-articular injection,DRUG|DEVICE,1,4,50 Years,79 Years,ALL,False,Bone Therapeutics S.A,INDUSTRY,0,0,,1.0,0,1,1,0,1,2.5,0,1,0,0,1,5.159055299214529,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,0,5,1,1,0,1,2,1,,2018-04-27,,,0,2,0
NCT01762202,"Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.","Phase 2 Multicenter, Study to Assess the Efficacy and the Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab (FCO2) Chemoimmunotherapy in Young (≤65 Yrs) Patients With Chronic Lymphocytic Leukemia (CLL).",COMPLETED,2013-11-05,2018-10,2020-10-14,INTERVENTIONAL,PHASE2,80.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,B-cell Lymphoid Leukemia|Young Patients,Cyclophosphamide|Fludarabine|Ofatumumab,DRUG,1,6,18 Years,65 Years,ALL,False,Gruppo Italiano Malattie EMatologiche dell'Adulto,OTHER,0,22,Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.394449154672439,medium,1,1,0,1,0,0,1,0,0,1,0,0,1,0,7,1,1,0,0,3,1,2013-11-05,,,2013.0,0,3,1
NCT02652702,Study Comparing Circular Stapler-assisted Colostomy vs Hand-stitching Colostomy of Colorectal Cancer Patients,Randomized Clinical Trial Comparing the Safety and Efficiency of Circular Stapler-assisted Colostomy With Hand-stitching Colostomy for Colorectal Cancer Patients,TERMINATED,2016-12,2020-01,2020-07-07,INTERVENTIONAL,PHASE2,60.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Carcinoma,circular stapler-assisted colostomy|conventional hand-stitching colostomy,PROCEDURE,1,0,18 Years,80 Years,ALL,False,Zhejiang University,OTHER,0,1,China,0.0,0,1,0,0,0,2.0,1,0,0,0,1,4.110873864173311,medium,1,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,2,1,,,,,0,1,0
NCT00618553,Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting,The Efficacy of Pulmonary Rehabilitation in Improving Surgical Eligibility for Lung Resection,ACTIVE_NOT_RECRUITING,2008-01-28,2028-09-01,2026-01-12,INTERVENTIONAL,PHASE2,75.0,ESTIMATED,,SINGLE_GROUP,SUPPORTIVE_CARE,NONE,Lung Cancer,Questionnaire|Pulmonary Rehabilitation,OTHER|BEHAVIORAL,1,1,,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,1,United States,,0,1,0,0,0,2.0,1,0,0,0,1,4.330733340286331,medium,1,0,0,1,0,0,0,0,1,0,0,0,0,0,2,1,0,0,0,2,1,2008-01-28,2028-09-01,7522.0,2008.0,0,1,0
NCT05799053,Peppermint Oil for the Treatment of Irritable Bowel Syndrome or Functional Abdominal Pain in Children: the MINT Study,Peppermint Oil for the Treatment of Irritable Bowel Syndrome or Functional Abdominal Pain in Children: the MINT Study,COMPLETED,2022-05-12,2024-11-30,2025-05-30,INTERVENTIONAL,PHASE3,228.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Irritable Bowel Syndrome|Functional Abdominal Pain Syndrome|Child|Adolescent|Therapeutics|Adverse Drug Event,Small intestinal release peppermint oil|Peppermint sweets|Placebo,DRUG,1,17,8 Years,17 Years,ALL,False,St. Antonius Hospital,OTHER,0,3,Netherlands,1.0,0,0,1,0,0,3.0,0,0,0,0,6,5.43372200355424,large,0,1,0,1,0,0,1,0,0,0,1,1,1,1,18,1,1,0,0,3,1,2022-05-12,2024-11-30,933.0,2022.0,1,3,1
NCT01817153,Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock.,Effect of Intravenous Hydrocortison on Post-ischemic Brachial Artery Dilation and on Thenar Oxygen Saturation in Adult Septic Shock. A Human Placebo-controlled Randomized Study.,TERMINATED,2013-11-05,2019-11-05,2020-02-11,INTERVENTIONAL,PHASE2|PHASE3,10.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Septic Shock|Adult,hydrocortison hemisuccinate|placebo followed by hydrocortisone hemisuccinate,DRUG,1,0,18 Years,,ALL,False,Centre Hospitalier Régional d'Orléans,OTHER,0,1,France,0.0,0,1,1,0,1,2.5,0,0,0,0,2,2.3978952727983707,small,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,1,0,0,2,1,2013-11-05,2019-11-05,2191.0,2013.0,0,3,1
NCT03054337,Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD),"Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)",COMPLETED,2016-10,2017-08-28,2021-04-08,INTERVENTIONAL,PHASE2,51.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Anemia|Non-dialysis Dependent Chronic Kidney Disease,Vadadustat|Placebo,DRUG,1,25,20 Years,,ALL,False,Akebia Therapeutics,INDUSTRY,0,18,Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.9512437185814275,medium,1,1,1,0,0,0,1,0,0,0,1,1,1,1,26,1,1,0,0,2,1,,2017-08-28,,,0,3,1
NCT01615445,Resveratrol Supplementation on Exercise in Healthy Sedentary Adults,A Pilot Randomized Controlled Clinical Trial of Resveratrol Supplementation on Exercise in Healthy Sedentary Adults,COMPLETED,2009-02,2011-08,2014-06-23,INTERVENTIONAL,PHASE2,13.0,ACTUAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,QUADRUPLE,Sedentary Lifestyle,Resveratrol|placebo,DRUG,2,1,18 Years,65 Years,ALL,True,Ottawa Hospital Research Institute,OTHER,0,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.6390573296152584,small,1,1,0,1,0,0,0,0,0,0,1,1,0,0,3,1,1,0,0,2,1,,,,,0,1,0
NCT04359095,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial,COMPLETED,2020-08-18,2021-06-30,2021-08-12,INTERVENTIONAL,PHASE2|PHASE3,650.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,COVID-19,Emtricitabine/tenofovir|Colchicine Pill|Rosuvastatin|Standard treatment,DRUG|OTHER,2,7,18 Years,,ALL,False,Universidad Nacional de Colombia,OTHER,6,6,Colombia,1.0,0,1,1,0,1,2.5,0,0,0,0,1,6.478509642208569,xlarge,0,1,0,1,0,1,1,0,0,0,1,0,1,1,9,1,1,0,0,4,1,2020-08-18,2021-06-30,316.0,2020.0,1,3,1
NCT01124695,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single Agent Tamoxifen,COMPLETED,2011-01-07,2022-12,2023-06-29,INTERVENTIONAL,PHASE2,124.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer|Stage IV Breast Cancer,tamoxifen,DRUG,1,5,18 Years,,ALL,False,ECOG-ACRIN Cancer Research Group,NETWORK,1,294,Canada|Peru|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.8283137373023015,medium,0,1,0,0,0,1,1,1,1,0,0,0,1,0,6,1,1,0,0,1,0,2011-01-07,,,2011.0,0,3,1
NCT02705339,Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC),Genomic Landscape of EGFR Mutant NSCLC Prior to Rociletinib and at the Time of Disease Progression Following Rociletinib,WITHDRAWN,2016-05,2020-04,2016-05-17,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Carcinoma, Non-Small-Cell Lung|Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer",Rociletinib|Biopsy|Blood draw,DRUG|PROCEDURE,1,4,18 Years,,ALL,False,Washington University School of Medicine,OTHER,1,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,3,0.0,,1,1,0,1,0,1,0,0,0,0,0,0,1,0,5,1,1,0,0,3,1,,,,,0,2,0
NCT00102739,SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP),See Detailed Description,COMPLETED,2005-02,2007-01,2013-04-15,INTERVENTIONAL,PHASE2,99.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Purpura, Thrombocytopaenic, Idiopathic",SB497115,DRUG,1,1,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,30,United Kingdom|Russia|Poland|Taiwan|New Zealand|Slovenia|Thailand|Pakistan|Germany|Greece|Romania|South Korea|Hong Kong,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.605170185988092,medium,1,1,1,0,0,0,1,1,0,1,1,1,1,1,2,1,1,0,0,1,0,,,,,0,1,0
NCT00814177,Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients,Management of Prothrombin Times Outside the Therapeutic Range in Patients on Warfarin and With Otherwise Stable Levels,COMPLETED,2006-07,2009-04,2012-08-01,INTERVENTIONAL,PHASE2,160.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Atrial Fibrillation|Venous Thromboembolism|Ischemic Stroke|Myocardial Infarction,warfarin|warfarin,DRUG,1,0,18 Years,,ALL,False,Hamilton Health Sciences Corporation,OTHER,0,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,1,4,5.081404364984463,medium,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,2,1,,,,,0,2,0
NCT03110575,12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients,A 12-Week Open-Label Extension Study to Evaluate TNX-102 SL Taken Daily at Bedtime in Patients With PTSD,TERMINATED,2017-06-20,2018-07-27,2025-02-06,INTERVENTIONAL,PHASE3,190.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,PTSD,TNX-102 SL,DRUG,1,1,18 Years,75 Years,ALL,False,"Tonix Pharmaceuticals, Inc.",INDUSTRY,1,32,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.25227342804663,medium,0,1,1,0,0,1,1,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2017-06-20,2018-07-27,402.0,2017.0,1,0,0
NCT02571777,Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma,"A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma",COMPLETED,2015-12-08,2019-06-14,2020-07-22,INTERVENTIONAL,PHASE3,3092.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Asthma,QVM149 150/50/160|QVM149 150/50/80|QMF149 150/320|QMF149 150/160|salmeterol/fluticasone,DRUG,1,23,18 Years,75 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,403,Estonia|Jordan|Canada|Ireland|Austria|Lithuania|Latvia|Thailand|South Africa|China|Hungary|Argentina|Russia|Bulgaria|Portugal|Spain|Romania|Belgium|Israel|Italy|Chile|Finland|Sweden|Colombia|Vietnam|France|Lebanon|Germany|Greece|Netherlands|Poland|India|Peru|United Kingdom|Croatia|Denmark|Slovakia|Philippines|Switzerland|Mexico|Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,8.03689677268507,xlarge,0,1,1,0,1,0,1,1,0,1,1,1,1,1,24,1,1,0,0,5,1,2015-12-08,2019-06-14,1284.0,2015.0,1,3,1
NCT03608501,"A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation","An Open-Label, Single-Arm Phase II Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-Naive Multiple Myeloma Patients Non-Eligible for Autologous Stem-Cell Transplantation",WITHDRAWN,2019-09-30,2023-05-31,2020-01-14,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma,Ixazomib|Thalidomide|Dexamethasone,DRUG,1,4,18 Years,,ALL,False,Takeda,INDUSTRY,0,6,Brazil,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,1,0,1,0,1,0,0,0,0,0,1,0,5,1,1,0,0,3,1,2019-09-30,2023-05-31,1339.0,2019.0,1,1,0
NCT00476112,A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter,"A Phase II/III Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Centred Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter",COMPLETED,2003-08,2004-09,2008-04-02,INTERVENTIONAL,PHASE2|PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Atrial Flutter,Vernakalant Injection 20 mg/mL,DRUG,1,1,18 Years,,ALL,False,Advanz Pharma,INDUSTRY,1,24,Sweden|Canada|Denmark|United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.110873864173311,medium,1,1,1,0,0,1,1,1,1,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,2,0
NCT02175381,Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC,A Phase I/II Trial of the Carboplatin/Gemcitabine Combination as First Line Treatment for Elderly Patients With Stage IV NSCLC.,COMPLETED,2011-02,2014-04,2015-05-15,INTERVENTIONAL,PHASE1|PHASE2,69.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,NSCLC,Carboplatin|Gemcitabine,DRUG,1,4,70 Years,,ALL,False,Hellenic Oncology Research Group,OTHER,0,5,Greece,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.248495242049359,medium,1,1,0,1,0,0,1,0,0,0,0,0,1,0,5,1,1,0,0,2,1,,,,,0,2,0
NCT02538081,Nicotinic Receptors and Schizophrenia,Nicotinic Receptors and Schizophrenia,WITHDRAWN,2015-08,2016-08,2017-05-30,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Schizophrenia,Risperidone plus Placebo|Risperidone plus DMXB-A,DRUG,2,25,18 Years,70 Years,ALL,False,VA Office of Research and Development,FED,1,1,United States,0.0,1,1,0,0,1,1.5,0,0,1,0,1,0.0,,1,1,0,0,0,1,0,0,1,0,1,1,1,1,27,1,1,0,0,2,1,,,,,0,3,1
NCT00242281,APC-111 MP Tablet Once a Day vs.Penicillin VK Four Times a Day Both for 10 Days in Patients With Strep Throat,"A Phase III, Multicenter Study to Evaluate the Safety/Efficacy of APC-111 MP Tablet QD vs. Penicillin VK QID Both for 10 Days Treatment of Pharyngitis Secondary to S.Pyogenes in Adolescents/Adults",COMPLETED,2005-11,2006-07,2006-10-25,INTERVENTIONAL,PHASE3,600.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Sore Throat|Pharyngitis|Tonsillitis,"APC-111 MP Tablet, 775 mg",DRUG,1,3,12 Years,,ALL,False,Advancis Pharmaceutical Corporation,INDUSTRY,0,41,Canada|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,3,6.398594934535208,xlarge,0,0,1,0,0,0,1,1,1,0,1,1,1,1,4,1,1,0,0,1,0,,,,,0,2,0
NCT00004081,Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer,"A Phase II Trial of Weekly, Low-Dose Docetaxel (Taxotere) in Patients With Platinum-Resistant Epithelial Ovarian or Primary Peritoneal Serous Cancer",COMPLETED,1999-07,2003-03,2012-08-13,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,,TREATMENT,NONE,Ovarian Cancer|Peritoneal Cavity Cancer,docetaxel,DRUG,0,0,18 Years,,FEMALE,False,Beth Israel Deaconess Medical Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.4339872044851463,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,1,0
NCT05348681,A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS),"A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Hidradenitis Suppurativa",TERMINATED,2022-07-18,2023-02-28,2023-06-13,INTERVENTIONAL,PHASE2,25.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hidradenitis Suppurativa,RIST4721|Placebo,DRUG,2,1,18 Years,,ALL,False,"Aristea Therapeutics, Inc.",INDUSTRY,0,12,Canada|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.258096538021482,small,1,1,1,0,0,0,1,1,1,0,1,1,1,1,3,1,1,0,0,2,1,2022-07-18,2023-02-28,225.0,2022.0,1,2,0
NCT01660581,Intracardiac CD133+ Cells in Patients With No-option Resistant Angina,"A Randomized,Prospective,Double-blind Study to Evaluate Intracardiac Injections of Bone Marrow,Autologous CD133+Cells(Electromechanical Mapping Based)in Patients With Resistant Angina and no Effective Revascularization Option. RegentVsel",COMPLETED,2012-06,2016-09,2017-09-28,INTERVENTIONAL,PHASE2,31.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Stable Angina,intramyocardial injection (electromechanical mapping based)|Placebo,BIOLOGICAL,1,6,18 Years,75 Years,ALL,False,Medical University of Silesia,OTHER,0,1,Poland,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4657359027997265,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,7,1,0,1,0,2,1,,,,,0,2,0
NCT02143219,Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer,"Phase-2 Study Evaluating Overall Response Rate (Efficacy) and Autonomy Daily Living Preservation (Tolerance) of ""FOLFIRINOX "" Pharmacogenetic Dose Adjusted, in Elderly Patients (70 yo. or Older) With a Metastatic Pancreatic Adenocarcinoma.",COMPLETED,2014-07-31,2020-11-25,2022-07-28,INTERVENTIONAL,PHASE2,72.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pancreatic Metastatic Cancer|Toxicity,Oxaliplatine|Folinic acid|Irinotecan|5-FU,DRUG,1,1,70 Years,,ALL,False,Institut Cancerologie de l'Ouest,OTHER,0,6,France,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.290459441148391,medium,1,1,0,1,0,0,1,0,0,1,0,0,1,0,2,1,1,0,0,4,1,2014-07-31,2020-11-25,2309.0,2014.0,0,2,0
NCT01203319,The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines,The Immunogenicity and Safety of 60mcg and 30mcg Recombinant Hepatitis B Vaccines in People Aged 16 and Older Who Failed to Respond to Routine Administration of 10mcg Recombinant Hepatitis B Vaccines,COMPLETED,2006-11,2011-03,2012-04-27,INTERVENTIONAL,PHASE2|PHASE3,1091.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Hepatitis b,60mcg/1.0ml recombinant hepatitis B vaccine|30mcg/1.0ml recombinant hepatitis B vaccine|10mcg/1.0ml recombinant hepatitis B vaccine,BIOLOGICAL,2,4,16 Years,,ALL,False,Jiangsu Province Centers for Disease Control and Prevention,NETWORK,1,0,,1.0,0,1,1,0,1,2.5,0,0,0,0,1,6.9957661563048505,xlarge,0,1,0,0,0,1,0,0,0,0,1,1,0,1,6,1,0,1,0,3,1,,,,,0,3,1
NCT06248619,A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease,"A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Teprotumumab in Participants With Moderate-to-Severe Active Thyroid Eye Disease",ACTIVE_NOT_RECRUITING,2024-07-05,2026-09-02,2026-01-28,INTERVENTIONAL,PHASE3,89.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Thyroid Eye Disease,Teprotumumab|Placebo,OTHER|BIOLOGICAL,1,7,18 Years,80 Years,ALL,False,Amgen,INDUSTRY,0,38,United Kingdom|Argentina|Australia|United States|Canada|Taiwan|France|Spain|Germany|Japan|Italy,,0,0,1,0,0,3.0,0,0,0,0,1,4.499809670330265,medium,1,1,1,0,1,0,1,1,1,1,1,1,1,1,8,1,0,1,0,2,1,2024-07-05,2026-09-02,789.0,2024.0,1,3,1
NCT01844830,"Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients","A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing The Efficacy And Safety Of Intranasally Administered Kovacaine Mist To Placebo For Anesthetizing Maxillary Teeth In Pediatric Patients",COMPLETED,2013-05,2013-07,2017-08-30,INTERVENTIONAL,PHASE3,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Anesthesia,Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Placebo,DRUG,1,11,3 Years,17 Years,ALL,False,"St. Renatus, LLC",INDUSTRY,2,2,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.51085950651685,medium,1,1,1,0,0,1,1,0,1,0,1,1,1,1,12,1,1,0,0,2,1,,,,,0,2,0
NCT02191930,Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma,Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II Trial -,COMPLETED,2015-09,2022-03-16,2024-08-23,INTERVENTIONAL,PHASE2,70.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hodgkin Lymphoma,B-CAP|Brentuximab Vedotin,DRUG,1,0,60 Years,99 Years,ALL,False,University of Cologne,OTHER,0,1,Germany,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.2626798770413155,medium,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,2,1,,2022-03-16,,,0,1,0
NCT00789828,Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1),"A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC)",COMPLETED,2009-08,2014-10,2016-02-03,INTERVENTIONAL,PHASE3,117.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Tuberous Sclerosis|Subependymal Giant Cell Astrocytoma,Everolimus|Placebo,DRUG,1,10,,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,24,United Kingdom|Russia|Australia|United States|Canada|Poland|Germany|Netherlands|Belgium|Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.770684624465665,medium,0,1,1,0,1,0,1,1,1,1,1,1,1,1,11,1,1,0,0,2,1,,,,,0,4,1
NCT04842565,cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria,Phase II Trial of cTACE Plus Sintilimab for Treatment of Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria,COMPLETED,2021-05-01,2023-05-01,2024-05-22,INTERVENTIONAL,PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatocellular Carcinoma,Sintilimab|TACE,DRUG|DEVICE,1,5,20 Years,75 Years,ALL,False,Fudan University,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.044522437723423,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,6,1,1,0,1,2,1,2021-05-01,2023-05-01,730.0,2021.0,1,2,0
NCT00148265,A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema,Phase II/III Multicentre Randomised Clinical Trial of Laser Treatment Plus 4 mg Intravitreal Triamcinolone Injection to Reduce Diabetic Macular Oedema,COMPLETED,2005-04,2009-05,2010-06-23,INTERVENTIONAL,PHASE2|PHASE3,54.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Diabetic Macular Oedema,Triamcinolone acetate,DRUG,1,3,18 Years,,ALL,False,University of Sydney,OTHER,3,1,Australia,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.007333185232471,medium,1,1,0,1,0,1,0,0,0,0,1,1,1,1,4,1,1,0,0,1,0,,,,,0,1,0
NCT05107765,Effects of Pioglitazone on Stress Reactivity and Alcohol Craving,Effects of Pioglitazone on Stress Reactivity and Alcohol Craving,COMPLETED,2022-05-12,2024-08-16,2025-08-27,INTERVENTIONAL,PHASE1|PHASE2,67.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alcohol Use Disorder,Pioglitazone|Placebo,DRUG,10,22,18 Years,,ALL,False,"The University of Texas Health Science Center, Houston",OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.219507705176107,medium,1,1,0,1,0,1,0,0,1,0,1,1,1,1,32,1,1,0,0,2,1,2022-05-12,2024-08-16,827.0,2022.0,1,3,1
NCT01443728,Vitamin D for Sickle-cell Respiratory Complications,Vitamin D for Sickle-cell Respiratory Complications,COMPLETED,2011-12-13,2015-02-15,2024-08-09,INTERVENTIONAL,PHASE2,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Sickle Cell Disease|Vitamin D Deficiency|Acute Chest Syndrome|Asthma|Respiratory Infections,"Experimental: Vitamin D3 100,000 IU|Active Comparator: Vitamin D3 12,000 IU",DRUG,1,13,3 Years,20 Years,ALL,False,"Gary M Brittenham, MD",OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,5,4.2626798770413155,medium,1,1,0,1,0,0,0,0,1,0,1,1,1,1,14,1,1,0,0,2,1,2011-12-13,2015-02-15,1160.0,2011.0,0,3,1
NCT00811967,Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED),Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis,TERMINATED,2003-02,2006-05,2017-03-13,INTERVENTIONAL,PHASE3,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Hepatitis C, Chronic|Liver Cirrhosis",PegIntron (peginterferon alfa-2b; SCH 54031)|Rebetol (ribavirin; SCH 18908),DRUG|BIOLOGICAL,1,1,20 Years,70 Years,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,2,3.9318256327243257,small,1,1,1,0,1,0,0,0,0,0,1,0,1,1,2,1,1,1,0,2,1,,,,,0,2,0
NCT02210065,Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation,The Pre-Emptive Use of Recipient-Derived Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation After Allogeneic Stem Cell Transplantation,COMPLETED,2015-03-03,2019-05-13,2020-03-17,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Leukemia|Lymphoma,Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs),BIOLOGICAL,2,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,1.9459101490553132,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,0,0,1,0,1,0,2015-03-03,2019-05-13,1532.0,2015.0,1,1,0
NCT06353165,"Anti-bacterial Clinical Study on Teeth, Tongue, Cheek, Gum, and Saliva",A Clinical Study to Investigate Stannous Fluoride Toothpaste on Antibacterial Effects in the Different Regions of the Mouth as Compared to Colgate Cavity Protection Toothpaste,COMPLETED,2023-03-08,2023-04-12,2024-04-15,INTERVENTIONAL,PHASE3,100.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,"Plaque, Dental",Stannous fluoride toothpaste|Colgate Dental Cream,DRUG,5,0,18 Years,70 Years,ALL,True,Colgate Palmolive,INDUSTRY,0,1,Thailand,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.61512051684126,medium,0,1,1,0,0,0,0,0,0,0,1,1,0,1,5,0,1,0,0,2,1,2023-03-08,2023-04-12,35.0,2023.0,1,1,0
NCT02953665,Safety and Efficacy of Liraglutide in Parkinson's Disease,"A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease",COMPLETED,2017-04-03,2022-08-03,2024-03-07,INTERVENTIONAL,PHASE2,63.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Parkinson Disease,Liraglutide|Placebo,DRUG,3,3,25 Years,85 Years,ALL,False,Cedars-Sinai Medical Center,OTHER,2,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,4.1588830833596715,medium,1,1,0,1,0,1,0,0,1,0,1,1,1,1,6,1,1,0,0,2,1,2017-04-03,2022-08-03,1948.0,2017.0,1,2,0
NCT02807428,Study to Evaluate Safety/Efficacy of a Single Preop Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery,"A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Intrathecal Preoperative Administration of AYX1 Injection in Patients Undergoing Unilateral Total Knee Arthroplasty",COMPLETED,2017-02-20,2017-12-19,2018-10-17,INTERVENTIONAL,PHASE2,210.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Post-surgical Pain,AYX1 Injection 660 mg/6 mL|Placebo Injection 6 mL,DRUG,1,3,40 Years,,ALL,False,"Adynxx, Inc.",INDUSTRY,0,9,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.351858133476067,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,4,1,1,0,0,2,1,2017-02-20,2017-12-19,302.0,2017.0,1,1,0
NCT00695565,Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy,"A Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy and Safety of Clonidine Topical Gel, 0.1% With Placebo in the Management of Pain Associated With Painful Diabetic Neuropathy",COMPLETED,2008-05,2010-02,2016-11-08,INTERVENTIONAL,PHASE2,180.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Painful Diabetic Neuropathy,Placebo Gel|Clonidine Topical Gel (ARC-4558),DRUG,1,13,18 Years,80 Years,ALL,False,Arcion Therapeutics Inc,INDUSTRY,0,16,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.198497031265826,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,14,1,1,0,0,2,1,,,,,0,2,0
NCT02219165,Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study,Efficacy of IntraVenous ImmunoGlobulins (IVIG) in Toxic Shock Syndromes (Staphylococcal and Streptococcal): a Paediatric Pilot Study.,COMPLETED,2015-01-08,2019-04-19,2025-09-04,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,OTHER,QUADRUPLE,Toxic Shock Syndrome,Intravenous human immunoglobulin|Albumin,DRUG,4,7,1 Month,17 Years,ALL,False,Hospices Civils de Lyon,OTHER,0,1,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,0,0,0,0,1,1,1,0,1,11,1,1,0,0,2,1,2015-01-08,2019-04-19,1562.0,2015.0,1,2,0
NCT01768767,Trial of Ketamine and Lithium Therapy in Bipolar Depression,Novel Approach of Combined Lithium-Ketamine Therapy in Bipolar Depression: To Preserve Efficacy and Minimize Adverse Effects,WITHDRAWN,2013-01,2013-01,2023-03-01,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Bipolar Depression,Placebo|Ketamine|Ketamine/Lithium,DRUG,1,2,18 Years,65 Years,ALL,False,Yale University,OTHER,1,0,,0.0,0,1,0,0,0,2.0,0,0,1,0,1,0.0,,1,1,0,1,0,1,0,0,0,0,1,1,1,0,3,1,1,0,0,3,1,,,,,0,1,0
NCT00109967,CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,A Phase II Study of CCI-779 in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma,COMPLETED,2005-05,2012-03,2014-04-17,INTERVENTIONAL,PHASE2,71.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Recurrent Mantle Cell Lymphoma,rituximab|temsirolimus,DRUG|BIOLOGICAL,1,4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,195,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.276666119016055,medium,1,1,0,1,0,0,1,0,1,0,0,0,1,0,5,1,1,1,0,2,1,,,,,0,1,0
NCT01936896,Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction,Alpha-1 Anti-Trypsin (AAT) to Quench the Acute Inflammatory Response in ST-segment Elevation Acute Myocardial Infarction,COMPLETED,2013-12,2014-07,2016-02-12,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Myocardial Infarction,Alpha 1-Antitrypsin,DRUG,1,1,21 Years,99 Years,ALL,False,Virginia Commonwealth University,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,1,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT00011362,Dexamethasone Therapy in VLBW Infants at Risk of CLD,Randomized Clinical Trial of Dexamethasone Therapy in Very-Low-Birth-Weight Infants at Risk for Chronic Lung Disease (CLD),COMPLETED,1992-09,1994-04,2019-03-22,INTERVENTIONAL,PHASE3,371.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Bronchopulmonary Dysplasia",Dexamethasone Early|Dexamethasone Late,DRUG,1,6,13 Days,15 Days,ALL,False,NICHD Neonatal Research Network,NETWORK,1,13,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,5,5.918893854273146,large,0,1,0,0,0,1,1,0,1,0,1,1,1,1,7,1,1,0,0,2,1,,,,,0,3,1
NCT01479946,Electrochemotherapy For The Treatment Of Breast Cancer That Has Spread to the Skin,An International Randomized Phase II Study Comparing Early Electrochemotherapy to Delayed or No Electrochemotherapy in Patients With Cutaneous Breast Cancer Metastases,WITHDRAWN,2011-10,2015-06,2014-12-09,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer|Skin Metastases,Electrochemotherapy,DRUG,1,3,18 Years,,ALL,False,Uppsala University Hospital,OTHER,0,1,Sweden,0.0,0,1,0,0,0,2.0,1,0,0,0,2,0.0,,1,1,0,1,0,0,0,0,0,0,1,0,1,1,4,1,1,0,0,1,0,,,,,0,1,0
NCT01673646,Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism,"A Multicenter, Open-label, Randomized, Phase II Study to Evaluate Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Pasireotide LAR in Japanese Patients With Active Acromegaly or Pituitary Gigantism",COMPLETED,2012-10-16,2017-04-10,2019-09-16,INTERVENTIONAL,PHASE2,33.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acromegaly|Pituitary Gigantism,Pasireotide LAR,DRUG,1,17,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,27,Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.5263605246161616,small,1,1,1,0,1,0,1,0,0,0,1,0,1,1,18,1,1,0,0,1,0,2012-10-16,2017-04-10,1637.0,2012.0,0,2,0
NCT02109146,Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma,"A Randomized, Open-label, Phase 3 Trial Evaluating Adjuvant Transarterial Chemoembolization for TNM Stage I and II Hepatocellular Carcinoma Recurrence After Curative Resection",COMPLETED,2014-03-26,2023-05-13,2024-05-29,INTERVENTIONAL,PHASE3,332.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hepatocellular Carcinoma|Transcatheter Arterial Chemoembolization,Prophylactic Transcatheter Arterial Chemoembolization|Observation,DRUG|OTHER,1,3,18 Years,80 Years,ALL,False,Zhejiang University,OTHER,0,1,China,1.0,0,0,1,0,0,3.0,1,0,0,0,2,5.808142489980444,large,0,1,0,1,0,0,0,0,0,0,1,0,1,1,4,1,1,0,0,2,1,2014-03-26,2023-05-13,3335.0,2014.0,0,2,0
NCT03119961,Blood Brain Barrier Opening in Alzheimer' Disease,Phase 1/2 Open Single-arm Monocentric Study Evaluating the Tolerance and Interest of Transient Opening of the Blood-Brain Barrier by Low Intensity Pulsed Ultrasound With the SONOCLOUD® Implantable Medical Device in Mild Alzheimer's Disease Patients (MMSE 20-26),COMPLETED,2017-06-26,2020-10-07,2022-04-12,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Alzheimer Disease,SONOCLOUD®,DEVICE,1,1,50 Years,85 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,2,1,France,1.0,1,1,0,0,1,1.5,0,0,1,0,1,2.3978952727983707,small,1,1,0,1,0,1,0,0,0,1,0,0,1,0,2,1,0,0,1,1,0,2017-06-26,2020-10-07,1199.0,2017.0,1,1,0
NCT01578642,Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease,A Feasibility Study: An Evaluation of the Effect of Long-Term Electrical Stimulation on Lower Esophageal Sphincter (LES) Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD),COMPLETED,2010-09,2013-05,2014-02-12,INTERVENTIONAL,PHASE2,24.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Gastroesophageal Reflux Disease,EndoStim LES Stimulation System,DEVICE,2,4,21 Years,65 Years,ALL,False,EndoStim Inc.,INDUSTRY,0,1,Chile,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.2188758248682006,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,6,1,0,0,1,1,0,,,,,0,1,0
NCT01899742,The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium,"DB2116960: A Randomized, Double-Dummy, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of UMEC/VI (a Fixed Combination of Umeclidinium and Vilanterol) With Tiotropium In Subjects With COPD Who Continue To Have Symptoms on Tiotropium",COMPLETED,2014-09-15,2015-07-22,2018-01-24,INTERVENTIONAL,PHASE3,497.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Pulmonary Disease, Chronic Obstructive",Umeclidinium/Vilanterol 62.5/25 mcg|Tiotropium 18 mcg,DRUG,1,1,40 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,64,Estonia|Argentina|Russia|Ukraine|United States|Sweden|South Africa|Germany|Norway|South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.210600077024653,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,2,1,1,0,0,2,1,2014-09-15,2015-07-22,310.0,2014.0,0,2,0
NCT00521586,Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine,"A Phase 3, Randomized, Double-blind Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) When Administered Concomitantly With Trivalent Inactivated Influenza Vaccine In Healthy Adults 50-59 Years Of Age Who Are Naive To 23-valent Pneumococcal Polysaccharide Vaccine And To Evaluate The Immune Response Of A Second Dose Of 13vpnc Administered 5 Years After Initial 13vpnc Vaccination",COMPLETED,2007-09,2013-12,2015-04-09,INTERVENTIONAL,PHASE3,1116.0,ACTUAL,RANDOMIZED,CROSSOVER,PREVENTION,TRIPLE,Influenza,13 valent pneumococcal conjugate vaccine|13 valent pneumococcal conjugate vaccine,BIOLOGICAL,2,0,50 Years,59 Years,ALL,True,Pfizer,INDUSTRY,0,41,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.018401799069201,xlarge,0,1,1,0,1,0,1,0,1,0,1,1,0,0,2,0,0,1,0,2,1,,,,,0,1,0
NCT02176369,Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial,Maintenance Metronomic Per OS Navelbine In Advanced NSCLC Patients After Previous Platinum Based Chemotherapy: A Multicenter Randomized Best Supportive Care Controlled Phase II Study - MA.NI.LA. Trial,COMPLETED,2013-02,2018-10-27,2019-04-22,INTERVENTIONAL,PHASE2,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non-small Cell Lung Cancer Stage IIIB|Non-small Cell Lung Cancer Stage IV,Vinorelbine,DRUG,1,6,18 Years,,ALL,False,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",OTHER,1,20,Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.795790545596741,medium,0,1,0,1,0,1,1,0,0,1,1,0,1,1,7,1,1,0,0,1,0,,2018-10-27,,,0,2,0
NCT02628769,A Study to Evaluate the Anti-inflammatory Effects of Solithromycin in Chronic Obstructive Pulmonary Disease,"A Single-center, Double-blind, Randomised, Placebo-controlled Crossover Study to Evaluate the Effect of Solithromycin on Airway Inflammation in Male and Female Patients With Chronic Obstructive Pulmonary Disease",TERMINATED,2015-07,2017-01-05,2019-12-30,INTERVENTIONAL,PHASE2,6.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,"Pulmonary Disease, Chronic Obstructive",Solithromycin|Placebo,DRUG,1,11,45 Years,,ALL,False,Imperial College London,OTHER,1,1,United Kingdom,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,0,0,0,1,1,1,1,0,12,1,1,0,0,2,1,,2017-01-05,,,0,2,0
NCT01911169,Vitamin D to Improve Endothelial Function in SLE,Vitamin D Repletion to Improve Endothelial Function in Lupus Patients,COMPLETED,2011-06,2014-01,2017-10-27,INTERVENTIONAL,PHASE2,9.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,PREVENTION,QUADRUPLE,Atherosclerosis|Systemic Lupus Erythematosus,Cholecalciferol,DRUG,1,1,18 Years,80 Years,ALL,False,Medical University of South Carolina,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,1,0,1,2,2.302585092994046,small,1,1,0,1,0,0,0,0,1,0,1,1,0,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT03271541,A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia,"A Phase II, Single Arm, Multicenter, Proof-of-Mechanism Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent Βeta-Thalassemia",COMPLETED,2017-10-26,2018-06-29,2018-10-05,INTERVENTIONAL,PHASE2,12.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Beta-Thalassemia,Bitopertin,DRUG,3,12,18 Years,55 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,4,Lebanon|Italy|Thailand,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.5649493574615367,small,1,1,1,0,1,0,1,1,0,1,0,0,1,0,15,1,1,0,0,1,0,2017-10-26,2018-06-29,246.0,2017.0,1,2,0
NCT01856283,Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells,"An Open Label, Single Arm, Phase II Study of Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients, in Order to Verify Disappearance of CD34+/Lin-Ph+ Cells From Bone Marrow During Treatment",COMPLETED,2013-03,2021-01,2021-01-13,INTERVENTIONAL,PHASE2,87.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Leukemia, Myeloid, Chronic-Phase",Nilotinib 300mg BID,DRUG,1,1,18 Years,,ALL,False,Niguarda Hospital,OTHER,0,17,Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.477336814478207,medium,1,1,0,1,0,0,1,0,0,1,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT01270841,Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism,"A Randomized, Double Blind, Placebo and Active Controlled, Parallel, Multi-Center Phase IIb Study to Evaluate Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism",COMPLETED,2011-01,2011-12,2014-07-28,INTERVENTIONAL,PHASE2,83.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Secondary Hypogonadism,Placebo|topical testosterone|Androxal,DRUG,1,3,21 Years,65 Years,MALE,False,Repros Therapeutics Inc.,INDUSTRY,0,18,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.430816798843313,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,1,4,1,1,0,0,3,1,,,,,0,1,0
NCT04065841,"Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.","A Randomized, Double-blind, Parallel-group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (LJN452) & Licogliflozin (LIK066) Combination Therapy and Each Monotherapy, Compared With Placebo for Treatment of Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis.(ELIVATE)",TERMINATED,2019-12-30,2022-10-27,2025-01-28,INTERVENTIONAL,PHASE2,234.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,Non Alcoholic Steatohepatitis (NASH),Tropifexor|Licogliflozin|Placebo,DRUG|OTHER,2,8,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,80,Estonia|Canada|South Africa|Argentina|Russia|Bulgaria|Spain|Belgium|Italy|Chile|United States|Colombia|Singapore|Germany|South Korea|India|United Kingdom|Turkey (Türkiye)|Denmark|Puerto Rico|Brazil|Taiwan|Mexico|Japan,0.0,0,1,0,0,0,2.0,0,0,0,0,1,5.459585514144159,large,0,1,1,0,1,0,1,1,1,1,1,1,1,0,10,1,1,0,0,3,1,2019-12-30,2022-10-27,1032.0,2019.0,1,3,1
NCT00410605,"Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma",Phase II Trial of Bevacizumab Combined With Lenalidomide and Dexamethasone (BEV/REV/DEX) in Relapsed or Refractory Multiple Myeloma,COMPLETED,2006-11,2014-06,2017-09-01,INTERVENTIONAL,PHASE2,39.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma in Relapse|Stage II Multiple Myeloma|Stage III Multiple Myeloma,bevacizumab|lenalidomide|dexamethasone,DRUG|BIOLOGICAL,2,4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,3.6888794541139363,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,6,1,1,1,0,3,1,,,,,0,3,1
NCT00023205,Impact of Literacy Level on Patient Education and Health Among People With Arthritis,Literacy in Arthritis Management: A Randomized Controlled Clinical Trial of a Novel Education Intervention,COMPLETED,2002-11,2006-12,2013-12-24,INTERVENTIONAL,PHASE2,134.0,ACTUAL,RANDOMIZED,PARALLEL,,DOUBLE,Rheumatoid Arthritis|Psoriatic Arthritis|Polyarthritis,11th grade reading level arthritis materials|Interactive in-person arthritis education,BEHAVIORAL,3,5,18 Years,,ALL,False,Brigham and Women's Hospital,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,3,4.90527477843843,medium,0,1,0,1,0,1,0,0,1,0,1,1,0,1,8,1,0,0,0,2,1,,,,,0,3,1
NCT07229456,Evaluation of the Role of N Acetyl Cysteine and Vitamin D in Improving Outcomes After Corrosive Ingestion,Evaluation of the Role of N Acetyl Cysteine and Vitamin D in Improving Outcomes After Corrosive Ingestion,ACTIVE_NOT_RECRUITING,2024-10-01,2025-12-01,2025-11-17,INTERVENTIONAL,PHASE3,80.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,DOUBLE,Corrosive Injury,N Acetyl Cysteine|Vitamin D (Cholecalciferol )|control group,DRUG,1,0,,18 Years,ALL,False,Ain Shams University,OTHER,0,1,Egypt,,0,0,1,0,0,3.0,0,0,0,0,1,4.394449154672439,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,3,1,2024-10-01,2025-12-01,426.0,2024.0,1,1,0
NCT01225094,Curcumin to Prevent Complications After Elective Abdominal Aortic Aneurysm (AAA) Repair,Curcumin to Prevent Perioperative Complications After Elective Abdominal Aortic Aneurysm Repair: a Randomized Controlled Trial,COMPLETED,2011-11,2016-08,2017-03-07,INTERVENTIONAL,PHASE2|PHASE3,606.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Acute Kidney Injury|Abdominal Aortic Aneurysm,curcumin|placebo,DRUG|OTHER,4,3,18 Years,,ALL,False,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,OTHER,1,10,Canada,1.0,0,1,1,0,1,2.5,0,0,0,0,2,6.408528791059498,xlarge,0,1,0,1,0,1,1,0,0,0,1,1,0,1,7,1,1,0,0,2,1,,,,,0,4,1
NCT00006994,S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat,"S9908, A Double-Blind, Placebo-Controlled Trial To Study The Efficacy And Safety Of L-Glutamine (In AES0014 Delivery Vehicle) Upon Radiation Therapy-Induced Oral Mucositis In Head and Neck Cancer Patients, Phase III",TERMINATED,2001-11,2006-04,2015-11-18,INTERVENTIONAL,PHASE3,23.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,DOUBLE,Cancer-related Problem/Condition|Head and Neck Cancer|Pain,glutamine|radiation therapy|l-glutamine placebo,DRUG|DIETARY_SUPPLEMENT|RADIATION,1,4,18 Years,90 Years,ALL,False,SWOG Cancer Research Network,NETWORK,1,107,Canada|United States,0.0,0,0,1,0,0,3.0,1,0,0,0,3,3.1780538303479458,small,1,1,0,0,0,1,1,1,1,0,1,1,0,1,5,1,1,0,0,3,1,,,,,0,3,1
NCT01436266,Effect of Preoperative Buccal Misoprostol on Blood Loss in Second-trimester Dilation and Evacuation Abortion,Effect of Preoperative Buccal Misoprostol on Blood Loss in Second-trimester,TERMINATED,2011-07,2012-08,2017-05-30,INTERVENTIONAL,PHASE3,3.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Abortion|Blood Loss,Misoprostol|Folic acid,DRUG|OTHER,1,0,18 Years,50 Years,FEMALE,False,Boston University,OTHER,0,1,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,2,1.3862943611198906,small,1,1,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,2,1,,,,,0,2,0
NCT01914666,An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain,Phase 3 Clinical Study of Duloxetine Hydrochloride in Patients With CLBP - Open Label Long Term Extension Study,COMPLETED,2013-09,2014-12,2016-01-27,INTERVENTIONAL,PHASE3,151.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Back Pain Lower Back Chronic,Duloxetine,DRUG,1,9,20 Years,79 Years,ALL,False,Eli Lilly and Company,INDUSTRY,1,1,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.0238805208462765,medium,0,1,1,0,1,1,0,0,0,0,0,0,1,0,10,1,1,0,0,1,0,,,,,0,1,0
NCT05089656,Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA),"A Randomized, Sham-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Intrathecal OAV101 in Type 2 Spinal Muscular Atrophy (SMA) Patients Who Are ≥ 2 to < 18 Years of Age, Treatment Naive, Sitting, and Never Ambulatory",COMPLETED,2022-02-01,2025-04-29,2026-01-13,INTERVENTIONAL,PHASE3,126.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Type 2 Spinal Muscular Atrophy,OAV101|Sham control,PROCEDURE|GENETIC,1,9,2 Years,17 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,42,Denmark|Malaysia|United States|Brazil|Vietnam|Taiwan|Thailand|South Africa|China|Singapore|Mexico|India|Saudi Arabia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.844187086458591,medium,0,1,1,0,1,0,1,1,1,0,1,1,1,0,10,1,0,0,0,2,1,2022-02-01,2025-04-29,1183.0,2022.0,1,3,1
NCT00561366,"A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS","A Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With Amyotrophic Lateral Sclerosis (ALS)",WITHDRAWN,,,2012-02-09,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Amyotrophic Lateral Sclerosis,Placebo|Arimoclomol,DRUG,1,6,18 Years,,ALL,False,CytRx,INDUSTRY,0,35,Canada|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,1,1,1,0,1,1,1,1,7,1,1,0,0,2,1,,,,,0,3,1
NCT01842594,A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma,A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma,TERMINATED,2012-08,2015-01,2015-11-03,INTERVENTIONAL,PHASE2,13.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Sarcoma,Sirolimus and hydroxychloroquine,DRUG,1,1,21 Years,75 Years,ALL,False,Shin Kong Wu Ho-Su Memorial Hospital,OTHER,0,1,Taiwan,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.6390573296152584,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT00855894,A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer,An Open-label Phase II Multicenter Study of the Safety and Activity (as Measured by FDG-PET Imaging Changes) of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer,COMPLETED,2009-03,2012-03,2013-05-21,INTERVENTIONAL,PHASE2,41.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Non-Small Cell Lung Cancer,Pertuzumab|Erlotinib,DRUG,1,4,18 Years,,ALL,False,"Genentech, Inc.",INDUSTRY,1,10,Australia|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.7376696182833684,small,1,1,1,0,0,1,1,1,1,0,0,0,1,0,5,1,1,0,0,2,1,,,,,0,2,0
NCT00144066,A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer,A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer,COMPLETED,2003-01,,2005-09-02,INTERVENTIONAL,PHASE3,600.0,,RANDOMIZED,PARALLEL,TREATMENT,NONE,Lung Cancer,platinum-based chemotherapy alone (up to six cycles)|platinum-based chemotherapy followed by maintenance therapy with gefitinib,DRUG,1,1,20 Years,74 Years,ALL,False,West Japan Thoracic Oncology Group,OTHER,0,0,,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.398594934535208,xlarge,0,0,0,1,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT02308956,Task Sharing for the Care of Severe Mental Disorders in a Low-income Country,"Task Sharing for the Care of Severe Mental Disorders in a Low-income Country: a Randomised, Controlled Non-inferiority Trial",COMPLETED,2015-03,2017-11-16,2017-11-29,INTERVENTIONAL,PHASE3,324.0,ACTUAL,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,SINGLE,Schizophrenia|Bipolar Disorder|Major Depressive Disorder|Schizoaffective Disorder,Integrated mental health in primary care|Psychiatric nurse-led specialist care,BEHAVIORAL,1,13,25 Years,,ALL,False,University of Cape Town,OTHER,5,1,Ethiopia,1.0,0,0,1,0,0,3.0,0,0,1,0,4,5.783825182329737,large,0,1,0,1,0,1,0,0,0,0,1,0,0,1,14,1,0,0,0,2,1,,2017-11-16,,,0,3,1
NCT01608022,A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus,,COMPLETED,2012-07,2015-10,2016-09-07,INTERVENTIONAL,PHASE2,48.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Esophageal Squamous Cell Carcinoma,PF804,DRUG,1,0,20 Years,,ALL,False,Yonsei University,OTHER,0,1,South Korea,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.8918202981106265,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT03135522,Pilot of Zinc Acetate to Improve Chronic Cough,Pilot of Zinc Acetate to Improve Chronic Cough,COMPLETED,2018-02-14,2019-12-11,2021-01-20,INTERVENTIONAL,PHASE2,34.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cough,Zinc Acetate 50 Mg Oral Capsule|Placebo oral capsule,DRUG,1,3,18 Years,,ALL,False,Johns Hopkins University,OTHER,2,5,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.5553480614894135,small,1,1,0,1,0,1,1,0,1,0,1,1,1,1,4,1,1,0,0,2,1,2018-02-14,2019-12-11,665.0,2018.0,1,1,0
NCT02157922,A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis,"A Double-blind, Randomized, Placebo-controlled Cross Over Study of Inhaled Alginate Oligosaccharide (OligoG) Administered for 28 Days in Subjects With Cystic Fibrosis",COMPLETED,2014-10,2017-09,2018-04-19,INTERVENTIONAL,PHASE2,65.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Cystic Fibrosis,alginate oligosaccharide,DRUG,1,1,18 Years,,ALL,False,AlgiPharma AS,INDUSTRY,2,18,United Kingdom|Denmark|Sweden|Germany|Norway,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.189654742026425,medium,1,1,1,0,0,1,1,1,0,1,1,1,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT01889251,A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion,A Phase III Study of A01016 125μg Intravitreal Injection in Subjects With Symptomatic Vitreomacular Adhesion - Comparison Study to Sham Injection,COMPLETED,2013-07,2014-09,2015-11-30,INTERVENTIONAL,PHASE3,251.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Symptomatic Vitreomacular Adhesion,Ocriplasmin|Sham injection,DRUG,1,0,20 Years,,ALL,False,Alcon Research,INDUSTRY,0,1,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.529429087511423,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT05230251,Radioligand fOr locAl raDiorecurrent proStaTe cancER,Radioligand fOr locAl raDiorecurrent proStaTe cancER,COMPLETED,2022-03-17,2024-12-31,2025-09-12,INTERVENTIONAL,PHASE1|PHASE2,3.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,177Lu-PNT2002|High Dose Radiation,DRUG|RADIATION,1,1,18 Years,,MALE,False,Glenn Bauman,OTHER,1,1,Canada,1.0,1,1,0,0,1,1.5,1,0,0,0,1,1.3862943611198906,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,2,1,1,0,0,2,1,2022-03-17,2024-12-31,1020.0,2022.0,1,2,0
NCT05101629,Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy,A Phase-II Open-label Study of Pembrolizumab and Lenvatinib in Patients With Advanced Stage Hepatocellular Carcinoma Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy,COMPLETED,2022-05-11,2025-06-30,2025-07-23,INTERVENTIONAL,PHASE2,32.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatocellular Carcinoma,Pembrolizumab|Lenvatinib Capsules,DRUG,1,3,18 Years,,ALL,False,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,OTHER,2,12,Germany,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4965075614664802,small,1,1,0,1,0,1,1,0,0,1,0,0,1,0,4,1,1,0,0,2,1,2022-05-11,2025-06-30,1146.0,2022.0,1,1,0
NCT04365231,Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial,Efficacy Evaluation of Hydroxychloroquine Azithromycin in the Treatment of COVID-19 in Pregnant Women: an Open-label Randomized Clinical Trial,WITHDRAWN,2020-04-01,2021-04-01,2020-11-20,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,COVID19,Hydroxychloroquine and azithromycin treatment|conventional management of patients,DRUG|OTHER,1,2,18 Years,,FEMALE,False,"Hospital St. Joseph, Marseille, France",OTHER,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,0,1,1,3,1,1,0,0,2,1,2020-04-01,2021-04-01,365.0,2020.0,1,1,0
NCT05290545,Haplo-PBSC+Cord vs Haplo-PBSC+BM for Hematological Malignancies Undergoing Allo-HSCT,A Comparative Study of Haploidentical Transplantation Supported by Third-party Cord Blood and Haploidentical Transplantation in Hematological Malignancies,COMPLETED,2022-02-15,2024-03-30,2024-08-13,INTERVENTIONAL,PHASE3,314.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hematological Malignancies|Hematopoietic Stem Cell Transplantation,PBSCs|Cord|BMSCs,OTHER,1,5,18 Years,65 Years,ALL,False,"Nanfang Hospital, Southern Medical University",OTHER,6,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.752572638825633,large,0,1,0,1,0,1,0,0,0,0,1,0,1,1,6,1,0,0,0,3,1,2022-02-15,2024-03-30,774.0,2022.0,1,3,1
NCT05119972,"Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）","A Multi-center, Phase Ib/IIa Clinical Trial to Evaluate the Tolerability, PK and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis",COMPLETED,2021-10-21,2023-12-21,2025-03-19,INTERVENTIONAL,PHASE1|PHASE2,15.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Idiopathic Pulmonary Fibrosis (IPF),ZSP1603|Placebo,DRUG,2,2,40 Years,,ALL,False,"Guangdong Raynovent Biotech Co., Ltd",INDUSTRY,0,1,China,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.772588722239781,small,1,1,1,0,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,2021-10-21,2023-12-21,791.0,2021.0,1,2,0
NCT04442295,An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome,An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet Syndrome,COMPLETED,2020-06-29,2023-11-14,2025-05-18,INTERVENTIONAL,PHASE1|PHASE2,62.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Dravet Syndrome,STK-001 - Single Ascending Doses|STK-001 - Multiple Ascending Doses,DRUG,3,4,2 Years,18 Years,ALL,False,"Stoke Therapeutics, Inc",INDUSTRY,0,18,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.143134726391533,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,0,7,1,1,0,0,2,1,2020-06-29,2023-11-14,1233.0,2020.0,1,3,1
NCT01255475,Blood Pressure Reduction in Heart Failure,"Effect of Blood Pressure Reduction in Patients With Chronic Heart Failure - Randomized, Double-blind, Placebo-controlled Trial",COMPLETED,2011-01,2013-01,2014-06-10,INTERVENTIONAL,PHASE2|PHASE3,21.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Heart Failure|Cardiac Failure|Congestive Heart Failure,Hydralazine/amlodipine|Placebo,DRUG,2,7,18 Years,,ALL,False,University of Sao Paulo,OTHER,1,1,Brazil,1.0,0,1,1,0,1,2.5,0,0,0,1,3,3.091042453358316,small,1,1,0,1,0,1,0,0,0,0,1,1,1,1,9,1,1,0,0,2,1,,,,,0,4,1
NCT03021395,Efficacy of Decitabine in Clearance of MRD,Efficacy of Decitabine in Clearance of MRD,WITHDRAWN,2017-02-08,2022-12,2025-05-30,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,AML,Decitabine,DRUG,1,3,14 Years,55 Years,ALL,False,"Institute of Hematology & Blood Diseases Hospital, China",OTHER,0,1,China,0.0,1,1,0,0,1,1.5,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,1,4,1,1,0,0,1,0,2017-02-08,,,2017.0,1,1,0
NCT00083239,Study of Talabostat in Advanced Melanoma,,COMPLETED,,,2007-06-08,INTERVENTIONAL,PHASE2,,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Melanoma|Skin Cancer,talabostat (PT-100) tablets,DRUG,0,0,18 Years,,ALL,False,Point Therapeutics,INDUSTRY,0,6,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,0.0,,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,1,0
NCT04858139,Exploring the Effect of Lactate Administration After Ischemic Stroke on Brain Metabolism,"""Exploration de l'Effet Sur le métabolisme cérébral de l'Administration de Lactate après Accident Vasculaire cérébral Chez l'Homme"" (French Title)",TERMINATED,2021-08-05,2025-03-27,2025-04-17,INTERVENTIONAL,PHASE2,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Stroke, Acute",Lactate|Placebo,DRUG,2,7,18 Years,,ALL,False,Centre Hospitalier Universitaire Vaudois,OTHER,0,1,Switzerland,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.367295829986474,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,9,1,1,0,0,2,1,2021-08-05,2025-03-27,1330.0,2021.0,1,2,0
NCT01081977,Effect of Timing of Umbilical Cord Clamping on Haematological and Clinical Outcomes of Infants,Effect of Timing of Umbilical Cord Clamping on Haematological and Clinical Outcomes of Infants at Birth and Three Months of Age,COMPLETED,2008-08,2010-04,2012-08-02,INTERVENTIONAL,PHASE2,340.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Anemia|Ferritin|Complications|Hemorrhage|Jaundice,Early Cord Clamping|Delayed Cord Clamping,PROCEDURE,2,1,1 Minute,3 Months,ALL,True,Aga Khan University,OTHER,0,1,Pakistan,1.0,0,1,0,0,0,2.0,0,0,0,0,5,5.831882477283517,large,0,1,0,1,0,0,0,0,0,0,1,1,0,1,3,1,0,0,0,2,1,,,,,0,2,0
NCT00354575,Effect of Chinese Herb on Chronic Constipation for Residents in Long-Term Care Units,"A Randomized, Placebo-Controlled, Double-Blind, Parallel Study on the Efficacy and Safety of Traditional Chinese Medicines for Chronic Constipation Residents in Long-Term Care Units",COMPLETED,2006-09,2008-06,2008-08-18,INTERVENTIONAL,PHASE2,168.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Constipation,Chinese Herb: CCH1,DRUG,3,4,20 Years,,ALL,False,National Taiwan University Hospital,OTHER,0,1,Taiwan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.1298987149230735,medium,0,1,0,1,0,0,0,0,0,0,1,1,1,1,7,1,1,0,0,1,0,,,,,0,1,0
NCT00571675,A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC),"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)",COMPLETED,2007-10,2010-09,2010-11-09,INTERVENTIONAL,PHASE2,220.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hormone Refractory Prostate Cancer,"AT-101, prednisone and docetaxel|placebo, prednisone and docetaxel",DRUG,1,3,18 Years,,ALL,False,Ascenta Therapeutics,INDUSTRY,0,35,Russia|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.3981627015177525,large,0,1,1,0,0,0,1,1,1,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT00725075,Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001),"A Multi-center, Double-blind, Flexible-dose Efficacy Trial With Org 25935 Versus Placebo as add-on Therapy in Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia Treated With a Stable Dose of a Second Generation Antipsychotic (GIANT)",COMPLETED,2007-04-10,2008-10-24,2018-10-16,INTERVENTIONAL,PHASE2,215.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Schizophrenia,MK-8435 (Org 25935) 4-8 mg|Placebo|MK-8435 (Org 25935) 12-16 mg,DRUG,1,12,18 Years,55 Years,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,1,0,1,5.375278407684165,large,0,1,1,0,1,0,0,0,0,0,1,1,1,1,13,1,1,0,0,3,1,2007-04-10,2008-10-24,563.0,2007.0,0,2,0
NCT00062075,Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,A Phase 2 Study of Depsipeptide in Patients With Relapsed or Refractory AML,COMPLETED,2003-05,,2015-12-04,INTERVENTIONAL,PHASE2,47.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Promyelocytic Leukemia (M3)|Recurrent Adult Acute Myeloid Leukemia,romidepsin,DRUG,2,0,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,8,3.871201010907891,small,1,0,0,1,0,0,1,0,1,0,0,0,1,0,2,0,1,0,0,1,0,,,,,0,1,0
NCT00674375,Risk Score Alerts for Chest Pain Care,Can Risk Score Alerts Improve Office Care for Chest Pain?,COMPLETED,2008-11,2010-01,2015-03-18,INTERVENTIONAL,PHASE3,8000.0,ACTUAL,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,SINGLE,Chest Pain|Acute Myocardial Infarction,Electronic risk alerts,OTHER,3,2,30 Years,,ALL,False,Harvard Vanguard Medical Associates,OTHER,1,2,United States,1.0,0,0,1,0,0,3.0,0,0,0,1,2,8.987321812850125,xlarge,0,1,0,1,0,1,1,0,1,0,1,0,0,1,5,1,0,0,0,1,0,,,,,0,1,0
NCT00733057,Minocycline for the Treatment of Early-Phase Schizophrenia,A Double Blind Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia,COMPLETED,2003-08,2007-03,2008-08-12,INTERVENTIONAL,PHASE3,70.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Negative and Cognitive Symptoms in Schizophrenia,Minocycline|Placebo (200 mg/day),DRUG,1,1,18 Years,35 Years,ALL,False,Shalvata Mental Health Center,OTHER,1,1,Israel,1.0,0,0,1,0,0,3.0,0,0,1,0,1,4.2626798770413155,medium,1,1,0,1,0,1,0,0,0,0,1,1,0,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT03374657,"A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa","An Open-label First-in-human Single Ascending Dose Study to Explore Safety, Tolerability and Efficacy of Subretinal Administration of CPK850 Gene Therapy in Patients With Retinitis Pigmentosa Due to Mutations in the Retinaldehyde Binding Protein 1 (RLBP1) Gene",ACTIVE_NOT_RECRUITING,2018-08-22,2026-05-11,2026-01-15,INTERVENTIONAL,PHASE1|PHASE2,12.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Retinitis Pigmentosa,CPK850,BIOLOGICAL,2,12,18 Years,70 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,1,Sweden,,1,1,0,0,1,1.5,0,0,0,0,1,2.5649493574615367,small,1,1,1,0,1,0,0,0,0,0,0,0,1,0,14,1,0,1,0,1,0,2018-08-22,2026-05-11,2819.0,2018.0,1,2,0
NCT00238212,S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma,Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma,COMPLETED,2005-10,,2013-01-14,INTERVENTIONAL,PHASE2,50.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Adenocarcinoma of the Extrahepatic Bile Duct|Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Cholangiocarcinoma of the Extrahepatic Bile Duct|Cholangiocarcinoma of the Gallbladder|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Squamous Cell Carcinoma of the Gallbladder|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer,sorafenib tosylate|laboratory biomarker analysis,DRUG|OTHER,1,3,,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,10,3.9318256327243257,small,1,0,0,1,0,0,0,0,1,0,0,0,1,0,4,1,1,0,0,2,1,,,,,0,2,0
NCT01574612,Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old,An Open Label Multi Center Phase III Subject/Caregiver Initiated Safety Study of Xerese(Acyclovir and Hydrocortisone)Cream 5%/1% in the Treatment of Recurrent Herpes Labialis in Children,COMPLETED,2012-03,2013-02,2014-05-22,INTERVENTIONAL,PHASE3,54.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Herpes Labialis,acyclovir/hydrocortisone cream,DRUG,1,0,6 Years,11 Years,ALL,False,Meda Pharmaceuticals,INDUSTRY,1,10,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.007333185232471,medium,1,1,1,0,0,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT02755246,Polyamine-enriched Diet in Healthy Older Adults With Subjective Cognitive Decline,Effect of Polyamine-enriched Dietary Supplementation on Cognitive Function in Healthy Older Adults With Subjective Cognitive Decline,COMPLETED,2016-04,2016-09,2021-04-26,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Subjective Cognitive Decline,Polyamine supplementation|Placebo supplementation,DIETARY_SUPPLEMENT,1,2,60 Years,80 Years,ALL,True,"Charite University, Berlin, Germany",OTHER,2,1,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,1,0,0,0,1,1,1,1,1,3,1,0,0,0,2,1,,,,,0,1,0
NCT00547846,A Phase II Clinical Study of PDC-748 in Patients With Acute Cough,A Phase II Clinical Study of PDC-748 in Patients With Acute Cough,COMPLETED,2007-10,,2009-01-12,INTERVENTIONAL,PHASE2,,,RANDOMIZED,FACTORIAL,TREATMENT,TRIPLE,Acute Cough,PDC-748,DRUG,0,0,20 Years,,ALL,False,PhytoHealth Corporation,INDUSTRY,0,1,Taiwan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT07212946,Ayahuasca and Esketamine for Major Depression,Four Doses of Ayahuasca or Esketamine in Major Depressive Disorder: a Double-blind Randomized Trial,COMPLETED,2022-10-30,2025-10-01,2025-12-29,INTERVENTIONAL,PHASE2,22.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Major Depression Severe,Ayahuasca|Esketamine,DRUG,1,0,18 Years,65 Years,ALL,False,University of Sao Paulo,OTHER,0,1,Brazil,1.0,0,1,0,0,0,2.0,0,0,1,0,1,3.1354942159291497,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,2022-10-30,2025-10-01,1067.0,2022.0,1,1,0
NCT02395627,Reversing Therapy Resistance With Epigenetic-Immune Modification,"Reversing Therapy Resistance With Epigenetic-immune Modification: Phase II Trial of Vorinostat, Tamoxifen and Pembrolizumab in Hormone Receptor Expressing Advanced Breast Cancer",TERMINATED,2015-05-04,2019-06-08,2020-07-07,INTERVENTIONAL,PHASE2,38.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Neoplasms,Tamoxifen|Vorinostat|Pembrolizumab,DRUG,2,5,18 Years,,ALL,False,"University of California, San Francisco",OTHER,2,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6635616461296463,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,7,1,1,0,0,3,1,2015-05-04,2019-06-08,1496.0,2015.0,1,2,0
NCT02078661,Safety and Efficacy of PG101 for Dry Eye Syndrome,"A Single Center, Randomized, Double-Masked, Placebo Controlled Study Evaluating the Safety and Efficacy of 0.25% PG101 and 1.0% PG101 in Subjects With Dry Eye Syndrome",COMPLETED,2013-12,2014-01,2014-03-05,INTERVENTIONAL,PHASE1|PHASE2,72.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dry Eye Syndrome,PG101,DRUG,1,1,18 Years,,ALL,False,"Rhodes Pharmaceuticals, L.P.",INDUSTRY,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.290459441148391,medium,1,1,1,0,0,1,0,0,1,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,1,0
NCT00145561,The Pharmacokinetic Study of Saquinavir New Tablet Formulation in HIV-infected Pregnant Women.,"The Pharmacokinetics of SAquinavir (Invirase New Tablet Formulation) 1,000mg + Ritonavir (Norvir) 100mg q12h in HIV-infected Pregnant Women (SARA)",COMPLETED,2005-08,2008-02,2020-10-19,INTERVENTIONAL,PHASE1|PHASE2,40.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,HIV Infections,Saquinavir and Ritonavir,DRUG,1,2,18 Years,40 Years,FEMALE,False,Radboud University Medical Center,OTHER,1,10,United Kingdom|Thailand|Spain|Germany|Netherlands,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.713572066704308,small,1,1,0,1,0,1,1,1,0,1,0,0,1,0,3,1,1,0,0,1,0,,,,,0,2,0
NCT01293461,Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes,"A Randomized, Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration in Patients With Type 1 Diabetes Mellitus",COMPLETED,2011-04,2012-10,2013-03-01,INTERVENTIONAL,PHASE1|PHASE2,72.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 1 Diabetes|Diabetes Mellitus|Peripheral Diabetic Neuropathy,CBX129801|Placebo,DRUG,2,4,18 Years,65 Years,ALL,False,Cebix Incorporated,INDUSTRY,0,8,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,3,4.290459441148391,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,4,1
NCT00131742,Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B,"A Phase III Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B",COMPLETED,2004-07,2007-01,2015-05-12,INTERVENTIONAL,PHASE3,,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Hepatitis B,telbivudine|lamivudine,DRUG,0,0,16 Years,70 Years,ALL,,Novartis,INDUSTRY,1,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,0,0,2,1,,,,,0,1,0
NCT01262586,Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.,Pilot Study to Assess the Difference in Glycemic Profiles Between Vildagliptin and Glimepiride Using Continuous Glucose Monitoring Device,COMPLETED,2010-11,2011-03,2016-11-18,INTERVENTIONAL,PHASE3,24.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type II Diabetes Mellitus,Vildagliptin|Glimepiride,DRUG,1,1,18 Years,70 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,1,Germany,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.2188758248682006,small,1,1,1,0,1,0,0,0,0,1,1,0,1,0,2,1,1,0,0,2,1,,,,,0,1,0
NCT00196586,Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients,Pilot Study of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin for the Treatment of Chronic Hepatitis C in HIV-HCV Coinfected Patients Non Responders to Three Months of Therapy With Pegylated Interferon Alpha 2a and Ribavirin. ANRS HC09 SECOIIA,COMPLETED,2003-04,2006-11,2007-11-16,INTERVENTIONAL,PHASE2,75.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,HIV Infections|Chronic Hepatitis C,Interleukin 2|pegylated interferon alpha 2a|ribavirin,DRUG,1,1,18 Years,65 Years,ALL,False,French National Agency for Research on AIDS and Viral Hepatitis,OTHER_GOV,1,1,France,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.330733340286331,medium,1,0,0,1,0,1,0,0,0,1,0,0,1,0,2,1,1,0,0,3,1,,,,,0,2,0
NCT03442673,Chemotherapy and G-CSF for Mobilization,A Randomized Phase II Trial Comparing Stem Cell Mobilization With Chemotherapy and Cytokine (G-CSF) Versus Cytokine (G-CSF) Alone in Myeloma Patients (MOCCCA-trial).,COMPLETED,2018-09-17,2024-05-01,2025-03-28,INTERVENTIONAL,PHASE2,137.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,Vinorelbine|Gemcitabine|G-CSF,DRUG,1,9,18 Years,,ALL,False,"Insel Gruppe AG, University Hospital Bern",OTHER,0,1,Switzerland,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.927253685157205,medium,0,1,0,1,0,0,0,0,0,0,1,0,1,1,10,1,1,0,0,3,1,2018-09-17,2024-05-01,2053.0,2018.0,1,2,0
NCT00625573,Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01),Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01),COMPLETED,2007-09,2009-03,2009-09-18,INTERVENTIONAL,PHASE2,29.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Colorectal Cancer,Abraxane,DRUG,1,1,18 Years,90 Years,ALL,False,"Mt. Sinai Medical Center, Miami",OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4011973816621555,small,1,0,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT00507169,SVT-40776 in Patients Suffering From Overactive Bladder Syndrome,,COMPLETED,2006-09,2007-09,2011-06-08,INTERVENTIONAL,PHASE2,,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Overactive Bladder (OAB),SVT-40776,DRUG,0,0,18 Years,80 Years,ALL,False,Salvat,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,,,,,0,0,0
NCT00231569,Dose-escalating Safety Study in Subjects on Stable Statin Therapy,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Pharmacodynamics of ISIS 301012 in Hypercholesterolemic Subjects on Stable Statin Therapy",COMPLETED,2005-09,2007-12,2016-08-03,INTERVENTIONAL,PHASE2,74.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hypercholesterolemia,ISIS 301012 or Placebo|ISIS 301012 or Placebo|ISIS 301012 or Placebo|ISIS 301012 or Placebo|ISIS 301012 or Placebo|ISIS 301012 or Placebo|ISIS 301012 or Placebo,DRUG,1,4,18 Years,65 Years,ALL,False,"Kastle Therapeutics, LLC",INDUSTRY,1,5,Netherlands|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.31748811353631,medium,1,1,1,0,0,1,1,1,1,0,1,1,1,1,5,1,1,0,0,7,1,,,,,0,2,0
NCT00136669,Acupuncture For Pancreatic Cancer Pain,Acupuncture For Pancreatic Cancer Pain: A Randomized Phase III Study,COMPLETED,2003-09,2005-09,2006-09-08,INTERVENTIONAL,PHASE3,60.0,,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Pancreatic Neoplasms|Pain,Acupuncture,PROCEDURE,2,0,0 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.110873864173311,medium,1,0,0,1,0,0,0,0,1,0,1,0,1,1,2,0,0,0,0,1,0,,,,,0,1,0
NCT01652469,Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.,A Randomized Phase III Trial of Erlotinib Versus Docetaxel in Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Who Failed First Line Platinum Based Doublet Chemotherapy Stratified by VeriStrat Good vs VeriStrat Poor,COMPLETED,2012-08,2015-12,2022-08-24,INTERVENTIONAL,PHASE3,81.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Carcinoma, Non-Small-Cell Lung",Erlotinib|Docetaxel,DRUG,1,4,18 Years,,ALL,False,ETOP IBCSG Partners Foundation,NETWORK,1,32,United Kingdom|Denmark|Ireland|Netherlands|Austria|Spain|Italy|Switzerland|Hungary|Greece|Belgium|Israel,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.406719247264253,medium,1,1,0,0,0,1,1,1,0,1,1,0,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT02607683,Phase 2b/3 Study of XAF5 Ointment for Steatoblepharon (Undereye Bags),"A Phase 2b/3, Multicenter, Dose-ranging, Randomized, Double-masked, Placebo-controlled Study of XAF5 Ointment for Reduction of Lower Lid Steatoblepharon",COMPLETED,2016-01-01,2016-10-31,2017-11-08,INTERVENTIONAL,PHASE2|PHASE3,300.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Steatoblepharon,XAF5 (concentration A: 0.1%)|XAF5 (concentration B: 0.035%)|Matching placebo,DRUG,1,0,40 Years,70 Years,ALL,False,"Topokine Therapeutics, Inc.",INDUSTRY,0,6,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.707110264748875,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,3,1,2016-01-01,2016-10-31,304.0,2016.0,1,2,0
NCT00358683,A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease,"Open Label Long Term Clinical Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87055 Study.",WITHDRAWN,2007-11,,2012-05-28,INTERVENTIONAL,PHASE3,0.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Crohn's Disease,Certolizumab pegol,DRUG,1,1,18 Years,,ALL,,UCB Pharma,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,1,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT04574583,"Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta ""Trap""/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)","Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta ""Trap""/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)",COMPLETED,2020-11-24,2023-05-19,2025-02-03,INTERVENTIONAL,PHASE1|PHASE2,12.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Metastatic Cancer|Solid Tumors,SX-682|M7824|MVA-BN-CV301|recombinant fowlpox viral (FPV)-CV301,DRUG|BIOLOGICAL,5,4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,2,2.5649493574615367,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,9,1,1,1,0,4,1,2020-11-24,2023-05-19,906.0,2020.0,1,4,1
NCT04331041,Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma,Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma,ACTIVE_NOT_RECRUITING,2021-08-24,2027-04-30,2025-12-30,INTERVENTIONAL,PHASE2,42.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Pancreas Cancer|Cancer of the Pancreas|Pancreas Adenocarcinoma,Adaptive stereotactic body radiation therapy|Defactinib|Tumor biopsy|Research blood draw,DRUG|PROCEDURE|DEVICE,1,6,18 Years,,ALL,False,Washington University School of Medicine,OTHER,2,1,United States,,0,1,0,0,0,2.0,1,0,0,0,3,3.7612001156935624,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,7,1,1,0,1,4,1,2021-08-24,2027-04-30,2075.0,2021.0,1,3,1
NCT05430854,Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study,An Open-Label Extension Study To Evaluate The Long- Term Safety And Tolerability Of Daxdilimab (Hzn-7734) In Subjects With Systemic Lupus Erythematosus,TERMINATED,2022-06-01,2023-10-31,2024-09-19,INTERVENTIONAL,PHASE2,155.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Systemic Lupus Erythematosus,Daxdilimab,BIOLOGICAL,3,3,18 Years,72 Years,ALL,False,Amgen,INDUSTRY,0,52,Argentina|United States|Poland|Taiwan|Spain|Mexico|Greece|India|Serbia,0.0,0,1,0,0,0,2.0,0,1,0,0,1,5.049856007249537,medium,0,1,1,0,1,0,1,1,1,1,0,0,1,0,6,1,0,1,0,1,0,2022-06-01,2023-10-31,517.0,2022.0,1,2,0
NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)","A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea",COMPLETED,2012-05-16,2015-03-20,2019-07-23,INTERVENTIONAL,PHASE3,606.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Clostridium Difficile Infection,Surotomycin|Vancomycin|Placebo,DRUG,4,10,18 Years,90 Years,ALL,False,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.408528791059498,xlarge,0,1,1,0,1,0,0,0,0,0,1,1,1,1,14,1,1,0,0,3,1,2012-05-16,2015-03-20,1038.0,2012.0,0,2,0
NCT00646594,Atlantis Symbicort,"A Two Stage Randomized, Open-Label, Parallel Group, Phase III, Multicenter, 7 Month Study to Assess the Efficacy & Safety of SYMBICORT pMDI Adminstered Either as Fixed or as an Adjustable Regimen Versus a Fixed Regimen of Advair in Subjects 12 Yrs of Age and Older With Asthma.",COMPLETED,2003-11,2005-01,2009-03-27,INTERVENTIONAL,PHASE3,1200.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Asthma,budesonide/formoterol (Symbicort)|fluticasone/salmeterol (Advair),DRUG,1,3,12 Years,,ALL,False,AstraZeneca,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.0909098220799835,xlarge,0,0,1,0,1,0,0,0,0,0,1,0,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00205894,Occipital Nerve Stimulation to Treat Chronic Headaches,Multicenter Feasibility Study of the Bion for Occipital Nerve Stimulation for Treatment of Chronic Headaches,COMPLETED,2004-01,2007-09,2008-09-05,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Headache Disorders,bion microstimulator,DEVICE,2,0,18 Years,,ALL,False,Boston Scientific Corporation,INDUSTRY,0,2,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.044522437723423,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,2,0,0,0,1,1,0,,,,,0,1,0
NCT02606266,Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance,Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance,TERMINATED,2017-07-11,2018-12-11,2019-11-18,INTERVENTIONAL,PHASE2|PHASE3,1.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Congenital Cytomegalovirus (CMV),Valganciclovir,DRUG,1,3,6 Months,12 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,1,France,0.0,0,1,1,0,1,2.5,0,0,0,0,1,0.6931471805599453,small,1,1,0,1,0,0,0,0,0,1,1,0,1,1,4,1,1,0,0,1,0,2017-07-11,2018-12-11,518.0,2017.0,1,1,0
NCT04315051,A Trial of Safety/Efficacy of Test Article in Patients With Interdigital T. Pedis,"Clinical Trial Protocol DBI-204 Double-Blind, Randomized, Placebo Controlled Trial of the Safety and Efficacy of DBI-001 Gel in Patients With Interdigital Tinea Pedis",TERMINATED,2019-09-12,2020-06-30,2021-06-18,INTERVENTIONAL,PHASE2,39.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Interdigital Tinea Pedis,Cohort 1 J. Lividum|Placebo Gel,DRUG|OTHER,1,0,18 Years,,ALL,True,"DermBiont, Inc.",INDUSTRY,0,1,Dominican Republic,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6888794541139363,small,1,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,2,1,2019-09-12,2020-06-30,292.0,2019.0,1,1,0
NCT03715829,A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects,"A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO",COMPLETED,2018-11-26,2021-02-05,2022-03-25,INTERVENTIONAL,PHASE2,366.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Active Non-segmental Vitiligo,PF-06651600|PF-06651600|PF-06651600|PF-06651600|PF-06651600|placebo|PF06700841|narrow-band UVB phototherapy,DRUG|DEVICE,9,24,18 Years,65 Years,ALL,False,Pfizer,INDUSTRY,0,92,Australia|United States|Canada|South Korea|Taiwan|Spain|Germany|Japan|Belgium|Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.905361848054571,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,33,1,1,0,1,8,1,2018-11-26,2021-02-05,802.0,2018.0,1,3,1
NCT00328653,Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC),"Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1% Ophthalmic Cationic Emulsion) Versus Vehicle in Patients With VKC",COMPLETED,2006-05,,2021-12-14,INTERVENTIONAL,PHASE2|PHASE3,118.0,ACTUAL,RANDOMIZED,PARALLEL,,DOUBLE,"Conjunctivitis, Vernal",Cyclosporine NOVA22007 0.05%|Cyclosporine NOVA22007 0.1%|Vehicle,DRUG,2,2,4 Years,,ALL,False,Santen SAS,INDUSTRY,0,1,France,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.77912349311153,medium,0,1,1,0,0,0,0,0,0,1,1,1,0,1,4,1,1,0,0,3,1,,,,,0,2,0
NCT00433745,Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy,Wilm's Tumor 1 (WT1) Peptide Vaccination for Patients With High Risk Hematological Malignancies,COMPLETED,2007-02,2009-11,2014-07-08,INTERVENTIONAL,PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Myelodysplastic Syndrome|Acute Myeloid Leukemia (AML)|Chronic Myeloid Leukemia (CML),WT1 Peptide Vaccine,DRUG,1,1,18 Years,85 Years,ALL,False,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,1.6094379124341003,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT04493853,Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency,"A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.",ACTIVE_NOT_RECRUITING,2020-07-13,2027-03-29,2026-01-20,INTERVENTIONAL,PHASE3,1012.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hormone-Sensitive Prostate Cancer,Capivasertib|Placebo|Abiraterone Acetate,DRUG|OTHER,1,13,18 Years,130 Years,MALE,False,AstraZeneca,INDUSTRY,0,323,Canada|Austria|Thailand|South Africa|China|Hong Kong|Argentina|Russia|Australia|Bulgaria|Spain|Belgium|Israel|Chile|United States|Vietnam|France|Czechia|Germany|Netherlands|Poland|South Korea|India|Peru|United Kingdom|Turkey (Türkiye)|Brazil|Slovakia|Philippines|Taiwan|Mexico|Japan,,0,0,1,0,0,3.0,1,0,0,0,1,6.920671504248683,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,14,1,1,0,0,3,1,2020-07-13,2027-03-29,2450.0,2020.0,1,3,1
NCT01688037,NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study),"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder",COMPLETED,2012-09,2013-10,2017-11-08,INTERVENTIONAL,PHASE2,109.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Tardive Dyskinesia,NBI-98854|NBI-98854|Placebo,DRUG,1,2,18 Years,85 Years,ALL,False,Neurocrine Biosciences,INDUSTRY,0,51,Puerto Rico|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.700480365792417,medium,0,1,1,0,0,0,1,1,1,0,1,1,1,1,3,1,1,0,0,3,1,,,,,0,2,0
NCT00397072,Epothilone in Recurrent Glioblastoma Patients,Phase II Study: Systemic Treatment With iv ZK219477-Epothilone in Recurrent Glioblastoma Patients,COMPLETED,2006-06,2008-12,2014-04-17,INTERVENTIONAL,PHASE2,15.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Glioblastoma,ZK 219477,DRUG,1,3,18 Years,70 Years,ALL,False,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,OTHER,0,1,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.772588722239781,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT00132639,Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (NSCLC),Randomized Phase II Study of the Induction Chemotherapy With Docetaxel Alone vs CDDP + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (JCOG 0204-MF),COMPLETED,2002-10,2008-11,2016-09-22,INTERVENTIONAL,PHASE2,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Pulmonary Neoplasms,Preoperative docetaxel-cisplatin combination chemotherapy|Preoperative docetaxel monotherapy,DRUG,1,7,20 Years,74 Years,ALL,False,Haruhiko Fukuda,OTHER,1,1,Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.394449154672439,medium,1,1,0,1,0,1,0,0,0,0,1,0,1,1,8,1,1,0,0,2,1,,,,,0,2,0
NCT04643639,Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis,An Open-label Randomized Controlled Experimental Endotoxemia Study on the Effects of the Cytokine-adsorber CytoSorb on the Development of Immunoparalysis in Humans,COMPLETED,2020-09-16,2022-10-19,2022-12-22,INTERVENTIONAL,PHASE3,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Sepsis|Immune Deficiency|Hemoperfusion|Blood Purification,CytoSorb hemoperfusion,DEVICE,1,10,18 Years,35 Years,MALE,True,Radboud University Medical Center,OTHER,1,1,Netherlands,1.0,0,0,1,0,0,3.0,0,0,0,0,4,3.2188758248682006,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,11,1,0,0,1,1,0,2020-09-16,2022-10-19,763.0,2020.0,1,2,0
NCT03900377,Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma,"A Multicenter, Open-label, Phase I/II Study to Investigate the Safety and Tolerability of SyB L-0501RI (Bendamustine Hydrochloride for Injection) Administered As an Intravenous (IV) Rapid Infusion Over 10 Minutes",COMPLETED,2019-04-01,2021-02-26,2023-11-24,INTERVENTIONAL,PHASE1|PHASE2,37.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Lymphoma, B-cell, Diffuse",SyB L-0501RI,DRUG,6,7,20 Years,79 Years,ALL,False,SymBio Pharmaceuticals,INDUSTRY,0,14,Japan,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.6375861597263857,small,1,1,1,0,0,0,1,0,0,0,0,0,1,1,13,1,1,0,0,1,0,2019-04-01,2021-02-26,697.0,2019.0,1,2,0
NCT00004339,Study of Tetrathiomolybdate in Patients With Wilson Disease,,COMPLETED,1994-01,,2006-05-09,INTERVENTIONAL,PHASE3,90.0,,RANDOMIZED,,TREATMENT,DOUBLE,Wilson Disease,tetrathiomolybdate|trientine,DRUG,0,0,0 Years,,ALL,False,National Center for Research Resources (NCRR),NIH,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.51085950651685,medium,1,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,0,2,1,,,,,0,1,0
NCT03215277,A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis,"A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosing Spondylitis",COMPLETED,2017-10-04,2020-05-25,2023-07-27,INTERVENTIONAL,PHASE2,76.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ankylosing Spondylitis,Bimekizumab|Certolizumab pegol|Placebo,DRUG|OTHER,4,2,18 Years,,ALL,False,UCB Biopharma SRL,INDUSTRY,0,34,Russia|United States|Netherlands|Poland|Czechia|Germany|Greece|Moldova,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.343805421853684,medium,1,1,1,0,0,0,1,1,1,1,1,1,1,1,6,1,1,0,0,3,1,2017-10-04,2020-05-25,964.0,2017.0,1,3,1
NCT02918877,Anesthetics to Prevent Lung Injury in Cardiac Surgery,Anesthetics to Prevent Lung Injury in Cardiac Surgery,COMPLETED,2017-06-09,2021-02-01,2021-05-05,INTERVENTIONAL,PHASE1|PHASE2,51.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Inflammatory Lung Injury|Ischemia-Reperfusion Lung Injury|Postoperative Pulmonary Complications,Sevoflurane|Propofol,DRUG,1,6,18 Years,,ALL,False,Beth Israel Deaconess Medical Center,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,1,0,0,3,3.9512437185814275,medium,1,1,0,1,0,0,0,0,1,0,1,0,0,1,7,1,1,0,0,2,1,2017-06-09,2021-02-01,1333.0,2017.0,1,4,1
NCT01748877,"Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia","A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia (PHN)",COMPLETED,2013-01,2014-06,2014-06-19,INTERVENTIONAL,PHASE2,188.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Post Herpetic Neuralgia,NXN-462|Placebo,DRUG,1,8,18 Years,,ALL,False,NeurAxon Inc.,INDUSTRY,0,25,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.241747015059643,medium,0,1,1,0,0,0,1,1,1,0,1,1,1,1,9,1,1,0,0,2,1,,,,,0,3,1
NCT05776875,Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC,Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC,TERMINATED,2023-06-07,2024-12-05,2025-01-15,INTERVENTIONAL,PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatocellular Carcinoma|BCLC Stage B Hepatocellular Carcinoma,Atezolizumab Injection|Bevacizumab|Transarterial chemoembolization,DRUG|COMBINATION_PRODUCT,1,5,18 Years,,ALL,False,Yale University,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,2,1.3862943611198906,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,6,1,1,0,0,3,1,2023-06-07,2024-12-05,547.0,2023.0,1,3,1
NCT01971775,Clinical Study for Energy Based Devices in Open Gastrectomy for Gastric Cancer,Clinical Study for Energy Based Devices in Open Gastrectomy for Gastric Cancer: Conventional Monopolar Electrosurgery vs. Ultrasonically Activated Shear(UAS),COMPLETED,2011-08,,2013-10-29,INTERVENTIONAL,PHASE3,56.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Gastric Cancer,Ultrasonically activated Shears|Conventional Monopolar Electrocautery,DEVICE,2,5,20 Years,75 Years,ALL,False,Seoul National University Hospital,OTHER,1,1,South Korea,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.04305126783455,medium,1,1,0,1,0,1,0,0,0,0,1,0,1,1,7,1,0,0,1,2,1,,,,,0,2,0
NCT00991757,An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ 333369 as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study: Open-Label Extension Period",COMPLETED,2007-02,2010-10,2013-06-18,INTERVENTIONAL,PHASE3,991.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Epilepsy|Complex Partial Seizures|Epilepsy, Complex Partial|Epilepsies, Partial",carisbamate,DRUG,1,1,16 Years,,ALL,False,"SK Life Science, Inc.",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,1,0,4,6.899723107284872,xlarge,0,1,1,0,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT04998201,Study of ARO-APOC3 in Adults With Mixed Dyslipidemia,"A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Mixed Dyslipidemia",COMPLETED,2021-09-28,2023-08-14,2025-10-03,INTERVENTIONAL,PHASE2,353.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Mixed Dyslipidemia,ARO-APOC3|Placebo,DRUG,1,17,18 Years,,ALL,False,Arrowhead Pharmaceuticals,INDUSTRY,0,30,Australia|United States|Canada|New Zealand|Hungary|Poland,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.869296913133774,large,0,1,1,0,0,0,1,1,1,0,1,1,1,1,18,1,1,0,0,2,1,2021-09-28,2023-08-14,685.0,2021.0,1,3,1
NCT03924401,Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant,Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant (ASCENT),ACTIVE_NOT_RECRUITING,2019-08-22,2026-01,2025-05-13,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Graft Versus Host Disease,Abatacept,DRUG,1,15,,20 Years,ALL,False,Emory University,OTHER,4,9,United States,,0,1,0,0,0,2.0,0,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,1,1,0,1,0,0,0,0,0,16,1,1,0,0,1,0,2019-08-22,,,2019.0,1,1,0
NCT00229112,Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of Diabetic Foot Infections in Adults (0826-034),"A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in Adults.",COMPLETED,2001-04,2004-04,2017-02-17,INTERVENTIONAL,PHASE3,400.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Foot Infections in Diabetic Patients,"MK0826, ertapenem sodium / Duration of Treatment - 24 weeks|Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks",DRUG,1,1,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.993961427306569,large,0,0,1,0,1,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT00933712,Dermacyd Silver Floral (Lactic Acid) - Compatibility.,Study for Dermatological Evaluation of Topic Compatibility. Primary and Accumulated Dermical Irritability and Dermical Sensitivity for the Product Dermacyd Silver Floral (Lactic Acid).,COMPLETED,2009-06,2009-07,2010-09-14,INTERVENTIONAL,PHASE3,55.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hygiene,LACTIC ACID(ND),DRUG,1,0,18 Years,60 Years,ALL,True,Sanofi,INDUSTRY,0,1,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.02535169073515,medium,1,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT03640481,Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy,"A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)",TERMINATED,2018-10-11,2023-12-11,2024-12-12,INTERVENTIONAL,PHASE2,159.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Chronic Graft-versus-host-disease,Belumosudil (KD025),DRUG,1,15,12 Years,,ALL,True,"Kadmon, a Sanofi Company",INDUSTRY,0,35,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,5.075173815233827,medium,0,1,1,0,1,0,1,0,1,0,1,0,1,1,16,1,1,0,0,1,0,2018-10-11,2023-12-11,1887.0,2018.0,1,1,0
NCT00565019,Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Dupuytren's Contracture,The Effects of Steroid Injection With Percutaneous Needle Aponeurotomy in Patients With Dupuytren's Contracture: a Randomized Controlled Study,COMPLETED,2007-11,2013-06,2013-12-13,INTERVENTIONAL,PHASE3,51.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Dupuytren's Contracture,Triamcinolone Acetonide,DRUG,1,0,18 Years,,ALL,False,Sunnybrook Health Sciences Centre,OTHER,1,1,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.9512437185814275,medium,1,1,0,1,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,,,,,0,0,0
NCT01294319,Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men,Evaluation of Cortisol Resistance in Young Sedentary and Endurance-trained Men and Elderly Sedentary Men,COMPLETED,2011-01-24,2016-08-10,2024-07-15,INTERVENTIONAL,PHASE2,51.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Cortisol Resistance|Negative Feedback|ACTH|Mineralcorticoid|Glucocorticoid,Mifepristone|Placebo|Spironolactone|Combined|Dexamethasone,DRUG,1,1,18 Years,80 Years,MALE,False,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,5,3.9512437185814275,medium,1,1,0,1,0,0,0,0,1,0,1,1,1,0,2,1,1,0,0,5,1,2011-01-24,2016-08-10,2025.0,2011.0,0,2,0
NCT00366730,Study of Nitazoxanide in the Treatment of Amebiasis in Children,"Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Children",COMPLETED,2004-02,2005-11,2006-08-21,INTERVENTIONAL,PHASE3,50.0,,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Amebiasis,Nitazoxanide,DRUG,1,2,1 Year,11 Years,ALL,False,Romark Laboratories L.C.,INDUSTRY,0,2,Egypt,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.9318256327243257,small,1,0,1,0,0,0,1,0,0,0,1,1,1,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT00357630,Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary,Phase II Protocol: Gemcitabine for Metastatic Cancer With Unknown Primary Site - Analysis of Symptom Benefit,COMPLETED,2006-06,,2020-11-02,INTERVENTIONAL,PHASE2,52.0,ESTIMATED,,,TREATMENT,NONE,Carcinoma of Unknown Primary|Pain,gemcitabine hydrochloride|quality-of-life assessment,DRUG|PROCEDURE,1,3,18 Years,120 Years,ALL,False,Eastern Cooperative Oncology Group,NETWORK,1,37,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.970291913552122,medium,1,0,0,0,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,2,1,,,,,0,2,0
NCT00095888,3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer,A Phase II Trial Of Gemcitabine And Triapine In Refractory Metastatic Breast Cancer,TERMINATED,2004-10,,2013-01-16,INTERVENTIONAL,PHASE2,68.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer,triapine|gemcitabine hydrochloride|laboratory biomarker analysis|pharmacological study,DRUG|OTHER,1,6,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,3,4.23410650459726,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,7,1,1,0,0,4,1,,,,,0,3,1
NCT07141446,Evaluation of Efficacy of Neem (Azadirachta Indica) Versus Triamcinolone Acetonide in the Treatment of Oral Lichen Planus.,Evaluation of Efficacy of Neem (Azadirachta Indica) Versus Triamcinolone Acetonide in the Treatment of Oral Lichen Planus: A Randomized Controlled Trial.,COMPLETED,2023-02-05,2024-02-28,2025-09-03,INTERVENTIONAL,PHASE1|PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Oral Lichen Planus,Neem gel|Triamcinolone Acetonide,DRUG,3,1,20 Years,85 Years,ALL,False,Goa Dental College,OTHER_GOV,0,1,India,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,1,4,1,1,0,0,2,1,2023-02-05,2024-02-28,388.0,2023.0,1,2,0
NCT00820703,The ASCEND Study: A Study to Investigate the Safety and Clinical Effect of Nexagon to Treat Slow Healing Diabetic Foot Ulcers,"A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-escalation, Single-center Study of the Safety and Clinical Effect of Nexagon® in the Treatment of Participants With Diabetic Foot Ulcers",TERMINATED,2009-04,2009-12,2010-08-31,INTERVENTIONAL,PHASE1|PHASE2,24.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetic Foot Ulcer,Nexagon®|Nexagon® vehicle,DRUG,1,2,18 Years,,ALL,False,"OcuNexus Therapeutics, Inc.",INDUSTRY,0,1,New Zealand,0.0,1,1,0,0,1,1.5,0,0,0,0,1,3.2188758248682006,small,1,0,1,0,0,0,0,0,0,0,1,1,1,1,3,1,1,0,0,2,1,,,,,0,2,0
NCT00181688,Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer,A Phase II Study of ZD1839 (Iressa) Plus Anastrozole (Arimidex) in Patients With Relapsed Ovarian Cancer,COMPLETED,2003-10,2006-03,2012-12-05,INTERVENTIONAL,PHASE2,35.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Ovarian Cancer|Peritoneal Carcinoma|Tubal Carcinoma,Iressa (ZD1839)|Arimidex (Anastrozole),DRUG,1,2,18 Years,,FEMALE,False,Massachusetts General Hospital,OTHER,2,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,3.58351893845611,small,1,0,0,1,0,1,1,0,1,0,0,0,1,0,3,1,1,0,0,2,1,,,,,0,2,0
NCT01795742,Equivalence of a Human-Powered Nebulizer to an Electric Nebulizer,Equivalence of a Human-Powered Nebulizer to an Electric Nebulizer in the Treatment of Mild to Moderate Asthma in El Salvador,COMPLETED,2012-08,2012-10,2013-02-21,INTERVENTIONAL,PHASE2,110.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Asthma,Human-Powered Nebulizer,DEVICE,1,1,6 Years,65 Years,ALL,False,Marquette University,OTHER,0,1,El Salvador,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.709530201312334,medium,0,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,0,0,1,1,0,,,,,0,0,0
NCT04298086,A Study of the Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer,Pharmacodynamic Response to Exercise Treatment and Plant-Based Diet in Overweight/Obese Postmenopausal Women With Primary Hormone Receptor Positive Breast Cancer: A Phase 2 Randomized Control Trial,ACTIVE_NOT_RECRUITING,2020-03-04,2026-03,2025-07-11,INTERVENTIONAL,PHASE2,43.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer|Primary Hormone Receptor Positive Breast Cancer,Exercise Treatment|Plant-Based Diet|Physical activity|Nutrition counseling|Replication Exercise Test,OTHER,1,0,18 Years,,FEMALE,False,Memorial Sloan Kettering Cancer Center,OTHER,4,7,United States,,0,1,0,0,0,2.0,1,0,0,0,2,3.784189633918261,small,1,1,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,5,1,2020-03-04,,,2020.0,1,2,0
NCT04235686,8 Week Multi-site Study of MYDAYIS® for Bipolar Depression,An 8 Week Randomized Double Blind Placebo Controlled Multi-site Study Assessing Efficacy and Safety of MYDAYIS&#174; (D-amphetamine / L-amphetamine) for Bipolar Depression,COMPLETED,2020-07-17,2025-07-25,2025-08-12,INTERVENTIONAL,PHASE2,74.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Bipolar Depression,Mydayis Extended-Release Capsule|Placebo,DRUG,1,12,18 Years,55 Years,ALL,False,Mayo Clinic,OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,4.31748811353631,medium,1,1,0,1,0,1,1,0,1,0,1,1,1,1,13,1,1,0,0,2,1,2020-07-17,2025-07-25,1834.0,2020.0,1,2,0
NCT01699386,Growth of Infants Fed an Elemental Medical Food,Growth of Infants Fed an Elemental Medical Food,COMPLETED,1999-04,2000-12,2012-10-03,INTERVENTIONAL,PHASE3,213.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Healthy Infants,Control Study Formula|Experimental Study Formula,OTHER,1,3,,9 Days,ALL,True,Abbott Nutrition,INDUSTRY,0,2,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.365976015021851,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,4,1,0,0,0,2,1,,,,,0,1,0
NCT03710941,Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenously Administered REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis",WITHDRAWN,2019-02-19,2020-11-05,2019-04-29,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Sporadic Inclusion Body Myositis,REGN2477+REGN1033|Matching placebo,DRUG,1,22,45 Years,75 Years,ALL,False,Regeneron Pharmaceuticals,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,1,1,23,1,1,0,0,2,1,2019-02-19,2020-11-05,625.0,2019.0,1,2,0
NCT03538054,Dextromethorphan in Fibromyalgia,Dextromethorphan in Fibromyalgia,COMPLETED,2018-06-26,2020-03-18,2022-08-26,INTERVENTIONAL,PHASE2,27.0,ACTUAL,NON_RANDOMIZED,CROSSOVER,OTHER,SINGLE,Fibromyalgia,Dextromethorphan|Placebo,DRUG,1,2,23 Years,65 Years,FEMALE,False,University of Alabama at Birmingham,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.332204510175204,small,1,1,0,1,0,0,0,0,1,0,0,0,0,0,3,1,1,0,0,2,1,2018-06-26,2020-03-18,631.0,2018.0,1,1,0
NCT02088541,Selinexor (KPT-330) in Older Patients With Relapsed AML,"A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed or Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation",COMPLETED,2014-03,2018-01-08,2023-01-26,INTERVENTIONAL,PHASE2,317.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Myeloid Leukemia (AML),Selinexor|Hydroxyurea|Ara-C,DRUG,1,11,60 Years,,ALL,False,Karyopharm Therapeutics Inc,INDUSTRY,0,78,United Kingdom|Denmark|United States|Canada|Poland|France|Spain|Italy|Germany|Netherlands|Israel,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.762051382780177,large,0,1,1,0,0,0,1,1,1,1,1,0,1,1,12,1,1,0,0,3,1,,2018-01-08,,,0,3,1
NCT05304754,"""Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients""",Phase I / II Study on Infusion of Alloreactive or Stimulated Natural Killer Cells With IL-15 ex Vivo After Haploidentical Transplantation of Hematopoietic Progenitors in Pediatric Patients With Hematological Neoplasms,ACTIVE_NOT_RECRUITING,2020-11-30,2026-07,2025-04-06,INTERVENTIONAL,PHASE1|PHASE2,18.0,ESTIMATED,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,High-risk Leukemias,NK cells stimulated ex vivo with IL-15|Alloreactive NK cells,BIOLOGICAL,2,3,,21 Years,ALL,False,Instituto de Investigación Hospital Universitario La Paz,OTHER,0,10,Spain,,1,1,0,0,1,1.5,1,0,0,0,1,2.9444389791664403,small,1,0,0,1,0,0,1,0,0,1,0,0,1,1,5,1,0,1,0,2,1,2020-11-30,,,2020.0,1,2,0
NCT06884254,Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.,"A Phase 3, Randomized, Multicenter, Parallel-arm, Double-blind Study to Compare Efficacy and Safety of EG1206A (EirGenix' Pertuzumab) and Perjeta® (Pertuzumab) Sourced From EU as Neoadjuvant Treatment in Combination With Trastuzumab and Chemotherapy in Patients With HER2-positive Hormone Receptor-negative Early Breast Cancer",WITHDRAWN,2025-05,2027-12,2025-10-14,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Early Breast Cancer,EG1206A|Perjeta,DRUG,1,0,18 Years,70 Years,ALL,False,"EirGenix, Inc.",INDUSTRY,0,1,United States,0.0,0,0,1,0,0,3.0,1,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT02443805,Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR,"A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis",COMPLETED,2015-09-29,2018-06-25,2019-10-14,INTERVENTIONAL,PHASE3,1607.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Rhinitis, Allergic, Perennial|House Dust Mite Allergy",300 IR|Placebo,BIOLOGICAL,1,2,12 Years,65 Years,ALL,False,Stallergenes Greer,INDUSTRY,0,2,France|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,7.382746449738912,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,3,1,0,1,0,2,1,2015-09-29,2018-06-25,1000.0,2015.0,1,3,1
NCT02306694,Prospective Biomarkers of Bone Metabolism in Hemophilia A,Prospective Biomarkers of Bone Metabolism in Hemophilia A,COMPLETED,2014-12,2018-04-16,2020-04-01,INTERVENTIONAL,PHASE3,16.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hemophilia|Bone Disease,Advate,DRUG,4,0,16 Years,85 Years,MALE,False,Oregon Health and Science University,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,2.833213344056216,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,0,1,0,0,1,0,,2018-04-16,,,0,1,0
NCT01451866,Comparison Between Classic Leg-press Training and Complex Leg-press Training on a Dynamic Leg-press,Comparison of a Classic Leg-press Training Compared to a Complex Training on a Dynamic Leg-press With Visual Feed-back. Pilot-study,COMPLETED,2011-09,2011-11,2014-11-25,INTERVENTIONAL,PHASE2|PHASE3,34.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Healthy,resistance training|complex resistance training,OTHER,1,3,18 Years,65 Years,ALL,True,University of Applied Sciences of Western Switzerland,OTHER,0,1,Switzerland,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.5553480614894135,small,1,1,0,1,0,0,0,0,0,0,1,0,0,1,4,1,0,0,0,2,1,,,,,0,2,0
NCT00113022,Org 24448 to Treat Major Depression,"An Investigation of the Antidepressant Efficacy and Safety of an AMPAkine (Org 24448) in Major Depressive Disorder, A Double-Blind, Placebo-Controlled, Randomized Study",TERMINATED,2005-05,2007-02,2012-07-13,INTERVENTIONAL,PHASE2,9.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Depression,Org 24448|Placebo,DRUG,1,0,21 Years,70 Years,ALL,False,National Institute of Mental Health (NIMH),NIH,0,2,United States,0.0,0,1,0,0,0,2.0,0,0,1,0,1,2.302585092994046,small,1,1,0,1,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT02434822,A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic,Safety and Immunogenicity of Two Doses of Oral Cholera Vaccine (ShancholTM) in Subjects Aged 1 Year and Older in Dominican Republic,COMPLETED,2015-04,2016-07,2018-03-26,INTERVENTIONAL,PHASE3,336.0,ACTUAL,NON_RANDOMIZED,PARALLEL,PREVENTION,NONE,Cholera,Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell,BIOLOGICAL,2,1,1 Year,,ALL,True,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,0,1,Dominican Republic,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.820082930352362,large,0,1,1,0,1,0,0,0,0,0,0,0,0,1,3,1,0,1,0,3,1,,,,,0,1,0
NCT00379522,Vasopressin in Traumatic Hemorrhagic Shock Study,"A Multicenter, Randomized, Controlled Trial Assessing Arginine Vasopressin Versus Saline Placebo in Refractory Traumatic Hemorrhagic Shock Patients (VITRIS-study)",COMPLETED,2010-07,2014-10,2014-11-05,INTERVENTIONAL,PHASE2|PHASE3,64.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Shock|Hypovolemia|Hemorrhagic Shock,Vasopressin|Saline placebo,DRUG,1,3,18 Years,,ALL,False,Volker Wenzel,OTHER,0,14,Germany|Austria,1.0,0,1,1,0,1,2.5,0,0,0,0,3,4.174387269895637,medium,1,1,0,1,0,0,1,1,0,1,1,1,1,0,4,1,1,0,0,2,1,,,,,0,4,1
NCT02319031,"Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis","Open-Label, Randomized Study of Daclatasvir, Sofosbuvir, and Ribavirin for 12 vs. 16 Weeks in Treatment Naive and Treatment Experienced Patients With Genotype 3 Chronic Hepatitis C Infection Subjects With Compensated Advanced Fibrosis/Cirrhosis (F3/F4)",COMPLETED,2015-02,2015-12,2017-01-27,INTERVENTIONAL,PHASE3,53.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hepatitis C,Daclatasvir|Sofosbuvir|Ribavirin,DRUG,1,2,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,10,France|Australia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.9889840465642745,medium,1,1,1,0,1,0,1,1,0,1,1,0,1,1,3,1,1,0,0,3,1,,,,,0,2,0
NCT01268202,Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis,Curative Efficacy of Pravastatine in Patients Presented Delayed Cutaneous and Subcutaneous Radio-induced Fibrosis,COMPLETED,2010-12-17,2019-04-18,2019-06-13,INTERVENTIONAL,PHASE2,61.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Fibrosis,Pravastatin,DRUG,1,2,18 Years,,ALL,False,"Gustave Roussy, Cancer Campus, Grand Paris",OTHER,1,3,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.127134385045092,medium,1,1,0,1,0,1,1,0,0,1,0,0,1,0,3,1,1,0,0,1,0,2010-12-17,2019-04-18,3044.0,2010.0,0,0,0
NCT03898102,Zinc Supplement in Regorafenib Treated mCRC Patient,Zinc Supplement in Metastatic Colorectal Cancer Patients Receiving Regorafenib: Phase II Prospective Randomized Trial,COMPLETED,2016-03,2019-03,2019-04-01,INTERVENTIONAL,PHASE2,65.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Colorectal Cancer Metastatic,Regorafenib|Zinc gluconate supplement,DRUG|DIETARY_SUPPLEMENT,1,8,20 Years,,ALL,False,Chang Gung Memorial Hospital,OTHER,0,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.189654742026425,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,9,1,1,0,0,2,1,,,,,0,2,0
NCT01409837,The Effect and Safety of Lisinopril in Non-hypertensive Men With Infertility From Low Sperm Count,"A 5-year Prospective, Placebo-controlled, Crossover Evaluation of the Efficacy and Tolerability of Low-dose Lisinopril in Normotensives With Idiopathic Oligospermic Infertility",COMPLETED,1998-03,2006-12,2013-11-25,INTERVENTIONAL,PHASE2,33.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Oligospermia,Lisinopril,DRUG,8,1,24 Years,34 Years,MALE,False,University Of Nigeria Teaching Hospital,NETWORK,0,1,Nigeria,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.5263605246161616,small,1,1,0,0,0,0,0,0,0,0,1,1,1,0,9,1,1,0,0,1,0,,,,,0,1,0
NCT00731445,Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC),"Phase I/II Dose Escalation, Pharmacokinetic, Safety, and Efficacy Study of Oral Z-208 in Patients With Advanced Hepatocellular Carcinoma",COMPLETED,2008-07,2012-06,2012-07-03,INTERVENTIONAL,PHASE1|PHASE2,43.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Advanced Hepatocellular Carcinoma,Z-208,DRUG,2,4,20 Years,79 Years,ALL,False,Zeria Pharmaceutical,INDUSTRY,0,1,Japan,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.784189633918261,small,1,0,1,0,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,1,0,,,,,0,2,0
NCT00236145,Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain,"A Randomised, Open-label, Parallel-group Study to Evaluate the Efficacy and Safety of ACTIQ (Oral Transmucosal Fentanyl Citrate) Titrated According to 2 Regimens in Patients With Cancer and Breakthrough Pain",COMPLETED,2004-06,,2013-01-29,INTERVENTIONAL,PHASE3,,,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breakthrough Pain,ACTIQ (Oral transmucosal fentanyl citrate),DRUG,1,0,18 Years,,ALL,False,Cephalon,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,,,,,0,0,0
NCT00005645,ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment,Phase II Trial of ILX295501 Administered Orally Once Weekly x 3 Repeated Every 6 Weeks in Patients With Stage III/IV Ovarian Cancer,WITHDRAWN,1999-05,,2018-09-18,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,,TREATMENT,,Fallopian Tube Cancer|Metastatic Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer,ILX-295501,DRUG,0,0,18 Years,120 Years,FEMALE,False,"Genzyme, a Sanofi Company",INDUSTRY,0,8,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,4,0.0,,1,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,1,0
NCT02677545,Ticagrelor Versus Clopidogrel in Carotid Artery Stenting,Prevention of Cerebral Ischaemia in Stent Treatment for Carotid Artery Stenosis - A Randomised Multi-centre Phase II Trial Comparing Ticagrelor Versus Clopidogrel With Outcome Assessment on MRI (PRECISE-MRI),COMPLETED,2016-12,2022-04-28,2022-06-28,INTERVENTIONAL,PHASE2,210.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Carotid Artery Stenosis,Ticagrelor|Clopidogrel|Aspirin,DRUG,1,4,40 Years,,ALL,False,"University Hospital, Basel, Switzerland",OTHER,0,15,United Kingdom|Switzerland|Germany|Netherlands|Belgium|Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.351858133476067,large,0,1,0,1,0,0,1,1,0,1,1,0,1,1,5,1,1,0,0,3,1,,2022-04-28,,,0,2,0
NCT02342795,Randomized Controlled Trial Methods for Novel Tobacco Products Evaluation,Randomized Controlled Trial Methods for Novel Tobacco Products Evaluation,COMPLETED,2015-06,2018-07,2018-09-07,INTERVENTIONAL,PHASE1|PHASE2,520.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Nontherapeutic,e-cigarette|cigarette substitute,OTHER,1,2,21 Years,65 Years,ALL,True,Virginia Commonwealth University,OTHER,3,2,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,6.255750041753367,xlarge,0,1,0,1,0,1,1,0,1,0,1,1,0,1,3,1,0,0,0,2,1,,,,,0,2,0
NCT00108095,A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered With Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting (PONV) and Post-discharge Nausea and Vomiting (PDNV) in Female Subjects With Known Risk Factors for PONV Who Are Undergoing Surgical Procedures Associated With an Increased Emetogenic Risk",COMPLETED,2004-10,2005-08,2017-01-20,INTERVENTIONAL,PHASE2,701.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Postoperative Nausea and Vomiting|Nausea and Vomiting, Postoperative",intravenous ondansetron,DRUG,1,2,18 Years,55 Years,FEMALE,False,GlaxoSmithKline,INDUSTRY,0,58,United States|Canada|Hungary|Spain|Germany|Belgium,1.0,0,1,0,0,0,2.0,0,0,0,0,2,6.553933404025811,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,3,1,1,0,0,1,0,,,,,0,2,0
NCT01734239,A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018),"A Phase III, Open-Label Clinical Trial to Study the Safety and Immunogenicity of V110 in Subjects 50 Years of Age and Older and in Subjects 2 to 49 Years of Age at Increased Risk for Pneumococcal Disease, From the Russian Population",COMPLETED,2013-06-03,2013-10-22,2018-10-30,INTERVENTIONAL,PHASE3,102.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,PREVENTION,NONE,Pneumococcal Disease,Pneumovax™ 23,BIOLOGICAL,5,0,2 Years,,ALL,True,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.634728988229636,medium,0,1,1,0,1,0,0,0,0,0,0,0,0,0,5,0,0,1,0,1,0,2013-06-03,2013-10-22,141.0,2013.0,0,0,0
NCT03448939,A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea,"A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea",COMPLETED,2018-06-18,2019-05-24,2021-12-14,INTERVENTIONAL,PHASE3,361.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Papulopustular Rosacea,S5G4T-1|S5G4T-2,DRUG,2,1,18 Years,,ALL,False,"Sol-Gel Technologies, Ltd.",INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.8916442118257715,large,0,1,1,0,0,0,0,0,1,0,1,1,1,1,3,1,1,0,0,2,1,2018-06-18,2019-05-24,340.0,2018.0,1,1,0
NCT02223039,A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis,"Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of AbGn-168H Administered by Intravenous Infusion to Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Double-blind, Placebo-controlled)",COMPLETED,2014-05,2015-02,2016-04-14,INTERVENTIONAL,PHASE2,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Moderate to Severe Chronic Plaque Psoriasis,AbGn-168H|Placebo,BIOLOGICAL,1,7,18 Years,75 Years,ALL,False,AbGenomics B.V Taiwan Branch,INDUSTRY,0,15,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.9318256327243257,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,8,1,0,1,0,2,1,,,,,0,2,0
NCT00782275,Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma,A Phase II Trial of Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma,COMPLETED,2009-04,2015-05,2018-01-24,INTERVENTIONAL,PHASE2,41.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Renal Cell Carcinoma|Kidney Cancer,bevacizumab|temsirolimus,DRUG,1,2,18 Years,,ALL,False,Beth Israel Deaconess Medical Center,OTHER,4,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.7376696182833684,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,3,1,1,0,0,2,1,,,,,0,2,0
NCT00589875,Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma,A Phase IIa Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas,COMPLETED,2007-03,2016-08,2024-04-03,INTERVENTIONAL,PHASE2,52.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Malignant Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma|High Grade Glioma,CAN-2409|Valacyclovir|Temozolomide|Radiation therapy,DRUG|RADIATION|BIOLOGICAL,1,1,18 Years,,ALL,False,"Candel Therapeutics, Inc.",INDUSTRY,0,4,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,3.970291913552122,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,0,2,1,1,1,0,4,1,,,,,0,2,0
NCT01138475,Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery,"A Prospective, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Pilot Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery",COMPLETED,2010-07,2015-08,2017-03-22,INTERVENTIONAL,PHASE3,49.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Gastric Bypass|Parathyroid Hormone,Paricalcitol|Cholecalciferol|Placebo,DRUG,1,8,18 Years,100 Years,ALL,True,"Kerstyn C. Zalesin, M.D.",OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,3.912023005428146,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,9,1,1,0,0,3,1,,,,,0,3,1
NCT00656175,Raltegravir Therapy for Women With HIV and Fat Accumulation,Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation,COMPLETED,2008-09,2011-12,2012-12-19,INTERVENTIONAL,PHASE2,39.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,HIV Infections|Lipodystrophy,raltegravir,DRUG,1,0,18 Years,,FEMALE,False,"University of California, Los Angeles",OTHER,5,5,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.6888794541139363,small,1,1,0,1,0,1,1,1,1,0,1,0,1,1,1,0,1,0,0,1,0,,,,,0,2,0
NCT03845075,"48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)","A 24-week Phase 2, Double-blind, Randomized, Placebo- Controlled, Single-center Safety and Efficacy Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO), and With a 24-week Open-label Extension, in Total 48 Weeks",COMPLETED,2019-02-25,2020-10-16,2024-02-13,INTERVENTIONAL,PHASE2,21.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hypothalamic Injury-induced Obesity (HIO),Tesofensine/Metoprolol|Placebo,DRUG,9,17,18 Years,75 Years,ALL,False,Saniona,INDUSTRY,0,1,Denmark,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.091042453358316,small,1,1,1,0,0,0,0,0,0,0,1,1,1,1,26,1,1,0,0,2,1,2019-02-25,2020-10-16,599.0,2019.0,1,2,0
NCT01626495,Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma,CHP 959 - A Phase I/IIA Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRzeta and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant Or Refractory CD19+ Leukemia and Lymphoma,COMPLETED,2011-08-17,2019-07-11,2020-03-23,INTERVENTIONAL,PHASE1|PHASE2,73.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,B Cell Leukemia|B Cell Lymphoma,CART-19,BIOLOGICAL,1,3,1 Year,24 Years,ALL,False,University of Pennsylvania,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,2,4.30406509320417,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,4,1,0,1,0,1,0,2011-08-17,2019-07-11,2885.0,2011.0,0,2,0
NCT01531595,Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer,Phase 2 Study of Bevacizumab in Combination with Alternating XELIRI and XELOX As First-line Treatment of Patients with Metastatic Colorectal Cancer,ACTIVE_NOT_RECRUITING,2012-02,2025-12,2024-12-12,INTERVENTIONAL,PHASE2,100.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Colorectal Cancer,Bevacizumab plus alternating XELOX/XELIRI,DRUG,2,4,18 Years,,ALL,False,Pia Osterlund,OTHER,0,1,Finland,,0,1,0,0,0,2.0,1,0,0,0,1,4.61512051684126,medium,0,0,0,1,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,1,0,,,,,0,1,0
NCT00488839,IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis,"A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the PK and PD of IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis",COMPLETED,2007-06,2008-05,2019-11-06,INTERVENTIONAL,PHASE3,173.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Multiple Sclerosis,IPX056 20 mg|IPX056 40 mg|Encapsulated Baclofen 20 mg|Placebo Baclofen Tablet|IPX056 10 mg|IPX056 30 mg|IPX056 35 mg|Placebo IPX056 20 mg|Placebo IPX056 40 mg,DRUG,1,2,18 Years,,ALL,False,"Impax Laboratories, LLC",INDUSTRY,0,31,Estonia|Ukraine|United States|Canada|Latvia,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.159055299214529,medium,0,1,1,0,0,0,1,1,1,0,1,1,1,1,3,1,1,0,0,9,1,,,,,0,2,0
NCT04412057,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury",COMPLETED,2020-07-17,2021-01-19,2022-03-24,INTERVENTIONAL,PHASE2,88.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,COVID-19 Pneumonia|Acute Lung Injury|ARDS,CERC-002|Placebo,DRUG,1,1,18 Years,,ALL,False,"Aevi Genomic Medicine, LLC, a Cerecor company",INDUSTRY,0,11,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,4.48863636973214,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,2,1,2020-07-17,2021-01-19,186.0,2020.0,1,2,0
NCT04678557,"A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus","An Open-Label Phase 1/2 Study to Evaluate the Safety, Engraftment, and Efficacy of VC-01™Combination Product in Subjects With Type 1 Diabetes Mellitus [T1DM]",TERMINATED,2019-06-25,2021-11-19,2023-10-18,INTERVENTIONAL,PHASE1|PHASE2,31.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,OTHER,NONE,Type 1 Diabetes,VC-01 Combination Product,COMBINATION_PRODUCT,2,0,18 Years,65 Years,ALL,False,ViaCyte,INDUSTRY,0,4,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,1,3.4657359027997265,small,1,1,1,0,0,0,1,0,1,0,0,0,0,0,2,0,0,0,0,1,0,2019-06-25,2021-11-19,878.0,2019.0,1,1,0
NCT00523757,Aldosterone Blockade in Heart Failure,Aldosterone-blockade Randomized Controlled Trial In CHF - Diastolic,COMPLETED,2007-08,2010-04-30,2018-11-07,INTERVENTIONAL,PHASE3,8.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Heart Failure,Spironolactone|Placebo,DRUG,1,0,18 Years,90 Years,ALL,False,Justin Ezekowitz,OTHER,0,1,Canada,1.0,0,0,1,0,0,3.0,0,0,0,1,1,2.1972245773362196,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,,2010-04-30,,,0,1,0
NCT02660112,(+) Epicatechin to Treat Friedreich's Ataxia,"A Phase II, Open Label Prospective Single Center Drug Study Evaluating the Safety and Efficacy of (+)-Epicatechin in Subjects With Friedreich's Ataxia",COMPLETED,2016-09,2018-12-30,2019-12-05,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Friedreich's Ataxia,(+)-Epicatechin,DRUG,2,0,10 Years,50 Years,ALL,False,Ralitza Gavrilova,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,0,1,0,0,1,0,,2018-12-30,,,0,0,0
NCT00273312,Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma,"An Open-label, Phase II Trial of Patupilone (EPO906) as Monotherapy to Evaluate Activity of Patupilone in Patients With Advanced Unresectable and/or Metastatic Hepatocellular Carcinoma (HCC)",COMPLETED,2006-01,,2017-02-07,INTERVENTIONAL,PHASE2,25.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hepatocellular Carcinoma,Patupilone,DRUG,1,2,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,7,South Korea|Taiwan|Hong Kong|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.258096538021482,small,1,1,1,0,1,0,1,1,1,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,1,0
NCT00320112,Improving Insulin Therapy With Enhanced Care Management,Improving Insulin Therapy With Enhanced Care Management and Peer Support,COMPLETED,2007-02,2010-03,2015-04-24,INTERVENTIONAL,PHASE3,244.0,ACTUAL,RANDOMIZED,PARALLEL,,NONE,Diabetes,Reciprocal Diabetes Peer Support Program|Nurse Case management|group outpatient counseling visits,BEHAVIORAL,1,3,21 Years,,ALL,False,US Department of Veterans Affairs,FED,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.501258210544727,large,0,1,0,0,0,0,0,0,1,0,1,0,0,1,4,1,0,0,0,3,1,,,,,0,1,0
NCT00992212,"Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10","A Phase II, Open Label Study to Evaluate the Immunogenicity, Tolerability and Safety of an Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects Aged 18 Years and Above",COMPLETED,2009-08,2009-11,2016-12-01,INTERVENTIONAL,PHASE2,418.0,ACTUAL,NON_RANDOMIZED,PARALLEL,PREVENTION,NONE,Pandemic Influenza Disease,Monovalent A/H1N1 influenza vaccine,BIOLOGICAL,1,0,18 Months,,ALL,True,Novartis Vaccines,INDUSTRY,0,5,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.037870919922137,large,0,1,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,,,,,0,0,0
NCT01629381,Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy,Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy: a Randomized Double-blind Trial (ERIKA Study),COMPLETED,2012-05,2014-03,2021-05-21,INTERVENTIONAL,PHASE2,500.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Venous Thromboembolism|Haemorrhage,Rivaroxaban|placebo,DRUG,2,2,18 Years,,ALL,False,University of Padova,OTHER,0,9,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,2,6.2166061010848646,large,0,1,0,1,0,0,1,0,0,1,1,1,0,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT01453881,Fine Particle pMDI Formoterol/Beclomethasone in Asthmatics With and Without Spacer: Comparative Efficacy Evaluation,Randomized Clinical Trials to Compare Asthma Control Efficacy of the Fine-particle Combination Formoterol/Beclomethasone by pMDI Administered With and Without Spacer.,COMPLETED,2011-04,2013-06,2015-03-31,INTERVENTIONAL,PHASE3,45.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Asthma,Spacer|Comparator,DEVICE,1,1,18 Years,65 Years,ALL,False,Universidade Federal de Pernambuco,OTHER,1,1,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.828641396489095,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,2,1,0,0,1,2,1,,,,,0,1,0
NCT01891019,Thalidomide in the Treatment of Chronic Plaque Psoriasis.,Thalidomide in the Treatment of Chronic Plaque Psoriasis.,COMPLETED,2003-04,2009-06,2018-08-13,INTERVENTIONAL,PHASE2,21.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Psoriasis, Plaque-type",Thalidomide oral,DRUG,1,1,18 Years,,ALL,False,Wake Forest University,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.091042453358316,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT00970203,Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer,"Feasibility, Safety and Efficacy Evaluation of Alpha-Type 1 Dendritic Cell(DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With PSA Progression After Local Therapy for Prostate Cancer",COMPLETED,2009-09,2019-10-05,2020-11-03,INTERVENTIONAL,PHASE2,13.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,"Cancer of Prostate|Cancer of the Prostate|Neoplasms, Prostate|Neoplasms, Prostatic|Prostate Cancer|Prostate Neoplasms|Prostatic Cancer",androgen ablation (AA)|DC1 vaccine,BIOLOGICAL,3,5,18 Years,,MALE,False,Roswell Park Cancer Institute,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,7,2.6390573296152584,small,1,1,0,1,0,1,0,0,1,0,1,0,1,0,8,1,0,1,0,2,1,,2019-10-05,,,0,3,1
NCT02876003,Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma,"An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 in Patients With PSMA Positive Recurrent or Progressive Glioblastoma",WITHDRAWN,2016-09,2020-10,2017-02-24,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Glioblastoma,G-202,DRUG,1,4,18 Years,,ALL,False,"GenSpera, Inc.",INDUSTRY,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,1,0,0,1,0,0,1,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,0,0
NCT04828161,"A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19","A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 - The ""EMPATHY"" Trial",TERMINATED,2021-05-10,2022-01-27,2026-01-27,INTERVENTIONAL,PHASE2|PHASE3,407.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,COVID-19,ensovibep|Placebo,DRUG,2,16,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,1,48,United States|South Africa|Hungary|Netherlands|India,0.0,0,1,1,0,1,2.5,0,0,0,0,1,6.0112671744041615,large,0,1,1,0,1,1,1,1,1,0,1,1,1,1,18,1,1,0,0,2,1,2021-05-10,2022-01-27,262.0,2021.0,1,4,1
NCT00262470,Treatment of Orthostatic Intolerance,Treatment of Orthostatic Intolerance,ACTIVE_NOT_RECRUITING,1997-04,2029-12,2025-10-08,INTERVENTIONAL,PHASE1|PHASE2,150.0,ESTIMATED,NON_RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Tachycardia|Chronic Orthostatic Intolerance,Acetazolamide|Atomoxetine|NO Drug|Clonidine|Entacapone|Entacapone & Propranolol|Atomoxetine & Propranolol|Indomethacin|Mecamylamine|Isosorbide Dinitrate|Melatonin|Midodrine|Modafinil|Octreotide|Placebo|Propranolol|Modafinil & Propranolol|Sertraline|IV Saline|Drinking Water|Breathing Device|memantine|Abdominal binder,PROCEDURE|DRUG|RADIATION|DIETARY_SUPPLEMENT|DEVICE|OTHER,1,5,18 Years,70 Years,ALL,True,Satish R. Raj,OTHER,1,1,United States,,1,1,0,0,1,1.5,0,0,0,0,2,5.017279836814924,medium,0,0,0,1,0,1,0,0,1,0,0,0,1,0,6,1,1,0,1,23,1,,,,,0,4,1
NCT00217386,Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes,Therapy of Early Stage Myelodysplastic Syndrome (MDS) With ATG and Etanercept,COMPLETED,2004-03,,2010-09-15,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,,,TREATMENT,NONE,Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,anti-thymocyte globulin|etanercept,BIOLOGICAL,3,0,18 Years,,ALL,False,Fred Hutchinson Cancer Center,OTHER,1,4,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,3.4339872044851463,small,1,0,0,1,0,1,1,0,1,0,0,0,1,0,3,0,0,1,0,2,1,,,,,0,2,0
NCT03070886,Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery,Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel,COMPLETED,2017-04-05,2025-10-31,2026-01-14,INTERVENTIONAL,PHASE2|PHASE3,612.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Stage I Prostate Adenocarcinoma AJCC v7|Stage II Prostate Adenocarcinoma AJCC v7|Stage III Prostate Adenocarcinoma AJCC v7,Bicalutamide|Degarelix|Docetaxel|External Beam Radiation Therapy|Flutamide|Goserelin|Goserelin Acetate|Laboratory Biomarker Analysis|Leuprolide|Leuprolide Acetate|Nilutamide,DRUG|OTHER|RADIATION,2,6,18 Years,,MALE,False,NRG Oncology,OTHER,1,313,Puerto Rico|Canada|United States,1.0,0,1,1,0,1,2.5,1,0,0,0,3,6.418364935936212,xlarge,0,1,0,1,0,1,1,1,1,0,1,0,1,1,8,1,1,0,0,11,1,2017-04-05,2025-10-31,3131.0,2017.0,1,5,1
NCT01127386,Lenalidomide for Lean Body Mass and Muscle Strength in Inflammatory Cancer Cachexia Syndrome,"Effect of Lenalidomide (Revlimid®) in Solid Tumour Patients With Inflammatory Cancer Cachexia Syndrome on Lean Body Mass and Muscle Strength: A Multicenter, Proof-of-concept Study of Fixed Dose or CRP-response-guided Dose of Lenalidomide in Relation to New Standard Basic Cachexia Management (Receiving Placebo).",COMPLETED,2009-03,2012-12,2017-08-01,INTERVENTIONAL,PHASE1|PHASE2,200.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cancer Cachexia Syndrome,"Lenalidomide|Lenalidomide|basic cachexia management (prokinetics, physical activity counselling, nutritional counselling)",DRUG|OTHER,2,6,18 Years,,ALL,False,"Florian Strasser, MD ABHPM",OTHER,1,1,Switzerland,1.0,1,1,0,0,1,1.5,1,0,0,0,1,5.303304908059076,medium,0,1,0,1,0,1,0,0,0,0,1,1,1,1,8,1,1,0,0,3,1,,,,,0,3,1
NCT00148486,"A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)","A Fourteen-week Placebo-controlled Dose-response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)",COMPLETED,2003-06,,2013-10-29,INTERVENTIONAL,PHASE2,261.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Parkinson Disease,NS 2330,DRUG,2,16,40 Years,80 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,55,Canada|United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,5.568344503761097,large,0,0,1,0,0,0,1,1,1,0,1,1,1,1,18,1,1,0,0,1,0,,,,,0,2,0
NCT01967173,Best African American Response to Asthma Drugs,Best African American Response to Asthma Drugs,COMPLETED,2014-02,2017-07-01,2018-11-15,INTERVENTIONAL,PHASE3,574.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Asthma,Flovent Diskus® 100 mcg|Flovent Diskus® 250 mcg|Flovent Diskus® 500 mcg|Advair Diskus® 100/50 mcg|Advair Diskus® 250/50 mcg,DRUG,1,0,5 Years,,ALL,False,Milton S. Hershey Medical Center,OTHER,1,28,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.354370040797351,xlarge,0,1,0,1,0,1,1,0,1,0,1,1,1,0,1,0,1,0,0,5,1,,2017-07-01,,,0,1,0
NCT01531673,Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation,"A Phase 2, Multicenter, Double-Blinded, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/Ivacaftor Cotherapy in Subjects With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation",COMPLETED,2012-02,2014-03,2018-04-13,INTERVENTIONAL,PHASE2,194.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cystic Fibrosis,VX-661|Ivacaftor|Placebo matched to VX-661|Placebo matched to ivacaftor,DRUG,4,14,12 Years,,ALL,False,Vertex Pharmaceuticals Incorporated,INDUSTRY,0,36,Germany|Canada|United Kingdom|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.272999558563747,medium,0,1,1,0,0,0,1,1,1,1,1,1,1,1,18,1,1,0,0,4,1,,,,,0,3,1
NCT00222469,Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer,A Phase II Trial of Bevacizumab Plus Gemcitabine™ and Oxaliplatin™ as First Line Therapy in Metastatic or Locally Advanced (Unresectable) Pancreatic Cancer,COMPLETED,2005-08,2007-05,2008-07-09,INTERVENTIONAL,PHASE2,50.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,PREVENTION,NONE,Metastatic Pancreatic Cancer,bevacizumab|gemcitabine|oxaliplatin,DRUG,1,2,18 Years,,ALL,False,University of Oklahoma,OTHER,3,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,1,1,0,1,0,0,0,0,0,3,1,1,0,0,3,1,,,,,0,1,0
NCT02730169,Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism,"A Phase IIb Multicentre, Double-Blind, Dose-Ranging, Randomised, Placebo-Controlled Study Evaluating Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism",COMPLETED,2016-05-12,2018-05-19,2022-09-14,INTERVENTIONAL,PHASE2,271.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hypogonadotropic Hypogonadism,BGS649|Placebo,DRUG,1,7,18 Years,65 Years,MALE,False,Mereo BioPharma,INDUSTRY,0,63,United Kingdom|Spain|Italy|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.605802066295998,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,8,1,1,0,0,2,1,2016-05-12,2018-05-19,737.0,2016.0,1,3,1
NCT02491983,"Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer","A Randomized, Multicenter, Open-label, Phase II Trial to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With HER2 Negative, ER+ Metastatic Breast Cancer",COMPLETED,2015-08,2020-01,2024-12-09,INTERVENTIONAL,PHASE2,486.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Breast Cancer,Palbociclib|Fulvestrant|Letrozole,DRUG,1,5,18 Years,,FEMALE,False,MedSIR,OTHER,0,48,United Kingdom|Russia|France|Spain|Czechia|Germany|Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,6.18826412308259,large,0,1,0,1,0,0,1,1,0,1,1,0,1,1,6,1,1,0,0,3,1,,,,,0,3,1
NCT02802254,Increasing Risk Perception of Physical Activity Using Patient-targeted Feedback.,Increasing Risk Perception of Physical Activity Using Patient-targeted Feedback: Randomized Controlled Trial.,COMPLETED,2016-08,2017-06,2022-08-09,INTERVENTIONAL,PHASE2|PHASE3,121.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Hypertension|Coronary Disease|Cardiac Diseases,Patient-targeted individual physical-activity-feedback|Pedometer,BEHAVIORAL|DEVICE,1,10,18 Years,75 Years,ALL,False,Universitätsklinikum Hamburg-Eppendorf,OTHER,0,2,Germany,1.0,0,1,1,0,1,2.5,0,0,0,1,3,4.804021044733257,medium,0,1,0,1,0,0,1,0,0,1,1,1,0,1,11,1,0,0,1,2,1,,,,,0,4,1
NCT01433354,"Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)",An Open-label Study to Evaluate the Long-term Safety and Tolerability of AFQ056 in Adolescent Patients With Fragile X Syndrome,TERMINATED,2011-11,2014-09,2016-03-24,INTERVENTIONAL,PHASE2|PHASE3,119.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Fragile X Syndrome,AFQ056,DRUG,1,0,12 Years,18 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,28,United Kingdom|Denmark|Australia|United States|Sweden|France|Spain|Italy|Switzerland|Germany|Netherlands|Belgium|Israel,0.0,0,1,1,0,1,2.5,0,0,0,0,1,4.787491742782046,medium,0,1,1,0,1,0,1,1,1,1,0,0,1,0,1,0,1,0,0,1,0,,,,,0,2,0
NCT02263105,Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas,Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas: A Single-arm Prospective Phase II Clinical Study,COMPLETED,2014-10,2018-06,2018-07-17,INTERVENTIONAL,PHASE2,67.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,High-grade Gliomas,CDDP|Temozolomide,DRUG,1,1,18 Years,75 Years,ALL,False,Huashan Hospital,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.219507705176107,medium,1,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,2,1,,,,,0,1,0
NCT03541005,Evaluation of Obex® in Overweight and Obesity,Efficacy and Safety of the Obex® Nutritional Supplement in Overweight and Obese Subjects: Phase III.,COMPLETED,2018-10-01,2021-07-03,2021-10-21,INTERVENTIONAL,PHASE3,160.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Overweight and Obesity,Obex|Placebo,DIETARY_SUPPLEMENT,3,13,20 Years,65 Years,ALL,False,Catalysis SL,INDUSTRY,0,1,Cuba,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.081404364984463,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,16,1,0,0,0,2,1,2018-10-01,2021-07-03,1006.0,2018.0,1,2,0
NCT01085266,An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease,HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease,TERMINATED,2010-02,,2016-10-12,INTERVENTIONAL,PHASE3,362.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Huntington Disease,Dimebon (latrepirdine),DRUG,0,0,30 Years,,ALL,False,"Medivation, Inc.",INDUSTRY,1,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.8944028342648505,large,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT04579666,MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS),"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Subjects With Amyotrophic Lateral Sclerosis (ALS)",TERMINATED,2020-09-30,2023-07-13,2025-04-24,INTERVENTIONAL,PHASE2,249.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,Pegcetacoplan (APL-2)|Placebo,DRUG|OTHER,5,11,18 Years,,ALL,False,"Apellis Pharmaceuticals, Inc.",INDUSTRY,0,60,United Kingdom|Ukraine|Australia|United States|Ireland|Netherlands|Poland|France|Spain|Czechia|Germany|Japan|Belgium|Italy,0.0,0,1,0,0,0,2.0,0,0,0,0,2,5.521460917862246,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,16,1,1,0,0,2,1,2020-09-30,2023-07-13,1016.0,2020.0,1,4,1
NCT00003156,Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus,Evaluation of Topotecan in the Treatment of Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus,TERMINATED,1998-06,,2013-04-11,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Sarcoma,topotecan hydrochloride,DRUG,0,0,,,FEMALE,False,Gynecologic Oncology Group,NETWORK,1,46,Canada|United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,1,0
NCT02314156,Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy,Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy,COMPLETED,2015-10,2021-05,2023-02-22,INTERVENTIONAL,PHASE2,67.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Ductal Breast Carcinoma In Situ|Lobular Breast Carcinoma In Situ|Stage 0 Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer,Telapristone Acetate|Placebo|Telapristone Acetate|Placebo|Laboratory Biomarker Analysis|Questionnaire Administration,DRUG|OTHER,1,7,18 Years,,FEMALE,False,Northwestern University,OTHER,1,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,9,4.219507705176107,medium,1,1,0,1,0,1,1,0,1,0,1,1,0,1,8,1,1,0,0,6,1,,,,,0,3,1
NCT00619229,Alprostadil in Maculopathy Study (AIMS),"Confirmatory, Prospective, Randomized, Double-blind, Placebo-controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Dry Age-related Macular Degeneration.",TERMINATED,2006-07,2010-02,2014-10-27,INTERVENTIONAL,PHASE3,37.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Macular Degeneration,Alprostadil (prostaglandin E1)|Placebo,DRUG|OTHER,1,10,50 Years,,ALL,False,UCB Pharma,INDUSTRY,0,6,Germany,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.6375861597263857,small,1,1,1,0,0,0,1,0,0,1,1,1,1,1,11,1,1,0,0,2,1,,,,,0,2,0
NCT02154529,Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer,A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer,TERMINATED,2014-05,2015-09-13,2022-04-27,INTERVENTIONAL,PHASE1|PHASE2,17.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,HER-2 Positive Breast Cancer|Metastatic Malignant Neoplasm to Brain,Tesevatinib|Trastuzumab,DRUG,2,5,18 Years,,FEMALE,False,"Kadmon Corporation, LLC",INDUSTRY,0,6,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,2,2.8903717578961645,small,1,1,1,0,0,0,1,0,1,0,0,0,1,1,7,1,1,0,0,2,1,,2015-09-13,,,0,4,1
NCT05280002,Adipose-tissue-derived Total-Stromal-cells (TOST) Therapy in Knee Osteoarthritis,Outcomes of Single Intra-articular Injection of Adipose-tissue-derived Total-Stromal-cells (TOST) Therapy in Knee Osteoarthritis,COMPLETED,2018-01-01,2021-12-31,2022-03-15,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Osteoarthritis Knees,Adipose Tissue derived Total-Stromal-Cells (TOST),BIOLOGICAL,3,0,40 Years,80 Years,ALL,False,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",OTHER,1,1,Bangladesh,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.4339872044851463,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,3,0,0,1,0,1,0,2018-01-01,2021-12-31,1460.0,2018.0,1,0,0
NCT01435902,A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise,"A Randomized, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Asthmatic Adolescent and Adult Subjects With Exercise-Induced Bronchoconstriction",WITHDRAWN,2012-01,2012-08,2014-06-23,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Asthma,Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone Propionate Inhalation Powder,DRUG,1,5,12 Years,50 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,1,0,6,1,1,0,0,2,1,,,,,0,2,0
NCT01828502,Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer,Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer,WITHDRAWN,2013-10,2016-06,2014-10-29,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Pediatric Cancer,Education|Cotinine Education,BEHAVIORAL,1,2,2 Years,12 Years,ALL,False,University of South Florida,OTHER,1,10,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,1,1,0,1,0,1,0,0,1,3,1,0,0,0,2,1,,,,,0,1,0
NCT06083753,Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Oral PIPE-307 as an Adjunctive Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis",COMPLETED,2023-11-06,2025-08-04,2025-10-23,INTERVENTIONAL,PHASE2,182.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Relapsing Remitting Multiple Sclerosis,PIPE-307 Dose A|PIPE-307 Dose B|Placebo,DRUG,2,8,18 Years,50 Years,ALL,False,Contineum Therapeutics,INDUSTRY,0,21,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.209486152841421,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,10,1,1,0,0,3,1,2023-11-06,2025-08-04,637.0,2023.0,1,2,0
NCT02392637,"Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers","A Phase II Study of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers",COMPLETED,2015-04-02,2020-08-13,2022-02-02,INTERVENTIONAL,PHASE2,62.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Stage III Intrahepatic Cholangiocarcinoma AJCC v7|Stage IIIA Gallbladder Cancer AJCC v7|Stage IIIB Gallbladder Cancer AJCC v7|Stage IVA Gallbladder Cancer AJCC v7|Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7|Stage IVB Gallbladder Cancer AJCC v7|Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7|Unresectable Extrahepatic Bile Duct Carcinoma|Unresectable Gallbladder Carcinoma,Cisplatin|Gemcitabine Hydrochloride|Laboratory Biomarker Analysis|Nab-paclitaxel,DRUG|OTHER,1,2,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,9,4.143134726391533,medium,1,1,0,1,0,1,1,0,1,0,0,0,1,0,3,1,1,0,0,4,1,2015-04-02,2020-08-13,1960.0,2015.0,1,2,0
NCT00665145,Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509,A Phase 2 Study of Stem-Cell-Mobilization in Subjects With Diabetic Neuropathy Receiving SB-509,COMPLETED,2008-01,2009-10,2012-11-01,INTERVENTIONAL,PHASE2,23.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Diabetes Mellitus, Type 1|Diabetes Mellitus, Type 2|Diabetic Polyneuropathy",SB-509|SB-509|Placebo|SB-509,DRUG,1,1,18 Years,70 Years,ALL,False,Sangamo Therapeutics,INDUSTRY,0,4,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,3.1780538303479458,small,1,1,1,0,0,0,1,0,1,0,1,0,1,1,2,1,1,0,0,4,1,,,,,0,2,0
NCT02927145,"A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate","A Phase I/IIa Clinical Trial to Assess the Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Falciparum Malaria Vaccine Candidate RH5.1/AS01",COMPLETED,2016-10-17,2019-06-27,2022-02-18,INTERVENTIONAL,PHASE1|PHASE2,88.0,ACTUAL,NON_RANDOMIZED,PARALLEL,PREVENTION,NONE,Malaria,RH5.1/ ASO1,BIOLOGICAL,3,3,18 Years,45 Years,ALL,True,University of Oxford,OTHER,0,2,United Kingdom,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.48863636973214,medium,1,1,0,1,0,0,1,0,0,1,0,0,0,1,6,1,0,1,0,1,0,2016-10-17,2019-06-27,983.0,2016.0,1,2,0
NCT05297045,A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Oral RGT001-075 in Adult Patients With Uncontrollable Type 2 Diabetes Mellitus on Metformin Therapy",TERMINATED,2022-03-29,2023-05-30,2023-11-18,INTERVENTIONAL,PHASE2,17.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,RGT001-075|Placebo,DRUG|OTHER,1,37,18 Years,75 Years,ALL,False,Regor Pharmaceuticals Inc.,INDUSTRY,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.8903717578961645,small,1,1,1,0,0,0,0,0,1,0,1,1,1,1,38,1,1,0,0,2,1,2022-03-29,2023-05-30,427.0,2022.0,1,2,0
NCT01217372,Nephrolithiasis Prevention by Lemon Juice,"A Prospective, Randomized, Open Blind Endpoint (Probe) Trial to Assess the Possibility to Prevent Stone Recurrence by Lemon Juice Supplementation in Patients With Recurrent Calcium Oxalate Nephrolithiasis (LIMONE Study)",COMPLETED,2009-01,2021-02-16,2021-04-01,INTERVENTIONAL,PHASE2,203.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Nephrolithiasis,Lemon supplementation,DIETARY_SUPPLEMENT,9,0,18 Years,80 Years,ALL,False,Mario Negri Institute for Pharmacological Research,OTHER,0,1,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.318119993844216,large,0,1,0,1,0,0,0,0,0,1,1,0,0,1,9,0,0,0,0,1,0,,2021-02-16,,,0,1,0
NCT00658372,A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2),"A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder",TERMINATED,2008-05,2009-03,2012-11-16,INTERVENTIONAL,PHASE3,360.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Generalized Anxiety Disorder,PD 0332334|PD 0332334|Paroxetine|Placebo,DRUG,2,19,18 Years,65 Years,ALL,False,Pfizer,INDUSTRY,0,33,Hungary|Taiwan|Russia|United States,0.0,0,0,1,0,0,3.0,0,0,1,0,1,5.8888779583328805,large,0,1,1,0,1,0,1,1,1,0,1,1,1,1,21,1,1,0,0,4,1,,,,,0,3,1
NCT04625972,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults","A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post-exposure Prophylaxis of COVID-19",COMPLETED,2020-12-02,2022-07-25,2023-11-21,INTERVENTIONAL,PHASE3,1131.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,COVID-19,AZD7442|Placebo,DRUG,2,6,18 Years,120 Years,ALL,False,AstraZeneca,INDUSTRY,1,57,United Kingdom|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.0317412587631285,xlarge,0,1,1,0,1,1,1,1,1,1,1,1,0,1,8,1,1,0,0,2,1,2020-12-02,2022-07-25,600.0,2020.0,1,3,1
NCT00010972,Use of Acupuncture for Dental Pain: Testing a Model,Use of Acupuncture for Dental Pain: Testing a Model,COMPLETED,,,2006-08-18,INTERVENTIONAL,PHASE3,,,RANDOMIZED,,TREATMENT,,"Tooth, Impacted",Acupuncture,PROCEDURE,0,0,18 Years,40 Years,ALL,False,National Center for Complementary and Integrative Health (NCCIH),NIH,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,,,,,0,0,0
NCT00915772,Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid,Extension Study Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid Versus Metformin 1000 mg Bid,COMPLETED,2009-06,,2014-05-14,INTERVENTIONAL,PHASE3,567.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2",Linagliptin + metformin|Linagliptin+metformin|Metformin,DRUG,6,7,18 Years,80 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,112,Estonia|Croatia|Russia|Ukraine|Mexico|Tunisia|Sweden|Canada|Lithuania|France|Germany|Netherlands|Romania|India,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.342121418721152,xlarge,0,1,1,0,0,0,1,1,0,1,1,1,1,0,13,1,1,0,0,3,1,,,,,0,3,1
NCT04480372,SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II,"Overcoming Resistance to Immunotherapy Combining Gemcitabine With Atezolizumab in Advanced NSCLC and Mesothelioma Progressing Under Immune-checkpoint Inhibitors or Gemcitabine. A Multicenter, Single-arm, Open Label Phase II Trial With Two Cohorts",COMPLETED,2021-03-17,2024-04-03,2024-07-01,INTERVENTIONAL,PHASE2,68.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Malignant Pleural Mesothelioma|Non-small Cell Lung Cancer,Gemcitabine|Atezolizumab,DRUG,2,12,18 Years,,ALL,False,Swiss Cancer Institute,OTHER,0,12,Switzerland,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.23410650459726,medium,1,1,0,1,0,0,1,0,0,0,0,0,1,0,14,1,1,0,0,2,1,2021-03-17,2024-04-03,1113.0,2021.0,1,3,1
NCT00540072,Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae,,COMPLETED,2001-07-30,2002-02-27,2019-11-14,INTERVENTIONAL,PHASE3,,,RANDOMIZED,PARALLEL,,DOUBLE,"Pneumonia, Bacterial",daptomycin,DRUG,0,0,18 Years,,ALL,,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,2001-07-30,2002-02-27,212.0,2001.0,0,0,0
NCT04451772,A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State,"A Phase 2, Long-Term Extension (LTE) Study With Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)",COMPLETED,2020-07-27,2024-01-03,2025-01-14,INTERVENTIONAL,PHASE2,185.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Systemic Lupus Erythematosus (SLE),Elsubrutinib|Placebo for Elsubrutinib|Upadacitinib|Placebo for Upadacitinib,DRUG,1,4,18 Years,65 Years,ALL,False,AbbVie,INDUSTRY,0,87,United Kingdom|Argentina|Mexico|Australia|Bulgaria|United States|Colombia|Hungary|Puerto Rico|Poland|South Korea|Taiwan|New Zealand|Spain|China|Germany|Japan|Italy,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.225746673713202,medium,0,1,1,0,1,0,1,1,1,1,1,1,1,1,5,1,1,0,0,4,1,2020-07-27,2024-01-03,1255.0,2020.0,1,2,0
NCT02258295,Hyaluronate Injection for Lateral Epicondylitis,Hyaluronate Injection for Lateral Epicondylitis: A Double-blind Randomized Controlled Trial,COMPLETED,2017-01-18,2019-09-01,2020-04-24,INTERVENTIONAL,PHASE3,35.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Tennis Elbow,Intragel|Saline,DRUG,1,2,18 Years,80 Years,ALL,False,Shaare Zedek Medical Center,OTHER,0,1,Israel,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.58351893845611,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,3,1,1,0,0,2,1,2017-01-18,2019-09-01,956.0,2017.0,1,1,0
NCT01908595,Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis,"An Open-label, Multi-center, Long-term Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis",COMPLETED,2013-08,2015-05,2015-09-02,INTERVENTIONAL,PHASE3,480.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Psoriasis,M518101,DRUG,1,0,18 Years,,ALL,False,Maruho North America Inc.,INDUSTRY,0,31,United States,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.175867270105761,large,0,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT00109395,Lorazepam Sedation for Critically Ill Children,A Randomized Controlled Trial Comparing Lorazepam With Midazolam for Sedation of Mechanically Ventilated Pediatric Patients,COMPLETED,2004-09,2007-09,2023-03-20,INTERVENTIONAL,PHASE2|PHASE3,179.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Critical Illness,Lorazepam|Midazolam|Lorazepam CI,DRUG,3,0,1 Day,18 Years,ALL,False,"The Emmes Company, LLC",INDUSTRY,1,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.19295685089021,medium,0,1,1,0,0,1,0,0,1,0,1,0,1,1,3,0,1,0,0,3,1,,,,,0,2,0
NCT05174039,"An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease","An Open-label Safety, Pharmacokinetic, and Efficacy Study of the Combination of Miglustat for the Treatment of CLN3 Disease in Patients 17 Years of Age and Older",COMPLETED,2022-03-10,2024-05-30,2025-09-09,INTERVENTIONAL,PHASE1|PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Batten Disease,Miglustat 100 milligrams (mg) Oral Capsule,DRUG,1,6,17 Years,,ALL,False,Beyond Batten Disease Foundation,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,7,1,1,0,0,1,0,2022-03-10,2024-05-30,812.0,2022.0,1,2,0
NCT04399239,AuriNovo for Auricular Reconstruction,"A Multicenter, Single Arm, Prospective, Open-Label, Staged Study of the Safety and Efficacy of the AuriNovo Construct for Auricular Reconstruction in Subjects With Unilateral Microtia",TERMINATED,2021-08-09,2023-05-18,2024-03-04,INTERVENTIONAL,PHASE1|PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Microtia,AuriNovo,COMBINATION_PRODUCT,3,0,6 Years,25 Years,ALL,False,3DBio Therapeutics,INDUSTRY,0,2,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,1,1.0986122886681098,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,3,0,0,0,0,1,0,2021-08-09,2023-05-18,647.0,2021.0,1,1,0
NCT00866177,MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma,Phase II Trial of Hyd-sulfate AZD6244 [NSC 748727] in Patients With BRAF or NRAS Mutated Melanomas,COMPLETED,2009-03,2013-09,2015-08-11,INTERVENTIONAL,PHASE2,167.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Recurrent Melanoma|Stage III Skin Melanoma|Stage IV Skin Melanoma,Laboratory Biomarker Analysis|Selumetinib,DRUG|OTHER,1,0,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,5.123963979403259,medium,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,2,1,,,,,0,2,0
NCT05144139,A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above,"A Phase I/II Clinical Trial to Evaluate the Safety, Immunogenicity and Immune Persistence of COVID-19 mRNA Vaccine in Healthy People Aged 18 Years and Above.",COMPLETED,2021-12-03,2022-11-11,2022-12-28,INTERVENTIONAL,PHASE1|PHASE2,480.0,ACTUAL,RANDOMIZED,SEQUENTIAL,PREVENTION,DOUBLE,COVID-19 Pandemic,COVID-19 mRNA vaccine,BIOLOGICAL,3,3,18 Years,,ALL,True,Stemirna Therapeutics,INDUSTRY,0,1,Laos,1.0,1,1,0,0,1,1.5,0,0,0,0,1,6.175867270105761,large,0,1,1,0,0,0,0,0,0,0,1,1,0,0,6,1,0,1,0,1,0,2021-12-03,2022-11-11,343.0,2021.0,1,2,0
NCT00704639,Chemoradiation Treatment for Head and Neck Cancer,"A Phase II Study of Cetuximab, Carboplatin and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma",COMPLETED,2008-04,2015-12,2017-07-12,INTERVENTIONAL,PHASE1|PHASE2,60.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Head and Neck Cancer,Cetuximab|Carboplatin|Radiotherapy,DRUG|RADIATION,1,5,18 Years,,ALL,False,Trans Tasman Radiation Oncology Group,OTHER,0,1,Australia,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,3,1,,,,,0,3,1
NCT06060977,"A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants","A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants With 50% or Greater Scalp Hair Loss",COMPLETED,2023-09-25,2025-01-14,2025-04-30,INTERVENTIONAL,PHASE1|PHASE2,29.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Alopecia Areata (AA),IMG-007,DRUG,1,1,18 Years,65 Years,ALL,False,Inmagene LLC,INDUSTRY,0,17,Canada|United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.4011973816621555,small,1,1,1,0,0,0,1,1,1,0,0,0,1,0,2,1,1,0,0,1,0,2023-09-25,2025-01-14,477.0,2023.0,1,2,0
NCT04427501,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,"A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness",COMPLETED,2020-06-17,2023-02-21,2024-04-11,INTERVENTIONAL,PHASE2|PHASE3,3307.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,COVID-19,LY3819253|LY3832479|LY3853113|Placebo,DRUG,7,19,0 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,2,12,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,8.104099056143582,xlarge,0,1,1,0,1,1,1,0,1,0,1,1,1,0,26,1,1,0,0,4,1,2020-06-17,2023-02-21,979.0,2020.0,1,3,1
NCT05157412,Role of Doxycycline in Chronic Rhinosinusitis With Nasal Polyps,Role of Doxycycline in the Management of Patients With Chronic Rhinosinusitis With Nasal Polyps,COMPLETED,2021-07-01,2024-01-01,2024-08-13,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Nasal Polyps|Chronic Rhinosinusitis With Nasal Polyps,Doxycycline 100 mg Oral Tablet|Prednisolone 20 mg,DRUG,2,2,18 Years,80 Years,ALL,False,Assiut University,OTHER,0,1,Egypt,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,1,4,1,1,0,0,2,1,2021-07-01,2024-01-01,914.0,2021.0,1,2,0
NCT01769066,Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC,Random Open Exploratory Clinical Research of Sequential Gefitinib With Pemetrexed/Platinum Compare With Pemetrexed/Platinum Treatment for Advanced Non-small Cell Lung Cancer Exploratory Clinical Research,COMPLETED,2009-12,,2016-02-23,INTERVENTIONAL,PHASE2|PHASE3,117.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,NSCLC,Sequential Gefitinib With Pemetrexed/Platinum|Pemetrexed/Platinum,DRUG,1,1,18 Years,70 Years,ALL,False,Fudan University,OTHER,0,1,China,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.770684624465665,medium,0,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT02274766,Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia,ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study),COMPLETED,2014-10,2016-03-10,2018-01-10,INTERVENTIONAL,PHASE3,77.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dyskinesia|Levodopa-Induced Dyskinesia (LID)|Parkinson's Disease (PD),ADS-5102|Placebo,DRUG|OTHER,1,1,30 Years,85 Years,ALL,False,"Adamas Pharmaceuticals, Inc.",INDUSTRY,0,51,United States|Austria|France|Spain|Germany,1.0,0,0,1,0,0,3.0,0,0,1,0,3,4.356708826689592,medium,1,1,1,0,0,0,1,1,1,1,1,1,1,1,2,1,1,0,0,2,1,,2016-03-10,,,0,3,1
NCT02793622,Prevention of Malaria in HIV-uninfected Pregnant Women and Infants,Prevention of Malaria in HIV-uninfected Pregnant Women and Infants,COMPLETED,2016-09,2018-12-04,2021-04-14,INTERVENTIONAL,PHASE3,782.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Malaria,Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy,DRUG,3,11,16 Years,,FEMALE,True,"University of California, San Francisco",OTHER,2,1,Uganda,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.663132695990803,xlarge,0,1,0,1,0,1,0,0,0,0,1,1,0,1,14,1,1,0,0,2,1,,2018-12-04,,,0,2,0
NCT00217022,Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis,"A Randomized, Double-Blind, Placebo Controlled Trial of Budesonide for the Treatment of Active Lymphocytic Colitis",TERMINATED,2003-06,2008-02,2021-11-02,INTERVENTIONAL,PHASE2|PHASE3,16.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Lymphocytic Colitis|Diarrhea,Placebo|Budesonide,DRUG|OTHER,1,1,18 Years,100 Years,ALL,False,Mayo Clinic,OTHER,2,1,United States,0.0,0,1,1,0,1,2.5,0,1,0,0,2,2.833213344056216,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,3,1
NCT01165229,"Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older","Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older",COMPLETED,2010-08-02,2015-07-24,2020-04-27,INTERVENTIONAL,PHASE3,14819.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Herpes Zoster|Herpes Zoster Vaccine,Herpes Zoster Vaccine GSK1437173A|Placebo,BIOLOGICAL,3,27,70 Years,,ALL,True,GlaxoSmithKline,INDUSTRY,0,213,United Kingdom|Estonia|Finland|Mexico|Australia|United States|Sweden|Canada|Brazil|South Korea|Taiwan|France|Spain|Czechia|Germany|Japan|Italy|Hong Kong,1.0,0,0,1,0,0,3.0,0,0,0,0,2,9.603732898850078,,0,1,1,0,0,0,1,1,1,1,1,1,0,1,30,1,0,1,0,2,1,2010-08-02,2015-07-24,1817.0,2010.0,0,4,1
NCT05879822,A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive,A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive,ACTIVE_NOT_RECRUITING,2023-10-30,2026-07-22,2025-12-17,INTERVENTIONAL,PHASE2,73.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Advanced Solid Tumor,INCB099280,DRUG,3,3,18 Years,,ALL,False,Incyte Corporation,INDUSTRY,0,54,Turkey (Türkiye)|Brazil|New Zealand|South Africa|China|Georgia|Hungary|Greece|Romania,,0,1,0,0,0,2.0,1,0,0,0,1,4.30406509320417,medium,1,1,1,0,0,0,1,1,0,0,1,0,1,1,6,1,1,0,0,1,0,2023-10-30,2026-07-22,996.0,2023.0,1,2,0
NCT00391651,Short Course Nitrofurantoin for Acute Cystitis,Short Course Nitrofurantoin For Acute Cystitis,COMPLETED,2002-01,2005-07,2014-06-05,INTERVENTIONAL,PHASE2,338.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Urinary Tract Infection,Nitrofurantoin 100mg twice daily x 5 days|TMP/SMX DS twice daily x 3 days,DRUG,1,0,18 Years,45 Years,FEMALE,True,University of Washington,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.82600010738045,large,0,1,0,1,0,1,0,0,1,0,1,0,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT00415129,Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly,,COMPLETED,2006-06,2009-03,2014-01-14,INTERVENTIONAL,PHASE2,600.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,PREVENTION,NONE,Influenza|Orthomyxoviridae Infections,"A/H5N1 inactivated, split-virion influenza virus|A/H5N1 inactivated, split-virion influenza virus",BIOLOGICAL,1,0,18 Years,,ALL,True,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,0,4,United Kingdom|Belgium,1.0,0,1,0,0,0,2.0,0,0,0,0,2,6.398594934535208,xlarge,0,1,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,0,2,1,,,,,0,3,1
NCT04101331,Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides,A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients With Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT),COMPLETED,2019-11-13,2024-01-11,2024-11-05,INTERVENTIONAL,PHASE2,108.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Peripheral T Cell Lymphoma|Transformed Mycosis Fungoides,AFM13,DRUG,1,16,18 Years,,ALL,False,Affimed GmbH,INDUSTRY,0,69,Russia|Turkey (Türkiye)|Australia|United States|South Korea|France|Spain|Germany|Poland|Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.6913478822291435,medium,0,1,1,0,0,0,1,1,1,1,0,0,1,0,17,1,1,0,0,1,0,2019-11-13,2024-01-11,1520.0,2019.0,1,3,1
NCT00233831,Millimeter Wave Therapy (MWT) for Analgesia After Total Knee Replacement,Millimeter Wave Therapy (MWT) Versus Placebo for Analgesia and Wound Healing After Elective Total Knee Arthroplasty - a Randomized Controlled Trial,COMPLETED,2004-03,2007-10,2011-02-28,INTERVENTIONAL,PHASE2|PHASE3,80.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Pain|Acute Pain,Generator of electromagnetic millimeter waves,DEVICE,1,1,35 Years,80 Years,ALL,False,University Medicine Greifswald,OTHER,0,1,Germany,1.0,0,1,1,0,1,2.5,0,0,0,0,2,4.394449154672439,medium,1,0,0,1,0,0,0,0,0,1,1,1,1,1,2,1,0,0,1,1,0,,,,,0,2,0
NCT01566331,Safe Delivery Using a Belt on the Belly of Pregnant Woman,Safe Natural Delivery by Using a New Inflatable Ergonomic Three Chambers Belt,COMPLETED,2011-01,2011-03,2016-12-12,INTERVENTIONAL,PHASE2,80.0,ACTUAL,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,SINGLE,Other Obstetric Trauma - Delivered,Baby-guardTM,DEVICE,1,0,23 Years,42 Years,FEMALE,True,University of Padova,OTHER,1,1,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.394449154672439,medium,1,1,0,1,0,1,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,,,,,0,0,0
NCT00960531,A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease,"A Phase 2a, Multicenter, Randomized, Third-party Un-blinded, Long-term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of Acc-001 With Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer Disease",TERMINATED,2009-07,2013-12,2016-04-01,INTERVENTIONAL,PHASE2,160.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alzheimer Disease,ACC-001+ QS21 (3mcg)|ACC-001 (10 mcg) + QS-21|ACC-001+QS-21 (30mcg),BIOLOGICAL,1,0,50 Years,85 Years,ALL,False,Pfizer,INDUSTRY,1,28,United States,0.0,0,1,0,0,0,2.0,0,0,1,0,1,5.081404364984463,medium,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,3,1,,,,,0,1,0
NCT00000953,Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients,"Evaluation of Brovavir ( BV-ara-U; SQ 32,756 ) Versus Acyclovir in the Treatment of Localized Herpes Zoster in HIV-Infected Patients",COMPLETED,,,2011-03-01,INTERVENTIONAL,PHASE2,180.0,,,,TREATMENT,,HIV Infections|Chickenpox,Sorivudine|Acyclovir,DRUG,0,0,18 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,2,44,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.198497031265826,medium,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,2,1,,,,,0,2,0
NCT02209753,BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis,"Phase II, Randomized, Double-blind, Placebo Controlled, Multi-center, Four Week Trial of BIRB 796 BS 5, 10, 20 and 30 mg Oral Tablets Versus Placebo Administered BID in Patients With Moderate to Severe Plaque-type Psoriasis",COMPLETED,2001-06,,2014-08-06,INTERVENTIONAL,PHASE2,182.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Psoriasis,"BIRB 796 BS, low dose|BIRB 796 BS, medium dose 1|BIRB 796 BS, medium dose 2|BIRB 796 BS, high dose|Placebo",DRUG,7,19,18 Years,75 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.209486152841421,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,26,1,1,0,0,5,1,,,,,0,2,0
NCT01662037,Bosentan Therapy in Children With Functional Single Ventricle,Bosentan Therapy for High Risk Staged Fontan Procedure in Children With Functional Single Ventricle,COMPLETED,2010-01,2012-06,2012-08-10,INTERVENTIONAL,PHASE2,34.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Congenital Heart Defects|Functional Single Ventricle,Bosentan,DRUG,1,2,4 Months,18 Years,ALL,False,Shanghai Jiao Tong University School of Medicine,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,0,0,0,1,2,3.5553480614894135,small,1,1,0,1,0,0,0,0,0,0,0,0,1,1,3,1,1,0,0,1,0,,,,,0,1,0
NCT00281437,Health First-Study 2,Health First: Health and Psychological Outcomes of Physical Activity- Study 2,COMPLETED,,,2024-11-05,INTERVENTIONAL,PHASE2|PHASE3,200.0,,RANDOMIZED,PARALLEL,TREATMENT,NONE,Exercise Adherence|Sedentary Adults|Lifestyle|Traditional,choice of exercise program,BEHAVIORAL,0,0,25 Years,65 Years,ALL,True,University of Alberta,OTHER,0,1,Canada,1.0,0,1,1,0,1,2.5,0,0,0,0,4,5.303304908059076,medium,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,,,,,0,2,0
NCT00832637,"Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers","Gemcitabine and Cisplatin With Erlotinib in Hepatocellular Carcinoma (HCC) and Biliary Tree Cancer (BTC) (Intra- and Extra-hepatic Cholangiocarcinoma, Bile Duct Cancer, Adenocarcinoma of the Ampulla of Vater and Gallbladder Carcinoma)",TERMINATED,2007-08,2017-03-15,2018-06-29,INTERVENTIONAL,PHASE2,33.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatocellular Carcinoma|Cholangiocellular Carcinoma|Cholangiocarcinoma of the Extrahepatic Bile Duct|Bile Duct Cancer|Periampullary Adenocarcinoma|Gallbladder Cancer|Extrahepatic Bile Duct Cancer,Cisplatin|Erlotinib|Gemcitabine,DRUG,1,4,18 Years,,ALL,False,New Mexico Cancer Research Alliance,OTHER,0,2,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,7,3.5263605246161616,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,5,1,1,0,0,3,1,,2017-03-15,,,0,2,0
NCT02366637,An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease,"A Randomized, Double-blind, Placebo-controlled 2-way Crossover Study To Evaluate The Efficacy, Safety And Tolerability Of Pf-03715455 Administered Twice Daily By Inhalation For 4 Weeks In Subjects With Moderate To Severe Chronic Obstructive Pulmonary Disease (Copd)",TERMINATED,2015-01,2015-05,2016-07-06,INTERVENTIONAL,PHASE2,13.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,"Pulmonary Disease, Chronic Obstructive",Placebo|PF-03715455,DRUG,1,5,40 Years,80 Years,ALL,False,Pfizer,INDUSTRY,0,5,United Kingdom,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.6390573296152584,small,1,1,1,0,1,0,1,0,0,1,1,1,1,0,6,1,1,0,0,2,1,,,,,0,2,0
NCT01541345,Lateral Ridge Augmentation Using Autogenous Bone Blocks or Xenogenic Bone Block Grafts Loaded With Recombinant Human Bone Morphogenic Protein 2,"A Phase III, Randomized, Controlled Clinical Trial of Lateral Ridge Augmentation Using Autogenous Bone Blocks or Xenogenic Bone Block Grafts Loaded With Recombinant Human Bone Morphogenic Protein 2",COMPLETED,2011-02,2019-06-04,2021-12-02,INTERVENTIONAL,PHASE3,24.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Missing Teeth,Autogenous bone graft|InductOs|Augmentation surgery,DRUG|PROCEDURE|DEVICE,1,3,20 Years,75 Years,ALL,False,University of Zurich,OTHER,0,2,Austria|Switzerland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.2188758248682006,small,1,1,0,1,0,0,1,1,0,0,1,0,0,1,4,1,1,0,1,3,1,,2019-06-04,,,0,2,0
NCT03343145,"A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients","A Randomized, Open-label, Active-controlled, Multi-center, Phase III Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy",COMPLETED,2017-01-12,2019-07-29,2020-12-28,INTERVENTIONAL,PHASE3,143.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Breast Cancer,Leucostim 5µg/kg/day|Neupogen 5µg/kg/day,BIOLOGICAL,1,3,18 Years,70 Years,FEMALE,False,"Dong-A ST Co., Ltd.",INDUSTRY,0,1,Indonesia,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.969813299576001,medium,0,1,1,0,0,0,0,0,0,0,1,0,0,1,4,1,0,1,0,2,1,2017-01-12,2019-07-29,928.0,2017.0,1,1,0
NCT04571645,Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dociparstat Sodium in Combination With Standard Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia",TERMINATED,2021-04-30,2022-05-16,2024-04-15,INTERVENTIONAL,PHASE3,9.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Myeloid Leukemia,Dociparstat|Control,DRUG|OTHER,1,0,18 Years,,ALL,False,Jazz Pharmaceuticals,INDUSTRY,0,14,United States,0.0,0,0,1,0,0,3.0,1,0,0,0,1,2.302585092994046,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2021-04-30,2022-05-16,381.0,2021.0,1,1,0
NCT02518672,Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC),Role of DHA Monoglyceride (MAG-DHA) in the Resolution of Pulmonary Inflammation of Patients With Cystic Fibrosis.,TERMINATED,2015-10,2016-11,2017-10-04,INTERVENTIONAL,PHASE2,11.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Cystic Fibrosis,MAG-DHA|Placebo,DIETARY_SUPPLEMENT,1,10,18 Years,,ALL,False,SCF Pharma,INDUSTRY,2,1,Canada,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.4849066497880004,small,1,1,1,0,0,1,0,0,0,0,1,1,1,1,11,1,0,0,0,2,1,,,,,0,2,0
NCT01175395,20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD),An Open-Label Study of the Safety and Tolerability of Combining 20089 (Triamcinolone Acetonide Intravitreal Injection) When Used Adjunctively With Lucentis® 0.5 mg Intravitreal Injection in Subjects With Subfoveal Neovascular AMD,COMPLETED,2010-09,2013-01,2014-10-20,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Age-Related Macular Degeneration|Choroidal Neovascularization,IBI-20089/Lucentis,DRUG,1,1,55 Years,,ALL,False,University of Illinois at Chicago,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,2,2.3978952727983707,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,2,0
NCT05512377,"Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder","Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 (Brigimadlin) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours",COMPLETED,2022-12-13,2025-09-25,2026-01-21,INTERVENTIONAL,PHASE2,99.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pancreatic Neoplasms|Solid Tumors|Biliary Tract Cancer|Lung Neoplasms|Bladder Cancer,brigimadlin,DRUG,1,10,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,60,United Kingdom|Australia|United States|Austria|Taiwan|Thailand|France|South Africa|Spain|Singapore|Switzerland|Germany|Japan|Belgium|South Korea|Saudi Arabia,1.0,0,1,0,0,0,2.0,1,0,0,0,5,4.605170185988092,medium,1,1,1,0,0,0,1,1,1,1,0,0,1,0,11,1,1,0,0,1,0,2022-12-13,2025-09-25,1017.0,2022.0,1,3,1
NCT01721577,Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas,"Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas",TERMINATED,2012-12,2015-12,2023-05-22,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Anaplastic Ependymoma,AXL1717,DRUG,2,6,18 Years,,ALL,False,Rush University Medical Center,OTHER,1,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,6,2.3978952727983707,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,8,1,1,0,0,1,0,,,,,0,3,1
NCT00088777,Nondrug Treatment Programs for Adults With Fibromyalgia,Behavioral Preparation for Treating Fibromyalgia,COMPLETED,2005-01,2010-04,2011-08-12,INTERVENTIONAL,PHASE2,300.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Fibromyalgia,Behavioral coping skills training plus physical therapy|Stress management education plus physical therapy,BEHAVIORAL,1,0,21 Years,65 Years,ALL,False,University of Utah,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.707110264748875,large,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,2,1,,,,,0,1,0
NCT00851877,"Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer","A Phase I/II Study of Nab-paclitaxel, Cisplatin and Cetuximab With Concurrent Radiation Therapy for Local-regionally Advanced Head-and-neck Squamous Cell Carcinoma",COMPLETED,2009-03-01,2015-08-03,2020-08-21,INTERVENTIONAL,PHASE1|PHASE2,37.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Head and Neck Cancer,Cetuximab|Cisplatin|Nab-Paclitaxel|intensity-modulated radiation therapy,DRUG|RADIATION|BIOLOGICAL,2,2,18 Years,120 Years,ALL,False,University of Texas Southwestern Medical Center,OTHER,0,2,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.6375861597263857,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,4,1,1,1,0,4,1,2009-03-01,2015-08-03,2346.0,2009.0,0,2,0
NCT02901275,Enhancing Medication-based Analgesia in Humans,Using Dronabinol to Enhance the Analgesic Effect of Hydromorphone in Humans,COMPLETED,2016-12,2020-03-23,2023-11-07,INTERVENTIONAL,PHASE2,29.0,ACTUAL,,SINGLE_GROUP,BASIC_SCIENCE,TRIPLE,"Pain|Cannabis|Opioid Use, Unspecified",Within-subject test of blinded study medications,DRUG,3,0,18 Years,75 Years,ALL,True,Johns Hopkins University,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,3.4011973816621555,small,1,1,0,1,0,0,0,0,1,0,0,1,0,0,3,0,1,0,0,1,0,,2020-03-23,,,0,1,0
NCT02555657,Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119),COMPLETED,2015-10-13,2020-11-10,2021-12-10,INTERVENTIONAL,PHASE3,622.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Triple Negative Breast Cancer,pembrolizumab|capecitabine|eribulin|gemcitabine|vinorelbine,DRUG|BIOLOGICAL,3,14,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.434546518787453,xlarge,0,1,1,0,1,0,0,0,0,0,1,0,1,1,17,1,1,1,0,5,1,2015-10-13,2020-11-10,1855.0,2015.0,1,2,0
NCT05249101,A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma,"A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat Plus Capecitabine or Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on FOLFIRINOX",ACTIVE_NOT_RECRUITING,2022-08-15,2026-07,2025-12-19,INTERVENTIONAL,PHASE1|PHASE2,70.0,ESTIMATED,RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Metastatic Pancreatic Adenocarcinoma,Ivaltinostat|Capecitabine,DRUG,4,5,18 Years,,ALL,False,"CG Pharmaceuticals, Inc",INDUSTRY,0,16,United States,,1,1,0,0,1,1.5,1,0,0,0,1,4.2626798770413155,medium,1,0,1,0,0,0,1,0,1,0,1,0,1,0,9,1,1,0,0,2,1,2022-08-15,,,2022.0,1,3,1
NCT01569581,"A Protected Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants and Children","A Phase III Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants and Children",COMPLETED,2012-03,2013-03,2023-10-11,INTERVENTIONAL,PHASE3,12000.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,The Efficacy of Inactivated EV71 Vaccine (KMB17) Against HFMD in Chinese Children and Infants,100U/0.5ml in 6-11 months old infants|100U/0.5ml in 12-23 months old infants|100U/0.5ml in 24-35 months old children|100U/0.5ml in 36-71 months old children,BIOLOGICAL,3,2,6 Months,71 Months,ALL,True,"Institute of Medical Biology, Chinese Academy of Medical Sciences",OTHER,1,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,9.392745258631441,,0,1,0,1,0,1,0,0,0,0,1,1,0,1,5,1,0,1,0,4,1,,,,,0,1,0
NCT04598919,Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis,Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis,ACTIVE_NOT_RECRUITING,2020-11-12,2025-06-30,2024-11-14,INTERVENTIONAL,PHASE1|PHASE2,49.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Idiopathic Pulmonary Fibrosis (IPF),Saracatinab|Placebo,DRUG,5,5,40 Years,,ALL,False,National Jewish Health,OTHER,6,4,United States,,1,1,0,0,1,1.5,0,0,0,0,1,3.912023005428146,small,1,0,0,1,0,1,1,0,1,0,1,1,1,1,10,1,1,0,0,2,1,2020-11-12,2025-06-30,1691.0,2020.0,1,3,1
NCT05190419,Study to Assess the Efficacy and Safety of Orismilast in Psoriasis,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults With Moderate-to-Severe Plaque-Type Psoriasis",COMPLETED,2021-12-30,2022-12-20,2024-04-16,INTERVENTIONAL,PHASE2,202.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Psoriasis|Skin Diseases,Orismilast modified release tablets|Placebo,DRUG,1,11,18 Years,,ALL,False,UNION therapeutics,INDUSTRY,0,34,Germany|Poland|United Kingdom|United States,1.0,0,1,0,0,0,2.0,0,1,0,0,2,5.313205979041787,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,12,1,1,0,0,2,1,2021-12-30,2022-12-20,355.0,2021.0,1,4,1
NCT02206230,Trial of Hypofractionated Radiation Therapy for Glioblastoma,A Randomized Controlled Trial of Conventional Versus Hypofractionated Radiation Therapy With Temozolomide for Patients With Newly Diagnosed Glioblastoma,COMPLETED,2014-09-25,2023-02-14,2024-01-31,INTERVENTIONAL,PHASE2,133.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Glioblastoma,Hypofractionated radiation therapy|Standard radiation therapy,RADIATION,1,3,18 Years,70 Years,ALL,False,AHS Cancer Control Alberta,OTHER,1,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.897839799950911,medium,0,1,0,1,0,1,0,0,0,0,1,0,1,1,4,1,0,0,0,2,1,2014-09-25,2023-02-14,3064.0,2014.0,0,1,0
NCT00000328,Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3,Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III,WITHDRAWN,1997-07,1997-08,2017-05-04,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Heroin Dependence|Opioid-Related Disorders,Opioid-Related Disorders,DRUG,7,0,18 Years,65 Years,ALL,False,"University of Colorado, Denver",OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,0.0,,1,1,0,1,0,1,0,0,1,0,1,1,1,1,7,0,1,0,0,1,0,,,,,0,2,0
NCT03128528,Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure,"Randomized, Double-blind, Placebo Controlled, Parallel-group, Prospective Clinical Study to Analyse the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure",COMPLETED,2017-07-01,2020-04-30,2020-09-28,INTERVENTIONAL,PHASE2,84.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Chronic Heart Failure,Empagliflozin 10mg|Placebo Oral Tablet,DRUG,1,13,18 Years,75 Years,ALL,False,University of Erlangen-Nürnberg Medical School,OTHER,0,1,Germany,1.0,0,1,0,0,0,2.0,0,0,0,1,1,4.442651256490317,medium,1,1,0,1,0,0,0,0,0,1,1,1,1,1,14,1,1,0,0,2,1,2017-07-01,2020-04-30,1034.0,2017.0,1,2,0
NCT00046865,Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer,Treatment of Chemotherapy-Induced Nausea With Acupressure: A Phase III Trial,COMPLETED,2002-07-01,2006-03-23,2018-11-14,INTERVENTIONAL,PHASE3,57.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Breast Cancer|Drug-induced Nausea and Vomiting,acupressure therapy|management of therapy complications|nausea and vomiting therapy,PROCEDURE,0,0,18 Years,,FEMALE,False,M.D. Anderson Cancer Center,OTHER,1,2,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,2,4.060443010546419,medium,1,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,3,1,2002-07-01,2006-03-23,1361.0,2002.0,0,2,0
NCT00430365,Maintenance Therapy Using Lenalidomide in Myeloma,"Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).",COMPLETED,2006-06,2018-09,2019-04-26,INTERVENTIONAL,PHASE3,614.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Myeloma,lenalidomide|placebo,DRUG,1,3,18 Years,65 Years,ALL,True,"University Hospital, Toulouse",OTHER,2,77,France|Belgium|Switzerland,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.421622267806518,xlarge,0,0,0,1,0,1,1,1,0,1,1,1,1,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT01210365,Safety and Efficacy of Furosemide 40mg + Amiloride Hydrochloride 10mg to Reduct Edema,Safety and Efficacy of the Combination of Furosemide 40 mg + Amiloride Hydrochloride 10 mg in the Reduction of Edema of Cardiac Origin in Patients With Congestive Heart Failure Functional Class II (NYHA),TERMINATED,2011-01-01,2013-03,2022-06-03,INTERVENTIONAL,PHASE3,27.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Congestive Heart Failure,Diurisa®|Lasix ®,DRUG,1,0,18 Years,,ALL,False,Eurofarma Laboratorios S.A.,INDUSTRY,0,4,Brazil,0.0,0,0,1,0,0,3.0,0,0,0,1,1,3.332204510175204,small,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,2,1,2011-01-01,,,2011.0,0,1,0
NCT01190228,Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV,"Assessment of the Memory Immune Response, Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With a Single Dose of JE-CV and Long-Term Follow-Up",COMPLETED,2010-08-25,2015-10-12,2022-03-28,INTERVENTIONAL,PHASE3,454.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Japanese Encephalitis|Varicella,JE-CV Vaccine|Varicella Vaccine,BIOLOGICAL,9,0,36 Months,42 Months,ALL,True,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,0,1,Philippines,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.12029741895095,large,0,1,1,0,1,0,0,0,0,0,1,0,0,1,9,0,0,1,0,2,1,2010-08-25,2015-10-12,1874.0,2010.0,0,3,1
NCT01144702,Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum,"Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Uncomplicated Malaria by Plasmodium Falciparum, Juruá Valley, State of Acre, Brazil, 2009.",COMPLETED,2010-11,2014-07,2015-05-19,INTERVENTIONAL,PHASE2|PHASE3,163.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Falciparum Malaria,artesunate & mefloquine combination,DRUG,1,1,6 Months,70 Years,ALL,False,Oswaldo Cruz Foundation,OTHER,3,2,Brazil,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.099866427824199,medium,0,1,0,1,0,1,1,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT02449902,TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy,"A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of TX-12-004-HR in Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy (VVA)",COMPLETED,2013-07,2013-09,2015-12-14,INTERVENTIONAL,PHASE2,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Menopause|Vulvovaginal Atrophy|Painful Intercourse|Dyspareunia,Estradiol|placebo,DRUG,10,0,40 Years,75 Years,FEMALE,False,TherapeuticsMD,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,4,3.9318256327243257,small,1,1,1,0,0,0,0,0,1,0,1,1,1,1,10,0,1,0,0,2,1,,,,,0,3,1
NCT01252953,REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification,"REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease",ACTIVE_NOT_RECRUITING,2011-06,2037-01-31,2024-06-25,INTERVENTIONAL,PHASE3,30449.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Atherosclerotic Cardiovascular Disease,Anacetrapib|Placebo anacetrapib,DRUG,1,3,50 Years,,ALL,False,University of Oxford,OTHER,1,1,United Kingdom,,0,0,1,0,0,3.0,0,0,0,1,1,10.323841273138044,,0,1,0,1,0,1,0,0,0,1,1,1,0,1,4,1,1,0,0,2,1,,2037-01-31,,,0,1,0
NCT03635437,Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes,"A Phase I/II, 3-Arm, Open Label, Single Centre Study to Investigate the Safety and Effect of Oral GABA Therapy on Beta-Cell Regeneration in Type 1-diabetes Patients",COMPLETED,2018-09-05,2022-09-27,2022-11-02,INTERVENTIONAL,PHASE1|PHASE2,35.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 1 Diabetes Mellitus,Gamma-Aminobutyric Acid (GABA)|Alprazolam,DRUG,1,12,18 Years,50 Years,ALL,False,Per-Ola Carlsson,OTHER,1,1,Sweden,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.58351893845611,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,13,1,1,0,0,2,1,2018-09-05,2022-09-27,1483.0,2018.0,1,3,1
NCT03428945,Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus,Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D),TERMINATED,2018-08-15,2022-10-31,2024-04-09,INTERVENTIONAL,PHASE2,273.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Type1 Diabetes Mellitus,Hydroxychloroquine|Placebo,DRUG,1,0,3 Years,,ALL,False,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,1,51,United Kingdom|Australia|United States|Sweden|Canada|Italy,0.0,0,1,0,0,0,2.0,0,0,0,0,1,5.6131281063880705,large,0,1,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,2,1,2018-08-15,2022-10-31,1538.0,2018.0,1,2,0
NCT00178945,Botulinum Toxin Type A (Botox) for the Treatment of Cervical Dystonia and Upper Thoracic Muscular Pain,"Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Botulinum Toxin Type A (Botox) for the Treatment of Pain Associated With Cervical Dystonia and Refractory Cervicothoracic Myofascial Pain Syndrome",COMPLETED,2004-03,2006-03,2016-06-01,INTERVENTIONAL,PHASE1|PHASE2,20.0,,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Refractory Cervicothoracic Myofascial Pain Syndrome (CMPS)|Cervical Dystonia,Botulinum Toxin Type A,DRUG,1,2,18 Years,,ALL,True,Vanderbilt University,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,2,3.044522437723423,small,1,0,0,1,0,0,0,0,1,0,1,1,1,0,3,1,1,0,0,1,0,,,,,0,2,0
NCT00251745,Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn,A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (60 mg Once-Daily (QD) and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD),COMPLETED,2005-12,2006-05,2011-04-28,INTERVENTIONAL,PHASE3,908.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Gastroesophageal Reflux Disease,Dexlansoprazole MR|Dexlansoprazole MR|Placebo,DRUG,2,2,18 Years,,ALL,False,Takeda,INDUSTRY,0,95,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.812345094177479,xlarge,0,1,1,0,1,0,1,0,1,0,1,1,1,1,4,1,1,0,0,3,1,,,,,0,1,0
NCT00665639,Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis,"A Phase 3, Randomized, Double-Blind, Comparative Trial of Two Dosing Regimens of Micafungin (FK463) Versus Caspofungin for the Treatment of Esophageal Candidiasis",COMPLETED,2004-06,2004-12,2014-08-20,INTERVENTIONAL,PHASE3,454.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Candidiasis, Oral",micafungin|caspofungin,DRUG,1,3,16 Years,,ALL,False,Astellas Pharma Inc,INDUSTRY,0,31,Argentina|South Africa|Brazil|Peru,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.12029741895095,large,0,1,1,0,0,0,1,1,0,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT02535195,Effect of Ginger Supplement on Non-alcoholic Fatty Liver,,COMPLETED,2013-03,2015-08,2015-08-28,INTERVENTIONAL,PHASE2|PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Non-alcoholic Fatty Liver Disease,Ginger supplement|Placebo (starch),DIETARY_SUPPLEMENT,2,1,18 Years,70 Years,ALL,True,Dr Azita Hekmatdoost,OTHER,0,0,,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,3,1,0,0,0,2,1,,,,,0,2,0
NCT04682639,A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects With Eosinophilic Esophagitis",COMPLETED,2020-12-15,2023-06-30,2024-05-06,INTERVENTIONAL,PHASE2,108.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,DOUBLE,Eosinophilic Esophagitis,Etrasimod|Placebo|Etrasimod,DRUG,1,4,18 Years,65 Years,ALL,False,Pfizer,INDUSTRY,1,256,Australia|United States|Canada|Spain|Switzerland|Germany|Netherlands|Belgium,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.6913478822291435,medium,0,1,1,0,1,1,1,1,1,1,1,1,1,0,5,1,1,0,0,3,1,2020-12-15,2023-06-30,927.0,2020.0,1,2,0
NCT01134575,CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL),"Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) With CMC-544 (Inotuzumab Ozogamycin), With or Without Later Addition of Rituximab",COMPLETED,2010-06-04,2018-04-18,2024-07-16,INTERVENTIONAL,PHASE2,90.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Acute Lymphoblastic Leukemia,CMC-544 (Inotuzumab Ozogamycin)|Rituximab,DRUG,1,0,16 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.51085950651685,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,2,1,2010-06-04,2018-04-18,2875.0,2010.0,0,1,0
NCT01538875,Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy,Hydralazine vs. Labetalol for the Management of Hypertensive Crisis in Patients With Hypertensive Disorders of Pregnancy. A Randomized Controlled Trial.,COMPLETED,2012-07,2013-05,2013-05-17,INTERVENTIONAL,PHASE3,261.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Hypertension, Pregnancy Induced",Hydralazine|Labetalol,DRUG,1,2,,,FEMALE,False,"Saint Thomas Hospital, Panama",OTHER,0,1,Panama,1.0,0,0,1,0,0,3.0,0,0,0,1,1,5.568344503761097,large,0,1,0,1,0,0,0,0,0,0,1,0,1,1,3,1,1,0,0,2,1,,,,,0,1,0
NCT01014975,A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients,"A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Stroke",COMPLETED,2009-11,2014-02,2015-10-21,INTERVENTIONAL,PHASE1|PHASE2,40.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Acute Ischemic Stroke,Plasmin (Human)|Plasmin (Human)|Plasmin (Human),BIOLOGICAL,1,0,18 Years,85 Years,ALL,False,Grifols Therapeutics LLC,INDUSTRY,0,23,Australia|Slovakia|Austria|France|Spain|Serbia,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.713572066704308,small,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,3,1,,,,,0,3,1
NCT05875701,Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines,A Phase 3 Study to Evaluate the Immunogenicity and Safety of Novavax COVID-19 Vaccine(s) as Second or Subsequent Booster After mRNA Vaccines in Individuals 18 to 49 Years of Age,COMPLETED,2023-03-28,2023-11-11,2025-06-26,INTERVENTIONAL,PHASE3,147.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,COVID-19,NVX-CoV2373|SARS-CoV-2 rS antigen/Matrix-M Adjuvant,BIOLOGICAL,1,10,18 Years,49 Years,ALL,True,Novavax,INDUSTRY,0,5,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.997212273764115,medium,0,1,1,0,0,0,1,0,1,0,1,0,0,1,11,1,0,1,0,2,1,2023-03-28,2023-11-11,228.0,2023.0,1,2,0
NCT00075101,"Sleep, Fatigue, and Dexamethosone in Children With Leukemia","Sleep, Fatigue, and Dexamethosone in Childhood Cancer",COMPLETED,2000-09,2006-09,2008-08-18,INTERVENTIONAL,PHASE3,134.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Leukemia,Dexamethosone,DRUG,1,2,5 Years,21 Years,ALL,False,National Institute of Nursing Research (NINR),NIH,0,1,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.90527477843843,medium,0,0,0,1,0,0,0,0,1,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT04919512,A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder,"A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy",ACTIVE_NOT_RECRUITING,2022-07-07,2027-03-07,2026-01-16,INTERVENTIONAL,PHASE2,163.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Urinary Bladder Neoplasms,TAR-200|Cetrelimab,DRUG|BIOLOGICAL,1,3,18 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,109,United Kingdom|United States|South Korea|France|Spain|Italy|Germany|Netherlands|Belgium|Israel,,0,1,0,0,0,2.0,0,0,0,0,1,5.099866427824199,medium,0,1,1,0,0,0,1,1,1,1,1,0,1,1,4,1,1,1,0,2,1,2022-07-07,2027-03-07,1704.0,2022.0,1,2,0
NCT00285012,Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).,"A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial With 40-Week Follow-Up Evaluating The Safety And Efficacy Of Varenicline Tartrate For Smoking Cessation In Patients With Mild-To-Moderate Chronic Obstructive Pulmonary Disease",COMPLETED,2006-05,2009-04,2010-04-20,INTERVENTIONAL,PHASE3,504.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Smoking Cessation,placebo|Varenicline Tartarate,DRUG,1,9,35 Years,,ALL,False,Pfizer,INDUSTRY,0,32,France|Spain|Italy|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.22455842927536,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,10,1,1,0,0,2,1,,,,,0,3,1
NCT05427812,Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma,"A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma",TERMINATED,2022-09-27,2024-11-19,2025-01-17,INTERVENTIONAL,PHASE1|PHASE2,29.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Relapsed/Refractory Multiple Myeloma,ISB 1442 SC injection escalating doses|ISB 1442 SC injection at RP2D,DRUG,3,14,18 Years,,ALL,False,Ichnos Sciences SA,INDUSTRY,0,15,India|Australia|United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,3.4011973816621555,small,1,1,1,0,0,0,1,1,1,0,1,0,1,0,17,1,1,0,0,2,1,2022-09-27,2024-11-19,784.0,2022.0,1,4,1
NCT00688519,Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies,"A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety and Efficacy of Emulsion Formulation U0267, Versus Vehicle in Subjects With Plaque-type Psoriasis",COMPLETED,2008-03,2008-12,2017-01-02,INTERVENTIONAL,PHASE3,336.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Psoriasis,U0267|Vehicle,DRUG,1,5,12 Years,,ALL,False,"Stiefel, a GSK Company",INDUSTRY,1,13,United States,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.820082930352362,large,0,1,1,0,1,1,1,0,1,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT00546819,ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED),"A Phase IIb Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids",COMPLETED,2007-10,2010-08,2017-04-12,INTERVENTIONAL,PHASE2,309.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Herpes Zoster,"Zoster Vaccine, Live|Comparator: Placebo",BIOLOGICAL,1,2,60 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.736572297479192,large,0,1,1,0,1,0,0,0,0,0,1,1,0,1,3,1,0,1,0,2,1,,,,,0,1,0
NCT02907619,An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy,"A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF PF-06252616 IN BOYS WITH DUCHENNE MUSCULAR DYSTROPHY",TERMINATED,2016-10-13,2018-11-22,2020-11-23,INTERVENTIONAL,PHASE2,59.0,ACTUAL,,,TREATMENT,NONE,Duchenne Muscular Dystrophy,PF-06252616,BIOLOGICAL,28,22,6 Years,18 Years,MALE,False,Pfizer,INDUSTRY,0,47,United Kingdom|United States|Canada|Japan|Italy,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.0943445622221,medium,1,1,1,0,1,0,1,1,1,1,0,0,1,0,50,1,0,1,0,1,0,2016-10-13,2018-11-22,770.0,2016.0,1,2,0
NCT00227019,Phase 2 Trial of Bevacizumab in Combination With Pemetrexed,Phase II Trial of Bevacizumab in Combination With Pemetrexed as Second Line Therapy in Patients With Stable Brain Metastases From Non-small Cell Lung Cancer (NSCLC) (Excluding Squamous Cell Carcinoma),COMPLETED,2006-03,2016-12,2017-03-06,INTERVENTIONAL,PHASE2,16.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-small Cell Lung Cancer (NSCLC)|Lung Cancer|Neoplasm Metastasis,Bevacizumab|Pemetrexed|Vitamin B12|Folate|Dexamethasone,DRUG,1,2,18 Years,,ALL,False,Heather Wakelee,OTHER,2,4,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,2.833213344056216,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,3,1,1,0,0,5,1,,,,,0,2,0
NCT03630419,Specialized Food Plan Based on Individual Physiological Comprehensive Body Assessments Accompanied With Cellular Repair Therapy to Decrease Inflammation Cognitively Impaired Patients,Determining if a Personalized Mito Food Plan Diet and Cellular Repair Therapy Based on Individual Physiological and Cellular Comprehensive Body Assessments in Patients With Alzheimer's Disease Decreases Inflammation and Oxidative Stress,COMPLETED,2018-02-10,2018-07-28,2018-10-02,INTERVENTIONAL,PHASE1|PHASE2,5.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Mild Cognitive Impairment|Alzheimer Disease,Mito-Food Plan|Cellular Repair Therapy,OTHER|DIETARY_SUPPLEMENT,3,1,55 Years,90 Years,ALL,True,"Perseverance Research Center, LLC",OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,1,0,2,1.791759469228055,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,0,0,0,2,1,2018-02-10,2018-07-28,168.0,2018.0,1,3,1
NCT03937830,"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)",ACTIVE_NOT_RECRUITING,2021-03-10,2027-12-31,2026-01-23,INTERVENTIONAL,PHASE2,27.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Hepatocellular Cancer|Hepatocellular Carcinoma|Metastatic Hepatocellular Carcinoma,durvalumab|Doxorubicin-Eluting Beads|TACE|bevacizumab|Tremelimumab,DRUG|PROCEDURE,2,4,18 Years,120 Years,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,,0,1,0,0,0,2.0,1,0,0,0,3,3.332204510175204,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,6,1,1,0,0,5,1,2021-03-10,2027-12-31,2487.0,2021.0,1,3,1
NCT01471730,The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery,"The ZEroPLASmaTrial (ZEPLAST): a Randomized, Controlled Trial on Transfusion Avoidance in High Transfusion-risk Cardiac Surgery Patients",COMPLETED,2011-11,2014-12,2015-03-31,INTERVENTIONAL,PHASE3,119.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Heart Disease,Fibrinogen|Saline solution|Prothrombin complex,DRUG,1,3,18 Years,,ALL,False,IRCCS Policlinico S. Donato,OTHER,1,1,Italy,1.0,0,0,1,0,0,3.0,0,0,0,1,1,4.787491742782046,medium,0,1,0,1,0,1,0,0,0,1,1,1,1,1,4,1,1,0,0,3,1,,,,,0,1,0
NCT05205330,"Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers","An Open-label, Single-arm, Phase Ib/IIa Trial to Evaluate the Safety and Efficacy of the EP4 Receptor Antagonist Vorbipiprant (CR6086) in Combination With the PD-1 Inhibitor Balstilimab (AGEN2034), in Patients With Pretreated Mismatch-repair-proficient and Microsatellite Stable Metastatic Colorectal Cancer, and Other Metastatic GI Cancers.",ACTIVE_NOT_RECRUITING,2021-11-23,2027-06,2025-10-29,INTERVENTIONAL,PHASE1|PHASE2,107.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Refractory Metastatic Colorectal Cancer|Solid Tumor|Metastatic Microsatellite-stable Colorectal Cancer|Mismatch Repair Protein Proficient|Metastatic GI Cancers|Gastric Cancer,CR6086|AGEN2034,DRUG|BIOLOGICAL,3,7,18 Years,,ALL,False,Rottapharm Biotech,INDUSTRY,1,3,Italy,,1,1,0,0,1,1.5,1,0,0,0,6,4.68213122712422,medium,0,0,1,0,0,1,1,0,0,1,0,0,1,0,10,1,1,1,0,2,1,2021-11-23,,,2021.0,1,4,1
NCT03320330,"Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors","A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors",COMPLETED,2018-01-31,2024-06-30,2024-07-15,INTERVENTIONAL,PHASE1|PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Recurrent Malignant Solid Neoplasm|Recurrent Osteosarcoma|Refractory Malignant Solid Neoplasm|Refractory Osteosarcoma,Laboratory Biomarker Analysis|Pepinemab|Pharmacological Study,OTHER|BIOLOGICAL,9,3,12 Months,30 Years,ALL,False,Children's Oncology Group,NETWORK,1,24,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,4,3.295836866004329,small,1,1,0,0,0,1,1,0,1,0,0,0,1,0,12,1,0,1,0,3,1,2018-01-31,2024-06-30,2342.0,2018.0,1,4,1
NCT01416428,Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies,"Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies",TERMINATED,2011-10-15,2019-08-12,2022-11-08,INTERVENTIONAL,PHASE1|PHASE2,210.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma|Waldenstrom Macroglobulinemia,oprozomib,DRUG,1,17,18 Years,,ALL,False,Amgen,INDUSTRY,0,19,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,2,5.351858133476067,large,0,1,1,0,1,0,1,0,1,0,0,0,1,1,18,1,1,0,0,1,0,2011-10-15,2019-08-12,2858.0,2011.0,0,3,1
NCT01350128,PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),"A Randomized, Double-Blind, Chronic Dosing (7 Days), Three-Period, Six-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-Center Study to Assess Efficacy and Safety of Four Doses of PT001 in Patients With Moderate to Severe COPD, Compared With Atrovent® HFA Inhalation Aerosol (Open-Label) as An Active Control",COMPLETED,2011-05-01,2011-10-01,2018-06-20,INTERVENTIONAL,PHASE2,103.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Chronic Obstructive Pulmonary Disease,PT001 MDI|Ipratropium Bromide HFA Inhalation Aerosol|Placebo MDI,DRUG|OTHER,1,8,40 Years,80 Years,ALL,False,"Pearl Therapeutics, Inc.",INDUSTRY,0,8,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.6443908991413725,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,0,9,1,1,0,0,3,1,2011-05-01,2011-10-01,153.0,2011.0,0,2,0
NCT00666328,Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE),The Evaluation of Patients With Acute Hypertension and Intracerebral Hemorrhage With Intravenous Clevidipine Treatment (ACCELERATE),COMPLETED,2008-06,2010-04,2014-08-29,INTERVENTIONAL,PHASE3,37.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hypertension|Hemorrhage,clevidipine,DRUG,1,9,18 Years,,ALL,False,The Medicines Company,INDUSTRY,0,17,Germany|United States,1.0,0,0,1,0,0,3.0,0,0,0,1,2,3.6375861597263857,small,1,1,1,0,0,0,1,1,1,1,0,0,1,0,10,1,1,0,0,1,0,,,,,0,3,1
NCT05151328,Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation,"A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Plecanatide in the Treatment of Functional Constipation in Chinese Patients for up to 12 Weeks",COMPLETED,2022-03-18,2023-10-26,2024-07-11,INTERVENTIONAL,PHASE3,648.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,QUADRUPLE,Functional Constipation,Plecanatide,DRUG,1,13,18 Years,,ALL,False,"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.",INDUSTRY,0,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.47543271670409,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,1,0,14,1,1,0,0,1,0,2022-03-18,2023-10-26,587.0,2022.0,1,1,0
NCT01266928,Does Vitamins C and E Supplementation of After Preterm Rupture of Membranes Prolong the Duration of Latency? A Prospective Randomized Controlled Study,,COMPLETED,2011-01,2011-11,2012-02-07,INTERVENTIONAL,PHASE3,244.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Preterm Premature Rupture of Membranes,vitamine C and E,DRUG,1,1,18 Years,40 Years,FEMALE,True,Erzincan Military Hospital,OTHER,0,1,Turkey (Türkiye),1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.501258210544727,large,0,1,0,1,0,0,0,0,0,0,1,0,0,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT00553267,Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension,"An Eight-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 10mg Monotherapy",COMPLETED,2007-11,,2014-02-13,INTERVENTIONAL,PHASE3,947.0,ACTUAL,,PARALLEL,TREATMENT,,Hypertension,fixed dose combination of telmisartan+amlodipine|amlodipine,DRUG,1,9,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,97,United Kingdom|Russia|Turkey (Türkiye)|Ukraine|Australia|Bulgaria|Slovakia|Ireland|Austria|New Zealand|Spain|Czechia|Switzerland|Italy,1.0,0,0,1,0,0,3.0,0,0,0,1,1,6.854354502255021,xlarge,0,1,1,0,0,0,1,1,0,1,0,0,1,1,10,1,1,0,0,2,1,,,,,0,3,1
NCT05003700,Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma,"Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma：a Prospective, Single-arm，Phase II Trial.",COMPLETED,2021-08-12,2024-07-04,2024-11-05,INTERVENTIONAL,PHASE2,39.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatocellular Carcinoma,Hepatic arterial infusion chemotherapy|Lenvatinib|Camrelizumab,PROCEDURE|DRUG,1,7,18 Years,75 Years,ALL,False,"Nanfang Hospital, Southern Medical University",OTHER,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.6888794541139363,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,8,1,1,0,0,3,1,2021-08-12,2024-07-04,1057.0,2021.0,1,2,0
NCT03328507,A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects,A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects,COMPLETED,2017-11-09,2019-11-12,2023-10-24,INTERVENTIONAL,PHASE2,121.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Colonoscopy,BLI4900|PEG Control,DRUG,1,0,18 Years,85 Years,ALL,False,Braintree Laboratories,INDUSTRY,0,4,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.804021044733257,medium,0,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,2,1,2017-11-09,2019-11-12,733.0,2017.0,1,1,0
NCT02445807,A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis,"A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days",COMPLETED,2015-12,2016-07,2018-05-15,INTERVENTIONAL,PHASE3,265.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Stable Plaque Psoriasis,DFD06-Cream|Vehicle Cream,DRUG,1,2,18 Years,,ALL,False,"Promius Pharma, LLC",INDUSTRY,0,30,United States,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.583496308781699,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,3,1,1,0,0,2,1,,,,,0,1,0
NCT01878292,Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder,"A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder",COMPLETED,2013-07-11,2016-10-05,2019-12-24,INTERVENTIONAL,PHASE3,529.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Major Depressive Disorder,Placebo|Vilazodone|Vilazodone,DRUG,1,1,12 Years,17 Years,ALL,False,Forest Laboratories,INDUSTRY,0,52,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.272877006546167,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,3,1,2013-07-11,2016-10-05,1182.0,2013.0,0,1,0
NCT00912392,Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC),"Etoposide-Carboplatin (EC) Versus EC Plus Endostar in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC): Randomized, Open Label, Placebo-controlled, Multicentre Study",COMPLETED,2009-05,2012-12,2014-09-03,INTERVENTIONAL,PHASE2,138.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Small Cell Lung Cancer,Endostar|Etoposide-Carboplatin,DRUG,1,7,18 Years,75 Years,ALL,False,"Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd",INDUSTRY,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.9344739331306915,medium,0,1,1,0,0,0,0,0,0,0,1,0,1,1,8,1,1,0,0,2,1,,,,,0,2,0
NCT04353492,An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab,"A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient-reported Outcomes (PRO) in Patients With Relapsing Multiple Sclerosis (RMS) Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod",COMPLETED,2020-07-14,2025-03-11,2025-11-12,INTERVENTIONAL,PHASE3,562.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Relapsing Multiple Sclerosis,Ofatumumab,BIOLOGICAL,1,1,18 Years,60 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,123,Estonia|Canada|Austria|Latvia|Slovenia|Hungary|Saudi Arabia|Argentina|Russia|Australia|Bulgaria|Portugal|Spain|Norway|Belgium|Italy|United States|Lebanon|Czechia|Germany|Poland|Greece|United Kingdom|Turkey (Türkiye)|Slovakia|Switzerland|Mexico,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.333279628139691,xlarge,0,1,1,0,1,0,1,1,1,1,0,0,1,0,2,1,0,1,0,1,0,2020-07-14,2025-03-11,1701.0,2020.0,1,1,0
NCT00158600,A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease,"Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy and Pharmacokinetics of Myozyme in Patients With Late-Onset Pompe Disease.",COMPLETED,2005-09,2007-09,2015-04-28,INTERVENTIONAL,PHASE3,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Pompe Disease (Late-onset)|Glycogen Storage Disease Type II (GSD-II)|Acid Maltase Deficiency Disease|Glycogenosis 2,alglucosidase alfa|Placebo,DRUG|BIOLOGICAL,6,2,8 Years,,ALL,False,"Genzyme, a Sanofi Company",INDUSTRY,0,8,France|Netherlands|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,4,4.51085950651685,medium,1,1,1,0,1,0,1,1,1,1,1,1,1,1,8,1,1,1,0,2,1,,,,,0,4,1
NCT02338700,Safety and Efficacy Study of Mix Vaccine in Prostate Carcinoma Patient,Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Prostate Carcinoma Patient,COMPLETED,2015-01,2015-08,2015-09-10,INTERVENTIONAL,PHASE1|PHASE2,20.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostatic Neoplasms,MV|standard treatment,OTHER|BIOLOGICAL,1,2,18 Years,80 Years,ALL,False,"Fuda Cancer Hospital, Guangzhou",OTHER,0,1,China,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.044522437723423,small,1,0,0,1,0,0,0,0,0,0,1,0,1,1,3,1,0,1,0,2,1,,,,,0,2,0
NCT01887600,Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis,"A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis",COMPLETED,2013-09-03,2017-11-01,2024-11-14,INTERVENTIONAL,PHASE3,594.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Anemia in Chronic Kidney Disease in Non-dialysis Patients,Roxadustat|Placebo,DRUG,2,51,18 Years,,ALL,False,Astellas Pharma Europe B.V.,INDUSTRY,1,138,Estonia|South Africa|Hungary|Russia|Bulgaria|Spain|Romania|Belgium|Italy|Ukraine|Colombia|Georgia|Poland|Greece|Peru|United Kingdom|Dominican Republic|Turkey (Türkiye)|Guatemala|Belarus|Panama|Serbia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.38856140554563,xlarge,0,1,1,0,0,1,1,1,0,1,1,1,1,1,53,1,1,0,0,2,1,2013-09-03,2017-11-01,1520.0,2013.0,0,3,1
NCT03626636,A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration,"A Randomized Controlled, Double-Masked, Crossover Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration",COMPLETED,2017-08-01,2019-04-04,2020-07-08,INTERVENTIONAL,PHASE2,42.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Dry Age-related Macular Degeneration,Risuteganib|Sham,DRUG|OTHER,1,0,50 Years,85 Years,ALL,False,"Allegro Ophthalmics, LLC",INDUSTRY,0,7,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.7612001156935624,small,1,1,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,0,0,2,1,2017-08-01,2019-04-04,611.0,2017.0,1,1,0
NCT05137236,A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters,"A Phase 2A, Randomized, Stratified, Observer-Blind Study to Evaluate the Immunogenicity and Safety of mRNA-1283 Vaccine Boosters for SARS-CoV-2",COMPLETED,2021-12-06,2023-03-23,2025-07-17,INTERVENTIONAL,PHASE2,540.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,SARS-CoV-2,mRNA-1283|mRNA-1283.211|mRNA-1273|mRNA-1283.529,BIOLOGICAL,9,10,18 Years,,ALL,True,"ModernaTX, Inc.",INDUSTRY,0,17,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.293419278846481,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,0,1,19,1,0,1,0,4,1,2021-12-06,2023-03-23,472.0,2021.0,1,2,0
NCT01793636,A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer,"An Open Label, Randomised Phase II Study, Comparing AZD2014 Versus Everolimus With Advanced Metastatic Renal Cancer and Progression on VEGF Targeted Therapy",TERMINATED,2013-02,2015-11,2014-06-24,INTERVENTIONAL,PHASE2,49.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Clear Cell Renal Carcinoma,AZD2014|Everolimus,DRUG,1,1,18 Years,,ALL,False,Queen Mary University of London,OTHER,2,9,United Kingdom,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.912023005428146,small,1,1,0,1,0,1,1,0,0,1,1,0,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT04120766,Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging,Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging: SMArT-HS,ACTIVE_NOT_RECRUITING,2021-12-01,2026-11-30,2025-12-15,INTERVENTIONAL,PHASE2,64.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dementia|Mild Cognitive Impairment,Nicorandil|Placebo,DRUG,1,1,70 Years,,ALL,False,"Gregory Jicha, MD, PhD",OTHER,1,1,United States,,0,1,0,0,0,2.0,0,0,0,0,2,4.174387269895637,medium,1,1,0,1,0,1,0,0,1,0,1,1,1,1,2,1,1,0,0,2,1,2021-12-01,2026-11-30,1825.0,2021.0,1,2,0
NCT05108766,A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis,"A Phase Ⅲ, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis",COMPLETED,2020-12-17,2022-07-08,2023-04-12,INTERVENTIONAL,PHASE3,220.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Plaque Psoriasis,Tildrakizumab 100 mg|Placebo,DRUG,1,3,18 Years,70 Years,ALL,False,"Shenzhen Kangzhe Pharmaceutical Co., Ltd.",INDUSTRY,0,1,China,1.0,0,0,1,0,0,3.0,0,1,0,0,1,5.3981627015177525,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,2020-12-17,2022-07-08,568.0,2020.0,1,1,0
NCT04351256,Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy,Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy - Employing Optimized (Hypofractionated) Radiotherapy to Foster Durvalumab Efficacy,ACTIVE_NOT_RECRUITING,2020-05-20,2026-06-30,2025-12-05,INTERVENTIONAL,PHASE2,51.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"NSCLC, Stage III",Durvalumab Injection [Imfinzi]|Thoracic Radiotherapy (TRT) conventionally|Thoracic Radiotherapy (TRT) hypofractionated,DRUG|RADIATION,2,8,18 Years,,ALL,False,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,OTHER,2,14,Germany,,0,1,0,0,0,2.0,0,0,0,0,1,3.9512437185814275,medium,1,1,0,1,0,1,1,0,0,1,1,0,1,1,10,1,1,0,0,3,1,2020-05-20,2026-06-30,2232.0,2020.0,1,2,0
NCT00890656,Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage,Phase II Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage,COMPLETED,2003-06,2011-01,2012-02-20,INTERVENTIONAL,PHASE2,90.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Lymphoblastic Leukemia,Cyclophosphamide (CTX)|Vincristine|Doxorubicin|Decadron|G-CSF|Methotrexate (MTX)|Ara-C|Pegaspargase,DRUG,1,0,,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.51085950651685,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,8,1,,,,,0,1,0
NCT02597322,Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN),"An Open-label, Non-randomized, Multicenter, Two Stage Designed Phase II Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)",COMPLETED,2012-02,2017-06,2025-04-06,INTERVENTIONAL,PHASE2,21.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,cT2a N0NxM0 Renal Tumor,AXITINIB,DRUG,1,5,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,1,1,France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.091042453358316,small,1,1,0,1,0,1,0,0,0,1,0,0,1,0,6,1,1,0,0,1,0,,,,,0,1,0
NCT02032251,Reduction of Sperm DNA Fragmentation by Oral Ginger,Reduction of Sperm DNA Fragmentation by Oral Ginger (Zingiberofficinale) Extract Treatment,COMPLETED,2009-12,2010-11,2014-01-09,INTERVENTIONAL,PHASE2,71.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Infertility,oral administration of ginger|Placebo,DRUG,1,3,20 Years,50 Years,MALE,True,Royan Institute,OTHER_GOV,0,1,Iran,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.276666119016055,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00405951,Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer,A Phase I/II Study of Obatoclax Mesylate (GX15-070MS) Administered Every 3 Weeks in Combination With Docetaxel to Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC),COMPLETED,2006-10,2009-09,2016-07-21,INTERVENTIONAL,PHASE1|PHASE2,47.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lung Cancer,Obatoclax mesylate 250 ml|Docetaxel,DRUG,1,1,18 Years,,ALL,False,Gemin X,INDUSTRY,0,7,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.871201010907891,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,2,1,1,0,0,2,1,,,,,0,2,0
NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,Phase 2 Study of Androgen Deprivation Therapy (ADT) Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,TERMINATED,2015-11,2017-09-14,2018-11-28,INTERVENTIONAL,PHASE2,19.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostatic Neoplasms,Doxorubicin|Ketoconazole|Docetaxel|Estramustine|Degarelix,DRUG,1,16,18 Years,,MALE,False,"The University of Texas Health Science Center, Houston",OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.995732273553991,small,1,1,0,1,0,0,0,0,1,0,0,0,1,1,17,1,1,0,0,5,1,,2017-09-14,,,0,2,0
NCT05856331,Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema,"Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of SAR447537 (INBRX-101) Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema",COMPLETED,2023-10-12,2025-08-06,2025-08-11,INTERVENTIONAL,PHASE2,99.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alpha 1-Antitrypsin Deficiency|Emphysema,SAR447537|Zemaira,DRUG,1,10,18 Years,80 Years,ALL,False,Sanofi,INDUSTRY,0,65,United Kingdom|Denmark|Australia|United States|Sweden|New Zealand|Spain|Poland,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.605170185988092,medium,1,1,1,0,1,0,1,1,1,1,1,1,1,1,11,1,1,0,0,2,1,2023-10-12,2025-08-06,664.0,2023.0,1,4,1
NCT01165931,Coronary Vasomotor Response After Riociguat Exposure,A Study to Compare the Acute Coronary Vasodilating Effects of the sGC Stimulator Riociguat (BAY 63-2521) With the Nitric Oxide Donor Nitroglycerin in Patients With Coronary Artery Disease,WITHDRAWN,2012-05,2013-01,2013-10-23,INTERVENTIONAL,PHASE2,0.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Coronary Artery Disease,Riociguat (BAY63-2521),DRUG,1,1,18 Years,90 Years,ALL,False,Bayer,INDUSTRY,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT00570102,Nutritional Prevention Pilot Trial for Type 1 Diabetes,Trial to Reduce IDDM in the Genetically at Risk (TRIGR): the Pilot Study,COMPLETED,1995-02,2008-01,2012-11-28,INTERVENTIONAL,PHASE2,230.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Type 1 Diabetes Mellitus,A highly hydrolyzed formula|A regular cow's milk based formula,DIETARY_SUPPLEMENT,1,0,1 Day,7 Days,ALL,True,University of Helsinki,OTHER,5,18,Finland,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.442417710521793,large,0,1,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,2,1,,,,,0,1,0
NCT03595553,Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection,"A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of Clostridium Difficile Infection (CDI)",COMPLETED,2019-01-28,2021-11-17,2023-03-03,INTERVENTIONAL,PHASE3,759.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Clostridioides Difficile Infection,Ridinilazole|Vancomycin,DRUG,1,7,18 Years,,ALL,False,Summit Therapeutics,INDUSTRY,0,149,Argentina|Russia|Australia|Bulgaria|United States|Canada|Brazil|Poland|New Zealand|Spain|Hungary|Greece|Romania|South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.633318433280377,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,8,1,1,0,0,2,1,2019-01-28,2021-11-17,1024.0,2019.0,1,3,1
NCT01732445,Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis,"A Phase 2 Pilot Trial of Ruxolitinib Combined With Danazol for Patients With Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering From Anemia",COMPLETED,2013-04,2017-08-10,2017-10-18,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,SUPPORTIVE_CARE,NONE,Anemia|Primary Myelofibrosis|Secondary Myelofibrosis,ruxolitinib phosphate|danazol|quality-of-life assessment|questionnaire administration,DRUG|OTHER,1,2,18 Years,,ALL,False,Mayo Clinic,OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,2.70805020110221,small,1,1,0,1,0,1,1,0,1,0,0,0,0,0,3,1,1,0,0,4,1,,2017-08-10,,,0,2,0
NCT03740737,Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1),"A Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Trial Investigating the Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Women Aged 18-34 Years Undergoing Assisted Reproductive Technology",COMPLETED,2018-10-26,2020-11-11,2024-01-18,INTERVENTIONAL,PHASE3,579.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Infertility,Follitropin delta|Placebo,DRUG|OTHER,1,68,18 Years,34 Years,FEMALE,False,Ferring Pharmaceuticals,INDUSTRY,0,23,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.363028103540465,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,1,1,69,1,1,0,0,2,1,2018-10-26,2020-11-11,747.0,2018.0,1,2,0
NCT00005072,Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer,Phase I/II Study Evaluating the Safety and Efficacy of Leuvectin Immunotherapy for the Treatment of Locally Recurrent Prostate Cancer Following Radiation Therapy (Summary Last Updated: 02/2001),TERMINATED,2000-11,2003-04,2014-07-29,INTERVENTIONAL,PHASE1|PHASE2,25.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,Leuvectin,BIOLOGICAL,1,0,18 Years,,MALE,False,Vical,INDUSTRY,2,2,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,3.258096538021482,small,1,1,1,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,,,,,0,1,0
NCT02623972,A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer,A Phase 2 Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer,ACTIVE_NOT_RECRUITING,2016-02-26,2026-12,2025-11-25,INTERVENTIONAL,PHASE2,22.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Inflammatory Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast,Eribulin|Adriamycin|Cyclophosphamide,DRUG,1,4,18 Years,,ALL,False,Dana-Farber Cancer Institute,OTHER,1,2,United States,,0,1,0,0,0,2.0,1,1,0,0,2,3.1354942159291497,small,1,1,0,1,0,1,1,0,1,0,0,0,1,1,5,1,1,0,0,3,1,2016-02-26,,,2016.0,1,2,0
NCT03649139,Effect and Underlying Immunological Mechanisms of Sublingual Immunotherapy in Allergic Rhinitis,"Effect and Underlying Immunological Mechanisms of Sublingual Immunotherapy in Seasonal Allergic Rhinitis: a Randomized, Double Blind, Placebo Controlled Trial",COMPLETED,2017-04-01,2018-10-30,2019-06-11,INTERVENTIONAL,PHASE3,71.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Seasonal Allergic Rhinitis,sublingual immunotherapy drops|Placebo drops,DRUG,1,5,18 Years,60 Years,ALL,False,Beijing Tongren Hospital,OTHER,1,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.276666119016055,medium,1,1,0,1,0,1,0,0,0,0,1,1,1,1,6,1,1,0,0,2,1,2017-04-01,2018-10-30,577.0,2017.0,1,2,0
NCT01144377,A Study of LY2541546 in Women With Low Bone Mineral Density,A Phase 2 Randomized Study of LY2541546 Versus Placebo in Postmenopausal Women With Low Bone Mineral Density: An Evaluation of the Dose Response Relationship Using Bone Mineral Density,COMPLETED,2010-08,2013-02,2019-09-17,INTERVENTIONAL,PHASE2,154.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Osteoporosis,LY2541546|Placebo,DRUG,1,7,45 Years,85 Years,FEMALE,False,Eli Lilly and Company,INDUSTRY,0,8,Estonia|Denmark|United States|Lithuania|Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.043425116919247,medium,0,1,1,0,1,0,1,1,1,0,1,1,1,1,8,1,1,0,0,2,1,,,,,0,3,1
NCT00990457,Evaluating the Effects Two Diets Combined With Exercise in Persons With Abdominal Obesity (The SHAPE5 Study),Two Diets With Exercise in Abdominal Obesity: Cardiovascular Effects,COMPLETED,2009-10,2011-09,2013-04-04,INTERVENTIONAL,PHASE3,77.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Overweight|Obese|Sedentary|Abdominal Obesity,Weight Loss Diets Plus Exercise,BEHAVIORAL,1,1,30 Years,65 Years,ALL,True,Johns Hopkins University,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,4,4.356708826689592,medium,1,1,0,1,0,1,0,0,1,0,1,0,1,1,2,1,0,0,0,1,0,,,,,0,1,0
NCT01154101,"Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis","A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis",COMPLETED,2010-06-07,2011-11-09,2017-10-13,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Psoriasis,Placebo|SRT2104,DRUG,6,6,18 Years,80 Years,ALL,False,"Sirtris, a GSK Company",INDUSTRY,1,8,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.713572066704308,small,1,1,1,0,1,1,1,0,1,0,1,1,1,1,12,1,1,0,0,2,1,2010-06-07,2011-11-09,520.0,2010.0,0,2,0
NCT02365701,Study of Motilitone to Treat Functional Dyspepsia,"Double-blind, Placebo-controlled, Randomized, 4-week, Phase II Clinical Trial for Assessment of Efficacy and Safety of Motilitone in Patients With Functional Dyspepsia",COMPLETED,2015-06,2018-02,2019-05-21,INTERVENTIONAL,PHASE2,45.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Dyspepsia,Motilitone 30mg|Placebo,DRUG,2,0,18 Years,65 Years,ALL,False,"Dong-A ST Co., Ltd.",INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.828641396489095,small,1,1,1,0,0,0,0,0,1,0,1,1,1,1,2,0,1,0,0,2,1,,,,,0,1,0
NCT01431612,Effects of Adrenergic Drugs on the Fluid Balance During Surgery,The Effects of ß1-receptor Blockade and α1-adrenergic Agonist on the Kinetics of Lactated Ringer's Solution During Surgery,COMPLETED,2008-11,2010-10,2011-09-09,INTERVENTIONAL,PHASE1|PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,SINGLE,Ovarian Cyst,Esmolol administration|Phenylephrine infusion|Lactated Ringer´s solution,DRUG,1,1,20 Years,50 Years,FEMALE,False,Sodertalje Hospital,OTHER,1,1,China,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,1,0,0,0,0,1,0,0,1,2,1,1,0,0,3,1,,,,,0,2,0
NCT00812981,A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.,Non-inferiority Study of GSK Biologicals' Pandemic Influenza Vaccine 1562902A.,COMPLETED,2008-11-15,2009-06-07,2018-08-20,INTERVENTIONAL,PHASE3,320.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Influenza,GSK1562902A|GSK1562902A,BIOLOGICAL,1,16,18 Years,59 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,1,Taiwan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.771441123130016,large,0,1,1,0,0,0,0,0,0,0,1,1,0,1,17,1,0,1,0,2,1,2008-11-15,2009-06-07,204.0,2008.0,0,2,0
NCT04098081,1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma,"1911GCCC: Open Label, Phase 2 Trial of Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy",ACTIVE_NOT_RECRUITING,2019-12-12,2027-12-31,2025-07-01,INTERVENTIONAL,PHASE2,15.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Advanced Pancreatic Cancer,galeterone|Gemcitabine,DRUG,1,2,18 Years,,ALL,False,"University of Maryland, Baltimore",OTHER,0,1,United States,,0,1,0,0,0,2.0,1,0,0,0,1,2.772588722239781,small,1,1,0,1,0,0,0,0,1,0,1,0,1,0,3,1,1,0,0,2,1,2019-12-12,2027-12-31,2941.0,2019.0,1,1,0
NCT06079281,Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa,"A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 (Recombinant Alkaline Phosphatase) Administered Subcutaneously in Adolescent (12 to < 18 Years of Age) and Adult Participants With Hypophosphatasia Who Have Not Previously Been Treated With Asfotase Alfa",ACTIVE_NOT_RECRUITING,2024-01-03,2028-03-29,2026-01-29,INTERVENTIONAL,PHASE3,124.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hypophosphatasia,ALXN1850|Placebo,DRUG,1,9,12 Years,130 Years,ALL,False,"Alexion Pharmaceuticals, Inc.",INDUSTRY,0,65,United Kingdom|Argentina|Turkey (Türkiye)|Australia|United States|Canada|Brazil|Poland|South Korea|Taiwan|France|Spain|Italy|China|Germany|Japan|Israel,,0,0,1,0,0,3.0,0,0,0,0,1,4.8283137373023015,medium,0,1,1,0,0,0,1,1,1,1,1,1,1,1,10,1,1,0,0,2,1,2024-01-03,2028-03-29,1547.0,2024.0,1,3,1
NCT01826981,"Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection","A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection",COMPLETED,2013-04,2015-05,2018-11-16,INTERVENTIONAL,PHASE2,359.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Chronic Hepatitis C,LDV/SOF|SOF|RBV|Peg-IFN|GS-9669|VEL,DRUG,2,9,18 Years,,ALL,False,Gilead Sciences,INDUSTRY,0,2,New Zealand,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.886104031450156,large,0,1,1,0,1,0,1,0,0,0,1,0,1,1,11,1,1,0,0,6,1,,,,,0,2,0
NCT00493181,"Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients",The Effect of Interleukin 11 on Thrombocytopenia Associated With Imatinib or Other Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myelogenous Leukemia,COMPLETED,2005-10,2011-01,2012-02-20,INTERVENTIONAL,PHASE2,8.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Leukemia|Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia,Interleukin-11 (IL-11 or Neumega),DRUG,1,0,,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,2.1972245773362196,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,1,0
NCT00481312,Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU),"A Prospective, Multi-centre, Randomised, Double-blind Comparison of Intravenous Dexmedetomidine With Midazolam for Continuous Sedation of Ventilated Patients in Intensive Care Unit",COMPLETED,2007-06,2009-10,2012-05-07,INTERVENTIONAL,PHASE3,501.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Continuous Sedation in Initially Sedated Adults in ICU,Dexmedetomidine|Midazolam,DRUG,2,2,18 Years,,ALL,False,"Orion Corporation, Orion Pharma",INDUSTRY,0,43,United Kingdom|Estonia|Finland|France|Switzerland|Germany|Netherlands|Belgium|Norway,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.218600119691729,xlarge,0,1,1,0,0,0,1,1,0,1,1,1,1,1,4,1,1,0,0,2,1,,,,,0,2,0
NCT02810119,To Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Conjunctivochalasis,"A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis",COMPLETED,2016-11,2017-10,2017-10-27,INTERVENTIONAL,PHASE2,13.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Conjunctivochalasis,LO2A|Placebo,DRUG,1,4,18 Years,,ALL,False,Ocuwize LTD,INDUSTRY,0,1,Israel,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.6390573296152584,small,1,1,1,0,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT03564119,A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea,"A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea",COMPLETED,2018-06-21,2019-06-10,2021-12-15,INTERVENTIONAL,PHASE3,372.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Papulopustular Rosacea,S5G4T-1|S5G4T-2,DRUG,2,1,18 Years,,ALL,False,"Sol-Gel Technologies, Ltd.",INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.921578419643816,large,0,1,1,0,0,0,0,0,1,0,1,1,1,1,3,1,1,0,0,2,1,2018-06-21,2019-06-10,354.0,2018.0,1,1,0
NCT04455230,A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190,"A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT190) in Subjects With Fabry Disease",COMPLETED,2020-09-08,2023-09-28,2023-12-07,INTERVENTIONAL,PHASE1|PHASE2,3.0,ACTUAL,,SINGLE_GROUP,OTHER,NONE,Fabry Disease|Lysosomal Storage Diseases,FLT190,GENETIC,1,0,18 Years,,MALE,False,Spur Therapeutics,INDUSTRY,0,2,Germany|United Kingdom,1.0,1,1,0,0,1,1.5,0,0,0,0,2,1.3862943611198906,small,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,2020-09-08,2023-09-28,1115.0,2020.0,1,3,1
NCT01460030,An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism,An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism,COMPLETED,2011-11,2013-02,2017-03-03,INTERVENTIONAL,PHASE3,,,,,TREATMENT,,Parathyroid Carcinoma|Hypercalcemia|Primary Hyperparathyroidism,Cinacalcet HCl,DRUG,1,1,20 Years,,ALL,False,"Kyowa Kirin Co., Ltd.",INDUSTRY,0,1,Japan,1.0,0,0,1,0,0,3.0,1,0,0,0,3,0.0,,0,0,1,0,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT00477230,Pivotal Clinical Study of Endoscopic Ablation for Atrial Fibrillation (AF) in Patients That Have Failed Drugs,Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System for the Treatment of Symptomatic Atrial Fibrillation (AF),TERMINATED,2007-03,2009-05,2012-06-27,INTERVENTIONAL,PHASE3,64.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Atrial Fibrillation,Endoscopic Ablation System|Standard Anti-arrhythmic Drug (AAD) Therapy,DRUG|DEVICE,1,0,18 Years,80 Years,ALL,False,CardioFocus,INDUSTRY,0,18,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,4.174387269895637,medium,1,1,1,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,1,2,1,,,,,0,1,0
NCT05846230,Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine,"A Randomised, Double-blind, Parallel Group, Roll-over Study Evaluating Long-term Safety and Efficacy of Oral Doses of BI 1291583 q.d. in Patients With Bronchiectasis (Clairleafᵀᴹ)",ACTIVE_NOT_RECRUITING,2023-09-08,2027-03-31,2026-01-21,INTERVENTIONAL,PHASE2,268.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Bronchiectasis,BI 1291583|Placebo matching BI 1291583,DRUG,1,2,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,102,Canada|Latvia|Hungary|Australia|Bulgaria|Portugal|Spain|Belgium|Italy|Israel|United States|France|Czechia|South Korea|Netherlands|Poland|Germany|United Kingdom|Turkey (Türkiye)|Denmark|Mexico|Japan,,0,1,0,0,0,2.0,0,0,0,0,1,5.594711379601839,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,3,1,1,0,0,2,1,2023-09-08,2027-03-31,1300.0,2023.0,1,2,0
NCT04427228,Single vs Multi-fraction SRS Patients on Immunotherapy,MIGRAINE: Randomized trIal of Single Versus Multifraction Radiosurgery on Immunotherapy,WITHDRAWN,2020-06-29,2022-12-12,2023-08-28,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Brain Cancer|Brain Metastases,Radiosurgery Single Treatment|Radiosurgery Three Treatments,RADIATION,1,9,18 Years,,ALL,False,University of Chicago,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,2,0.0,,1,1,0,1,0,0,0,0,1,0,1,0,1,1,10,1,0,0,0,2,1,2020-06-29,2022-12-12,896.0,2020.0,1,3,1
NCT05315128,Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers,Intralesional Methotrexate Versus Intramuscular Methotrexate in the Treatment of Non-melanoma Skin Cancers,COMPLETED,2020-07-06,2021-12-06,2022-04-07,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Non-melanoma Skin Cancers,Methotrexate,DRUG,1,3,20 Years,90 Years,ALL,False,Zagazig University,OTHER_GOV,0,1,Egypt,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,1,0,2020-07-06,2021-12-06,518.0,2020.0,1,0,0
NCT02839265,FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer,FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer,COMPLETED,2016-07,2024-11-22,2025-01-31,INTERVENTIONAL,PHASE2,33.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-small Cell Lung Cancer (NSCLC),FLT3 Ligand Therapy (CDX-301)|Stereotactic Body Radiotherapy (SBRT),DRUG|RADIATION,1,4,18 Years,,ALL,False,Albert Einstein College of Medicine,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.5263605246161616,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,5,1,1,0,0,2,1,,2024-11-22,,,0,1,0
NCT02368665,A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy,"A Randomized, Double-blind, Multi-center, Phase III Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil Combination in Patients With Essential Hypertension Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy",COMPLETED,2014-12,2016-11,2023-05-06,INTERVENTIONAL,PHASE3,180.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Essential Hypertension,"Amlodipine 5mg|Amlodipine 5mg, Candesartan cilexetil 16mg|Amlodipine 10mg, Candesartan cilexetil 16mg",DRUG,1,4,19 Years,75 Years,ALL,False,HK inno.N Corporation,INDUSTRY,0,19,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,1,1,5.198497031265826,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,5,1,1,0,0,3,1,,,,,0,1,0
NCT03647267,Effects of Pneumatic Vitreolysis on Vitreomacular Traction,Randomized Clinical Trial Assessing the Effects of Pneumatic Vitreolysis on Vitreomacular Traction,COMPLETED,2018-10-16,2020-08-06,2022-09-21,INTERVENTIONAL,PHASE3,46.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Vitreomacular Traction,Pneumatic Vitreolysis (C3F8 injection)|Observation,OTHER|DEVICE,1,4,18 Years,,ALL,False,Jaeb Center for Health Research,OTHER,2,41,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.8501476017100584,small,1,1,0,1,0,1,1,0,1,0,1,1,1,1,5,1,0,0,1,2,1,2018-10-16,2020-08-06,660.0,2018.0,1,1,0
NCT02511067,Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study,"Evaluation Of the Safety, Tolerability and Efficacy of Ranibizumab and Tocilizumab in Eyes With Diabetic Macular Edema.",WITHDRAWN,2016-10-01,2016-10-05,2023-08-15,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,SINGLE,Diabetic Macular Edema,Tocilizumab|Ranibizumab,DRUG,2,3,18 Years,,ALL,False,University of Nebraska,OTHER,1,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,0,0,1,0,1,0,5,1,1,0,0,2,1,2016-10-01,2016-10-05,4.0,2016.0,1,1,0
NCT00869167,Ramelteon for Insomnia Comorbid With Asthma,Ramelteon for Insomnia Comorbid With Asthma,TERMINATED,2008-03,2009-06,2013-05-01,INTERVENTIONAL,PHASE3,2.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Insomnia|Asthma,Ramelteon,DRUG,2,3,18 Years,60 Years,ALL,False,Northwestern University,OTHER,1,1,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,2,1.0986122886681098,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,5,1,1,0,0,1,0,,,,,0,1,0
NCT00331500,Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis,A Comparative Study of Olopatadine 0.2% Versus Vehicle in Patients With Seasonal Allergic Conjunctivitis or Rhinoconjunctivitis,COMPLETED,2006-04-18,2006-07-27,2017-08-14,INTERVENTIONAL,PHASE3,287.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Allergic Conjunctivitis,"Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|Olopatadine Hydrochloride Ophthalmic Solution Vehicle",DRUG,1,1,10 Years,,ALL,False,Alcon Research,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.662960480135946,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2006-04-18,2006-07-27,100.0,2006.0,0,1,0
NCT01603407,Finding the Optimum Regimen for Duchenne Muscular Dystrophy,Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen,COMPLETED,2013-01,2019-11,2022-08-12,INTERVENTIONAL,PHASE3,196.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Duchenne Muscular Dystrophy,Prednisone|Prednisone|Deflazacort,DRUG,3,14,4 Years,7 Years,MALE,False,University of Rochester,OTHER,3,32,United Kingdom|United States|Canada|Germany|Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.2832037287379885,medium,0,1,0,1,1,1,1,1,1,1,1,1,1,1,17,1,1,0,0,3,1,,,,,0,3,1
NCT03203005,"IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients","A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments",COMPLETED,2017-09-18,2019-12-20,2020-02-05,INTERVENTIONAL,PHASE1|PHASE2,22.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hepatocellular Carcinoma,IMA970A plus CV8102 and Cyclophosphamide,DRUG,2,5,18 Years,,ALL,False,"National Cancer Institute, Naples",OTHER,3,6,United Kingdom|Spain|Germany|Belgium|Italy,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.1354942159291497,small,1,1,0,1,0,1,1,1,0,1,0,0,1,0,7,1,1,0,0,1,0,2017-09-18,2019-12-20,823.0,2017.0,1,3,1
NCT03549494,Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction,Effect of Ocoxin®-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced Stomach Cancer and Esophagogastric Junction. Phase II Clinical Trial.,COMPLETED,2018-10-25,2023-02-15,2024-02-07,INTERVENTIONAL,PHASE2,45.0,ACTUAL,,SINGLE_GROUP,SUPPORTIVE_CARE,NONE,Stomach Neoplasm|Gastrointestinal Neoplasms|Digestive System Neoplasm|Esophageal Neoplasms|Head and Neck Neoplasms|Gastrointestinal Disease|Digestive System Disease|Esophageal Diseases|Stomach Diseases|Esophagogastric Junction Disorder,Ocoxin-Viusid®,DIETARY_SUPPLEMENT,4,4,18 Years,,ALL,False,Catalysis SL,INDUSTRY,0,1,Cuba,1.0,0,1,0,0,0,2.0,0,0,0,0,10,3.828641396489095,small,1,1,1,0,0,0,0,0,0,0,0,0,0,0,8,1,0,0,0,1,0,2018-10-25,2023-02-15,1574.0,2018.0,1,2,0
NCT00047294,"Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Phase II Study Of Temozolomide, Thalidomide And Celecoxib In Patients With Newly Diagnosed Glioblastoma Multiforme In The Post-Radiation Setting",COMPLETED,2001-04,2007-09,2017-07-11,INTERVENTIONAL,PHASE2,,,,,TREATMENT,NONE,Brain and Central Nervous System Tumors,celecoxib|temozolomide|thalidomide|adjuvant therapy,DRUG|PROCEDURE,0,0,18 Years,120 Years,ALL,False,Dana-Farber Cancer Institute,OTHER,1,4,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,4,1,,,,,0,1,0
NCT00571766,Effects of Oral L-Arginine on Chronic Hypertension in Pregnancy,Effects of Oral L-Arginine on Chronic Hypertension in Pregnancy,COMPLETED,2007-11,2008-12,2009-09-10,INTERVENTIONAL,PHASE3,80.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Hypertension in Pregnancy,L-Arginine|Placebo,DRUG,1,1,18 Years,40 Years,FEMALE,True,University of Modena and Reggio Emilia,OTHER,0,1,Italy,1.0,0,0,1,0,0,3.0,0,0,0,1,1,4.394449154672439,medium,1,0,0,1,0,0,0,0,0,1,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT02688556,Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca,"A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca",COMPLETED,2016-02,2016-12,2022-08-29,INTERVENTIONAL,PHASE3,745.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Keratoconjunctivitis Sicca,cyclosporine|vehicle of OTX-101,DRUG,1,3,18 Years,,ALL,False,Sun Pharmaceutical Industries Limited,INDUSTRY,0,3,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.61472560020376,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT02019056,Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis,"A Multicenter, Randomized, Double-blind, Placebo-controlled,Phase 2 Study to Evaluate the Efficacy, Safety of MG in Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis",COMPLETED,2010-11,2014-12,2015-04-29,INTERVENTIONAL,PHASE2,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Alcoholic Fatty Liver Disease|Alcoholic Hepatitis,"Placebo /bid P.O|MG-1|MG-2 : MG1000mg, Placebo /bid P.O|metadoxine",DRUG,5,0,18 Years,70 Years,ALL,False,PharmaKing,INDUSTRY,0,1,South Korea,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.51085950651685,medium,1,1,1,0,0,0,0,0,0,0,1,1,1,1,5,0,1,0,0,4,1,,,,,0,2,0
NCT00122356,Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment,"Maintaining Skeletal Health in Postmenopausal Women With Surgically Resected Stage I-IIIa Hormone-receptor Positive Breast Cancer Who Are Receiving Anastrozole, Through the Use of Alendronate as Determined by the Osteoporosis Australia Bone Maintenance Algorithm",COMPLETED,2005-09,2013-03,2013-03-13,INTERVENTIONAL,PHASE3,303.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Breast Cancer,Alendronate sodium,DRUG,1,7,,,FEMALE,False,Barwon Health,OTHER_GOV,1,8,Australia,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.717027701406222,large,0,1,0,1,0,1,1,0,0,0,1,0,0,1,8,1,1,0,0,1,0,,,,,0,1,0
NCT02143622,Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients,"A Phase Ib/II, Multicenter Study of LJM716 in Combination With Cetuximab in Patients With Platinum-pretreated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",WITHDRAWN,2015-03,2018-08,2016-04-21,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Head and Neck Squamous Cell Carcinoma,LJM716|cetuximab,BIOLOGICAL,3,6,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,0,,0.0,1,1,0,0,1,1.5,1,0,0,0,1,0.0,,1,1,1,0,1,0,0,0,0,0,0,0,1,0,9,1,0,1,0,2,1,,,,,0,3,1
NCT01497951,Photodynamic Therapy for Oral Precursor Lesions,A Randomized Controlled Trial: Photodynamic Treatment for the Therapy of Premalignant Mucosal Oral Lesions.,COMPLETED,2011-05,2017-01,2017-05-17,INTERVENTIONAL,PHASE3,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Leukoplakia|Lichen,Aminolaevulinic acid|Methylcellulose Placebo,OTHER,1,1,18 Years,,ALL,False,Medical University of Vienna,OTHER,0,1,Austria,1.0,0,0,1,0,0,3.0,0,0,0,0,2,3.367295829986474,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,0,0,0,2,1,,,,,0,2,0
NCT00792831,Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia,"Open Label, Uncontrolled, Pilot, Phase II Study of ITF2357 Administered Orally to Subjects With Chronic Lymphocytic Leukemia (CLL) Refractory/Relapsed After Conventional Chemotherapy or Relapsed After Autologous Bone Marrow Transplantation",TERMINATED,2008-02,2009-04,2022-01-27,INTERVENTIONAL,PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Lymphocytic Leukemia,ITF2357,DRUG,1,3,18 Years,75 Years,ALL,False,Italfarmaco,INDUSTRY,0,1,Italy,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.3862943611198906,small,1,1,1,0,0,0,0,0,0,1,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT04863131,Safety and Immunogenicity of EXG-5003,Safety and Immunogenicity of Intradermal SARS-CoV-2 Vaccine EXG-5003 in Healthy Adults,COMPLETED,2021-04-28,2023-01-24,2023-01-26,INTERVENTIONAL,PHASE1|PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,COVID-19,EXG-5003|Placebo,BIOLOGICAL,1,4,20 Years,55 Years,ALL,True,Fujita Health University,OTHER,1,1,Japan,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.713572066704308,small,1,1,0,1,0,1,0,0,0,0,1,1,0,1,5,1,0,1,0,2,1,2021-04-28,2023-01-24,636.0,2021.0,1,2,0
NCT02488902,"A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum","A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum in Semi-immune Adults Living in the Kassena-Nankana District of Northern Ghana",COMPLETED,1998-08,2003-03,2018-09-13,INTERVENTIONAL,PHASE2,521.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Malaria,Placebo|Tafenoquine 25mg|Tafenoquine 50mg|Tafenoquine 100 mg|Tafenoquine 200 mg|Mefloquine 250 mg,DRUG,1,1,18 Years,60 Years,ALL,True,U.S. Army Medical Research and Development Command,FED,1,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.257667587882639,xlarge,0,1,0,0,0,1,0,0,0,0,1,1,1,1,2,1,1,0,0,6,1,,,,,0,1,0
NCT02609802,The Different Analgesic Potency of Volatile Anesthetics at Equi-MAC,The Different Analgesic Potency of Sevoflurane and Desflurane at Equi-minimum Alveolar Concentration,COMPLETED,2015-11,2016-07-28,2017-11-08,INTERVENTIONAL,PHASE3,77.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Orthopedic Disorders,Sevoflurane|Desflurane,DRUG,1,0,19 Years,65 Years,ALL,False,Kangbuk Samsung Hospital,OTHER,0,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.356708826689592,medium,1,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,2,1,,2016-07-28,,,0,1,0
NCT04815902,Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis,The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis,ACTIVE_NOT_RECRUITING,2021-05-18,2025-06-01,2024-04-16,INTERVENTIONAL,PHASE1|PHASE2,100.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Osteoarthritis, Knee",Fisetin|Losartan|Placebo - Losartan|Placebo Fisetin,DRUG,1,19,40 Years,85 Years,ALL,False,Steadman Philippon Research Institute,OTHER,1,1,United States,,1,1,0,0,1,1.5,0,1,0,0,1,4.61512051684126,medium,0,0,0,1,0,1,0,0,1,0,1,1,1,1,20,1,1,0,0,4,1,2021-05-18,2025-06-01,1475.0,2021.0,1,3,1
NCT03696953,The Efficacy of Probiotics to Reduce Antepartum Group B Streptococcus Colonization.,The Efficacy of Probiotics to Reduce Antepartum Group B Streptococcus Colonization,ACTIVE_NOT_RECRUITING,2019-02-01,2024-09-30,2024-03-21,INTERVENTIONAL,PHASE2,109.0,ACTUAL,RANDOMIZED,FACTORIAL,PREVENTION,TRIPLE,Group B Streptococcus Carrier in Childbirth|Gastrointestinal Symptoms,Florajen3,BIOLOGICAL,1,2,18 Years,,FEMALE,True,Marquette University,OTHER,2,1,United States,,0,1,0,0,0,2.0,0,0,0,0,2,4.700480365792417,medium,0,1,0,1,0,1,0,0,1,0,1,1,0,0,3,1,0,1,0,1,0,2019-02-01,2024-09-30,2068.0,2019.0,1,1,0
NCT04058353,A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes),"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)",COMPLETED,2019-08-28,2020-06-12,2021-07-02,INTERVENTIONAL,PHASE3,271.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cystic Fibrosis,ELX/TEZ/IVA|IVA|TEZ/IVA,DRUG,1,6,12 Years,,ALL,False,Vertex Pharmaceuticals Incorporated,INDUSTRY,0,93,United Kingdom|Denmark|Australia|United States|Canada|Ireland|France|Spain|Italy|Germany|Netherlands|Belgium|Israel,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.605802066295998,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,7,1,1,0,0,3,1,2019-08-28,2020-06-12,289.0,2019.0,1,3,1
NCT01018953,Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome,"Phase II, Open, Adaptive, Dose Escalating, Multicentre Titration Study to Assess the Efficacy and Safety of Repeated Subcutaneous Administration of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome",TERMINATED,2010-02,2011-01,2020-11-20,INTERVENTIONAL,PHASE2,8.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Carcinoid Syndrome,BIM 23A760,DRUG,1,6,18 Years,75 Years,ALL,False,Ipsen,INDUSTRY,0,54,United Kingdom|Russia|Finland|Ukraine|Sweden|Slovakia|Ireland|Poland|Austria|Latvia|France|Spain|Czechia|Italy|Germany|Netherlands|Belgium|Israel,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.1972245773362196,small,1,1,1,0,0,0,1,1,0,1,0,0,1,0,7,1,1,0,0,1,0,,,,,0,2,0
NCT01126437,Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease,"A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler (TIOSPIR)",COMPLETED,2010-05,2013-05,2014-06-20,INTERVENTIONAL,PHASE3,17183.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Pulmonary Disease, Chronic Obstructive",tiotropium 18 mcg|tiotropium 1.25 mcg (2 actuations/day)|tiotropium 2.5 mcg (2 actuations/day),DRUG,2,7,40 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,1191,Canada|Ireland|Austria|Lithuania|Latvia|Thailand|South Africa|China|Hungary|Tunisia|Argentina|Russia|Australia|Bulgaria|Portugal|Spain|Romania|Norway|Belgium|Israel|Italy|Finland|Ukraine|United States|Sweden|Colombia|France|Georgia|Germany|Greece|Netherlands|Poland|India|South Korea|Peru|United Kingdom|Croatia|Turkey (Türkiye)|Denmark|Malaysia|Puerto Rico|Brazil|Guatemala|Philippines|Slovakia|Taiwan|New Zealand|Switzerland|Mexico|Panama|Serbia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,9.751733997308591,,0,1,1,0,0,0,1,1,1,1,1,1,1,1,9,1,1,0,0,3,1,,,,,0,3,1
NCT04724772,Use of Tranexamic Acid in Blepharoplasties,Comparison of Clinical Outcomes Following Upper Lid Blepharoplasty With and Without Tranexamic Acid as an Additive to Traditional Local Anesthetic.,WITHDRAWN,2020-02-20,2023-09-20,2024-07-23,INTERVENTIONAL,PHASE3,0.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,"Pain, Postoperative|Bruising",Tranexamic acid injection,DRUG,2,0,18 Years,,ALL,True,Northwestern University,OTHER,0,1,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,2,0.0,,1,1,0,1,0,0,0,0,1,0,0,0,0,0,2,0,1,0,0,1,0,2020-02-20,2023-09-20,1308.0,2020.0,1,1,0
NCT02236195,Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes,"An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma",COMPLETED,2014-10,2016-07,2017-09-01,INTERVENTIONAL,PHASE2,17.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Urothelial Carcinoma,Mocetinostat,DRUG,1,2,18 Years,,ALL,False,Mirati Therapeutics Inc.,INDUSTRY,0,14,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.8903717578961645,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT04404595,"Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers","Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects with Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers",ACTIVE_NOT_RECRUITING,2020-10-23,2035-09-01,2025-01-08,INTERVENTIONAL,PHASE1|PHASE2,110.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Gastric Cancer|Pancreatic Cancer,CT041,BIOLOGICAL,5,20,18 Years,76 Years,ALL,False,"CARsgen Therapeutics Co., Ltd.",INDUSTRY,0,16,Canada|United States,,1,1,0,0,1,1.5,1,0,0,0,2,4.709530201312334,medium,0,0,1,0,0,0,1,1,1,0,0,0,1,0,25,1,0,1,0,1,0,2020-10-23,2035-09-01,5426.0,2020.0,1,4,1
NCT00326339,Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1),"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Dose Ranging Study to Evaluate Up to Three Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate",COMPLETED,2006-08,2007-12,2009-04-20,INTERVENTIONAL,PHASE2,189.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Rheumatoid Arthritis,R788|Placebo,DRUG,1,12,18 Years,75 Years,ALL,False,Rigel Pharmaceuticals,INDUSTRY,0,38,Mexico|United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.247024072160486,medium,0,1,1,0,0,0,1,1,1,0,1,1,1,1,13,1,1,0,0,2,1,,,,,0,3,1
NCT01827839,Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster,Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster,COMPLETED,2013-06-10,2014-11-25,2018-10-18,INTERVENTIONAL,PHASE3,96.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Herpes Zoster,Herpes Zoster vaccine (GSK1437173A),BIOLOGICAL,8,4,50 Years,,ALL,True,GlaxoSmithKline,INDUSTRY,0,4,Canada|Russia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.574710978503383,medium,1,1,1,0,0,0,1,1,0,0,0,0,0,0,12,1,0,1,0,1,0,2013-06-10,2014-11-25,533.0,2013.0,0,2,0
NCT01468077,A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment,"Multicenter, Randomized, Parallel Group Study to Compare the Incidence of Tocilizumab Related Infusion Reactions in Patients With Moderate to Severe Active RA, When Infusion is Given Over 31 Minutes Compared to 1 Hour",COMPLETED,2011-11,2013-09,2015-08-17,INTERVENTIONAL,PHASE2,47.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Rheumatoid Arthritis,Tocilizumab,DRUG,1,15,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,8,Iceland|Denmark,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.871201010907891,small,1,1,1,0,1,0,1,1,0,0,1,0,1,1,16,1,1,0,0,1,0,,,,,0,2,0
NCT02039401,Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis,"A Phase I/II, Open Label Study to Assess the Safety and Tolerability of VM202 in Subjects With Amyotrophic Lateral Sclerosis",COMPLETED,2014-03-11,2024-03-06,2025-10-06,INTERVENTIONAL,PHASE1|PHASE2,18.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Amyotrophic Lateral Sclerosis,VM202,BIOLOGICAL,1,3,21 Years,75 Years,ALL,False,"Helixmith Co., Ltd.",INDUSTRY,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.9444389791664403,small,1,1,1,0,0,0,0,0,1,0,0,0,1,0,4,1,0,1,0,1,0,2014-03-11,2024-03-06,3648.0,2014.0,0,1,0
NCT02522481,Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141,A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason™/SonoVue® in Subjects Undergoing Pharmacologic Stress Echocardiography With Dobutamine for the Diagnosis of Coronary Artery Disease,COMPLETED,2015-09-24,2018-02-25,2021-06-11,INTERVENTIONAL,PHASE3,175.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Coronary Artery Disease,Lumason,DRUG,2,2,18 Years,,ALL,False,"Bracco Diagnostics, Inc",INDUSTRY,0,17,Germany|Canada|Italy|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.170483995038151,medium,0,1,1,0,0,0,1,1,1,1,0,0,0,0,4,1,1,0,0,1,0,2015-09-24,2018-02-25,885.0,2015.0,1,1,0
NCT01260519,Effect of Heparin on Femoral Arterial Sheaths Thrombosis During Diagnostic Coronary Angiography,Efficacy of a Single Dose Intravenous Heparin During Diagnostic Angiography in Reducing Sheath-clot Formation: A Randomized Controlled Trial,COMPLETED,2008-07,2010-10,2010-12-15,INTERVENTIONAL,PHASE3,304.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Diagnostic Coronary Angiography,Heparin,DRUG,1,0,18 Years,80 Years,ALL,False,"Prince Sultan Cardiac Center, Adult Cardiology Department.",OTHER,0,1,Saudi Arabia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.720311776607412,large,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,,,,,0,0,0
NCT02583919,"Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes","Double Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly for 26 Weeks in Patients With Type 2 Diabetes Being Treated With Metformin",COMPLETED,2015-09,2017-05-11,2018-06-25,INTERVENTIONAL,PHASE2,79.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes,ISIS-GCGRRx- Dose Level 1|ISIS-GCGRRx- Dose Level 2|Placebo,DRUG,1,1,18 Years,75 Years,ALL,False,"Ionis Pharmaceuticals, Inc.",INDUSTRY,0,19,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.382026634673881,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,3,1,,2017-05-11,,,0,1,0
NCT04068519,"Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody","Phase I/II Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activities of Anti-PD-1 Monoclonal Antibody BGB-A317 in Chinese Patients With Advanced Solid Tumors",COMPLETED,2016-12-28,2020-05-31,2024-10-26,INTERVENTIONAL,PHASE1|PHASE2,300.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Solid Tumors,Tislelizumab,DRUG,6,11,18 Years,,ALL,False,BeiGene,INDUSTRY,0,12,China,1.0,1,1,0,0,1,1.5,1,0,0,0,1,5.707110264748875,large,0,1,1,0,0,0,1,0,0,0,0,0,1,0,17,1,1,0,0,1,0,2016-12-28,2020-05-31,1250.0,2016.0,1,2,0
NCT00286130,Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer,"A Randomised, Open-label Phase II Study Evaluating the Efficacy and Safety of Folfox6 + Cetuximab as First-line Therapy in Patients With Metastatic Colorectal Cancer",COMPLETED,2005-07,2007-10,2012-05-01,INTERVENTIONAL,PHASE2,150.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Colorectal Cancer,"Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan|FOLFOX 6|FOLFIRI",DRUG,1,4,18 Years,,ALL,False,Central European Cooperative Oncology Group,OTHER,0,27,Cyprus|Croatia|Turkey (Türkiye)|Bosnia and Herzegovina|Bulgaria|Slovakia|Austria|Portugal|Slovenia|Czechia|Hungary|Romania|Israel,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.017279836814924,medium,0,1,0,1,0,0,1,1,0,0,1,0,1,1,5,1,1,0,0,3,1,,,,,0,2,0
NCT02093130,Study of Pomegranate Juice on Memory in Older Adults,"Twelve-Month, Double-blind, Placebo-Controlled Study of Pomegranate Juice in Normal Aging",COMPLETED,2014-01,2018-05,2020-03-02,INTERVENTIONAL,PHASE2,212.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Impact of Pomegranate Juice on Memory in Older Adults,Pomegranate Juice|Placebo,DIETARY_SUPPLEMENT,1,1,50 Years,75 Years,ALL,True,"University of California, Los Angeles",OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.3612921657094255,large,0,0,0,1,0,1,0,0,1,0,1,1,1,1,2,1,0,0,0,2,1,,,,,0,1,0
NCT02431728,The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program,"The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program: A Randomized, Double Blind, Placebo, Controlled Trial",COMPLETED,2015-05,2016-01,2016-08-08,INTERVENTIONAL,PHASE1|PHASE2,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Substance Withdrawal Syndrome,Melatonin|Matched Placebo,DIETARY_SUPPLEMENT,4,2,18 Years,,MALE,False,Duquesne University,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.2626798770413155,medium,1,1,0,1,0,0,0,0,1,0,1,1,1,1,6,1,0,0,0,2,1,,,,,0,3,1
NCT00499265,Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery,"A Randomized, Open Label, Phase II Proof of Concept Study of WX-671 in Combination With Gemcitabine vs.Gemcitabine Alone in Patients With Locally Advanced, Non Resectable Pancreatic Cancer in Order to Evaluate the Anti-Tumor Activity of the Combination Therapy",COMPLETED,2007-04,2010-05,2012-03-29,INTERVENTIONAL,PHASE2,95.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Pancreatic Cancer,gemcitabine hydrochloride|Serine Proteinase Inhibitor WX-671|Serine Proteinase Inhibitor WX-671,DRUG,2,0,18 Years,,ALL,False,Heidelberg Pharma AG,INDUSTRY,0,39,Russia|Ukraine|Hungary|Spain|Germany|Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.564348191467836,medium,1,1,1,0,0,0,1,1,0,1,1,0,1,1,2,0,1,0,0,3,1,,,,,0,2,0
NCT01832467,Cetuximab Rechallenge Study,A Pilot Case-control Study of Second or Third Line Treatment With Cetuximab-containing Chemotherapy in Patients With Metastatic Colorectal Cancer Who Were Previously Treated With Cetuximab-based Chemotherapy,COMPLETED,2013-04-24,2020-04-07,2020-06-18,INTERVENTIONAL,PHASE2,17.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Colorectal Cancer,cetuximab-containing chemotherapy,DRUG,1,3,18 Years,,ALL,False,Chinese University of Hong Kong,OTHER,0,1,Hong Kong,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.8903717578961645,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,4,1,1,0,0,1,0,2013-04-24,2020-04-07,2540.0,2013.0,0,0,0
NCT01251536,Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer,A Two Arm Phase II Study of FOLFIRI in Combination With Standard or Escalating Dose of Cetuximab as First Line Treatment of K-Ras Wild Type Metastatic Colorectal Cancer: Everest 2,COMPLETED,2010-12,2019-07,2019-10-11,INTERVENTIONAL,PHASE2,108.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Cancer,Dose escalation of cetuximab|Standard first line treatment with cetuximab + Folfiri,DRUG,1,17,18 Years,,ALL,False,Universitaire Ziekenhuizen KU Leuven,OTHER,1,30,Austria|France|Spain|Hungary|Belgium,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.6913478822291435,medium,0,1,0,1,0,1,1,1,0,1,0,0,1,1,18,1,1,0,0,2,1,,,,,0,3,1
NCT02261207,Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor,Phase II Study on Axitinib in Advanced VEGFR and/or PDGFR Solitary Fibrous Tumor,COMPLETED,2014-11,2018-03,2021-09-28,INTERVENTIONAL,PHASE2,17.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Solitary Fibrous Tumor,Axitinib,DRUG,1,1,18 Years,,ALL,False,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",OTHER,0,1,Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.8903717578961645,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT04811092,Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13),"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients",COMPLETED,2022-03-18,2025-04-03,2025-05-13,INTERVENTIONAL,PHASE3,321.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Pulmonary Arterial Hypertension,Sotatercept|Placebo,DRUG|OTHER,1,13,18 Years,,ALL,False,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",INDUSTRY,0,152,Canada|Austria|Argentina|Australia|Portugal|Spain|Belgium|Italy|Israel|United States|Sweden|Colombia|France|Czechia|Germany|Netherlands|Poland|Greece|South Korea|United Kingdom|Croatia|Denmark|Brazil|Taiwan|New Zealand|Switzerland|Serbia,1.0,0,0,1,0,0,3.0,0,0,0,1,1,5.7745515455444085,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,14,1,1,0,0,2,1,2022-03-18,2025-04-03,1112.0,2022.0,1,3,1
NCT00423592,Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension,"A Phase 2, Open-label, Multicenter Study Evaluating Ambrisentan in Subjects With Pulmonary Arterial Hypertension Who Have Previously Discontinued Endothelin Receptor Antagonist Therapy Due to Serum Aminotransferase Abnormalities",COMPLETED,2005-05,2009-03,2013-06-17,INTERVENTIONAL,PHASE2,36.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Pulmonary Hypertension,ambrisentan,DRUG,1,15,12 Years,75 Years,ALL,False,Gilead Sciences,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,1,1,3.6109179126442243,small,1,1,1,0,1,0,0,0,0,0,0,0,1,0,16,1,1,0,0,1,0,,,,,0,1,0
NCT03482050,"A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)","A Phase I/IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Theraputic Effects of Transplantation of Astrocytes Derived From Human Embryonic Stem Cells (hESC), in Patients With Amyotrophic Lateral Sclerosis (ALS)",COMPLETED,2018-04-12,2020-06-22,2021-01-15,INTERVENTIONAL,PHASE1|PHASE2,16.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,ALS (Amyotrophic Lateral Sclerosis),AstroRx,BIOLOGICAL,1,5,18 Years,70 Years,ALL,False,Kadimastem,INDUSTRY,0,1,Israel,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.833213344056216,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,6,1,0,1,0,1,0,2018-04-12,2020-06-22,802.0,2018.0,1,2,0
NCT00364091,Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis,"A Multi-Center, Randomized, Double-Masked Parallel Group Study Evaluating the Efficacy, Safety, and QOL of R89674 0.25% Ophthalmic Solution Compared to Vehicle or an Active Control in a Modified Model of Environmental Seasonal Allergic Conjunctivitis",COMPLETED,2006-08,,2011-09-27,INTERVENTIONAL,PHASE3,365.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Allergic Conjunctivitis,R89674 0.025% ophthalmic solution,DRUG,1,1,10 Years,,ALL,False,Vistakon Pharmaceuticals,INDUSTRY,0,6,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.902633333401366,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT00572091,Aachen Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Device to Reduce Mitral Regurgitation,"An Open-Label, Single-Arm Pilot Study of the Safety and Efficacy of the Percutaneous Transvenous Mitral Annuloplasty Device Used to Reduce Mitral Regurgitation",COMPLETED,2007-02,2008-11,2008-11-06,INTERVENTIONAL,PHASE1|PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Heart Failure|Mitral Regurgitation,PTMA Implant,DEVICE,1,2,50 Years,,ALL,False,Viacor,INDUSTRY,0,1,Germany,1.0,1,1,0,0,1,1.5,0,0,0,1,2,1.6094379124341003,small,1,1,1,0,0,0,0,0,0,1,0,0,1,0,3,1,0,0,1,1,0,,,,,0,2,0
NCT00040391,A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer,"A Phase II, Randomized, Open-label, Controlled, Dose-elevation, Multicenter Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer",TERMINATED,2002-06,,2016-12-01,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Colorectal Neoplasms|Diarrhea,Investigational drug|Irinotecan|5-fluorouracil|Leucovorin,DRUG,0,0,18 Years,,ALL,False,Celgene Corporation,INDUSTRY,1,28,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,0.0,,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,4,1,,,,,0,2,0
NCT03308591,Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients,"Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients, A Multicenter, Prospective and Randomized Controlled Trial",COMPLETED,2016-01-11,2022-02-01,2024-10-31,INTERVENTIONAL,PHASE3,774.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Uterine Cervical Neoplasm|Cervical Cancer|Uterine Cervical Cancer,NACT|RT+PLND|Adjuvant chemotherapy,DRUG|PROCEDURE,1,1,,65 Years,FEMALE,False,Huazhong University of Science and Technology,OTHER,0,1,China,1.0,0,0,1,0,0,3.0,1,0,0,0,3,6.652863029353347,xlarge,0,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,3,1,2016-01-11,2022-02-01,2213.0,2016.0,1,2,0
NCT01869491,Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study,"A Multi-centre, Randomised, Double-blind, Two Arm, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Double Action Chewable Tablets in Patients With Gastro-esophageal Reflux Disease",COMPLETED,2013-06-05,2014-05,2025-05-08,INTERVENTIONAL,PHASE3,1107.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Gastroesophageal Reflux Disease|Dyspepsia,Compound Sodium Alginate Double Action Chewable Tablets|Matching placebo tablets,DRUG,1,6,18 Years,65 Years,ALL,False,Reckitt Benckiser Healthcare (UK) Limited,INDUSTRY,0,2,China,1.0,0,0,1,0,0,3.0,0,0,0,0,2,7.010311867307229,xlarge,0,1,1,0,0,0,1,0,0,0,1,1,1,1,7,1,1,0,0,2,1,2013-06-05,,,2013.0,0,3,1
NCT01621191,"An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057)",An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Fibromyalgia,COMPLETED,2012-06,2014-02,2015-02-11,INTERVENTIONAL,PHASE3,149.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Fibromyalgia,Duloxetine,DRUG,1,7,20 Years,74 Years,ALL,False,Eli Lilly and Company,INDUSTRY,1,1,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.0106352940962555,medium,0,1,1,0,1,1,0,0,0,0,0,0,1,0,8,1,1,0,0,1,0,,,,,0,1,0
NCT00001191,The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid,The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid,COMPLETED,1983-02-03,2007-12-10,2017-07-02,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Gastrinoma|Zollinger Ellison Syndrome,Pantoprazole|Omeprazole,DRUG,0,0,18 Years,,ALL,False,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,0.0,,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,2,1,1983-02-03,2007-12-10,9076.0,1983.0,0,2,0
NCT00608491,Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study),CARdiorenal REScue Study in Acute Decompensated Heart Failure: CARRESS,COMPLETED,2008-03,2012-06,2013-06-24,INTERVENTIONAL,PHASE3,188.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Heart Failure,Stepped pharmacologic care|Ultrafiltration,DRUG|DEVICE,2,68,18 Years,,ALL,False,Duke University,OTHER,2,9,Canada|United States,1.0,0,0,1,0,0,3.0,0,0,0,1,1,5.241747015059643,medium,0,1,0,1,0,1,1,1,1,0,1,0,1,1,70,1,1,0,1,2,1,,,,,0,3,1
NCT01266018,Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer,Phase II Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer,TERMINATED,2011-01,2014-01,2022-10-25,INTERVENTIONAL,PHASE2,22.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Small Cell Lung Cancer,ADI-PEG 20 (Arginine deiminase pegylated),DRUG,1,4,18 Years,,ALL,False,Ludwig Institute for Cancer Research,OTHER,10,8,United Kingdom|United States|Taiwan|Germany|Belgium,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.1354942159291497,small,1,1,0,1,0,1,1,1,1,1,0,0,1,0,5,1,1,0,0,1,0,,,,,0,1,0
NCT02426918,Study of Debio 1450 for Bacterial Skin Infections,"A Phase 2, Randomized, Double-Blind, Multicenter Study of Safety, Tolerability, and Efficacy of Debio 1450 vs Vancomycin (IV)/Linezolid (Oral) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococcus Sensitive or Resistant to Methicillin",COMPLETED,2015-05,2016-09,2019-11-13,INTERVENTIONAL,PHASE2,330.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Bacterial Infections,Debio 1450 IV|Debio 1450 Oral|Linezolid|Debio 1450 Oral Placebo|Linezolid Placebo|Vancomycin IV,DRUG,1,4,18 Years,70 Years,ALL,False,Debiopharm International SA,INDUSTRY,0,22,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.802118375377063,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,5,1,1,0,0,6,1,,,,,0,1,0
NCT00004690,Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis,,COMPLETED,1996-09,1998-09,2015-03-25,INTERVENTIONAL,PHASE3,90.0,,RANDOMIZED,,TREATMENT,DOUBLE,Ichthyosis,monolaurin cream,DRUG,0,0,2 Years,,ALL,False,Cellegy Pharmaceuticals,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.51085950651685,medium,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT02393690,Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer,Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers,COMPLETED,2015-05-04,2023-12-31,2024-07-26,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Carcinoma|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7,Iodine I-131|Placebo Administration|Selumetinib,DRUG|OTHER|RADIATION,1,4,18 Years,,ALL,False,Academic and Community Cancer Research United,OTHER,1,11,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,11,4.110873864173311,medium,1,1,0,1,0,1,1,0,1,0,1,1,1,1,5,1,1,0,0,3,1,2015-05-04,2023-12-31,3163.0,2015.0,1,2,0
NCT00219297,Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer,"An Open-label, Multi-center, Phase II Study to Evaluate the Activity of Patupilone (EPO906), in the Treatment of Recurrent or Progressive Brain Metastases in Patients With Non-small Cell Lung Cancer.",COMPLETED,2005-11-16,2010-06-24,2021-02-21,INTERVENTIONAL,PHASE2,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Brain Metastasis|Non-small Cell Lung Cancer,Patupilone,DRUG,1,2,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,12,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.9318256327243257,small,1,1,1,0,1,0,1,0,1,0,0,0,1,0,3,1,1,0,0,1,0,2005-11-16,2010-06-24,1681.0,2005.0,0,1,0
NCT01543490,Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects,"A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (0.1% Dexamethasone) Compared to Vehicle in the Treatment of Subjects With Blepharitis",COMPLETED,2018-03-30,2020-02-04,2021-11-19,INTERVENTIONAL,PHASE3,558.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Active, Symptomatic Blepharitis",ISV-305|Vehicle,DRUG|OTHER,1,1,1 Year,,ALL,False,Sun Pharmaceutical Industries Limited,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.326149473155099,xlarge,0,1,1,0,0,0,0,0,1,0,1,1,1,1,2,1,1,0,0,2,1,2018-03-30,2020-02-04,676.0,2018.0,1,1,0
NCT04465097,Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer,Neoadjuvant Tucidinostat and Exemestane in Estrogen Receptor-Positive Early Breast Cancer （NeoTEE）,COMPLETED,2020-07-08,2023-10-01,2023-10-17,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,Tucidinostat|Exemestane|Ovarian function suppression,DRUG,1,4,18 Years,,FEMALE,False,"First Affiliated Hospital, Sun Yat-Sen University",OTHER,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,5,1,1,0,0,3,1,2020-07-08,2023-10-01,1180.0,2020.0,1,1,0
NCT02608697,A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia",COMPLETED,2015-10,2016-06,2017-06-20,INTERVENTIONAL,PHASE2,153.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hypercholesterolemia,CAT-2054|Placebo|Atorvastatin,DRUG,1,2,18 Years,74 Years,ALL,False,Catabasis Pharmaceuticals,INDUSTRY,0,34,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.0369526024136295,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,3,1,1,0,0,3,1,,,,,0,1,0
NCT01745510,Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm Neonates,"Efficacy of Enteral Administration of the Docosahexaenoic Acid on Necrotizing Enterocolitis, Cytokines and Hospital Stay in Preterm Neonates",COMPLETED,2012-10,2017-10,2021-03-24,INTERVENTIONAL,PHASE1|PHASE2,225.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Necrotizing Enterocolitis,Docosahexaenoic acid (DHA)|Placebo,DIETARY_SUPPLEMENT,1,7,60 Minutes,2 Weeks,ALL,False,"Coordinación de Investigación en Salud, Mexico",OTHER_GOV,1,1,Mexico,1.0,1,1,0,0,1,1.5,0,1,0,0,1,5.420534999272286,large,0,1,0,1,0,1,0,0,0,0,1,1,0,1,8,1,0,0,0,2,1,,,,,0,3,1
NCT02558010,Perioperative Methadone Use to Decrease Opioid Requirement in Pediatric Spinal Fusion Patients,Perioperative Methadone Use to Decrease Opioid Requirement in Pediatric Spinal Fusion Patients,COMPLETED,2016-02-01,2023-01-01,2023-11-18,INTERVENTIONAL,PHASE3,58.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,Scoliosis|Pain,Methadone|Normal Saline|Morphine,DRUG|OTHER,1,0,10 Years,18 Years,ALL,False,Medical College of Wisconsin,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.07753744390572,medium,1,1,0,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,3,1,2016-02-01,2023-01-01,2526.0,2016.0,1,2,0
NCT01614210,Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance,Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance,COMPLETED,2012-08,2016-11,2018-08-01,INTERVENTIONAL,PHASE2,52.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer,Tamoxifen|Breast cancer surgery,DRUG|PROCEDURE,1,3,18 Years,,ALL,False,University of Utah,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.970291913552122,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,4,1,1,0,0,2,1,,,,,0,1,0
NCT00489710,Talabostat in Treating Patients With Metastatic Kidney Cancer,A Phase II Study of Talabostat in Patients With Metastatic Renal Cell Carcinoma,WITHDRAWN,2006-12,2007-05-30,2023-08-22,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Kidney Cancer,talabostat mesylate|enzyme inhibitor therapy|flow cytometry|laboratory biomarker analysis|non-specific immune-modulator therapy,DRUG|DIAGNOSTIC_TEST|BIOLOGICAL,1,2,19 Years,120 Years,ALL,False,University of Nebraska,OTHER,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,3,1,1,1,0,5,1,,2007-05-30,,,0,1,0
NCT05599360,Vyxeos for Induction of Low- or Intermediate-risk.,"Vyxeos for Induction of Newly Diagnosed Low- or Intermediate-risk AML Patients, Age 18-70. A Pilot Study",ACTIVE_NOT_RECRUITING,2022-08-07,2028-09-07,2024-12-02,INTERVENTIONAL,PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Leukemia, Myeloid, Acute",Vyxeos|Mylotarg,DRUG,2,4,18 Years,70 Years,ALL,False,Shaare Zedek Medical Center,OTHER,0,1,Israel,,0,1,0,0,0,2.0,1,0,0,0,1,3.044522437723423,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,2,1,2022-08-07,2028-09-07,2223.0,2022.0,1,2,0
NCT06609460,Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications,"A Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter Dose Ranging Study to Evaluate Efficacy and Safety of CD388, a Novel Long-acting Antiviral Conjugate, for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications",COMPLETED,2024-09-20,2025-09-19,2025-10-20,INTERVENTIONAL,PHASE2,5071.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Influenza,CD388 Injection|Placebo,COMBINATION_PRODUCT,2,14,18 Years,63 Years,ALL,True,Cidara Therapeutics Inc.,INDUSTRY,0,57,United Kingdom|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,8.531490496117062,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,0,1,16,1,0,0,0,2,1,2024-09-20,2025-09-19,364.0,2024.0,1,3,1
NCT00621920,Efficacy Study of Bowel Preparation Before Colonoscopy,Efficacy Study of Bowel Preparation Before Colonoscopy,COMPLETED,2008-01,2008-04,2012-02-10,INTERVENTIONAL,PHASE2,72.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Bowel Cleansing Prior to Colonoscopy,FM-601,DRUG,1,0,50 Years,,ALL,True,"C.B. Fleet Company, Inc.",INDUSTRY,0,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.290459441148391,medium,1,1,1,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT00121420,Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases,Phase II Trial of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases,TERMINATED,,,2014-05-09,INTERVENTIONAL,PHASE2,45.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Neoplasm Metastasis|Brain Neoplasms,Motexafin gadolinium,DRUG,1,3,18 Years,,ALL,False,Pharmacyclics LLC.,INDUSTRY,0,12,Canada|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,3.828641396489095,small,1,0,1,0,0,0,1,1,1,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,2,0
NCT03756220,Ascorbic Acid and Thiamine Effect in Septic Shock,"Combination Therapy of Vitamin C and Thiamine for Septic Shock: Multi-center, Double-blinded, Randomized, Controlled Study",COMPLETED,2018-12-01,2020-04-14,2020-10-28,INTERVENTIONAL,PHASE2,116.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Septic Shock|Sepsis,Combination therapy of vitamin C and thiamine|Normal saline solution,DRUG,1,16,19 Years,89 Years,ALL,False,Tae Gun Shin,OTHER,1,6,South Korea,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.762173934797756,medium,0,1,0,1,0,1,1,0,0,0,1,1,1,1,17,1,1,0,0,2,1,2018-12-01,2020-04-14,500.0,2018.0,1,3,1
NCT02477020,A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia",COMPLETED,2015-07-01,2016-07-27,2017-09-29,INTERVENTIONAL,PHASE2,164.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia,TAK-063 20 mg|Placebo,DRUG,1,11,18 Years,65 Years,ALL,False,Takeda,INDUSTRY,0,15,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,5.10594547390058,medium,0,1,1,0,1,0,1,0,1,0,1,1,1,1,12,1,1,0,0,2,1,2015-07-01,2016-07-27,392.0,2015.0,1,2,0
NCT00908024,Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors,A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors,TERMINATED,2009-10,2012-12,2013-06-18,INTERVENTIONAL,PHASE1|PHASE2,54.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Colorectal Cancer|Head and Neck Cancer|Neoplasm Metastasis,BMS-754807|cetuximab (Erbitux®),DRUG,1,4,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,5,Canada|United States,0.0,1,1,0,0,1,1.5,1,0,0,0,3,4.007333185232471,medium,1,1,1,0,1,0,1,1,1,0,0,0,1,0,5,1,1,0,0,2,1,,,,,0,4,1
NCT04774224,Baricitinib in New-onset Type 1 Diabetes,"A Phase 2, Randomised, Placebo Controlled Study Investigating the Efficacy of Baricitinib in New Onset Type 1 Diabetes Mellitus",COMPLETED,2020-10-30,2024-05-06,2024-12-03,INTERVENTIONAL,PHASE2,91.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 1 Diabetes,Baricitinib|Placebo,DRUG,1,7,10 Years,30 Years,ALL,False,St Vincent's Institute of Medical Research,OTHER,2,4,Australia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.5217885770490405,medium,1,1,0,1,0,1,1,0,0,0,1,1,1,1,8,1,1,0,0,2,1,2020-10-30,2024-05-06,1284.0,2020.0,1,2,0
NCT00653523,Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457),"Open-label, Long-term Study of Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors",COMPLETED,2007-12-01,2009-06-01,2024-05-21,INTERVENTIONAL,PHASE3,151.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hypercholesterolemia,Ezetimibe|Simvastatin,DRUG,1,0,20 Years,,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.0238805208462765,medium,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,2,1,2007-12-01,2009-06-01,548.0,2007.0,0,1,0
NCT04597359,To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring,A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers,ACTIVE_NOT_RECRUITING,2021-10-05,2032-12-31,2026-01-28,INTERVENTIONAL,PHASE2,360.0,ESTIMATED,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Prostate Carcinoma,Placebo Administration|Quality-of-Life Assessment|Questionnaire Administration|Sinecatechins,DRUG|OTHER,1,9,21 Years,,ALL,False,ECOG-ACRIN Cancer Research Group,NETWORK,1,353,Puerto Rico|Guam|United States,,0,1,0,0,0,2.0,1,0,0,0,1,5.8888779583328805,large,0,0,0,0,0,1,1,1,1,0,1,1,0,1,10,1,1,0,0,4,1,2021-10-05,2032-12-31,4105.0,2021.0,1,3,1
NCT00298259,Trial of Operative Fixation of Fractured Ribs in Patients With Flail Chest,Prospective Randomised Trial of Operative Fixation of Fractured Ribs in Patients With Flail Chest,COMPLETED,2007-01,2012-03,2012-12-11,INTERVENTIONAL,PHASE2,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Flail Chest|Ventilation,operative fixation of fractured ribs,PROCEDURE,2,0,18 Years,75 Years,ALL,False,The Alfred,OTHER,0,1,Australia,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.8918202981106265,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,2,0,0,0,0,1,0,,,,,0,1,0
NCT00506779,Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma,A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC),TERMINATED,2003-12-29,2015-04,2020-11-18,INTERVENTIONAL,PHASE1|PHASE2,17.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Uterine Cancer,Imatinib Mesylate|Paclitaxel,DRUG,1,2,,,FEMALE,False,M.D. Anderson Cancer Center,OTHER,0,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,2.8903717578961645,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,3,1,1,0,0,2,1,2003-12-29,,,2003.0,0,2,0
NCT00285103,SPC2996 in Chronic Lymphocytic Leukaemia,"An Open-labelled, International, Multicenter, Dose Escalating, Phase I/II Study of SPC2996,an LNA Antisense Molecule Against Bcl-2, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia",COMPLETED,2005-06,2007-12,2011-02-02,INTERVENTIONAL,PHASE1|PHASE2,46.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Chronic Lymphocytic Leukemia,SPC2996,DRUG,1,1,18 Years,,ALL,False,Santaris Pharma A/S,INDUSTRY,0,12,United Kingdom|France|Denmark|United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.8501476017100584,small,1,0,1,0,0,0,1,1,1,1,0,0,1,0,2,1,1,0,0,1,0,,,,,0,2,0
NCT00514527,A Study for Patients With Complicated Skin and Skin Structure Infections,Nuvocid® (Oritavancin) at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (SIMPLIFI),COMPLETED,2007-08,2008-05,2008-08-14,INTERVENTIONAL,PHASE2,294.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Staphylococcal Skin Infections|Wounds and Injuries|Abscess|Cellulitis|Streptococcal Infections,oritavancin,DRUG,1,1,18 Years,,ALL,False,Targanta Therapeutics Corporation,INDUSTRY,0,66,Ukraine|Australia|United States|Romania|Italy|India,1.0,0,1,0,0,0,2.0,0,0,0,0,5,5.68697535633982,large,0,0,1,0,0,0,1,1,1,1,1,1,1,1,2,1,1,0,0,1,0,,,,,0,2,0
NCT05132127,Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan,"An Open-label Study for Sutimlimab in Participants With Cold Agglutinin Disease (CAD) Who Have Completed the CARDINAL Study (BIVV009-03/EFC16215, Part B) or CADENZA Study (BIVV009-04/EFC16216, Part B) in Japan",COMPLETED,2021-11-11,2022-11-15,2025-09-15,INTERVENTIONAL,PHASE3,7.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cold Agglutinin Disease,sutimlimab,DRUG,2,0,20 Years,,ALL,False,Sanofi,INDUSTRY,0,5,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,2.0794415416798357,small,1,1,1,0,1,0,1,0,0,0,0,0,1,0,2,0,1,0,0,1,0,2021-11-11,2022-11-15,369.0,2021.0,1,0,0
NCT01304927,Vitamin D Supplementation and Male Infertility: The CBG-study a Randomized Clinical Trial,Vitamin D Supplementation and Male Infertility: The Copenhagen Bone-Gonadal Study a Double Blinded Randomized Clinical Trial,COMPLETED,2011-02,2016-05,2016-06-08,INTERVENTIONAL,PHASE2|PHASE3,307.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Male Infertility,Cholecalciferol and calcium|Placebo,DRUG|OTHER,6,39,18 Years,,MALE,False,"Rigshospitalet, Denmark",OTHER,0,1,Denmark,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.730099782973574,large,0,1,0,1,0,0,0,0,0,0,1,1,1,1,45,1,1,0,0,2,1,,,,,0,3,1
NCT00114361,48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection,Peginterferon Alfa-2a and Ribavirin Combination Therapy in Patients With HBeAg-negative Chronic HBV Infection (PARC Study),COMPLETED,2005-03,2010-04,2010-06-22,INTERVENTIONAL,PHASE3,138.0,ACTUAL,RANDOMIZED,FACTORIAL,,DOUBLE,Hepatitis B,Ribavirin|Peginterferon alpha 2a,DRUG,1,5,18 Years,70 Years,ALL,False,Foundation for Liver Research,OTHER,0,1,Netherlands,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.9344739331306915,medium,0,1,0,1,0,0,0,0,0,0,1,1,0,0,6,1,1,0,0,2,1,,,,,0,2,0
NCT06730061,A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC),"A Phase III, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Elafibranor 80 mg in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)",ACTIVE_NOT_RECRUITING,2025-01-16,2032-04-08,2026-02-02,INTERVENTIONAL,PHASE3,18.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Primary Biliary Cholangitis,Elafibranor,DRUG,1,43,18 Years,75 Years,ALL,False,Ipsen,INDUSTRY,0,16,Japan,,0,0,1,0,0,3.0,0,0,0,0,1,2.9444389791664403,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,44,1,1,0,0,1,0,2025-01-16,2032-04-08,2639.0,2025.0,1,1,0
NCT00490061,Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy,A Multi-Institutional Phase II Study of Radiation and GW572016 (Lapatinib) for Patients With Stage III-IV Head and Neck Cancer Who Cannot Tolerate Concurrent Chemoradiotherapy.,TERMINATED,2007-07,2016-06,2017-03-06,INTERVENTIONAL,PHASE2,17.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Head and Neck Cancer|Carcinoma, Squamous Cell|Head and Neck Cancers","Lapatinib|Radiotherapy (radiation)|G.E. Healthcare 1.5T MR, systems revision 12.0 M5|DCE-MRI",DRUG|PROCEDURE|DEVICE,1,1,18 Years,,ALL,False,Quynh-Thu Le,OTHER,1,5,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,3,2.8903717578961645,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,2,1,1,0,1,4,1,,,,,0,2,0
NCT02911142,Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma,Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma,ACTIVE_NOT_RECRUITING,2017-07-03,2027-10-01,2025-07-28,INTERVENTIONAL,PHASE1|PHASE2,17.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,Primary Effusion Lymphoma|B-Cell Neoplasm,"Lenalidomide|Rituximab|Prednisone|Etoposide|Doxorubicin|Vincristine|Cyclophosphamide|CT of neck, chest, abdomen and pelvis|18FDG-PET scan|MRI Brain|Bone marrow biopsy|EKG|Echocardiogram|Ultrasound|Bronchoscopy|Endoscopy|CXR: PA/lat/decub",DRUG|PROCEDURE|DIAGNOSTIC_TEST,3,15,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,,1,1,0,0,1,1.5,1,0,0,0,2,2.8903717578961645,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,18,1,1,0,0,17,1,2017-07-03,2027-10-01,3742.0,2017.0,1,4,1
NCT03563170,QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine,"Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy w/ Adenoviral & Yeast-based Vaccines to Induce T-cell Responses in Subjects w/ Advanced, Unresectable & Untransplantable HCC",WITHDRAWN,2018-05-25,2019-08-23,2021-03-18,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent,ETBX-011|GI-4000|haNK for infusion|avelumab|Capecitabine|Cyclophosphamide|5-Fluorouracil|Leucovorin|nab-Paclitaxel|Sorafenib|SBRT|Aldoxorubicin hydrochloride|ETBX-051|ETBX-061|GI-6207|GI-6301|Cetuximab|N-803,DRUG|PROCEDURE|BIOLOGICAL,4,9,18 Years,,ALL,False,"ImmunityBio, Inc.",INDUSTRY,0,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,2,0.0,,1,1,1,0,0,0,0,0,1,0,1,0,1,1,13,1,1,1,0,18,1,2018-05-25,2019-08-23,455.0,2018.0,1,4,1
NCT03060070,Ketamine Versus Dexmedetomidine With Local Anesthetic in TAP Block,Comparison of the Analgesic Effect of Ketamine Versus Dexmedetomidine Added to Local Anesthetic in TAP Block for Lower Abdominal Cancer Surgery,COMPLETED,2017-03-10,2017-07-01,2017-07-05,INTERVENTIONAL,PHASE2|PHASE3,90.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Postoperative Analgesia|Lower Abdominal Cancer,Ketamine|dexmedetomidine|control group,DRUG,1,0,18 Years,65 Years,ALL,False,Assiut University,OTHER,1,1,Egypt,1.0,0,1,1,0,1,2.5,1,0,0,0,2,4.51085950651685,medium,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,0,0,3,1,2017-03-10,2017-07-01,113.0,2017.0,1,3,1
NCT01906073,Nasal Fentanyl for Chronic Cancer Pain,"An Open Label, Cross-over, Randomized Controlled Multicenter Phase III Study Comparing Standard Oral SR-morphine by the Clock Medications With Self-controlled Nasal Fentanyl for Chronic Cancer Pain Requiring Opioids",WITHDRAWN,2017-01,2020-12,2020-12-10,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Cancer|Pain,intranasal fentanyl spray|slow release morphine,DRUG,1,3,18 Years,,ALL,False,Norwegian University of Science and Technology,OTHER,7,0,,0.0,0,0,1,0,0,3.0,1,0,0,0,2,0.0,,1,1,0,1,0,1,0,0,0,0,1,0,1,0,4,1,1,0,0,2,1,,,,,0,2,0
NCT03891173,A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma,"A Phase II, Open-Label, Randomized Study Immunoconjugate L-DOS47 in Combination With Vinorelbine/Cisplatin Versus Vinorelbine/Cisplatin Alone in Patients With Lung Adenocarcinoma",TERMINATED,2019-02-19,2020-05-22,2022-08-12,INTERVENTIONAL,PHASE2,9.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Lung Adenocarcinoma,L-DOS47|Cisplatin|Vinorelbine,DRUG,1,3,18 Years,,ALL,False,Helix BioPharma Corporation,INDUSTRY,1,4,Poland|Ukraine,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.302585092994046,small,1,1,1,0,0,1,1,1,0,0,1,0,1,1,4,1,1,0,0,3,1,2019-02-19,2020-05-22,458.0,2019.0,1,2,0
NCT00261573,A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia,The Safety and Efficacy of Galantamine in the Treatment of Vascular and Mixed Dementia,COMPLETED,1998-12,2000-12,2011-05-18,INTERVENTIONAL,PHASE3,593.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Alzheimer Disease|Vascular Dementia,galantamine hydrobromide,DRUG,1,1,40 Years,,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,1,0,2,6.386879319362645,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,1,0
NCT00498173,Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism,"Targeted Pharmacologic Interventions for Autism: A Double-Blind, Placebo-Controlled Trial of Atomoxetine in Children and Adolescents With Autism",COMPLETED,2007-07,2015-10,2025-11-14,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,TRIPLE,Autism,Atomoxetine|Placebo,DRUG,1,14,5 Years,15 Years,ALL,False,Massachusetts General Hospital,OTHER,1,2,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,1,1,0,1,0,1,1,1,0,15,1,1,0,0,2,1,,,,,0,2,0
NCT02943473,Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients,A Phase 2 Study of the Effect of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib on Disease Response in Patients With High Risk Smoldering Multiple Myeloma,TERMINATED,2017-05-18,2019-09-10,2020-12-16,INTERVENTIONAL,PHASE2,9.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,High Risk Smoldering Multiple Myeloma,Ibrutinib,DRUG,1,10,18 Years,,ALL,False,Icahn School of Medicine at Mount Sinai,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.302585092994046,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,11,1,1,0,0,1,0,2017-05-18,2019-09-10,845.0,2017.0,1,1,0
NCT01626573,"A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis","A Double- Blind, Placebo Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis",COMPLETED,2012-03,2013-10,2019-03-12,INTERVENTIONAL,PHASE2,106.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Rheumatoid Arthritis,Itacitinib|Itacitinib Placebo,DRUG,2,1,18 Years,75 Years,ALL,False,Incyte Corporation,INDUSTRY,0,18,Puerto Rico|United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.672828834461906,medium,0,1,1,0,0,0,1,1,1,0,1,1,1,1,3,1,1,0,0,2,1,,,,,0,2,0
NCT00729469,Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity,"Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity, Symptoms of Vulvar and Vaginal Atrophy (VVA), Associated With Menopause: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 60 mg Dose With Placebo in Postmenopausal Women",COMPLETED,2008-07,2009-08,2018-05-18,INTERVENTIONAL,PHASE3,919.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Atrophy|Vaginal Diseases,Ospemifene 60 mg|Placebo,DRUG,8,8,40 Years,80 Years,FEMALE,False,Shionogi,INDUSTRY,2,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.824373670043086,xlarge,0,1,1,0,0,1,0,0,0,0,1,1,1,1,16,1,1,0,0,2,1,,,,,0,3,1
NCT01530269,C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma,C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma,COMPLETED,2012-04,2019-01,2019-03-07,INTERVENTIONAL,PHASE2,300.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Prostate Cancer|Prostate Adenocarcinoma,C11-Sodium Acetate,DRUG,1,1,18 Years,90 Years,MALE,False,Phoenix Molecular Imaging,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,5.707110264748875,large,0,1,0,1,0,0,0,0,1,0,0,0,0,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT05676073,Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19,"A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHEN26 Capsule in Patients With Mild to Moderate COVID-19",COMPLETED,2022-12-08,2023-01-27,2023-06-18,INTERVENTIONAL,PHASE2,91.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,COVID-19,SHEN26 dose 1|SHEN26 dose 2|SHEN26 placebo,DRUG,1,11,18 Years,65 Years,ALL,False,"Shenzhen Kexing Pharmaceutical Co., Ltd.",NETWORK,0,4,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.5217885770490405,medium,1,1,0,0,0,0,1,0,0,0,1,1,1,1,12,1,1,0,0,3,1,2022-12-08,2023-01-27,50.0,2022.0,1,2,0
NCT03794583,Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD),An Open-Label Extension Study of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD),TERMINATED,2018-12-21,2022-11-29,2025-12-11,INTERVENTIONAL,PHASE3,41.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pulmonary Hypertension|Chronic Obstructive Pulmonary Disease,Inhaled treprostinil solution,DRUG,1,3,18 Years,,ALL,False,United Therapeutics,INDUSTRY,1,31,Israel|Italy|United States,0.0,0,0,1,0,0,3.0,0,0,0,1,2,3.7376696182833684,small,1,1,1,0,0,1,1,1,1,1,0,0,1,0,4,1,1,0,0,1,0,2018-12-21,2022-11-29,1439.0,2018.0,1,2,0
NCT01891968,Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation,Phase II Study of Subcutaneous Bortezomib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome,COMPLETED,2013-08-07,2017-01-18,2018-04-23,INTERVENTIONAL,PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Leukemia,Bortezomib,DRUG,1,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.772588722239781,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,2013-08-07,2017-01-18,1260.0,2013.0,0,0,0
NCT02073968,PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer,PET-Adjusted IMRT for NSCLC Trial (PAINT),COMPLETED,2013-07,2020-11,2024-01-25,INTERVENTIONAL,PHASE2,35.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Malignant Neoplasm in the Brain|Recurrent Non-Small Cell Lung Carcinoma|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,Carboplatin|Computed Tomography|Intensity-Modulated Radiation Therapy|Paclitaxel|Positron Emission Tomography|Proton Beam Radiation Therapy,DRUG|PROCEDURE|RADIATION,1,6,18 Years,,ALL,False,Albert Einstein College of Medicine,OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,7,3.58351893845611,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,7,1,1,0,0,6,1,,,,,0,3,1
NCT00008268,Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma,A Phase II Study Of Blood Stem Cell Mobilization With Intravenous Melphalan (60 MG/M2) + G-CSF In Patients With Multiple Myeloma,COMPLETED,2000-08,2003-06,2013-06-18,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Multiple Myeloma and Plasma Cell Neoplasm,filgrastim|melphalan,DRUG|BIOLOGICAL,0,0,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,2,1,,,,,0,1,0
NCT03355768,Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL,Randomized Study of Romidepsin Versus the Combination of Romidepsin Plus Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL),WITHDRAWN,2018-09-01,2018-11-01,2018-12-19,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,OTHER,NONE,"Lymphoma, T-Cell, Peripheral",Romidepsin|Pralatrexate,DRUG,1,7,18 Years,90 Years,ALL,False,Jennifer Amengual,OTHER,1,0,,0.0,0,0,1,0,0,3.0,1,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,0,0,1,0,0,1,8,1,1,0,0,2,1,2018-09-01,2018-11-01,61.0,2018.0,1,2,0
NCT00560950,Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007),"A Multicenter, Open-Label Study of the Safety, Tolerability, and Immunogenicity of Revaccination With PNEUMOVAX(TM) 23 Vaccine (Pneumococcal Vaccine Polyvalent, Merck & Co., Inc.) in Older Adults",COMPLETED,2007-07,2008-05,2017-04-11,INTERVENTIONAL,PHASE3,143.0,ACTUAL,NON_RANDOMIZED,PARALLEL,PREVENTION,NONE,Pneumococcal Infection,pneumococcal 23v polysaccharide vaccine,BIOLOGICAL,8,0,59 Years,,ALL,True,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.969813299576001,medium,0,1,1,0,1,0,0,0,0,0,0,0,0,1,8,0,0,1,0,1,0,,,,,0,1,0
NCT01169350,18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma,A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Soft Tissue Sarcoma,TERMINATED,2010-02,2013-08,2017-11-17,INTERVENTIONAL,PHASE2,8.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Recurrent Adult Soft Tissue Sarcoma|Stage I Adult Soft Tissue Sarcoma|Stage II Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma,fludeoxyglucose F 18|18F-fluoromisonidazole|positron emission tomography|computed tomography|laboratory biomarker analysis,PROCEDURE|OTHER|RADIATION,1,3,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,2,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,5,2.1972245773362196,small,1,1,0,1,0,0,1,0,1,0,0,0,0,0,4,1,0,0,0,5,1,,,,,0,2,0
NCT01062490,Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS),Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome (MDS),COMPLETED,2004-11,2009-10,2010-02-04,INTERVENTIONAL,PHASE2,45.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Myelodysplastic Syndrome,Treosulfan,DRUG,2,0,18 Years,60 Years,ALL,False,medac GmbH,INDUSTRY,0,1,Finland,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.828641396489095,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,2,0,1,0,0,1,0,,,,,0,0,0
NCT00204490,Soy Isoflavones and Breast Cancer Risk Reduction,Mammographic Density and Soy Isoflavones,COMPLETED,2004-04,2023-05-31,2024-05-16,INTERVENTIONAL,PHASE2,197.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Breast Cancer,isoflavones|carbohydrate,DIETARY_SUPPLEMENT,2,1,30 Years,42 Years,FEMALE,True,"The University of Texas Medical Branch, Galveston",OTHER,2,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.288267030694535,medium,0,1,0,1,0,1,0,0,1,0,1,1,1,1,3,1,0,0,0,2,1,,2023-05-31,,,0,1,0
NCT03067597,An Open-label Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term,"A Multicentre, Open-label Phase III Trial Investigating the Efficacy and Safety of FE 999901 Vaginal Insert in Pregnant Women at Term (≥37 Weeks and <41 Weeks of Gestation) Requiring Cervical Ripening",COMPLETED,2017-02-22,2018-02-24,2021-04-09,INTERVENTIONAL,PHASE3,68.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cervical Ripening,Dinoprostone,DRUG,1,18,20 Years,,FEMALE,False,Ferring Pharmaceuticals,INDUSTRY,0,14,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.23410650459726,medium,1,1,1,0,0,0,1,0,0,0,0,0,1,0,19,1,1,0,0,1,0,2017-02-22,2018-02-24,367.0,2017.0,1,1,0
NCT03329690,DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01],"A Phase 2, Multicenter, Open-label Study of DS-8201a in Subjects With HER2-expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma",COMPLETED,2017-11-02,2020-12-11,2022-03-18,INTERVENTIONAL,PHASE2,233.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Neoplasm, Gastrointestinal",DS-8201a|Physician's Choice,DRUG,2,15,20 Years,,ALL,False,"Daiichi Sankyo Co., Ltd.",INDUSTRY,1,66,South Korea|Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.455321115357702,large,0,1,1,0,0,1,1,1,0,0,1,0,1,1,17,1,1,0,0,2,1,2017-11-02,2020-12-11,1135.0,2017.0,1,3,1
NCT00005810,Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy,"A Phase II Study of Estramustine, Docetaxel, and Carboplatin With G-CSF Support in Men With Hormone Refractory Prostate Cancer",COMPLETED,2000-03,2006-06,2016-07-14,INTERVENTIONAL,PHASE2,40.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,filgrastim|carboplatin|docetaxel|estramustine phosphate sodium,DRUG|BIOLOGICAL,1,0,18 Years,,MALE,False,Alliance for Clinical Trials in Oncology,OTHER,1,7,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.713572066704308,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,1,1,0,4,1,,,,,0,1,0
NCT00385710,Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine),Randomized Placebo-controlled Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy,COMPLETED,2006-11,2010-07,2012-11-05,INTERVENTIONAL,PHASE2,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Progressive Supranuclear Palsy,valproic acid|Placebo,DRUG,1,1,45 Years,75 Years,ALL,False,Nantes University Hospital,OTHER,0,4,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.367295829986474,small,1,1,0,1,0,0,1,0,0,1,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT03927313,"Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM","Phase IIA Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid With or Without Aspirin, for HIV-associated Tuberculous Meningitis",COMPLETED,2019-06-12,2021-03-31,2021-09-28,INTERVENTIONAL,PHASE2,52.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Tuberculosis Meningitis|HIV-1-infection,Linezolid|High dose rifampicin|Aspirin|Standard of Care anti-tuberculous therapy|Dexamethasone,DRUG,1,10,18 Years,,ALL,False,University of Cape Town,OTHER,0,4,South Africa,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.970291913552122,medium,1,1,0,1,0,0,1,0,0,0,1,0,1,1,11,1,1,0,0,5,1,2019-06-12,2021-03-31,658.0,2019.0,1,3,1
NCT01623713,Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia,"A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia",COMPLETED,2012-06,2013-11,2013-11-19,INTERVENTIONAL,PHASE2,260.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Schizophrenia|Iloperidone|Efficacy,iloperidone|Risperidone,DRUG,1,4,18 Years,65 Years,ALL,False,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",INDUSTRY,0,1,China,1.0,0,1,0,0,0,2.0,0,0,1,0,3,5.564520407322694,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00425113,Metronidazole for Pulmonary Tuberculosis (South Korea),"A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Metronidazole Combined With Antituberculous Chemotherapy vs. Antituberculous Chemotherapy With Placebo in Subjects With Multi-Drug Resistant Pulmonary Tuberculosis",COMPLETED,2006-12,2013-02,2013-07-10,INTERVENTIONAL,PHASE2,35.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Tuberculosis|Multi-Drug Resistant Tuberculosis,Metronidazole|Blood Draw|CT Scan|PET Scan,DRUG|PROCEDURE,1,1,20 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,2,South Korea,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.58351893845611,small,1,1,0,1,0,0,1,0,0,0,1,1,1,1,2,1,1,0,0,4,1,,,,,0,2,0
NCT05145413,A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia",COMPLETED,2021-11-12,2025-03-19,2025-03-28,INTERVENTIONAL,PHASE3,396.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia,Xanomeline and Trospium Chloride Capsules|Placebo,DRUG,1,6,18 Years,65 Years,ALL,False,Karuna Therapeutics,INDUSTRY,0,166,United Kingdom|Bulgaria|United States|Japan|Romania|Poland|India|Serbia,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.983936280687191,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,7,1,1,0,0,2,1,2021-11-12,2025-03-19,1223.0,2021.0,1,3,1
NCT00086060,Pain Management Techniques for Fibromyalgia,Locus of Pain Control: Neural Substrates and Modifiability,COMPLETED,2004-05,2008-02,2011-10-10,INTERVENTIONAL,PHASE1|PHASE2,97.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Fibromyalgia,Exercise regimen|Relaxation training|Standard Care,BEHAVIORAL,3,3,18 Years,60 Years,ALL,True,University of Michigan,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.584967478670572,medium,1,1,0,1,0,1,0,0,1,0,1,0,1,1,6,1,0,0,0,3,1,,,,,0,3,1
NCT01263860,A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients,A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus,COMPLETED,2010-12,2014-06,2014-11-18,INTERVENTIONAL,PHASE3,242.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Chronic Hepatitis C,Peginterferon alfa2a|Ribavirin|Peginterferon alfa2a|Ribavirin,DRUG,1,2,18 Years,70 Years,ALL,False,"Third Affiliated Hospital, Sun Yat-Sen University",OTHER,0,4,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.493061443340548,large,0,1,0,1,0,0,1,0,0,0,1,0,1,1,3,1,1,0,0,4,1,,,,,0,1,0
NCT05926960,"A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma","A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI-PD-1 THERAPY",ACTIVE_NOT_RECRUITING,2023-06-13,2026-01-19,2025-12-18,INTERVENTIONAL,PHASE2,38.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Melanoma,encorafenib|binimetinib|pembrolizumab|ipilimumab|nivolumab,DRUG,1,10,18 Years,,ALL,False,Pfizer,INDUSTRY,1,24,Slovakia|Spain|Germany|Poland|Italy,,0,1,0,0,0,2.0,1,0,0,0,1,3.6635616461296463,small,1,1,1,0,1,1,1,1,0,1,1,0,1,1,11,1,1,0,0,5,1,2023-06-13,2026-01-19,951.0,2023.0,1,3,1
NCT04976660,TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors,Phase I/II First-in-Human Study of TT-4 As a Single Agent in Participants with Advanced Selected Solid Tumors,WITHDRAWN,2022-12-15,2023-09-30,2025-03-18,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,Colorectal Cancer|Gastric Cancer|Hepatocellular Carcinoma|Pancreatic Cancer,TT-4,DRUG,3,6,18 Years,,ALL,False,"Tarus Therapeutics, Inc.",INDUSTRY,0,0,,0.0,1,1,0,0,1,1.5,1,0,0,0,4,0.0,,1,1,1,0,0,0,0,0,0,0,0,0,1,0,9,1,1,0,0,1,0,2022-12-15,2023-09-30,289.0,2022.0,1,3,1
NCT06326060,A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight,Investigation of the Safety and Efficacy of Once Weekly NNC0519-0130 in Participants With Overweight or Obesity - a Dose Finding Study,COMPLETED,2024-03-18,2025-05-01,2025-11-25,INTERVENTIONAL,PHASE2,355.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Obesity,NNC0519-0130|Placebo|Tirzepatide,DRUG,1,20,18 Years,75 Years,ALL,False,Novo Nordisk A/S,INDUSTRY,0,51,Japan|Australia|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.87493073085203,large,0,1,1,0,0,0,1,1,1,0,1,1,1,1,21,1,1,0,0,3,1,2024-03-18,2025-05-01,409.0,2024.0,1,3,1
NCT02088060,A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients,"A Four-week, Multicentre, Double-blinded, Randomised, Active- and Placebo- Controlled, Parallel-group Trial Investigating Efficacy and Safety of Cannabidiol in Acute, Early-stage Schizophrenic Patients",TERMINATED,2015-12-08,2024-09-16,2024-12-27,INTERVENTIONAL,PHASE2,150.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia,Cannabidiol|Olanzapine|Placebo Cannabidiol|Placebo Olanzapine,DRUG,1,12,18 Years,65 Years,ALL,False,"Central Institute of Mental Health, Mannheim",OTHER,5,6,Germany|Denmark,0.0,0,1,0,0,0,2.0,0,0,1,0,1,5.017279836814924,medium,0,0,0,1,0,1,1,1,0,1,1,1,1,1,13,1,1,0,0,4,1,2015-12-08,2024-09-16,3205.0,2015.0,1,3,1
NCT01110720,Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy,"A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy",COMPLETED,2010-10,2012-12,2013-01-17,INTERVENTIONAL,PHASE2|PHASE3,313.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Progressive Supranuclear Palsy,Davunetide|Placebo,DRUG,3,2,41 Years,85 Years,ALL,False,Allon Therapeutics,INDUSTRY,0,48,United Kingdom|Australia|United States|Canada|France|Germany,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.749392985908253,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,5,1,1,0,0,2,1,,,,,0,3,1
NCT03098420,Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section,Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section: A Prospective Randomized Double-Blinded Clinical Study,TERMINATED,2016-07,2021-05-20,2021-06-18,INTERVENTIONAL,PHASE2|PHASE3,29.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Post Surgical Pain,2mg Dexamethasone|4mg Dexamethasone|Ropivacaine (TAP blocks)|Morphine|Bupivacaine Hydrochloride|Normal saline 1ml|Normal saline 0.5ml,DRUG,1,2,18 Years,,FEMALE,True,University of Alabama at Birmingham,OTHER,0,1,United States,0.0,0,1,1,0,1,2.5,0,0,0,0,1,3.4011973816621555,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,3,1,1,0,0,7,1,,2021-05-20,,,0,2,0
NCT00590720,A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma,"A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Effect on Exercise Challenge Testing of Multiple Fixed Subcutaneous Doses of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, in Adults With Stable Asthma and Exercise-Induced Bronchoconstriction",TERMINATED,2008-03,2009-10,2014-03-21,INTERVENTIONAL,PHASE2,11.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Asthma,MEDI528 50 mg|PLACEBO,OTHER|BIOLOGICAL,2,17,18 Years,50 Years,ALL,False,MedImmune LLC,INDUSTRY,0,12,Canada|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.4849066497880004,small,1,1,1,0,0,0,1,1,1,0,1,1,1,1,19,1,0,1,0,2,1,,,,,0,3,1
NCT03488524,Open Label Extension Study of AMX0035 in Patients With ALS,"Evaluation of the Safety, Tolerability, Efficacy, and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for Treatment of Amyotrophic Lateral Sclerosis: Open-Label Extension",COMPLETED,2018-03-29,2021-03-01,2025-08-13,INTERVENTIONAL,PHASE2,90.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Amyotrophic Lateral Sclerosis|ALS,AMX0035,DRUG,1,7,,,ALL,False,Amylyx Pharmaceuticals Inc.,INDUSTRY,1,24,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.51085950651685,medium,1,1,1,0,0,1,1,0,1,0,0,0,1,0,8,1,1,0,0,1,0,2018-03-29,2021-03-01,1068.0,2018.0,1,2,0
NCT00024024,BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma,A Phase I-II Trial Of BMS-275291 In Patients With HIV-Related Kaposi's Sarcoma,COMPLETED,2001-08,,2013-02-11,INTERVENTIONAL,PHASE1|PHASE2,59.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Sarcoma,rebimastat,DRUG,0,0,16 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,3,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.0943445622221,medium,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,1,0
NCT00355524,"A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents","A Phase II, Open-label Trial, to Investigate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of TMC114/Rtv b.i.d in Treatment-Experienced HIV-1 Infected Children and Adolescents",COMPLETED,2006-06,2011-03,2013-07-08,INTERVENTIONAL,PHASE2,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,HIV-1|HIV Infections,TMC114|Ritonavir,DRUG,8,6,6 Years,17 Years,ALL,False,"Tibotec Pharmaceuticals, Ireland",INDUSTRY,0,22,Argentina|United States|Canada|Brazil|France|South Africa|Spain|Romania,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.394449154672439,medium,1,1,1,0,0,0,1,1,1,1,1,0,1,1,14,1,1,0,0,2,1,,,,,0,4,1
NCT00523523,Training the Arm and Hand After Stroke Using Auditory Rhythm Cues,Auditory Rhythm Cues + Task Practice: Effects on UE Motor Function Post-stroke,COMPLETED,2007-08,2010-06,2012-02-06,INTERVENTIONAL,PHASE1|PHASE2,11.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Stroke|Hemiplegia,Constraint-Induced Movement Therapy + auditory rhythm cues|Constraint-Induced Movement Therapy,BEHAVIORAL,1,1,21 Years,95 Years,ALL,False,University of Florida,OTHER,2,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,2,2.4849066497880004,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,2,1,0,0,0,2,1,,,,,0,3,1
NCT01432223,Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab,Phase II Study of Primary Chemotherapy With Anthracycline-based Regimen Followed by Nab-paclitaxel and Trastuzumab in Patients With HER2 Positive Breast Cancer,COMPLETED,2011-09,2014-05,2015-04-22,INTERVENTIONAL,PHASE2,46.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer|HER-2 Positive Breast Cancer|Effects of Chemotherapy,Nab-paclitaxel,DRUG,1,5,20 Years,70 Years,FEMALE,False,Osaka Medical College,OTHER,0,1,Japan,1.0,0,1,0,0,0,2.0,1,0,0,0,3,3.8501476017100584,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,1,0,,,,,0,2,0
NCT02819323,A Safety and Efficacy Study of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy,A Safety and Efficacy Study of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy,COMPLETED,2016-06,2018-03-27,2021-05-03,INTERVENTIONAL,PHASE3,91.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Colonoscopy,PEG-ELS|BLI800,DRUG,1,0,12 Years,16 Years,ALL,False,Braintree Laboratories,INDUSTRY,0,27,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.5217885770490405,medium,1,1,1,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,2,1,,2018-03-27,,,0,1,0
NCT00545623,Acupuncture and Relaxation Response for GI Symptoms and HIV Medication Adherence,Acupuncture and Relaxation Response for GI Symptoms and HIV Medication Adherence,COMPLETED,2007-04,2010-09,2014-09-03,INTERVENTIONAL,PHASE2,130.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,TRIPLE,HIV Infections,Acupuncture|Relaxation Response|sham acupuncture,PROCEDURE|OTHER|BEHAVIORAL,1,0,18 Years,,ALL,False,Boston University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.875197323201151,medium,0,1,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,3,1,,,,,0,1,0
NCT00163280,"Safety, Tolerability and Efficacy of ATL-104 in Oral Mucositis","Randomised Double-Blind Placebo-Controlled Study of Orally Administered ATL-104 to Assess Safety, Tolerance and Effect on Oral Mucositis in Patients Following Treatment With Chemotherapy and Peripheral Blood Stem Cell Transplant (PBSCT)",COMPLETED,2004-07,2005-12,2008-02-12,INTERVENTIONAL,PHASE2,63.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Mucositis,ATL-104,DRUG,2,2,18 Years,65 Years,ALL,False,Alizyme,INDUSTRY,0,8,United Kingdom,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.1588830833596715,medium,1,1,1,0,0,0,1,0,0,1,1,1,0,1,4,1,1,0,0,1,0,,,,,0,0,0
NCT03655080,Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression,Novel Approach of Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression,TERMINATED,2019-01-09,2021-06-15,2025-02-04,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cord Compression,Radiation therapy|nab-Paclitaxel,DRUG|RADIATION,1,10,18 Years,,ALL,False,Washington University School of Medicine,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,11,1,1,0,0,2,1,2019-01-09,2021-06-15,888.0,2019.0,1,2,0
NCT02915159,A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Primary Sjögrens Syndrome",COMPLETED,2016-12-06,2019-07-23,2020-08-10,INTERVENTIONAL,PHASE3,250.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Sjogrens Disease,Abatacept|Placebo,OTHER|BIOLOGICAL,1,40,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,71,Argentina|Mexico|Australia|United States|Puerto Rico|Sweden|Brazil|South Korea|France|Czechia|Germany|Japan|Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.5254529391317835,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,41,1,0,1,0,2,1,2016-12-06,2019-07-23,959.0,2016.0,1,3,1
NCT00149396,Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver,"A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver",COMPLETED,2004-07,2008-12,2018-04-24,INTERVENTIONAL,PHASE1|PHASE2,32.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Colorectal Cancer|Liver Neoplasms,NV1020,DRUG,5,7,18 Years,,ALL,False,MediGene,INDUSTRY,0,5,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,2,3.4965075614664802,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,12,1,1,0,0,1,0,,,,,0,3,1
NCT00105196,A Study of Aripiprazole in Patients With Major Depressive Disorder,A Study of Aripiprazole in Patients With Major Depressive Disorder,COMPLETED,2005-03,2008-03,2013-12-02,INTERVENTIONAL,PHASE3,349.0,ACTUAL,RANDOMIZED,PARALLEL,DIAGNOSTIC,DOUBLE,Major Depressive Disorder,Aripiprazole+ ADT|Placebo+ ADT,DRUG,1,4,18 Years,65 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,1,34,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.857933154483459,large,0,1,1,0,0,1,1,0,1,0,1,1,0,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT00073762,Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Two Fixed Doses (200 Mg, Or 400 Mg) Of DVS-233 SR In Adult Outpatients With Major Depressive Disorder",COMPLETED,,2004-09,2009-08-19,INTERVENTIONAL,PHASE3,375.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Major Depressive Disorder,DVS-233 SR,DRUG,0,0,18 Years,75 Years,ALL,False,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.929589143389895,large,0,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,,,,,0,0,0
NCT04017962,A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection,"An Open-label, Single-arm Study of Letermovir (LTV) for Prevention of Recurrent CMV Infection in High-risk Hematopoietic Cell Transplant (HCT) Recipients",COMPLETED,2019-07-19,2025-07-29,2025-08-11,INTERVENTIONAL,PHASE2,102.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,CMV|CMV Infection|Hematopoietic Cell Transplant,Letermovir Pill|blood draw,DRUG|OTHER,1,4,12 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,4.634728988229636,medium,0,1,0,1,0,1,1,0,1,0,0,0,1,0,5,1,1,0,0,2,1,2019-07-19,2025-07-29,2202.0,2019.0,1,2,0
NCT01566162,"A Twelve Week, Open Label Extension Study in Patients With Schizophrenia","A Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia",COMPLETED,2012-04,2013-11,2019-04-09,INTERVENTIONAL,PHASE3,191.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Schizophrenia,Lurasidone,DRUG,3,6,18 Years,,ALL,False,"Sumitomo Pharma America, Inc.",INDUSTRY,0,63,Russia|United States|Slovakia|France|South Africa|Italy|Serbia,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.2574953720277815,medium,0,1,1,0,0,0,1,1,1,1,0,0,1,0,9,1,1,0,0,1,0,,,,,0,2,0
NCT01940146,Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis,Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis,COMPLETED,2014-10,2014-12,2019-05-03,INTERVENTIONAL,PHASE2,222.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Seasonal Allergic Rhinitis,SPARC Placebo|SPARC1310 I|SPARC1310 II|SPARC1310 III,DRUG,1,0,18 Years,65 Years,ALL,False,Sun Pharma Advanced Research Company Limited,INDUSTRY,0,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.407171771460119,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,4,1,,,,,0,1,0
NCT00429403,Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer,Phase III Randomized Study of a Goserelin Acetate for Preservation of Ovarian Function in Patients With Primary Breast Cancer (PBC),TERMINATED,2006-08,2010-07,2016-05-09,INTERVENTIONAL,PHASE3,1.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,Goserelin,DRUG,1,0,15 Years,46 Years,FEMALE,False,M.D. Anderson Cancer Center,OTHER,0,2,Japan|United States,0.0,0,0,1,0,0,3.0,1,0,0,0,1,0.6931471805599453,small,1,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,0,1,0,,,,,0,1,0
NCT03597503,Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment,Assessment of Efficacy and Safety of SPN-810 for the Treatment of Impulsive Aggression (IA) in Adolescent Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction With Standard ADHD Treatment,TERMINATED,2018-07-31,2020-01-22,2024-04-24,INTERVENTIONAL,PHASE3,41.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Attention Deficit Hyperactivity Disorder,SPN-810|Placebo,DRUG,1,3,12 Years,17 Years,ALL,False,"Supernus Pharmaceuticals, Inc.",INDUSTRY,0,38,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.7376696182833684,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,4,1,1,0,0,2,1,2018-07-31,2020-01-22,540.0,2018.0,1,1,0
NCT02974803,Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,A Phase II Study of Concurrent Dabrafenib and Trametinib With Stereotactic Radiation in the Management of Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,TERMINATED,2018-02-09,2020-07-29,2021-08-20,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Melanoma|Brain Metastases,Dabrafenib|Trametinib,DRUG,1,4,18 Years,,ALL,False,Canadian Cancer Trials Group,NETWORK,1,6,Canada,0.0,0,1,0,0,0,2.0,1,0,0,0,2,1.9459101490553132,small,1,1,0,0,0,1,1,0,0,0,0,0,1,0,5,1,1,0,0,2,1,2018-02-09,2020-07-29,901.0,2018.0,1,2,0
NCT01718327,A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma,A Phase II Open-label Single Arm Study of Sunitinib in Patients With Advanced Cholangiocarcinoma,COMPLETED,2011-09-01,2016-11-17,2017-01-31,INTERVENTIONAL,PHASE2,53.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Unresectable and Advanced Cholangiocarcinoma,Sunitinib,DRUG,1,4,18 Years,80 Years,ALL,False,GERCOR - Multidisciplinary Oncology Cooperative Group,OTHER,0,6,France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.9889840465642745,medium,1,1,0,1,0,0,1,0,0,1,0,0,1,0,5,1,1,0,0,1,0,2011-09-01,2016-11-17,1904.0,2011.0,0,0,0
NCT01362803,AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors,A Phase I/II Study of the Mitogen Activated Protein Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; Hydrogen Sulfate in Children With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN),ACTIVE_NOT_RECRUITING,2011-09-21,2032-01-01,2026-01-16,INTERVENTIONAL,PHASE1|PHASE2,99.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Neurofibromatosis 1|Neurofibromatosis Type 1|NF1|Neurofibroma, Plexiform",AZD6244,DRUG,2,7,2 Years,18 Years,ALL,False,National Cancer Institute (NCI),NIH,0,4,United States,,1,1,0,0,1,1.5,0,0,0,0,4,4.605170185988092,medium,1,1,0,1,0,0,1,0,1,0,0,0,1,0,9,1,1,0,0,1,0,2011-09-21,2032-01-01,7407.0,2011.0,0,3,1
NCT03700242,"Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year","Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Intradermal or Intramuscular Post-Exposure Prophylaxis Regimen at One Year",COMPLETED,2018-09-26,2020-04-08,2022-04-25,INTERVENTIONAL,PHASE3,570.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Healthy Volunteers (Rabies Immunization),HDCV|HDCV|PVRV|PVRV,BIOLOGICAL,1,14,2 Years,,ALL,True,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,0,2,Philippines,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.3473892096560105,xlarge,0,1,1,0,1,0,1,0,0,0,1,0,0,1,15,1,0,1,0,4,1,2018-09-26,2020-04-08,560.0,2018.0,1,2,0
NCT00715442,Pre-Surgical Sutent in Renal Cell Carcinoma (RCC),Phase II Non-Randomized Pre-Surgical Study Evaluating Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) Who Are Eligible for Cytoreductive Nephrectomy,ACTIVE_NOT_RECRUITING,2008-06-24,2026-12-04,2025-12-23,INTERVENTIONAL,PHASE2,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Renal Cell Carcinoma,Sunitinib|Nephrectomy,DRUG|PROCEDURE,2,0,,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,2,United States,,0,1,0,0,0,2.0,1,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,2,0,1,0,0,2,1,2008-06-24,2026-12-04,6737.0,2008.0,0,1,0
NCT03234686,Deferiprone to Delay Dementia (The 3D Study),Deferiprone to Delay Dementia (The 3D Study): a Clinical Proof of Concept Study,COMPLETED,2018-01-19,2023-02-23,2024-07-03,INTERVENTIONAL,PHASE2,81.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Mild Cognitive Impairment|Prodromal Alzheimer's Disease|Mild Alzheimer's Disease,Deferiprone 600mg delayed release tablets|Placebo Oral Tablet,DRUG,1,2,65 Years,,ALL,False,Neuroscience Trials Australia,OTHER,1,8,Australia,1.0,0,1,0,0,0,2.0,0,0,1,0,3,4.406719247264253,medium,1,1,0,1,0,1,1,0,0,0,1,1,1,1,3,1,1,0,0,2,1,2018-01-19,2023-02-23,1861.0,2018.0,1,2,0
NCT02313870,Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid,Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid,COMPLETED,2008-01-22,2015-12-31,2022-02-01,INTERVENTIONAL,PHASE3,322.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Bullous Pemphigoid,clobetasol propionate + Methotrexate|clobetasol propionate alone,DRUG,1,5,18 Years,,ALL,False,"University Hospital, Montpellier",OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.777652323222656,large,0,1,0,1,0,0,0,0,0,1,1,0,1,1,6,1,1,0,0,2,1,2008-01-22,2015-12-31,2900.0,2008.0,0,2,0
NCT02200770,N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders,"A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders.",COMPLETED,2015-04-01,2020-11-06,2021-12-03,INTERVENTIONAL,PHASE2|PHASE3,231.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders,Inebilizumab|Placebo,DRUG|OTHER,1,16,18 Years,,ALL,False,MedImmune LLC,INDUSTRY,0,98,Estonia|Canada|Thailand|South Africa|Hungary|Hong Kong|Moldova|Russia|Australia|Bulgaria|Spain|Israel|United States|Colombia|Czechia|Germany|Poland|South Korea|Peru|Turkey (Türkiye)|Taiwan|New Zealand|Mexico|Japan|Serbia,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.44673737166631,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,17,1,1,0,0,2,1,2015-04-01,2020-11-06,2046.0,2015.0,1,4,1
NCT01991873,Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer,Randomized Phase II Study for Evaluation of Efficacy and Safety of Maintenance Treatment With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction Treatment With mFOLFOX6 Plus Panitumumab and Re-induction With mFOLFOX6 Plus Panitumumab in Case of Progression for First-line Treatment of Patients With Metastatic Colorectal Cancer,COMPLETED,2014-04,2023-02-18,2023-06-15,INTERVENTIONAL,PHASE2,387.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Colorectal Cancer,Maintenance Chemotherapy|Panitumumab (Within maintenance phase)|mFOLFOX6 (Within re-induction phase)|Panitumumab (Within re-induction phase),DRUG,1,7,18 Years,,ALL,False,AIO-Studien-gGmbH,OTHER,2,2,Germany,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.961005339623274,large,0,1,0,1,0,1,1,0,0,1,1,0,1,1,8,1,1,0,0,4,1,,2023-02-18,,,0,2,0
NCT03688269,Minimal Effective Concentration (EC90) of Ropivacaine,Determination of the Minimal Effective Concentration (EC90) of Ropivacaine in Axillary Brachial Plexus Block With Intravenous Dexamethasone or Saline Injection,COMPLETED,2018-10-05,2020-05-04,2020-12-21,INTERVENTIONAL,PHASE3,146.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Anesthesia, Conduction|Ropivacaine|Dexamethasone|Axillary Brachial Plexus Block",Intravenous dexamethasone|Intravenous saline|Perineural ropivacaine,DRUG,1,8,18 Years,,ALL,False,Centre Hospitalier Universitaire de Besancon,OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,4,4.990432586778736,medium,0,1,0,1,0,0,0,0,0,1,1,1,1,1,9,1,1,0,0,3,1,2018-10-05,2020-05-04,577.0,2018.0,1,3,1
NCT02399969,Battlefield Acupuncture for the Treatment of Low Back Pain in the Emergency Department,Battlefield Acupuncture for the Treatment of Low Back Pain in the Emergency Department,COMPLETED,2015-03,2016-04,2016-05-05,INTERVENTIONAL,PHASE1|PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Low Back Pain,Battlefield Acupuncture,OTHER,3,6,18 Years,,ALL,True,Icahn School of Medicine at Mount Sinai,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,9,1,0,0,0,1,0,,,,,0,2,0
NCT01353469,Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy,"A Multicenter, Randomized, Active-controlled, Parallel-group Study to Assess the Efficacy and Safety of Insuman Comb 25 (Insulin Human) Versus Novolin® 30R Twice Daily Over 24 Weeks in Patients With Type 2 Diabetes Mellitus Who Are Under Insulin Therapy",COMPLETED,2011-05,2012-11,2013-02-27,INTERVENTIONAL,PHASE3,485.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,Insulin human/Insuman Comb 25 (HR1799)|Insulin human/Novolin® 30R,DRUG,1,1,18 Years,75 Years,ALL,False,Sanofi,INDUSTRY,0,23,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.186208623900494,large,0,1,1,0,1,0,1,0,0,0,1,0,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT04330586,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,A Trial of Ciclesonide to Assess The Antiviral Effect for Adults With Mild-to-moderate COVID-19,COMPLETED,2020-04-01,2021-03-31,2021-06-24,INTERVENTIONAL,PHASE2,68.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,COVID-19,Ciclesonide Metered Dose Inhaler [Alvesco],DRUG,1,5,19 Years,80 Years,ALL,False,Korea University Guro Hospital,OTHER,0,1,South Korea,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.23410650459726,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,1,6,1,1,0,0,1,0,2020-04-01,2021-03-31,364.0,2020.0,1,1,0
NCT00599170,Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma,Rituximab Plus CHOP Given Every Two Weeks With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma,COMPLETED,2008-01-10,2021-01-10,2021-11-17,INTERVENTIONAL,PHASE2,52.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Diffuse, Large B-Cell, Lymphoma",Rituximab,DRUG,1,1,,,ALL,False,University of Southern California,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.970291913552122,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2008-01-10,2021-01-10,4749.0,2008.0,0,0,0
NCT03439670,A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD),"A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)",COMPLETED,2018-06-29,2021-08-19,2023-03-09,INTERVENTIONAL,PHASE2,121.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Duchenne Muscular Dystrophy,Vamorolone|Prednisone|Placebo|Vamorolone|Prednisone|Placebo|Vamorolone|Vamorolone,DRUG|OTHER,1,0,4 Years,7 Years,MALE,False,"ReveraGen BioPharma, Inc.",INDUSTRY,4,33,United Kingdom|Australia|United States|Sweden|Canada|Netherlands|Spain|Czechia|Greece|Belgium|Israel,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.804021044733257,medium,0,1,1,0,0,1,1,1,1,1,1,1,1,1,1,0,1,0,0,8,1,2018-06-29,2021-08-19,1147.0,2018.0,1,2,0
NCT02412670,Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients With High Grade Upper Tract Urothelial Carcinoma,COMPLETED,2015-08-27,2022-05-10,2023-07-10,INTERVENTIONAL,PHASE2,36.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,High Grade Upper Tract Urothelial Carcinoma,Methotrexate|Vinblastine|Doxorubicin|Cisplatin|Gemcitabine|Carboplatin|Pegfilgrastim|Nephroureterectomy,DRUG|PROCEDURE,1,6,18 Years,,ALL,False,ECOG-ACRIN Cancer Research Group,NETWORK,1,134,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.6109179126442243,small,1,1,0,0,0,1,1,0,1,0,0,0,1,1,7,1,1,0,0,8,1,2015-08-27,2022-05-10,2448.0,2015.0,1,2,0
NCT01165970,Effect of Saliva Substitutes on Dental Hard Tissues in Situ,"Vergleichende, Randomisierte, Kontrollierte Und Doppelblinde In-situ-Studie Zur Wirkung Von Speichelersatzmitteln Auf Schmelz Und Dentin",TERMINATED,2009-01,2012-12,2011-11-15,INTERVENTIONAL,PHASE2|PHASE3,19.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Hyposalivation,Glandosane|Saliva natura,DRUG|DEVICE,1,1,18 Years,,ALL,False,"Charite University, Berlin, Germany",OTHER,0,2,Germany,0.0,0,1,1,0,1,2.5,0,0,0,0,1,2.995732273553991,small,1,1,0,1,0,0,1,0,0,1,1,1,1,0,2,1,1,0,1,2,1,,,,,0,2,0
NCT00541073,"Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery",Phase 2 Pharmacological Study of Pemetrexed Administered With Cisplatin and a Vitamin Supplement in Patients With Nonresectable Pleural Mesothelioma,COMPLETED,2007-06,,2011-05-17,INTERVENTIONAL,PHASE2,60.0,ESTIMATED,NON_RANDOMIZED,,TREATMENT,,Malignant Mesothelioma,vitamin B12|cisplatin|pemetrexed disodium|gene expression analysis|laboratory biomarker analysis|pharmacological study,DRUG|GENETIC|OTHER|DIETARY_SUPPLEMENT,1,3,18 Years,,ALL,False,Centre Oscar Lambret,OTHER,0,1,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.110873864173311,medium,1,0,0,1,0,0,0,0,0,1,0,0,1,0,4,1,1,0,0,6,1,,,,,0,1,0
NCT00404573,Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia,"A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia",COMPLETED,2006-11,,2008-01-07,INTERVENTIONAL,PHASE2,375.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Schizophrenia,RGH-188,DRUG,1,1,18 Years,65 Years,ALL,False,Forest Laboratories,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,5.929589143389895,large,0,0,1,0,0,0,0,0,1,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT01851083,Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury,A Phase 2 Multicenter Trial of Pediatric Autologous Bone Marrow Mononuclear Cells (BMMNCs) for Severe Traumatic Brain Injury (TBI),COMPLETED,2013-08,2020-10-12,2020-11-20,INTERVENTIONAL,PHASE2,47.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Traumatic Brain Injury,autologous bone marrow mononuclear cells|Placebo Infusion,OTHER|BIOLOGICAL,1,1,5 Years,17 Years,ALL,False,"The University of Texas Health Science Center, Houston",OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.871201010907891,small,1,1,0,1,0,1,1,0,1,0,1,1,1,1,2,1,0,1,0,2,1,,2020-10-12,,,0,1,0
NCT00037583,Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia,A Dose-Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (go) Given in Combination With Cytarabine and Daunorubicin in Relapsed or Refractory Patients and in Younger de Novo Patients With Acute Myeloid Leukemia (AML),COMPLETED,,2003-09,2009-08-21,INTERVENTIONAL,PHASE2,69.0,ACTUAL,,,TREATMENT,,Acute Myeloid Leukemia,Gemtuzumab Ozogamicin,DRUG,0,0,18 Years,59 Years,ALL,False,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.248495242049359,medium,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT02004041,Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis,"A Randomized, Double-Blind, Placebo-Controlled, Proof of Concept, Antipruritic Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis",COMPLETED,2013-12-10,2015-02-19,2024-06-11,INTERVENTIONAL,PHASE2,69.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Treatment-resistant Pruritus Associated With Atopic Dermatitis,VLY-686|Placebo,DRUG,1,0,18 Years,65 Years,ALL,False,Vanda Pharmaceuticals,INDUSTRY,0,5,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.248495242049359,medium,1,1,1,0,0,0,1,0,0,1,1,1,1,1,1,0,1,0,0,2,1,2013-12-10,2015-02-19,436.0,2013.0,0,1,0
NCT00623805,A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer,"A Randomized, Multicenter Phase III Trial to Assess the Efficacy and Safety of Bevacizumab and Capecitabine as Maintenance Treatment, After Initial Combination Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Patients With Metastatic Colorectal Adenocarcinoma",COMPLETED,2008-03,2012-05,2014-08-08,INTERVENTIONAL,PHASE3,123.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Cancer,Bevacizumab|Capecitabine|Oxaliplatin,DRUG,1,6,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,10,Turkey (Türkiye),1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.820281565605037,medium,0,1,1,0,1,0,1,0,0,0,1,0,1,1,7,1,1,0,0,3,1,,,,,0,2,0
NCT01397305,"An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer","An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer",COMPLETED,2011-04-14,2014-10-16,2020-09-09,INTERVENTIONAL,PHASE1|PHASE2,24.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Rectal Cancer,"[6R] 5,10-methylenetetrahydrofolate (arfolitixorin)|Pemetrexed",DRUG,1,7,18 Years,,ALL,False,Isofol Medical AB,INDUSTRY,0,1,Sweden,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.2188758248682006,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,8,1,1,0,0,2,1,2011-04-14,2014-10-16,1281.0,2011.0,0,3,1
NCT01428505,[18F]PBR111 and Microglial Activation in Multiple Sclerosis,A Study to Characterize the Novel TSPO PET Radioligand [18F]PBR111 as an in Vivo Marker of Microglial Activation in Multiple Sclerosis,TERMINATED,2011-07,2013-03,2016-02-08,INTERVENTIONAL,PHASE2,50.0,ACTUAL,,SINGLE_GROUP,BASIC_SCIENCE,NONE,Multiple Sclerosis,[18F]PBR111,RADIATION,1,5,20 Years,70 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,1,United Kingdom,0.0,0,1,0,0,0,2.0,0,1,0,0,1,3.9318256327243257,small,1,1,1,0,0,0,0,0,0,1,0,0,0,0,6,1,0,0,0,1,0,,,,,0,1,0
NCT01108705,Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment,"A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Asian Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed or Are Intolerant to Sorafenib",TERMINATED,2010-05,2013-10,2015-10-12,INTERVENTIONAL,PHASE3,87.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Carcinoma, Hepatocellular",Brivanib|Placebo,DRUG,1,4,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,32,South Korea|Singapore|China|Taiwan,0.0,0,0,1,0,0,3.0,1,0,0,0,1,4.477336814478207,medium,1,1,1,0,1,0,1,1,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00967018,A Long Term Safety Study of Degarelix in Patients With Prostate Cancer,"A Phase IIIb, Non-randomized, Open-label, Multi-Centre, Follow-on Safety Trial of Monthly Doses of Degarelix in Patients With Prostate Cancer",COMPLETED,2009-08,2011-12,2013-01-03,INTERVENTIONAL,PHASE3,77.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,Degarelix,DRUG,2,0,18 Years,,MALE,False,Ferring Pharmaceuticals,INDUSTRY,0,62,Turkey (Türkiye)|Sweden|Portugal|France|Spain|Belgium|Italy,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.356708826689592,medium,1,1,1,0,0,0,1,1,0,1,0,0,1,0,2,0,1,0,0,1,0,,,,,0,1,0
NCT00000118,Ganciclovir Implant Study for Cytomegalovirus Retinitis,,COMPLETED,1992-10,1993-12,2009-09-17,INTERVENTIONAL,PHASE3,,,RANDOMIZED,,TREATMENT,,HIV Infections|Acquired Immunodeficiency Syndrome|Cytomegalovirus Retinitis,Sustained-Release Intraocular Drug Delivery System,DEVICE,0,0,,,ALL,,National Eye Institute (NEI),NIH,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,3,0.0,,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,,,,,0,1,0
NCT06131918,Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy,"Assessment of Resveratrol, Alpha Lipoic Acid and Superoxide Dismutase on Oxidative Stress Biomarkers in Type 2 Diabetes Mellitus Patients With Neuropathy: A Randomized Control Trial",COMPLETED,2023-01-09,2024-05-05,2024-08-26,INTERVENTIONAL,PHASE2,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Peripheral Diabetic Neuropathy,"Resveratrol, Alpha lipoic acid, Super oxide dismutase|Resveratrol|Alpha lipoic acid|Super Oxide Dismutase",DRUG,2,3,40 Years,60 Years,ALL,False,Khyber Medical University Peshawar,OTHER,0,1,Pakistan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.61512051684126,medium,0,1,0,1,0,0,0,0,0,0,1,0,1,1,5,1,1,0,0,4,1,2023-01-09,2024-05-05,482.0,2023.0,1,1,0
NCT05253118,Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS),Phase II Study of Tislelizumab Plus Pemetrexed in Patients With Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS),ACTIVE_NOT_RECRUITING,2022-08-18,2026-02-28,2025-05-15,INTERVENTIONAL,PHASE2,28.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,DLBCL,Tislelizumab|Pemetrexed,DRUG,1,3,19 Years,,ALL,False,Seoul National University Hospital,OTHER,4,1,South Korea,,0,1,0,0,0,2.0,0,0,0,0,1,3.367295829986474,small,1,0,0,1,0,1,0,0,0,0,0,0,1,0,4,1,1,0,0,2,1,2022-08-18,2026-02-28,1290.0,2022.0,1,1,0
NCT03943290,Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX),An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) Previously Enrolled in Study A083-02 and in Patients With Charcot-Marie Tooth (CMT) Disease Types 1 and X Previously Enrolled in Study A083-03,TERMINATED,2019-05-10,2020-03-11,2022-09-26,INTERVENTIONAL,PHASE2,62.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Facioscapulohumeral Muscular Dystrophy|Charcot-Marie-Tooth Disease,ACE-083,DRUG,3,20,18 Years,,ALL,False,"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",INDUSTRY,0,24,Canada|Spain|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,4.143134726391533,medium,1,1,1,0,1,0,1,1,1,1,1,0,1,1,23,1,1,0,0,1,0,2019-05-10,2020-03-11,306.0,2019.0,1,3,1
NCT04072497,A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years,A Safety and Immunogenicity Study of a Zoster Vaccine in Healthy Adults >= 40 Years,COMPLETED,2018-11-20,2020-04-30,2023-12-27,INTERVENTIONAL,PHASE1|PHASE2,522.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Herpes Zoster,One shot of the zoster vaccine|One shot of the varicella vaccine|one shot of placebo,BIOLOGICAL,4,3,40 Years,,ALL,True,Shanghai Institute Of Biological Products,INDUSTRY,0,1,China,1.0,1,1,0,0,1,1.5,0,0,0,0,1,6.259581464064923,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,0,1,7,1,0,1,0,3,1,2018-11-20,2020-04-30,527.0,2018.0,1,3,1
NCT04375397,Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE),COMPLETED,2020-06-06,2021-06-08,2022-06-01,INTERVENTIONAL,PHASE2,46.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,CoronaVirus Induced Disease-2019 (COVID-19),Ibrutinib|Placebo,DRUG,1,11,18 Years,,ALL,False,AbbVie,INDUSTRY,1,9,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8501476017100584,small,1,1,1,0,1,1,1,0,1,0,1,1,1,1,12,1,1,0,0,2,1,2020-06-06,2021-06-08,367.0,2020.0,1,2,0
NCT00391313,CuraChik : A Trial of the Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease,CuraChik : Double Blind Placebo-controlled Randomized Trial : Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease.,TERMINATED,2006-05,2007-03,2015-08-28,INTERVENTIONAL,PHASE3,,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chikungunya Virus,Chloroquine,DRUG,0,0,18 Years,66 Years,ALL,False,Assistance Publique Hopitaux De Marseille,OTHER,0,1,France,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,0,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,,,,,0,0,0
NCT01937013,Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia,Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia,COMPLETED,2013-09-12,2017-12-21,2018-08-08,INTERVENTIONAL,PHASE2,52.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Frontotemporal Dementia,Intranasal oxytocin|Saline Nasal Mist,DRUG,1,1,30 Years,85 Years,ALL,True,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,OTHER,1,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.970291913552122,medium,1,1,0,1,0,1,0,0,0,0,1,1,1,0,2,1,1,0,0,2,1,2013-09-12,2017-12-21,1561.0,2013.0,0,1,0
NCT04144413,3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin),"A Phase IIIb, Prospective, Interventional, Multicentre, 3-year Study to Explore the Long-term Evolution of Sign and Symptoms, and Occurence of Complications in Dry Eye Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)",COMPLETED,2019-05-31,2023-07-14,2024-08-28,INTERVENTIONAL,PHASE3,350.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Dry Eye Disease With Severe Keratitis,Open-label Ikervis|Masked Ikervis|Vehicle Comparator: Masked Vehicle,DRUG|OTHER,1,1,18 Years,,ALL,False,Santen SAS,INDUSTRY,0,45,Russia|Turkey (Türkiye)|France|Spain|Czechia|Poland|Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.860786223465865,large,0,1,1,0,0,0,1,1,0,1,1,1,1,1,2,1,1,0,0,3,1,2019-05-31,2023-07-14,1505.0,2019.0,1,2,0
NCT02665260,Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum,Randomized Pilot Study Investigating the Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum,COMPLETED,2012-07,2016-01,2017-05-05,INTERVENTIONAL,PHASE2,94.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Molluscum Contagiosum,Cantharidin|Placebo|Gauze occlusion bandage,DRUG|DEVICE,1,1,2 Years,17 Years,ALL,True,Montefiore Medical Center,OTHER,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.553876891600541,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,1,3,1,,,,,0,1,0
NCT05999682,Improvement of Organ Function by Apigenin in Elderly Patients With Sepsis,"Improvement of Organ Function by Apigenin in Elderly Patients With Sepsis: A Single-center, Single-blind, Randomized, Placebo-controlled, Pilot Clinical Trial",COMPLETED,2023-09-01,2024-01-05,2024-03-13,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Sepsis|Septic Shock,apigenin|sterilized water,OTHER,1,16,65 Years,,ALL,False,Zhujiang Hospital,OTHER,0,1,China,1.0,1,1,0,0,1,1.5,0,0,0,0,2,3.044522437723423,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,17,1,0,0,0,2,1,2023-09-01,2024-01-05,126.0,2023.0,1,4,1
NCT03339882,Remifemin Preventing the Climacteric Symptoms in Breast Cancer,The Effect of Remifemin in Preventing the Climacteric Symptoms Caused by LHRH-a Treatment in Breast Cancer: a Randomized II-stage Clinic Research,COMPLETED,2017-01-04,2018-01-30,2018-07-06,INTERVENTIONAL,PHASE2,85.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Effect of Drugs|Safety Issues,Remifemin,DRUG,1,1,18 Years,55 Years,FEMALE,False,Zhejiang Cancer Hospital,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.454347296253507,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,1,0,2017-01-04,2018-01-30,391.0,2017.0,1,1,0
NCT03278782,Study of Pembrolizumab (MK-3475) in Combination With Romidepsin,A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma,ACTIVE_NOT_RECRUITING,2017-11-14,2027-07-31,2026-01-09,INTERVENTIONAL,PHASE1|PHASE2,39.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",Pembrolizumab|Romidepsin,DRUG|BIOLOGICAL,2,4,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,,1,1,0,0,1,1.5,1,0,0,0,11,3.6888794541139363,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,6,1,1,1,0,2,1,2017-11-14,2027-07-31,3546.0,2017.0,1,4,1
NCT00203424,Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib,A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer,COMPLETED,2006-01,2010-06,2016-03-25,INTERVENTIONAL,PHASE2,23.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,Erlotinib + Bevacizumab,DRUG,2,2,18 Years,,MALE,False,Translational Oncology Research International,OTHER,1,16,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.1780538303479458,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT03624023,TWB-103 for Treating Lower Limb Ulcers on Patients With DM,A Pilot Phase I/II Study to Evaluate the Safety and Efficacy of TWB-103 in Treating Lower Limb Ulcers on Patients With Diabetes Mellitus,COMPLETED,2019-12-19,2021-07-09,2023-07-12,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Diabetic Foot Ulcer,TWB-103,DRUG,1,7,20 Years,,ALL,False,"Transwell Biotech Co., Ltd.",INDUSTRY,0,2,Taiwan,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.3978952727983707,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,8,1,1,0,0,1,0,2019-12-19,2021-07-09,568.0,2019.0,1,2,0
NCT00003523,Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum,"Evaluation of Aminocamptothecin (9-AC, NSC #603071) in Recurrent, Platinum Resistant and Refractory Ovarian Cancer and Primary Peritoneal Carcinoma",COMPLETED,1999-01,2007-10,2013-06-21,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Ovarian Cancer|Primary Peritoneal Cavity Cancer,aminocamptothecin colloidal dispersion,DRUG,0,0,13 Years,,FEMALE,False,Gynecologic Oncology Group,NETWORK,1,65,Canada|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,0.0,,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,2,0
NCT00602459,Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia,"A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients With Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia",COMPLETED,2008-01-15,2023-04-15,2023-05-22,INTERVENTIONAL,PHASE2,418.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia,Cyclophosphamide|Fludarabine Phosphate|Laboratory Biomarker Analysis|Lenalidomide|Rituximab,DRUG|OTHER|BIOLOGICAL,1,5,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,3,364,Canada|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,6.037870919922137,large,0,1,0,1,0,1,1,1,1,0,1,0,1,1,6,1,1,1,0,5,1,2008-01-15,2023-04-15,5569.0,2008.0,0,4,1
NCT07102459,An Efficacy and Safety Study of LTG-001 Following Abdominoplasty,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After an Abdominoplasty",COMPLETED,2025-07-24,2026-01-07,2026-01-09,INTERVENTIONAL,PHASE2,343.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Pain|Postoperative Pain Control,Experimental: LTG-001 High Dose|Experimental: LTG-001 Low Dose|Active Comparator: HB/APAP|Placebo Comparator,DRUG,1,8,18 Years,65 Years,ALL,False,Latigo Biotherapeutics,INDUSTRY,0,5,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.840641657373398,large,0,1,1,0,0,0,1,0,1,0,1,1,1,1,9,1,1,0,0,4,1,2025-07-24,2026-01-07,167.0,2025.0,1,3,1
NCT02355080,A Bundled Rapid HIV/HCV Testing Intervention to Increase Receipt of Test Results,A Bundled Rapid HIV/HCV Testing Intervention to Increase Receipt of Test Results,COMPLETED,2016-04,2017-07,2018-02-23,INTERVENTIONAL,PHASE2|PHASE3,134.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Substance-related Disorders,On-site bundled rapid HIV/HCV testing|Standard of care (SOC),BEHAVIORAL,1,3,18 Years,,ALL,False,Columbia University,OTHER,3,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.90527477843843,medium,0,1,0,1,0,1,0,0,1,0,1,0,0,1,4,1,0,0,0,2,1,,,,,0,2,0
NCT03345979,A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia,"A Phase 3b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia in Subjects Hospitalized for Acute Exacerbation",COMPLETED,2017-11-15,2019-03-12,2020-08-11,INTERVENTIONAL,PHASE3,200.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia,Aripiprazole Lauroxil|Paliperidone Palmitate,DRUG|COMBINATION_PRODUCT,1,6,18 Years,65 Years,ALL,False,"Alkermes, Inc.",INDUSTRY,0,16,United States,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.303304908059076,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,7,1,1,0,0,2,1,2017-11-15,2019-03-12,482.0,2017.0,1,2,0
NCT04223479,"Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan","Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan",COMPLETED,2020-01-15,2022-03-10,2024-09-19,INTERVENTIONAL,PHASE2|PHASE3,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ulcerative Colitis,Probiotic Formula Capsule|Placebos,DRUG,8,1,35 Years,65 Years,ALL,True,University of Jordan,OTHER,0,1,Jordan,1.0,0,1,1,0,1,2.5,0,1,0,0,1,3.4339872044851463,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,9,1,1,0,0,2,1,2020-01-15,2022-03-10,785.0,2020.0,1,3,1
NCT00088296,"Effects of Osteoarthritis Pain, Morphine, and Placebo on Neuroendocrine Function in Men","Effects of Osteoarthritis Pain, Morphine and Placebo on Neuro-Endocrine Function in Men",COMPLETED,2004-07-13,2007-10-18,2017-07-02,INTERVENTIONAL,PHASE2,72.0,,,,TREATMENT,,Osteoarthritis,Blood Draw,PROCEDURE,0,0,30 Years,65 Years,MALE,True,National Center for Complementary and Integrative Health (NCCIH),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.290459441148391,medium,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,2004-07-13,2007-10-18,1192.0,2004.0,0,0,0
NCT00088062,STA-5326 in Crohn's Disease Patients,A Phase I/IIa Trial of STA-5326 in Crohn's Disease Patients With CDAI Scores of 220-450,COMPLETED,2004-02,2004-11,2005-06-24,INTERVENTIONAL,PHASE1|PHASE2,48.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Crohn's Disease,STA-5326,DRUG,0,0,18 Years,65 Years,ALL,False,Synta Pharmaceuticals Corp.,INDUSTRY,0,18,United States,1.0,1,1,0,0,1,1.5,0,1,0,0,1,3.8918202981106265,small,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,1,0
NCT06734962,Evaluation of Bone Regeneration After Apical Surgery Using Advanced Platelet-rich Fibrin: Utilization of Ultrasound for the Assessment of Periapical Lesions,Evaluation of Bone Regeneration After Apical Surgery Using Advanced Platelet-rich Fibrin: Utilization of Ultrasound for the Assessment of Periapical Lesions,ACTIVE_NOT_RECRUITING,2021-09-12,2025-09-30,2024-12-18,INTERVENTIONAL,PHASE2,44.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Periapical Lesions,Apical surgery procedure using A-PRF|Apical surgery without using A-PRF,PROCEDURE,1,1,18 Years,,ALL,False,Riga Stradins University,OTHER,0,1,Latvia,,0,1,0,0,0,2.0,0,0,0,0,1,3.8066624897703196,small,1,0,0,1,0,0,0,0,0,0,1,0,1,1,2,1,0,0,0,2,1,2021-09-12,2025-09-30,1479.0,2021.0,1,1,0
NCT01091246,A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children,"A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Children",COMPLETED,2010-03,2010-12,2011-09-26,INTERVENTIONAL,PHASE3,2312.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Healthy or Stable Chronic Illness,Q/LAIV (MEDI3250)|FluMist/B/Yamagata|FluMist/B/Victoria,BIOLOGICAL,1,33,2 Years,17 Years,ALL,True,MedImmune LLC,INDUSTRY,0,110,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.746300662231439,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,0,1,34,1,0,1,0,3,1,,,,,0,2,0
NCT01237288,Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets,Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets,COMPLETED,2010-09,2013-07,2013-10-01,INTERVENTIONAL,PHASE3,16.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Primary Hypophosphatemic Rickets,Z-521,DRUG,2,0,1 Year,14 Years,ALL,False,Zeria Pharmaceutical,INDUSTRY,0,4,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,2.833213344056216,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,2,0,1,0,0,1,0,,,,,0,0,0
NCT01005888,C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks,"LEVP2005-1/Part B: A Double-blind, Placebo-Controlled, Clinical Study to Investigate the Efficacy and Safety of Purified C1 Esterase Inhibitor (Human) as Prophylactic Treatment to Prevent HAE Attacks",COMPLETED,2005-03-14,2007-08-22,2021-06-11,INTERVENTIONAL,PHASE3,26.0,ACTUAL,RANDOMIZED,CROSSOVER,PREVENTION,DOUBLE,Hereditary Angioedema,C1 esterase inhibitor [human] (C1INH-nf)|Placebo (saline),DRUG|BIOLOGICAL,1,6,6 Years,,ALL,False,Shire,INDUSTRY,0,16,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.295836866004329,small,1,1,1,0,0,0,1,0,1,0,1,1,0,0,7,1,1,1,0,2,1,2005-03-14,2007-08-22,891.0,2005.0,0,2,0
NCT00253188,A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease,"Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease",COMPLETED,1997-02,1998-12,2011-05-18,INTERVENTIONAL,PHASE3,653.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Alzheimer Disease|Dementia,galantamine hydrobromide,DRUG,1,1,18 Years,,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,1,0,2,6.483107351457199,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,1,0
NCT01376388,Long-term Safety Study for GSK573719/GW642444 in Japanese,"A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg Once-daily in Combination With GW642444 25 mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Japanese Subjects With Chronic Obstructive Pulmonary Disease.",COMPLETED,2011-08,2012-12,2017-01-09,INTERVENTIONAL,PHASE3,131.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Pulmonary Disease, Chronic Obstructive",GSK573719/GW642444 Inhalation Powder,DRUG,2,10,40 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,23,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.882801922586371,medium,0,1,1,0,0,0,1,0,0,0,0,0,1,0,12,1,1,0,0,1,0,,,,,0,1,0
NCT00502788,Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study),Thalassemia Clinical Research Network - Hepatitis C Clinical Trial,COMPLETED,2003-05,2006-08,2014-03-04,INTERVENTIONAL,PHASE2,21.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hepatitis C|Thalassemia,Peginterferon Alfa-2a and Ribavirin|Ribavirin,DRUG,1,10,18 Years,44 Years,ALL,False,Carelon Research,OTHER,1,5,United Kingdom|Canada|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.091042453358316,small,1,1,0,1,0,1,1,1,1,1,0,0,1,0,11,1,1,0,0,2,1,,,,,0,4,1
NCT04170088,Comparison of Efficacy of Tranexamic Acid Mesotherapy Versus 0.9% Normal Saline for Melasma,Comparison of Efficacy of Tranexamic Acid Mesotherapy Versus 0.9% Normal Saline for Melasma; a Split Face Study in Tertiary Care Hospital of Karachi,COMPLETED,2018-09-01,2019-06-30,2019-12-17,INTERVENTIONAL,PHASE2|PHASE3,30.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Effect of Drugs|Adverse Effects of Medical Drugs,Tranexamic Acid|0.9% Normal Saline,DRUG,1,0,18 Years,50 Years,ALL,True,Jinnah Postgraduate Medical Centre,OTHER_GOV,0,1,Pakistan,1.0,0,1,1,0,1,2.5,0,0,0,0,2,3.4339872044851463,small,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,2,1,2018-09-01,2019-06-30,302.0,2018.0,1,3,1
NCT03541603,Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF,"A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)",COMPLETED,2018-11-14,2020-04-07,2024-11-20,INTERVENTIONAL,PHASE2,44.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Hypertension Pulmonary Secondary|Heart Failure, Right Sided|Heart Failure With Normal Ejection Fraction",Levosimendan|Matching Placebo,DRUG,1,7,18 Years,,ALL,False,"Tenax Therapeutics, Inc.",INDUSTRY,0,16,United States,1.0,0,1,0,0,0,2.0,0,0,0,1,3,3.8066624897703196,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,8,1,1,0,0,2,1,2018-11-14,2020-04-07,510.0,2018.0,1,3,1
NCT03760003,Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis,"A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose, Induction Study to Evaluate the Safety, Tolerability and Optimal Dose of ABX464 Compared With Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Have Inadequate Response, Loss of Response, or Intolerance With at Least One of the Following Agents: Immunosuppressant Treatment (i.e. Azathioprine, 6-mercaptopurine, Methotrexate), Tumor Necrosis Factor Alpha [TNF-α] Inhibitors, Vedolizumab, JAK Inhibitors and/or Corticosteroid Treatment",COMPLETED,2019-08-13,2021-04-16,2025-11-28,INTERVENTIONAL,PHASE2,355.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ulcerative Colitis,ABX464 100 mg|ABX464 50 mg|ABX464 25 mg|Placebo,DRUG,1,27,18 Years,75 Years,ALL,False,Abivax S.A.,INDUSTRY,0,130,United Kingdom|Ukraine|United States|Canada|Hungary|Slovakia|Austria|France|Slovenia|Spain|Czechia|Belarus|Germany|Poland|Belgium|Italy|Serbia,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.87493073085203,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,28,1,1,0,0,4,1,2019-08-13,2021-04-16,612.0,2019.0,1,3,1
NCT05163561,Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine,"A Phase III, Double Blind, Randomized, Active Controlled Study to Evaluate Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine",COMPLETED,2022-01-09,2023-04-29,2023-10-23,INTERVENTIONAL,PHASE3,1072.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Poliomyelitis,SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B|SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C|Sii Licensed IPV,BIOLOGICAL,1,4,6 Weeks,8 Weeks,ALL,True,Serum Institute of India Pvt. Ltd.,INDUSTRY,0,1,Bangladesh,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.9782137426306985,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,0,1,5,1,0,1,0,4,1,2022-01-09,2023-04-29,475.0,2022.0,1,1,0
NCT00276042,A Trial to Evaluate Faropenem Medoxomil in the Treatment of Acute Otitis Media,"Prospective, Randomized, Investigator-Blind Trial to Evaluate the Bacteriologic Eradication, Safety and Tolerability, and Pharmacokinetics of Different Dosages of Faropenem Medoxomil BID for 10 Days in the Treatment of Acute Otitis Media",COMPLETED,2006-01,,2008-02-08,INTERVENTIONAL,PHASE2,328.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Otitis Media,Faropenem Medoxomil,DRUG,1,1,6 Months,7 Years,ALL,False,Replidyne,INDUSTRY,0,2,Costa Rica|Israel,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.796057750765372,large,0,1,1,0,0,0,1,1,0,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,1,0
NCT01127542,RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial,A Single Arm Phase II Study to Investigate the Use of Lenalidomide in the Treatment of Patients With Early Stage CLL Associated With Poor Prognostic Factors,TERMINATED,2010-05,2011-12,2011-12-05,INTERVENTIONAL,PHASE2,1.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Lymphocytic Leukaemia,Lenalidomide,DRUG,1,3,18 Years,,ALL,False,The Christie NHS Foundation Trust,OTHER,2,9,United Kingdom,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.6931471805599453,small,1,1,0,1,0,1,1,0,0,1,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT06382142,A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer,A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer After Taxane Failure,ACTIVE_NOT_RECRUITING,2024-06-21,2026-06,2025-11-17,INTERVENTIONAL,PHASE3,418.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Triple-Negative Breast Cancer,BL-B01D1|Eribulin|Vinorelbine|Gemcitabine|Capecitabine,DRUG,2,5,18 Years,75 Years,ALL,False,"Sichuan Baili Pharmaceutical Co., Ltd.",INDUSTRY,1,1,China,,0,0,1,0,0,3.0,1,0,0,0,1,6.037870919922137,large,0,1,1,0,0,1,0,0,0,0,1,0,1,1,7,1,1,0,0,5,1,2024-06-21,,,2024.0,1,2,0
NCT00081042,ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma,"An Open-Label, Multicenter, Phase II Trial of ABI-007 (A Cremophor® -Free, Protein Stabilized, Nanoparticle Paclitaxel) in Previously Treated Patients With Metastatic Melanoma",COMPLETED,2004-02,2010-01,2013-12-19,INTERVENTIONAL,PHASE2,,,,,TREATMENT,NONE,Melanoma (Skin),paclitaxel albumin-stabilized nanoparticle formulation,DRUG,0,0,18 Years,,ALL,False,Jonsson Comprehensive Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT04493242,Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Phase II Clinical Trial,COMPLETED,2020-09-24,2021-05-22,2024-02-13,INTERVENTIONAL,PHASE2,102.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,COVID-19|ARDS,ExoFlo|Intravenous normal saline,OTHER|BIOLOGICAL,1,5,18 Years,85 Years,ALL,False,"Direct Biologics, LLC",INDUSTRY,0,6,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.634728988229636,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,6,1,0,1,0,2,1,2020-09-24,2021-05-22,240.0,2020.0,1,3,1
NCT01701986,"Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,COMPLETED,2012-10-25,2024-06-05,2025-02-28,INTERVENTIONAL,PHASE1|PHASE2,64.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hematopoietic Cell Transplantation Recipient|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma,Allogeneic Bone Marrow Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation|Anti-Thymocyte Globulin|Busulfan|Clofarabine|Gemcitabine Hydrochloride|Mycophenolate Mofetil|Peripheral Blood Stem Cell Transplantation|Pharmacological Study|Rituximab|Tacrolimus,PROCEDURE|DRUG|OTHER|BIOLOGICAL,2,2,12 Years,65 Years,ALL,True,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,4,4.174387269895637,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,1,0,11,1,2012-10-25,2024-06-05,4241.0,2012.0,0,3,1
NCT00395070,A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma,A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment With 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects With Recurrent Metastatic Melanoma,COMPLETED,2006-10,2013-07,2013-09-13,INTERVENTIONAL,PHASE3,390.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Metastatic Melanoma,Allovectin-7®|Dacarbazine (DTIC)|Temozolomide (TMZ),DRUG|BIOLOGICAL,1,2,18 Years,,ALL,False,Vical,INDUSTRY,0,88,Russia|Turkey (Türkiye)|United States|Canada|Brazil|Poland|France|Spain|Italy|Switzerland|Germany|Netherlands|Belgium|Israel,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.968707559985366,large,0,1,1,0,0,0,1,1,1,1,1,0,1,1,3,1,1,1,0,3,1,,,,,0,2,0
NCT01558869,Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma,"An Open-label, Single-centre, Single-arm Phase II Study of Capecitabine Combined With Oxaliplatin and Irinotecan (Xeloxiri) as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma",COMPLETED,2012-04,2016-12,2017-05-09,INTERVENTIONAL,PHASE2,37.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pancreatic Adenocarcinoma,Capecitabine|Oxaliplatin|Irinotecan,DRUG,1,3,18 Years,,ALL,False,The University of Hong Kong,OTHER,0,1,Hong Kong,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.6375861597263857,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,4,1,1,0,0,3,1,,,,,0,1,0
NCT01380769,A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer,"A Randomized, Phase 2, Study to Assess the Safety and Activity of CRLX101, a Nanoparticle Formulation of Camptothecin, in Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed One or Two Previous Regimens of Chemotherapy",COMPLETED,2011-06,2014-10,2020-05-28,INTERVENTIONAL,PHASE2,157.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non-Small Cell Lung Cancer,CRLX101|Best Supportive Care,DRUG|OTHER,1,1,18 Years,,ALL,False,NewLink Genetics Corporation,INDUSTRY,0,25,Russia|Ukraine,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.062595033026967,medium,0,1,1,0,0,0,1,1,0,0,1,0,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT00227669,"Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma",Randomized Phase II Study Evaluating the Efficacy of Gemcitabine Versus the Gemcitabine/Docetaxel Combination as Second Line Treatment in Metastatic or Relapsed and Inoperable Uterine or Soft Tissue Leiomyosarcomas,COMPLETED,2005-10,2012-08,2016-08-30,INTERVENTIONAL,PHASE2,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Sarcoma,docetaxel|gemcitabine hydrochloride,DRUG,1,6,18 Years,120 Years,FEMALE,False,UNICANCER,OTHER,0,32,France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.51085950651685,medium,1,1,0,1,0,0,1,0,0,1,1,0,1,1,7,1,1,0,0,2,1,,,,,0,2,0
NCT01003769,Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia,A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL),TERMINATED,2015-07-09,2018-12-14,2020-06-16,INTERVENTIONAL,PHASE1|PHASE2,5.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Recurrent Chronic Lymphocytic Leukemia,Lenalidomide|R-(-)-Gossypol Acetic Acid|Laboratory Biomarker Analysis,DRUG|OTHER,2,5,18 Years,,ALL,False,Mayo Clinic,OTHER,1,2,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,1.791759469228055,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,7,1,1,0,0,3,1,2015-07-09,2018-12-14,1254.0,2015.0,1,3,1
NCT00135083,Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus,"One Versus Two Versus Three Daily Rapid-acting Insulin Injections of APIDRA (Insulin Glulisine) as add-on to Lantus® and Oral Sensitizer Basal Therapy in Type 2 Diabetes: a Multicenter, Randomized, Parallel, Open-label Clinical Study",COMPLETED,2004-08,2007-11,2011-01-11,INTERVENTIONAL,PHASE3,347.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",insulin glulisine,DRUG,1,0,18 Years,79 Years,ALL,False,Sanofi,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.8522024797744745,large,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,,,,,0,0,0
NCT01687283,Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma,"A Multicenter, Randomized, Single Blind, Active Controlled, Parallel Group Study to Determine Efficacy and Safety of Nebulized Fluticasone Propionate 1mg BID Compared With Nebulized Budesonide 2mg BID Administered for 12 Weeks in Chinese Adult and Adolescent Patients With Severe Persistent Asthma",COMPLETED,2012-09-27,2013-11-07,2018-10-11,INTERVENTIONAL,PHASE3,316.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Asthma,fluticasone propionate inhalation solution|budesonide suspension,DRUG,2,9,17 Years,70 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,25,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.75890177387728,large,0,1,1,0,0,0,1,0,0,0,1,0,1,1,11,1,1,0,0,2,1,2012-09-27,2013-11-07,406.0,2012.0,0,2,0
NCT04906876,A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas,"A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas",WITHDRAWN,2021-09,2025-07,2021-07-28,INTERVENTIONAL,PHASE2,0.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Sarcoma|Soft Tissue Sarcoma|Metastatic Sarcoma|Undifferentiated Pleomorphic Sarcoma|Myxofibrosarcoma|Leiomyosarcoma|Liposarcoma|Angiosarcoma|Synovial Sarcoma|Rhabdomyosarcoma|Spindle Cell Sarcoma|High Grade Sarcoma|Bone Sarcoma,Gemcitabine|Docetaxel|9-ING-41,DRUG,1,1,10 Years,,ALL,False,Brown University,OTHER,1,2,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,13,0.0,,1,1,0,1,0,1,1,0,1,0,0,0,1,1,2,1,1,0,0,3,1,,,,,0,2,0
NCT00285389,Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years,Treatment in First Line of Mantle Cell Lymphoma for Patients Under 66 Years by the VAD-CHLORAMBUCIL -Rituximab Regimen Followed by Intensification and Autologous PBSC Transplantation After Marrow Purging With Rituximab,COMPLETED,2002-02,2008-12,2009-02-12,INTERVENTIONAL,PHASE2,39.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Mantle Cell Lymphoma,Adriblastin|dexamethasone|Chlorambucil|rituximab|cyclophosphamide|alkeran|Total body irradiation (8Gy/4fr)|vincristine,DRUG|PROCEDURE,1,5,18 Years,65 Years,ALL,False,French Innovative Leukemia Organisation,OTHER,1,3,France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.6888794541139363,small,1,1,0,1,0,1,1,0,0,1,0,0,1,0,6,1,1,0,0,8,1,,,,,0,2,0
NCT00497289,Comparison of Two Different Lipid Emulsions for Parenteral Nutrition in Preterm Infants,"Double-blind, Prospective, Randomized Comparison of a Medium Chain Triglycerides (MCT)/Long Chain Triglycerides (LCT)/Fish Oil (FO) Containing 20% Lipid Emulsion With a MCT/LCT Emulsion (20%) for Parenteral Nutrition in Preterm Infants",COMPLETED,2006-01,2008-02,2021-03-10,INTERVENTIONAL,PHASE2,48.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Preterm Infants|Parenteral Nutrition n-3 Fatty Acids,Lipofundin MCT/LCT 20 %|Lipidem 20%,DRUG,2,0,5 Hours,3 Days,ALL,False,B. Braun Melsungen AG,INDUSTRY,0,2,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.8918202981106265,small,1,1,1,0,0,0,1,0,0,1,1,1,0,1,2,0,1,0,0,2,1,,,,,0,2,0
NCT00300950,"Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer","A Phase 2 Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Mutant Ras Protein Combined With a Gemcitabine Regimen Versus a Gemcitabine Regimen With Placebo, in Patients With Post-resection R0/R1 Pancreatic Cancer With Tumor Sequence Confirmation of Ras Mutations.",COMPLETED,2006-01,2015-02,2015-04-06,INTERVENTIONAL,PHASE2,176.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,TRIPLE,Pancreas Cancer,GI-4000|Gemcitabine,DRUG|BIOLOGICAL,1,0,18 Years,,ALL,False,GlobeImmune,INDUSTRY,0,28,India|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.176149732573829,medium,0,1,1,0,0,0,1,1,1,0,1,1,1,0,1,0,1,1,0,2,1,,,,,0,2,0
NCT01727050,Fibrin Sealant Spray Versus Mechanical Stapling in Laparoscopic Totally Extraperitoneal Hernioplasty,Randomized Prospective Trial of Fibrin Sealant Spray Versus Mechanical Stapling in Laparoscopic Totally Extraperitoneal Hernioplasty,COMPLETED,2007-06,2011-12,2012-11-20,INTERVENTIONAL,PHASE3,129.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hernia,Fibrin sealant spray|Mechanical stapling,DEVICE,1,4,18 Years,70 Years,ALL,False,Chinese University of Hong Kong,OTHER,0,1,Hong Kong,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.867534450455582,medium,0,1,0,1,0,0,0,0,0,0,1,1,1,1,5,1,0,0,1,2,1,,,,,0,1,0
NCT03289650,Extended Release Tacrolimus vs. Twice-Daily Tacrolimus,Once-Daily Extended-Release Tacrolimus vs. Twice-Daily Tacrolimus: Impact on T-Cell Subpopulations and Markers of Renal Tubule-toxicity in Kidney Transplant Patients,COMPLETED,2017-09-05,2021-02-23,2023-04-10,INTERVENTIONAL,PHASE3,29.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,End Stage Renal Disease|Rejection of Renal Transplant,Tacrolimus|Tacrolimus Extended Release Oral Tablet [Envarsus],DRUG,1,5,18 Years,65 Years,ALL,False,Lorenzo Gallon,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,3.4011973816621555,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,6,1,1,0,0,2,1,2017-09-05,2021-02-23,1267.0,2017.0,1,3,1
NCT04388774,Low-Dose Ketamine in Children With ADNP Syndrome,A Phase 2A Open-Label Study Evaluating the Safety and Efficacy of Low-Dose Ketamine in Children With ADNP Syndrome,COMPLETED,2020-08-19,2021-06-08,2023-07-07,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,ADNP Syndrome,Ketamine,DRUG,1,12,5 Years,12 Years,ALL,False,Alexander Kolevzon,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,13,1,1,0,0,1,0,2020-08-19,2021-06-08,293.0,2020.0,1,2,0
NCT02863718,Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease Progression,"A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib Vs. Placebo in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia Patients with Risk of Early Disease Progression",COMPLETED,2014-04-30,2022-07-11,2024-12-30,INTERVENTIONAL,PHASE3,515.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Lymphocytic Leukemia,Ibrutinib|Placebo,DRUG,1,5,18 Years,,ALL,False,German CLL Study Group,OTHER,1,1,Germany,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.246106765481563,xlarge,0,1,0,1,0,1,0,0,0,1,1,1,1,1,6,1,1,0,0,2,1,2014-04-30,2022-07-11,2994.0,2014.0,0,2,0
NCT02745197,A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer,Factors That Regulate Components of a Nutritional Supplement to Support Skeletal Muscle in Cancer Patients,WITHDRAWN,2017-05,2018-10,2024-09-19,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,QUADRUPLE,Pancreatic Cancer,Nutritional Supplement|Placebo,DIETARY_SUPPLEMENT,1,3,19 Years,,ALL,False,University of Alberta,OTHER,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,1,0,1,4,1,0,0,0,2,1,,,,,0,1,0
NCT01668797,"Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia",COMPLETED,2012-10,2015-02,2017-01-13,INTERVENTIONAL,PHASE3,524.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Schizophrenia,Brexpiprazole|Placebo,DRUG,1,1,18 Years,65 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,1,49,Turkey (Türkiye)|Ukraine|Malaysia|United States|Puerto Rico|Colombia|Romania|Serbia,1.0,0,0,1,0,0,3.0,0,0,1,0,1,6.263398262591624,xlarge,0,1,1,0,0,1,1,1,1,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT01373710,Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis,Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis,COMPLETED,2011-05-19,2018-04-09,2025-11-24,INTERVENTIONAL,PHASE1|PHASE2,34.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Breast Cancer|Carcinomatous Meningitis,Trastuzumab,DRUG,1,10,18 Years,,ALL,False,Institut Curie,OTHER,9,10,France,1.0,1,1,0,0,1,1.5,1,0,0,0,2,3.5553480614894135,small,1,1,0,1,0,1,1,0,0,1,0,0,1,0,11,1,1,0,0,1,0,2011-05-19,2018-04-09,2517.0,2011.0,0,3,1
NCT04404660,A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL),"An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia",ACTIVE_NOT_RECRUITING,2020-06-03,2029-06-30,2025-09-09,INTERVENTIONAL,PHASE1|PHASE2,153.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia,AUTO1,BIOLOGICAL,2,9,18 Years,,ALL,False,Autolus Limited,INDUSTRY,0,34,United Kingdom|Spain|United States,,1,1,0,0,1,1.5,1,0,0,0,1,5.0369526024136295,medium,0,1,1,0,0,0,1,1,1,1,0,0,1,0,11,1,0,1,0,1,0,2020-06-03,2029-06-30,3314.0,2020.0,1,3,1
NCT05202860,Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis,Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis - a Double-blind Randomized Controlled Trial,ACTIVE_NOT_RECRUITING,2022-05-09,2034-06-19,2025-01-22,INTERVENTIONAL,PHASE2,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Actinic Keratoses|Basal Cell Carcinoma|Squamous Cell Carcinoma,HPV Vaccine|PLACEBO vaccine,BIOLOGICAL,1,6,18 Years,,ALL,False,Merete Haedersdal,OTHER,0,1,Denmark,,0,1,0,0,0,2.0,1,0,0,0,3,4.2626798770413155,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,7,1,0,1,0,2,1,2022-05-09,2034-06-19,4424.0,2022.0,1,3,1
NCT02250482,An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.,An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.,COMPLETED,2001-11,,2018-02-15,INTERVENTIONAL,PHASE3,,,,,TREATMENT,,Haemophilia A,Optivate® (Human Coagulation Factor VIII),BIOLOGICAL,1,0,12 Years,,ALL,False,Bio Products Laboratory,OTHER,0,8,United Kingdom|Poland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,,,,,0,1,0
NCT01469182,A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751),"A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet (SCH 39641/MK-3641) Treatment in Ragweed Allergic Adults (Phase 3, Protocol No.P05751)",COMPLETED,2011-11,2012-04,2017-03-03,INTERVENTIONAL,PHASE3,914.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Allergy,SCH 39641|Placebo for SCH 39641,DRUG|BIOLOGICAL,1,8,18 Years,,ALL,False,ALK-Abelló A/S,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.818924065275521,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,1,1,9,1,1,1,0,2,1,,,,,0,2,0
NCT00462982,Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma,A Phase II Study of SU11248 (Sunitinib) in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain,COMPLETED,2007-03,2008-08,2015-12-30,INTERVENTIONAL,PHASE2,8.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Kidney Cancer|Melanoma (Skin)|Metastatic Cancer,sunitinib malate,DRUG,1,0,18 Years,120 Years,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,2.1972245773362196,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,1,0
NCT02845882,LBL-2016 for Children or Adolescents in China,Modified BFM (Berlin-Frankfurt-Munster)Backbone Therapy for Chinese Children or Adolescents With Newly Diagnosed Lymphoblastic Lymphoma,ACTIVE_NOT_RECRUITING,2016-01,2031-12,2025-02-13,INTERVENTIONAL,PHASE3,150.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Lymphoblastic Lymphoma,"Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine|6-mercaptopurine,Methotrexate|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate|Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase|Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase|Methotrexate, 6-mercaptopurine",DRUG,2,1,12 Months,18 Years,ALL,False,"Children's Cancer Group, China",NETWORK,8,2,China,,0,0,1,0,0,3.0,1,0,0,0,1,5.017279836814924,medium,0,0,0,0,0,1,1,0,0,0,0,0,1,0,3,1,1,0,0,7,1,,,,,0,1,0
NCT00233324,Surfactant Positive Airway Pressure and Pulse Oximetry Trial,Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants,COMPLETED,2005-02,2016-08,2019-04-18,INTERVENTIONAL,PHASE3,1316.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,NONE,"Infant, Newborn, Diseases|Other Preterm Infants|Infant, Small for Gestational Age|Premature Birth|Bronchopulmonary Dysplasia|Retinopathy of Prematurity",Surfactant|Continuous Positive Airway Pressure (CPAP)|Supplemental oxygen with target saturation of 85 to 89%|Supplemental oxygen with target saturation of 91 to 95%,DRUG|DEVICE,2,17,24 Weeks,27 Weeks,ALL,False,NICHD Neonatal Research Network,NETWORK,3,22,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,6,7.183111701743281,xlarge,0,1,0,0,0,1,1,0,1,0,1,0,1,0,19,1,1,0,1,4,1,,,,,0,3,1
NCT06104124,A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity,"A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-severe Systemic Disease Activity",ACTIVE_NOT_RECRUITING,2024-01-24,2026-08-19,2026-01-16,INTERVENTIONAL,PHASE3,651.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Sjogren's Syndrome,Dazodalibep|Placebo,DRUG,1,13,18 Years,,ALL,False,Amgen,INDUSTRY,0,216,Canada|Hungary|Argentina|Australia|Portugal|Spain|Belgium|Italy|Israel|Chile|United States|France|Germany|Poland|Greece|South Korea|Peru|United Kingdom|Croatia|Puerto Rico|Brazil|Taiwan|New Zealand|Mexico|Japan|Serbia,,0,0,1,0,0,3.0,0,0,0,0,1,6.480044561926653,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,14,1,1,0,0,2,1,2024-01-24,2026-08-19,938.0,2024.0,1,3,1
NCT03250624,Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis,Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis,COMPLETED,2016-11-01,2017-06-26,2023-05-01,INTERVENTIONAL,PHASE2,63.0,ACTUAL,RANDOMIZED,PARALLEL,OTHER,SINGLE,Atopic Dermatitis,CD5024 0.3% cream|Placebo,DRUG,1,6,18 Years,60 Years,ALL,False,Galderma R&D,INDUSTRY,0,5,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.1588830833596715,medium,1,1,1,0,0,0,1,0,0,0,1,0,0,1,7,1,1,0,0,2,1,2016-11-01,2017-06-26,237.0,2016.0,1,2,0
NCT00806923,A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC),"A Randomized, Double-blind Study of the Effect of Avastin Plus Cisplatin and Gemcitabine or Placebo Plus Cisplatin and Gemcitabine on Progression-free Survival in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC",COMPLETED,2005-02,2011-02,2016-11-02,INTERVENTIONAL,PHASE3,1044.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non-Squamous Non-Small Cell Lung Cancer,Cisplatin|Gemcitabine|Placebo|bevacizumab [Avastin]|bevacizumab [Avastin],DRUG,1,2,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,154,Canada|Thailand|Hungary|Hong Kong|Argentina|Russia|Australia|Bulgaria|Spain|Belgium|Italy|Israel|France|Czechia|Germany|Poland|Greece|United Kingdom|Brazil|Taiwan,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.951772164398911,xlarge,0,1,1,0,1,0,1,1,0,1,1,0,1,1,3,1,1,0,0,5,1,,,,,0,2,0
NCT00368823,A Trial of Point of Care Information in Ambulatory Pediatrics,A Randomized Clinical Trial to Improve Prescribing Patterns in Ambulatory Pediatrics,COMPLETED,1999-11,2003-12,2006-08-29,INTERVENTIONAL,PHASE3,44.0,,RANDOMIZED,FACTORIAL,TREATMENT,DOUBLE,Acute Otitis Media|Allergic Rhinitis|Sinusitis|Constipation|Pharyngitis|Croup|Urticaria|Bronchiolitis,Electronic point-of-care delivery system,DEVICE,8,0,0 Years,,ALL,True,University of Washington,OTHER,1,2,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,8,3.8066624897703196,small,1,0,0,1,0,1,1,0,1,0,1,1,1,0,8,0,0,0,1,1,0,,,,,0,2,0
NCT03047980,Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome,Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome,COMPLETED,2017-01,2020-10-27,2021-11-01,INTERVENTIONAL,PHASE2|PHASE3,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Sturge-Weber Syndrome,Sirolimus,DRUG,1,3,3 Years,31 Years,ALL,False,"Anne Comi, MD",OTHER,5,2,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,1,0,,2020-10-27,,,0,1,0
NCT00197080,Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome,"A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients With Restless Legs Syndrome",COMPLETED,2005-06,2006-01,2016-09-23,INTERVENTIONAL,PHASE3,380.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Restless Legs Syndrome,Ropinirole Extended Release (XR),DRUG,1,1,18 Years,79 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,70,Canada|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.942799375126701,large,0,0,1,0,0,0,1,1,1,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,1,0
NCT06558279,A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis,"A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Ocular Myasthenia Gravis",ACTIVE_NOT_RECRUITING,2024-09-18,2027-12,2025-12-15,INTERVENTIONAL,PHASE3,141.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Myasthenia Gravis, Ocular",Efgartigimod PH20 SC|Placebo PH20 SC,OTHER|COMBINATION_PRODUCT,1,13,18 Years,,ALL,False,argenx,INDUSTRY,0,102,Canada|Austria|China|Australia|Portugal|Spain|United Arab Emirates|Belgium|Italy|Finland|United States|Sweden|France|Czechia|Georgia|Germany|Netherlands|Poland|Greece|South Korea|United Kingdom|Cyprus|Denmark|Japan|Serbia,,0,0,1,0,0,3.0,0,0,0,0,1,4.955827057601261,medium,0,1,1,0,0,0,1,1,1,1,1,1,1,1,14,1,0,0,0,2,1,2024-09-18,,,2024.0,1,3,1
NCT04531046,Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation,"Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B-Non Hodgkin Lymphoma (B-NHL) Who Are Ineligible to Autologous Stem Cell Transplantation",ACTIVE_NOT_RECRUITING,2021-03-10,2026-06,2024-10-09,INTERVENTIONAL,PHASE2,62.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,B-Cell Lymphoma Refractory|B-cell Lymphoma Recurrent,axicabtagene ciloleucel,DRUG,1,19,18 Years,,ALL,False,The Lymphoma Academic Research Organisation,OTHER,0,16,France|Belgium,,0,1,0,0,0,2.0,1,0,0,0,2,4.143134726391533,medium,1,1,0,1,0,0,1,1,0,1,0,0,1,0,20,1,1,0,0,1,0,2021-03-10,,,2021.0,1,3,1
NCT01294462,Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS),"A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid (ASA) Versus Clopidogrel on Top of Low Dose ASA in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes(ACS) for Whom PCI is Planned",COMPLETED,2011-02,2012-07,2014-06-27,INTERVENTIONAL,PHASE3,801.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Coronary Syndrome|Percutaneous Coronary Intervention,Ticagrelor|Clopidogrel|Acetylsalicylic acid ASA,DRUG,2,2,20 Years,,ALL,False,AstraZeneca,INDUSTRY,0,87,South Korea|Japan|Taiwan,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.687108607866515,xlarge,0,1,1,0,1,0,1,1,0,0,1,1,1,1,4,1,1,0,0,3,1,,,,,0,3,1
NCT00003746,Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia,Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine (CDA) in Patients With Hairy Cell Leukemia,COMPLETED,1998-09,2010-11,2012-05-15,INTERVENTIONAL,PHASE3,100.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,NONE,Leukemia,2-chlorodeoxyadenosine (CDA) daily|2-chlorodeoxyadenosine weekly,DRUG,2,5,18 Years,,ALL,False,Swiss Cancer Institute,OTHER,0,1,Switzerland,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.61512051684126,medium,0,1,0,1,0,0,0,0,0,0,1,0,1,0,7,1,1,0,0,2,1,,,,,0,2,0
NCT01826188,Combined THC and CBD Drops for Treatment of Crohn's Disease,"Combined THC and CBD Drops for Treatment of Crohn's Disease, a Phase II Double Blind Placebo Controlled Trial",COMPLETED,2013-03,2018-06,2019-03-08,INTERVENTIONAL,PHASE1|PHASE2,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Crohn's Disease,THC 5mg/ml and CBS 50mg/ml|Placebo,DRUG,1,5,20 Years,85 Years,ALL,False,Meir Medical Center,OTHER,0,1,Israel,1.0,1,1,0,0,1,1.5,0,1,0,0,1,3.9318256327243257,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,3,1
NCT01740388,"Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis","A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis",TERMINATED,2013-02,2013-11,2014-10-01,INTERVENTIONAL,PHASE3,136.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Bacterial Conjunctivitis,Besifloxacin|Vehicle,DRUG,2,2,1 Year,,ALL,False,Bausch & Lomb Incorporated,INDUSTRY,0,1,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,4.919980925828125,medium,0,1,1,0,0,0,0,0,1,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00029003,Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,Phase II Trial of Chronic Oral ZD1839 (Iressa®) (NSC-715055) in Both Previously-Untreated and Previously-Treated Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC),COMPLETED,2001-12,,2013-02-28,INTERVENTIONAL,PHASE2,90.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Bronchoalveolar Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer,gefitinib|laboratory biomarker analysis,DRUG|OTHER,1,4,,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,4.51085950651685,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,5,1,1,0,0,2,1,,,,,0,2,0
NCT01194427,A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer,A Multi-Institutional Phase II Study Evaluating Surrogate Biomarkers of Response to Short Term Oral Vorinostat and Tamoxifen in Women With Newly Diagnosed Breast Cancer,TERMINATED,2011-03,2011-11,2013-05-17,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,BASIC_SCIENCE,NONE,Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|Invasive Breast Cancer,Vorinostat and Tamoxifen,DRUG,1,0,18 Years,,FEMALE,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,4,1.0986122886681098,small,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,,,,,0,1,0
NCT00969527,Efficacy of Oncoxin Plus Viusid in the Treatment of Rheumatoid Arthritis,Assessment of the Efficacy of Oncoxin+Viusid Administration in the Treatment of Rheumatoid Arthritis,COMPLETED,2009-09,2011-04,2011-05-09,INTERVENTIONAL,PHASE3,86.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Rheumatoid Arthritis,Oncoxin + Viusid|Placebo,DIETARY_SUPPLEMENT,1,1,18 Years,,ALL,False,Catalysis SL,INDUSTRY,0,1,Cuba,1.0,0,0,1,0,0,3.0,0,1,0,0,1,4.465908118654584,medium,1,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,0,0,0,2,1,,,,,0,1,0
NCT01373242,Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance,Peanut Sublingual Immunotherapy and Induction of Clinical Tolerance in Peanut Allergic Children (SLIT Tolerance TLC) {Sublingual Immunotherapy for Peanut Allergy},COMPLETED,2011-06,2018-04-16,2019-06-12,INTERVENTIONAL,PHASE1|PHASE2,54.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Peanut Hypersensitivity|Food Hypersensitivity|Food Allergy|Peanut Allergy,Liquid peanut extract (Peanut SLIT),DRUG,5,5,1 Year,12 Years,ALL,False,"University of North Carolina, Chapel Hill",OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,4,4.007333185232471,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,10,1,1,0,0,1,0,,2018-04-16,,,0,3,1
NCT00151242,"Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia",Randomized Phase II/III-Study on All-Trans Retinoic Acid in Combination With Induction and Consolidation Therapy as Well as Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia,COMPLETED,2004-07,2013-08,2017-09-20,INTERVENTIONAL,PHASE2|PHASE3,920.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Myeloid Leukemia,Cytarabine|Idarubicin|Etoposide|All-trans retinoic acid|Pegfilgrastim,DRUG,3,8,18 Years,60 Years,ALL,False,University of Ulm,OTHER,0,34,Germany|Austria,1.0,0,1,1,0,1,2.5,1,0,0,0,1,6.825460036255307,xlarge,0,1,0,1,0,0,1,1,0,1,1,0,1,1,11,1,1,0,0,5,1,,,,,0,4,1
NCT00915486,A Dose Finding Study of Topically Applied I-020201 as an Adjunct to Good Standard-of-care in Patients With Chronic Diabetic Foot Ulcers,"A Randomized, Multi-center, Controlled, Parallel Group, Dose Finding Study of the Efficacy and Safety of Topically Applied I-020201 as an Adjunct to Good Standard-of-care Versus Good Standard-of-care Alone in Patients With Chronic Diabetic Foot Ulcers",COMPLETED,2009-05,2012-03,2012-03-16,INTERVENTIONAL,PHASE2,211.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetic Foot Ulcer,Good Standard of Care (GSoC)|Vehicle|I-020201,PROCEDURE|BIOLOGICAL,1,8,18 Years,,ALL,False,Kuros Biosurgery AG,INDUSTRY,0,34,Russia|Hungary|Czechia|Germany|Romania|Serbia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.356586274672012,large,0,1,1,0,0,0,1,1,0,1,1,1,1,1,9,1,0,1,0,3,1,,,,,0,3,1
NCT03940586,Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030),"A Phase 2b Open-label, Single-arm Study to Evaluate Pharmacokinetics, Efficacy, Safety and Tolerability of Letermovir in Pediatric Participants From Birth to Less Than 18 Years of Age at Risk of Developing CMV Infection and/or Disease Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)",COMPLETED,2019-08-08,2023-08-25,2024-08-22,INTERVENTIONAL,PHASE2,65.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Cytomegalovirus (CMV) Infection,Letermovir oral granules|Letermovir tablet|Letermovir intravenous,DRUG,23,6,,17 Years,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,40,Turkey (Türkiye)|Mexico|Australia|United States|Colombia|Poland|France|Spain|Germany|Japan|Israel,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.189654742026425,medium,1,1,1,0,1,0,1,1,1,1,0,0,0,0,29,1,1,0,0,3,1,2019-08-08,2023-08-25,1478.0,2019.0,1,3,1
NCT01088373,Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q,A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q,COMPLETED,2010-03-25,2016-07-25,2017-12-15,INTERVENTIONAL,PHASE2,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Myelodysplastic Syndromes,Azacitidine combined to Lenalidomide,DRUG,1,1,18 Years,75 Years,ALL,False,Groupe Francophone des Myelodysplasies,OTHER,1,34,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,1,1,0,0,1,0,0,1,0,2,1,1,0,0,1,0,2010-03-25,2016-07-25,2314.0,2010.0,0,0,0
NCT00983073,Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic,"An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Uncontrolled Severe Chronic Pain Due to Osteoarthritis of the Knee Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics.",COMPLETED,2009-09,2010-09,2019-10-21,INTERVENTIONAL,PHASE3,224.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Pain|Osteoarthritis,Tapentadol,DRUG,1,17,40 Years,,ALL,False,Grünenthal GmbH,INDUSTRY,0,24,United Kingdom|France|Spain|Germany|Poland,1.0,0,0,1,0,0,3.0,0,1,0,0,2,5.41610040220442,large,0,1,1,0,0,0,1,1,0,1,0,0,1,0,18,1,1,0,0,1,0,,,,,0,3,1
NCT00799383,Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia,Counteracting Risperidone-Induced Hyperprolactinemia in Youths,COMPLETED,2008-11,2014-03,2017-12-26,INTERVENTIONAL,PHASE3,47.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Risperidone-induced Hyperprolactinemia,Calcium and Vitamin D|Placebo,DRUG|OTHER,2,6,5 Years,17 Years,MALE,False,Chadi A. Calarge,OTHER,2,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.871201010907891,small,1,1,0,1,0,1,0,0,1,0,1,1,0,1,8,1,1,0,0,2,1,,,,,0,2,0
NCT02053883,Cethrin in Acute Cervical Spinal Cord Injury,"A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Cethrin in Subjects With Acute Cervical Spinal Cord Injury",WITHDRAWN,2015-07,,2014-11-26,INTERVENTIONAL,PHASE2|PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Spinal Cord Injury,Cethrin (BA-210)|Placebo,DRUG,1,7,18 Years,62 Years,ALL,False,"BioAxone BioSciences, Inc.",INDUSTRY,0,0,,0.0,0,1,1,0,1,2.5,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,1,1,8,1,1,0,0,2,1,,,,,0,3,1
NCT01793441,A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD),"A Multi-Center, Randomized, Double-Blind, 12-Week, Parallel Group, Placebo-Controlled Proof of Concept Study to Investigate the Efficacy and Safety of RG7314 in Individuals With Autism Spectrum Disorders (ASD)",COMPLETED,2013-09,2016-09,2017-02-03,INTERVENTIONAL,PHASE2,223.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Autism Spectrum Disorder,Placebo|RG7314,DRUG,3,13,18 Years,45 Years,MALE,False,Hoffmann-La Roche,INDUSTRY,0,56,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.4116460518550396,large,0,1,1,0,1,0,1,0,1,0,1,1,1,1,16,1,1,0,0,2,1,,,,,0,2,0
NCT02998541,Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo,"A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis",TERMINATED,2017-03-27,2019-05-13,2021-06-14,INTERVENTIONAL,PHASE3,219.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Adenoviral Conjunctivitis,SHP640|PVP-I 0.6%|Placebo,DRUG|OTHER,1,15,,,ALL,False,Shire,INDUSTRY,0,130,United Kingdom|Estonia|Australia|United States|Canada|Hungary|Austria|France|South Africa|Spain|Italy|Germany|Poland|Israel|India|Peru,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.393627546352362,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,16,1,1,0,0,3,1,2017-03-27,2019-05-13,777.0,2017.0,1,3,1
NCT04072354,A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia,"A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects With Schizophrenia",COMPLETED,2019-09-11,2023-09-12,2024-06-26,INTERVENTIONAL,PHASE3,463.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia,SEP-363856 50mg|SEP-363856 75mg|Placebo,DRUG,1,1,13 Years,65 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,0,58,Russia|Ukraine|Bulgaria|United States|Colombia|Serbia,1.0,0,0,1,0,0,3.0,0,0,1,0,1,6.139884552226255,large,0,1,1,0,0,0,1,1,1,0,1,1,1,1,2,1,1,0,0,3,1,2019-09-11,2023-09-12,1462.0,2019.0,1,2,0
NCT04338074,TXA and Corona Virus 2019 (COVID19) in Outpatients,Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients,TERMINATED,2020-06-01,2021-04-21,2021-05-13,INTERVENTIONAL,PHASE2,5.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,COVID-19,Tranexamic acid tablets|Placebo oral tablet,DRUG,1,0,19 Years,,ALL,False,University of Alabama at Birmingham,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.791759469228055,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2020-06-01,2021-04-21,324.0,2020.0,1,1,0
NCT00123318,A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer,A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer,COMPLETED,2003-02,2012-02,2013-06-18,INTERVENTIONAL,PHASE3,52.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Gastric Cancer,epirubicin|cisplatin|5-fluorouracil|Radiotherapy,DRUG|RADIATION,3,1,18 Years,,ALL,False,Trans Tasman Radiation Oncology Group,OTHER,1,19,New Zealand|Australia,1.0,0,0,1,0,0,3.0,1,0,0,0,1,3.970291913552122,medium,1,1,0,1,0,1,1,1,0,0,0,0,1,0,4,1,1,0,0,4,1,,,,,0,2,0
NCT01332318,Simulated Driving Study in Restless Legs Syndrome,"A Randomized, Double Blind, Active- and Placebo-Controlled, Parallel Group Safety Study Assessing Simulated Driving Performance in XP13512-(GSK1838262) Treated Patients With Restless Legs Syndrome",COMPLETED,2007-04,2007-11,2013-07-26,INTERVENTIONAL,PHASE2,130.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Restless Legs Syndrome,XP13512|Diphenhydramine|Placebo,DRUG,1,27,21 Years,65 Years,ALL,False,"XenoPort, Inc.",INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.875197323201151,medium,0,1,1,0,0,0,0,0,1,0,1,1,1,1,28,1,1,0,0,3,1,,,,,0,2,0
NCT04515290,A Phase IIa Clinical Trial on TSG-01 in the Treatment of Chronic Heart Failure in Patients With Coronary Heart Disease.,A Phase IIa Clinical Trial on TSG-01 in the Treatment of Chronic Heart Failure in Patients With Coronary Heart Disease.,COMPLETED,2020-05-07,2022-04-22,2022-10-26,INTERVENTIONAL,PHASE2,85.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Heart Failure,TSG-01|TSG-01 and Placebo|Placebo,DRUG,2,6,40 Years,75 Years,ALL,False,Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.,INDUSTRY,0,5,China,1.0,0,1,0,0,0,2.0,0,0,0,1,1,4.454347296253507,medium,1,1,1,0,0,0,1,0,0,0,1,1,1,1,8,1,1,0,0,3,1,2020-05-07,2022-04-22,715.0,2020.0,1,2,0
NCT02502097,A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016),"A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough",COMPLETED,2015-08-26,2016-07-14,2021-05-26,INTERVENTIONAL,PHASE2,51.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Idiopathic Pulmonary Fibrosis|Cough,Gefapixant|Placebo,DRUG|OTHER,4,22,40 Years,,ALL,False,"Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.9512437185814275,medium,1,1,1,0,1,0,0,0,0,0,1,1,1,0,26,1,1,0,0,2,1,2015-08-26,2016-07-14,323.0,2015.0,1,3,1
NCT01334710,A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer,A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer,TERMINATED,2011-03,2011-12,2017-11-21,INTERVENTIONAL,PHASE2,3.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Liver Cancer,Sorafenib and OSI-906,DRUG,1,1,18 Years,,ALL,False,Emory University,OTHER,1,3,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.3862943611198906,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT02397213,Ciclosporin to Protect Renal Function In Cardiac Surgery,Ciclosporin to Protect Renal Function In Cardiac Surgery: CiPRICS A Phase II Double Blind Randomized Placebo Controlled Study,COMPLETED,2015-04,2016-09,2016-10-13,INTERVENTIONAL,PHASE2,155.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Acute Kidney Injury,Ciclosporin|Placebo,DRUG,1,0,,,ALL,False,Region Skane,OTHER,1,1,Sweden,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.049856007249537,medium,0,1,0,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT00410813,"S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone",Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone Metastasis Predominant Metastatic Breast Cancer,COMPLETED,2007-03,2014-01,2017-07-02,INTERVENTIONAL,PHASE2,85.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer|Metastatic Cancer,dasatinib,DRUG,1,11,18 Years,,ALL,False,SWOG Cancer Research Network,NETWORK,1,117,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.454347296253507,medium,1,1,0,0,0,1,1,0,1,0,1,0,1,1,12,1,1,0,0,1,0,,,,,0,2,0
NCT02015260,A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts,"A Randomised, Multicentre, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate the Efficacy, Safety and Tolerability of Three Dose Regimens of Topical Nitric Oxide in Patients With Anogenital Warts",COMPLETED,2001-09,2003-05,2017-05-03,INTERVENTIONAL,PHASE2,299.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Anogenital Warts|Condylomata Acuminata,Topical NO|Placebo,DRUG,1,6,18 Years,,ALL,False,University of Aberdeen,OTHER,2,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.703782474656201,large,0,1,0,1,0,1,0,0,0,0,1,1,1,1,7,1,1,0,0,2,1,,,,,0,3,1
NCT01850420,A Study of IMC-1 In Patients With Fibromyalgia,"A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia",COMPLETED,2013-05,2014-03,2015-03-27,INTERVENTIONAL,PHASE2,143.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Fibromyalgia|Chronic Pain|Myofascial Pain,IMC-1,DRUG,1,2,18 Years,70 Years,ALL,False,"Innovative Med Concepts, LLC",INDUSTRY,0,12,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,4.969813299576001,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,3,1,1,0,0,1,0,,,,,0,1,0
NCT02077920,Methods of Chlorhexidine Cleansing to Prevent Ventilator-Associated Pneumonia (VAP),Prevention of Ventilator-Associated Pneumonia by Oropharyngeal and Subglottic Decontamination Via Bronchoscopy,COMPLETED,2014-03,2019-08,2019-08-14,INTERVENTIONAL,PHASE2,192.0,ACTUAL,NON_RANDOMIZED,PARALLEL,PREVENTION,NONE,Ventilator-associated Pneumonia,Chlorhexidine|0.9% sodium chloride injection|Endotracheal tube|Fiber bronchoscope,DRUG|DEVICE,1,5,,,ALL,False,General Hospital of Shenyang Military Region,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.262690188904886,medium,0,1,0,1,0,0,0,0,0,0,0,0,0,1,6,1,1,0,1,4,1,,,,,0,2,0
NCT00473460,Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis,"A Double-blind, Randomized, Placebo-controlled Study to Investigate Chronic Intermittent-pulse-therapy of Moxifloxacin as a Prevention of Acute in Exacerbation Out-patients With Chronic Bronchitis.",COMPLETED,2004-10,2007-01,2014-10-28,INTERVENTIONAL,PHASE3,1404.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,"Lung Diseases|Bronchitis, Chronic","Avelox (Moxifloxacin, BAY12-8039)|Placebo",DRUG,1,9,45 Years,90 Years,ALL,False,Bayer,INDUSTRY,0,78,United Kingdom|Argentina|Chile|Mexico|United States|Brazil|Ireland|Andorra|France|South Africa|Spain|Italy|Germany|Greece|Israel,1.0,0,0,1,0,0,3.0,0,0,0,0,2,7.247792581767846,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,0,1,10,1,1,0,0,2,1,,,,,0,4,1
NCT02819960,Prevention of Irinotecan Induced Diarrhea by Probiotics,Prevention of Irinotecan Induced Diarrhea by Probiotics: A Phase III Study,COMPLETED,2016-03,2022-11,2022-12-14,INTERVENTIONAL,PHASE3,233.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Diarrhea|Cancer,Probio-Tec® BG-VCap-6.5|Placebo,DRUG,1,4,18 Years,,ALL,False,S&D Pharma SK s.r.o.,INDUSTRY,1,1,Slovakia,1.0,0,0,1,0,0,3.0,1,0,0,0,2,5.455321115357702,large,0,1,1,0,0,1,0,0,0,0,1,1,0,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00050960,"Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer",Randomized Phase III Trial Comparing Targretin Capsules/Carboplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Chemotherapy-Naïve Patients With Advanced or Metastatic Non-Small Cell Lung Cancer,COMPLETED,2002-05,2005-03,2012-07-13,INTERVENTIONAL,PHASE3,612.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non-small Cell Lung Cancer,bexarotene with carboplatin and paclitaxel|carboplatin and paclitaxel,DRUG,1,0,,,ALL,False,Eisai Inc.,INDUSTRY,0,154,United States|Canada|Austria|France|Spain|Germany,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.418364935936212,xlarge,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,0,1,0,0,2,1,,,,,0,2,0
NCT02232620,A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors,A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors,TERMINATED,2017-03-13,2017-07-25,2023-11-14,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Gastrointestinal Stromal Tumors,BBI503,DRUG,1,5,18 Years,,ALL,False,"Sumitomo Pharma America, Inc.",INDUSTRY,0,1,Canada,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.0986122886681098,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,1,0,2017-03-13,2017-07-25,134.0,2017.0,1,1,0
NCT00421824,Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer,Phase II Randomized Trial of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer,COMPLETED,2006-05,2010-11,2011-01-04,INTERVENTIONAL,PHASE2,108.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Rectal Neoplasms,"Oxaliplatin, capecitabine|Oxaliplatin, capecitabine",DRUG,1,3,18 Years,75 Years,ALL,False,Sanofi,INDUSTRY,0,1,Spain,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.6913478822291435,medium,0,1,1,0,1,0,0,0,0,1,1,0,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00238524,A Trial to Assess the Efficacy and Safety of SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy,"A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 400mg/Day and 600mg/Day SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy",COMPLETED,2003-12,2005-01,2014-09-22,INTERVENTIONAL,PHASE3,357.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetic Neuropathy,SPM 927,DRUG,1,1,18 Years,,ALL,False,UCB Pharma,INDUSTRY,0,1,Germany,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.8805329864007,large,0,1,1,0,0,0,0,0,0,1,1,1,1,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT00027924,Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome,Fludarabine And Busulfan As Conditioning For Patients With Chronic Myeloid Leukemia Or Myelodysplastic Syndrome Transplanted With Hematopoietic Stem Cells From HLA-Compatible Related Or Unrelated Donors,COMPLETED,2001-10,2003-05,2010-04-02,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Leukemia|Myelodysplastic Syndromes,busulfan|cyclosporine|fludarabine phosphate|methotrexate|peripheral blood stem cell transplantation,DRUG|PROCEDURE,0,0,,65 Years,ALL,False,Fred Hutchinson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,0.0,,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,5,1,,,,,0,2,0
NCT01684124,An Assessment of the Feasibility and Safety of Conservative Oxygen Therapy in Critically Ill Patients,A Before-and-after Assessment of Conservative Oxygen Therapy vs. Standard Care in Critically Ill Mechanically Ventilated Patients,COMPLETED,2012-03,2013-03,2013-07-11,INTERVENTIONAL,PHASE1|PHASE2,105.0,ACTUAL,NON_RANDOMIZED,CROSSOVER,TREATMENT,NONE,Critical Illness,conservative O2 therapy|standard care,OTHER,1,1,18 Years,90 Years,ALL,False,Austin Health,OTHER_GOV,0,1,Australia,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.663439094112067,medium,0,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,0,0,0,2,1,,,,,0,2,0
NCT00092859,A 2-Year Study of an Investigational Drug in Obese Patients (0557-011),"A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of MK0557 in Obese Patients",COMPLETED,2003-08,2005-06,2017-01-02,INTERVENTIONAL,PHASE3,1500.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Obesity,MK0557,DRUG,1,1,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.313886831633462,xlarge,0,1,1,0,1,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT00266279,Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies,Phase II Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies,COMPLETED,2005-04,2009-10,2020-09-03,INTERVENTIONAL,PHASE2,17.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Head or Neck Cancer,"Oxaliplatin, Capecitabine",DRUG,1,1,18 Years,,ALL,False,University of Louisville,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.8903717578961645,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT04022096,Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Esophagitis,"A Phase 3, Double-blind, Randomized, Active-controlled Study to Evaluate the Safety and Efficacy of Tegoprazan as Maintenance Therapy in Patients With Healed Erosive Esophagitis",COMPLETED,2019-06-18,2021-06-23,2023-01-27,INTERVENTIONAL,PHASE3,351.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Healed Erosive Esophagitis,Tegoprazan 25mg QD|Lansoprazole 15mg QD,DRUG,1,1,20 Years,75 Years,ALL,False,HK inno.N Corporation,INDUSTRY,0,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.863631175598097,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2019-06-18,2021-06-23,736.0,2019.0,1,1,0
NCT00170196,Efficacy Studies of Corticosteroid Therapy in Community-Acquired Pneumonia,The CAPISCE-Trial: Community-Acquired Pneumonia; an Intervention Study With Corticosteroids,COMPLETED,2005-08,2008-09,2008-09-29,INTERVENTIONAL,PHASE3,216.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Pneumonia,prednisone,DRUG,1,6,18 Years,,ALL,False,Medical Center Alkmaar,OTHER,0,1,Netherlands,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.37989735354046,large,0,1,0,1,0,0,0,0,0,0,1,1,1,1,7,1,1,0,0,1,0,,,,,0,1,0
NCT00021762,Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV,"A Pilot Phase II Evaluation of the Effects on HIV Replication of Immunization With a gp120-Depleted, Inactivated Whole Virus Vaccine Combined With Exposures to Replicating Autologous HIV by Scheduled Treatment Interruptions, a Rollover Study of A5057",WITHDRAWN,,,2021-11-01,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,,TREATMENT,,HIV Infections,HIV-1 Immunogen|Structured Treatment Interruption,PROCEDURE|BIOLOGICAL,0,0,,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,2,1,,,,,0,1,0
NCT00282646,Safety and Feasibility Study of Autologous Bone Marrow Cell Transplantation in Patients With Peripheral Arterial Occlusive Disease (PAOD),(Intraarterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells for Induction of Neovascularization in Patients With Peripheral Arterial Occlusive Disease),COMPLETED,2005-10,2011-03,2021-10-26,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Arterial Occlusive Diseases,intraarterial stem cell therapy|Stem cells,PROCEDURE|OTHER,1,4,18 Years,80 Years,ALL,False,Johann Wolfgang Goethe University Hospital,OTHER,0,1,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.713572066704308,small,1,1,0,1,0,0,0,0,0,1,1,1,1,1,5,1,0,0,0,2,1,,,,,0,1,0
NCT01572662,Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning,Phase II Study of Timed Sequential Busulfan in Combination With Fludarabine in Allogeneic Stem Cell Transplantation,COMPLETED,2012-04-11,2022-08-11,2023-06-29,INTERVENTIONAL,PHASE2,201.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Leukemia|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Myeloid Leukemia|Chronic Lymphocytic Leukemia|Myeloproliferative Diseases|Non-Hodgkins Lymphoma|Hodgkins Lymphoma|Multiple Myeloma|Myelodysplastic Syndrome,Fludarabine monophosphate|Busulfan|Stem Cell Infusion|Tacrolimus|Methotrexate|G-CSF,DRUG|PROCEDURE,1,2,5 Years,75 Years,ALL,False,M.D. Anderson Cancer Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,10,5.308267697401205,large,0,1,0,1,0,0,0,0,1,0,0,0,1,0,3,1,1,0,0,6,1,2012-04-11,2022-08-11,3774.0,2012.0,0,2,0
NCT02082262,AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis,,COMPLETED,2014-03,2014-07,2016-03-14,INTERVENTIONAL,PHASE3,140.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Conjunctivitis, Allergic",AGN-229666,DRUG,1,0,10 Years,,ALL,False,Allergan,INDUSTRY,0,1,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.948759890378168,medium,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT04697888,Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease,Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease,COMPLETED,2013-04,2018-11,2021-06-11,INTERVENTIONAL,PHASE2|PHASE3,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Parenteral Nutrition-related Hepatitis,Omegaven,DRUG,1,0,,17 Years,ALL,False,Children's Mercy Hospital Kansas City,OTHER,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,1,0
NCT02493946,Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines,"Phase III, Randomised, Double Blind, Placebo Controlled and Open Label Phase Multicentre Study to Investigate the Efficacy and Safety of BTX-A-HAC NG in the Treatment of Moderate to Severe Glabellar Lines, and Assess the Long Term Efficacy and Safety of BTX-A-HAC NG Following Repeated Treatments in This Indication",COMPLETED,2015-04,2016-12,2022-09-28,INTERVENTIONAL,PHASE3,600.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Glabellar Lines,Botulinum toxin type A|Placebo,DRUG|BIOLOGICAL,1,17,18 Years,65 Years,ALL,False,Ipsen,INDUSTRY,0,24,Germany|France|United Kingdom,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.398594934535208,xlarge,0,1,1,0,0,0,1,1,0,1,1,1,1,1,18,1,1,1,0,2,1,,,,,0,3,1
NCT00854503,Metabolic and Vascular Effects of Statins in Untreated Dyslipidemic Diabetic Patients,,COMPLETED,2008-09,2010-12,2011-05-12,INTERVENTIONAL,PHASE3,30.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,SINGLE,Type 2 Diabetes|Diabetic Dyslipidemia,Simvastatin|Rosuvastatin,DRUG,1,1,50 Years,75 Years,ALL,False,University of Rome Tor Vergata,OTHER,0,1,Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,2,3.4339872044851463,small,1,1,0,1,0,0,0,0,0,1,1,0,1,0,2,1,1,0,0,2,1,,,,,0,2,0
NCT05988203,A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines,"A Randomized, Partially Observer-blind, Dose-escalation, Phase I/II Trial Evaluating the Safety and Immunogenicity of Investigational RNA-based Mpox Vaccine Candidates",ACTIVE_NOT_RECRUITING,2023-09-21,2026-03,2025-10-22,INTERVENTIONAL,PHASE1|PHASE2,96.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,PREVENTION,NONE,Monkeypox,BNT166a,BIOLOGICAL,6,0,18 Years,65 Years,ALL,True,BioNTech SE,INDUSTRY,0,8,United Kingdom|United States,,1,1,0,0,1,1.5,0,0,0,0,1,4.574710978503383,medium,1,1,1,0,0,0,1,1,1,1,0,0,0,0,6,0,0,1,0,1,0,2023-09-21,,,2023.0,1,3,1
NCT00021827,PTHrP and Osteoporosis,Pathophysiology of PTH-related Protein in Humans.,COMPLETED,1999-06,2001-12,2010-03-02,INTERVENTIONAL,PHASE2,,,RANDOMIZED,,TREATMENT,DOUBLE,Osteoporosis,Parathyroid hormone-related protein or ''PTHrP'',DRUG,0,0,50 Years,75 Years,FEMALE,False,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT01441427,Enteral Granulocyte Colony Stimulating Factor and Erythropoietin Early in Life Increases Feeding Tolerance in Preterm Infants: A Randomized Controlled Trial,,COMPLETED,2010-01,2011-08,2011-09-27,INTERVENTIONAL,PHASE1|PHASE2,93.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Feeding Intolerance|Necrotizing Enterocolitis,"recombinant human G-CSF, and rhEPO|rh G-CSF|rh EPO|rh G-GSF and rh EPO together|Placebo",DRUG,4,1,,1 Month,ALL,False,Ain Shams University,OTHER,0,0,,1.0,1,1,0,0,1,1.5,0,1,0,0,2,4.543294782270004,medium,1,1,0,1,0,0,0,0,0,0,1,1,0,1,5,1,1,0,0,5,1,,,,,0,3,1
NCT01652261,Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11),"Very Early FDG-PET/CT-response Adapted Therapy for Advanced Stage Hodgkin Lymphoma, a Randomized Phase III Non-inferiority Study of the EORTC Lymphoma Group",WITHDRAWN,2013-05,2014-10,2021-02-15,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hodgkin Lymphoma,ABVD + FDG-PET/CT Scan treatment adaptation|BEACOPPesc,DRUG,1,5,18 Years,60 Years,ALL,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,1,1,Denmark,0.0,0,0,1,0,0,3.0,1,0,0,0,1,0.0,,1,1,0,0,0,1,0,0,0,0,1,0,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT02540161,Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma,Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma,COMPLETED,2016-02-01,2020-04-27,2020-08-05,INTERVENTIONAL,PHASE2,43.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Malignant Glioma,Sym004 - 18 mg/kg|Sym004 - 24 mg/kg,DRUG,1,4,18 Years,,ALL,False,Annick Desjardins,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.784189633918261,small,1,1,0,1,0,1,0,0,1,0,0,0,1,1,5,1,1,0,0,2,1,2016-02-01,2020-04-27,1547.0,2016.0,1,1,0
NCT05663086,Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above,"A Randomized, Blinded, Positive-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 in Population Aged 18 Years and Above（Negative for Antibody Against COVID-19）",WITHDRAWN,2023-01-07,2023-06-27,2023-09-26,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,COVID-19,One dose group|Two doses group|Aged 18-59 years|Aged 60 years old and above,BIOLOGICAL,1,9,18 Years,,ALL,True,"Guangzhou Patronus Biotech Co., Ltd.",INDUSTRY,1,1,China,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,1,0,0,1,0,0,0,0,1,1,0,1,10,1,0,1,0,4,1,2023-01-07,2023-06-27,171.0,2023.0,1,2,0
NCT01641770,Oral Nutritional Supplementation in Hospital Patients,Oral Nutritional Supplementation in Hospital Patients,COMPLETED,2010-10,2011-10,2012-07-17,INTERVENTIONAL,PHASE3,212.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Malnutrition,Nutritional beverage 10003RF|Dietary Counseling|Dietary Counseling,OTHER,1,6,18 Years,,ALL,False,Abbott Nutrition,INDUSTRY,0,13,India,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.3612921657094255,large,0,1,1,0,0,0,1,0,0,0,1,0,1,1,7,1,0,0,0,3,1,,,,,0,2,0
NCT02604173,Altitude Sickness Prevention and Efficacy of Comparative Treatments,A Randomized Controlled Trial of Altitude Sickness Prevention and Efficacy of Comparative Treatments,COMPLETED,2016-08,2016-09,2018-12-12,INTERVENTIONAL,PHASE3,103.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Acute Mountain Sickness,Budesonide|Acetazolamide|Placebo,DRUG,1,2,18 Years,65 Years,ALL,True,Stanford University,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.6443908991413725,medium,0,1,0,1,0,0,0,0,1,0,1,1,0,1,3,1,1,0,0,3,1,,,,,0,1,0
NCT02721069,Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects,"A 12-Month Open-Label, Repeat-Dose Safety Study of NRL-1 in Epilepsy Subjects (DIAZ.001.05)",COMPLETED,2016-04-11,2020-07-23,2022-01-31,INTERVENTIONAL,PHASE3,175.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Repetitive Seizures|Breakthrough Seizures,NRL-1,DRUG,1,0,6 Years,65 Years,ALL,False,"Neurelis, Inc.",INDUSTRY,0,5,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.170483995038151,medium,0,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,0,2016-04-11,2020-07-23,1564.0,2016.0,1,1,0
NCT02818569,Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic,Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic,COMPLETED,2016-10,2018-06,2019-10-02,INTERVENTIONAL,PHASE1|PHASE2,15.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Sleep|Insomnia,Dexmedetomidine|Saline Placebo,DRUG|OTHER,2,3,18 Years,50 Years,ALL,True,Massachusetts General Hospital,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,2,2.772588722239781,small,1,1,0,1,0,0,0,0,1,0,1,1,1,0,5,1,1,0,0,2,1,,,,,0,3,1
NCT02337569,"A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency","A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency",COMPLETED,2015-01,2015-11,2019-04-17,INTERVENTIONAL,PHASE3,57.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Zinc Deficiency,NPC-02|Placebos,DRUG,1,0,20 Years,,ALL,False,Nobelpharma,INDUSTRY,0,1,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.060443010546419,medium,1,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT01306669,Influenza Vaccine Trial in HIV Uninfected Pregnant Women,"Vaccination of HIV-uninfected Pregnant Women With Trivalent Influenza Vaccine in the Prevention of Influenza Illness During Early Infancy and in Mothers: Randomized Controlled Phase III Trial Evaluating Safety, Immunogenicity and Efficacy",COMPLETED,2011-03-03,2013-05,2018-08-06,INTERVENTIONAL,PHASE3,2116.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Influenza,Trivalent influenza vaccine|Normal saline,BIOLOGICAL,2,5,18 Years,39 Years,FEMALE,True,"University of Witwatersrand, South Africa",OTHER,3,1,South Africa,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.6577552711348655,xlarge,0,1,0,1,0,1,0,0,0,0,1,1,0,1,7,1,0,1,0,2,1,2011-03-03,,,2011.0,0,2,0
NCT05619783,Extension Study Evaluating The Safety And Tolerability of AMX0035,"A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants With Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX)",COMPLETED,2022-12-29,2024-10-30,2025-01-13,INTERVENTIONAL,PHASE3,352.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Amyotrophic Lateral Sclerosis,AMX0035,DRUG,1,1,18 Years,,ALL,False,Amylyx Pharmaceuticals Inc.,INDUSTRY,0,46,United Kingdom|Sweden|Ireland|Poland|Portugal|France|Spain|Germany|Netherlands|Belgium|Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.8664680569332965,large,0,1,1,0,0,0,1,1,0,1,0,0,1,0,2,1,1,0,0,1,0,2022-12-29,2024-10-30,671.0,2022.0,1,1,0
NCT03080883,Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy,"A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy",COMPLETED,2017-07-14,2025-05-09,2025-05-18,INTERVENTIONAL,PHASE3,370.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Cerebral Vein Thrombosis|Deep Vein Thrombosis|Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Pulmonary Embolism|Splanchnic Vein Thrombosis,Apixaban,DRUG,1,2,18 Years,,ALL,False,Academic and Community Cancer Research United,OTHER,1,32,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,7,5.916202062607435,large,0,1,0,1,0,1,1,0,1,0,1,1,0,1,3,1,1,0,0,1,0,2017-07-14,2025-05-09,2856.0,2017.0,1,1,0
NCT04600141,Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection,Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection: a Randomized Clinical Trial,COMPLETED,2020-11-10,2021-12-31,2022-03-18,INTERVENTIONAL,PHASE3,308.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Covid19,Tocilizumab|Heparin - Therapeutic dosage|Heparin - Prophylactic dosage,DRUG,1,7,18 Years,,ALL,False,University of Sao Paulo,OTHER,1,3,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.733341276897746,large,0,1,0,1,0,1,1,0,0,0,1,0,1,1,8,1,1,0,0,3,1,2020-11-10,2021-12-31,416.0,2020.0,1,2,0
NCT00888654,Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy,"Phase II Trial of B-DIM (DIM: 3,3 Diindolylmethane) on Intermediate Endpoint Biomarkers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy",COMPLETED,2009-08,2014-04,2018-03-19,INTERVENTIONAL,PHASE2,41.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,B-Dim|Radical Prosatectomy,DRUG|PROCEDURE,1,2,18 Years,120 Years,MALE,False,Barbara Ann Karmanos Cancer Institute,OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.7376696182833684,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,3,1,1,0,0,2,1,,,,,0,1,0
NCT00809705,A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes,"A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Investigate the Effect of Taspoglutide on Gastric Emptying Measured by a Paracetamol Test After Single Dose and After Multiple Doses in Patients With Type 2 Diabetes",COMPLETED,2008-12,2009-10,2016-11-02,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Diabetes Mellitus Type 2,Placebo|taspoglutide|taspoglutide,DRUG,1,3,18 Years,75 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,3,Germany|United Kingdom,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.110873864173311,medium,1,1,1,0,1,0,1,1,0,1,1,1,1,1,4,1,1,0,0,3,1,,,,,0,2,0
NCT00168805,RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery,RE-MODEL (Thromboembolism Prevention After Knee Surgery). Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With a Half Dose (i.e.75 or 110 mg) on the Day of Surgery] Compared to Subcutaneous Enoxaparin 40 mg Once Daily for 6-10 Days,COMPLETED,2004-11,,2014-05-19,INTERVENTIONAL,PHASE3,2101.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,"Arthroplasty, Replacement, Knee|Thromboembolism",enoxaparin|dabigatran etexilate|dabigatran etexilate,DRUG,1,11,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,105,Finland|Denmark|Australia|Sweden|Hungary|Poland|Austria|France|South Africa|Spain|Czechia|Germany|Netherlands|Belgium|Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,2,7.650644551436897,xlarge,0,1,1,0,0,0,1,1,0,1,1,1,0,1,12,1,1,0,0,3,1,,,,,0,4,1
NCT04488094,Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation,"A Phase 2, Open-label, Non-randomized, Single Center Study to Explore Diagnostic Performance of [18F]FSPG PET/CT for the Assessment of Acute Allograft Rejection After Heart or Liver Transplantation",COMPLETED,2020-11-18,2023-03-31,2023-07-20,INTERVENTIONAL,PHASE2,7.0,ACTUAL,NON_RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,Graft Rejection|Heart Transplantation|Liver Transplantation,[18F]FSPG,DRUG,1,8,19 Years,79 Years,ALL,False,Asan Medical Center,OTHER,0,1,South Korea,1.0,0,1,0,0,0,2.0,0,0,0,1,3,2.0794415416798357,small,1,1,0,1,0,0,0,0,0,0,0,0,0,1,9,1,1,0,0,1,0,2020-11-18,2023-03-31,863.0,2020.0,1,2,0
NCT03507166,A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer,"A Multicenter, Open Label，Single Arm，Phase II Study to Evaluate the Effect and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer",COMPLETED,2017-12-28,2018-10-29,2019-08-21,INTERVENTIONAL,PHASE2,43.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Urothelial Carcinoma|Advanced Cancer,RC48-ADC,DRUG,1,6,18 Years,80 Years,ALL,False,"RemeGen Co., Ltd.",INDUSTRY,0,2,China,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.784189633918261,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,7,1,1,0,0,1,0,2017-12-28,2018-10-29,305.0,2017.0,1,2,0
NCT00248066,Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries,APPRAISAL Trial: A Phase IIa Study to Evaluate the Safety and Preliminary Efficacy of RESTEN-MP® When Used in Conjunction With a Bare Metal Stent in de Novo Native Coronary Artery Lesions,COMPLETED,2005-09,,2007-02-08,INTERVENTIONAL,PHASE2,50.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Coronary Artery Disease|Coronary Restenosis,RESTEN-MP,DRUG,2,7,18 Years,,ALL,False,"Sarepta Therapeutics, Inc.",INDUSTRY,1,3,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.9318256327243257,small,1,0,1,0,0,1,1,0,0,1,0,0,1,0,9,1,1,0,0,1,0,,,,,0,2,0
NCT02481856,A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber,A Dose-response Evaluation of the SQ Tree SLIT-tablet in Subjects With Moderate to Severe Allergic Rhinoconjunctivitis Induced by Pollens From the Birch Group During Controlled Exposure in an Environmental Exposure Chamber,COMPLETED,2015-06,2016-04,2017-01-19,INTERVENTIONAL,PHASE2,219.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Allergic Rhinoconjunctivitis,SQ tree SLIT-tablet|Placebo,DRUG,1,6,18 Years,65 Years,ALL,False,ALK-Abelló A/S,INDUSTRY,1,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.393627546352362,large,0,1,1,0,0,1,0,0,0,0,1,1,1,1,7,1,1,0,0,2,1,,,,,0,2,0
NCT01201356,Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis,"A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis",COMPLETED,2010-09-13,2018-10-19,2021-04-21,INTERVENTIONAL,PHASE3,4125.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Relapsing Forms of Multiple Sclerosis,Fingolimod,DRUG,1,10,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,458,Estonia|Jordan|Canada|Ireland|Austria|South Africa|Egypt|Hungary|Argentina|Russia|Australia|Portugal|Spain|Romania|Norway|Belgium|Israel|Italy|Finland|United States|Sweden|France|Czechia|Germany|Greece|Netherlands|Poland|South Korea|Peru|United Kingdom|Turkey (Türkiye)|Denmark|Malaysia|Brazil|Guatemala|Slovakia|Switzerland|Panama,1.0,0,0,1,0,0,3.0,0,1,0,0,1,8.325063693631197,xlarge,0,1,1,0,1,0,1,1,1,1,0,0,1,0,11,1,1,0,0,1,0,2010-09-13,2018-10-19,2958.0,2010.0,0,2,0
NCT01597518,Riluzole in Spinal Cord Injury Study,"A Multi-Center, Randomized, Placebo Controlled, Double-Blinded, Trial of Efficacy and Safety of Riluzole in Acute Spinal Cord Injury",TERMINATED,2013-10,2020-10-08,2021-04-19,INTERVENTIONAL,PHASE2|PHASE3,193.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Spinal Cord Injury,Riluzole|Placebo,DRUG,1,0,18 Years,75 Years,ALL,False,AOSpine North America Research Network,NETWORK,4,29,Canada|Australia|United States,0.0,0,1,1,0,1,2.5,0,0,0,0,1,5.267858159063328,medium,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,2,1,,2020-10-08,,,0,3,1
NCT04541290,Tacrolimus as Treatment of Breast Cancer-Related Lymphedema,Tacrolimus as Treatment of Breast Cancer-Related Lymphedema,COMPLETED,2020-09-22,2022-01-06,2022-02-09,INTERVENTIONAL,PHASE1|PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer Lymphedema,Protopic 0.1 % Topical Ointment,DRUG,1,6,30 Years,65 Years,FEMALE,False,Odense University Hospital,OTHER,0,1,Denmark,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.044522437723423,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,7,1,1,0,0,1,0,2020-09-22,2022-01-06,471.0,2020.0,1,2,0
NCT02973997,Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC),"Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study",COMPLETED,2018-02-07,2023-10-08,2025-08-29,INTERVENTIONAL,PHASE2,57.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Columnar Cell Variant Thyroid Gland Papillary Carcinoma|Follicular Variant Thyroid Gland Papillary Carcinoma|Metastatic Thyroid Gland Follicular Carcinoma|Metastatic Thyroid Gland Papillary Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Thyroid Gland Follicular Carcinoma|Recurrent Thyroid Gland Papillary Carcinoma|Stage III Differentiated Thyroid Gland Carcinoma AJCC v7|Stage III Thyroid Gland Follicular Carcinoma AJCC v7|Stage III Thyroid Gland Papillary Carcinoma AJCC v7|Stage IV Thyroid Gland Follicular Carcinoma AJCC v7|Stage IV Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Tall Cell Variant Thyroid Gland Papillary Carcinoma|Thyroid Gland Hurthle Cell Carcinoma|Unresectable Differentiated Thyroid Gland Carcinoma|Unresectable Thyroid Gland Carcinoma,Laboratory Biomarker Analysis|Lenvatinib|Lenvatinib Mesylate|Pembrolizumab,DRUG|OTHER|BIOLOGICAL,2,3,18 Years,,ALL,False,Academic and Community Cancer Research United,OTHER,1,7,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,26,4.060443010546419,medium,1,1,0,1,0,1,1,0,1,0,0,0,1,0,5,1,1,1,0,4,1,2018-02-07,2023-10-08,2069.0,2018.0,1,2,0
NCT06102213,Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation,"A Randomized, Open-Label, Multicenter, Phase 2a Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)",TERMINATED,2023-09-18,2024-08-12,2024-08-19,INTERVENTIONAL,PHASE2,46.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hematologic Malignancy,B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010),DRUG,3,4,18 Years,75 Years,ALL,False,Prolacta Bioscience,INDUSTRY,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8501476017100584,small,1,1,1,0,0,0,0,0,1,0,1,0,1,1,7,1,1,0,0,1,0,2023-09-18,2024-08-12,329.0,2023.0,1,1,0
NCT02762513,Expansion Trial for Axitinib In Head And Neck Cancer,"Phase II Expansion Trial Evaluating Axitinib in Patients With Unresectable Recurrent, or Metastatic Head and Neck Cancer Utilizing Choi Response Criteria Phase",COMPLETED,2016-08-30,2020-04-09,2021-05-05,INTERVENTIONAL,PHASE2,29.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Squamous Cell Carcinoma of the Head and Neck,Axitinib,DRUG,1,4,18 Years,,ALL,False,University of Michigan Rogel Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4011973816621555,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,5,1,1,0,0,1,0,2016-08-30,2020-04-09,1318.0,2016.0,1,0,0
NCT01557660,Inhaled Treprostinil for PAH: Open-label Extension,"Inhaled Treprostinil in Subjects With Pulmonary Arterial Hypertension: An Open-Label, Phase III, International, Multi-Center Study",WITHDRAWN,2012-06,2018-12,2012-03-26,INTERVENTIONAL,PHASE3,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pulmonary Arterial Hypertension,inhaled treprostinil,DRUG,1,1,18 Years,,ALL,False,United Therapeutics,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,1,1,0.0,,1,1,1,0,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT01694160,Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria,"Consultant in Nephrology. MD., Ph.D.",COMPLETED,2013-01,2015-12,2016-03-30,INTERVENTIONAL,PHASE3,77.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Proteinuria,Paricalcitol,DRUG,1,0,18 Years,70 Years,ALL,False,Oslo University Hospital,OTHER,0,1,Norway,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.356708826689592,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,,,,,0,0,0
NCT04357860,Clinical Trial of Sarilumab in Adults With COVID-19,Clinical Trial of Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release Syndrome,COMPLETED,2020-04-28,2021-04-06,2021-07-07,INTERVENTIONAL,PHASE2,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,SARS-CoV 2|SARS,Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Best available treatment,DRUG,1,15,18 Years,75 Years,ALL,False,Maimónides Biomedical Research Institute of Córdoba,OTHER,2,1,Spain,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.795790545596741,medium,0,1,0,1,0,1,0,0,0,1,1,0,1,1,16,1,1,0,0,3,1,2020-04-28,2021-04-06,343.0,2020.0,1,3,1
NCT00779220,"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis","A Randomized, Double-blind, Parallel-group, Study to Evaluate the Efficacy, Safety and PK/PD of Ocrelizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy",TERMINATED,2008-10,2015-03,2015-03-25,INTERVENTIONAL,PHASE2,152.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Rheumatoid Arthritis,placebo|methotrexate|ocrelizumabu 50mg|ocrelizumabu 200mg|ocrelizumab 500mg,DRUG,1,7,20 Years,,ALL,False,Chugai Pharmaceutical,INDUSTRY,0,7,Japan,0.0,0,1,0,0,0,2.0,0,1,0,0,1,5.030437921392435,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,8,1,1,0,0,5,1,,,,,0,2,0
NCT00790920,Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke,"A Randomised, Double-blind, Parallel-group Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke",COMPLETED,2008-12,,2015-09-18,INTERVENTIONAL,PHASE3,492.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Stroke,Desmoteplase|Placebo,DRUG,1,1,18 Years,85 Years,ALL,False,H. Lundbeck A/S,INDUSTRY,0,102,Estonia|India|Australia|Vietnam|Philippines|Austria|Poland|Taiwan|Thailand|France|Spain|Singapore|Switzerland|Germany|Netherlands|South Korea|Hong Kong,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.20050917404269,large,0,1,1,0,0,0,1,1,0,1,1,1,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT05633420,Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,"A Multi-Center Single Arm, Open-label, Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients",COMPLETED,2022-07-24,2022-11-20,2022-12-02,INTERVENTIONAL,PHASE2,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,COVID-19,Pyramax,DRUG,1,4,19 Years,,ALL,False,Shin Poong Pharmaceutical Co. Ltd.,INDUSTRY,0,2,South Korea,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,5,1,1,0,0,1,0,2022-07-24,2022-11-20,119.0,2022.0,1,0,0
NCT01415882,Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib,Phase 2 Trial of Ixazomib Combinations in Patients With Relapsed Multiple Myeloma,COMPLETED,2012-01-31,2025-04-30,2025-09-05,INTERVENTIONAL,PHASE2,165.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,Cyclophosphamide|Daratumumab|Dexamethasone|Ixazomib Citrate|Laboratory Biomarker Analysis,DRUG|OTHER|BIOLOGICAL,1,4,18 Years,,ALL,False,Mayo Clinic,OTHER,0,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,5.111987788356544,medium,0,1,0,1,0,0,1,0,1,0,1,0,1,1,5,1,1,1,0,5,1,2012-01-31,2025-04-30,4838.0,2012.0,0,2,0
NCT01616524,"Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3","A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, With and Without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naïve Genotype 2 and 3 Chronic Hepatitis C Subjects",COMPLETED,2012-07,2014-09,2015-10-09,INTERVENTIONAL,PHASE3,880.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hepatitis C Virus (HCV),Pegylated interferon lambda (pegIFNλ)|Pegylated interferon lambda (pegIFNλ)|Pegylated interferon alfa-2a (pegIFNα-2a)|Ribavirin|Ribavirin|Daclatasvir|Placebo matching Daclatasvir,DRUG|BIOLOGICAL,1,10,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,124,Hong Kong|Argentina|Russia|Australia|Belgium|Italy|Chile|Finland|United States|France|Singapore|South Korea|Netherlands|Greece|United Kingdom|Taiwan|New Zealand|Mexico|Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.78105762593618,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,11,1,1,1,0,7,1,,,,,0,3,1
NCT04109924,"TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study","A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-Treated Metastatic Colorectal Cancer (TABAsCO)",COMPLETED,2019-12-27,2024-09-05,2025-08-11,INTERVENTIONAL,PHASE2,42.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Colorectal Carcinoma|Metastatic Colon Adenocarcinoma|Metastatic Rectal Adenocarcinoma|Recurrent Colon Adenocarcinoma|Recurrent Colorectal Adenocarcinoma|Recurrent Rectal Adenocarcinoma|Stage III Colon Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Rectal Cancer AJCC v8|Stage IIIA Colon Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIB Rectal Cancer AJCC v8|Stage IIIC Colon Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IV Colon Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Rectal Cancer AJCC v8|Stage IVB Colon Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Rectal Cancer AJCC v8|Stage IVC Colon Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Stage IVC Rectal Cancer AJCC v8|Unresectable Colon Adenocarcinoma|Unresectable Colorectal Carcinoma|Unresectable Rectal Adenocarcinoma,Irinotecan|Bevacizumab|Trifluridine and Tipiracil Hydrochloride,DRUG|BIOLOGICAL,1,4,18 Years,,ALL,False,Roswell Park Cancer Institute,OTHER,1,4,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,27,3.7612001156935624,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,5,1,1,1,0,3,1,2019-12-27,2024-09-05,1714.0,2019.0,1,2,0
NCT00745823,A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071),"A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA™, in Treatment-Naïve HIV Infected Patients",TERMINATED,2008-09,2011-05,2017-03-21,INTERVENTIONAL,PHASE3,775.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,HIV,Comparator: Raltegravir 400 mg b.i.d.|Experimental: Raltegravir 800 mg q.d.|TRUVADA™,DRUG,3,7,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,6.654152520183219,xlarge,0,1,1,0,1,0,0,0,0,0,1,1,1,1,10,1,1,0,0,3,1,,,,,0,2,0
NCT04289779,Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer,A Phase 2 Study of CAbozantinib in Combination with AtezolizumaB As NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer,ACTIVE_NOT_RECRUITING,2020-05-21,2025-12,2024-12-04,INTERVENTIONAL,PHASE2,46.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Bladder Cancer,Cabozantinib|Atezolizumab|Cystectomy,DRUG|PROCEDURE,1,3,18 Years,,ALL,False,Deepak Kilari,OTHER,3,6,United States,,0,1,0,0,0,2.0,1,0,0,0,1,3.8501476017100584,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,3,1,2020-05-21,,,2020.0,1,1,0
NCT00726596,Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer,NJ 1808: Autophagic Cell Death With Hydroxychloroquine in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy For Prostate Cancer.,COMPLETED,2008-08,2018-01,2022-06-16,INTERVENTIONAL,PHASE2,64.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,hydroxychloroquine,DRUG,1,4,18 Years,,MALE,False,"Rutgers, The State University of New Jersey",OTHER,2,5,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.174387269895637,medium,1,1,0,1,0,1,1,0,1,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,0,0
NCT04752696,"Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma","A Phase 2 Study of Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Patients With Metastatic Pancreatic Ductal Adenocarcinoma",COMPLETED,2021-05-25,2024-12-24,2025-12-22,INTERVENTIONAL,PHASE2,41.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Pancreatic Ductal Adenocarcinoma,Onvansertib|Nanoliposomal irinotecan|Leucovorin|Fluorouracil,DRUG,1,6,18 Years,,ALL,False,Cardiff Oncology,INDUSTRY,0,6,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.7376696182833684,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,7,1,1,0,0,4,1,2021-05-25,2024-12-24,1309.0,2021.0,1,2,0
NCT01484496,A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE),"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects With Systemic Lupus Erythematosus (SLE)",COMPLETED,2011-11-16,2015-10-01,2018-06-06,INTERVENTIONAL,PHASE3,839.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Systemic Lupus Erythematosus,Placebo|Belimumab 200 mg SC|Standard therapy,DRUG|BIOLOGICAL,1,2,18 Years,,ALL,False,"Human Genome Sciences Inc., a GSK Company",INDUSTRY,1,207,Austria|Thailand|Hungary|Argentina|Russia|Bulgaria|Portugal|Spain|Romania|Belgium|Italy|Chile|Ukraine|United States|Sweden|Colombia|France|Czechia|Singapore|Germany|Poland|United Kingdom|Croatia|Denmark|Malaysia|Brazil|Philippines|Taiwan|Mexico|Japan|Serbia,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.733401891837359,xlarge,0,1,1,0,1,1,1,1,1,1,1,1,1,1,3,1,1,1,0,3,1,2011-11-16,2015-10-01,1415.0,2011.0,0,2,0
NCT04800562,A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica,"A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica",TERMINATED,2021-04-12,2023-04-14,2023-08-03,INTERVENTIONAL,PHASE2,4.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Necrobiosis Lipoidica,PCS499|placebo,DRUG|OTHER,1,0,18 Years,80 Years,ALL,False,Processa Pharmaceuticals,INDUSTRY,0,4,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.6094379124341003,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2021-04-12,2023-04-14,732.0,2021.0,1,1,0
NCT02197962,Efficacy of Radial Shockwave Therapy for Treatment of Pain in Knee Osteoarthritis,Efficacy of Radial Shockwave Therapy for Treatment of Pain in Knee Osteoarthritis,COMPLETED,2010-05,2015-12,2016-10-05,INTERVENTIONAL,PHASE2,105.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Knee Osteoarthritis,Extracorporeal Radial shockwaves|Placebo Radial Shockwaves,DEVICE,1,1,60 Years,,ALL,False,Marta Imamura,OTHER,1,2,Brazil,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.663439094112067,medium,0,1,0,1,0,1,1,0,0,0,1,1,1,1,2,1,0,0,1,2,1,,,,,0,1,0
NCT02647762,CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis,"A Phase 3, Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis",TERMINATED,2017-10-30,2020-11-30,2020-12-19,INTERVENTIONAL,PHASE3,244.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Rheumatoid Arthritis,CF101 1 mg|CF101 2 mg|Placebo|MTX,DRUG,3,2,18 Years,75 Years,ALL,False,Can-Fite BioPharma,INDUSTRY,0,35,Serbia|Bosnia and Herzegovina|Canada|Romania|Poland|Israel|Moldova,0.0,0,0,1,0,0,3.0,0,1,0,0,1,5.501258210544727,large,0,1,1,0,0,0,1,1,0,0,1,1,1,1,5,1,1,0,0,4,1,2017-10-30,2020-11-30,1127.0,2017.0,1,2,0
NCT00998946,Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma,"A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma",COMPLETED,2009-09,2012-08,2021-11-05,INTERVENTIONAL,PHASE2,29.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Lymphoma, B-Cell",Pralatrexate|Vitamin B12|Folic Acid,DRUG|DIETARY_SUPPLEMENT,1,3,18 Years,,ALL,False,"Spectrum Pharmaceuticals, Inc",INDUSTRY,0,11,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4011973816621555,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,4,1,1,0,0,3,1,,,,,0,1,0
NCT03129646,Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa,"An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa",COMPLETED,2018-01-24,2020-12-11,2024-02-29,INTERVENTIONAL,PHASE3,439.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Visceral Leishmaniasis,Miltefosine|Paromomycin|Sodium stibogluconate,DRUG,1,5,4 Years,50 Years,ALL,False,Drugs for Neglected Diseases,OTHER,5,7,Kenya|Uganda|Ethiopia|Sudan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.0867747269123065,large,0,1,0,1,0,1,1,1,0,0,1,0,1,1,6,1,1,0,0,3,1,2018-01-24,2020-12-11,1052.0,2018.0,1,3,1
NCT01269346,Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer,"A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer",COMPLETED,2010-12,2016-05,2023-06-22,INTERVENTIONAL,PHASE2,52.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,Eribulin Mesylate,DRUG,1,4,18 Years,,FEMALE,False,Eisai Inc.,INDUSTRY,0,26,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.970291913552122,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,0,0
NCT06677788,Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH,Efficacy and Safety of Roflumilast in Patients with Non-Alcoholic Steatohepatitis,COMPLETED,2022-04-01,2024-10-15,2024-11-07,INTERVENTIONAL,PHASE2,55.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Non-Alcoholic Steatohepatitis (NASH),Roflumilast 500 Mcg Oral Tablet|Vitamin E capsule,DRUG,1,2,19 Years,,ALL,False,Tanta University,OTHER,0,1,Egypt,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.02535169073515,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,1,3,1,1,0,0,2,1,2022-04-01,2024-10-15,928.0,2022.0,1,1,0
NCT03660488,Cefixime for Alternative Syphilis Treatment,Clinical Trial Evaluating the Clinical Efficacy of Cefixime for Treatment of Early Syphilis,COMPLETED,2018-09-03,2021-01-30,2022-07-26,INTERVENTIONAL,PHASE2,58.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Syphilis|Early Syphilis,Cefixime 400 milligram Oral Capsule [Suprax]|Benzathine Penicillin G,DRUG,1,0,18 Years,,ALL,False,"University of California, Los Angeles",OTHER,1,10,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.07753744390572,medium,1,1,0,1,0,1,1,0,1,0,1,0,1,1,1,0,1,0,0,2,1,2018-09-03,2021-01-30,880.0,2018.0,1,2,0
NCT00315588,Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation,Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation,COMPLETED,2000-12,2014-05,2017-04-12,INTERVENTIONAL,PHASE2,7.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 1",Islet Transplantation,DRUG,1,3,18 Years,60 Years,ALL,False,Rodolfo Alejandro,OTHER,4,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.0794415416798357,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT02554188,Fasting-mimicking Diet and Immunosenescence,Effect of Fasting-mimicking Diet on Immunosenescence and Vaccination in Older Adults: A Randomized Clinical Trial,WITHDRAWN,2019-05-01,2019-05-01,2019-10-30,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,SINGLE,Immunosenescence,Seasonal influenza (flu) vaccine|Diet,OTHER|BIOLOGICAL,1,5,50 Years,75 Years,ALL,True,University of Southern California,OTHER,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,0,0,1,6,1,0,1,0,2,1,2019-05-01,2019-05-01,0.0,2019.0,1,2,0
NCT05813288,A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3),"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants With Severe Eosinophilic Asthma",TERMINATED,2023-03-27,2025-12-08,2025-12-15,INTERVENTIONAL,PHASE3,654.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Eosinophilic Asthma|Asthma; Eosinophilic|Asthma,Dexpramipexole Dihydrochloride|Placebo,DRUG,1,12,12 Years,99 Years,ALL,False,Areteia Therapeutics,INDUSTRY,0,282,Austria|Lithuania|South Africa|China|Hungary|Argentina|Spain|Italy|Israel|Chile|Ukraine|United States|France|Czechia|Germany|South Korea|India|Peru|United Kingdom|Croatia|Turkey (Türkiye)|Puerto Rico|Brazil|Taiwan|Mexico|Japan,0.0,0,0,1,0,0,3.0,0,0,0,0,3,6.484635235635252,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,13,1,1,0,0,2,1,2023-03-27,2025-12-08,987.0,2023.0,1,4,1
NCT01534403,Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects,"A Phase 2, Multicenter, Open-label, Long-term, Extension Study to Assess the Safety of Epratuzumab Treatment in Japanese Subjects With Systemic Lupus Erythematosus",COMPLETED,2012-01,2015-02,2016-05-06,INTERVENTIONAL,PHASE2,17.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Systemic Lupus Erythematosus,Epratuzumab,BIOLOGICAL,2,5,18 Years,65 Years,ALL,False,UCB Pharma,INDUSTRY,0,6,Japan,1.0,0,1,0,0,0,2.0,0,1,0,0,1,2.8903717578961645,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,7,1,0,1,0,1,0,,,,,0,1,0
NCT01368003,STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling,A Biomarker Study of STA9090 in Castration-Resistant Prostate Cancer (CRPC) With Assessment of Androgen Receptor Pathway Signaling,WITHDRAWN,2011-04,2012-11,2015-09-01,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Adenocarcinoma of the Prostate,STA9090|STA9090 with Dutasteride,DRUG,1,4,18 Years,,MALE,False,"Toni Choueiri, MD",OTHER,0,2,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,0,1,0,1,0,1,0,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT00050427,A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer,A Phase 2 Study of ET-743 in Subjects With Advanced Breast Cancer,COMPLETED,2002-12,2006-12,2011-04-28,INTERVENTIONAL,PHASE2,53.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Neoplasms|Neoplasms|Neoplasms by Site|Breast Diseases|Skin Diseases,ET743|ET743,DRUG,1,5,18 Years,,FEMALE,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,1,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,5,3.9889840465642745,medium,1,1,1,0,0,1,0,0,0,0,1,0,1,1,6,1,1,0,0,2,1,,,,,0,3,1
NCT00562861,Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram,Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram,COMPLETED,2007-11,2014-07,2017-03-24,INTERVENTIONAL,PHASE2|PHASE3,119.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Bipolar Disorder|Bipolar Depression,citalopram + mood stabilizer|placebo + mood stabilizer,DRUG,1,0,18 Years,64 Years,ALL,False,Tufts Medical Center,OTHER,1,1,United States,1.0,0,1,1,0,1,2.5,0,0,1,0,2,4.787491742782046,medium,0,1,0,1,0,1,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,3,1
NCT01254786,Non-dependent HFPPV Versus CPAP for Video-assisted Thoracoscopy,Comparative Study of the Non-dependent Continuous Positive Pressure Ventilation and High Frequency Positive Pressure Ventilation During One-lung Ventilation for Thoracoscopy,COMPLETED,2010-05,2010-11,2010-12-08,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Elective Video-assisted Thoracoscopic Surgery|One-lung Ventilation Lasts at Least One Hour,Non-dependent lung ventilation|Non-dependent lung ventilation,PROCEDURE,1,2,18 Years,60 Years,ALL,False,King Faisal University,OTHER,0,1,Saudi Arabia,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.4339872044851463,small,1,1,0,1,0,0,0,0,0,0,1,1,1,0,3,1,0,0,0,2,1,,,,,0,2,0
NCT01463670,Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance,A Phase II Clinical Trial of Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance,COMPLETED,2011-10-28,2021-03-19,2022-05-06,INTERVENTIONAL,PHASE2,11.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma,lenalidomide,DRUG,1,1,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,7,11,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.4849066497880004,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2011-10-28,2021-03-19,3430.0,2011.0,0,0,0
NCT01090973,Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL),"Phase II Trial of Oral LBH 589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma",TERMINATED,2010-03,2011-03,2013-12-16,INTERVENTIONAL,PHASE2,1.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-Hodgkin's Lymphoma,LBH589,DRUG,1,6,18 Years,,ALL,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.6931471805599453,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,7,1,1,0,0,1,0,,,,,0,1,0
NCT02509273,"Efficacy, Safety and Pharmacokinetic Study of Intravenous Clonidine Versus Midazolam for Sedation in Paediatric Patients","A Double Blind, Randomised, Multicentre, Active Controlled, Parallel-group, Phase III Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Intravenous Clonidine (Hydrochloride) Compared to Midazolam for Sedation in Children From Birth to Less Than 18 Years of Age",TERMINATED,2016-05,2018-10-22,2019-01-09,INTERVENTIONAL,PHASE3,28.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Sedation in Intensive Care,Clonidine|Midazolam,DRUG,1,7,,18 Years,ALL,False,University of Erlangen-Nürnberg Medical School,OTHER,12,10,Estonia|Sweden|Spain|Czechia|Germany|Netherlands|Italy,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.367295829986474,small,1,1,0,1,0,1,1,1,0,1,1,1,1,1,8,1,1,0,0,2,1,,2018-10-22,,,0,3,1
NCT00877773,Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients,"Histology-Independent Study of the mTOR Inhibitor, Temsirolimus, in Patients With Advanced Cancer",TERMINATED,2009-04,2014-06,2016-08-25,INTERVENTIONAL,PHASE1|PHASE2,44.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Cancers,Temsirolimus,DRUG,1,0,,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,3.8066624897703196,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,1,0
NCT00232869,A Study of the SMART Stent in the Treatment SFA Disease.,A Clinical Investigation of the SIROlimus Coated Cordis SMART™ Nitinol Selfexpandable Stent for the Treatment of Obstructive Superficial Femoral Artery Disease.,COMPLETED,2001-02,2009-05,2010-02-04,INTERVENTIONAL,PHASE2,93.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Peripheral Artery Disease,drug-eluting stent|bare-metal stent,DEVICE,1,0,30 Years,,ALL,False,Cordis US Corp.,INDUSTRY,0,1,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.543294782270004,medium,1,1,1,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,1,2,1,,,,,0,1,0
NCT00261469,"An Open-label Study to Evaluate Topiramate Therapy in Migraine Patients, and Its Effects on Subject Responsiveness to Migraine Treatment With Triptans",Efficacy of Topiramate Prophylaxis as add-on to Triptan Therapy for Migraine,COMPLETED,2003-04,2004-11,2011-05-17,INTERVENTIONAL,PHASE2,38.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Headache,topiramate,DRUG,1,1,18 Years,65 Years,ALL,False,"Janssen-Ortho Inc., Canada",INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6635616461296463,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT00522769,Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents,Development of CBT Model for Adolescent Bulimia Nervosa,COMPLETED,2005-09,2009-05,2010-02-15,INTERVENTIONAL,PHASE1|PHASE2,26.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Bulimia Nervosa,Cognitive Behavioral Therapy,BEHAVIORAL,1,2,12 Years,18 Years,FEMALE,False,Kaiser Permanente,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.295836866004329,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,3,1,0,0,0,1,0,,,,,0,1,0
NCT04227769,IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes,IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes,TERMINATED,2020-01-13,2024-05-28,2025-01-29,INTERVENTIONAL,PHASE2,18.0,ACTUAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,Diabetes Mellitus Type 2 in Obese|Inflammation|Metabolic Disease|Glucose Metabolism Disorders (Including Diabetes Mellitus),Anakinra Prefilled Syringe,DRUG,2,12,18 Years,70 Years,ALL,True,"University Hospital, Basel, Switzerland",OTHER,0,1,Switzerland,0.0,0,1,0,0,0,2.0,0,0,0,0,4,2.9444389791664403,small,1,1,0,1,0,0,0,0,0,0,1,1,0,0,14,1,1,0,0,1,0,2020-01-13,2024-05-28,1597.0,2020.0,1,2,0
NCT04817254,Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,ACTIVE_NOT_RECRUITING,2021-12-08,2027-12-31,2025-12-23,INTERVENTIONAL,PHASE2,47.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Glioblastoma|Gliosarcoma|Malignant Glioma,TMZ|ipilimumab 3mg/kg|Nivolumab|ipilimumab 1mg/kg,DRUG,1,5,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,,0,1,0,0,0,2.0,1,0,0,0,3,3.871201010907891,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,6,1,1,0,0,4,1,2021-12-08,2027-12-31,2214.0,2021.0,1,3,1
NCT00704483,Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis,"A 12-week, Open Label, Multicenter, Titration Study, With a 9-month Maintenance Treatment Extension, to Demonstrate Efficacy of SBR759 Compared to Sevelamer HCl in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis",COMPLETED,2008-07,,2020-12-19,INTERVENTIONAL,PHASE2,321.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy,SBR759|Sevelamer HCl|SBR759|Sevelamer HCl,DRUG,1,1,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,66,United Kingdom|Finland|Australia|United States|Puerto Rico|Canada|Sweden|France|Switzerland|Germany|Norway|Belgium|Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.7745515455444085,large,0,1,1,0,1,0,1,1,1,1,1,0,1,1,2,1,1,0,0,4,1,,,,,0,2,0
NCT04535141,Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants,Addition of Olanzapine to Standard CINV Prophylaxis in Hematopoietic Stem Cell Transplant,COMPLETED,2020-08-18,2022-04-11,2023-05-09,INTERVENTIONAL,PHASE3,91.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,DOUBLE,Chemotherapy-induced Nausea and Vomiting,Olanzapine 5 MG|Placebo,DRUG,1,10,18 Years,,ALL,False,UNC Lineberger Comprehensive Cancer Center,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.5217885770490405,medium,1,1,0,1,0,1,0,0,1,0,1,1,0,1,11,1,1,0,0,2,1,2020-08-18,2022-04-11,601.0,2020.0,1,2,0
NCT05814341,Citrate Anticoagulation in Renal Replacement Therapy: Impact of a High Post-filter Calcium Target on Efficacy,The Effect of Increasing Post-Filter Ionized Target on the Efficacy of Regional Citrate Anticoagulation During Continuous Renal Replacement Therapy in Intensive Care: a Multicenter Randomized Controlled Non-Inferiority Trial,COMPLETED,2023-07-01,2024-12-15,2025-08-22,INTERVENTIONAL,PHASE3,108.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Renal Replacement Therapy,Citrate,DRUG,3,13,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.6913478822291435,medium,0,1,0,1,0,0,0,0,0,1,1,0,1,1,16,1,1,0,0,1,0,2023-07-01,2024-12-15,533.0,2023.0,1,1,0
NCT04767841,The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Patients With Knee Osteoarthritis,"The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Patients With Knee Osteoarthritis: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial",WITHDRAWN,2021-02-16,2024-12-31,2025-07-14,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Osteo Arthritis Knee,Metformin|Placebo,DRUG,1,7,30 Years,60 Years,ALL,False,Sadat City University,OTHER,0,1,Egypt,0.0,1,1,0,0,1,1.5,0,1,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,1,1,1,8,1,1,0,0,2,1,2021-02-16,2024-12-31,1414.0,2021.0,1,3,1
NCT00109954,Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery,"A Prospectively Randomized Controlled Clinical Trial Comparing TheraSphere With Cisplatin-Based TACE (Trans Arterial Chemo Embolization) in the Management of Advanced Stage, Unresectable Hepatocellular Carcinoma (HCC)",COMPLETED,2005-02,2005-12,2016-01-18,INTERVENTIONAL,PHASE3,120.0,ESTIMATED,RANDOMIZED,,TREATMENT,,Liver Cancer,cisplatin|brachytherapy|yttrium Y 90 glass microspheres,DRUG|RADIATION,3,0,18 Years,120 Years,ALL,False,University of Pittsburgh,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.795790545596741,medium,0,0,0,1,0,1,0,0,1,0,1,0,1,0,3,0,1,0,0,3,1,,,,,0,1,0
NCT00001354,Interleukin-2 Therapy for HIV Infection - Supplemental Procedures,A Randomized Trial of Interleukin-2 Therapy in HIV-Infected Patients,COMPLETED,1993-03,2002-03,2008-03-04,INTERVENTIONAL,PHASE2,60.0,,,,TREATMENT,,Acquired Immunodeficiency Syndrome|HIV Infection,Interleukin-2/Zidovudine (AZT),DRUG,0,0,,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.110873864173311,medium,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,1,0
NCT02752594,Consumption of Probiotics on Salivary Bacteria Causing Dental Caries,Evaluation of the Consumption of Probiotics on the Bacteria Causing Dental Caries: A Randomised Clinical Trial,COMPLETED,2015-04,2015-04,2016-04-27,INTERVENTIONAL,PHASE2|PHASE3,40.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Dental Caries,probiotic|placebo,OTHER|BIOLOGICAL,1,0,20 Years,25 Years,ALL,True,Sharda University,OTHER,0,0,,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.713572066704308,small,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,2,1,,,,,0,2,0
NCT02996760,Influence Instillation Plasma Rich in Growth Factors in Endometrial Cavity Endometrial Development in Assisted Reproduction.,Influence Instillation Plasma Rich in Growth Factors in Endometrial Cavity,TERMINATED,2018-03-14,2021-12-31,2022-04-07,INTERVENTIONAL,PHASE3,22.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Endometrial Development,"Growth Factor, Platelet-Derived",DRUG,1,1,18 Years,49 Years,FEMALE,False,IVI Bilbao,OTHER,0,1,Spain,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.1354942159291497,small,1,1,0,1,0,0,0,0,0,1,1,0,1,1,2,1,1,0,0,1,0,2018-03-14,2021-12-31,1388.0,2018.0,1,0,0
NCT01590160,"Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma","A Phase I/II Study of First Line Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma",COMPLETED,2013-08,2019-11-05,2019-11-13,INTERVENTIONAL,PHASE1|PHASE2,27.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Lung Cancer - Malignant Pleural Mesothelioma,Ganetespib,DRUG,1,1,18 Years,,ALL,False,"University College, London",OTHER,1,1,United Kingdom,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.332204510175204,small,1,1,0,1,0,1,0,0,0,1,1,0,1,1,2,1,1,0,0,1,0,,2019-11-05,,,0,1,0
NCT06196320,Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5,"Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5 Improving Neurological Functional Outcomes in Basilar Artery Occlusion With Tenecteplase in Extended Time Window: Multicentre, Prospective, Open-label, Blinded Endpoint (PROBE), Phase 3, Randomized Controlled Trial",COMPLETED,2024-01-24,2025-09-22,2025-11-26,INTERVENTIONAL,PHASE3,452.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Ischemic Stroke, Acute",Tenecteplase|Best Practice (which may include intravenous Alteplase),DRUG,1,10,18 Years,,ALL,False,Beijing Tiantan Hospital,OTHER,0,59,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.115892125483034,large,0,1,0,1,0,0,1,0,0,0,1,0,1,1,11,1,1,0,0,2,1,2024-01-24,2025-09-22,607.0,2024.0,1,2,0
NCT00519324,Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer,"A Single Arm, Multi-center Phase II Study of RAD001 in Patients With Advanced Gastric Carcinoma Whose Cancer Has Progressed Despite Prior Treatment",COMPLETED,2007-08,,2016-11-18,INTERVENTIONAL,PHASE2,54.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Gastric Cancer,Everolimus,DRUG,1,3,20 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,8,Japan,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.007333185232471,medium,1,1,1,0,1,0,1,0,0,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT00133224,Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients,"A Phase III Randomized, Open-Label Study of Docetaxel in Combination With CG1940 and CG8711 Versus Docetaxel and Prednisone in Taxane-Naïve Patients With Metastatic Hormone-Refractory Prostate Cancer With Pain",TERMINATED,2005-07,2009-06,2008-09-23,INTERVENTIONAL,PHASE3,408.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,Immunotherapy allogeneic GM-CSF secreting cellular vaccine|Chemotherapy (docetaxel and prednisone),DRUG|BIOLOGICAL,1,1,18 Years,,MALE,False,Cell Genesys,INDUSTRY,0,115,United Kingdom|United States|Sweden|Canada|Poland|France|Germany|Netherlands|Belgium|Italy,0.0,0,0,1,0,0,3.0,1,0,0,0,1,6.013715156042802,large,0,1,1,0,0,0,1,1,1,1,1,0,1,1,2,1,1,1,0,2,1,,,,,0,2,0
NCT04366323,Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19,"Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19",COMPLETED,2020-04-27,2021-12-30,2022-04-06,INTERVENTIONAL,PHASE1|PHASE2,26.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Sars-CoV2,ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS,DRUG,2,0,18 Years,80 Years,ALL,False,Andalusian Network for Design and Translation of Advanced Therapies,OTHER,0,6,Spain,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.295836866004329,small,1,1,0,1,0,0,1,0,0,1,1,0,1,1,2,0,1,0,0,1,0,2020-04-27,2021-12-30,612.0,2020.0,1,1,0
NCT00382759,Nonmyeloablative Stem Cell Transplant in Elderly,Nonmyeloablative Allogeneic Stem Cell Transplantation in Elderly Patients With Hematological Malignancies:Results From the GITMO (Gruppo Italiano Trapianto Midollo Osseo)Multicenter Prospective Clinical Trial,COMPLETED,2000-03,2007-03,2009-08-03,INTERVENTIONAL,PHASE2|PHASE3,50.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hematological Malignancies,stem cell transplant,PROCEDURE,3,2,60 Years,,ALL,False,Azienda Ospedaliera San Giovanni Battista,OTHER,0,1,Italy,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,5,1,0,0,0,1,0,,,,,0,1,0
NCT02087059,"A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis","A Multicenter, Open-label Clinical Study of the JAK Inhibitor Ruxolitinib (INC424) in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis",COMPLETED,2014-04,2015-04,2016-07-11,INTERVENTIONAL,PHASE3,51.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Primary Myelofibrosis (MF),Ruxolitinib,DRUG,1,4,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,29,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.9512437185814275,medium,1,1,1,0,1,0,1,0,0,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,0,0
NCT01209780,Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age,"A Multi-center, Phase III, Randomized, Observer Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Trivalent Subunit Inactivated Flu Vaccine in Healthy Children and Adolescents 3 to 17 Years of Age",COMPLETED,2010-09,2011-09,2014-03-11,INTERVENTIONAL,PHASE3,3116.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Seasonal Influenza,TIV|TIVf|Comparator TIV,BIOLOGICAL,2,6,3 Years,17 Years,ALL,True,Novartis Vaccines,INDUSTRY,0,13,Mexico|Colombia|Philippines|Panama,1.0,0,0,1,0,0,3.0,0,0,0,0,1,8.044626279767337,xlarge,0,1,1,0,1,0,1,1,0,0,1,1,0,1,8,1,0,1,0,3,1,,,,,0,3,1
NCT01825980,Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients,"Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of 3 Days of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus (HCV) Infected Patients",COMPLETED,2013-03,2014-12,2021-02-21,INTERVENTIONAL,PHASE1|PHASE2,54.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,DOUBLE,Hepatitis C,BZF961|Ritonavir|Placebo,DRUG,1,2,,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,3,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.007333185232471,medium,1,1,1,0,1,0,1,0,1,0,1,1,1,0,3,1,1,0,0,3,1,,,,,0,2,0
NCT03068780,Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa,"Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa",COMPLETED,2017-03-29,2022-05-27,2023-07-20,INTERVENTIONAL,PHASE3,223.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Epidermolysis Bullosa,Oleogel-S10|Control gel,DRUG,1,7,21 Days,,ALL,False,Amryt Research Limited,INDUSTRY,0,51,Ireland|Austria|Hungary|Hong Kong|Argentina|Russia|Australia|Spain|Romania|Italy|Israel|Chile|Ukraine|United States|Colombia|France|Czechia|Singapore|Georgia|Germany|Greece|United Kingdom|Denmark|Brazil|Switzerland|Serbia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.4116460518550396,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,8,1,1,0,0,2,1,2017-03-29,2022-05-27,1885.0,2017.0,1,3,1
NCT03204279,PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting,A Multicenter Multinational Randomized Double Blind PK/PD Dose-finding Study of Oral Netupitant Given With Oral Palonosetron in Pediatric Cancer Patients for Prevention of Nausea and Vomiting Associated With Emetogenic Chemotherapy,COMPLETED,2017-08-31,2019-09-30,2024-06-25,INTERVENTIONAL,PHASE2,67.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Chemotherapy-induced Nausea and Vomiting (CINV),Netupitant|Palonosetron|Netupitant|Palonosetron,DRUG,3,1,,17 Years,ALL,False,Helsinn Healthcare SA,INDUSTRY,0,17,Russia|Serbia|Ukraine|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.219507705176107,medium,1,1,1,0,0,0,1,1,1,0,1,1,0,1,4,1,1,0,0,4,1,2017-08-31,2019-09-30,760.0,2017.0,1,2,0
NCT00634179,A Phase I/II Trial of VR-CHOP in Lymphoma Patients,A Phase I/II Trial of VR-CHOP for Patients With Untreated Follicular Lymphoma and Other Low Grade B-Cell Lymphomas,COMPLETED,2008-02,2015-11,2016-10-27,INTERVENTIONAL,PHASE1|PHASE2,37.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Lymphoma, B-Cell|Follicular Lymphoma",Bortezomib|Rituximab|Doxorubicin|Cyclophosphamide|Vincristine|Prednisone,DRUG|BIOLOGICAL,1,1,18 Years,,ALL,False,Emory University,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,2,3.6375861597263857,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,1,0,6,1,,,,,0,3,1
NCT00652496,Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension,,COMPLETED,2005-01,2005-05,2008-04-03,INTERVENTIONAL,PHASE2,249.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Glaucoma|Ocular Hypertension,Bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.015% formulation 1 ophthalmic solution|Bimatoprost 0.015% formulation 2 ophthalmic solution|Bimatoprost 0.02% ophthalmic solution|Bimatoprost 0.03% ophthalmic solution,DRUG,1,3,18 Years,,ALL,False,Allergan,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,1,2,5.521460917862246,large,0,1,1,0,0,0,0,0,1,0,1,1,1,1,4,1,1,0,0,5,1,,,,,0,2,0
NCT01108562,Treatment of Postoperative Pain After Total Hip Arthroplasty Using Intravenous Lidocaine Infusion,"Treatment of Postoperative Pain After Total Hip Arthroplasty Using Intravenous Lidocaine Infusion in Combination With Patient Controlled Analgesia: a Prospective Randomized, Double-blinded, Placebo-controlled Study",WITHDRAWN,2008-02,,2015-04-06,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,RANDOMIZED,,TREATMENT,QUADRUPLE,Postoperative Pain Management After Total Hip Arthroplasty,Lidocaine|Normal Saline,DRUG|OTHER,1,0,18 Years,80 Years,ALL,True,Loma Linda University,OTHER,2,0,,0.0,1,1,0,0,1,1.5,0,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,0,0,2,1,,,,,0,2,0
NCT02420262,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus,COMPLETED,2015-07-26,2016-10-05,2018-03-29,INTERVENTIONAL,PHASE3,506.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes|Diabetes Mellitus, Type 2",insulin degludec/liraglutide|insulin glargine|insulin aspart,DRUG,1,4,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,117,Argentina|Russia|Turkey (Türkiye)|Mexico|United States|Slovakia|France|Spain|Czechia|Hungary|Greece|Israel,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.2285110035911835,xlarge,0,1,1,0,0,0,1,1,1,1,1,0,1,1,5,1,1,0,0,3,1,2015-07-26,2016-10-05,437.0,2015.0,1,3,1
NCT01746862,A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS),"A Randomized, Open-label, Two-arm Parallel Group, No Treatment Group-controlled, Multicenter Phase III Study to Evaluate the Safety and Efficacy of Saizen® 0.067 mg/kg/Day Subcutaneous Injection in Children With Idiopathic Short Stature",COMPLETED,2012-12,2015-03,2016-10-18,INTERVENTIONAL,PHASE3,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Idiopathic Short Stature,Saizen®|Saizen®,DRUG,1,7,5 Years,,ALL,False,"Merck KGaA, Darmstadt, Germany",INDUSTRY,0,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.51085950651685,medium,1,1,1,0,1,0,0,0,0,0,1,0,1,1,8,1,1,0,0,2,1,,,,,0,2,0
NCT00530946,A Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin,"A Multi-Center, Randomized Study To Evaluate Efficacy And Safety Of A Fixed Combination Therapy Of Amlodipine And Atorvastatin In The Treatment Of Concurrent Hypertension And Hyper-LDL-Cholesterolemia",COMPLETED,2007-09,2008-04,2021-01-28,INTERVENTIONAL,PHASE3,165.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hypertension|Hypercholesterolemia,Amlodipine 2.5mg/Atorvastatin 5mg|Amlodipine 2.5mg/Atorvastatin 10mg|Amlodipine 5mg/Atorvastatin 5mg|Amlodipine 5mg/Atorvastatin 10mg,DRUG,2,9,20 Years,79 Years,ALL,False,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,0,17,Japan,1.0,0,0,1,0,0,3.0,0,0,0,1,2,5.111987788356544,medium,0,1,1,0,1,0,1,0,0,0,1,0,1,1,11,1,1,0,0,4,1,,,,,0,3,1
NCT00391196,"A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients","A 1-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy And Safety Of CP-945,598 In The Treatment Of Overweight, Oral Agent-Treated Subjects With Type 2 Diabetes Mellitus",TERMINATED,2006-11,2009-01,2012-11-07,INTERVENTIONAL,PHASE3,975.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Obesity,"Placebo|CP-945,598|CP-945,598 Treatment B",DRUG,1,24,18 Years,70 Years,ALL,False,Pfizer,INDUSTRY,0,91,United Kingdom|Argentina|Mexico|Australia|United States|Sweden|Canada|Brazil|Slovakia|Czechia|Germany,0.0,0,0,1,0,0,3.0,0,0,0,0,1,6.883462586413092,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,25,1,1,0,0,3,1,,,,,0,3,1
NCT00423046,Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age,"Phase IIIb, Observer-blind Study to Compare Immunogenicity of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Versus Gardasil® [Quadrivalent Human Papillomavirus (HPV-6,11,16,18 L1 VLP) Recombinant Vaccine Merck & Co., Inc.]",COMPLETED,2007-01-24,2012-05-14,2020-01-02,INTERVENTIONAL,PHASE3,1106.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,"Infections, Papillomavirus|Papillomavirus Vaccines",GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)|Gardasil ® (Merck & Co. Inc)|Placebo|Placebo,BIOLOGICAL,1,30,18 Years,45 Years,FEMALE,True,GlaxoSmithKline,INDUSTRY,0,40,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,7.009408932708637,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,0,1,31,1,0,1,0,4,1,2007-01-24,2012-05-14,1937.0,2007.0,0,3,1
NCT04404088,"Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma","A Phase II Study of Acalabrutinib, Lenalidomide, and Rituximab (aR2) in Patients With Previously Untreated Follicular Lymphoma",ACTIVE_NOT_RECRUITING,2020-07-16,2028-03-01,2025-03-20,INTERVENTIONAL,PHASE2,60.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Ann Arbor Stage III Grade 1 Follicular Lymphoma|Ann Arbor Stage III Grade 2 Follicular Lymphoma|Ann Arbor Stage III Grade 3 Follicular Lymphoma|Ann Arbor Stage IV Grade 1 Follicular Lymphoma|Ann Arbor Stage IV Grade 2 Follicular Lymphoma|Ann Arbor Stage IV Grade 3 Follicular Lymphoma|Grade 3a Follicular Lymphoma,Acalabrutinib|Lenalidomide|Rituximab,DRUG|BIOLOGICAL,1,7,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,,0,1,0,0,0,2.0,1,0,0,0,7,4.110873864173311,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,8,1,1,1,0,3,1,2020-07-16,2028-03-01,2785.0,2020.0,1,3,1
NCT00954603,"A Double-blind, Randomized, Controlled Trial of Quetiapine Versus Haloperidol for the Treatment of Delirium",Compare Efficacy and Safety Between Quetiapine and Haloperidol in Treatment Delirium,TERMINATED,2009-06,2012-07,2011-06-23,INTERVENTIONAL,PHASE3,52.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Delirium,quetiapine|haloperidol,DRUG,1,1,18 Years,75 Years,ALL,False,Chiang Mai University,OTHER,0,1,Thailand,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.970291913552122,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT03477903,TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI),"A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Intolerance",TERMINATED,2018-08-25,2018-08-29,2019-09-24,INTERVENTIONAL,PHASE2,1.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Critical Illness|Enteral Nutrition|Enteral Feeding Intolerance,TAK-954|Metoclopramide|Normal Saline,DRUG,1,7,18 Years,,ALL,False,"Millennium Pharmaceuticals, Inc.",INDUSTRY,0,44,United Kingdom|Canada|Australia|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,3,0.6931471805599453,small,1,1,1,0,0,0,1,1,1,1,1,1,1,1,8,1,1,0,0,3,1,2018-08-25,2018-08-29,4.0,2018.0,1,4,1
NCT01685827,Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2,"Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label Study",COMPLETED,2012-10,2017-04-26,2018-02-20,INTERVENTIONAL,PHASE2|PHASE3,394.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Human African Trypanosomiasis (HAT)|Sleeping Sickness,Fexinidazole|Nifurtimox|Eflornithine,DRUG,1,4,15 Years,,ALL,False,Drugs for Neglected Diseases,OTHER,0,10,Central African Republic|Democratic Republic of the Congo|Republic of the Congo,1.0,0,1,1,0,1,2.5,0,0,0,0,2,5.978885764901122,large,0,1,0,1,0,0,1,1,0,0,1,0,1,1,5,1,1,0,0,3,1,,2017-04-26,,,0,4,1
NCT02052427,Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II),Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization II,COMPLETED,2014-01,2016-10,2016-10-28,INTERVENTIONAL,PHASE2,3.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Myocardial Ischemia,Celution System|Placebo,DEVICE,1,6,20 Years,80 Years,ALL,False,Cytori Therapeutics,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,1,1,1.3862943611198906,small,1,1,1,0,0,0,0,0,1,0,1,1,1,1,7,1,0,0,1,2,1,,,,,0,2,0
NCT03897127,Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics,Randomized Phase III Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics,ACTIVE_NOT_RECRUITING,2019-09-04,2027-06,2025-07-17,INTERVENTIONAL,PHASE3,882.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Myeloid Leukemia,Cytarabine|Daunorubicin|CPX-351,DRUG,1,4,18 Years,,ALL,False,University of Ulm,OTHER,1,62,Germany|Austria,,0,0,1,0,0,3.0,1,0,0,0,1,6.78332520060396,xlarge,0,0,0,1,0,1,1,1,0,1,1,0,1,1,5,1,1,0,0,3,1,2019-09-04,,,2019.0,1,2,0
NCT00718861,3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs,"A 3-year, Multicenter, Double-blind, Randomized, Placebo-controlled Extension to CZOL446H2301E1 to Evaluate the Efficacy and Long Term Safety of 6 and 9 Years Zoledronic Acid Treatment of Postmenopausal Women With Osteoporosis",COMPLETED,2008-05,2013-04,2014-10-09,INTERVENTIONAL,PHASE3,190.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Post-menopausal Osteoporosis,Placebo|Zoledronic acid,DRUG,1,10,65 Years,,FEMALE,False,Novartis Pharmaceuticals,INDUSTRY,0,57,Argentina|Finland|Australia|United States|Sweden|Canada|Colombia|Hungary|Poland|Thailand|New Zealand|France|Switzerland|Germany|Norway|Belgium|Italy|Hong Kong,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.25227342804663,medium,0,1,1,0,1,0,1,1,1,1,1,1,1,1,11,1,1,0,0,2,1,,,,,0,3,1
NCT02593461,Diafert® for Embryo Selection and Fertility Improvement,"A Prospective, Single-center, Randomized, Two-arm, Interventional Study to Evaluate the Implantation Rate of Embryos Selected on the Basis of Morphology and Granulocyte-Colony Stimulating Factor (G-CSF) Concentration in the Ovarian Follicular Fluid (FF) - FF G-CSF - Compared to the Implantation Rate of Embryos Selected on the Basis of Morphology Alone When Elective Single Embryo Transfer (SET) of a Fresh Embryo is Performed on Day 2/3 After Oocyte Retrieval",COMPLETED,2015-10-22,2017-04-07,2017-08-01,INTERVENTIONAL,PHASE3,14.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Infertility,Daifert|Control Group,OTHER|DEVICE,1,1,18 Years,,FEMALE,False,Forest Laboratories,INDUSTRY,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,2.70805020110221,small,1,1,1,0,0,0,0,0,0,1,1,0,1,1,2,1,0,0,1,2,1,2015-10-22,2017-04-07,533.0,2015.0,1,1,0
NCT01955161,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil,"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil",COMPLETED,2013-10,2016-07,2017-09-19,INTERVENTIONAL,PHASE3,933.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Alzheimer's Disease,Placebo|Idalopirdine,DRUG,1,10,50 Years,,ALL,False,H. Lundbeck A/S,INDUSTRY,1,137,Argentina|Chile|Ukraine|Denmark|Bulgaria|United States|Canada|France|South Africa|Spain|Czechia|Germany|Poland|Belgium|Italy|Romania,1.0,0,0,1,0,0,3.0,0,0,1,0,1,6.839476438228843,xlarge,0,1,1,0,0,1,1,1,1,1,1,1,1,1,11,1,1,0,0,2,1,,,,,0,3,1
NCT00137761,Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer,A Phase II Study of Docetaxel in Combination With ZD 1839 (IRESSA) in Previously Treated Patients With Metastatic Pancreatic Cancer,COMPLETED,2004-10,2009-03,2009-11-02,INTERVENTIONAL,PHASE2,32.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Metastatic Pancreatic Carcinoma,ZD 1839|Docetaxel,DRUG,1,1,18 Years,,ALL,False,Dana-Farber Cancer Institute,OTHER,3,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4965075614664802,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,2,1,1,0,0,2,1,,,,,0,1,0
NCT00492986,"An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma","An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma",COMPLETED,2005-10,2008-11,2014-12-30,INTERVENTIONAL,PHASE3,1150.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Carcinoma, Renal Cell","Nexavar (Sorafenib, BAY43-9006)",DRUG,1,1,18 Years,,ALL,False,Bayer,INDUSTRY,0,33,United Kingdom|Denmark|Sweden|Poland|France|Spain|Switzerland|Germany|Netherlands|Belgium|Italy,1.0,0,0,1,0,0,3.0,1,0,0,0,1,7.048386408721883,xlarge,0,1,1,0,0,0,1,1,0,1,0,0,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT04656470,Neuroimaging Study of Dexmedetomidine-Induced Analgesia,Neuroimaging Study of Dexmedetomidine-Induced Analgesia,COMPLETED,2022-03-04,2025-05-27,2025-12-03,INTERVENTIONAL,PHASE2|PHASE3,17.0,ACTUAL,,SINGLE_GROUP,BASIC_SCIENCE,NONE,Analgesia|Anesthesia,Dexmedetomidine,DRUG,1,0,18 Years,45 Years,ALL,True,Massachusetts General Hospital,OTHER,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,2,2.8903717578961645,small,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,2022-03-04,2025-05-27,1180.0,2022.0,1,2,0
NCT03693573,A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma,"An Open Label, Phase IIIB, Single Arm, Multicenter Safety Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma",WITHDRAWN,2019-01-11,2024-01-31,2018-11-15,INTERVENTIONAL,PHASE3,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Renal Cell Carcinoma,Atezolizumab|Bevacizumab,DRUG,1,9,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,1,0,0,0,1,0.0,,1,1,1,0,1,0,0,0,0,0,0,0,1,0,10,1,1,0,0,2,1,2019-01-11,2024-01-31,1846.0,2019.0,1,2,0
NCT05219370,"Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD","Treatment With Cannabis Oil Containing Canabidiol (CBD) Tetrahydrocannabinol (THC), Cannabidivarin (CBDV) or Cannabigerol (CBG) vs. Placebo of Persons Diagnosed With ADHD After Failure of Conventional Treatment",TERMINATED,2022-07-31,2022-12-31,2023-04-25,INTERVENTIONAL,PHASE2,8.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,ADHD|Hyperactivity|Attention Deficit,Cannabis oil,DRUG,2,2,18 Years,,ALL,False,Brlev Agricultural Crops Ltd,INDUSTRY,1,1,Israel,0.0,0,1,0,0,0,2.0,0,0,0,0,3,2.1972245773362196,small,1,1,1,0,0,1,0,0,0,0,1,1,1,0,4,1,1,0,0,1,0,2022-07-31,2022-12-31,153.0,2022.0,1,1,0
NCT01408069,Non-Inferiority Comparison of Migrane® Versus Parcel ® For Treatment of Tensional Cephaleia,"Multicentric, Randomizade, Double Blind, Double Dummy To Non-Inferiority Comparison Of Migrane® Versus Parcel ® For Treatment Of Tensional Cephaleia",WITHDRAWN,,,2021-02-24,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Tensional-type Headache,MIGRANE|PARCEL,DRUG,1,1,18 Years,65 Years,ALL,False,EMS,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT01245569,A Study in Patients With Chronic Obstructive Pulmonary Disease,"A 12-week, Multicentre, Multinational, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster® 100/6 (Beclomethasone Dipropionate 100 µg Plus Formoterol 6 µg/Actuation), 2 Puffs b.i.d., Versus Seretide® 500/50 (Fluticasone 500 µg Plus Salmeterol 50 µg/Actuation), 1 Inhalation b.i.d., in Patients With Chronic Obstructive Pulmonary Disease",COMPLETED,2011-04,2012-03,2017-03-30,INTERVENTIONAL,PHASE3,373.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Obstructive Pulmonary Disease,Foster® 100/6 µg/unit dose|Seretide Accuhaler® 500/50 µg/actuation,DRUG,2,4,40 Years,,ALL,False,Chiesi Farmaceutici S.p.A.,INDUSTRY,0,1,Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.924255797414532,large,0,1,1,0,0,0,0,0,0,1,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT00911183,Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial,Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial With Emphasis on Geriatric Assessment and Quality of Life,COMPLETED,2008-12-02,2015-01-01,2025-08-29,INTERVENTIONAL,PHASE2,67.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Lymphoma,filgrastim|pegfilgrastim|rituximab|cyclophosphamide|liposome-encapsulated doxorubicin citrate|prednisone|vincristine sulfate,DRUG|BIOLOGICAL,2,2,70 Years,120 Years,ALL,False,Institut Bergonié,OTHER,1,1,France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.219507705176107,medium,1,1,0,1,0,1,0,0,0,1,1,0,1,1,4,1,1,1,0,7,1,2008-12-02,2015-01-01,2221.0,2008.0,0,1,0
NCT03859141,Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml),"Open Phase I and Randomized, Double-blind, Controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6-35 Months",COMPLETED,2018-02-06,2018-11-02,2019-03-01,INTERVENTIONAL,PHASE3,2340.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Seasonal Influenza,Quadrivalent influenza vaccine|Quadrivalent influenza vaccine|Trivalent influenza vaccine (contains B/Victoria strain)|Trivalent influenza vaccine (contains B/Yamagata strain),BIOLOGICAL,2,10,6 Months,35 Months,ALL,True,"Sinovac Biotech Co., Ltd",INDUSTRY,0,2,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.75833346749091,xlarge,0,1,1,0,0,0,1,0,0,0,1,1,0,1,12,1,0,1,0,4,1,2018-02-06,2018-11-02,269.0,2018.0,1,2,0
NCT01890941,A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes,,COMPLETED,,,2015-10-19,INTERVENTIONAL,PHASE2,,,,,,,Dry Eye Syndromes,KCT-0809 ophthalmic solution|Placebo,DRUG,1,1,20 Years,,ALL,,"Kissei Pharmaceutical Co., Ltd.",INDUSTRY,0,1,Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,0,0,1,0,0,0,0,0,0,0,0,0,0,0,2,1,1,0,0,2,1,,,,,0,1,0
NCT03618641,CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease,Neoadjuvant Phase II Study of TLR9 Agonist CMP-001 in Combination With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease,COMPLETED,2018-08-08,2023-12-31,2025-05-14,INTERVENTIONAL,PHASE2,34.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,Melanoma|Lymph Node Cancer,CMP-001|Nivolumab,DRUG|BIOLOGICAL,1,9,18 Years,,ALL,False,Diwakar Davar,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.5553480614894135,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,10,1,1,1,0,2,1,2018-08-08,2023-12-31,1971.0,2018.0,1,3,1
NCT00037141,Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate),Evaluation of the Safety and Tolerability of Transurethral Alcohol Injection for the Treatment of BPH (Enlarged Prostate),COMPLETED,2002-03,2004-03,2007-10-10,INTERVENTIONAL,PHASE1|PHASE2,150.0,,RANDOMIZED,PARALLEL,TREATMENT,,Prostate Disease|BPH|Benign Prostatic Hyperplasia|Benign Prostatic Hypertrophy,dehydrated alcohol,DRUG,0,0,50 Years,80 Years,MALE,False,American Medical Systems,INDUSTRY,0,0,,1.0,1,1,0,0,1,1.5,0,0,0,0,4,5.017279836814924,medium,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,,,,,0,2,0
NCT00003305,Aminopterin in Treating Patients With Refractory Leukemia,A Phase II Trial of Aminopterin in Adults and Children With Refractory Acute Leukemia Grant Application Title: A Phase II Trial of Aminopterin in Acute Leukemia,COMPLETED,1997-07,2007-09,2014-01-06,INTERVENTIONAL,PHASE2,75.0,ESTIMATED,,,TREATMENT,,Leukemia,aminopterin|leucovorin calcium,DRUG,0,0,,,ALL,False,"Genzyme, a Sanofi Company",INDUSTRY,0,14,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.330733340286331,medium,1,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,2,1,,,,,0,1,0
NCT04650854,A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis,An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis,COMPLETED,2021-02-03,2024-01-25,2025-04-18,INTERVENTIONAL,PHASE3,165.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Generalized Myasthenia Gravis,Rozanolixizumab,DRUG,2,9,18 Years,,ALL,False,UCB Biopharma SRL,INDUSTRY,0,69,Russia|Denmark|United States|Canada|Poland|Taiwan|France|Spain|Czechia|Georgia|Germany|Japan|Italy|Serbia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.111987788356544,medium,0,1,1,0,0,0,1,1,1,1,1,0,1,0,11,1,1,0,0,1,0,2021-02-03,2024-01-25,1086.0,2021.0,1,2,0
NCT01229254,Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter,"A Phase II, Open-label, Dose Exposure Confirmation Study to Evaluate the Pharmacokinetics and Safety and Tolerability of Betrixaban (MK-4448) in Adult Patients With Nonvalvular Atrial Fibrillation or Atrial Flutter",COMPLETED,2010-09,2011-04,2023-08-07,INTERVENTIONAL,PHASE2,189.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Atrial Fibrillation|Atrial Flutter,Amiodarone|Betrixaban 60 mg|Betrixaban 90 mg|Betrixaban 30 mg,DRUG,1,1,18 Years,,ALL,False,Portola Pharmaceuticals,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.247024072160486,medium,0,1,1,0,0,0,0,0,0,0,0,0,1,1,2,1,1,0,0,4,1,,,,,0,2,0
NCT01467505,An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients,"A 2-Part, Open Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Chronically Infected With Genotype 1 Hepatitis C Virus Following Liver Transplantation",TERMINATED,2012-02,2014-04,2015-06-18,INTERVENTIONAL,PHASE2,61.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hepatitis C,Telaprevir|Ribavirin|Pegylated Interferon Alfa-2a|Immunosuppressant Regimen,DRUG,1,11,18 Years,65 Years,ALL,False,Vertex Pharmaceuticals Incorporated,INDUSTRY,0,22,Canada|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.127134385045092,medium,1,1,1,0,0,0,1,1,1,0,0,0,1,0,12,1,1,0,0,4,1,,,,,0,3,1
NCT00630994,Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis,Phase II Trial of Low Dose Decitabine (Dacogen) in Patients With Primary Myelofibrosis and Post ET/PV Myelofibrosis,TERMINATED,2008-03,2012-04,2015-12-30,INTERVENTIONAL,PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Myeloproliferative Disorders|Secondary Myelofibrosis,Dacogen,DRUG,1,4,18 Years,120 Years,ALL,False,Mayo Clinic,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,1.6094379124341003,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,1,0
NCT02972294,HiFIT Study : Hip Fracture: Iron and Tranexamic Acid,HiFIT Study: Interest of Intravenous Iron and Tranexamic Acid to Reduce Transfusion in Hip Fracture Patients,TERMINATED,2017-03-31,2021-09-16,2022-08-02,INTERVENTIONAL,PHASE3,419.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,TRIPLE,Hip Fractures Pathologic|Anemia,Iron Isomaltoside 1000|Tranexamic Acid|Placebos iron isomaltoside 1000|Placebos tranexamic acid,DRUG,1,15,18 Years,,ALL,False,"University Hospital, Angers",OTHER_GOV,0,13,France,0.0,0,0,1,0,0,3.0,0,0,0,0,2,6.040254711277414,large,0,1,0,1,0,0,1,0,0,1,1,1,1,0,16,1,1,0,0,4,1,2017-03-31,2021-09-16,1630.0,2017.0,1,3,1
NCT01198366,Study of AERAS-402 in Healthy Infants,"A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of AERAS-402 in BCG-vaccinated, HIV-uninfected Infants Without Evidence of Tuberculosis",COMPLETED,2010-09,2014-04,2017-05-08,INTERVENTIONAL,PHASE1|PHASE2,487.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Tuberculosis,AERAS-402 1.5 x 10^10 vp|AERAS-402 3.0 x 10^10 vp|AERAS-402 1.0 x 10^11 vp|Placebo,BIOLOGICAL,1,4,112 Days,182 Days,ALL,True,Aeras,OTHER,1,7,Kenya|Mozambique|South Africa,1.0,1,1,0,0,1,1.5,0,0,0,0,1,6.1903154058531475,large,0,1,0,1,0,1,1,1,0,0,1,1,0,1,5,1,0,1,0,4,1,,,,,0,3,1
NCT00654966,"Evaluation of the Effects of Urotensin-II and Soluble Epoxide Hydrolase Inhibitors on Skin Microvessel Tone in Patients With Heart Failure, and in Healthy Volunteers","Evaluation of the Effects of Urotensin-II and Soluble Epoxide Hydrolase Inhibitors on Skin Microvessel Tone in Patients With Heart Failure, and in Healthy Volunteers.",COMPLETED,2009-06,2010-12,2011-07-20,INTERVENTIONAL,PHASE2,16.0,ACTUAL,NON_RANDOMIZED,PARALLEL,BASIC_SCIENCE,NONE,Heart Failure,Urotensine II|Soluble epoxide hydrolase,DRUG,1,0,18 Years,80 Years,ALL,True,Monash University,OTHER,0,1,Australia,1.0,0,1,0,0,0,2.0,0,0,0,1,1,2.833213344056216,small,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT00307866,Identification of Hepatic Lesions,"A Prospective, Multicenter, Phase III b Clinical Study to Evaluate the Effectiveness of Unenhanced and SH U 555A (Resovist) Enhanced MRI, Compared to Contrast-Enhanced Dual-Phase Spiral CT in Assessing the Correct Final Therapy-Deciding Diagnosis, in Patients With Primary or Secondary Hepatic Malignancies.",COMPLETED,2001-04,2003-05,2009-05-18,INTERVENTIONAL,PHASE3,218.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,DIAGNOSTIC,NONE,Hepatic Neoplasms,"Resovist (BAY86-4884, SH U 555 A)",PROCEDURE,1,5,18 Years,,ALL,False,Bayer,INDUSTRY,0,19,Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.389071729816501,large,0,1,1,0,0,0,1,0,0,1,0,0,0,0,6,1,0,0,0,1,0,,,,,0,1,0
NCT03222856,Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes,A Phase II Study of Pembrolizumab and Eribulin in Patients With HR-positive/HER2-negative Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes,COMPLETED,2017-12-14,2020-12-23,2025-06-05,INTERVENTIONAL,PHASE2,44.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,Pembrolizumab|Eribulin,DRUG,1,10,18 Years,,FEMALE,False,MedSIR,OTHER,0,11,Spain,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.8066624897703196,small,1,1,0,1,0,0,1,0,0,1,0,0,1,0,11,1,1,0,0,2,1,2017-12-14,2020-12-23,1105.0,2017.0,1,2,0
NCT00514020,"Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer",Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors: A Phase II Study,COMPLETED,2007-08,2011-02,2012-11-01,INTERVENTIONAL,PHASE2,33.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Gastric Cancer,fluorouracil|leucovorin calcium|oxaliplatin|gene expression analysis|polymorphism analysis|protein expression analysis|pharmacological study,DRUG|GENETIC|OTHER,1,0,18 Years,,ALL,False,Vanderbilt-Ingram Cancer Center,OTHER,1,5,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.5263605246161616,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,1,0,0,7,1,,,,,0,1,0
NCT03682120,Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza,"A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59(R) Adjuvant",COMPLETED,2018-11-02,2020-04-30,2021-05-17,INTERVENTIONAL,PHASE2,372.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Avian Influenza|Influenza Immunisation,A/H7N9|MF59|Phosphate Buffered Saline (PBS) diluent,DRUG|OTHER|BIOLOGICAL,13,28,18 Years,64 Years,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,7,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.921578419643816,large,0,1,0,1,0,0,1,0,1,0,1,1,0,1,41,1,1,1,0,3,1,2018-11-02,2020-04-30,545.0,2018.0,1,3,1
NCT07143682,Letrozole Step up Protocol for Ovulation Induction in Infertile Women With Polycystic Ovary Syndrome,Letrozole Step up Compared to Conventional Protocol for Ovulation Induction in Infertile Women With Polycystic Ovary Syndrome,COMPLETED,2023-01-08,2024-06-30,2025-12-16,INTERVENTIONAL,PHASE3,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Polycystic Ovarian Syndrome (PCOS)|Infertility,Letrozol step up dose|Conventional fixed dose letrozole,DRUG,2,1,18 Years,35 Years,FEMALE,False,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",OTHER,0,1,Bangladesh,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.2626798770413155,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,1,3,1,1,0,0,2,1,2023-01-08,2024-06-30,539.0,2023.0,1,2,0
NCT00726882,A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies,"A Follow-up Study to Assess the Evolution and Persistence of Resistance to ABT-333 After Discontinuation of ABT-333 Therapy in HCV Genotype-1 Infected Subjects Who Participated in Phase 1, 2, or 3 ABT-333 Clinical Studies",COMPLETED,2008-08,2010-05,2015-01-08,INTERVENTIONAL,PHASE2,35.0,ACTUAL,,SINGLE_GROUP,,NONE,HCV Infection,Blood sample collection only|ABT-333,PROCEDURE|DRUG,1,1,18 Years,65 Years,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,0,7,Puerto Rico|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.58351893845611,small,1,1,1,0,1,0,1,1,1,0,0,0,0,0,2,1,1,0,0,2,1,,,,,0,2,0
NCT00451724,Intranasal Ketamine for Procedural Sedation in Pediatric Laceration Repair,Intranasal Ketamine for Procedural Sedation in Pediatric Laceration Repair,COMPLETED,2007-05,2010-02,2010-07-22,INTERVENTIONAL,PHASE2,45.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Laceration,Intranasal ketamine,DRUG,2,7,1 Year,7 Years,ALL,True,Rhode Island Hospital,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.828641396489095,small,1,0,0,1,0,0,0,0,1,0,1,1,1,1,9,1,1,0,0,1,0,,,,,0,1,0
NCT01516424,Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone,"A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone",COMPLETED,2012-02,2013-02,2018-11-27,INTERVENTIONAL,PHASE3,267.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia,Blonanserin|Risperidone,DRUG,1,4,18 Years,64 Years,ALL,False,"Sumitomo Pharma (Suzhou) Co., Ltd.",INDUSTRY,0,16,China,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.5909869805108565,large,0,1,1,0,0,0,1,0,0,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT00747123,"A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma","A Phase 2a, Multi-Center, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ACE-011 (hActRIIA-IgG1) in Patients With Osteolytic Lesions of Multiple Myeloma",COMPLETED,2008-09-01,2009-08-01,2024-10-03,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Multiple Myeloma,ACE-011|Placebo,BIOLOGICAL,6,2,18 Years,,ALL,False,Celgene,INDUSTRY,0,2,Russia,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4339872044851463,small,1,1,1,0,0,0,1,0,0,0,1,1,1,1,8,1,0,1,0,2,1,2008-09-01,2009-08-01,334.0,2008.0,0,2,0
NCT06348524,Ferumoxytol-enhanced Magnetic Resonance Imaging,Ferumoxytol-enhanced Magnetic Resonance Imaging,TERMINATED,2015-01-01,2022-12-30,2025-08-07,INTERVENTIONAL,PHASE3,36.0,ESTIMATED,,SINGLE_GROUP,DIAGNOSTIC,NONE,Coronary Artery Disease,Ferumoxytol injection,DRUG,1,2,18 Years,85 Years,ALL,False,Transmed Solutions,OTHER,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.6109179126442243,small,1,0,0,1,0,0,0,0,0,0,0,0,0,0,3,1,1,0,0,1,0,2015-01-01,2022-12-30,2920.0,2015.0,1,0,0
NCT02898259,"Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma","A Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B Cell Lymphoma",TERMINATED,2017-02-20,2022-06-06,2022-09-26,INTERVENTIONAL,PHASE1|PHASE2,19.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,B Cell Lymphoma|Lymphoma,Ixazomib|Lenalidomide|Rituximab,DRUG,1,6,18 Years,,ALL,False,Brian Hill,OTHER,1,2,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,2,2.995732273553991,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,7,1,1,0,0,3,1,2017-02-20,2022-06-06,1932.0,2017.0,1,4,1
NCT03345823,A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433",ACTIVE_NOT_RECRUITING,2018-03-21,2027-09,2025-08-05,INTERVENTIONAL,PHASE3,747.0,ESTIMATED,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,Crohn's Disease,Upadacitinib|Placebo for Upadacitinib,DRUG,3,11,18 Years,75 Years,ALL,False,AbbVie,INDUSTRY,0,466,Estonia|Canada|Ireland|Austria|Lithuania|Latvia|Slovenia|South Africa|Egypt|China|Hungary|Hong Kong|Argentina|Russia|Australia|Bulgaria|Portugal|Spain|Romania|Belgium|Israel|Italy|Chile|Ukraine|United States|Sweden|Colombia|France|Czechia|Singapore|Germany|Greece|Netherlands|Poland|South Korea|United Kingdom|Croatia|Turkey (Türkiye)|Denmark|Bosnia and Herzegovina|Malaysia|Puerto Rico|Brazil|Slovakia|Taiwan|Switzerland|Mexico|Japan|Serbia,,0,0,1,0,0,3.0,0,1,0,0,1,6.617402977974478,xlarge,0,0,1,0,1,0,1,1,1,1,1,1,1,0,14,1,1,0,0,2,1,2018-03-21,,,2018.0,1,3,1
NCT02393859,Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL),"Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL",COMPLETED,2015-11-10,2022-11-21,2024-05-29,INTERVENTIONAL,PHASE3,111.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Leukemia, Acute Lymphoblastic",Blinatumomab|Dexamethasone|Vincrisitne|Daunorubicin|Methotrexate|Ifosfamide|PEG-asparaginase|Erwinia-asparaginase,DRUG,2,10,0 Years,17 Years,ALL,False,Amgen,INDUSTRY,0,103,Austria|Argentina|Russia|Australia|Portugal|Spain|Romania|Norway|Belgium|Italy|Israel|Sweden|France|Czechia|Germany|Netherlands|Poland|Greece|United Kingdom|Turkey (Türkiye)|Denmark|Brazil|Switzerland|Mexico,1.0,0,0,1,0,0,3.0,1,0,0,0,1,4.718498871295094,medium,0,1,1,0,1,0,1,1,0,1,1,0,1,1,12,1,1,0,0,8,1,2015-11-10,2022-11-21,2568.0,2015.0,1,3,1
NCT04298879,IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma,"A Phase 2, Multicenter, Open-Label Study of IBI376, a PI3Kδ Inhibitor, in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma",COMPLETED,2020-04-07,2023-11-21,2024-06-05,INTERVENTIONAL,PHASE2,81.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Indolent Non-hodgkin Lymphoma,IBI376,DRUG,1,6,18 Years,,ALL,False,Innovent Biologics (Suzhou) Co. Ltd.,INDUSTRY,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.406719247264253,medium,1,1,1,0,0,0,0,0,0,0,0,0,1,0,7,1,1,0,0,1,0,2020-04-07,2023-11-21,1323.0,2020.0,1,1,0
NCT00003996,Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,"A Phase II Trial of Pre-irradiation Chemotherapy With BCNU, Cisplatin and Oral Etoposide Combined With Radiation Therapy in the Treatment of Grade 4 Astrocytoma (Glioblastoma)",COMPLETED,1999-05,2008-05,2016-12-07,INTERVENTIONAL,PHASE2,93.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Brain and Central Nervous System Tumors,carmustine|chemotherapy|cisplatin|etoposide|radiation therapy,DRUG|RADIATION,1,1,18 Years,,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,1,19,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.543294782270004,medium,1,1,0,1,0,1,1,0,1,0,0,0,1,0,2,1,1,0,0,5,1,,,,,0,1,0
NCT00003362,Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma,"Pilot Trial of Multi-Epitope Melanoma Peptide Vaccine Using GM-CSF, Montanide and QS-21 as Adjuvants",COMPLETED,1998-05,2001-02,2013-06-25,INTERVENTIONAL,PHASE2,,,RANDOMIZED,,TREATMENT,,Melanoma (Skin),QS21|gp100 antigen|incomplete Freund's adjuvant|sargramostim|tyrosinase peptide,BIOLOGICAL,0,0,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,5,1,,,,,0,1,0
NCT02784262,Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis,Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis,COMPLETED,2016-10,2018-12,2021-11-05,INTERVENTIONAL,PHASE2,11.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Disease|Nasal Polyposis|Rhinitis,botox injection Multiguide,DRUG,1,8,18 Years,70 Years,ALL,False,Norwegian University of Science and Technology,OTHER,1,1,Norway,1.0,0,1,0,0,0,2.0,0,0,0,0,3,2.4849066497880004,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,9,1,1,0,0,1,0,,,,,0,2,0
NCT04636762,A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC),"A Multi-center, Single Arm , Phase II Study of Atezolizumab Combined With Concurrent Chemoradiotherapy and Maintenance Therapy With Atezolizumab in Untreated Participants With Extensive-stage Small Cell Lung Cancer",COMPLETED,2020-06-01,2022-05-01,2022-06-14,INTERVENTIONAL,PHASE2,40.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Extensive-stage Small Cell Lung Cancer,Radiation Therapy,PROCEDURE,1,1,18 Years,75 Years,ALL,False,Second Xiangya Hospital of Central South University,OTHER,1,2,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.713572066704308,small,1,1,0,1,0,1,1,0,0,0,0,0,1,0,2,1,0,0,0,1,0,2020-06-01,2022-05-01,699.0,2020.0,1,0,0
NCT00034762,Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease,Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease.,COMPLETED,2000-12,2003-01,2011-02-01,INTERVENTIONAL,PHASE3,473.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Dementia|Alzheimer Disease|Mental Disorders,risperidone,DRUG,1,1,55 Years,,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,1,0,3,6.161207321695077,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,1,0
NCT05646862,"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy","A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy",ACTIVE_NOT_RECRUITING,2023-06-07,2029-03-30,2026-01-30,INTERVENTIONAL,PHASE3,420.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,Inavolisib|Fulvestrant|Alpelisib|Bupropion|Omeprazole|Midazolam,DRUG,10,12,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,145,United Kingdom|Argentina|Turkey (Türkiye)|Mexico|Australia|United States|Canada|Brazil|South Korea|Taiwan|France|South Africa|Spain|China|Germany|Poland|Belgium|Italy,,0,0,1,0,0,3.0,1,0,0,0,1,6.042632833682381,large,0,0,1,0,1,0,1,1,1,1,1,0,1,1,22,1,1,0,0,6,1,2023-06-07,2029-03-30,2123.0,2023.0,1,3,1
NCT06234046,Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin,Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin,COMPLETED,2023-05-28,2023-12-15,2024-01-31,INTERVENTIONAL,PHASE3,80.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Spontaneous Bacterial Peritonitis,Rifaximin 550Mg Tab|Ciprofloxacin 750 MG|ascitic fluid sample,DRUG|DIAGNOSTIC_TEST,1,0,18 Years,75 Years,ALL,True,Ain Shams University,OTHER,0,1,Egypt,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.394449154672439,medium,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,3,1,2023-05-28,2023-12-15,201.0,2023.0,1,1,0
NCT00871546,SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715),A Randomized Phase 2 Study of SCH 727965 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) or B-Cell Chronic Lymphocytic Leukemia (B-CLL),TERMINATED,2009-03,2010-12,2015-08-07,INTERVENTIONAL,PHASE2,8.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Lymphoma, Mantle-Cell|Leukemia, Lymphocytic, Chronic, B-Cell",SCH 727965|Bortezomib|Alemtuzumab,DRUG|BIOLOGICAL,2,4,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,2,2.1972245773362196,small,1,1,1,0,1,0,0,0,0,0,1,0,1,1,6,1,1,1,0,3,1,,,,,0,3,1
NCT00463788,"Cetuximab and Cisplatin in the Treatment of ""Triple Negative"" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer","Randomized Phase II Trial With Cetuximab and Cisplatin in the Treatment of ER-negative, PgR-negative, HER2-negative Metastatic Breast Carcinoma (""Basal Like"")",COMPLETED,2007-06,2011-02,2014-02-13,INTERVENTIONAL,PHASE2,181.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Neoplasm,"cetuximab, cisplatin|cisplatin",DRUG,1,4,18 Years,,FEMALE,False,"Merck KGaA, Darmstadt, Germany",INDUSTRY,0,46,United Kingdom|Australia|Ireland|Austria|Portugal|New Zealand|Spain|Italy|Germany|Belgium|Israel,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.204006687076795,medium,0,1,1,0,1,0,1,1,0,1,1,0,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00504803,Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease,Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning: a Pilot Study,COMPLETED,2006-12,2010-12,2011-09-02,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,PREVENTION,NONE,Hematological Malignancies,Mesenchymal stem cell infusion,PROCEDURE,1,1,,75 Years,ALL,True,University of Liege,OTHER,0,1,Belgium,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4339872044851463,small,1,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,1,0,,,,,0,0,0
NCT01868061,A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication",COMPLETED,2013-07-31,2017-01-02,2017-05-19,INTERVENTIONAL,PHASE3,1068.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Asthma,Lebrikizumab|Placebo,DRUG,1,9,18 Years,75 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,232,Canada|South Africa|Hungary|Argentina|Russia|Australia|Bulgaria|Spain|Romania|Belgium|Italy|Israel|Ukraine|United States|France|Czechia|Germany|Poland|South Korea|Peru|United Kingdom|Slovakia|New Zealand|Mexico|Japan|Serbia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.974478911025045,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,10,1,1,0,0,2,1,2013-07-31,2017-01-02,1251.0,2013.0,0,3,1
NCT00570661,"Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis","Phase II, Open Label, International, Multicentre Clinical Trial to Investigate Safety and Efficacy of Oral ITF2357 in Patients With Active Systemic Onset Juvenile Idiopathic Arthritis (SOJIA)",COMPLETED,2006-09-12,2013-06-10,2021-05-04,INTERVENTIONAL,PHASE2,17.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Active Systemic|Onset Juvenile Idiopathic Arthritis,ITF2357,DRUG,1,19,2 Years,25 Years,ALL,False,Italfarmaco,INDUSTRY,0,5,Romania|Serbia,1.0,0,1,0,0,0,2.0,0,1,0,0,2,2.8903717578961645,small,1,1,1,0,0,0,1,1,0,0,0,0,1,0,20,1,1,0,0,1,0,2006-09-12,2013-06-10,2463.0,2006.0,0,3,1
NCT04607642,Trial of BMX-001 or Placebo in Head and Neck Cancer Patients,"A Randomized, Blinded, Placebo Controlled Phase 2 Trial of Concurrent Radiation Therapy and Cisplatin With and Without BMX-001 in Patients With Locally Advanced Head and Neck Cancer",WITHDRAWN,2021-07,2025-07,2021-10-11,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Head and Neck Cancer,BMX-001|Radiation Therapy|Cisplatin|Placebo,DRUG|OTHER|RADIATION,1,7,18 Years,,ALL,False,"BioMimetix JV, LLC",INDUSTRY,2,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,1,0,0,1,0,0,0,0,1,1,1,1,8,1,1,0,0,4,1,,,,,0,2,0
NCT00828386,Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers,"A Randomized, Multicenter, Phase III Trial Comparing Induction CT With Docetaxel, Cisplatin and 5-FU (TPF) Followed by Concurrent CT-RT to Concurrent CT Alone, in Nasopharyngeal Cancers Staged as T2b, T3, T4 and/or With Lymph Node Involvement (>N1)",TERMINATED,2009-01,2017-04-19,2019-01-18,INTERVENTIONAL,PHASE3,83.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Nasopharyngeal Cancers,Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy,PROCEDURE,1,6,18 Years,70 Years,ALL,False,Groupe Oncologie Radiotherapie Tete et Cou,OTHER,0,5,Romania|France|Tunisia|Morocco,0.0,0,0,1,0,0,3.0,1,0,0,0,1,4.430816798843313,medium,1,1,0,1,0,0,1,1,0,1,1,0,1,1,7,1,0,0,0,1,0,,2017-04-19,,,0,2,0
NCT02301286,A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients,A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients,ACTIVE_NOT_RECRUITING,2015-01,2027-12,2024-03-18,INTERVENTIONAL,PHASE3,770.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Colon Cancer|Adjuvant Therapy,Acetylsalicylic acid|Placebo Acetylsalicylic acid,DRUG,1,2,45 Years,,ALL,False,Leiden University,OTHER,5,32,Netherlands,,0,0,1,0,0,3.0,1,0,0,0,2,6.647688373563329,xlarge,0,1,0,1,0,1,1,0,0,0,1,1,1,1,3,1,1,0,0,2,1,,,,,0,2,0
NCT00546286,A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153),"A 12 Week, Open-Label, Study to Evaluate the Effectiveness of Dorzolamide-Timolol as First Line Therapy to Reduce Intraocular Pressure in Patients With Untreated Open Angle Glaucoma (OAG) or Ocular Hypertension (OH)",COMPLETED,2006-05-31,2007-08-23,2017-04-04,INTERVENTIONAL,PHASE3,170.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Glaucoma|Ocular Hypertension,dorzolamide hydrochloride (+) timolol maleate|Comparator: dorzolamide HCl/timolol maleate + prostaglandin,DRUG,1,0,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,1,2,5.14166355650266,medium,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,2,1,2006-05-31,2007-08-23,449.0,2006.0,0,2,0
NCT01097486,Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy,Phase 2 Study Evaluating Safety and Preliminary Efficacy of NeoFuse When Combined With MasterGraft Matrix in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion With Anterior Cervical Plate Fixation,COMPLETED,2010-06,2014-07,2019-08-16,INTERVENTIONAL,PHASE2,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Cervical Degenerative Disc Disease|Degenerative Spondylolisthesis|Spinal Stenosis,NeoFuse|Allograft,PROCEDURE|BIOLOGICAL,1,1,18 Years,70 Years,ALL,False,"Mesoblast, Ltd.",INDUSTRY,0,8,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,3.2188758248682006,small,1,1,1,0,0,0,1,0,1,0,1,0,1,1,2,1,0,1,0,2,1,,,,,0,2,0
NCT01618370,Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases,Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases,COMPLETED,2012-07-22,2016-02-28,2017-03-31,INTERVENTIONAL,PHASE3,705.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostatic Neoplasms,Radium-223 dichloride (BAY88-8223),DRUG,2,1,18 Years,,MALE,False,Bayer,INDUSTRY,0,215,Canada|Ireland|Russia|Spain|Norway|Belgium|Italy|Israel|Finland|Sweden|France|Czechia|Germany|Poland|Netherlands|United Kingdom|Denmark|Switzerland|Mexico,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.559615237493242,xlarge,0,1,1,0,0,0,1,1,0,1,0,0,1,0,3,1,1,0,0,1,0,2012-07-22,2016-02-28,1316.0,2012.0,0,1,0
NCT01773070,A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study,A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection,COMPLETED,2013-06,2016-10,2017-12-06,INTERVENTIONAL,PHASE3,478.0,ACTUAL,,SINGLE_GROUP,OTHER,NONE,Hepatitis C,ABT-450/ritonavir|ABT-333|ABT-267,DRUG,2,3,18 Years,80 Years,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.171700597410915,large,0,1,1,0,1,0,0,0,0,0,0,0,0,0,5,1,1,0,0,3,1,,,,,0,1,0
NCT00493870,TAC Versus TC for Adjuvant Breast Cancer,Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients,COMPLETED,2007-05-29,2020-03-30,2023-03-02,INTERVENTIONAL,PHASE3,1961.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,Docetaxel|Doxorubicin|Cyclophosphamide,DRUG,2,5,18 Years,70 Years,FEMALE,False,US Oncology Research,INDUSTRY,1,95,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,7.581719640125308,xlarge,0,1,1,0,0,1,1,0,1,0,1,0,1,1,7,1,1,0,0,3,1,2007-05-29,2020-03-30,4689.0,2007.0,0,2,0
NCT02380573,"Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease","Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease",COMPLETED,2015-07,2023-07,2024-09-19,INTERVENTIONAL,PHASE2,117.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,QUADRUPLE,Mild Cognitive Impairment|MCI|Aging|Alzheimer's Disease|AD,Methylene Blue|FD&C Blue # 2|Phenazopyridine hydrochloride,DRUG,9,1,45 Years,89 Years,ALL,True,The University of Texas Health Science Center at San Antonio,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,5,4.770684624465665,medium,0,1,0,1,0,1,0,0,1,0,1,1,1,0,10,1,1,0,0,3,1,,,,,0,3,1
NCT00031473,Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients,A Randomized Phase III Study to Evaluate the Safety and Efficacy of Ribavirin Inhaled Solution in Preventing Progression of Upper Respiratory Tract Respiratory Syncytial Virus Infection to RSV Pneumonia in Blood and Bone Marrow Transplant (BMT) Recipient,TERMINATED,1997-11,2003-03,2010-08-27,INTERVENTIONAL,PHASE3,90.0,,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Respiratory Syncytial Virus Infections,Virazole (Ribavirin) Inhalation Solution,DRUG,0,0,5 Years,60 Years,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,11,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,4.51085950651685,medium,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,,,,,0,0,0
NCT02683369,"Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women","Effects of a Commercially-available, Low-dose Iron Supplement (BloodBuilder®/Iron Response®) on Markers of Iron Status Among Premenopausal and Non-anemic, Iron-deficient Women",COMPLETED,2016-02,2017-05,2019-08-16,INTERVENTIONAL,PHASE2|PHASE3,23.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-anemic Iron Deficiency,Blood Builder®/Iron Response®,DIETARY_SUPPLEMENT,4,8,18 Years,55 Years,FEMALE,True,"University of Maryland, Baltimore",OTHER,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.1780538303479458,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,12,1,0,0,0,1,0,,,,,0,2,0
NCT06168773,Combination of Haloperidol and Magnesium for Delirium Prevention in Critically Ill Elderly,Combination of Haloperidol and Magnesium for Delirium Prevention in Critically Ill Elderly Patients After Elective Major Surgery,COMPLETED,2022-11-01,2023-11-04,2023-12-13,INTERVENTIONAL,PHASE2|PHASE3,135.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Delirium in Old Age,Haloperidol Injection,DRUG,1,1,65 Years,80 Years,ALL,False,Ain Shams University,OTHER,0,1,Egypt,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.912654885736052,medium,0,1,0,1,0,0,0,0,0,0,1,1,0,1,2,1,1,0,0,1,0,2022-11-01,2023-11-04,368.0,2022.0,1,1,0
NCT01618669,A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT),"A Phase 3b, Open-Label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)",COMPLETED,2012-06,2014-12,2016-02-08,INTERVENTIONAL,PHASE3,1147.0,ACTUAL,RANDOMIZED,PARALLEL,,NONE,Coronary Artery Disease (CAD),Regadenoson|Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI),DRUG|PROCEDURE,1,11,18 Years,,ALL,False,"Astellas Pharma Global Development, Inc.",INDUSTRY,0,69,Puerto Rico|Argentina|Peru|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.045776576879511,xlarge,0,1,1,0,0,0,1,1,1,0,1,0,0,1,12,1,1,0,0,2,1,,,,,0,3,1
NCT06272383,Croup Dosing Study,Using a Single Dose of Dexamethasone at 0.6mg/kg of Body Weight Versus 0.15 mg/kg of Body Weight for the Treatment of Croup: an Internal Vanguard Randomized Controlled Non-Inferiority Trial.,COMPLETED,2024-06-05,2025-02-20,2025-09-08,INTERVENTIONAL,PHASE3,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Croup,0.15 mg/kg dexamethasone,DRUG,1,1,6 Months,5 Years,ALL,True,University of Manitoba,OTHER,0,1,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,2024-06-05,2025-02-20,260.0,2024.0,1,0,0
NCT00492141,Aerosol L9-NC and Temozolomide in Ewing's Sarcoma,Aerosol Liposomal 9-Nitro-20(S)-Camptothecin (L9-NC) and Temozolomide in Ewing's Sarcoma and Other Solid Tumors With Lung Involvement,COMPLETED,2006-06,2009-09,2012-08-02,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Ewing's Sarcoma,Temozolomide|L9-NC,DRUG,1,1,10 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,2,1,,,,,0,2,0
NCT01515241,Exploratory Study of Plaque Regression,EXPLORATORY STUDY OF PLAQUE REGRESSION:A Phase II Single Center Open-Label Exploratory Trial of the Effect of CER 001 in Subjects With Familial Hypercholesterolemia,COMPLETED,2012-01,2012-05,2014-03-03,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Heterozygous Familial Hypercholesterolemia,CER-001,DRUG,1,2,18 Years,,ALL,False,"Cerenis Therapeutics, SA",INDUSTRY,0,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT03930641,Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration,"An Open-Label, Single-Arm, Multicenter, Phase IIIb Study in Patients With Neovascular Age-Related Macular Degeneration to Evaluate the Safety of Brolucizumab 6 mg in Prefilled Syringe",COMPLETED,2019-05-23,2019-07-02,2021-01-05,INTERVENTIONAL,PHASE3,34.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Neovascular Age Related Macular Degeneration,RTH258,DRUG,1,0,50 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,3,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.5553480614894135,small,1,1,1,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,0,2019-05-23,2019-07-02,40.0,2019.0,1,0,0
NCT00751205,Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC),"(REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy.",COMPLETED,2008-08,2010-08,2014-10-28,INTERVENTIONAL,PHASE2,150.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Prostate Cancer|Ovarian Cancer,"Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid",DRUG,1,11,18 Years,70 Years,ALL,False,Bayer,INDUSTRY,0,22,United Kingdom|France|Germany|Netherlands|Belgium|Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,2,5.017279836814924,medium,0,1,1,0,0,0,1,1,0,1,1,1,1,1,12,1,1,0,0,2,1,,,,,0,4,1
NCT07019805,What Causes Low Blood Pressure After Anesthesia in Older Adults Having Non-Heart Surgery ?,Risk Factors for Post-Induction Hypotension Following General Anesthesia in Geriatric Patients Undergoing Elective Non-Cardiac Surgery : A Prospective Study,COMPLETED,2024-09-01,2025-03-15,2025-06-13,INTERVENTIONAL,PHASE3,220.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Geriatric|General Anesthesia Induced Hypotension|Elective Surgery|Hypotension|Risk Factor,"Standard General Anesthesia Induction Using Propofol, Fentanyl and Midazolam|Blood Pressure Continous Monitoring, syrnge pump for the anesthesia agent, and vasoconstrictor drug",DRUG|DEVICE,1,0,60 Years,,ALL,True,Indonesia University,OTHER,0,1,Indonesia,1.0,0,0,1,0,0,3.0,0,0,0,0,5,5.3981627015177525,large,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,2,1,2024-09-01,2025-03-15,195.0,2024.0,1,2,0
NCT03460405,"Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants","Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Indonesian Adults, Adolescents, Children and Infants (Phase II)",COMPLETED,2018-07-16,2020-01-30,2020-02-20,INTERVENTIONAL,PHASE2,600.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Safety Issues|Immunogenicity,Vi-DT Vaccine|Vi Polysaccharide Vaccine|IPV Vaccine,BIOLOGICAL,1,4,6 Months,40 Years,ALL,True,PT Bio Farma,INDUSTRY,0,2,Indonesia,1.0,0,1,0,0,0,2.0,0,0,0,0,2,6.398594934535208,xlarge,0,1,1,0,0,0,1,0,0,0,1,1,1,1,5,1,0,1,0,3,1,2018-07-16,2020-01-30,563.0,2018.0,1,2,0
NCT04189705,A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis,"A Multi-center, Randomized, Double-blind, Active-controlled, Non-inferiority, Phase 3 Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis",COMPLETED,2019-12-30,2020-04-23,2021-03-11,INTERVENTIONAL,PHASE3,392.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Acute Gastritis|Chronic Gastritis,MCT-SR|Mucosta Tab.,DRUG,1,0,19 Years,74 Years,ALL,False,"Korea Otsuka Pharmaceutical Co., Ltd.",INDUSTRY,0,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.973809611869261,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,2019-12-30,2020-04-23,115.0,2019.0,1,2,0
NCT00073905,Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer,"Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial",COMPLETED,2003-04,2009-01,2012-06-05,INTERVENTIONAL,PHASE2,44.0,ACTUAL,,SINGLE_GROUP,SUPPORTIVE_CARE,NONE,Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer|Pain,capecitabine plus gemcitabine,DRUG,1,1,18 Years,80 Years,ALL,False,Swiss Cancer Institute,OTHER,0,1,Switzerland,1.0,0,1,0,0,0,2.0,1,0,0,0,4,3.8066624897703196,small,1,1,0,1,0,0,0,0,0,0,0,0,0,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT02941705,Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs,Regress-HFpEF: Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs,COMPLETED,2017-07-12,2023-05-31,2024-07-25,INTERVENTIONAL,PHASE2,27.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Congestive Heart Failure|Heart Failure, Diastolic",Allogeneic Derived Cells|Placebo/Control Arm,BIOLOGICAL,1,0,50 Years,,ALL,False,Cedars-Sinai Medical Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,1,2,3.332204510175204,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,2,1,2017-07-12,2023-05-31,2149.0,2017.0,1,2,0
NCT00007605,"Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm",CSP #399 - The Effects of Antiarrhythmic Therapy in Maintaining Stability of Sinus Rhythm in Atrial Fibrillation,COMPLETED,1998-04,2003-12,2011-06-15,INTERVENTIONAL,PHASE3,706.0,ESTIMATED,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,"Atrial Fibrillation|Cerebrovascular Accident|Death, Sudden",Amiodarone|Sotalol,DRUG,1,0,,,ALL,False,US Department of Veterans Affairs,FED,0,28,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,3,6.561030665896573,xlarge,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,1,0,0,2,1,,,,,0,2,0
NCT04992494,Treatment for Migraine and Mood (Team-M),Treatment for Migraine and Mood (Team-M): A Pilot Trial of a Mindfulness-based Training Program,COMPLETED,2021-11-11,2022-06-13,2023-07-18,INTERVENTIONAL,PHASE2,27.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Migraine|Depression,MBCT-Telephone|MBCT-Video,BEHAVIORAL,4,0,18 Years,,ALL,False,NYU Langone Health,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,2,3.332204510175204,small,1,1,0,1,0,1,0,0,1,0,0,0,1,1,4,0,0,0,0,2,1,2021-11-11,2022-06-13,214.0,2021.0,1,2,0
NCT02040194,AM-101 in the Treatment of Acute Tinnitus 3,Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 3,COMPLETED,2014-01,2017-12-28,2023-09-14,INTERVENTIONAL,PHASE3,893.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Tinnitus,AM-101|Placebo,DRUG,3,8,18 Years,75 Years,ALL,False,Auris Medical AG,INDUSTRY,0,1,Germany,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.795705775173514,xlarge,0,1,1,0,0,0,0,0,0,1,1,1,1,1,11,1,1,0,0,2,1,,2017-12-28,,,0,2,0
NCT00659594,"Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older",COMPLETED,2004-11,2005-09,2016-12-02,INTERVENTIONAL,PHASE3,500.0,ACTUAL,RANDOMIZED,,TREATMENT,DOUBLE,"Rhinitis, Allergic, Seasonal|Hay Fever",Ciclesonide|Placebo,DRUG,1,6,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,1,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.2166061010848646,large,0,1,1,0,1,0,0,0,0,0,1,1,1,0,7,1,1,0,0,2,1,,,,,0,3,1
NCT01286766,Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma,A Randomized Phase II Trial of Neoadjuvant Combination Chemotherapy of DCS (Cisplatin + Docetaxel + S-1) and DCF (Docetaxel + Cisplatin + 5-FU) in Patients With Locally Advanced Gastric Adenocarcinoma,COMPLETED,2009-09,2012-06,2024-12-27,INTERVENTIONAL,PHASE2,6.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Gastric Cancer,DCS (docetaxel with cisplatin with TS-1)|DCF (docetaxel with cisplatin with 5-FU),DRUG,1,0,18 Years,70 Years,ALL,False,Yonsei University,OTHER,0,1,South Korea,1.0,0,1,0,0,0,2.0,1,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT02672566,Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction,Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction. Randomized Multicenter Trial,COMPLETED,2016-07-22,2020-01-22,2020-03-20,INTERVENTIONAL,PHASE3,82.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Fetal Growth Retardation,Enoxaparin|Usual care,DRUG|OTHER,1,10,18 Years,,FEMALE,False,Centre Hospitalier Universitaire de Saint Etienne,OTHER,0,8,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.418840607796598,medium,1,1,0,1,0,0,1,0,0,1,1,0,1,1,11,1,1,0,0,2,1,2016-07-22,2020-01-22,1279.0,2016.0,1,2,0
NCT05844956,A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1),"A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)",COMPLETED,2022-06-01,2024-02-29,2025-02-21,INTERVENTIONAL,PHASE1|PHASE2,17.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,"Lymphoma, Non-Hodgkin",DZD8586,DRUG,1,2,18 Years,,ALL,False,Dizal Pharmaceuticals,INDUSTRY,0,6,China,1.0,1,1,0,0,1,1.5,1,0,0,0,1,2.8903717578961645,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,3,1,1,0,0,1,0,2022-06-01,2024-02-29,638.0,2022.0,1,1,0
NCT02563522,Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers,"A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 to Treat Chronic Nonhealing Foot Ulcers in Diabetic Patients With Concomitant Peripheral Arterial Disease (PAD)",TERMINATED,2017-06-27,2019-09-24,2025-10-09,INTERVENTIONAL,PHASE3,44.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Foot Ulcer, Diabetic",Engensis (VM202)|Placebo,DRUG|GENETIC,1,0,18 Years,80 Years,ALL,False,"Helixmith Co., Ltd.",INDUSTRY,0,22,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.8066624897703196,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2017-06-27,2019-09-24,819.0,2017.0,1,1,0
NCT00260156,A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes,A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes,COMPLETED,2005-11,2008-12,2020-12-17,INTERVENTIONAL,PHASE3,59.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2",vildagliptin|placebo,DRUG,1,5,30 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,1,Switzerland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.0943445622221,medium,1,1,1,0,1,0,0,0,0,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT00156923,ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults,A Multi-Center Extension of Alkermes' Study ALK21-003-EXT (NCT01218971) to Evaluate the Long-Term Safety of Medisorb® Naltrexone,COMPLETED,2003-10,2007-01,2017-07-11,INTERVENTIONAL,PHASE3,108.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Alcoholism,Medisorb naltrexone 380 mg|Medisorb naltrexone 190 mg,DRUG,1,0,18 Years,,ALL,False,"Alkermes, Inc.",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.6913478822291435,medium,0,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT00467259,Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women,"A Randomized, Double-Blind, Placebo-controlled, Multicenter, 52-week Study to Evaluate the Endometrial Safety of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder.",COMPLETED,2007-04,2009-01,2011-12-15,INTERVENTIONAL,PHASE3,1271.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hypoactive Sexual Desire Disorder,Testosterone Transdermal System|Placebo patch,DRUG,1,2,45 Years,70 Years,FEMALE,False,Warner Chilcott,INDUSTRY,0,115,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.148345743900068,xlarge,0,1,1,0,0,0,1,0,1,0,1,1,1,1,3,1,1,0,0,2,1,,,,,0,1,0
NCT03726879,A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer",COMPLETED,2019-01-11,2023-08-24,2024-11-05,INTERVENTIONAL,PHASE3,454.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Breast Cancer,Atezolizumab|Placebo|Doxorubicin|Cyclophosphamide|Paclitaxel|Trastuzumab|Pertuzumab|Trastuzumab Emtansine,DRUG,2,21,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,1,76,Russia|United States|Canada|Brazil|Poland|South Korea|Taiwan|Spain|Czechia|Germany|Japan|Italy,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.12029741895095,large,0,1,1,0,1,1,1,1,1,1,1,1,1,1,23,1,1,0,0,8,1,2019-01-11,2023-08-24,1686.0,2019.0,1,3,1
NCT00688896,Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia,"A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia",COMPLETED,2002-06,2004-03,2008-06-03,INTERVENTIONAL,PHASE2,155.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type II Hyperlipidemia,JTT-705 600 mg and pravastatin 40 mg|JTT-705 300 mg and pravastatin 40 mg|Placebo and pravastatin 40 mg,DRUG,1,2,18 Years,65 Years,ALL,False,Akros Pharma Inc.,INDUSTRY,0,1,Netherlands,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.049856007249537,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,3,1,1,0,0,3,1,,,,,0,1,0
NCT01990196,Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer,"An Open-label, Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With and Without SRC or MEK Inhibition on the Development of EMT in Prostate Cancer",ACTIVE_NOT_RECRUITING,2014-09-23,2026-09-30,2025-08-17,INTERVENTIONAL,PHASE2,45.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,degarelix|enzalutamide|trametinib|dasatinib,DRUG,1,0,18 Years,,MALE,False,Jonsson Comprehensive Cancer Center,OTHER,5,1,United States,,0,1,0,0,0,2.0,1,0,0,0,1,3.828641396489095,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,1,0,1,0,0,4,1,2014-09-23,2026-09-30,4390.0,2014.0,0,1,0
NCT02768662,A 6-Month Extension Study of OTO-104 in Meniere's Disease,"A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease",TERMINATED,2016-08,2017-09,2023-01-20,INTERVENTIONAL,PHASE3,142.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Meniere's Disease,OTO-104,DRUG,1,0,18 Years,,ALL,False,"Otonomy, Inc.",INDUSTRY,0,1,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,4.962844630259907,medium,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT03713762,Peribulbar Block: Lidocaine-bupivacaine vs Lidocaine-bupivacaine-fentanyl,Anesthesia With Peribulbar Block: Lidocaine-bupivacaine vs Lidocaine-bupivacaine-fentanyl,COMPLETED,2009-10-01,2009-11-30,2018-10-23,INTERVENTIONAL,PHASE3,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Anesthesia, Local",peribulbar block 1 lidocaine/bupivacaine|peribulbar block 2 lidocaine/bupivacaine/fentanyl,DRUG,1,3,45 Years,90 Years,ALL,True,Centro Medico Docente la Trinidad,OTHER,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.2626798770413155,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,2009-10-01,2009-11-30,60.0,2009.0,0,1,0
NCT01203462,The PRIDE Study Probiotics on Regulation and Improving Digestive hEalth,"A Probiotic Double-blind Randomized Placebo Crossover Trial of Colonic Transit Time in Adult Females, The PRIDE Study The Study to Determine the Effects of Probiotics on Regulation and Improving Digestive hEalth",COMPLETED,2010-10,2011-07,2013-02-11,INTERVENTIONAL,PHASE3,68.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Digestive Irregularity|Digestive Discomfort|History of Straining During Bowel Movements|History of Hard or Lumpy Stools,Probiotic strain of Bifidobacterium|No Bifidobacterium,OTHER,1,10,18 Years,65 Years,FEMALE,True,Georgetown University,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,4,4.23410650459726,medium,1,1,0,1,0,1,0,0,1,0,1,1,1,0,11,1,0,0,0,2,1,,,,,0,3,1
NCT00814346,Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions,"Effect of Oral EGb761® on Brain Glucose Metabolism in Three Groups of Elderly With Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, Randomised, Double-blind, Parallel Groups, Placebo-controlled Study",COMPLETED,2008-10,2012-07,2019-02-08,INTERVENTIONAL,PHASE2,49.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Alzheimer's Disease|Cognitive Impairment,EGb761®|Placebo,DRUG,1,27,65 Years,,ALL,False,Ipsen,INDUSTRY,0,8,France,1.0,0,1,0,0,0,2.0,0,0,1,0,2,3.912023005428146,small,1,1,1,0,0,0,1,0,0,1,1,1,1,1,28,1,1,0,0,2,1,,,,,0,3,1
NCT04524403,"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia Taking Antipsychotic Medications (GRATITUDE II)",COMPLETED,2020-09-09,2022-08-25,2024-06-13,INTERVENTIONAL,PHASE2,150.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Antipsychotic-induced Weight Gain (AIWG),Miricorlilant|Miricorlilant|Placebo,DRUG,1,3,18 Years,65 Years,ALL,False,Corcept Therapeutics,INDUSTRY,0,40,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.017279836814924,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,4,1,1,0,0,3,1,2020-09-09,2022-08-25,715.0,2020.0,1,1,0
NCT02272803,Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan,"A Phase 2, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma in Japan",COMPLETED,2015-02-20,2021-07-21,2022-06-22,INTERVENTIONAL,PHASE2,82.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,Lenalidomide|Dexamethasone|Elotuzumab (BMS-901608),DRUG|BIOLOGICAL,1,3,20 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,1,28,Japan,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.418840607796598,medium,1,1,1,0,1,1,1,0,0,0,1,0,1,1,4,1,1,1,0,3,1,2015-02-20,2021-07-21,2343.0,2015.0,1,1,0
NCT03298061,Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921,Mepolizumab Long-term Access Programme for Subjects Who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard-of-care Therapy),COMPLETED,2015-04-14,2023-02-16,2024-03-12,INTERVENTIONAL,PHASE3,100.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Churg-Strauss Syndrome|Eosinophilic Granulomatosis With Polyangiitis,Mepolizumab|Prednisolone,DRUG,1,0,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,32,United Kingdom|United States|Canada|France|Germany|Japan|Belgium,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.61512051684126,medium,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,2,1,2015-04-14,2023-02-16,2865.0,2015.0,1,3,1
NCT02633761,Mifepristone-misoprostol vs. Misoprostol Alone for Second Trimester Fetal Death,"Mifepristone and Misoprostol Versus Misoprostol Alone for Treatment of Fetal Death at 14-28 Weeks of Pregnancy: A Randomized, Placebo-controlled Double-blinded Trial",TERMINATED,2015-04-01,2018-12-30,2019-02-11,INTERVENTIONAL,PHASE3,200.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Fetal Death,Mifepristone|Placebo|Misoprostol 200mcg,DRUG,1,0,18 Years,64 Years,FEMALE,True,Gynuity Health Projects,OTHER,0,3,Mexico|Vietnam,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.303304908059076,medium,0,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,3,1,2015-04-01,2018-12-30,1369.0,2015.0,1,2,0
NCT00931242,Study of Apremilast in Atopic or Contact Dermatitis,"A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis",COMPLETED,2009-06,2010-03,2010-12-20,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Atopic Dermatitis|Allergic Contact Dermatitis,Apremilast,DRUG,1,2,18 Years,,ALL,False,Tufts Medical Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,2.3978952727983707,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,1,0
NCT00420342,Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension,"A Double Blind, Randomized, Active-control Study to Evaluate Effects of Drospirenone/Estradiol (Angeliq) and Medroxyprogesterone Acetate/Conjugated Equine Estrogen (Prempro) on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension",COMPLETED,2007-01,2008-09,2015-06-02,INTERVENTIONAL,PHASE2,92.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Postmenopause|Hypertension|Pre-Hypertension,"Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)",DRUG,2,10,45 Years,65 Years,FEMALE,False,Bayer,INDUSTRY,0,9,United States,1.0,0,1,0,0,0,2.0,0,0,0,1,3,4.532599493153256,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,1,12,1,1,0,0,3,1,,,,,0,3,1
NCT03278886,St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene,Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation Among HIV-Infected Persons With Alcohol Problems,COMPLETED,2018-07-03,2018-12-19,2020-08-24,INTERVENTIONAL,PHASE1|PHASE2,11.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,HIV Infection|Alcohol Use|Pain,Low dose naltrexone|Nalmefene,DRUG,1,7,18 Years,,ALL,False,Boston Medical Center,OTHER,1,1,Russia,1.0,1,1,0,0,1,1.5,0,0,0,0,3,2.4849066497880004,small,1,1,0,1,0,1,0,0,0,0,1,1,1,1,8,1,1,0,0,2,1,2018-07-03,2018-12-19,169.0,2018.0,1,4,1
NCT02125786,A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma,A Phase II Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma,ACTIVE_NOT_RECRUITING,2014-05-07,2028-05,2025-05-08,INTERVENTIONAL,PHASE2,68.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Ependymoma,Irradiation|Surgery|^1^8F-Fluorodeoxyglucose|^1^1C-methionine|Photon therapy|Proton therapy,PROCEDURE|DRUG|DEVICE|RADIATION,2,24,1 Year,21 Years,ALL,False,St. Jude Children's Research Hospital,OTHER,0,1,United States,,0,1,0,0,0,2.0,0,0,0,0,1,4.23410650459726,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,1,26,1,1,0,1,6,1,2014-05-07,,,2014.0,0,2,0
NCT01260870,European Study of POBA Versus Cotavance(R) Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia (EURO CANAL),European Study of POBA Versus Cotavance Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia,TERMINATED,2011-08-15,2013-07-15,2024-01-30,INTERVENTIONAL,PHASE2,44.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,PAD|Infrapopliteal Lesions,Cotavance Paclitaxel Coated Balloon|Standard balloon angioplasty,DEVICE,1,1,18 Years,,ALL,False,Bayer,INDUSTRY,0,6,United Kingdom|Belgium|Austria|Switzerland,0.0,0,1,0,0,0,2.0,0,0,0,0,2,3.8066624897703196,small,1,1,1,0,0,0,1,1,0,1,1,0,1,1,2,1,0,0,1,2,1,2011-08-15,2013-07-15,700.0,2011.0,0,3,1
NCT03767270,"Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency","A Phase 1/2 Single Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered MRT5201 in Subjects With Ornithine Transcarbamylase Deficiency",WITHDRAWN,2019-12,2022-07,2019-09-17,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,Ornithine Transcarbamylase Deficiency,MRT5201|Placebo,OTHER|BIOLOGICAL,1,3,18 Years,,ALL,False,"Translate Bio, Inc.",INDUSTRY,0,0,,0.0,1,1,0,0,1,1.5,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,1,0,4,1,0,1,0,2,1,,,,,0,2,0
NCT00346073,Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years,A Study to Evaluate Immunogenicity and Safety of Boostrix Compared to Adacel When Administered as a Booster Vaccination in Adults Aged 19 to 64 Years of Age,COMPLETED,2006-07-13,2007-03-07,2018-08-07,INTERVENTIONAL,PHASE3,2337.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Acellular Pertussis|Diphtheria|Tetanus,Boostrix™|ADACEL®,BIOLOGICAL,4,11,19 Years,64 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,42,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,3,7.757051142032013,xlarge,0,1,1,0,0,0,1,0,1,0,1,0,0,1,15,1,0,1,0,2,1,2006-07-13,2007-03-07,237.0,2006.0,0,3,1
NCT04677569,Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex,"ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)",COMPLETED,2021-04-01,2026-01-15,2026-02-03,INTERVENTIONAL,PHASE3,425.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Mycobacterium Infections, Nontuberculous",ALIS|Azithromycin|Ethambutol|ELC (matching placebo for ALIS),DRUG,1,13,18 Years,,ALL,False,Insmed Incorporated,INDUSTRY,0,258,Canada|Austria|Hungary|Argentina|Australia|Portugal|Spain|Belgium|Italy|Israel|Chile|United States|France|South Korea|Poland|Germany|Greece|United Kingdom|Turkey (Türkiye)|Denmark|Taiwan|New Zealand|Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.054439346269371,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,14,1,1,0,0,4,1,2021-04-01,2026-01-15,1750.0,2021.0,1,3,1
NCT02924883,A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy",COMPLETED,2016-09-26,2020-02-06,2021-02-17,INTERVENTIONAL,PHASE2,202.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Metastatic Breast Cancer,Atezolizumab|Trastuzumab emtansine|Placebo,DRUG|OTHER,2,9,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,68,United Kingdom|Australia|United States|Canada|South Korea|Taiwan|Spain|Germany|Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.313205979041787,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,11,1,1,0,0,3,1,2016-09-26,2020-02-06,1228.0,2016.0,1,3,1
NCT02532283,"A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection","A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult and Elderly Hospitalized Patients With Influenza A Infection",COMPLETED,2015-12-11,2017-03-15,2020-03-27,INTERVENTIONAL,PHASE2,102.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Influenza A Virus,JNJ-63623872|Placebo|Oseltamivir,DRUG,3,16,18 Years,85 Years,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,68,Turkey (Türkiye)|Malaysia|Australia|United States|Sweden|Canada|Brazil|New Zealand|France|Spain|Singapore|Germany|Netherlands|Belgium|Hong Kong,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.634728988229636,medium,0,1,1,0,0,0,1,1,1,1,1,1,1,1,19,1,1,0,0,3,1,2015-12-11,2017-03-15,460.0,2015.0,1,3,1
NCT04393441,Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease,"A Multicenter, Single-masked, Randomized Study to Compare the Efficacy and Safety of a New Artificial Tear Formulation (011516X) With Systane® Ultra Multidose for 90 Days in Participants With Dry Eye Disease",COMPLETED,2020-06-29,2021-06-15,2024-06-26,INTERVENTIONAL,PHASE3,400.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Dry Eye Disease (DED),011516X (New Artificial Tear Formulation)|Systane Ultra Multidose|REFRESH PLUS®,DRUG,1,1,18 Years,,ALL,False,Allergan,INDUSTRY,0,26,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.993961427306569,large,0,1,1,0,0,0,1,0,1,0,1,0,1,1,2,1,1,0,0,3,1,2020-06-29,2021-06-15,351.0,2020.0,1,1,0
NCT01118754,Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients,"Phase I/II Prospective, Randomized, Double Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Compared to Placebo for the Treatment of Dry Eye Disease",COMPLETED,2010-04,2010-12,2011-11-03,INTERVENTIONAL,PHASE1|PHASE2,132.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Dry Eye,DE-101 ophthalmic suspension|DE-101 ophthalmic suspension|DE-101 ophthalmic suspension vehicle,DRUG,2,0,18 Years,,ALL,False,Santen Inc.,INDUSTRY,0,10,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.890349128221754,medium,0,0,1,0,0,0,1,0,1,0,1,1,1,1,2,0,1,0,0,3,1,,,,,0,2,0
NCT02763254,Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas,A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas,TERMINATED,2016-11,2018-02-17,2019-03-26,INTERVENTIONAL,PHASE2,1.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Hodgkin Lymphoma|Lymphoma, Large B-Cell, Diffuse|Post-transplant Lymphoproliferative Disorder",baltaleucel-T,BIOLOGICAL,1,1,12 Years,,ALL,False,Cell Medica Ltd,INDUSTRY,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,3,0.6931471805599453,small,1,1,1,0,0,0,0,0,1,0,0,0,1,0,2,1,0,1,0,1,0,,2018-02-17,,,0,1,0
NCT01003054,Autologous Transplantation for Chronic Myelogenous Leukemia,"Busulfan, Cyclophosphamide, Imatinib Mesylate and Autologous Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia",COMPLETED,2005-03,2009-10,2011-11-02,INTERVENTIONAL,PHASE2,24.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Chronic Myelogenous Leukemia,Busulfan|Cyclophosphamide|Imatinib Mesylate|Autologous Stem Cell Transplantation,DRUG|PROCEDURE,1,0,,70 Years,ALL,False,M.D. Anderson Cancer Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.2188758248682006,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,4,1,,,,,0,1,0
NCT03039205,Platelet Aggregation in Patients With Coronary Artery Disease and Kidney Dysfunction Taking Clopidogrel or Ticagrelor,Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor,COMPLETED,2017-11-07,2019-12-19,2020-04-24,INTERVENTIONAL,PHASE2,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Platelet Aggregation|Adenosine|Coronary Artery Disease|Kidney Dysfunction|Antiplatelet Therapy,Clopidogrel|Ticagrelor,DRUG,1,2,18 Years,,ALL,False,University of Sao Paulo,OTHER,1,1,Brazil,1.0,0,1,0,0,0,2.0,0,0,0,0,5,4.51085950651685,medium,1,1,0,1,0,1,0,0,0,0,1,1,1,1,3,1,1,0,0,2,1,2017-11-07,2019-12-19,772.0,2017.0,1,2,0
NCT00064194,"Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients With High-Grade Prostate Neoplasia","A Double-Blind, Placebo-Controlled, Randomized Study Of Combination Vitamin E, Selenium And Soy Protein Product In Subjects With High Grade Prostatic Intraepithelial Neoplasia",COMPLETED,2001-11-28,2008-04-30,2020-04-03,INTERVENTIONAL,PHASE3,310.0,ACTUAL,RANDOMIZED,,PREVENTION,TRIPLE,Precancerous/Nonmalignant Condition|Prostate Cancer,selenium|soy protein isolate|vitamin E,DIETARY_SUPPLEMENT,0,0,,120 Years,MALE,False,NCIC Clinical Trials Group,NETWORK,0,3,Canada,1.0,0,0,1,0,0,3.0,1,0,0,0,2,5.739792912179234,large,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,3,1,2001-11-28,2008-04-30,2345.0,2001.0,0,2,0
NCT02011594,Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma,Phase II Study of Maintenance Treatment of Nimotuzumab Versus No Maintenance for Advanced Esophageal Carcinoma,WITHDRAWN,2014-01,2015-02,2015-02-12,INTERVENTIONAL,PHASE2,0.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Stage IV Esophageal Squamous Cell Carcinoma,Nimotuzumab|Placebo,DRUG,1,3,18 Years,75 Years,ALL,False,Zhejiang University,OTHER,0,2,China,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,0,1,0,0,0,0,0,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00903994,"A Pilot Study on the Onset of Action of KTP, 20% in the Treatment of Acute Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee","An Open-Label, Phase II, Pilot Study on the Onset of Action of KTP, 20% in the Treatment of Acute Pain Associated With Tendonitis or Bursitis of the Shoulder, Elbow or Knee",COMPLETED,2007-06,2007-08,2020-02-18,INTERVENTIONAL,PHASE2,17.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,,"Tendonitis of the Shoulder, Elbow, or Knee",Ketoprofen Topical Patch 20%,DRUG,1,3,18 Years,,ALL,False,APR Applied Pharma Research s.a.,OTHER,0,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.8903717578961645,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT00397956,To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053),"An Open-Label, Single-Arm, Non-Comparative Study to Evaluate the Efficacy, Tolerability & Convenience of Invanz(TM) (Ertapenem Sodium) In the Treatment of Community-Acquired Sepsis in Adults",COMPLETED,2004-09,2005-12,2015-10-30,INTERVENTIONAL,PHASE3,30.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Sepsis,"MK0826, ertapenem sodium / Duration of Treatment: 14 Days",DRUG,1,1,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.4339872044851463,small,1,0,1,0,1,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT06091956,A Study of Deucravacitinib to Treat LPP and FFA,Deucravacitinib (BMS-986165) in the Treatment of Lichen Planopilaris,COMPLETED,2023-11-07,2024-12-24,2025-06-08,INTERVENTIONAL,PHASE2,12.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lichen Planopilaris,Deucravacitinib,DRUG,1,6,18 Years,,ALL,False,Mayo Clinic,OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.5649493574615367,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,7,1,1,0,0,1,0,2023-11-07,2024-12-24,413.0,2023.0,1,1,0
NCT00006356,Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer,A Randomized Phase III Study for the Treatment of Recurrent Epithelial Ovarian Cancer: Chemotherapy Alone Versus Chemotherapy Followed by Secondary Cytoreductive Surgery in Patients With a Treatment-Free Interval of More Than 12 Months,TERMINATED,2000-08,,2012-09-24,INTERVENTIONAL,PHASE3,38.0,ACTUAL,RANDOMIZED,,TREATMENT,,Ovarian Cancer,carboplatin|cisplatin|conventional surgery,DRUG|PROCEDURE,0,0,18 Years,,FEMALE,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,0,1,Italy,0.0,0,0,1,0,0,3.0,1,0,0,0,1,3.6635616461296463,small,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,3,1,,,,,0,1,0
NCT02408523,A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications,"A Double-blind, Randomized, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy",COMPLETED,2015-04,2019-06,2020-12-17,INTERVENTIONAL,PHASE3,242.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Epilepsy,Lacosamide Tablet|Lasosamide Oral Solution|Placebo Tablet|Placebo Oral Solution,DRUG|OTHER,1,4,4 Years,,ALL,False,"UCB BIOSCIENCES, Inc.",INDUSTRY,1,115,China|Hungary|Russia|Australia|Bulgaria|Portugal|Spain|Romania|Belgium|Italy|Israel|United States|France|Czechia|Germany|Poland|South Korea|Brazil|Slovakia|Taiwan|Mexico|Japan,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.493061443340548,large,0,1,1,0,0,1,1,1,1,1,1,1,1,1,5,1,1,0,0,4,1,,,,,0,2,0
NCT02180659,A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants,"A Randomized, Double-Blind, Double-Dummy, Active-Controlled Multicenter Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily Maintenance Dose of 8 mg or Less of Sublingual Buprenorphine or Buprenorphine/Naloxone to Four Probuphine® Subdermal Implants",COMPLETED,2014-07,2015-05,2019-01-11,INTERVENTIONAL,PHASE3,177.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Opioid Dependence,sublingual buprenorphine tablets|Buprenorphine implant|placebo implants|sublingual placebo tablets,DRUG,1,7,18 Years,65 Years,ALL,False,Titan Pharmaceuticals,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.181783550292085,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,8,1,1,0,0,4,1,,,,,0,2,0
NCT00283959,A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease,"A Phase 2, Open-Label, Single Dose Level, 12-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Patients With Fabry Disease",COMPLETED,2006-06-27,2008-05-08,2018-10-31,INTERVENTIONAL,PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Fabry Disease,migalastat HCl,DRUG,1,1,18 Years,65 Years,MALE,False,Amicus Therapeutics,INDUSTRY,0,2,Brazil|Australia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,1.6094379124341003,small,1,1,1,0,0,0,1,1,0,0,0,0,1,0,2,1,1,0,0,1,0,2006-06-27,2008-05-08,681.0,2006.0,0,1,0
NCT04303559,The Hemophilia Inhibitor Prevention Trial,"Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia A",TERMINATED,2021-10-11,2022-06-16,2023-04-11,INTERVENTIONAL,PHASE3,1.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Hemophilia A Without Inhibitor,Eloctate Injectable Product|Emicizumab Injection [Hemlibra],DRUG,1,5,4 Months,4 Years,MALE,False,Margaret Ragni,OTHER,1,3,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.6931471805599453,small,1,1,0,1,0,1,1,0,1,0,1,0,0,1,6,1,1,0,0,2,1,2021-10-11,2022-06-16,248.0,2021.0,1,2,0
NCT04778059,Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19,"Phase 2 Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravenous USB002 to Treat Patients With Respiratory Distress Due to COVID-19 Infection",TERMINATED,2021-07-27,2022-05-10,2023-12-01,INTERVENTIONAL,PHASE2,21.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"2019 Novel Coronavirus Infection|COVID-19 Virus Infection|SARS Coronavirus 2 Infection|SARS-CoV-2 Infection|Respiratory Distress Syndrome, Adult|Adult Respiratory Distress Syndrome",USB002|Placebo,DRUG,1,0,18 Years,,ALL,False,"US Biotest, Inc.",INDUSTRY,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,6,3.091042453358316,small,1,1,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,2021-07-27,2022-05-10,287.0,2021.0,1,2,0
NCT00000296,Role of Metabolites in Nicotine Dependence (4) - 13,Role of Metabolites in Nicotine Dependence (4),COMPLETED,1997-11,2001-12,2017-01-12,INTERVENTIONAL,PHASE2,0.0,,,CROSSOVER,TREATMENT,DOUBLE,Tobacco Use Disorder,Cotinine fumarate,DRUG,3,0,21 Years,45 Years,ALL,False,National Institute on Drug Abuse (NIDA),NIH,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,0,0,1,0,1,0,0,1,0,0,1,1,0,3,0,1,0,0,1,0,,,,,0,0,0
NCT02717962,"Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting",Phase 2 Study of VAL-083 Treatment for MGMT Unmethylated Bevacizumab-naïve Glioblastoma in the Adjuvant or Recurrent Setting,COMPLETED,2017-01-20,2024-12-30,2025-08-29,INTERVENTIONAL,PHASE2,118.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Glioma|Glioblastoma|Glioblastoma Multiforme|GBM|Brain Cancer,"VAL-083, Dianhydrogalactitol",DRUG,1,8,18 Years,,ALL,False,"Kintara Therapeutics, Inc.",INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,5,4.77912349311153,medium,0,1,1,0,0,0,0,0,1,0,0,0,1,1,9,1,1,0,0,1,0,2017-01-20,2024-12-30,2901.0,2017.0,1,2,0
NCT05069246,"The Clinical Assessment of Nigella Sativa Oil vs Chlorohexidine as a Therapeutic Aid for Gingivitis, Effect on Gingival IL-6 and IL-18 and Antimicrobial Efficacy.","The Clinical Assessment of Nigella Sativa Oil vs Chlorohexidine as a Therapeutic Aid for Gingivitis, Effect on Gingival IL-6 and IL-18 and Antimicrobial Efficacy.",COMPLETED,2020-12-08,2021-02-28,2021-10-06,INTERVENTIONAL,PHASE2,37.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Gingivitis,Nigella Sativa oil|Chlorhexidine mouthwash,DRUG|OTHER,4,2,20 Years,40 Years,FEMALE,False,Ishrat Rahman,OTHER,0,1,Saudi Arabia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6375861597263857,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,6,1,1,0,0,2,1,2020-12-08,2021-02-28,82.0,2020.0,1,2,0
NCT00098046,Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection,Pharmacokinetics and Safety of Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection,COMPLETED,2005-07,2007-07,2007-09-26,INTERVENTIONAL,PHASE3,76.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Chickenpox|Herpes Zoster,famciclovir,DRUG,2,1,1 Year,12 Years,ALL,False,Novartis,INDUSTRY,0,5,Panama|Costa Rica|Guatemala|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.343805421853684,medium,1,0,1,0,1,0,1,1,1,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,2,0
NCT00844246,Translating Evidence Based Developmental Screening Into Pediatric Primary Care,Translating Evidence Based Developmental Screening Into Pediatric Primary Care ( Aims 2 and 3 ),COMPLETED,2008-11,2010-10,2011-11-10,INTERVENTIONAL,PHASE2,2314.0,ACTUAL,RANDOMIZED,PARALLEL,SCREENING,NONE,Developmental Delays,Developmental screening using ASQ and MCHAT|Developmental screening using ASQ and MCHAT,OTHER,1,4,,30 Months,ALL,True,Children's Hospital of Philadelphia,OTHER,1,4,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,7.747164966520335,xlarge,0,1,0,1,0,1,1,0,1,0,1,0,0,1,5,1,0,0,0,2,1,,,,,0,1,0
NCT01297946,Closed-loop Control of Glucose Levels in the Context of Exercise in Adults With Type-1 Diabetes,"An Open-label, Randomized, Two-way, Cross-over Study to Assess the Efficacy of Dual-hormone Closed-loop Strategy as Compared to Conventional CSII Therapy in Regulating Glucose Levels in Adults With Type-1 Diabetes in the Context of Exercise",COMPLETED,,,2012-04-23,INTERVENTIONAL,PHASE1|PHASE2,15.0,ESTIMATED,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type 1 Diabetes,Conventional continuous subcutaneous insulin infusion therapy|Dual-hormone closed-loop,DEVICE,1,17,18 Years,65 Years,ALL,False,Institut de Recherches Cliniques de Montreal,OTHER,4,1,Canada,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.772588722239781,small,1,0,0,1,0,1,0,0,0,0,1,0,1,0,18,1,0,0,1,2,1,,,,,0,3,1
NCT00472303,A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine,"A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) PR* in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain",COMPLETED,2007-07,2012-06,2019-11-04,INTERVENTIONAL,PHASE3,622.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Tumor|Pain,Tapentadol Extended Release|Matching Placebo after Tapentadol in the Titration Phase.|Morphine Sulphate Controlled Release,DRUG,1,22,18 Years,,ALL,False,Grünenthal GmbH,INDUSTRY,1,71,Croatia|Russia|Serbia|Bulgaria|Sweden|Hungary|Slovakia|Austria|France|Spain|Czechia|Germany|Poland|Romania|Italy|Moldova,1.0,0,0,1,0,0,3.0,1,0,0,0,2,6.434546518787453,xlarge,0,1,1,0,0,1,1,1,0,1,1,1,1,1,23,1,1,0,0,3,1,,,,,0,4,1
NCT03770403,A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.,"A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness",COMPLETED,2019-03-01,2022-06-30,2023-07-14,INTERVENTIONAL,PHASE3,151.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Generalized Myasthenia Gravis,ARGX-113,BIOLOGICAL,1,1,18 Years,,ALL,False,argenx,INDUSTRY,0,52,Russia|Denmark|United States|Canada|Hungary|Netherlands|Poland|France|Czechia|Georgia|Germany|Japan|Belgium|Italy|Serbia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.0238805208462765,medium,0,1,1,0,0,0,1,1,1,1,0,0,1,0,2,1,0,1,0,1,0,2019-03-01,2022-06-30,1217.0,2019.0,1,1,0
NCT01651403,"Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection","A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients With Chronic Hepatitis B Infection",ACTIVE_NOT_RECRUITING,2012-12-06,2027-07,2026-01-30,INTERVENTIONAL,PHASE3,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Chronic Hepatitis B,Tenofovir DF|TDF Placebo,DRUG,2,27,2 Years,11 Years,ALL,False,Gilead Sciences,INDUSTRY,0,21,United States|Taiwan|Romania|South Korea|India,,0,0,1,0,0,3.0,0,0,0,0,1,4.51085950651685,medium,1,1,1,0,1,0,1,1,1,0,1,1,1,1,29,1,1,0,0,2,1,2012-12-06,,,2012.0,0,3,1
NCT02278861,Oral Isotretinoin Versus Topical Tretinoin for Actinic Keratosis,"Low Dose Oral Isotretinoin Versus Topical Tretinoin for Prevention of Actinic Keratosis in Immunocompetent Patients: a Randomized, Comparative Trial",COMPLETED,2011-11,2014-05,2014-10-30,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Actinic Keratosis,"Oral isotretinoin|Tretinoin 0,05% cream|Sunscreen FPS 60",DRUG,1,5,50 Years,75 Years,ALL,False,Universidade Federal de Goias,OTHER,3,1,Brazil,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,1,0,0,0,0,1,0,0,1,6,1,1,0,0,3,1,,,,,0,2,0
NCT00367861,Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance,A Prospective Multicentric Randomized Study of Glivec® in Patients With Advanced Gastrointestinal Stromal Tumors Expressing C-kit Comparing Treatment Interruption After 5 Years vs Treatment Maintenance,COMPLETED,2002-05,2013-05,2014-02-24,INTERVENTIONAL,PHASE3,564.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Sarcoma|Gastro-intestinal Stromal Tumors (GIST),interruption of Glivec®,DRUG,1,2,18 Years,,ALL,False,Centre Leon Berard,OTHER,1,8,France,1.0,0,0,1,0,0,3.0,1,0,0,0,2,6.336825731146441,xlarge,0,1,0,1,0,1,1,0,0,1,1,0,1,1,3,1,1,0,0,1,0,,,,,0,1,0
NCT04418661,Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies,"A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of SAR442720 in Combination With Other Agents in Participants With Advanced Malignancies",TERMINATED,2020-06-09,2024-04-04,2025-05-29,INTERVENTIONAL,PHASE1|PHASE2,65.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Metastatic Neoplasm,Vociprotafib|Pembrolizumab|Adagrasib,DRUG,8,16,18 Years,,ALL,False,Sanofi,INDUSTRY,2,20,Argentina|Chile|Australia|United States|Taiwan|Spain|South Korea,0.0,1,1,0,0,1,1.5,1,0,0,0,1,4.189654742026425,medium,1,1,1,0,1,1,1,1,1,1,0,0,1,0,24,1,1,0,0,3,1,2020-06-09,2024-04-04,1395.0,2020.0,1,4,1
NCT00391586,"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung","INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung",TERMINATED,2006-07,2012-05,2015-08-17,INTERVENTIONAL,PHASE2,45.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Carcinoma, Non-Small-Cell Lung",Erlotinib|Platinum-based chemotherapy,DRUG,2,0,18 Years,80 Years,ALL,False,New Mexico Cancer Research Alliance,OTHER,1,5,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,3.828641396489095,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,2,0,1,0,0,2,1,,,,,0,1,0
NCT06159686,The Efficacy of Hemp-containing Cream Versus Placebo in the Treatment of Uremic Pruritus,"This Study Aims to Compare the Efficacy of Hemp-containing Cream and a Placebo in the Treatment of Uremic Pruritus in Hemodialysis Patients. Patients Were Randomly Assigned Either the Hemp-containing Cream or a Placebo and Evaluated the WI-NRS and Skindex-10 Scores at Week 2, 4.",COMPLETED,2023-09-15,2023-12-08,2024-03-27,INTERVENTIONAL,PHASE1|PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Uremic Pruritus,Hemp|Placebo,DRUG,1,3,18 Years,,ALL,True,Thammasat University Hospital,OTHER,0,1,Thailand,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,2023-09-15,2023-12-08,84.0,2023.0,1,2,0
NCT00099970,Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy,Phase II Open-Label Study of Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemo,COMPLETED,2004-12,2006-03,2008-08-05,INTERVENTIONAL,PHASE2,40.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Melanoma|Metastases,M200 (volociximab) in Combination with Dacarbazine (DTIC),DRUG,1,4,18 Years,,ALL,False,"PDL BioPharma, Inc.",INDUSTRY,0,7,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.713572066704308,small,1,0,1,0,0,0,1,0,1,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,1,0
NCT00227370,Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation,"A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV After Lung Transplantation",COMPLETED,2003-07,2008-12,2024-10-04,INTERVENTIONAL,PHASE3,136.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Cytomegalovirus Infections,valganciclovir|Placebo,DRUG|OTHER,2,5,18 Years,,ALL,False,Duke University,OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.919980925828125,medium,0,1,0,1,0,1,0,0,1,0,1,1,0,1,7,1,1,0,0,2,1,,,,,0,2,0
NCT00938470,"Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction","Randomized Phase II Trial of Extended Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia",COMPLETED,2010-01,2018-03,2018-03-29,INTERVENTIONAL,PHASE2,73.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Adenocarcinoma of the Gastroesophageal Junction|Esophageal Cancer|Gastric Cancer,capecitabine|docetaxel|fluorouracil|oxaliplatin|radiation therapy|therapeutic conventional surgery,DRUG|PROCEDURE|RADIATION,1,4,18 Years,,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,1,187,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,4.30406509320417,medium,1,1,0,1,0,1,1,0,1,0,1,0,1,1,5,1,1,0,0,6,1,,,,,0,2,0
NCT05677373,"Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma",Phase I/II Study of BET and MEK Inhibition in Advanced Uveal Melanoma,WITHDRAWN,2023-01-13,2025-07-31,2023-08-18,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Advanced Uveal Melanoma|Metastatic Uveal Melanoma|Unresectable Uveal Melanoma,BRD4 Inhibitor PLX2853|Trametinib|Computed Tomography|Magnetic Resonance Imaging|Biospecimen collection|Biospecimen collection,DRUG|PROCEDURE,2,7,18 Years,,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,0,0,,0.0,1,1,0,0,1,1.5,1,0,0,0,3,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,9,1,1,0,0,6,1,2023-01-13,2025-07-31,930.0,2023.0,1,4,1
NCT02706483,Long Term Safety Study of Plecanatide,"An Open Label, Long Term Safety and Tolerability Study of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)",COMPLETED,2016-01,2017-06,2020-08-18,INTERVENTIONAL,PHASE3,2272.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Irritable Bowel Syndrome,Plecanatide,DRUG,1,0,18 Years,85 Years,ALL,False,"Bausch Health Americas, Inc.",INDUSTRY,0,204,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.728855823852543,xlarge,0,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT03161041,Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study,Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis - French Part of the Main Bev-IP Study,WITHDRAWN,2018-09-21,2018-11-13,2018-11-14,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Colorectal Carcinomatosis,Cytoreductive surgery combined with HIPEC|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).,PROCEDURE|DRUG,1,8,18 Years,85 Years,ALL,False,Hospices Civils de Lyon,OTHER,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,9,1,1,0,0,2,1,2018-09-21,2018-11-13,53.0,2018.0,1,2,0
NCT02278341,Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis,"A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Patients on Stable Dialysis",COMPLETED,2014-11-21,2018-07-06,2024-11-27,INTERVENTIONAL,PHASE3,838.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Anemia|End Stage Renal Disease (ESRD),Roxadustat|Epoetin alfa|Darbepoetin alfa|Iron,DRUG,2,43,18 Years,,ALL,False,Astellas Pharma Europe B.V.,INDUSTRY,1,143,United Kingdom|Croatia|Russia|Bulgaria|Hungary|Slovakia|Portugal|France|Spain|Czechia|Georgia|Germany|Poland|Belgium|Italy|Romania|Serbia,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.732210706467206,xlarge,0,1,1,0,0,1,1,1,0,1,1,0,1,1,45,1,1,0,0,4,1,2014-11-21,2018-07-06,1323.0,2014.0,0,4,1
NCT00129805,Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS),"Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial",COMPLETED,2001-01,2004-09,2008-08-19,INTERVENTIONAL,PHASE3,1510.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Cerebral Infarction,MCI-9042|Aspirin,DRUG,1,1,20 Years,,ALL,False,Tanabe Pharma Corporation,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.32052696227274,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,0,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT00716794,A Phase I/II Study of HE3235 in Patients With Prostate Cancer,"A Phase I/II, Open-Label, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Potential Activity of HE3235 When Administered Orally to Patients With Prostate Cancer",COMPLETED,2008-07,2011-03,2011-03-09,INTERVENTIONAL,PHASE1|PHASE2,64.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,HE3235,DRUG,3,2,18 Years,,MALE,False,Harbor Therapeutics,INDUSTRY,0,8,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.174387269895637,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,1,0
NCT05593666,"A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis","A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis",ACTIVE_NOT_RECRUITING,2022-12-27,2025-12-30,2025-12-18,INTERVENTIONAL,PHASE2,101.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Primary Visceral Leishmaniasis,LXE408|Placebo|AmBisome®,DRUG|OTHER,1,14,18 Years,,ALL,False,Drugs for Neglected Diseases,OTHER,1,2,India,,0,1,0,0,0,2.0,0,0,0,0,1,4.624972813284271,medium,0,1,0,1,0,1,1,0,0,0,1,1,1,1,15,1,1,0,0,3,1,2022-12-27,2025-12-30,1099.0,2022.0,1,2,0
NCT04944966,Safety and Efficacy of Maytenus Senegalensis for the Treatment of Uncomplicated Malaria,Evaluation of Safety and Efficacy of Maytenus Senegalensis for the Treatment of Uncomplicated Malaria Episodes in Adult Patients as Compared to Artemether-lumefantrine,COMPLETED,2021-06-02,2022-09-25,2023-07-18,INTERVENTIONAL,PHASE2,12.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Malaria,Maytenus Senegalensis,DRUG,8,1,18 Years,45 Years,MALE,True,Ifakara Health Institute,OTHER,3,1,Tanzania,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.5649493574615367,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,9,1,1,0,0,1,0,2021-06-02,2022-09-25,480.0,2021.0,1,1,0
NCT01141556,Effects of High-dose Intravenous Selenium (Selenase®) in Adult Patients Subjected to Elective All-cause Heart Surgery,Effects of High-dose Intravenous Selenium (Selenase®) on the Systemic Inflammatory Response Syndrome and Related Organ Dysfunction,COMPLETED,2010-12,2012-09,2012-10-25,INTERVENTIONAL,PHASE3,410.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Heart; Surgery, Heart, Functional Disturbance as Result|Self Efficacy",Selenase,DRUG,1,4,18 Years,,ALL,False,"University Hospital, Basel, Switzerland",OTHER,0,3,Switzerland,1.0,0,0,1,0,0,3.0,0,0,0,1,2,6.018593214496234,large,0,1,0,1,0,0,1,0,0,0,1,1,1,1,5,1,1,0,0,1,0,,,,,0,1,0
NCT00543556,MK0767 in Type 2 Diabetes (0767-012),,TERMINATED,2001-10,2003-11,2015-06-15,INTERVENTIONAL,PHASE2,514.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,MK0767,DRUG,0,0,21 Years,75 Years,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,6.244166900663736,xlarge,0,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,,,,,0,0,0
NCT00859222,LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma,Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma,COMPLETED,2009-03,2015-12,2017-03-14,INTERVENTIONAL,PHASE1|PHASE2,51.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Malignant Glioma,LBH589|bevacizumab,DRUG,3,3,18 Years,,ALL,False,"Patrick Y. Wen, MD",OTHER,7,5,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.9512437185814275,medium,1,1,0,1,0,1,1,0,1,0,0,0,1,0,6,1,1,0,0,2,1,,,,,0,3,1
NCT00194922,Study to Determine the Effectiveness of the Probiotic E. Coli Strain M17 in Treating Irritable Bowel Syndrome (IBS),"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Tolerance and Efficacy of the Probiotic E. Coli Strain M17 on Symptoms and Quality of Life in Individuals With Irritable Bowel Syndrome (IBS)",COMPLETED,2004-08,2006-11,2008-04-04,INTERVENTIONAL,PHASE2,35.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Irritable Bowel Syndrome (IBS),E. Coli Strain M17 Probiotic,DIETARY_SUPPLEMENT,1,1,18 Years,80 Years,ALL,False,Weill Medical College of Cornell University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.58351893845611,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,2,1,0,0,0,1,0,,,,,0,0,0
NCT00375622,Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial,,COMPLETED,2005-02,2006-06,2006-09-13,INTERVENTIONAL,PHASE2,60.0,,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Hereditary Hemorrhagic Telangiectasia,Tamoxifen,DRUG,3,2,18 Years,,ALL,False,Rabin Medical Center,OTHER,0,1,Israel,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.110873864173311,medium,1,0,0,1,0,0,0,0,0,0,1,1,1,0,5,1,1,0,0,1,0,,,,,0,0,0
NCT03950622,Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",COMPLETED,2019-06-13,2020-03-30,2021-04-26,INTERVENTIONAL,PHASE3,1205.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Pneumococcal Infections,V114|Prevnar 13®,BIOLOGICAL,5,7,50 Years,,ALL,True,Merck Sharp & Dohme LLC,INDUSTRY,0,30,United States|Canada|Taiwan|Spain|Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.095064377287131,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,0,1,12,1,0,1,0,2,1,2019-06-13,2020-03-30,291.0,2019.0,1,3,1
NCT00836875,A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children,"A Prospective, Open-label, Non-randomized, Multi-center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients.",TERMINATED,2009-05,2013-05,2017-06-16,INTERVENTIONAL,PHASE3,31.0,ACTUAL,NON_RANDOMIZED,,TREATMENT,NONE,Invasive Aspergillosis,Voriconazole,DRUG,1,4,2 Years,17 Years,ALL,False,Pfizer,INDUSTRY,0,25,United States|Canada|Netherlands|Thailand|Spain|Czechia|Singapore|Poland,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.4657359027997265,small,1,1,1,0,1,0,1,1,1,1,0,0,1,0,5,1,1,0,0,1,0,,,,,0,1,0
NCT05763875,Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.,"A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy (VictORION-Mono)",COMPLETED,2023-03-15,2024-06-20,2025-10-16,INTERVENTIONAL,PHASE3,350.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Hypercholesterolemia,Inclisiran|Ezetimibe|Matching Placebo for Inclisiran|Matching Placebo for Ezetimibe,DRUG,1,8,18 Years,75 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,42,Mexico|United States|Colombia|Hungary|Germany,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.860786223465865,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,9,1,1,0,0,4,1,2023-03-15,2024-06-20,463.0,2023.0,1,3,1
NCT03559257,A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine,"A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study",COMPLETED,2018-07-31,2019-09-19,2020-07-08,INTERVENTIONAL,PHASE3,463.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Migraine,Galcanezumab|Placebo,DRUG,1,18,18 Years,75 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,69,United Kingdom|United States|Puerto Rico|Canada|Hungary|Netherlands|France|Spain|Czechia|Germany|Japan|Belgium|South Korea,1.0,0,0,1,0,0,3.0,0,0,1,0,1,6.139884552226255,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,19,1,1,0,0,2,1,2018-07-31,2019-09-19,415.0,2018.0,1,3,1
NCT00002101,A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo,A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo,COMPLETED,,,2005-06-24,INTERVENTIONAL,PHASE3,450.0,,,,TREATMENT,DOUBLE,Mycobacterium Avium-Intracellulare Infection|HIV Infections,Ethambutol hydrochloride|Clarithromycin|Rifabutin,DRUG,0,0,13 Years,,ALL,False,Pharmacia,INDUSTRY,0,44,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.111467339502679,large,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,3,1,,,,,0,2,0
NCT00085501,"S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",Phase II Selection Design Trial Of Concurrent Chemotherapy + Cetuximab Vs. Chemotherapy Followed By Cetuximab In Advanced Non-Small Cell Lung Cancer (NSCLC),COMPLETED,2004-07,2011-07,2012-11-01,INTERVENTIONAL,PHASE2,242.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Lung Cancer,cetuximab|carboplatin|paclitaxel,DRUG,3,2,18 Years,,ALL,False,SWOG Cancer Research Network,NETWORK,1,163,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.493061443340548,large,0,1,0,0,0,1,1,0,1,0,1,0,1,1,5,1,1,0,0,3,1,,,,,0,1,0
NCT04666012,Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers,"A Phase 1/2a Study (Dose Escalation, Single Center, Open, Phase 1 and Multicenter, Open, Phase 2a) to Assess the Safety and Immunogenicity of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers",COMPLETED,2020-12-29,2023-03-27,2023-07-28,INTERVENTIONAL,PHASE1|PHASE2,150.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,PREVENTION,NONE,COVID-19,AdCLD-CoV19,BIOLOGICAL,2,6,19 Years,64 Years,ALL,True,"Cellid Co., Ltd.",INDUSTRY,0,5,South Korea,1.0,1,1,0,0,1,1.5,0,0,0,0,1,5.017279836814924,medium,0,1,1,0,0,0,1,0,0,0,0,0,0,0,8,1,0,1,0,1,0,2020-12-29,2023-03-27,818.0,2020.0,1,2,0
NCT03105219,IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease,IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease,WITHDRAWN,2017-07-01,2021-05-30,2020-11-09,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Diabetic Kidney Disease,Ivabradine|Sham Comparator,DRUG|OTHER,1,9,,,ALL,False,"Nanjing First Hospital, Nanjing Medical University",OTHER,0,1,China,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,0,1,1,10,1,1,0,0,2,1,2017-07-01,2021-05-30,1429.0,2017.0,1,2,0
NCT00656630,Medication Development in Alcoholism: Acamprosate Versus Naltrexone,Medication Development in Protracted Abstinence in Alcoholism: Acamprosate Versus Naltrexone,COMPLETED,2007-12,2010-01,2017-03-29,INTERVENTIONAL,PHASE2,68.0,ACTUAL,RANDOMIZED,PARALLEL,OTHER,TRIPLE,Alcoholism,Acamprosate|Naltrexone|Placebo,DRUG,1,4,18 Years,55 Years,ALL,False,The Scripps Research Institute,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.23410650459726,medium,1,1,0,1,0,1,0,0,1,0,1,1,0,1,5,1,1,0,0,3,1,,,,,0,1,0
NCT00293930,A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis,,COMPLETED,,2006-11,2007-12-24,INTERVENTIONAL,PHASE3,645.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Psoriasis,Tacrolimus,DRUG,0,0,12 Years,,ALL,False,Astellas Pharma Inc,INDUSTRY,1,32,Canada|United States,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.470799503782602,xlarge,0,1,1,0,0,1,1,1,1,0,1,1,1,1,0,0,1,0,0,1,0,,,,,0,1,0
NCT05898828,Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer,Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer,WITHDRAWN,2024-08-02,2024-08-02,2024-08-05,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,"Neoplasms|Esophageal Neoplasms|Esophagus Neoplasm|Esophagus Cancer|Neoplasms, Esophageal|Esophageal Cancer (EsC)",Nivolumab|Entinostat|Montanide(R) ISA-51 VG Adjuvant|H1299 Cell Lysates,DRUG|BIOLOGICAL,2,3,18 Years,120 Years,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,6,0.0,,1,1,0,1,0,0,0,0,1,0,0,0,1,0,5,1,1,1,0,4,1,2024-08-02,2024-08-02,0.0,2024.0,1,3,1
NCT00623428,A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response,"A Randomized, Open-label Study of the Effects of 24 vs 48 Weeks of Combination Therapy With PEGASYS (Peginterferon Alfa-2a 40KD) Plus COPEGUS (Ribavirin) on Sustained Virological Response in Patients With Chronic Hepatitis C, Genotype 2 or 3 Who do Not Achieve a Rapid Viral Response",COMPLETED,2008-06,2012-05,2013-07-22,INTERVENTIONAL,PHASE3,235.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Hepatitis C, Chronic",peginterferon alfa-2a|Ribavirin,DRUG,2,5,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,101,Mexico|Australia|United States|Puerto Rico|Canada|Brazil|Austria|Switzerland|Germany|Belgium,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.4638318050256105,large,0,1,1,0,1,0,1,1,1,1,1,0,1,1,7,1,1,0,0,2,1,,,,,0,3,1
NCT00807365,Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly,Six Month Treatment of GHRH in the Elderly,TERMINATED,2007-12-17,2010-04-29,2017-04-27,INTERVENTIONAL,PHASE2,5.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Elderly,GHRH,DRUG,1,0,65 Years,85 Years,ALL,False,Johns Hopkins University,OTHER,1,2,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.791759469228055,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,0,2007-12-17,2010-04-29,864.0,2007.0,0,0,0
NCT04340167,Study of Anti-CD22 CAR-T Cells Treating Leukemia Children,Phase II Study of Autologous Humanized Anti-CD22 Chimeric Antigen Receptor T Cells Treating Refractory or Relapsed B Acute Lymphoblastic Leukemia Children,COMPLETED,2020-05-01,2024-04-03,2025-05-18,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoblastic Leukemia",Autologous humanized anti-CD22 chimeric antigen receptor T cells,BIOLOGICAL,1,0,0 Years,18 Years,ALL,False,Beijing Boren Hospital,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,3,2.70805020110221,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,2020-05-01,2024-04-03,1433.0,2020.0,1,1,0
NCT00002567,High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission,PHASE II STUDY EVALUATING AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR ACUTE LEUKEMIAS,COMPLETED,1994-03,2000-11,2013-06-27,INTERVENTIONAL,PHASE2,45.0,ESTIMATED,,,TREATMENT,,Bone Marrow Ablation|Leukemia,filgrastim|etoposide|peripheral blood stem cell transplantation|low-LET electron therapy|low-LET photon therapy,DRUG|RADIATION|PROCEDURE|BIOLOGICAL,0,0,16 Years,65 Years,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.828641396489095,small,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,5,1,,,,,0,2,0
NCT03055767,Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population,Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Randomized Double Blinded Placebo Cross-over Study in the Pediatric Pain Population,COMPLETED,2017-03-01,2020-04-20,2023-10-18,INTERVENTIONAL,PHASE2,17.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,"Migraine Disorders|Headache, Migraine|Pediatrics",OnabotulinumtoxinA|Placebo (Saline),DRUG|OTHER,4,8,8 Years,17 Years,ALL,False,"University of California, Irvine",OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,3,2.8903717578961645,small,1,1,0,1,0,1,1,0,1,0,1,1,1,0,12,1,1,0,0,2,1,2017-03-01,2020-04-20,1146.0,2017.0,1,3,1
NCT02130700,"Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer","A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Previously Been Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer",COMPLETED,2014-04,2017-11,2018-05-07,INTERVENTIONAL,PHASE2,17.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer,VT-464: given orally twice daily in 28-day cycles|VT-464: given orally once daily in 28-day cycles,DRUG,4,3,18 Years,,MALE,False,Innocrin Pharmaceutical,INDUSTRY,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.8903717578961645,small,1,1,1,0,0,1,0,0,1,0,0,0,1,1,7,1,1,0,0,2,1,,,,,0,2,0
NCT00241007,A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension,A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension,COMPLETED,2003-12,2005-03,2011-11-08,INTERVENTIONAL,PHASE3,836.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hypertension,"VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE",DRUG,1,5,18 Years,,ALL,True,Novartis,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,1,1,6.729824070489475,xlarge,0,1,1,0,1,0,0,0,1,0,1,1,1,1,6,1,1,0,0,1,0,,,,,0,1,0
NCT00550407,An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients,"Study SCA104779, an Evaluation of BW430C (Lamotrigine) Versus Placebo in the Prevention of Mood Episodes in Bipolar I Disorder Patients",COMPLETED,2007-11,2009-10,2016-11-23,INTERVENTIONAL,PHASE3,215.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Bipolar Disorder,lamotrigine|Placebo,DRUG,1,11,20 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,60,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.375278407684165,large,0,1,1,0,0,0,1,0,0,0,1,1,1,1,12,1,1,0,0,2,1,,,,,0,2,0
NCT00029107,Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis,Rituximab (Anti-CD20) for the Treatment of Hepatitis C Associated Cryoglobulinemic Vasculitis,COMPLETED,2001-12,2011-05,2012-04-16,INTERVENTIONAL,PHASE2,47.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hepatitis C|Vasculitis,Rituximab,DRUG,1,0,18 Years,75 Years,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.871201010907891,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,1,0,,,,,0,1,0
NCT02222207,Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration,"A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration",TERMINATED,2014-10,2015-06,2016-09-08,INTERVENTIONAL,PHASE2,52.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Macular Degeneration,"Regorafenib, ophthalmic oily suspension (BAY73-4506)|Sham IVT|Ranibizumab|Placebo",DRUG|PROCEDURE,2,2,50 Years,,ALL,False,Bayer,INDUSTRY,0,149,Chile|Australia|United States|Canada|Colombia|Hungary|Slovakia|Austria|South Korea|France|Spain|Czechia|Italy|Switzerland|Germany|Japan|Israel|Hong Kong,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.970291913552122,medium,1,1,1,0,0,0,1,1,1,1,1,1,1,1,4,1,1,0,0,4,1,,,,,0,2,0
NCT00947011,Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1),The Effect of Dipeptidyl Peptidase-4 Inhibition on GLP-1 Induced Insulin Secretion and Glucose Turnover During Mild Stable Hyperglycemia in Young and Old Normal Volunteers,TERMINATED,2009-03,2010-03,2017-07-12,INTERVENTIONAL,PHASE2,12.0,ACTUAL,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,DOUBLE,Glucose Homeostasis,Placebo|Januvia,DRUG,1,1,21 Years,75 Years,ALL,True,Johns Hopkins University,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.5649493574615367,small,1,1,0,1,0,1,0,0,1,0,1,1,0,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT00772811,"Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma","Allogeneic Non-Myeloablative Stem Cell Transplantation Using Fludarabine and Melphalan Conditioning Regimen for Chronic Lymphocytic Leukemia, Lymphoma, and Multiple Myeloma",COMPLETED,2001-07,2010-12,2011-02-17,INTERVENTIONAL,PHASE2,38.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Chronic Lymphocytic Leukemia|Lymphoma|Multiple Myeloma,Flu-Mel,DRUG,1,1,15 Years,65 Years,ALL,False,Cooperative Study Group A for Hematology,NETWORK,0,1,South Korea,1.0,0,1,0,0,0,2.0,1,0,0,0,3,3.6635616461296463,small,1,1,0,0,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT04477811,Comparative Study Evaluating the Effect of Vitamin K1 Versus Vitamin K2 on Vascular Calcification in Dialysis Patients,Comparative Study Evaluating the Effect of the Administration of Vitamin K1 Versus Vitamin K2 on Vascular Calcification in Dialysis Patients,COMPLETED,2020-07-25,2021-01-01,2021-07-21,INTERVENTIONAL,PHASE2|PHASE3,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,End Stage Renal Disease on Dialysis,Vitamin K1|Vitamin k2|placebo,DRUG|OTHER,1,3,18 Years,75 Years,ALL,False,Ain Shams University,OTHER,0,1,Egypt,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.713572066704308,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,3,1,2020-07-25,2021-01-01,160.0,2020.0,1,2,0
NCT03993171,31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.,"A Phase 2, Open-Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Multiple Sclerosis.",COMPLETED,2019-12-19,2025-07-31,2025-12-19,INTERVENTIONAL,PHASE2,33.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Multiple Sclerosis,gold nanocrystals,DRUG,1,0,18 Years,55 Years,ALL,False,Clene Nanomedicine,INDUSTRY,1,1,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,3.5263605246161616,small,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,2019-12-19,2025-07-31,2051.0,2019.0,1,0,0
NCT00000134,Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT),Cytomegalovirus Retinitis Retreatment Trial,COMPLETED,1992-12,1995-03,2015-09-14,INTERVENTIONAL,PHASE3,279.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,DOUBLE,HIV Infections|Acquired Immunodeficiency Syndrome|Cytomegalovirus Retinitis,Ganciclovir|Foscarnet,DRUG,1,0,18 Years,,ALL,False,Johns Hopkins Bloomberg School of Public Health,OTHER,16,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,3,5.634789603169249,large,0,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,0,0,2,1,,,,,0,2,0
NCT00262132,Mycophenolate for Pulmonary Sarcoidosis,Mycophenolate for Pulmonary Sarcoidosis,TERMINATED,2003-09,2006-08,2018-06-18,INTERVENTIONAL,PHASE3,20.0,,NON_RANDOMIZED,SINGLE_GROUP,,NONE,Pulmonary Sarcoidosis,Mycophenolate,DRUG,0,0,18 Years,,ALL,False,Medical University of South Carolina,OTHER,1,1,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,3.044522437723423,small,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT02455999,Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain,,COMPLETED,2015-06,,2016-04-05,INTERVENTIONAL,PHASE2,66.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ocular Pain|Dry Eye Syndrome,SYL1001|SYL1001|Placebo,DRUG,4,4,18 Years,,ALL,False,"Sylentis, S.A.",INDUSTRY,0,6,Estonia|Spain,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.204692619390966,medium,1,1,1,0,0,0,1,1,0,1,1,1,1,1,8,1,1,0,0,3,1,,,,,0,4,1
NCT04770532,"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin","A 26-week Trial Comparing the Effect and Safety of Once Weekly Insulin Icodec and Once Daily Insulin Degludec, Both With or Without Non-insulin Anti-diabetic Drugs, in Subjects With Type 2 Diabetes Treated With Basal Insulin",COMPLETED,2021-03-05,2022-03-01,2025-12-15,INTERVENTIONAL,PHASE3,526.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Diabetes Mellitus, Type 2",Insulin degludec|Insulin Icodec,DRUG,1,10,,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,88,Ukraine|Bulgaria|United States|Portugal|South Africa|Japan|Germany|Poland|South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.267200548541362,xlarge,0,1,1,0,0,0,1,1,1,1,1,0,1,1,11,1,1,0,0,2,1,2021-03-05,2022-03-01,361.0,2021.0,1,3,1
NCT00908232,Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD,"Efficacy and Safety of Velcade Plus Dexamethasone (VD), VD+Cyclophosphamide or VD Plus Lenalidomide in MMY Patients Who Are Refractory or Have Relapsed After Their Primary Therapy for MMY and Have Achieved Stable Disease After 4 Cycles of VD",COMPLETED,2008-05,2011-08,2015-01-15,INTERVENTIONAL,PHASE2,163.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,Cyclophosphamide|Bortezomib|Dexamethasone|Lenalidomide,DRUG,1,5,18 Years,,ALL,False,Janssen-Cilag International NV,INDUSTRY,0,42,United Kingdom|Turkey (Türkiye)|Hungary|Poland|Lithuania|France|Spain|Germany|Greece|Serbia,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.099866427824199,medium,0,1,1,0,0,0,1,1,0,1,1,0,1,1,6,1,1,0,0,4,1,,,,,0,3,1
NCT01281332,Mechanical Device for the Relief of Hot Flashes,Evaluation of a Novel Mechanical Device for Relief of Menopausal Vasomotor Symptoms.,COMPLETED,2013-09,2014-08,2015-09-11,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hot Flashes,Menopod|Inactive device,DEVICE,1,1,40 Years,65 Years,FEMALE,True,Queen's University,OTHER,1,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.713572066704308,small,1,1,0,1,0,1,0,0,0,0,1,1,1,1,2,1,0,0,1,2,1,,,,,0,1,0
NCT00986232,ProQuad Dose Selection Study (V221-011)(COMPLETED),"A Dose Selection Study in Healthy Children Comparing Measles Mumps, Rubella, and Varicella (ProQuad) Vaccine to M-M-R II Given Concomitantly With Process Upgrade Varicella Vaccine (PUVV) in Separate Injections",COMPLETED,1999-04,2000-09,2015-04-10,INTERVENTIONAL,PHASE2,1551.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Measles|Mumps|Rubella|Varicella,"Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|Comparator: M-M-R II|Comparator: PUVV",BIOLOGICAL,1,8,12 Months,23 Months,ALL,True,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,4,7.347299700743164,xlarge,0,1,1,0,1,0,0,0,0,0,1,1,0,1,9,1,0,1,0,3,1,,,,,0,3,1
NCT03338998,"Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).","A Phase II, Patient- and Investigator-blinded, Randomized, Placebo-controlled Study to Evaluate Efficacy, Safety and Tolerability of BAF312 (Siponimod) in Patients With Stroke Due to Intracerebral Hemorrhage (ICH)",COMPLETED,2017-12-24,2020-05-13,2022-08-12,INTERVENTIONAL,PHASE2,32.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Hemorrhagic Stroke|Intracerebral Hemorrhage (ICH),BAF312 solution|Matching Placebo for BAF312 solution|BAF312 tablet|Matching Placebo for BAF312 tablet,DRUG,1,1,18 Years,85 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,11,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.4965075614664802,small,1,1,1,0,1,0,1,0,1,0,1,1,1,1,2,1,1,0,0,4,1,2017-12-24,2020-05-13,871.0,2017.0,1,2,0
NCT02318563,Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome,"A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Dravet Syndrome",WITHDRAWN,2017-12-30,2018-06-17,2018-01-04,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Dravet Syndrome,Cannabidiol Oral Solution|Placebo Solution,DRUG,1,7,1 Year,30 Years,ALL,False,INSYS Therapeutics Inc,INDUSTRY,0,0,,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,1,1,1,1,8,1,1,0,0,2,1,2017-12-30,2018-06-17,169.0,2017.0,1,2,0
NCT03381287,A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia,"A Randomized, Double Blind, Placebo Controlled, Multicenter, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of HTD1801 in Adults With Hypercholesterolemia",COMPLETED,2018-04-13,2018-12-31,2023-03-03,INTERVENTIONAL,PHASE1|PHASE2,50.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,Hypercholesterolemia,"HTD1801 Tablets, 500 mg|HTD1801 Tablets, 1000 mg|HTD1801 Tablets, 2000 mg|Placebo to match 500 mg HTD1801|Placebo to match 1000 mg HTD1801|Placebo to match 2000 mg HTD1801",DRUG,1,10,18 Years,70 Years,ALL,False,HighTide Biopharma Pty Ltd,INDUSTRY,0,3,Australia,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.9318256327243257,small,1,1,1,0,0,0,1,0,0,0,1,1,1,0,11,1,1,0,0,6,1,2018-04-13,2018-12-31,262.0,2018.0,1,3,1
NCT03678493,A Study of FMT in Patients With AML Allo HSCT in Recipients,A Randomized Placebo-Controlled Clinical Trial of Fecal Microbiota Transplantation in Patients With Acute Myeloid Leukemia and Allogeneic Hematopoietic Cell Transplantation Recipients,COMPLETED,2019-09-09,2023-12-04,2024-05-16,INTERVENTIONAL,PHASE2,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Myeloid Leukemia|Allogeneic Hematopoietic Cell Transplantation,Fecal Microbiota Transplant (FMT)|Placebo,OTHER|BIOLOGICAL,1,7,18 Years,,ALL,False,"Masonic Cancer Center, University of Minnesota",OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.61512051684126,medium,0,1,0,1,0,0,0,0,1,0,1,0,1,1,8,1,0,1,0,2,1,2019-09-09,2023-12-04,1547.0,2019.0,1,3,1
NCT03365687,Vitamin D In the Prevention of Viral-induced Asthma in Preschoolers,Vitamin D In the Prevention of Viral-induced Asthma in Preschoolers: a Randomized Controlled Multicenter Trial (DIVA),COMPLETED,2018-10-01,2024-12-31,2025-06-03,INTERVENTIONAL,PHASE3,323.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Asthma|Asthma Exacerbations|Preschool Child|Vitamin D|Upper Respiratory Infection|Randomized Controlled Study|Symptoms|Bronchodilator Agents,Vitamin D|Placebo,DIETARY_SUPPLEMENT,1,11,1 Year,5 Years,ALL,False,Professor Francine Ducharme,OTHER,2,9,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,8,5.780743515792329,large,0,1,0,1,0,1,1,0,0,0,1,1,0,1,12,1,0,0,0,2,1,2018-10-01,2024-12-31,2283.0,2018.0,1,3,1
NCT05348993,Single or Repeat Dose of G03-52-01 in Adult Subjects,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of G03-52-01 in Adult Subjects",COMPLETED,2022-06-29,2025-02-04,2025-02-11,INTERVENTIONAL,PHASE2,625.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Healthy|Botulinum Toxin,G03-52-01|Placebo,DRUG,14,7,18 Years,65 Years,ALL,True,"Alachua Government Services, Inc.",INDUSTRY,1,15,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,6.439350371100098,xlarge,0,1,1,0,0,1,1,0,1,0,1,1,0,1,21,1,1,0,0,2,1,2022-06-29,2025-02-04,951.0,2022.0,1,3,1
NCT00421993,A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris,"A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel Compared With Adapalene Topical Gel, 0.1%; Benzoyl Peroxide Topical Gel, 2.5% and Topical Gel Vehicle in Subjects With Acne Vulgaris",COMPLETED,2006-10,2007-12,2021-02-18,INTERVENTIONAL,PHASE3,1670.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acne Vulgaris,Adapalene/Benzoyl Peroxide|Adapalene|Benzoyl Peroxide|Topical Gel Vehicle,DRUG,3,3,12 Years,,ALL,False,Galderma R&D,INDUSTRY,0,62,United States|Canada|Hungary|Germany|Poland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.421177528595393,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,6,1,1,0,0,4,1,,,,,0,3,1
NCT00959621,Low Molecular Weight Heparin and/or Aspirin in Prevention of Habitual Abortion,Role of LMWH (Enoxaparine) With or Without Aspirin in the Prevention of Habitual Abortion; Special Attention to the Thrombophilic Status of the Mother,COMPLETED,2002-01,2008-12,2009-08-14,INTERVENTIONAL,PHASE3,220.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Habitual Abortion,Aspirin|Klexane|Klexane and ASA,DRUG,1,1,,,FEMALE,True,University of Helsinki,OTHER,3,1,Finland,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.3981627015177525,large,0,1,0,1,0,1,0,0,0,0,1,0,0,1,2,1,1,0,0,3,1,,,,,0,1,0
NCT01227421,Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza,"A Randomized, Double-Blind, Placebo Controlled Study of Nitazoxanide in Adults and Adolescents With Acute Uncomplicated Influenza",COMPLETED,2010-12,2011-05,2023-10-12,INTERVENTIONAL,PHASE2|PHASE3,624.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Influenza,Nitazoxanide|Nitazoxanide|Placebo,DRUG,1,14,12 Years,65 Years,ALL,False,Romark Laboratories L.C.,INDUSTRY,0,1,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,6.437751649736401,xlarge,0,1,1,0,0,0,0,0,1,0,1,1,1,1,15,1,1,0,0,3,1,,,,,0,3,1
NCT00459914,Sleep Apnea and Refractory Hypertension: Prevalence and Effect of CPAP Treatment,"Sleep Apnea in Patients With Refractory Hypertension: Study of the Prevalence and the Effect of CPAP Treatment on Blood Pressure Control, Endothelial Dysfunction and Angiogenesis.",COMPLETED,2005-01,2008-12,2009-01-29,INTERVENTIONAL,PHASE2,130.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Hypertension|Sleep Apnea,cpap treatment during sleep,DEVICE,1,1,18 Years,75 Years,ALL,False,Fundacio Catalana de Pneumologia,OTHER,0,1,Spain,1.0,0,1,0,0,0,2.0,0,0,0,1,2,4.875197323201151,medium,0,1,0,1,0,0,0,0,0,1,1,0,0,1,2,1,0,0,1,1,0,,,,,0,1,0
NCT03239106,A Study Examining the Medication Apremilast as Treatment for Chronic Itch,An Open Label Study of Apremilast in Chronic Idiopathic Pruritus,COMPLETED,2017-12-01,2019-09-19,2021-07-13,INTERVENTIONAL,PHASE2,10.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Itch,Apremilast,DRUG,1,3,18 Years,,ALL,False,Washington University School of Medicine,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2017-12-01,2019-09-19,657.0,2017.0,1,0,0
NCT01003106,Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions,RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach(RELATE),COMPLETED,2009-11,2015-04,2016-03-15,INTERVENTIONAL,PHASE1|PHASE2,81.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Retinal Vein Occlusion,Ranibizumab 0.5mg (monthly)|Ranibizumab 2.0mg (monthly)|Pro re nata (prn) ranibizumab|Pro re nata (prn) Laser photocoagulation,DRUG|PROCEDURE,1,4,18 Years,,ALL,False,"Peter A Campochiaro, MD",OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.406719247264253,medium,1,1,0,1,0,1,0,0,1,0,1,0,1,1,5,1,1,0,0,4,1,,,,,0,2,0
NCT01946204,A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer",ACTIVE_NOT_RECRUITING,2013-10-14,2027-12-31,2026-02-02,INTERVENTIONAL,PHASE3,1207.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Prostatic Neoplasms,Apalutamide|Placebo,DRUG,1,5,18 Years,,MALE,False,"Aragon Pharmaceuticals, Inc.",INDUSTRY,0,379,Canada|Austria|Hungary|Russia|Australia|Spain|Romania|Norway|Belgium|Israel|Finland|United States|Sweden|France|Czechia|Germany|Netherlands|Poland|South Korea|United Kingdom|Denmark|Slovakia|Taiwan|New Zealand|Japan,,0,0,1,0,0,3.0,0,0,0,0,1,7.0967213784947605,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,6,1,1,0,0,2,1,2013-10-14,2027-12-31,5191.0,2013.0,0,3,1
NCT01409304,Effectiveness of Deep Transcranial Magnetic Stimulation in Depression,Effectiveness of Deep Transcranial Magnetic Stimulation for Treating Major Depression: a Pilot Study,COMPLETED,2011-10,2012-12,2013-01-18,INTERVENTIONAL,PHASE2|PHASE3,18.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Major Depressive Disorder,Deep Transcranial Magnetic Stimulation (DTMS),DEVICE,1,1,18 Years,60 Years,ALL,False,Douglas Mental Health University Institute,OTHER,1,1,Canada,1.0,0,1,1,0,1,2.5,0,0,0,0,1,2.9444389791664403,small,1,1,0,1,0,1,0,0,0,0,0,0,1,0,2,1,0,0,1,1,0,,,,,0,1,0
NCT00004884,Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer,Randomized Phase II Study of Docetaxel/Gemcitabine vs. Docetaxel/Cisplatin in Metastatic or Locoregionally Advanced Pancreatic Carcinoma,COMPLETED,1999-07,,2012-09-24,INTERVENTIONAL,PHASE2,96.0,ACTUAL,RANDOMIZED,,TREATMENT,,Pancreatic Cancer,cisplatin|docetaxel|gemcitabine hydrochloride,DRUG,0,0,18 Years,,ALL,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,0,19,United Kingdom|Turkey (Türkiye)|Poland|France|Egypt|Germany|Netherlands|Belgium,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.574710978503383,medium,1,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,3,1,,,,,0,2,0
NCT02014584,Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia,A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia,COMPLETED,2014-07-02,2016-03-19,2018-10-11,INTERVENTIONAL,PHASE3,117.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Alopecia,Dutasteride|Placebo,DRUG,3,55,18 Years,50 Years,MALE,False,"Stiefel, a GSK Company",INDUSTRY,1,18,Chile|Taiwan|Singapore|South Korea|Hong Kong,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.770684624465665,medium,0,1,1,0,1,1,1,1,0,0,1,1,1,1,58,1,1,0,0,2,1,2014-07-02,2016-03-19,626.0,2014.0,0,3,1
NCT03445884,68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Myocardial Angiogenesis,68Ga-NODAGA-E[c(RGDγK)]2: a Novel Positron Emission Tomography (PET) Tracer for in Vivo Molecular Imaging of Myocardial Angiogenesis Following Myocardial Infarction,COMPLETED,2018-02-20,2020-07-01,2020-07-14,INTERVENTIONAL,PHASE2,42.0,ACTUAL,NON_RANDOMIZED,PARALLEL,PREVENTION,NONE,Acute Myocardial Infarction,68Ga-NODAGA-E[c(RGDyK)]2,DRUG,1,3,50 Years,,ALL,True,"Rigshospitalet, Denmark",OTHER,0,1,Denmark,1.0,0,1,0,0,0,2.0,0,0,0,1,1,3.7612001156935624,small,1,1,0,1,0,0,0,0,0,0,0,0,0,1,4,1,1,0,0,1,0,2018-02-20,2020-07-01,862.0,2018.0,1,0,0
NCT04570384,Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19,"Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline (Turnobi) to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness",COMPLETED,2020-10-15,2021-09-30,2023-02-22,INTERVENTIONAL,PHASE2,65.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Hypoxemic Respiratory Failure,L-Citrulline|Placebo,DRUG,6,9,18 Years,65 Years,ALL,False,"Asklepion Pharmaceuticals, LLC",INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.189654742026425,medium,1,1,1,0,0,0,0,0,1,0,1,1,1,1,15,1,1,0,0,2,1,2020-10-15,2021-09-30,350.0,2020.0,1,2,0
NCT03324984,1% Chloroprocaine(PF) vs. Bupivacaine Spinals,Comparison of 1% Chloroprocaine vs. Hyperbaric Bupivacaine Spinals in Patients Undergoing Hemorrhoidectomies in an Ambulatory Surgery Center: A Double-Blind Randomized Controlled Pilot Trial.,COMPLETED,2019-09-11,2023-02-01,2025-02-28,INTERVENTIONAL,PHASE2,110.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Return of Motor and Sensory Blockade|Anesthesia, Spinal|Decrease Discharge Time Status Post Hemorrhoidectomy",1% chloroprocaine|0.75% bupivacaine,DRUG,2,2,18 Years,,ALL,False,Montefiore Medical Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,4.709530201312334,medium,0,1,0,1,0,0,0,0,1,0,1,1,1,1,4,1,1,0,0,2,1,2019-09-11,2023-02-01,1239.0,2019.0,1,2,0
NCT00126984,Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine,"A Phase II, Open (Partially Double-blind), Randomized, Controlled Dose-range Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Investigational Vaccination Regimens Versus MENINGITEC™ or MENCEVAX™ ACWY When Given as One Dose to Children Aged 12 to 14 Months and 3 to 5 Years Old",COMPLETED,2005-07,2008-02,2016-10-07,INTERVENTIONAL,PHASE2,508.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,"Infections, Meningococcal",Conjugated meningococcal ACWY-TT (vaccine)|DTPa/Hib containing vaccine|Meningitec|Mencevax ACWY,BIOLOGICAL,1,7,12 Months,14 Months,ALL,True,GlaxoSmithKline,INDUSTRY,0,42,Germany|Austria,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.2324480165505225,xlarge,0,1,1,0,0,0,1,1,0,1,1,0,0,1,8,1,0,1,0,4,1,,,,,0,3,1
NCT01545284,Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis,Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis,COMPLETED,2012-03,2014-01,2014-07-24,INTERVENTIONAL,PHASE2|PHASE3,9.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Hand Dermatitis,Acitretin,DRUG,1,6,18 Years,,ALL,False,Innovaderm Research Inc.,OTHER,1,2,Canada,1.0,0,1,1,0,1,2.5,0,0,0,0,1,2.302585092994046,small,1,1,0,1,0,1,1,0,0,0,0,0,1,0,7,1,1,0,0,1,0,,,,,0,2,0
NCT00579384,A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy,A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram Response in Patients With Photosensitive Epilepsy,COMPLETED,2007-10,2008-07,2012-04-05,INTERVENTIONAL,PHASE2,12.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Photosensitive Epilepsy,JNJ-26489112|Placebo,DRUG,1,1,18 Years,60 Years,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,1,0,1,2.5649493574615367,small,1,1,1,0,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,2,1,,,,,0,1,0
NCT00412984,Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation,"A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation",COMPLETED,2006-12-31,2011-05-25,2018-07-03,INTERVENTIONAL,PHASE3,20976.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Atrial Fibrillation|Atrial Flutter,warfarin|apixaban,DRUG,2,12,,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,1111,Canada|Austria|South Africa|China|Hungary|Hong Kong|Argentina|Russia|Australia|Spain|Romania|Norway|Belgium|Israel|Italy|Chile|Finland|Ukraine|United States|Sweden|Colombia|France|Czechia|Singapore|Germany|Netherlands|Poland|South Korea|India|Peru|United Kingdom|Turkey (Türkiye)|Denmark|Malaysia|Puerto Rico|Brazil|Philippines|Taiwan|Switzerland|Mexico|Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,2,9.95118187839879,,0,1,1,0,1,0,1,1,1,1,1,1,0,1,14,1,1,0,0,2,1,2006-12-31,2011-05-25,1606.0,2006.0,0,4,1
NCT00504322,Efficacy Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma,"Phase II, Randomized, Double-blinded, Placebo-Control, Toxicity/Efficacy Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdcuCD40L) to Patients With Stage I, II or III Esophageal Carcinoma",WITHDRAWN,2011-07,2011-07,2016-05-04,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Esophageal Neoplasms,AdcuCD40L|Placebo,GENETIC,1,0,18 Years,75 Years,ALL,False,Weill Medical College of Cornell University,OTHER,0,0,,0.0,1,1,0,0,1,1.5,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,2,1,,,,,0,2,0
NCT00337051,Renal Transplantation and Inhaled Anesthetic Sevoflurane (SEVOREIN),Sevoflurane-induced Prevention of Ischemia-reperfusion Lesions in Renal Allograft Transplants Recipients,COMPLETED,2006-06,2010-06,2010-06-23,INTERVENTIONAL,PHASE3,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,End-stage Chronic Renal Disease|Severe Acute Kidney Failure|Renal Transplantation,Sevoflurane|Propofol,DRUG,1,7,18 Years,,ALL,False,"University Hospital, Bordeaux",OTHER,1,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,3,4.795790545596741,medium,0,1,0,1,0,1,0,0,0,1,1,1,1,1,8,1,1,0,0,2,1,,,,,0,3,1
NCT00886522,Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies,Intrabone Infusion of Cord Blood Hemopoietic Stem Cells in Adult Patients With High Risk Haematological Malignancies.,COMPLETED,2009-04,2013-05,2021-03-19,INTERVENTIONAL,PHASE2,23.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hematological Malignancies,Intrabone cord blood infusion,PROCEDURE,1,5,18 Years,65 Years,ALL,False,IRCCS Azienda Ospedaliero-Universitaria di Bologna,OTHER,0,1,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.1780538303479458,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,6,1,0,0,0,1,0,,,,,0,1,0
NCT02927951,The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy,"A Randomized, Double-blind, Placebo-Controlled, Cross-over Study on the Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy",COMPLETED,2011-01,2013-12,2016-10-07,INTERVENTIONAL,PHASE3,44.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Diabetic Peripheral Neuropathy|Nerve Pain,Pregabalin|Placebo,DRUG,1,3,40 Years,75 Years,ALL,False,Eastern Virginia Medical School,OTHER,1,2,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,3.8066624897703196,small,1,1,0,1,0,1,1,0,1,0,1,1,1,0,4,1,1,0,0,2,1,,,,,0,2,0
NCT00822029,Use of Oral Bisphosphonates in the Treatment of Osteoporosis of Non-walking Children With Cerebral Palsy,Use of Oral Bisphosphonates in the Treatment of Osteoporosis of Non-walking Children With Cerebral Palsy,TERMINATED,2009-02,2011-02,2012-03-26,INTERVENTIONAL,PHASE3,2.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Osteoporosis|Cerebral Palsy,FOSAMAX|PLACEBO,DRUG|OTHER,1,1,10 Years,18 Years,ALL,False,Department of Clinical Research and Innovation,OTHER,0,1,France,0.0,0,0,1,0,0,3.0,0,0,0,0,2,1.0986122886681098,small,1,1,0,1,0,0,0,0,0,1,1,1,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT00277329,Study of XL999 in Patients With Non-small Cell Lung Cancer,A Phase 2 Study of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer,TERMINATED,2005-12,2008-07,2010-02-22,INTERVENTIONAL,PHASE2,9.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Non-small Cell Lung Cancer,XL999,DRUG,2,4,18 Years,,ALL,False,"Symphony Evolution, Inc.",INDUSTRY,0,4,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.302585092994046,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,6,1,1,0,0,1,0,,,,,0,1,0
NCT01547702,Classroom-based Distance Intervention for Teachers of Children With Attention Deficit Hyperactivity Disorder,Randomized-controlled Trial of a Classroom-based Distance Intervention for Teachers of Elementary School-aged Children With ADHD,COMPLETED,2012-02,2013-05,2014-03-28,INTERVENTIONAL,PHASE2,116.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Attention Deficit Hyperactivity Disorder (ADHD),Teacher Help for ADHD,BEHAVIORAL,1,10,6 Years,12 Years,ALL,False,Dalhousie University,OTHER,0,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.762173934797756,medium,0,1,0,1,0,0,0,0,0,0,1,0,1,1,11,1,0,0,0,1,0,,,,,0,1,0
NCT00517153,Miglustat in Niemann-Pick Type C Disease,A Phase II Randomized Controlled Study of Miglustat in Adult and Juvenile Patients With Niemann-Pick Type C Disease,COMPLETED,2002-01,2008-01,2025-02-04,INTERVENTIONAL,PHASE2,29.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Niemann-Pick Type C Disease,miglustat,DRUG,1,1,4 Years,,ALL,False,Actelion,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4011973816621555,small,1,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT04042753,Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors,Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Aggressive Pituitary Tumors,ACTIVE_NOT_RECRUITING,2019-07-31,2026-07,2025-08-08,INTERVENTIONAL,PHASE2,9.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Pituitary|Pituitary Tumor|Pituitary Carcinoma|Pituitary Cancer,Ipilimumab|Nivolumab|Nivolumab,DRUG,1,1,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,0,8,United States,,0,1,0,0,0,2.0,1,0,0,0,4,2.302585092994046,small,1,0,0,1,0,0,1,0,1,0,0,0,1,0,2,1,1,0,0,3,1,2019-07-31,,,2019.0,1,2,0
NCT00455637,Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?,"A Phase II, Randomised, Double-blind, Dose-ranging Study in Children and Young People to Determine the Optimal Dose of Botulinum Toxin Type-A (Dysport®) in Managing the Symptoms of Hip Muscle Spasticity Due to Cerebral Palsy",TERMINATED,2007-03,2008-03-17,2019-08-02,INTERVENTIONAL,PHASE2,6.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Cerebral Palsy,Botulinum toxin type A,BIOLOGICAL,2,3,4 Years,16 Years,ALL,False,Ipsen,INDUSTRY,0,1,United Kingdom,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.9459101490553132,small,1,1,1,0,0,0,0,0,0,1,1,1,1,0,5,1,0,1,0,1,0,,2008-03-17,,,0,0,0
NCT00459745,"A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia","A Multi-Center, Prospective, Longitudinal, Randomized, Double-Blind, Phase III Study to Evaluate the Efficacy and Safety of Daily Administration of Pravastatin 40 mg or Fenofibrate 160 mg or Pravafen (the Combination of Pravastatin and Fenofibrate 40/160 mg) for 12 Weeks Followed by a 52-Week Open-Label Safety Phase of the Pravafen Alone in the Treatment of Combined Hyperlipidemia.",COMPLETED,2007-04,2009-07,2018-04-24,INTERVENTIONAL,PHASE3,481.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Combined Hyperlipidemia,Pravafen|Pravastatin|Fenofibrate,DRUG,1,2,18 Years,75 Years,ALL,False,Shionogi,INDUSTRY,1,57,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.1779441140506,large,0,1,1,0,0,1,1,0,1,0,1,1,1,1,3,1,1,0,0,3,1,,,,,0,1,0
NCT00215995,"Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas","A Phase II Study of Cisplatin and Irinotecan Induction Chemotherapy, Followed by ZD 1839 (IRESSA) in Adult Patients With Surgically Unresectable and/or Metastatic Esophageal or Gastric Carcinomas",COMPLETED,2003-07,2007-05,2012-01-13,INTERVENTIONAL,PHASE2,21.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Esophageal Cancer|Gastric Cancer,Cisplatin|Irinotecan|ZD 1839,DRUG,1,3,18 Years,,ALL,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,3,Puerto Rico|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.091042453358316,small,1,1,0,1,0,1,1,1,1,0,0,0,1,0,4,1,1,0,0,3,1,,,,,0,3,1
NCT00647595,Effect of Physical Activity on Metabolic Syndrome in Pregnancy & Fetal Outcome,Effect of Physical Activity on Metabolic Syndrome in Pregnancy & Fetal Outcome,COMPLETED,2007-10,2008-12,2015-04-22,INTERVENTIONAL,PHASE3,100.0,ESTIMATED,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Obesity|Pregnancy|Diabetes Mellitus,Experimental group,BEHAVIORAL,1,6,18 Years,45 Years,FEMALE,True,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,3,4.61512051684126,medium,0,0,0,1,0,0,0,0,1,0,1,0,0,1,7,1,0,0,0,1,0,,,,,0,2,0
NCT01564095,TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion,TOP-Study (Tacrolimus Organ Perfusion): A Prospective Multicenter Trial for Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion,TERMINATED,2011-10,2013-07,2017-03-23,INTERVENTIONAL,PHASE2|PHASE3,25.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Terminal Liver Disease|Ischemia Reperfusion Injury|Graft Dysfunction|Graft Failure|Poor Graft Quality,Tacrolimus|HTK/Placebo,DRUG,1,5,18 Years,,ALL,False,Ludwig-Maximilians - University of Munich,OTHER,0,7,Germany,0.0,0,1,1,0,1,2.5,0,0,0,0,5,3.258096538021482,small,1,1,0,1,0,0,1,0,0,1,1,0,1,1,6,1,1,0,0,2,1,,,,,0,4,1
NCT00859339,"Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC","A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123",TERMINATED,2009-03,2011-04,2016-04-14,INTERVENTIONAL,PHASE2,9.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Transitional Cell Carcinoma of the Bladder,Gemcitabine|Cisplatin|Sunitinib Malate|Radical Cystectomy,DRUG|PROCEDURE,1,4,18 Years,,ALL,False,"Noah Hahn, M.D.",OTHER,2,5,United Kingdom|United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.302585092994046,small,1,1,0,1,0,1,1,1,1,1,0,0,1,0,5,1,1,0,0,4,1,,,,,0,2,0
NCT00231439,Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg),Post-Polio Syndrome Treated With Intravenous Immunoglobulin (IvIg),COMPLETED,2003-08,2004-07,2005-12-13,INTERVENTIONAL,PHASE2|PHASE3,40.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Post-Polio Syndrome,IvIg,DRUG,3,1,0 Years,75 Months,ALL,True,Haukeland University Hospital,OTHER,0,0,,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.713572066704308,small,1,0,0,1,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,1,0,,,,,0,1,0
NCT00136175,"Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder","Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Transitional Cell Carcinoma of the Bladder",COMPLETED,1999-11,2007-10,2015-01-21,INTERVENTIONAL,PHASE2,68.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Bladder Cancer,Paclitaxel|Carboplatin|Gemcitabine,DRUG,2,0,18 Years,,ALL,False,University of Michigan Rogel Cancer Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.23410650459726,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,0,1,0,0,3,1,,,,,0,1,0
NCT06463457,Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED),Comeback From Long coursE ADT With RElugolix and Darolutamide in Hormone-sensitive Prostate Cancer (CLEARED),ACTIVE_NOT_RECRUITING,2024-12-13,2028-11-30,2025-04-27,INTERVENTIONAL,PHASE2,33.0,ESTIMATED,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostate Cancer|Advanced Prostate Cancer|Hormone Sensitive Prostate Cancer,Darolutamide|Relugolix,DRUG,2,3,18 Years,,MALE,False,"Atish Choudhury, MD",OTHER,4,3,United States,,0,1,0,0,0,2.0,1,0,0,0,3,3.5263605246161616,small,1,0,0,1,0,1,1,0,1,0,0,0,1,1,5,1,1,0,0,2,1,2024-12-13,2028-11-30,1448.0,2024.0,1,2,0
NCT01832857,"Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients","An Open Label, Phase 2 Trial to Evaluate the Safety, Tolerability and Efficacy of CPI-613 in Cancer Patients",TERMINATED,2013-06,2016-12,2016-12-29,INTERVENTIONAL,PHASE2,7.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cancer,CPI-613,DRUG,1,3,18 Years,,ALL,False,Cornerstone Pharmaceuticals,INDUSTRY,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,2.0794415416798357,small,1,1,1,0,0,0,0,0,1,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT05949801,Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial Based on Standard Treatment to Evaluate the Effect of Injectable Neucardin on Cardiac Function and Reverse Ventricular Remodeling in Patients With Chronic Systolic Heart Failure",COMPLETED,2023-04-13,2024-10-14,2025-01-28,INTERVENTIONAL,PHASE3,202.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Systolic Heart Failure,Neucardin|Placebo,DRUG,1,16,18 Years,75 Years,ALL,False,"Zensun Sci. & Tech. Co., Ltd.",INDUSTRY,0,103,China,1.0,0,0,1,0,0,3.0,0,0,0,1,1,5.313205979041787,large,0,1,1,0,0,0,1,0,0,0,1,1,1,1,17,1,1,0,0,2,1,2023-04-13,2024-10-14,550.0,2023.0,1,2,0
NCT01986881,"Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)","Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study",COMPLETED,2013-11-04,2019-12-27,2022-09-23,INTERVENTIONAL,PHASE3,8246.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 Diabetes Mellitus,Ertugliflozin|Placebo|Glycemic Rescue,DRUG,7,119,40 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,1,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,9.017604776833355,xlarge,0,1,1,0,1,1,0,0,0,0,1,1,1,1,126,1,1,0,0,3,1,2013-11-04,2019-12-27,2244.0,2013.0,0,2,0
NCT02330419,Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM),Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among MSM,COMPLETED,2015-04,2021-01,2025-04-20,INTERVENTIONAL,PHASE2,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Binge Drinking|HIV,Placebo|Naltrexone|Medical Management (MM) counseling for alcohol use:|Urinalysis for novel alcohol biochemical markers:|Behavioral survey measurements:|Dried Blood Spot (DSB) Testing for Phosphatidylethanol|Ecological Momentary Assessment,DRUG|BEHAVIORAL|DIAGNOSTIC_TEST,6,0,18 Years,70 Years,MALE,True,"University of California, San Francisco",OTHER,2,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.795790545596741,medium,0,1,0,1,0,1,0,0,1,0,1,1,1,1,6,0,1,0,0,7,1,,,,,0,3,1
NCT06162728,"Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)","A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines and/or Omalizumab, or Who Cannot Tolerate Omalizumab",ACTIVE_NOT_RECRUITING,2023-11-29,2026-10-31,2026-01-22,INTERVENTIONAL,PHASE1|PHASE2,88.0,ACTUAL,RANDOMIZED,SEQUENTIAL,TREATMENT,QUADRUPLE,Chronic Spontaneous Urticaria,Briquilimab|Placebo,DRUG|OTHER,1,6,18 Years,,ALL,False,"Jasper Therapeutics, Inc.",INDUSTRY,0,23,Germany|United States,,1,1,0,0,1,1.5,0,0,0,0,1,4.48863636973214,medium,1,1,1,0,0,0,1,1,1,1,1,1,1,0,7,1,1,0,0,2,1,2023-11-29,2026-10-31,1067.0,2023.0,1,4,1
NCT00016328,CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme,A Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme,COMPLETED,2001-05,,2013-07-18,INTERVENTIONAL,PHASE2,33.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor,temsirolimus|laboratory biomarker analysis|pharmacological study,DRUG|OTHER,1,5,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,4,3.5263605246161616,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,6,1,1,0,0,3,1,,,,,0,3,1
NCT00190528,A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer,Phase III Trial of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Bulky Stage I/II Cervical Cancer: Japan Clinical Oncology Group Trial (JCOG0102),TERMINATED,2002-02,2009-02,2016-09-22,INTERVENTIONAL,PHASE3,200.0,ACTUAL,RANDOMIZED,PARALLEL,DIAGNOSTIC,NONE,Cervical Neoplasms,neoadjuvant chemotherapy + radical hysterectomy|radical hysterectomy,DRUG|PROCEDURE,1,7,20 Years,70 Years,FEMALE,False,Haruhiko Fukuda,OTHER,1,1,Japan,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.303304908059076,medium,0,1,0,1,0,1,0,0,0,0,1,0,0,1,8,1,1,0,0,2,1,,,,,0,2,0
NCT03651700,Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Chronic Aphasia,"A Phase II, Randomized Blinded Study of the Effects of Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for the Treatment of Chronic Aphasia",COMPLETED,2019-03-28,2024-08-31,2025-10-14,INTERVENTIONAL,PHASE2,86.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Aphasia,Active TMS|Sham TMS|CILT,BEHAVIORAL|DEVICE,1,1,18 Years,80 Years,ALL,False,H. Branch Coslett,OTHER,2,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.465908118654584,medium,1,1,0,1,0,1,0,0,1,0,1,1,1,1,2,1,0,0,1,3,1,2019-03-28,2024-08-31,1983.0,2019.0,1,1,0
NCT01585792,Double Blind Comparative Study of TAK-875,,COMPLETED,2012-05,2012-12,2013-04-16,INTERVENTIONAL,PHASE3,80.0,ACTUAL,,,TREATMENT,,Diabetic Patients,TAK-875|TAK-875|Glimepiride|Placebo,DRUG,1,0,20 Years,,ALL,,Takeda,INDUSTRY,0,2,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.394449154672439,medium,1,1,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,4,1,,,,,0,1,0
NCT00086892,Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer,"A Phase II Evaluation of Cetuximab (C225, NSC #714692) in Combination With Carboplatin (NSC #241240) in the Treatment of Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer",COMPLETED,2004-06,,2014-02-14,INTERVENTIONAL,PHASE2,,,,,TREATMENT,NONE,Ovarian Cancer|Primary Peritoneal Cavity Cancer,cetuximab|carboplatin,DRUG|BIOLOGICAL,0,0,18 Years,,FEMALE,False,Gynecologic Oncology Group,NETWORK,2,76,Australia|United States|Canada|Japan|Norway,1.0,0,1,0,0,0,2.0,1,0,0,0,2,0.0,,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,2,1,,,,,0,3,1
NCT04823611,A Study of AZD8233 in Participants With Dyslipidemia.,"A Phase 1 and 2 Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of AZD8233 Following a Multiple Subcutaneous Dose Administration in Japanese Participants With Dyslipidemia",COMPLETED,2021-01-20,2022-09-10,2024-12-24,INTERVENTIONAL,PHASE1|PHASE2,87.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Dyslipidemia,Part A:Placebo|Part A:AZD8233|Part B:Placebo|Part B:AZD8233|Part C: Placebo|Part C: AZD8233,DRUG,1,8,20 Years,75 Years,ALL,False,AstraZeneca,INDUSTRY,0,7,Japan,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.477336814478207,medium,1,1,1,0,1,0,1,0,0,0,1,1,1,1,9,1,1,0,0,6,1,2021-01-20,2022-09-10,598.0,2021.0,1,3,1
NCT03168711,Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS),Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS),COMPLETED,2017-10-01,2020-01-07,2021-02-18,INTERVENTIONAL,PHASE2,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Amyotrophic Lateral Sclerosis,Inosine|Placebo,DRUG,2,0,18 Years,85 Years,ALL,False,Massachusetts General Hospital,OTHER,2,3,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8918202981106265,small,1,1,0,1,0,1,1,0,1,0,1,1,1,1,2,0,1,0,0,2,1,2017-10-01,2020-01-07,828.0,2017.0,1,1,0
NCT00186511,Expanding Rural Access: Distance Delivery of Support,Expanding Rural Access: Distance Delivery of Support,COMPLETED,2004-11,2006-06,2006-12-05,INTERVENTIONAL,PHASE2,40.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Breast Cancer|Stress Disorders, Post-Traumatic|Depression",workbook/journal on coping with breast cancer|supportive expressive group therapy using videoconferencing,BEHAVIORAL,2,2,21 Years,,FEMALE,False,Stanford University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,1,0,3,3.713572066704308,small,1,0,0,1,0,1,0,0,1,0,0,0,1,0,4,1,0,0,0,2,1,,,,,0,2,0
NCT01735071,Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer,"Multicenter, Randomized, Non-comparative, Phase II Trial on the Efficacy and Safety of the Combination of Bevacizumab and Trabectedin With or Without Carboplatin in Adult Women With Platinum Partially Sensitive Recurring Ovarian Cancer.",COMPLETED,2013-07,2018-03-18,2019-11-19,INTERVENTIONAL,PHASE2,71.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Ovarian Epithelial Cancer Recurrent,"bevacizumab and trabectedin|bevacizumab, trabectedin and carboplatin",DRUG,2,14,18 Years,,FEMALE,False,Mario Negri Institute for Pharmacological Research,OTHER,2,7,Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.276666119016055,medium,1,1,0,1,0,1,1,0,0,1,1,0,1,1,16,1,1,0,0,2,1,,2018-03-18,,,0,2,0
NCT02437344,Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence,Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence,COMPLETED,2015-01,2016-12,2019-04-08,INTERVENTIONAL,PHASE2,16.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Opioid Dependence,CI-581aa|Naltrexone titration and XR-NTX initiation,DRUG,1,1,21 Years,60 Years,ALL,False,New York State Psychiatric Institute,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.833213344056216,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,1,1,0,0,2,1,,,,,0,1,0
NCT00004234,"Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx",A Comparison of Acute Oral Mucositis Between Morning and Afternoon Radiotherapy in Patients Receiving Radiation Treatment for Cancer of the Head and Neck,COMPLETED,1999-08-02,2009-02-10,2020-04-06,INTERVENTIONAL,PHASE3,,,RANDOMIZED,,SUPPORTIVE_CARE,,Head and Neck Cancer|Oral Complications,management of therapy complications|radiation therapy,PROCEDURE|RADIATION,0,0,16 Years,120 Years,ALL,False,NCIC Clinical Trials Group,NETWORK,0,14,Canada,1.0,0,0,1,0,0,3.0,1,0,0,0,2,0.0,,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,2,1,1999-08-02,2009-02-10,3480.0,1999.0,0,2,0
NCT03776864,Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,A Phase II Trial of Umbralisib and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,TERMINATED,2019-09-26,2021-09-14,2023-05-03,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hodgkin's Lymphoma,Pembrolizumab|Umbralisib,DRUG|BIOLOGICAL,1,2,18 Years,,ALL,False,University of Washington,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,3,1,1,1,0,2,1,2019-09-26,2021-09-14,719.0,2019.0,1,1,0
NCT04533399,A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults,"A Phase 2A/B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV",COMPLETED,2020-08-17,2022-01-19,2022-02-17,INTERVENTIONAL,PHASE2,4422.0,ACTUAL,RANDOMIZED,SEQUENTIAL,PREVENTION,QUADRUPLE,SARS-CoV-2 Infection|COVID-19,SARS-CoV-2 rS/Matrix-M1 Adjuvant|Placebo,OTHER|BIOLOGICAL,11,39,18 Years,84 Years,ALL,True,Novavax,INDUSTRY,1,14,South Africa,1.0,0,1,0,0,0,2.0,0,0,0,0,2,8.394573477868327,xlarge,0,1,1,0,0,1,1,0,0,0,1,1,0,0,50,1,0,1,0,2,1,2020-08-17,2022-01-19,520.0,2020.0,1,3,1
NCT00096499,SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel,"A Phase II Study of SB-715992 (NSC-727990, IND-70273) in Taxane-Resistant Androgen-Independent Metastatic Prostate Cancer",COMPLETED,2005-04,,2013-01-25,INTERVENTIONAL,PHASE2,40.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage IV Prostate Cancer,ispinesib|pharmacological study|laboratory biomarker analysis,DRUG|OTHER,1,3,18 Years,,MALE,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,3.713572066704308,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,4,1,1,0,0,3,1,,,,,0,2,0
NCT04623398,Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency),Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency): Pilot Study.,COMPLETED,2022-02-21,2024-08-26,2025-10-02,INTERVENTIONAL,PHASE3,22.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Autism Spectrum Disorder,Lithium Carbonate|Placebo,DRUG,1,10,7 Years,18 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.1354942159291497,small,1,1,0,1,0,0,0,0,0,1,1,1,1,1,11,1,1,0,0,2,1,2022-02-21,2024-08-26,917.0,2022.0,1,2,0
NCT04914598,A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions,"A Randomized, Controlled, Double-blind, Multi-center Phase Ⅲ Registration Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions",ACTIVE_NOT_RECRUITING,2021-07-28,2026-06,2026-01-02,INTERVENTIONAL,PHASE3,290.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Malignant Pleural Effusion,"ENDOSTAR，cisplatin|Placebo , cisplatin",DRUG,1,0,18 Years,,ALL,False,"Jiangsu Simcere Pharmaceutical Co., Ltd.",INDUSTRY,0,1,China,,0,0,1,0,0,3.0,0,0,0,0,1,5.673323267171493,large,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,2021-07-28,,,2021.0,1,1,0
NCT02565498,Preoperative vs Postoperative IMRT for Extremity/Truncal STS,Phase III Study of Preoperative vs Postoperative Intensity Modulated Radiation Therapy For Truncal/Extremity Soft Tissue Sarcoma,ACTIVE_NOT_RECRUITING,2016-06,2029-05,2024-02-20,INTERVENTIONAL,PHASE3,210.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Adult Soft Tissue Sarcoma,Preoperative intensity modulated radiation therapy|Postoperative intensity modulated radiation therapy,RADIATION,1,9,18 Years,,ALL,False,"Mount Sinai Hospital, Canada",OTHER,1,8,Canada|Belgium|United States,,0,0,1,0,0,3.0,1,0,0,0,1,5.351858133476067,large,0,1,0,1,0,1,1,1,1,0,1,0,1,1,10,1,0,0,0,2,1,,,,,0,3,1
NCT02311998,Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML,A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-Positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase,COMPLETED,2015-04-16,2022-03-23,2023-07-17,INTERVENTIONAL,PHASE1|PHASE2,22.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|CD22 Positive|Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive",Bosutinib|Inotuzumab Ozogamicin,DRUG|BIOLOGICAL,2,2,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,7,3.1354942159291497,small,1,1,0,1,0,1,0,0,1,0,0,0,1,1,4,1,1,1,0,2,1,2015-04-16,2022-03-23,2533.0,2015.0,1,3,1
NCT00040898,Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed,Sho-Saiko-To After Ablation for Non-Resectable Hepatocellular Carcinoma (HCC): A Phase II Trial With Historical Control,COMPLETED,2001-01,,2013-01-18,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Liver Cancer,Sho-saiko-to,DIETARY_SUPPLEMENT,0,0,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,,,,,0,0,0
NCT05215951,Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC,"The Efficacy and Safety of Osimertinib With Platinum Plus Pemetrexed Chemotherapy as First-line Treatment in Advanced Non-small Cell Lung Cancer Patients With Uncommon Epidermal Growth Factor Receptor Mutations: A phase2, Open Label, Single Arm, Multicenter, Exploratory Study",TERMINATED,2022-01-19,2023-03-09,2025-10-15,INTERVENTIONAL,PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lung Cancer,osimertinib,DRUG,1,8,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,6,China,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.6094379124341003,small,1,1,1,0,1,0,1,0,0,0,0,0,1,0,9,1,1,0,0,1,0,2022-01-19,2023-03-09,414.0,2022.0,1,1,0
NCT00402051,Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC),A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin in the First Line Therapy of Advanced NSCLC,COMPLETED,2006-11,2009-05,2010-02-17,INTERVENTIONAL,PHASE2,133.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non-Small-Cell Lung Cancer,Pemetrexed|Cisplatin|Carboplatin,DRUG,1,4,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,12,Germany,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.897839799950911,medium,0,1,1,0,1,0,1,0,0,1,1,0,1,1,5,1,1,0,0,3,1,,,,,0,1,0
NCT01163929,"A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer",A Phase II Neoadjuvant Study of RAD001 (Everolimus) in Combination With Paclitaxel and Trastuzumab For Operable HER2 Positive Breast Cancer,WITHDRAWN,2010-07,2012-03,2012-10-24,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,paclitaxel,DRUG,1,1,18 Years,65 Years,FEMALE,False,University of Kansas,OTHER,1,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,0,0,1,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT01708629,Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects,A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3,TERMINATED,2012-09,2015-10,2020-01-03,INTERVENTIONAL,PHASE3,1881.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Plaque Psoriasis,210 mg brodalumab|140 mg brodalumab|ustekinumab|placebo,DRUG,2,0,18 Years,75 Years,ALL,False,"Bausch Health Americas, Inc.",INDUSTRY,0,157,Russia|Australia|United States|Canada|Poland|Latvia|France|Hungary|Greece|Belgium|Italy,0.0,0,0,1,0,0,3.0,0,1,0,0,1,7.540090320145325,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,2,0,1,0,0,4,1,,,,,0,2,0
NCT06827002,Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults,Cissus Quadrangularis (CQR-300®) and Dichrostachys Glomerata (Dyglomera®) Extracts Increase GLP-1 Levels and Inhibit Dipeptidyl Phosphate-4 Activity in Healthy Overweight and Obese Adults,ACTIVE_NOT_RECRUITING,2023-02-12,2026-01,2025-10-14,INTERVENTIONAL,PHASE1|PHASE2,248.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Obesity and Overweight|Appetite Regulation,Dichrostachys glomerata|Cissus quadrangularia|Dextrin|Semaglutide (Rybelsus®),DRUG,7,1,18 Years,65 Years,ALL,False,University of Yaounde 1,OTHER,1,1,Cameroon,,1,1,0,0,1,1.5,0,0,0,0,2,5.517452896464707,large,0,1,0,1,0,1,0,0,0,0,1,1,1,1,8,1,1,0,0,4,1,2023-02-12,,,2023.0,1,4,1
NCT04459702,A Study of Combination Therapies to Treat COVID-19 Infection,"A Phase IIa Randomized, Controlled Study of Combination Therapies to Treat COVID-19 Infection",WITHDRAWN,2020-07,2021-12,2021-04-08,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,COVID|COVID-19|Corona Virus Infection|Coronavirus Infection|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere|Coronavirus-19|SARS-CoV 2|SARS Pneumonia,hydroxychloroquine|Azithromycin|Ritonavir|Lopinavir,DRUG,2,38,18 Years,65 Years,ALL,False,ProgenaBiome,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,8,0.0,,1,1,0,1,0,1,0,0,1,0,1,1,1,1,40,1,1,0,0,4,1,,,,,0,3,1
NCT06245902,An Acute Migraine Factorial Study,A Clinical Trial to Assess a Single Dose of Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine,COMPLETED,2017-02-18,2018-02-08,2024-02-07,INTERVENTIONAL,PHASE2,92.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Migraine With or Without Aura,Naltrexone and Acetaminophen|Naltrexone and Acetaminophen-High Dose|Naltrexone Alone (regular dose)|Acetaminophen Alone|Matching Placebo,DRUG,3,3,18 Years,,ALL,False,"Allodynic Therapeutics, Inc",INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,4.532599493153256,medium,1,1,1,0,0,0,0,0,1,0,1,1,1,1,6,1,1,0,0,5,1,2017-02-18,2018-02-08,355.0,2017.0,1,2,0
NCT00368602,Beta Blocker for Chronic Wound Healing,Beta Adrenergic Receptor Modulation of Burn Wound Healing,TERMINATED,2005-06,2007-06,2015-04-07,INTERVENTIONAL,PHASE2,40.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Ulcer|Burns,Timoptic|Placebo,DRUG|OTHER,1,1,18 Years,85 Years,ALL,True,"University of California, Davis",OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,3.713572066704308,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT01194453,Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer,"A Phase 2,Open-label Study of First Line Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced and Metastatic Non Small Cell Lung Cancer and Biomarker Study",COMPLETED,2009-11,2012-08,2016-06-16,INTERVENTIONAL,PHASE2,288.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non-small Cell Lung Cancer|Efficacy,"cisplatin, dexamethasone,vitamin B12, folic acid|cisplatin, gemcitabine",DRUG,1,1,18 Years,75 Years,ALL,False,Sun Yat-sen University,OTHER,0,1,China,1.0,0,1,0,0,0,2.0,1,0,0,0,2,5.666426688112432,large,0,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT01830153,RAD001 in Advanced Sarcoma,A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas,COMPLETED,2010-04,,2013-04-12,INTERVENTIONAL,PHASE2,41.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Soft Tissue Sarcomas|Bone Sarcomas,RAD001,DRUG,1,4,17 Years,,ALL,False,Asan Medical Center,OTHER,1,8,South Korea,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.7376696182833684,small,1,1,0,1,0,1,1,0,0,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,1,0
NCT01387737,Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus,"An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of TA-7284 in Subjects With Type 2 Diabetes Mellitus",COMPLETED,2011-05,2012-12,2026-01-08,INTERVENTIONAL,PHASE3,1299.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Type 2 Diabetes Mellitus,TA-7284-Low|TA-7284-High,DRUG,1,4,20 Years,,ALL,False,Tanabe Pharma Corporation,INDUSTRY,0,7,Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.170119543449628,xlarge,0,1,1,0,0,0,1,0,0,0,1,0,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT00365937,Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides,Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides,TERMINATED,2006-08,2013-12-13,2019-03-06,INTERVENTIONAL,PHASE1|PHASE2,19.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Melanoma,Immunological peptides and immunological adjuvants|HLA-A2 peptides|Montanide ISA51|IMP321,BIOLOGICAL,1,1,18 Years,,ALL,False,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,OTHER,1,1,Belgium,0.0,1,1,0,0,1,1.5,1,0,0,0,1,2.995732273553991,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,2,1,0,1,0,4,1,,2013-12-13,,,0,2,0
NCT00576537,Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors,"Phase ll Trial of Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Patients With Atypical or Malignant, Primary or Metastatic Brain Tumors of the Central Nervous System",COMPLETED,2001-03,2011-10,2019-05-03,INTERVENTIONAL,PHASE2,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Glioblastoma,Dendritic Cell Immunotherapy,BIOLOGICAL,1,0,,,ALL,False,Cedars-Sinai Medical Center,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,,,,,0,0,0
NCT02651272,Macitentan in Pulmonary Hypertension of Sickle Cell Disease,The Safety and Efficacy of Macitentan for Treatment of Pulmonary Hypertension in Sickle Cell Disease,TERMINATED,2015-07,2019-12-18,2020-12-08,INTERVENTIONAL,PHASE2,4.0,ACTUAL,,SINGLE_GROUP,OTHER,NONE,Pulmonary Hypertension|Sickle Cell Disease,macitentan,DRUG,1,11,18 Years,,ALL,False,Boston University,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,1,2,1.6094379124341003,small,1,1,0,1,0,1,0,0,1,0,0,0,0,0,12,1,1,0,0,1,0,,2019-12-18,,,0,2,0
NCT00000495,Prevention of Hypertension: A Randomized Trial,,COMPLETED,1978-12,,2014-11-24,INTERVENTIONAL,PHASE3,,,RANDOMIZED,PARALLEL,PREVENTION,,Cardiovascular Diseases|Heart Diseases|Hypertension|Vascular Diseases,"diet, reducing|diet, sodium-restricted|alcohol restriction|exercise",BEHAVIORAL,0,0,30 Years,44 Years,ALL,False,Northwestern University,OTHER,1,0,,1.0,0,0,1,0,0,3.0,0,0,0,1,4,0.0,,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,4,1,,,,,0,2,0
NCT03091595,E4/DRSP Ovarian Function Inhibition Study,"A Single-center, Randomized, Open-label, Two-arm Study to Evaluate the Ovarian Function Inhibition of a Monophasic Combined Oral Contraceptive (COC) Containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and a Monophasic COC Containing 20mcg Ethinylestradiol (EE)/3 mg DRSP (YAZ®), Administered Orally Once Daily in a 24/4 Day Regimen for Three Consecutive Cycles",COMPLETED,2017-02-07,2018-06-08,2023-05-03,INTERVENTIONAL,PHASE2,82.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Prevention of Pregnancy,15 mg E4/3 mg DRSP|20 mcg EE/3 mg DRSP,DRUG,2,16,18 Years,35 Years,FEMALE,True,Estetra,INDUSTRY,0,1,Netherlands,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.418840607796598,medium,1,1,1,0,0,0,0,0,0,0,1,0,0,1,18,1,1,0,0,2,1,2017-02-07,2018-06-08,486.0,2017.0,1,2,0
NCT02184975,Cold Knife Conization With and Without Lateral Hemostatic Sutures,Randomized Clinical Trial Comparing Cold Knife Conization of the Cervix With and Without Lateral Hemostatic Sutures,COMPLETED,2009-03,2013-10,2014-07-09,INTERVENTIONAL,PHASE2,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Cervical Intraepithelial Neoplasia|Cervix Neoplasms,Cold Knife Conization with stitches|Cold knife Conization without stitches,PROCEDURE,1,0,15 Years,80 Years,FEMALE,False,Barretos Cancer Hospital,OTHER,0,1,Brazil,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.61512051684126,medium,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,2,1,,,,,0,2,0
NCT04582539,To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma,"A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma",TERMINATED,2021-08-19,2024-08-15,2025-10-22,INTERVENTIONAL,PHASE1|PHASE2,22.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,Myelodysplastic Syndromes|Multiple Myeloma|Anemia,INCB000928,DRUG,5,18,18 Years,,ALL,False,Incyte Corporation,INDUSTRY,0,15,France|Italy|United States,0.0,1,1,0,0,1,1.5,1,0,0,0,3,3.1354942159291497,small,1,1,1,0,0,0,1,1,1,1,0,0,1,0,23,1,1,0,0,1,0,2021-08-19,2024-08-15,1092.0,2021.0,1,4,1
NCT01621477,T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,TERMINATED,2012-08,2015-12,2017-02-20,INTERVENTIONAL,PHASE2,34.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Acute Lymphoblastic Leukemia|Acute Myelocytic Leukemia|Chronic Myelocytic Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndrome|Hodgkin or Non-Hodgkin Lymphoma|Sarcoma, Myeloid",clofarabine|cytarabine|busulfan|Plerixafor|cyclophosphamide|antithymocyte globulin (rabbit)|stem cells|Tacrolimus|mycophenolate mofetil,DRUG|BIOLOGICAL,1,6,,21 Years,ALL,False,St. Jude Children's Research Hospital,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,7,3.5553480614894135,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,7,1,1,1,0,9,1,,,,,0,3,1
NCT00807612,QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer,A Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer,TERMINATED,2009-01,2010-08,2024-09-25,INTERVENTIONAL,PHASE1|PHASE2,15.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Advanced Squamous Non-Small Cell Lung Cancer,AMG 479|AMG 479|Carboplatin|AMG 479|Paclitaxel,DRUG|BIOLOGICAL,2,4,18 Years,,ALL,False,"NantCell, Inc.",INDUSTRY,0,25,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,2.772588722239781,small,1,1,1,0,0,0,1,0,1,0,0,0,1,1,6,1,1,1,0,5,1,,,,,0,3,1
NCT02834312,E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes),"A Multicentre Dose-Finding, Randomised, Double-Blind, Placebo-Controlled Study to Select the Daily Oral Dose of Estetrol (E4) for the Treatment of Vasomotor Symptoms in Post-Menopausal Women",COMPLETED,2016-05,2018-01-22,2024-11-18,INTERVENTIONAL,PHASE2,260.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hot Flushes,Estetrol|Placebo,DRUG,4,29,40 Years,65 Years,FEMALE,True,Donesta Bioscience,INDUSTRY,1,1,Belgium,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.564520407322694,large,0,1,1,0,0,1,0,0,0,0,1,1,1,1,33,1,1,0,0,2,1,,2018-01-22,,,0,2,0
NCT00661219,Depression Related Improvement With Vardenafil for Erectile Response,A Randomized Double-blind Multi-center Parallel Group Three Month Study to Compare the Tolerability and Efficacy of Flexible Dose Vardenafil Versus Placebo in Men With Depression and Erectile Dysfunction.,COMPLETED,2002-12,2003-11,2014-12-23,INTERVENTIONAL,PHASE3,280.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Erectile Dysfunction|Depression,"Levitra (Vardenafil, BAY38-9456)|Placebo",DRUG,1,9,18 Years,,MALE,False,Bayer,INDUSTRY,0,52,United States|Canada|France|Spain|Italy,1.0,0,0,1,0,0,3.0,0,0,1,0,2,5.638354669333745,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,10,1,1,0,0,2,1,,,,,0,4,1
NCT01684930,"Nitrites, Exercise, and Peripheral Arterial Disease","Increased Plasma Nitrite, Tissue Oxygenation and Functional Changes in PAD",COMPLETED,2012-06,2014-11,2017-08-29,INTERVENTIONAL,PHASE2,32.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Peripheral Arterial Disease,Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training,DRUG|OTHER,2,4,40 Years,75 Years,ALL,False,Duke University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4965075614664802,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT03181828,Manipulating the Gut Microbiome Study,Manipulating the Gut Microbiome Study,TERMINATED,2017-03-24,2018-06-05,2021-12-15,INTERVENTIONAL,PHASE1|PHASE2,4.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Urea Cycle Disorder,Acetohydroxamic Acid Oral Tablet|No treatment,DRUG|OTHER,1,1,18 Years,60 Years,ALL,True,Nicholas Ah Mew,OTHER,0,1,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,1,1.6094379124341003,small,1,1,0,1,0,0,0,0,1,0,1,0,1,0,2,1,1,0,0,2,1,2017-03-24,2018-06-05,438.0,2017.0,1,2,0
NCT03196765,"Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy","Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)",WITHDRAWN,2018-08,2020-12-01,2019-03-07,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,X-Linked Adrenoleukodystrophy,Sobetirome (NV1205),DRUG,1,1,4 Years,18 Years,MALE,False,"NeuroVia, Inc.",INDUSTRY,0,13,United Kingdom|Argentina|Chile|Russia|Ukraine|Australia|Colombia|France,0.0,1,1,0,0,1,1.5,0,0,0,0,1,0.0,,1,1,1,0,0,0,1,1,0,1,0,0,1,0,2,1,1,0,0,1,0,,2020-12-01,,,0,2,0
NCT01190267,"Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)","A 26-week, Multi-center, Open-label, Flexible Dose, Long-term Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia",COMPLETED,2010-09-28,2013-10-07,2024-05-22,INTERVENTIONAL,PHASE3,204.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Schizophrenia, Paranoid|Schizophrenia, Disorganized|Schizophrenia, Undifferentiated",asenapine,DRUG,2,0,12 Years,17 Years,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,1,0,3,5.3230099791384085,large,0,1,1,0,0,0,0,0,0,0,0,0,1,0,2,0,1,0,0,1,0,2010-09-28,2013-10-07,1105.0,2010.0,0,1,0
NCT03005067,To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold,"A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Subjects With Symptoms of Common Cold",COMPLETED,2016-12-29,2017-06-07,2018-06-19,INTERVENTIONAL,PHASE2,171.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Common Cold,Carbomer 980 (1146A)|Placebo,DRUG|OTHER,1,3,18 Years,75 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,24,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.147494476813453,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,4,1,1,0,0,2,1,2016-12-29,2017-06-07,160.0,2016.0,1,1,0
NCT02497300,Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease,Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease,COMPLETED,2015-03,2021-07,2022-12-21,INTERVENTIONAL,PHASE2,21.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Chronic Kidney Disease|Albuminuria,Spironolactone|Amiloride,DRUG,3,2,18 Years,65 Years,ALL,False,University of Alabama at Birmingham,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.091042453358316,small,1,1,0,1,0,1,0,0,1,0,1,1,1,0,5,1,1,0,0,2,1,,,,,0,2,0
NCT02250300,MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation,MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation,COMPLETED,2014-11-19,2020-10-06,2023-03-08,INTERVENTIONAL,PHASE1|PHASE2,68.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Allogeneic Hematopoietic Stem Cell Transplantation,MLN9708 (2.3 mg)|MLN9708 (4.0 mg)|MLN9708 (3.0 mg),DRUG,3,0,18 Years,,ALL,False,Mehdi Hamadani,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.23410650459726,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,1,3,0,1,0,0,3,1,2014-11-19,2020-10-06,2148.0,2014.0,0,2,0
NCT02861300,CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer,Phase I/II Study of CB-839 and Capecitabine in Patients With Advanced Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer,COMPLETED,2016-09-12,2023-01-10,2024-12-19,INTERVENTIONAL,PHASE1|PHASE2,50.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Colorectal Cancer|Colon Cancer|Rectal Cancer|Solid Tumor,CB-839|Capecitabine,DRUG,2,4,19 Years,,ALL,False,"David Bajor, MD",OTHER,0,2,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,4,3.9318256327243257,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,6,1,1,0,0,2,1,2016-09-12,2023-01-10,2311.0,2016.0,1,4,1
NCT03398200,Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma,HBO Effects on Blood Count Recovery and Post-transplant Outcomes Following High-dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma,COMPLETED,2018-05-10,2023-03-28,2025-02-07,INTERVENTIONAL,PHASE2,99.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Myeloma,Hyperbaric Oxygen Therapy|No Hyperbaric Oxygen Therapy,OTHER|BIOLOGICAL,1,5,18 Years,75 Years,ALL,False,Omar Aljitawi,OTHER,0,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.605170185988092,medium,1,1,0,1,0,0,1,0,1,0,1,0,1,1,6,1,0,1,0,2,1,2018-05-10,2023-03-28,1783.0,2018.0,1,2,0
NCT00000307,Naltrexone as Adjunct in Alcoholic Cocaine Dependent Patients - 4,Naltrexone as an Adjunct in Alcoholic Cocaine Dependent Patients,COMPLETED,2003-04,2007-04,2017-01-12,INTERVENTIONAL,PHASE2,0.0,,,,TREATMENT,,Alcohol-Related Disorders|Cocaine-Related Disorders,Naltrexone,DRUG,1,0,18 Years,50 Years,ALL,False,National Institute on Drug Abuse (NIDA),NIH,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,0.0,,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,1,0
NCT04279392,"Healthy Body, Healthy Bones After Bariatric Surgery Trial","Feasibility of Bisphosphonate Use on Sleeve Gastrectomy Associated Bone Loss: Healthy Body, Healthy Bones Trial",COMPLETED,2020-09-01,2022-12-30,2024-09-24,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Bariatric Surgery Candidate|Bone Loss|Bone Resorption,Zoledronic Acid 5 mg/Bag 100 ml Inj|Placebos,DRUG,1,4,19 Years,,ALL,True,University of Nebraska,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,3,2.3978952727983707,small,1,1,0,1,0,0,0,0,1,0,1,1,0,1,5,1,1,0,0,2,1,2020-09-01,2022-12-30,850.0,2020.0,1,3,1
NCT03831607,A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD,"A Phase 2, Open-label Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis",COMPLETED,2018-12-27,2019-11-26,2024-03-07,INTERVENTIONAL,PHASE2,67.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Hyperphosphatemia,KHK7791,DRUG,1,2,20 Years,79 Years,ALL,False,"Kyowa Kirin Co., Ltd.",INDUSTRY,0,1,Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.219507705176107,medium,1,1,1,0,0,0,0,0,0,0,0,0,1,0,3,1,1,0,0,1,0,2018-12-27,2019-11-26,334.0,2018.0,1,0,0
NCT00767507,Maintenance of Platelet Inhibition With Cangrelor,BRIDGE: Maintenance of Platelet inihiBition With cangRelor After dIscontinuation of ThienopyriDines in Patients Undergoing surGEry,COMPLETED,2008-10,2011-07,2014-04-04,INTERVENTIONAL,PHASE2,221.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Acute Coronary Syndrome (ACS),cangrelor|Placebo,DRUG|OTHER,2,4,18 Years,90 Years,ALL,False,The Medicines Company,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.402677381872279,large,0,1,1,0,0,0,0,0,1,0,1,1,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT00051792,Yoga for Treating Shortness of Breath in Chronic Obstructive Pulmonary Disease (COPD),Efficacy of Yoga for Self-Management of Dyspnea in COPD,COMPLETED,2003-01,2004-07,2006-08-18,INTERVENTIONAL,PHASE1|PHASE2,36.0,,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Pulmonary Disease, Chronic Obstructive|Lung Diseases, Obstructive|Pulmonary Emphysema|Chronic Bronchitis",yoga,BEHAVIORAL,0,0,40 Years,,ALL,False,National Center for Complementary and Integrative Health (NCCIH),NIH,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,4,3.6109179126442243,small,1,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,,,,,0,2,0
NCT00270192,Antenatal Educational Intervention for Improvement of Breastfeeding,The Effects Of Antenatal Breast Preparation On The Successful Initiation And Continuation Of Breastfeeding In Singaporean Mothers,COMPLETED,2002-05,2004-12,2006-10-24,INTERVENTIONAL,PHASE3,450.0,,RANDOMIZED,PARALLEL,ECT,SINGLE,Breastfeeding,individual lactation counseling and educational material|educational material alone|routine antenatal care without educational intervention,BEHAVIORAL,1,1,21 Years,55 Years,FEMALE,True,"National University Hospital, Singapore",OTHER,0,1,Singapore,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.111467339502679,large,0,0,0,1,0,0,0,0,0,0,1,0,0,1,2,1,0,0,0,3,1,,,,,0,1,0
NCT00762736,Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus,"A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS™) in Combination With TAK-536 in Subjects With Type II Diabetes",COMPLETED,2004-07,2005-10,2012-02-28,INTERVENTIONAL,PHASE2,704.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Diabetes Mellitus,Pioglitazone and azilsartan|Pioglitazone and azilsartan|Pioglitazone|Pioglitazone and azilsartan|Pioglitazone and azilsartan|Pioglitazone,DRUG,1,12,18 Years,,ALL,False,Takeda,INDUSTRY,0,78,Argentina|Chile|United States|Mexico|Peru,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.558197802812269,xlarge,0,1,1,0,1,0,1,1,1,0,1,1,1,1,13,1,1,0,0,6,1,,,,,0,3,1
NCT06511336,Alkaline Water and Salivary Bacterial Count,Evaluation of Alkaline Water Effect on Salivary Streptococcus Mutans in Children,ACTIVE_NOT_RECRUITING,2024-07-01,2024-08-15,2024-07-19,INTERVENTIONAL,PHASE3,60.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Dental Caries,Alkaline water (FLO water- Bottled drinking water- the Egyption Saudi Company for natural water- made in Egypt,DRUG,1,0,10 Years,12 Years,ALL,True,Pharos University in Alexandria,OTHER,0,1,Egypt,,0,0,1,0,0,3.0,0,0,0,0,1,4.110873864173311,medium,1,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,2024-07-01,2024-08-15,45.0,2024.0,1,0,0
NCT01620736,Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load,Phase II Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load,WITHDRAWN,2012-01,2014-12,2018-01-24,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Human T-cell Leukemia Virus Type 1 Infection,Raltegravir,DRUG,1,5,18 Years,,ALL,False,Washington University School of Medicine,OTHER,1,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,0,0,0,0,1,0,6,1,1,0,0,1,0,,,,,0,1,0
NCT00212836,Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817),"A Multicenter, Double-Blind, Flexible -Dose, 6-Month Trial Comparing the Efficacy Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia",COMPLETED,2005-04-21,2007-08-02,2024-08-15,INTERVENTIONAL,PHASE3,481.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Schizophrenia,asenapine|olanzapine,DRUG,1,4,18 Years,,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,1,0,1,6.1779441140506,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,2005-04-21,2007-08-02,833.0,2005.0,0,1,0
NCT04335136,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,COMPLETED,2020-04-30,2020-12-26,2021-08-02,INTERVENTIONAL,PHASE2,185.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,COVID-19,RhACE2 APN01|Physiological saline solution,DRUG,1,16,18 Years,80 Years,ALL,False,Apeiron Biologics,INDUSTRY,0,22,United Kingdom|Russia|Denmark|Austria|Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.225746673713202,medium,0,1,1,0,0,0,1,1,0,1,1,1,1,1,17,1,1,0,0,2,1,2020-04-30,2020-12-26,240.0,2020.0,1,3,1
NCT05021536,Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (ALS)",ACTIVE_NOT_RECRUITING,2021-10-28,2026-01-01,2024-08-14,INTERVENTIONAL,PHASE3,664.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Amyotrophic Lateral Sclerosis,Placebo|AMX0035,DRUG|OTHER,1,5,18 Years,,ALL,False,Amylyx Pharmaceuticals Inc.,INDUSTRY,0,69,United Kingdom|United States|Sweden|Ireland|Poland|Portugal|France|Spain|Germany|Netherlands|Belgium|Italy,,0,0,1,0,0,3.0,0,0,0,0,1,6.499787040655854,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,6,1,1,0,0,2,1,2021-10-28,2026-01-01,1526.0,2021.0,1,3,1
NCT00004911,Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction,A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy,COMPLETED,2000-01,2003-02,2012-06-06,INTERVENTIONAL,PHASE1|PHASE2,,,,,SUPPORTIVE_CARE,,"Colorectal Cancer|Constipation, Impaction, and Bowel Obstruction|Gastric Cancer|Gastrointestinal Carcinoid Tumor|Gastrointestinal Stromal Tumor|Quality of Life|Small Intestine Cancer",bowel obstruction management|quality-of-life assessment,PROCEDURE,0,0,18 Years,,ALL,False,Northwestern University,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,7,0.0,,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,2,1,,,,,0,3,1
NCT00228371,STIMEP : Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy,"Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy Associated With Dopaminergic Metabolism Deficit. A Randomized, Double Blind, Controlled Trial.",TERMINATED,2005-09,2010-03,2015-05-28,INTERVENTIONAL,PHASE2|PHASE3,4.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Epilepsy|Drug Resistant,Neurostimulation,DEVICE,1,3,18 Years,50 Years,ALL,False,"University Hospital, Grenoble",OTHER,1,3,France,0.0,0,1,1,0,1,2.5,0,0,1,0,2,1.6094379124341003,small,1,1,0,1,0,1,1,0,0,1,1,1,1,0,4,1,0,0,1,1,0,,,,,0,2,0
NCT01809964,Clinical Trial to Evaluate ANT-1401 in Crow's Feet,Clinical Trial to Evaluate ANT-1401 in Subjects With Lateral Canthal Lines,COMPLETED,2013-03,2013-10,2014-01-10,INTERVENTIONAL,PHASE2,109.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Lateral Canthal Lines|Crows Feet,ANT-1401|Vehicle,BIOLOGICAL,1,1,30 Years,60 Years,ALL,True,Anterios Inc.,INDUSTRY,0,7,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.700480365792417,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,2,1,0,1,0,2,1,,,,,0,2,0
NCT03519464,Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia,"A Phase 2, Open-Label Study to Assess the Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in Patients With Idiopathic CD4 T Cell Lymphocytopenia",ACTIVE_NOT_RECRUITING,2019-02-04,2026-12-31,2025-12-05,INTERVENTIONAL,PHASE2,54.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Idiopathic CD4 T Cell Lymphocytopenia,Gardasil 9,BIOLOGICAL,1,2,18 Years,70 Years,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,1,United States,,0,1,0,0,0,2.0,0,0,0,0,1,4.007333185232471,medium,1,1,0,1,0,0,0,0,1,0,0,0,0,0,3,1,0,1,0,1,0,2019-02-04,2026-12-31,2887.0,2019.0,1,0,0
NCT04642664,Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer,Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC): A Prospective Clinical Study,COMPLETED,2018-12-01,2021-01-01,2021-06-03,INTERVENTIONAL,PHASE2,22.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Biliary Tract Cancer|Cholangiocarcinoma|Biomarker|Hepatobiliary Neoplasm,Apatinib plus Camrelizumab,DRUG,2,2,18 Years,,ALL,False,Peking Union Medical College Hospital,OTHER,0,2,China,1.0,0,1,0,0,0,2.0,1,0,0,0,4,3.1354942159291497,small,1,1,0,1,0,0,1,0,0,0,0,0,1,0,4,1,1,0,0,1,0,2018-12-01,2021-01-01,762.0,2018.0,1,1,0
NCT06816264,A Study of HRS-5346 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events,"A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Oral HRS-5346 in Adult Patients at High Risk of Cardiovascular Events With Elevated Lipoprotein(a)",COMPLETED,2025-02-18,2025-09-29,2025-11-17,INTERVENTIONAL,PHASE2,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Treatment of Lipoprotein Disorder,HRS-5346|Placebo,DRUG,1,4,18 Years,,ALL,False,"Shandong Suncadia Medicine Co., Ltd.",INDUSTRY,0,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.795790545596741,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,2025-02-18,2025-09-29,223.0,2025.0,1,1,0
NCT02650609,Treatment of Chronic Subdural Hematoma by Corticosteroids,Treatment of Chronic Subdural Hematoma by Corticosteroids,COMPLETED,2016-06-24,2020-03-20,2020-06-09,INTERVENTIONAL,PHASE3,202.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Chronic Subdural Hematomas,Methylprednisolone|Placebo,DRUG,1,12,18 Years,,ALL,False,Rennes University Hospital,OTHER,0,17,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.313205979041787,large,0,1,0,1,0,0,1,0,0,1,1,1,1,1,13,1,1,0,0,2,1,2016-06-24,2020-03-20,1365.0,2016.0,1,2,0
NCT00023309,Lamivudine and Adefovir to Treat Chronic Hepatitis B,Combination of Lamivudine and Adefovir Dipivoxil for Treatment of Chronic Hepatitis B,COMPLETED,2001-08,2013-08,2016-09-23,INTERVENTIONAL,PHASE2,41.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,HBV (Hepatitis B Virus)|Hepatitis B|Hepatitis,Lamivudine and adefovir|Adefovir alone,DRUG,1,4,18 Years,,ALL,False,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,3.7376696182833684,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,5,1,1,0,0,2,1,,,,,0,2,0
NCT00294099,H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults,"A Phase I-II, Randomized, Controlled, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Given Alone or With Aluminum Hydroxide to Healthy Elderly Adults",COMPLETED,2006-03,2007-03,2013-06-03,INTERVENTIONAL,PHASE1|PHASE2,600.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Influenza,Aluminum hydroxide|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur),BIOLOGICAL,5,3,65 Years,,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,7,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,6.398594934535208,xlarge,0,1,0,1,0,0,1,0,1,0,1,1,0,1,8,1,0,1,0,2,1,,,,,0,3,1
NCT04720157,"An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC","An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)",ACTIVE_NOT_RECRUITING,2021-06-09,2027-02-11,2026-02-02,INTERVENTIONAL,PHASE3,1145.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Prostatic Neoplasms,177Lu-PSMA-617|68Ga-PSMA-11|ARDT|ADT,DRUG,1,16,18 Years,100 Years,MALE,False,Novartis Pharmaceuticals,INDUSTRY,2,166,Canada|Austria|China|Spain|Belgium|United States|Sweden|France|Czechia|Singapore|Germany|Netherlands|Poland|South Korea|United Kingdom|Denmark|Taiwan|Switzerland|Japan,,0,0,1,0,0,3.0,0,0,0,0,1,7.044032897274685,xlarge,0,1,1,0,1,1,1,1,1,1,1,0,1,1,17,1,1,0,0,4,1,2021-06-09,2027-02-11,2073.0,2021.0,1,3,1
NCT00297401,Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus,The Effect of Protein Kinase C Inhibition on Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus,COMPLETED,2006-03,2007-11,2016-08-29,INTERVENTIONAL,PHASE3,20.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Diabetes Mellitus, Type 1",ruboxistaurin|placebo,DRUG,3,1,18 Years,,ALL,False,"Chromaderm, Inc.",INDUSTRY,1,1,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.044522437723423,small,1,1,1,0,0,1,0,0,0,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00055601,Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer,A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and Gemcitabine/Paclitaxel/Cisplatin Adjuvant Chemotherapy,COMPLETED,2002-12,2018-05-14,2018-06-15,INTERVENTIONAL,PHASE2,97.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Bladder Cancer,cisplatin|fluorouracil|paclitaxel|radiation therapy|Gemcitabine|Radical cystectomy,DRUG|PROCEDURE|RADIATION,1,2,,120 Years,ALL,False,Radiation Therapy Oncology Group,NETWORK,3,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.584967478670572,medium,1,1,0,0,0,1,1,0,1,0,1,0,1,1,3,1,1,0,0,6,1,,2018-05-14,,,0,1,0
NCT03135912,Three-Arm Trial of Novel Treatment for Tinea Pedis,Three-Arm Trial of Novel Treatment for Tinea Pedis,COMPLETED,2017-01-03,2017-08-02,2017-10-06,INTERVENTIONAL,PHASE2,90.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Tinea Pedis,Experimental Drug SESC 01|Placebo|Terbinafine Hydrochloride,DRUG,1,4,18 Years,,ALL,False,South End Skin Care,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.51085950651685,medium,1,1,1,0,0,0,0,0,1,0,1,1,1,1,5,1,1,0,0,3,1,2017-01-03,2017-08-02,211.0,2017.0,1,1,0
NCT00163319,Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101),Comparison of Inhaled Ciclesonide (640 mcg/Day) and Fluticasone Propionate (1000 mcg/Day) in Patients With Moderate and Severe Persistent Asthma,COMPLETED,2004-11,2005-11,2016-12-02,INTERVENTIONAL,PHASE3,500.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Asthma,Ciclesonide,DRUG,1,23,18 Years,75 Years,ALL,False,AstraZeneca,INDUSTRY,0,89,United Kingdom|France|Spain|Switzerland|Netherlands|Belgium|Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.2166061010848646,large,0,0,1,0,1,0,1,1,0,1,1,1,1,1,24,1,1,0,0,1,0,,,,,0,2,0
NCT01681030,The Fibrin Pad Cardiovascular Study,"A Randomized, Controlled, Comparative Phase II Study Evaluating the Safety and Effectiveness of EVARREST™ Fibrin Sealant Patch as an Adjunct to Hemostasis During Cardiovascular Surgery",COMPLETED,2012-08-01,2013-09-03,2018-06-12,INTERVENTIONAL,PHASE2,42.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cardiovascular Disease,EVARREST™|Topical hemostat|Standard of Care,OTHER|BIOLOGICAL,1,4,18 Years,,ALL,False,"Ethicon, Inc.",INDUSTRY,0,6,United States,1.0,0,1,0,0,0,2.0,0,0,0,1,1,3.7612001156935624,small,1,1,1,0,0,0,1,0,1,0,1,0,1,1,5,1,0,1,0,3,1,2012-08-01,2013-09-03,398.0,2012.0,0,1,0
NCT00397930,Yoga in Treating Sleep Disturbance in Cancer Survivors,Yoga for Persistent Sleep Disturbance in Cancer Survivors,COMPLETED,2006-10,2013-06,2017-02-20,INTERVENTIONAL,PHASE2,410.0,ACTUAL,RANDOMIZED,FACTORIAL,SUPPORTIVE_CARE,NONE,Fatigue|Cancer|Sleep Disorders,Standard Care Control Condition|Yoga Intervention (YOCAS),PROCEDURE,1,0,21 Years,120 Years,ALL,False,Gary Morrow,OTHER,1,11,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,6.018593214496234,large,0,1,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,2,1,,,,,0,2,0
NCT00146328,Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects,A Long Term Open Label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV-1 Infected Subjects,COMPLETED,2001-04,,2014-03-06,INTERVENTIONAL,PHASE2|PHASE3,997.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,HIV Infections,Tipranavir,DRUG,24,2,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,233,United Kingdom|Argentina|Denmark|Australia|United States|Mexico|Canada|Brazil|Netherlands|Austria|Portugal|France|Spain|Switzerland|Germany|Greece|Belgium|Italy,1.0,0,1,1,0,1,2.5,0,0,0,0,1,6.905753276311464,xlarge,0,1,1,0,0,0,1,1,1,1,0,0,1,1,26,1,1,0,0,1,0,,,,,0,3,1
NCT00205465,Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765,"A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of VX-765 in Subjects With Chronic Plaque Psoriasis Requiring Systemic Therapy",COMPLETED,2004-12,2005-09,2007-12-05,INTERVENTIONAL,PHASE2,64.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Psoriasis,VX-765,DRUG,3,5,18 Years,70 Years,ALL,,Vertex Pharmaceuticals Incorporated,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.174387269895637,medium,1,0,1,0,0,0,0,0,0,0,1,1,1,1,8,1,1,0,0,1,0,,,,,0,1,0
NCT05870865,A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis,"A Randomized, Double-Blind, Vehicle-Controlled, Phase 2 Trial to Evaluate the Anti-pruritic Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN008 in Adults With Mild to Moderate Atopic Dermatitis",COMPLETED,2023-05-03,2023-12-28,2025-05-16,INTERVENTIONAL,PHASE2,144.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Dermatitis, Atopic|Pruritus",ASN008|ASN008 Matching Vehicle,DRUG|OTHER,1,4,18 Years,,ALL,False,"Formation Bio, Inc.",INDUSTRY,0,27,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.976733742420574,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,5,1,1,0,0,2,1,2023-05-03,2023-12-28,239.0,2023.0,1,2,0
NCT01703065,Cabozantinib in Men With Castration-Resistant Prostate Cancer,A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and the Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer,TERMINATED,2013-06-18,2015-09-18,2018-12-04,INTERVENTIONAL,PHASE2,9.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Adenocarcinoma of the Prostate|Castration-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer,Cabozantinib,DRUG,1,4,18 Years,,MALE,False,University of Washington,OTHER,2,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,5,2.302585092994046,small,1,1,0,1,0,1,0,0,1,0,0,0,1,1,5,1,1,0,0,1,0,2013-06-18,2015-09-18,822.0,2013.0,0,1,0
NCT02091167,Bilateral Prefrontal Modulation in Crack-cocaine Addiction,Prefrontal Modulation by Repetitive Bilateral Transcranial Direct Current Stimulation (tDCS) in Crack-cocaine Addicted Inpatients.,COMPLETED,2013-11,2018-07,2019-06-24,INTERVENTIONAL,PHASE2,33.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Drug Addiction|Executive Dysfunction,transcranial Direct Current Stimulation,DEVICE,2,0,18 Years,60 Years,ALL,True,Federal University of Espirito Santo,OTHER,3,1,Brazil,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.5263605246161616,small,1,1,0,1,0,1,0,0,0,0,1,1,1,1,2,0,0,0,1,1,0,,,,,0,1,0
NCT02187107,A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials,"An Open Label Trial of TMC114/Rtv in HIV-1 Infected Subjects Who Were Randomized in the Trials TMC114-C201, TMC114-C207 or in Sponsor Selected Phase I Trials",COMPLETED,2005-01,2009-03,2014-08-25,INTERVENTIONAL,PHASE2,52.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,HIV,TMC114|rtv,DRUG,1,2,18 Years,,ALL,False,"Tibotec Pharmaceuticals, Ireland",INDUSTRY,0,11,United Kingdom|Russia|Denmark|Australia|Austria|Germany|Poland|Belgium,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.970291913552122,medium,1,1,1,0,0,0,1,1,0,1,0,0,1,0,3,1,1,0,0,2,1,,,,,0,2,0
NCT02713607,Lipidome and Microbiome Profile of Acne,Lipidome and Microbiome Profile of Acne,ACTIVE_NOT_RECRUITING,2016-03,2027-01,2025-01-07,INTERVENTIONAL,PHASE1|PHASE2,30.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,HEALTH_SERVICES_RESEARCH,NONE,Acne Vulgaris,Doxycycline,DRUG,2,9,15 Years,,ALL,True,"University of California, Davis",OTHER,0,1,United States,,1,1,0,0,1,1.5,0,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,0,0,0,1,0,0,0,0,0,11,1,1,0,0,1,0,,,,,0,2,0
NCT04385407,Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients,Sofosbuvir in Combination With Ribavirin or Simeprevir: Real-life Study of Patients With Hepatitis C Genotype 4,COMPLETED,2015-04,2016-07,2020-05-12,INTERVENTIONAL,PHASE2,203.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Chronic Hepatitis C Virus Infection,Sofosbuvir + Simeprevir + Ribavirin,DRUG,2,2,18 Years,70 Years,ALL,False,Beni-Suef University,OTHER,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.318119993844216,large,0,1,0,1,0,0,0,0,0,0,1,0,1,1,4,1,1,0,0,1,0,,,,,0,0,0
NCT02392507,A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC,"A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)",COMPLETED,2015-10-12,2019-11-06,2020-11-19,INTERVENTIONAL,PHASE2,54.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Carcinoma, Non-Small Cell Lung Cancer (NSCLC)",Necitumumab|Nab-Paclitaxel|Carboplatin,DRUG,1,6,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.007333185232471,medium,1,1,1,0,1,1,0,0,1,0,0,0,1,0,7,1,1,0,0,3,1,2015-10-12,2019-11-06,1486.0,2015.0,1,2,0
NCT01349192,Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF),Early MRSA Therapy in CF - Culture Based vs. Observant Therapy (Treat or Observe) (Star-TOO - STaph Aureus Resistance - Treat or Observe),TERMINATED,2011-04,2015-05,2017-05-15,INTERVENTIONAL,PHASE2,47.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Cystic Fibrosis|Methicillin-resistant Staphylococcus Aureus,Rifampin|Trimethoprim/Sulfamethoxazole|Minocycline|Mupirocin|chlorhexidine gluconate oral rinse|2% Chlorhexidine solution wipes|Environmental Decontamination,DRUG|BEHAVIORAL,1,3,4 Years,45 Years,ALL,False,"University of North Carolina, Chapel Hill",OTHER,13,13,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,2,3.871201010907891,small,1,1,0,1,0,1,1,0,1,0,1,0,1,1,4,1,1,0,0,7,1,,,,,0,2,0
NCT03001011,Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China,"A Randomized, Double Blind, Parallel Group Study For Assessing The Efficacy And Safety Of Renvela® Tablets For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease Not On Dialysis Versus Placebo",COMPLETED,2017-06-07,2019-08-16,2022-03-25,INTERVENTIONAL,PHASE3,202.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hyperphosphatemia,Placebo|Sevelamer Carbonate (GZ419831),DRUG,1,13,18 Years,,ALL,False,Sanofi,INDUSTRY,0,38,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.313205979041787,large,0,1,1,0,1,0,1,0,0,0,1,1,1,1,14,1,1,0,0,2,1,2017-06-07,2019-08-16,800.0,2017.0,1,2,0
NCT00596011,Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia,"Phase II, Randomized, Double-blind, Multi-centered Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia (HGPIN) or Atypical Small Acinar Proliferation (ASAP)",COMPLETED,2007-11-14,2018-07-27,2019-10-04,INTERVENTIONAL,PHASE2,97.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Prostatic Hyperplasia,Polyphenon E|Placebo,DRUG,2,3,30 Years,80 Years,MALE,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,10,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.584967478670572,medium,1,1,0,1,0,1,1,0,1,0,1,1,0,1,5,1,1,0,0,2,1,2007-11-14,2018-07-27,3908.0,2007.0,0,1,0
NCT01554371,Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies,A Phase Ib/II Study of Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies,COMPLETED,2012-03-27,2019-12-31,2021-02-03,INTERVENTIONAL,PHASE1|PHASE2,44.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Malignant Solid Tumour|Breast Cancer Nos Metastatic Recurrent|Neuropathy,Eribulin|Cyclophosphamide,DRUG,2,4,18 Years,80 Years,ALL,False,"University of California, San Francisco",OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,3,3.8066624897703196,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,6,1,1,0,0,2,1,2012-03-27,2019-12-31,2835.0,2012.0,0,4,1
NCT03779334,A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,An Open-Label Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy,ACTIVE_NOT_RECRUITING,2019-08-07,2027-02-28,2026-01-26,INTERVENTIONAL,PHASE2,26.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Muscular Atrophy, Spinal",Risdiplam,DRUG,1,27,1 Day,6 Weeks,ALL,False,Hoffmann-La Roche,INDUSTRY,0,7,Russia|Australia|United States|Brazil|Taiwan|Poland|Belgium,,0,1,0,0,0,2.0,0,0,0,0,1,3.295836866004329,small,1,1,1,0,1,0,1,1,1,0,0,0,1,0,28,1,1,0,0,1,0,2019-08-07,2027-02-28,2762.0,2019.0,1,2,0
NCT01646034,High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer,High-dose Alkylating Chemotherapy in Oligo-metastatic Breast Cancer Harboring Homologous Recombination Deficiency,ACTIVE_NOT_RECRUITING,2014-09,2026-10,2022-10-12,INTERVENTIONAL,PHASE3,74.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,"carboplatin, thiotepa, and cyclophosphamide|chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)",DRUG,1,5,18 Years,,FEMALE,False,The Netherlands Cancer Institute,OTHER,0,1,Netherlands,,0,0,1,0,0,3.0,1,0,0,0,1,4.31748811353631,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT05167734,Practical Anemia Bundle for SusTained Blood Recovery,The Practical Anemia Bundle for SusTained Blood Recovery (PABST-BR) Clinical Trial,COMPLETED,2021-11-30,2024-11-26,2025-04-06,INTERVENTIONAL,PHASE2,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Anemia|Critical Illness,Iron Dextran|Erythropoietin (EPO),DRUG,1,16,18 Years,,ALL,False,Mayo Clinic,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.61512051684126,medium,0,1,0,1,0,1,0,0,1,0,1,0,1,1,17,1,1,0,0,2,1,2021-11-30,2024-11-26,1092.0,2021.0,1,3,1
NCT01041911,To Evaluate the Dose Response of 3 Doses of Euphorbia Prostrata in Patients With First and Second Degree Hemorrhoids,"Double-blind, Randomized, Placebo-controlled, Dose Response Study to Evaluate the Safety and Efficacy of Three Doses of Euphorbia Prostrata Dry Extract Tablets in Patients of Hemorrhoids",COMPLETED,2010-03,2010-11,2012-12-06,INTERVENTIONAL,PHASE2,102.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hemorrhoids,Euphorbia tablets|Euphorbia tablets|Euphorbia tablets|Placebo tablets,DRUG,1,1,18 Years,,ALL,False,Panacea Biotec Ltd,INDUSTRY,0,6,India,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.634728988229636,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,2,1,1,0,0,4,1,,,,,0,1,0
NCT00138671,A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD,"Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects With Type 1 or Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: A One-Year, Multicenter, Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial",TERMINATED,2003-01,2008-09,2010-02-02,INTERVENTIONAL,PHASE3,105.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetes Mellitus|Chronic Obstructive Pulmonary Disease,Subcutaneous Insulin|Inhaled Insulin,DRUG,2,21,30 Years,77 Years,ALL,False,Pfizer,INDUSTRY,0,88,United States|Canada|Brazil|Germany|Costa Rica,0.0,0,0,1,0,0,3.0,0,0,0,0,2,4.663439094112067,medium,0,1,1,0,1,0,1,1,1,1,1,0,1,1,23,1,1,0,0,2,1,,,,,0,4,1
NCT02389244,A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas,"A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas",ACTIVE_NOT_RECRUITING,2014-09,2026-03-11,2025-09-16,INTERVENTIONAL,PHASE2,163.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Ewing Sarcomas|Chondrosarcomas|Osteosarcomas|Chondroma|CIC-Rearranged Sarcoma,Regorafenib|Placebo,DRUG,1,11,10 Years,,ALL,False,UNICANCER,OTHER,0,19,France,,0,1,0,0,0,2.0,1,0,0,0,5,5.099866427824199,medium,0,1,0,1,0,0,1,0,0,1,1,1,1,1,12,1,1,0,0,2,1,,2026-03-11,,,0,3,1
NCT02434744,Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus",COMPLETED,2015-04,2016-03,2023-11-18,INTERVENTIONAL,PHASE2,121.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Type 2 Diabetes Mellitus,KD026|Placebo|Metformin,DRUG,1,11,18 Years,75 Years,ALL,False,Response Pharmaceuticals,INDUSTRY,0,10,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.804021044733257,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,12,1,1,0,0,3,1,,,,,0,2,0
NCT00486044,Evaluating Simvastatin's Potential Role in Therapy,Effect of Statins on Pathobiology of Alzheimer's Disease,COMPLETED,2005-02,2009-06,2019-03-05,INTERVENTIONAL,PHASE2,103.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Alzheimer Disease,Simvastatin|Placebo,DRUG,1,3,35 Years,69 Years,ALL,True,"University of Wisconsin, Madison",OTHER,7,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,4.6443908991413725,medium,0,1,0,1,0,1,0,0,1,0,1,1,0,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00001034,The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV,"A Randomized, Comparative, Placebo-Controlled Trial of the Safety and Efficacy of Oral Ganciclovir for Prophylaxis of Cytomegalovirus (CMV) Retinal and Gastrointestinal Mucosal Disease in HIV-Infected Individuals With Severe Immunosuppression",COMPLETED,,1995-08,2021-11-04,INTERVENTIONAL,PHASE2,850.0,,,PARALLEL,TREATMENT,,Cytomegalovirus Retinitis|HIV Infections|Gastrointestinal Diseases,Ganciclovir,DRUG,0,0,13 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,1,17,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,6.7464121285733745,xlarge,0,0,0,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,,,,,0,1,0
NCT00151034,"Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer","Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer",COMPLETED,2000-09,2007-10,2015-01-21,INTERVENTIONAL,PHASE2,33.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Urologic Neoplasms,Trastuzumab|Paclitaxel|Carboplatin|Gemcitabine,DRUG,1,0,18 Years,,ALL,False,University of Michigan Rogel Cancer Center,OTHER,1,11,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.5263605246161616,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,1,0,0,4,1,,,,,0,1,0
NCT00099164,Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS),A Randomized Trial of 17 Alpha-Hydroxyprogesterone Caproate for Prevention of Preterm Birth in Multifetal Gestation (STTARS),COMPLETED,2004-04,2007-09,2019-02-21,INTERVENTIONAL,PHASE3,795.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Preterm Birth|Pregnancy|Multifetal,17 alpha-hydroxyprogesterone caproate (17P),DRUG,1,27,,,FEMALE,True,The George Washington University Biostatistics Center,OTHER,1,14,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,3,6.679599185844383,xlarge,0,1,0,1,0,1,1,0,1,0,1,1,0,1,28,1,1,0,0,1,0,,,,,0,2,0
NCT00040209,JP-1730 to Treat Parkinson's Disease,Alpha-2 Adrenergic Antagonist Treatment of Parkinson's Disease,COMPLETED,2002-06,2005-07,2008-03-04,INTERVENTIONAL,PHASE2,30.0,,,,TREATMENT,,Parkinson Disease,JP 1730|IV Levodopa|IV Apomorphine,DRUG,0,0,,,ALL,False,National Institute of Neurological Disorders and Stroke (NINDS),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,3.4339872044851463,small,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,3,1,,,,,0,1,0
NCT02710409,A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older,"A Double-blind,Randomized,Positive-controlled, Non-inferiority Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Chinese Subjects Aged 3 Years and Older",COMPLETED,2016-01,2016-08,2016-09-01,INTERVENTIONAL,PHASE3,3664.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Influenza,Quadrivalent influenza vaccine|Trivalent influenza vaccine A|Trivalent influenza vaccine B,BIOLOGICAL,2,5,3 Years,,ALL,True,Jiangsu Province Centers for Disease Control and Prevention,NETWORK,1,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,8.206583614320753,xlarge,0,1,0,0,0,1,0,0,0,0,1,1,0,1,7,1,0,1,0,3,1,,,,,0,2,0
NCT04267809,Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection,Modulating Endoplasmic Reticulum Stress as a Prophylactic Approach Against Symptomatic Viral Infection,COMPLETED,2021-10-22,2023-07-31,2024-04-17,INTERVENTIONAL,PHASE2,32.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,DOUBLE,Endoplasmic Reticulum Stress|Viral Infection|Yellow Fever,Metformin Hydrochloride|Calcium and Vitamin D,DRUG,1,1,21 Years,40 Years,ALL,True,Singapore General Hospital,OTHER,1,1,Singapore,1.0,0,1,0,0,0,2.0,0,0,0,0,3,3.4965075614664802,small,1,1,0,1,0,1,0,0,0,0,1,1,0,1,2,1,1,0,0,2,1,2021-10-22,2023-07-31,647.0,2021.0,1,2,0
NCT00002399,A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients,"A Multicenter, Randomized, Double-Blind, Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Multiple Doses of SCH 56592 Versus Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients",COMPLETED,,,2005-06-24,INTERVENTIONAL,PHASE2,500.0,,,,TREATMENT,DOUBLE,"Candidiasis, Oral|HIV Infections",Posaconazole|Fluconazole,DRUG,0,0,18 Years,65 Years,ALL,False,Schering-Plough,INDUSTRY,0,53,Argentina|Chile|Dominican Republic|Mexico|United States|Venezuela|Canada|Guatemala|Thailand|France|South Africa|Honduras|Spain|Germany|Panama|Belgium|Israel|Ethiopia,1.0,0,1,0,0,0,2.0,0,0,0,0,2,6.2166061010848646,large,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,2,1,,,,,0,3,1
NCT00118209,Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma,Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas,COMPLETED,2005-05,2021-11-15,2021-11-17,INTERVENTIONAL,PHASE3,524.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Large B Cell Lymphoma,rituximab|cyclophosphamide|doxorubicin|vincristine|prednisone|etoposide|filgrastim|pegfilgrastim,DRUG|BIOLOGICAL,1,2,18 Years,,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,1,47,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.263398262591624,xlarge,0,1,0,1,0,1,1,0,1,0,1,0,1,1,3,1,1,1,0,8,1,,2021-11-15,,,0,1,0
NCT02076399,A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP),"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura",COMPLETED,2014-07-14,2016-04-21,2019-02-12,INTERVENTIONAL,PHASE3,76.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Immune Thrombocytopenic Purpura,Fostamatinib disodium|Placebo,DRUG,1,6,18 Years,,ALL,False,Rigel Pharmaceuticals,INDUSTRY,0,52,United Kingdom|Denmark|Australia|United States|Canada|Hungary|Netherlands|Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.343805421853684,medium,1,1,1,0,0,0,1,1,1,1,1,1,1,1,7,1,1,0,0,2,1,2014-07-14,2016-04-21,647.0,2014.0,0,3,1
NCT02696499,Treatment of Uremic Pruritus With PA101B,Treatment of Uremic Pruritus With Inhaled PA101B in Patients With End-Stage Renal Disease Requiring Hemodialysis,COMPLETED,2016-02,2016-12,2018-04-20,INTERVENTIONAL,PHASE2,70.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Uremic Pruritus,PA101B|Placebo,DRUG,1,4,18 Years,80 Years,ALL,False,Patara Pharma,INDUSTRY,0,13,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.2626798770413155,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,1,5,1,1,0,0,2,1,,,,,0,1,0
NCT03822832,A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated,"Phase IIa, Multicentre, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Treatment With BI 655130 in Adult Patients With Moderate to Severe Atopic Dermatitis",COMPLETED,2019-02-12,2020-07-22,2025-10-20,INTERVENTIONAL,PHASE2,51.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Dermatitis, Atopic",BI 655130|Placebo,DRUG,1,8,18 Years,75 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,23,Canada|Japan|United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.9512437185814275,medium,1,1,1,0,0,0,1,1,1,0,1,1,1,1,9,1,1,0,0,2,1,2019-02-12,2020-07-22,526.0,2019.0,1,3,1
NCT05815498,A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19,"A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283 Compared With mRNA-1273 in Participants Aged ≥12 Years for the Prevention of COVID-19",COMPLETED,2023-03-28,2025-04-12,2025-05-07,INTERVENTIONAL,PHASE3,14246.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,COVID-19,mRNA-1283.222|mRNA-1273.222|mRNA-1283.815|mRNA-1273.815,BIOLOGICAL,9,4,12 Years,,ALL,True,"ModernaTX, Inc.",INDUSTRY,0,230,United Kingdom|Canada|Japan|United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,9.564301637217232,,0,1,1,0,0,0,1,1,1,1,1,1,0,1,13,1,0,1,0,4,1,2023-03-28,2025-04-12,746.0,2023.0,1,3,1
NCT00632398,Multimedia Training for Family Caregivers in Use of Touch and Massage in Supportive Cancer Care,Couples and Cancer: Building Partner Efficacy in Caring,COMPLETED,2008-03,2009-09,2015-12-15,INTERVENTIONAL,PHASE2,228.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Cancer,"Attention control (reading)|Touch, Caring and Cancer DVD program",BEHAVIORAL,7,2,21 Years,120 Years,ALL,False,"Collinge and Associates, Inc.",OTHER,1,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.43372200355424,large,0,1,0,1,0,1,1,0,1,0,1,0,0,1,9,1,0,0,0,2,1,,,,,0,2,0
NCT02942498,Clinical Trial for Asses the Safety and Efficacy of Vitamin C and Vitamin E in Combination Versus Placebo for Treating Cognitive and Behavior Disorder in Children With Fragile X Syndrome,"Clinical Trials Phase III, Double Blind, Crossover to Asses the Safety and Efficacy of Vitamin C and Vitamin E in Combination Versus Placebo for Treating Cognitive and Behavior Disorder in Children With Fragile X Syndrome",COMPLETED,2016-07,2018-10-31,2022-07-22,INTERVENTIONAL,PHASE3,34.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,X Fragile Syndrome,Vitamin C 10mg/Kg Vitamin E 10 mg/Kg|Placebo,DRUG,7,4,1 Year,8 Years,ALL,False,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud,OTHER,1,1,Spain,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.5553480614894135,small,1,1,0,1,0,1,0,0,0,1,1,1,1,1,11,1,1,0,0,2,1,,2018-10-31,,,0,2,0
NCT05012098,Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).,Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).,COMPLETED,2022-06-21,2024-07-09,2025-08-08,INTERVENTIONAL,PHASE2,11.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Olfactory Neuroblastoma|Esthesioneuroblastoma|Neoplasm of the Nasal Cavity,Bintrafusp alfa/M7824|Ibuprofen|PET scan|CT scan|Tumor tissue biopsy|Brain MRI|Dotate scan|PET FDG scan|Nuclear bone scan|EKG,DRUG|PROCEDURE|DIAGNOSTIC_TEST,1,4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,3,2.4849066497880004,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,5,1,1,0,0,10,1,2022-06-21,2024-07-09,749.0,2022.0,1,2,0
NCT04939363,"A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;","A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome. GIVeRS Protocol: On Behalf of the Israeli CLL Study Group",COMPLETED,2021-08-08,2024-12-04,2024-12-10,INTERVENTIONAL,PHASE2,12.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Richter's Syndrome,Obinutuzumab with Ibrutinib and Venetoclax,COMBINATION_PRODUCT,2,3,18 Years,,ALL,False,Bnai Zion Medical Center,OTHER_GOV,1,4,Israel,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.5649493574615367,small,1,1,0,1,0,1,1,0,0,0,0,0,1,0,5,1,0,0,0,1,0,2021-08-08,2024-12-04,1214.0,2021.0,1,0,0
NCT05907122,A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma,"A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting",COMPLETED,2023-07-26,2025-10-31,2025-11-13,INTERVENTIONAL,PHASE3,256.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Melanoma,ABP 206|FDA-licensed Nivolumab|EU-authorized Nivolumab,DRUG,2,11,18 Years,99 Years,ALL,False,Amgen,INDUSTRY,0,76,Lithuania|Thailand|South Africa|Moldova|Argentina|Spain|Romania|Italy|Chile|United States|Vietnam|Georgia|South Korea|Netherlands|Croatia|Malaysia|Bosnia and Herzegovina|Brazil|Taiwan|Mexico|Japan|Serbia,1.0,0,0,1,0,0,3.0,1,0,0,0,1,5.54907608489522,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,13,1,1,0,0,3,1,2023-07-26,2025-10-31,828.0,2023.0,1,3,1
NCT02186951,Antibiotherapy During Therapeutic Hypothermia to Prevent Infectious Complications,Prevention of Early Ventilator-associated Pneumonia With Antibiotic Therapy in Patients Treated With Mild Therapeutic Hypothermia After Cardiac Arrest.,COMPLETED,2014-08-18,2017-09-14,2020-03-18,INTERVENTIONAL,PHASE3,197.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Ventilator-associated Pneumonia|Cardiac Arrests With Shockable Rhythm|Mild Therapeutic Hypothermia|Preventive Antibiotics,Amoxicillin - clavulanic acid|Placebo,DRUG,1,2,18 Years,,ALL,False,"University Hospital, Limoges",OTHER,0,16,France,1.0,0,0,1,0,0,3.0,0,0,0,1,4,5.288267030694535,medium,0,1,0,1,0,0,1,0,0,1,1,1,1,1,3,1,1,0,0,2,1,2014-08-18,2017-09-14,1123.0,2014.0,0,2,0
NCT04400929,Using GM-CSF as a Host Directed Therapeutic Against COVID-19,Using GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated Trial,COMPLETED,2020-06-02,2022-02-04,2022-05-10,INTERVENTIONAL,PHASE2,2.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"COVID|Sars-CoV2|ARDS, Human",Sargramostim|Normal Saline 0.9%,DRUG|OTHER,1,0,21 Years,80 Years,ALL,False,Singapore General Hospital,OTHER,0,1,Singapore,1.0,0,1,0,0,0,2.0,0,0,0,0,3,1.0986122886681098,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,2020-06-02,2022-02-04,612.0,2020.0,1,2,0
NCT05363631,Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab,Phase I/II Study of Seleno-L Methionine (SLM) in Sequential Combination With Fixed Doses and Schedules of Axitinib and Pembrolizumab (SAP) in Locally Advanced and Metastatic Clear Cell Renal Cell Carcinoma (ccRCC),ACTIVE_NOT_RECRUITING,2022-09-19,2026-12-31,2025-12-10,INTERVENTIONAL,PHASE1|PHASE2,55.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Clear Cell Renal Cell Carcinoma|Clear Cell Renal Cell Carcinoma Metastatic,Selenomethionine (SLM)|Axitinib|Pembrolizumab,DRUG,2,2,18 Years,,ALL,False,Mohammed Milhem,OTHER,1,1,United States,,1,1,0,0,1,1.5,1,0,0,0,2,4.02535169073515,medium,1,0,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,0,0,3,1,2022-09-19,2026-12-31,1564.0,2022.0,1,3,1
NCT04916002,A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer,"A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer",TERMINATED,2021-11-30,2024-10-31,2025-12-05,INTERVENTIONAL,PHASE2,77.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Merkel Cell Carcinoma|Cutaneous Squamous Cell Carcinoma|Basal Cell Carcinoma|Triple Negative Breast Cancer|Non-Small Cell Lung Cancer|Oropharynx Squamous Cell Carcinoma,vidutolimod|cemiplimab,DRUG,1,5,18 Years,,ALL,False,Regeneron Pharmaceuticals,INDUSTRY,0,24,Australia|United States,0.0,0,1,0,0,0,2.0,1,0,0,0,6,4.356708826689592,medium,1,1,1,0,0,0,1,1,1,0,0,0,1,1,6,1,1,0,0,2,1,2021-11-30,2024-10-31,1066.0,2021.0,1,4,1
NCT03761537,Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7,"A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre, Phase 3 Trial Investigating the Efficacy, Safety, and Tolerability of Tralokinumab Administered in Combination With Topical Corticosteroids to Adult Subjects With Severe Atopic Dermatitis",COMPLETED,2018-12-13,2020-09-28,2025-03-11,INTERVENTIONAL,PHASE3,277.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Atopic Dermatitis,Tralokinumab|Placebo,DRUG|OTHER,1,11,18 Years,,ALL,False,LEO Pharma,INDUSTRY,0,74,United Kingdom|France|Spain|Czechia|Germany|Poland|Belgium,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.627621113690637,large,0,1,1,0,0,0,1,1,0,1,1,1,1,1,12,1,1,0,0,2,1,2018-12-13,2020-09-28,655.0,2018.0,1,3,1
NCT03596645,A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis,"A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis",ACTIVE_NOT_RECRUITING,2018-10-29,2027-02-20,2026-02-02,INTERVENTIONAL,PHASE3,84.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Colitis, Ulcerative",Golimumab|Infliximab,DRUG,1,9,2 Years,17 Years,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,58,United States|Brazil|Poland|Taiwan|France|Spain|Italy|South Korea|Netherlands|Belgium|Israel,,0,0,1,0,0,3.0,0,1,0,0,1,4.442651256490317,medium,1,1,1,0,0,0,1,1,1,1,1,0,1,1,10,1,1,0,0,2,1,2018-10-29,2027-02-20,3036.0,2018.0,1,3,1
NCT03349645,Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee,An Open Label Extension Study to Assess the Safety of Long-Term Treatment With a 4 mL Intra-Articular Injection of Ampion in Adults With Pain Due to Severe Osteoarthritis of the Knee,TERMINATED,2017-12-08,2018-10-04,2022-10-03,INTERVENTIONAL,PHASE3,94.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Severe Osteoarthritis of the Knee,4 mL injection of AMPION™,BIOLOGICAL,1,0,40 Years,85 Years,ALL,False,Ampio Pharmaceuticals. Inc.,INDUSTRY,0,11,United States,0.0,0,0,1,0,0,3.0,0,1,0,0,1,4.553876891600541,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,2017-12-08,2018-10-04,300.0,2017.0,1,0,0
NCT02617745,Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid,Impact of the Platelet Level During Radiotherapy Associated With Temozolomide in Patients Treated for Glioblastoma,COMPLETED,2015-11-30,2024-06-05,2026-01-02,INTERVENTIONAL,PHASE2,244.0,ACTUAL,,SINGLE_GROUP,OTHER,NONE,Glioblastoma,Platelet level determination,OTHER,1,2,18 Years,,ALL,False,Centre Henri Becquerel,OTHER,0,1,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.501258210544727,large,0,1,0,1,0,0,0,0,0,1,0,0,0,0,3,1,0,0,0,1,0,2015-11-30,2024-06-05,3110.0,2015.0,1,0,0
NCT04318145,Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects,"A Multi-Center, Unblinded, Single-Arm Study to Evaluate Sex Differences in the Acute Effects of PL-3994 on Myocardial cGMP Enhancement and Hemodynamics in Heart Failure With Preserved Ejection Fraction",TERMINATED,2020-11-12,2023-12-08,2025-12-15,INTERVENTIONAL,PHASE2,15.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Heart Failure With Preserved Ejection Fraction,PL-3994 Aqueous Intravenous Solution Dose Ascention|PL-3994 Aqueous Intravenous Solution Single Dose,DRUG,2,6,21 Years,,ALL,False,"Palatin Technologies, Inc",INDUSTRY,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,1,1,2.772588722239781,small,1,1,1,0,0,0,0,0,1,0,0,0,1,0,8,1,1,0,0,2,1,2020-11-12,2023-12-08,1121.0,2020.0,1,2,0
NCT00126672,RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS,A Phase II Multi-Center Study of Rapamycin for Treating Kidney Angiomyolipomas in TSC or LAM Patients,COMPLETED,2005-12-20,2010-04,2022-04-25,INTERVENTIONAL,PHASE2,36.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Nonmalignant Neoplasm|Tuberous Sclerosis|Lymphangioleimyomatosis|Kidney Angiomyolipoma,Rapamycin,DRUG,1,2,3 Years,65 Years,ALL,False,Dana-Farber Cancer Institute,OTHER,3,7,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,4,3.6109179126442243,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,3,1,1,0,0,1,0,2005-12-20,,,2005.0,0,1,0
NCT00565253,Inhaled Nitric Oxide in Pulmonary Embolism,"Inhaled Nitric Oxide in Pulmonary Embolism, a Randomized, Double-Blind Placebo-Controlled Study",COMPLETED,2005-03,2009-12,2010-06-23,INTERVENTIONAL,PHASE2,30.0,ESTIMATED,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Pulmonary Embolism,Inhaled nitric oxide (NO),DRUG,1,1,18 Years,,ALL,False,Medical University of Vienna,OTHER,0,1,Austria,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4339872044851463,small,1,0,0,1,0,0,0,0,0,0,1,1,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT02271945,Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas,A Phase 1b/2 Open-label Study to Evaluate the Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapy in Subjects With Relapsed or Refractory Aggressive B-cell Lymphomas,COMPLETED,2014-12-01,2016-05-24,2018-03-12,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Relapsed/Refractory Aggressive B-cell Lymphomas,MEDI-551 12 mg/kg|MEDI0680 2.5 mg/kg|MEDI0680 10 mg/kg,DRUG,5,11,18 Years,99 Years,ALL,False,MedImmune LLC,INDUSTRY,0,6,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,2.3978952727983707,small,1,1,1,0,0,0,1,0,1,0,1,0,1,1,16,1,1,0,0,3,1,2014-12-01,2016-05-24,540.0,2014.0,0,3,1
NCT04321395,Vigabatrin and Insulin Sensitivity,The Effect of Vigabatrin on Insulin Sensitivity,COMPLETED,2021-08-23,2024-05-15,2025-01-14,INTERVENTIONAL,PHASE2,4.0,ACTUAL,,SINGLE_GROUP,OTHER,NONE,NAFLD|Obesity,Vigabatrin,DRUG,1,2,18 Years,60 Years,ALL,False,Washington University School of Medicine,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,1.6094379124341003,small,1,1,0,1,0,0,0,0,1,0,0,0,0,0,3,1,1,0,0,1,0,2021-08-23,2024-05-15,996.0,2021.0,1,1,0
NCT02072395,Gastric Plication and Banding,Treatment of Morbid Obesity With Gastric Plication and Gastric Banding,COMPLETED,2012-02,2016-06,2017-02-20,INTERVENTIONAL,PHASE2,17.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Morbid Obesity,Plication,PROCEDURE,2,0,18 Years,70 Years,ALL,False,Ohio State University,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.8903717578961645,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,0,0,0,0,1,0,,,,,0,0,0
NCT01080677,Caffeine/Propranolol Intervention for Acute Migraine,Randomized Double-Blind Study to Evaluate the Dose-Related Efficacy and Safety of Caffeine/Propranolol in the Treatment of Acute Migraine,COMPLETED,2007-01,2009-12,2017-02-24,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,DOUBLE,Migraine Disorders,caffeine/propranolol combination tablet|placebo,DRUG,1,3,18 Years,50 Years,ALL,True,Stanford University,OTHER,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,4.110873864173311,medium,1,1,0,1,0,0,0,0,1,0,1,1,1,0,4,1,1,0,0,2,1,,,,,0,1,0
NCT00589277,Message Framing for Telephone Quitline Callers,Promoting Tobacco and Cancer Control: Message Framing for Telephone Quitline Callers,COMPLETED,2007-08,2009-05,2021-08-26,INTERVENTIONAL,PHASE1|PHASE2,2032.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Smoking|Nicotine Dependence,Gain-Framed counseling & Gain-framed materials|Standard care counseling + standard materials,BEHAVIORAL,1,2,18 Years,,ALL,False,Yale University,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,2,7.617267813628347,xlarge,0,1,0,1,0,1,0,0,1,0,1,0,1,0,3,1,0,0,0,2,1,,,,,0,3,1
NCT05110001,Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction,Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction,COMPLETED,2022-08-03,2025-06-30,2026-01-30,INTERVENTIONAL,PHASE3,330.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acanthamoeba Keratitis|Fungal Keratitis,Moxifloxacin Ophthalmic|Chlorhexidine Gluconate|Natamycin|Rose Bengal|Placebo,DRUG|OTHER,1,2,18 Years,,ALL,False,"University of California, San Francisco",OTHER,4,2,Brazil|India,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.802118375377063,large,0,1,0,1,0,1,1,1,0,0,1,1,1,1,3,1,1,0,0,5,1,2022-08-03,2025-06-30,1062.0,2022.0,1,3,1
NCT01577212,Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy,Individualized Dose Escalation for Non-small Cell Lung Cancer (NSCLC) Using Volumetric Modulated Arc Therapy (VMAT),TERMINATED,2012-03,2014-09,2015-11-09,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Stage III Non-small Cell Lung Cancer|Individualized Radiation Dose Escalation,Individualized dose escalation,RADIATION,2,5,18 Years,85 Years,ALL,False,Radboud University Medical Center,OTHER,0,1,Netherlands,0.0,0,1,0,0,0,2.0,1,0,0,0,2,1.9459101490553132,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,7,1,0,0,0,1,0,,,,,0,2,0
NCT01126112,Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer,Phase II Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer,COMPLETED,2010-05,2014-07,2015-03-24,INTERVENTIONAL,PHASE2,33.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Colorectal Cancer,Panitumumab,BIOLOGICAL,1,12,70 Years,,ALL,False,Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD),OTHER,1,1,Spain,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.5263605246161616,small,1,1,0,1,0,1,0,0,0,1,0,0,1,0,13,1,0,1,0,1,0,,,,,0,1,0
NCT01200212,A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer,A Randomized Phase III Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer,TERMINATED,2009-07,2012-10,2013-05-22,INTERVENTIONAL,PHASE3,432.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,"Taxane, Avastin|Taxane, Avastin, Xeloda",DRUG,1,8,18 Years,,ALL,False,GBG Forschungs GmbH,OTHER,0,1,Germany,0.0,0,0,1,0,0,3.0,1,0,0,0,1,6.07073772800249,large,0,0,0,1,0,0,0,0,0,1,1,0,1,1,9,1,1,0,0,2,1,,,,,0,2,0
NCT04264819,Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration,"A One-year, Single-arm, Open-label, Multicenter Study Assessing the Effect of Brolucizumab on Disease Control in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration (SWIFT)",COMPLETED,2020-12-14,2023-05-10,2024-11-07,INTERVENTIONAL,PHASE3,295.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Neovascular Age-Related Macular Degeneration,RTH258/Brolucizumab,DRUG,1,10,50 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,51,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.69035945432406,large,0,1,1,0,1,0,1,0,0,1,0,0,1,0,11,1,1,0,0,1,0,2020-12-14,2023-05-10,877.0,2020.0,1,1,0
NCT00312728,A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT),A Phase II Trial of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous Non-Small Cell Lung Cancer,COMPLETED,2006-03,2009-06,2023-01-06,INTERVENTIONAL,PHASE2,115.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-Small Cell Lung Cancer|Brain Neoplasms,bevacizumab|First-Line Chemotherapy Agents|Second-Line Chemotherapy Agents,DRUG,1,5,18 Years,,ALL,False,"Genentech, Inc.",INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.7535901911063645,medium,0,1,1,0,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,3,1,,,,,0,3,1
NCT00003465,Temozolomide in Treating Patients With Anaplastic Oligodendroglioma,"Phase II Treatment of Adults With Newly Diagnosed, Progressive or Recurrent Primary Malignant Anaplastic Oligodendroglioma With Temodal",COMPLETED,1998-03,2001-02,2013-06-20,INTERVENTIONAL,PHASE2,60.0,ESTIMATED,,,TREATMENT,,Brain and Central Nervous System Tumors,temozolomide,DRUG,0,0,18 Years,,ALL,False,Duke University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.110873864173311,medium,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT00590967,A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy,A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy With Concurrent Weekly Cisplatin in Patients With Stage I-IVA Cervical Cancer Who Have FDG PET Positive Pelvic or Para-Aortic Lymph Nodes,TERMINATED,2003-05,2013-01,2016-08-29,INTERVENTIONAL,PHASE2,69.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Cervical Cancer,IMRT extended field external beam radiation therapy|Brachytherapy|Cisplatin,DRUG|RADIATION,3,1,18 Years,,FEMALE,False,Washington University School of Medicine,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,4.248495242049359,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,1,4,1,1,0,0,3,1,,,,,0,1,0
NCT06868667,"Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma",ACTIVE_NOT_RECRUITING,2021-07-28,2026-06-19,2025-05-09,INTERVENTIONAL,PHASE3,24.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,Belantamab mafodotin|Daratumumab|Bortezomib|Dexamethasone,DRUG,1,22,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,16,Japan,,0,0,1,0,0,3.0,1,0,0,0,1,3.2188758248682006,small,1,1,1,0,0,0,1,0,0,0,1,0,1,1,23,1,1,0,0,4,1,2021-07-28,2026-06-19,1787.0,2021.0,1,2,0
NCT04861207,Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes,Assessment of Tolerance and Effectiveness of Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes,ACTIVE_NOT_RECRUITING,2021-10-07,2027-12-31,2025-04-24,INTERVENTIONAL,PHASE2,40.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Acute Myeloid Leukemia Myelodysplastic Syndromes,Cladribine,DRUG,1,6,18 Years,60 Years,ALL,False,Maria Sklodowska-Curie National Research Institute of Oncology,OTHER,1,1,Poland,,0,1,0,0,0,2.0,1,0,0,0,1,3.713572066704308,small,1,0,0,1,0,1,0,0,0,0,0,0,1,0,7,1,1,0,0,1,0,2021-10-07,2027-12-31,2276.0,2021.0,1,1,0
NCT02802592,EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT),EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT),TERMINATED,2015-05,2017-02-27,2019-02-26,INTERVENTIONAL,PHASE1|PHASE2,4.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cardiac Surgery-CABG|Cardiac Valve Replacement,Epogen|Normal Saline,DRUG,1,3,18 Years,64 Years,ALL,False,Johns Hopkins University,OTHER,0,1,United States,0.0,1,1,0,0,1,1.5,0,0,0,1,2,1.6094379124341003,small,1,1,0,1,0,0,0,0,1,0,1,1,1,1,4,1,1,0,0,2,1,,2017-02-27,,,0,3,1
NCT00003392,High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer,Multiple Cycles of High Dose Chemotherapy Supported With Filgrastim and Peripheral Blood Progenitor Cells in Patients With Metastatic Breast Cancer,COMPLETED,1997-09,2003-01,2012-02-22,INTERVENTIONAL,PHASE2,61.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,filgrastim|carboplatin|cyclophosphamide|melphalan|paclitaxel|bone marrow ablation with stem cell support|peripheral blood stem cell transplantation,DRUG|PROCEDURE|BIOLOGICAL,0,0,18 Years,65 Years,ALL,False,UNC Lineberger Comprehensive Cancer Center,OTHER,1,14,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.127134385045092,medium,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,1,0,7,1,,,,,0,1,0
NCT03824236,"A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults","Efficacy, Immunogenicity and Safety Study Evaluating a Fractional (Fx) Booster Dose of GSK Biologicals' Candidate Malaria Vaccine (SB257049) in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults",COMPLETED,2019-02-05,2019-09-26,2020-08-14,INTERVENTIONAL,PHASE2,61.0,ACTUAL,NON_RANDOMIZED,PARALLEL,PREVENTION,NONE,Malaria,"RTS,S/AS01E (SB257049)",BIOLOGICAL,1,10,18 Years,55 Years,ALL,True,GlaxoSmithKline,INDUSTRY,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.127134385045092,medium,1,1,1,0,0,1,0,0,1,0,0,0,0,1,11,1,0,1,0,1,0,2019-02-05,2019-09-26,233.0,2019.0,1,1,0
NCT02573311,Actual Use Study of Tamsulosin in Men,"A 6-month OTC-simulated, Open Label, Uncontrolled Study of Tamsulosin 0.4 mg in Men",COMPLETED,2015-09-23,2016-08-01,2020-04-08,INTERVENTIONAL,PHASE3,1117.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Urological Manifestations,tamsulosin hydrochloride,DRUG,1,8,18 Years,,MALE,False,Boehringer Ingelheim,INDUSTRY,0,40,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.0192966537150445,xlarge,0,1,1,0,0,0,1,0,1,0,0,0,1,0,9,1,1,0,0,1,0,2015-09-23,2016-08-01,313.0,2015.0,1,1,0
NCT02773771,Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit,Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit (STROMA-ICU),WITHDRAWN,2017-01,2019-01,2021-05-05,INTERVENTIONAL,PHASE2|PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Muscle Atrophy,beta-hydroxy-beta-methylbutyrate|Placebo|Vital HP®,DIETARY_SUPPLEMENT,2,6,18 Years,,ALL,False,Massachusetts General Hospital,OTHER,0,0,,0.0,0,1,1,0,1,2.5,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,1,1,0,1,8,1,0,0,0,3,1,,,,,0,3,1
NCT05459571,Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma,"A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy of Axicabtagene Ciloleucel Concomitant With Prophylactic Steroids In Subjects With Relapsed Or Refractory Large B-Cell Lymphoma In The Outpatient Setting",COMPLETED,2022-08-09,2025-11-24,2026-02-02,INTERVENTIONAL,PHASE2,35.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Relapsed or Refractory Large B-cell Lymphoma,Axicabtagene Ciloleucel|Cyclophosphamide|Fludarabine|Dexamethasone,DRUG|BIOLOGICAL,1,25,18 Years,,ALL,False,"Kite, A Gilead Company",INDUSTRY,0,16,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.58351893845611,small,1,1,1,0,1,0,1,0,1,0,0,0,1,0,26,1,1,1,0,4,1,2022-08-09,2025-11-24,1203.0,2022.0,1,2,0
NCT03449134,A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027),"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN027)",COMPLETED,2018-03-14,2020-08-17,2021-06-16,INTERVENTIONAL,PHASE3,732.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Cough,Placebo|Gefapixant,DRUG,3,6,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,156,United Kingdom|Argentina|Turkey (Türkiye)|Ukraine|Denmark|United States|Canada|Poland|South Korea|Taiwan|France|Spain|Czechia|Hungary|Japan|Israel|Peru,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.597145701886651,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,9,1,1,0,0,2,1,2018-03-14,2020-08-17,887.0,2018.0,1,3,1
NCT00138944,Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension,Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension,COMPLETED,2007-01,2008-07,2013-04-17,INTERVENTIONAL,PHASE3,85.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Essential Hypertension,placebo|eplerenone,DRUG,1,0,18 Years,75 Years,ALL,False,University of Erlangen-Nürnberg Medical School,OTHER,0,1,Germany,1.0,0,0,1,0,0,3.0,0,0,0,1,1,4.454347296253507,medium,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT02875834,A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia,"A Phase 3 Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ZS, in Patients With Hyperkalemia-HARMONIZE Global",COMPLETED,2017-03-03,2018-02-14,2020-08-19,INTERVENTIONAL,PHASE3,267.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hyperkalemia,Sodium Zirconium Cyclosilicate (ZS) 10g|Sodium Zirconium Cyclosilicate (ZS) 5g|Sodium Zirconium Cyclosilicate (ZS) 10g|Placebo,DRUG,1,12,18 Years,90 Years,ALL,False,AstraZeneca,INDUSTRY,0,45,South Korea|Japan|Russia|Taiwan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.5909869805108565,large,0,1,1,0,1,0,1,1,0,0,1,1,1,1,13,1,1,0,0,4,1,2017-03-03,2018-02-14,348.0,2017.0,1,3,1
NCT00231244,Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in a Compassionate Use Registry (SECURE),Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in a Compassionate Use Registry,COMPLETED,2002-03,2008-11,2009-12-07,INTERVENTIONAL,PHASE3,252.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Coronary Artery Disease,CYPHER Sirolimus-Eluting Coronary Stent,DEVICE,1,0,18 Years,,ALL,False,Cordis US Corp.,INDUSTRY,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.53338948872752,large,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,,,,,0,0,0
NCT06215144,Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD,A Phase 2/3 Randomized Double-Blind Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR in Pediatric Subjects With Attention-Deficit/Hyperactivity Disorder,TERMINATED,2024-01-25,2025-11-06,2026-01-15,INTERVENTIONAL,PHASE2|PHASE3,95.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Attention-Deficit/Hyperactivity Disorder (ADHD),NRCT-101SR,DRUG,1,0,13 Years,17 Years,ALL,False,"Neurocentria, Inc.",INDUSTRY,0,13,United States,0.0,0,1,1,0,1,2.5,0,0,0,0,1,4.564348191467836,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,1,0,2024-01-25,2025-11-06,651.0,2024.0,1,1,0
NCT05764122,A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well,"A Multicenter, Operationally Seamless, Double-Blind, Dose-Ranging, Placebo-Controlled, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Intravenous BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well",WITHDRAWN,2024-03-29,2025-07-07,2024-02-12,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Ischemic Stroke,BIIB131|Placebo,DRUG,3,17,18 Years,85 Years,ALL,False,Biogen,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,1,0,1,0,0,0,0,0,1,1,1,1,20,1,1,0,0,2,1,2024-03-29,2025-07-07,465.0,2024.0,1,2,0
NCT01813422,GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound,"A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization",COMPLETED,2013-04-18,2016-07-29,2019-02-20,INTERVENTIONAL,PHASE3,970.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Hypercholesterolemia,Evolocumab|Placebo,DRUG|BIOLOGICAL,1,3,18 Years,99 Years,ALL,False,Amgen,INDUSTRY,0,226,Canada|Ireland|South Africa|Hungary|Argentina|Russia|Australia|Spain|Iceland|Norway|Belgium|Italy|Israel|Chile|United States|Sweden|France|Czechia|Singapore|Germany|Greece|Netherlands|Poland|South Korea|United Kingdom|Denmark|Malaysia|Brazil|Philippines|Taiwan|Switzerland|Mexico,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.878326468291325,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,4,1,1,1,0,2,1,2013-04-18,2016-07-29,1198.0,2013.0,0,2,0
NCT04727151,TAC T-cells for the Treatment of HER2-positive Solid Tumors,"A Phase 1/2 Trial Investigating the Safety and Efficacy of Autologous TAC T Cell Monotherapy, and TAC T Cells in Combination With Pembrolizumab, in Relapsed HER2-Positive Solid Tumors",TERMINATED,2021-04-19,2024-03-25,2025-06-08,INTERVENTIONAL,PHASE1|PHASE2,28.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,HER2 Positive Gastric Cancer|Metastatic HER2 Positive Gastroesophageal Junction Cancer,TAC01-HER2|TAC01-HER2 plus pembrolizumab,BIOLOGICAL,1,8,18 Years,,ALL,False,"Triumvira Immunologics, Inc.",INDUSTRY,1,11,Canada|United States,0.0,1,1,0,0,1,1.5,1,0,0,0,2,3.367295829986474,small,1,1,1,0,0,1,1,1,1,0,0,0,1,0,9,1,0,1,0,2,1,2021-04-19,2024-03-25,1071.0,2021.0,1,5,1
NCT01335529,Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin,"Pilot Study to Assess the Efficacy and Safety of Boceprevir, in Combination With Peg-Interferon Alfa and Ribavirin, in Patients With HCV/HIV Co-infection Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin",COMPLETED,2011-05,2014-05,2014-10-13,INTERVENTIONAL,PHASE2,69.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,HCV Coinfection|HIV-1 Infection,"Boceprevir, Peg-interferon alfa 2b and Ribavirin",DRUG,1,23,18 Years,,ALL,False,"ANRS, Emerging Infectious Diseases",OTHER_GOV,2,1,France,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.248495242049359,medium,1,1,0,1,0,1,0,0,0,1,0,0,1,0,24,1,1,0,0,1,0,,,,,0,2,0
NCT00395629,Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis,"A Phase I/II Open Label, Dose Escalation Trial and a Six Month Extension to Explore the Safety and Efficacy of ICL670 in Patients With Iron Overload Resulting From Hereditary Hemochromatosis.",COMPLETED,2006-08,2009-03,2011-05-30,INTERVENTIONAL,PHASE1|PHASE2,49.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Iron Overload|Hereditary Hemochromatosis,Deferasirox (ICL670),DRUG,1,1,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,18,Australia|United States|Canada|France|Germany|Italy,1.0,1,1,0,0,1,1.5,0,0,0,0,2,3.912023005428146,small,1,1,1,0,1,0,1,1,1,1,0,0,1,0,2,1,1,0,0,1,0,,,,,0,3,1
NCT00970502,"Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer","Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation",COMPLETED,2007-02,2010-11,2017-04-10,INTERVENTIONAL,PHASE1|PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cancer of the Pharynx|Cancer of the Larynx|Cancer of the Neck|Paranasal Sinus Neoplasms|Cancer of the Head,erlotinib + celecoxib,DRUG,1,3,18 Years,,ALL,False,Johnny Kao,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,5,2.772588722239781,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,2,0
NCT00003902,Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement,Phase I/II of Capecitabine and Vinorelbine in Elderly Patients (At Least 65 Years) With Metastatic Breast Cancer With or Without Bone Involvement,COMPLETED,1999-03,2005-09,2012-05-15,INTERVENTIONAL,PHASE1|PHASE2,110.0,ESTIMATED,,,TREATMENT,,Breast Cancer,capecitabine|vinorelbine tartrate,DRUG,3,2,65 Years,,FEMALE,False,Swiss Cancer Institute,OTHER,0,1,Switzerland,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.709530201312334,medium,0,0,0,1,0,0,0,0,0,0,0,0,1,0,5,1,1,0,0,2,1,,,,,0,2,0
NCT03434353,Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB),"A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects",TERMINATED,2018-02-28,2021-01-26,2022-04-04,INTERVENTIONAL,PHASE2,123.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Chronic Hepatitis B,Inarigivir Soproxil|TAF,DRUG,2,11,18 Years,70 Years,ALL,False,Gilead Sciences,INDUSTRY,1,13,South Korea|Hong Kong,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.820281565605037,medium,0,1,1,0,1,1,1,1,0,0,1,0,1,1,13,1,1,0,0,2,1,2018-02-28,2021-01-26,1063.0,2018.0,1,3,1
NCT04634253,A Study of LY3462817 in Participants With Rheumatoid Arthritis,A Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants With Moderately to Severely Active Rheumatoid Arthritis,COMPLETED,2021-01-04,2022-06-29,2023-07-12,INTERVENTIONAL,PHASE2,98.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Rheumatoid Arthritis,Placebo|LY3462817,DRUG,1,7,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,26,United Kingdom|Mexico|United States|Puerto Rico|Czechia|Hungary|Poland,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.59511985013459,medium,1,1,1,0,1,0,1,1,1,1,1,1,1,1,8,1,1,0,0,2,1,2021-01-04,2022-06-29,541.0,2021.0,1,3,1
NCT00372437,A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine,A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine,COMPLETED,2006-09,2008-12,2015-07-01,INTERVENTIONAL,PHASE1|PHASE2,47.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Tumors,MGCD0103|Gemcitabine,DRUG,2,2,18 Years,,ALL,False,Mirati Therapeutics Inc.,INDUSTRY,0,8,Canada|United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.871201010907891,small,1,1,1,0,0,0,1,1,1,0,0,0,1,0,4,1,1,0,0,2,1,,,,,0,3,1
NCT00896337,EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries,A Boston Scientific Trial of the EPIC™ Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries,COMPLETED,2009-05,2013-12,2015-05-07,INTERVENTIONAL,PHASE3,125.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Iliac Artery Stenosis,Epic™ Nitinol Stent System|Anti-platelet therapy|Anti-coagulation therapy,DRUG|DEVICE,1,63,18 Years,,ALL,False,Boston Scientific Corporation,INDUSTRY,0,28,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.836281906951478,medium,0,1,1,0,0,0,1,0,1,0,0,0,1,0,64,1,1,0,1,3,1,,,,,0,2,0
NCT01528345,"Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer","A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy",TERMINATED,2012-04,2015-04,2016-07-11,INTERVENTIONAL,PHASE2,97.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Metastatic Breast Cancer,Dovitinib|Fulvestrant|Dovitinib Placebo,DRUG,1,5,18 Years,,FEMALE,False,Novartis Pharmaceuticals,INDUSTRY,0,67,Argentina|Russia|United States|Brazil|Poland|Austria|Taiwan|France|South Africa|Spain|Hungary|Netherlands|Belgium|Italy|Peru,0.0,0,1,0,0,0,2.0,1,0,0,0,1,4.584967478670572,medium,1,1,1,0,1,0,1,1,1,1,1,1,1,0,6,1,1,0,0,3,1,,,,,0,3,1
NCT00078195,Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies,"Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered With Omalizumab, an Anti-IgE Monoclonal Antibody (ITN019AD)",COMPLETED,2003-04,2005-05,2016-10-18,INTERVENTIONAL,PHASE2,168.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Hay Fever|Hypersensitivity|Allergy|Rhinitis,omalizumab|Placebo omalizumab|Ragweed rush immunotherapy (RIT)|Placebo rush immunotherapy (RIT)|Ragweed immunotherapy (IT)|Placebo immunotherapy (IT),BIOLOGICAL,1,7,18 Years,50 Years,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,1,3,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,4,5.1298987149230735,medium,0,0,0,1,0,1,1,0,1,0,1,1,1,1,8,1,0,1,0,6,1,,,,,0,3,1
NCT00020839,Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain,Temozolomide Versus Temozolomide + Whole Brain Radiation In Stage IV Melanoma Patients With Asymptomatic Brain Metastases,TERMINATED,2001-04,,2012-09-24,INTERVENTIONAL,PHASE3,23.0,ACTUAL,RANDOMIZED,,TREATMENT,,Melanoma (Skin)|Metastatic Cancer,temozolomide|radiation therapy,DRUG|RADIATION,0,0,18 Years,,ALL,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,0,33,United Kingdom|Austria|Portugal|France|Czechia|Switzerland|Germany|Netherlands|Belgium|Italy|Norway,0.0,0,0,1,0,0,3.0,1,0,0,0,2,3.1780538303479458,small,1,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,2,1,,,,,0,3,1
NCT03284177,A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients,"A Multicenter, Open-label Trial to Investigate the Safety of C13-CAC and the Relationship Among C13-CAC Breath Test, Gastric pH, and the Improvement of Symptoms in PPI Resistant GERD Patients",COMPLETED,2017-10-31,2018-12-04,2019-04-01,INTERVENTIONAL,PHASE2,55.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Gastroesophageal Reflux Disease,Calcium (13C)Carbonate|Gastric acid inhibitors|Gastric pH monitoring,DRUG|OTHER,1,1,20 Years,89 Years,ALL,False,"Otsuka Pharmaceutical Co., Ltd.",INDUSTRY,0,13,Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.02535169073515,medium,1,1,1,0,0,0,1,0,0,0,0,0,0,0,2,1,1,0,0,3,1,2017-10-31,2018-12-04,399.0,2017.0,1,1,0
NCT02727777,Phase II Study of TAK228 in Relapsed Lymphoma,Phase II Study of TAK228 in Relapsed Lymphoma,TERMINATED,2017-03-01,2018-07-10,2020-03-12,INTERVENTIONAL,PHASE1|PHASE2,4.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Lymphoma,TAK228|Blood Sugar Testing,DRUG|OTHER,1,1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,1,1.6094379124341003,small,1,1,0,1,0,1,0,0,1,0,0,0,1,1,2,1,1,0,0,2,1,2017-03-01,2018-07-10,496.0,2017.0,1,2,0
NCT03863977,Post-operative Analgesic Effects of Dexamethasone Added to Bupivacaine in Transversusabdominis Plane (TAP) Block,Comparison of Post-operative Analgesic Effects of Two Doses of Dexamethasone Added to Bupivacaine in Ultrasound-guided Transversusabdominis Plane (TAP) Block for Inguinal Hernia Repair,COMPLETED,2019-03-15,2020-01-01,2020-04-28,INTERVENTIONAL,PHASE2|PHASE3,90.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Postoperative Analgesia,Dexamethasone|Bupivacaine,DRUG,1,1,18 Years,60 Years,MALE,False,Assiut University,OTHER,0,1,Egypt,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.51085950651685,medium,1,1,0,1,0,0,0,0,0,0,1,1,0,1,2,1,1,0,0,2,1,2019-03-15,2020-01-01,292.0,2019.0,1,2,0
NCT01202877,PKC412 and 5-Azacytidine,A Combination of PKC412 and 5-Azacytidine for the Treatment of Patients With Refractory or Relapsed Acute Leukemia and Myelodysplastic Syndrome (MDS),COMPLETED,2011-03,2015-07,2018-10-16,INTERVENTIONAL,PHASE1|PHASE2,54.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Leukemia,5-azacytidine|PKC412,DRUG,2,0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,2,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,4.007333185232471,medium,1,1,0,1,0,1,0,0,1,0,0,0,1,0,2,0,1,0,0,2,1,,,,,0,2,0
NCT01063257,Clofarabine in High Risk Myelodysplastic Syndrome (MDS),A Phase I/II Multicenter Study of IV Clofarabine in Patients With High-Risk Myelodysplastic Syndrome Who Have Failed Therapy With Azacitidine: the NIDEVOL Study,COMPLETED,2010-04,2014-03,2014-03-19,INTERVENTIONAL,PHASE1|PHASE2,76.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Myelodysplastic Syndrome,Clofarabine,DRUG,1,5,18 Years,,ALL,False,Groupe Francophone des Myelodysplasies,OTHER,1,5,France,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.343805421853684,medium,1,1,0,1,0,1,1,0,0,1,0,0,1,1,6,1,1,0,0,1,0,,,,,0,2,0
NCT02650401,Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options,"A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options",ACTIVE_NOT_RECRUITING,2016-05-03,2026-06-30,2025-12-24,INTERVENTIONAL,PHASE1|PHASE2,69.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Solid Tumors|CNS Tumors,Entrectinib,DRUG,7,62,0 Years,18 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,26,United Kingdom|United States|Canada|France|Spain|China|Germany|Italy|Hong Kong,,1,1,0,0,1,1.5,1,0,0,0,2,4.248495242049359,medium,1,1,1,0,1,0,1,1,1,1,0,0,1,0,69,1,1,0,0,1,0,2016-05-03,2026-06-30,3710.0,2016.0,1,4,1
NCT03030612,A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS),"A Phase I/II, Open-label, Dose-Escalating Study With a Proof of Concept Cohort to Evaluate the Safety, Tolerability and Efficacy of ARGX-110 in Combination With Azacytidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)",COMPLETED,2016-12,2022-08,2023-08-09,INTERVENTIONAL,PHASE1|PHASE2,38.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,"Leukemia, Myeloid, Acute|Myelodysplastic Syndromes",ARGX-110|AZA,DRUG,2,28,18 Years,,ALL,False,"OncoVerity, Inc.",INDUSTRY,2,7,France|Switzerland,1.0,1,1,0,0,1,1.5,1,0,0,0,2,3.6635616461296463,small,1,1,1,0,0,1,1,1,0,1,0,0,1,0,30,1,1,0,0,2,1,,,,,0,5,1
NCT00099957,A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes,A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes,COMPLETED,2003-09,2005-06,2012-05-02,INTERVENTIONAL,PHASE2,38.0,,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Diabetes Mellitus, Type 2",vildagliptin,DRUG,1,5,30 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,1,Switzerland,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.6635616461296463,small,1,0,1,0,1,0,0,0,0,0,1,1,1,1,6,1,1,0,0,1,0,,,,,0,1,0
NCT05244057,A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients,"A Phase II of Randomized, Double-blind, Placebo-controlled, Multi-center Study of Hepalatide for Injection Combined With Pegylated Interferon and TAF as Finite Treatment in Chronic Hepatitis B Patients",COMPLETED,2022-08-23,2024-06-24,2024-07-15,INTERVENTIONAL,PHASE2,8.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Chronic Hepatitis B,Hepalatide|Placebo of Hepalatide|Tenofovir Alafenamide Tablets|Pegylated Interferon alfa 2a,DRUG,1,5,18 Years,60 Years,ALL,False,"Shanghai HEP Pharmaceutical Co., Ltd.",INDUSTRY,2,1,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.1972245773362196,small,1,1,1,0,0,1,0,0,0,0,1,1,1,1,6,1,1,0,0,4,1,2022-08-23,2024-06-24,671.0,2022.0,1,2,0
NCT00265057,Study of ADH-1 Given Intravenously to Patients With Solid Tumors,"Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Weekly in 3 Week Cycles by Intravenous Infusion in Patients With N-Cadherin Expressing, Incurable, Solid Tumors (Adherex Protocol Number AHX-01-004)",COMPLETED,2005-06,2008-01,2010-12-28,INTERVENTIONAL,PHASE1|PHASE2,,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Neoplasms,ADH -1 (Exherin™),DRUG,0,0,18 Years,,ALL,False,"Adherex Technologies, Inc.",INDUSTRY,0,3,Italy|Switzerland,1.0,1,1,0,0,1,1.5,0,0,0,0,1,0.0,,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,,,,,0,2,0
NCT00326157,PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation,Phase II Pilot Study on Safety of Administration of 3mg/kg/Day Three Times a Week Until Day 22 (21 Days After Transplantation Day) and 7 mg/kg Weekly From Day 29 to the End of Treatment (Day 50-8th Week) of AmBisome® in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem-cell Transplantation,COMPLETED,2006-06,2009-11,2010-02-12,INTERVENTIONAL,PHASE2,34.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,PREVENTION,NONE,Fungus Diseases,AmBisome,DRUG,4,14,18 Years,,ALL,False,Gilead Sciences,INDUSTRY,0,1,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.5553480614894135,small,1,1,1,0,1,0,0,0,0,1,0,0,0,0,18,1,1,0,0,1,0,,,,,0,1,0
NCT02547701,Clinical Trial on Onychomycosis With P-3058 Nail Solution in Pediatric Population,"Multicentre, Open Label Study to Assess the Tolerability of P-3058 Nail Solution in Paediatric Patients Affected by Mild-to-moderate Onychomycosis",COMPLETED,2014-08,2017-09,2018-03-08,INTERVENTIONAL,PHASE3,20.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Onychomycosis,P-3058,DRUG,1,0,2 Years,17 Years,ALL,False,Polichem S.A.,INDUSTRY,0,5,Latvia|Spain|Germany|Belgium|Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.044522437723423,small,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,1,0,,,,,0,1,0
NCT01882101,Comparison of PTNS and Biofeedback for Fecal Incontinence,Comparison of Posterior Tibial Nerve Stimulation and Biofeedback for Fecal Incontinence: Prospective Randomized Controlled Trial,WITHDRAWN,2014-01,2014-12,2017-04-27,INTERVENTIONAL,PHASE3,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Fecal Incontinence,Posterior tibial nerve stimulation|Biofeedback,PROCEDURE,1,4,20 Years,80 Years,ALL,False,Seoul National University Hospital,OTHER,5,6,South Korea,0.0,0,0,1,0,0,3.0,0,0,0,0,1,0.0,,1,1,0,1,0,1,1,0,0,0,1,0,1,1,5,1,0,0,0,2,1,,,,,0,1,0
NCT03122301,Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer,Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer: A Pilot Randomized Sham-Controlled Trial,TERMINATED,2017-06-01,2020-07-01,2022-08-09,INTERVENTIONAL,PHASE2,2.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,SINGLE,Hot Flashes|Hot Flushes|Vasomotor Symptoms,Stellate Ganglion Block injection with bupivicaine|Saline,DRUG,1,0,30 Years,70 Years,FEMALE,False,Northwestern University,OTHER,2,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,3,1.0986122886681098,small,1,1,0,1,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,2,1,2017-06-01,2020-07-01,1126.0,2017.0,1,2,0
NCT00886730,Primary Care Patients With Depression for Internet-Based Social Support,Feasibility Study of Methods of Referral Primary Care Patients With Depression for Internet-Based Social Support,COMPLETED,2008-10,2011-05,2012-12-17,INTERVENTIONAL,PHASE1|PHASE2,49.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,SINGLE,Depressive Disorder,Simple Card|Patient Centered Brochure|Physician's endorsement,BEHAVIORAL,1,1,18 Years,,ALL,False,University of Chicago,OTHER,1,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.912023005428146,small,1,1,0,1,0,1,0,0,1,0,1,0,0,1,2,1,0,0,0,3,1,,,,,0,2,0
NCT02581930,Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma,A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance,ACTIVE_NOT_RECRUITING,2016-08-17,2026-03-17,2025-09-08,INTERVENTIONAL,PHASE2,18.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Melanoma|Recurrent Cutaneous Melanoma|Stage IV Cutaneous Melanoma AJCC v6 and v7,Ibrutinib|Laboratory Biomarker Analysis|Pharmacogenomic Study|Pharmacological Study,DRUG|OTHER,1,2,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,13,United States,,0,1,0,0,0,2.0,1,0,0,0,3,2.9444389791664403,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,3,1,1,0,0,4,1,2016-08-17,2026-03-17,3499.0,2016.0,1,2,0
NCT05475665,Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients,"A Randomized, Double-blind, Multicenter, Placebo-control, Parallel Group Phase # Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients",COMPLETED,2022-07-14,2023-06-13,2023-08-18,INTERVENTIONAL,PHASE3,157.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Essential Hypertension,Irbesartan/Amlodipine|Irbesartan,DRUG,1,4,19 Years,,ALL,False,Handok Inc.,INDUSTRY,0,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,1,1,5.062595033026967,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,5,1,1,0,0,2,1,2022-07-14,2023-06-13,334.0,2022.0,1,1,0
NCT00502528,Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction,Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction,COMPLETED,2007-05,2012-08,2013-04-30,INTERVENTIONAL,PHASE2,57.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,ST-Elevation Myocardial Infarction,Placebo|BQ-123,DRUG,1,10,18 Years,,ALL,False,Medical University of Vienna,OTHER,0,1,Austria,1.0,0,1,0,0,0,2.0,0,0,0,1,1,4.060443010546419,medium,1,1,0,1,0,0,0,0,0,0,1,1,1,1,11,1,1,0,0,2,1,,,,,0,2,0
NCT01833065,Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation,"A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period",TERMINATED,2013-04,2014-04,2015-10-20,INTERVENTIONAL,PHASE3,314.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Chronic Idiopathic Constipation,Elobixibat 10 mg/day|Elobixibat 5 mg/day|Placebo,DRUG,1,7,18 Years,,ALL,False,Ferring Pharmaceuticals,INDUSTRY,0,97,United Kingdom|Mexico|United States|Sweden|Canada|Brazil|Hungary|Slovakia|South Africa|Czechia|Germany|Poland,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.752572638825633,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,8,1,1,0,0,3,1,,,,,0,3,1
NCT03181100,Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer,Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,ACTIVE_NOT_RECRUITING,2017-07-27,2027-07-31,2026-01-09,INTERVENTIONAL,PHASE2,50.0,ESTIMATED,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Thyroid Gland Carcinoma|Poorly Differentiated Thyroid Gland Carcinoma|Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Thyroid Gland Anaplastic Carcinoma|Unresectable Thyroid Gland Carcinoma,Atezolizumab|Bevacizumab|Cobimetinib|Nab-paclitaxel|Paclitaxel|Vemurafenib,DRUG|BIOLOGICAL,1,6,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,,0,1,0,0,0,2.0,1,0,0,0,7,3.9318256327243257,small,1,0,0,1,0,1,0,0,1,0,0,0,1,1,7,1,1,1,0,6,1,2017-07-27,2027-07-31,3656.0,2017.0,1,3,1
NCT04150900,1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck,1922GCCC: PHASE 2 STUDY OF PEMBROLIZUMAB AND BAVITUXIMAB FOR PROGRESSIVE RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK,ACTIVE_NOT_RECRUITING,2020-01-13,2027-01-01,2025-02-28,INTERVENTIONAL,PHASE2,7.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Squamous Cell Carcinoma,Bavituximab|Pembrolizumab,DRUG,1,4,18 Years,,ALL,False,"University of Maryland, Baltimore",OTHER,0,1,United States,,0,1,0,0,0,2.0,1,0,0,0,1,2.0794415416798357,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,5,1,1,0,0,2,1,2020-01-13,2027-01-01,2545.0,2020.0,1,1,0
NCT05958407,A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy,"A Phase 3b, Interventional, Adaptive, Clinical Trial to Evaluate the Efficacy and Safety of Tralokinumab 300 mg Every Second Week Monotherapy Compared With Placebo in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy",COMPLETED,2023-08-28,2025-09-22,2026-01-06,INTERVENTIONAL,PHASE3,235.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Atopic Dermatitis|Atopic Hand Eczema,Tralokinumab|Placebo,DRUG,1,21,18 Years,,ALL,False,LEO Pharma,INDUSTRY,0,69,United Kingdom|United States|Canada|Poland|France|Spain|Germany|Netherlands|Belgium|South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.4638318050256105,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,22,1,1,0,0,2,1,2023-08-28,2025-09-22,756.0,2023.0,1,4,1
NCT02738736,Clarifying Optimal Sodium Intake Project,Clarifying Optimal Sodium Intake Project- Objective 1,COMPLETED,2016-04,2020-08,2021-04-28,INTERVENTIONAL,PHASE2,269.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Blood Pressure|Hypertension|Kidney Disease|Cardiovascular Disease,Sodium Reduction,BEHAVIORAL,5,8,40 Years,,ALL,True,University College Hospital Galway,OTHER,2,1,Ireland,1.0,0,1,0,0,0,2.0,0,0,0,1,4,5.598421958998375,large,0,1,0,1,0,1,0,0,0,0,1,0,1,1,13,1,0,0,0,1,0,,,,,0,2,0
NCT02301936,Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease,An Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Subjects With Sickle Cell Disease,COMPLETED,2015-03-02,2016-04-18,2018-11-19,INTERVENTIONAL,PHASE2,10.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Hepatitis C Virus Infection,LDV/SOF,DRUG,2,7,18 Years,,ALL,False,Gilead Sciences,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.3978952727983707,small,1,1,1,0,1,0,0,0,1,0,0,0,1,1,9,1,1,0,0,1,0,2015-03-02,2016-04-18,413.0,2015.0,1,1,0
NCT01187407,A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment,"A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 mg to 18 mg Once Daily and LY2216684 Fixed-Dose 6 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment",COMPLETED,2011-03,2013-08,2018-04-24,INTERVENTIONAL,PHASE3,1480.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Major Depressive Disorder (MDD),LY2216684|Placebo|SSRI,DRUG,1,19,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,54,Croatia|Finland|United States|Puerto Rico|Slovakia|Czechia|Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.300472814267799,xlarge,0,1,1,0,1,0,1,1,1,0,1,1,1,1,20,1,1,0,0,3,1,,,,,0,3,1
NCT03899792,A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors,A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors,ACTIVE_NOT_RECRUITING,2019-06-13,2029-05,2026-01-06,INTERVENTIONAL,PHASE1|PHASE2,36.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Medullary Thyroid Cancer|Infantile Myofibromatosis|Infantile Fibrosarcoma|Papillary Thyroid Cancer|Soft Tissue Sarcoma,Selpercatinib,DRUG,2,23,6 Months,21 Years,ALL,False,Eli Lilly and Company,INDUSTRY,1,26,United Kingdom|Denmark|Australia|United States|Canada|South Korea|France|Spain|Germany|Japan|Italy,,1,1,0,0,1,1.5,1,0,0,0,5,3.6109179126442243,small,1,1,1,0,1,1,1,1,1,1,0,0,1,0,25,1,1,0,0,1,0,2019-06-13,,,2019.0,1,4,1
NCT01688492,Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer,A Phase 2 Study Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer,ACTIVE_NOT_RECRUITING,2012-09,2026-09,2025-08-12,INTERVENTIONAL,PHASE1|PHASE2,54.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,Ipilimumab,DRUG,2,3,18 Years,,MALE,False,Memorial Sloan Kettering Cancer Center,OTHER,3,3,United States,,1,1,0,0,1,1.5,1,0,0,0,1,4.007333185232471,medium,1,0,0,1,0,1,1,0,1,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,1,0
NCT00110136,St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer,A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer,TERMINATED,2006-03-16,2008-04-01,2021-09-29,INTERVENTIONAL,PHASE2,9.0,ACTUAL,,SINGLE_GROUP,SUPPORTIVE_CARE,NONE,Breast Cancer|Hot Flashes,St. John's Wort,DRUG,1,5,18 Years,,FEMALE,False,Wake Forest University Health Sciences,OTHER,1,19,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,2,2.302585092994046,small,1,1,0,1,0,1,1,0,1,0,0,0,0,0,6,1,1,0,0,1,0,2006-03-16,2008-04-01,747.0,2006.0,0,2,0
NCT00731211,Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma,A Phase II Trial of Pazopanib in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Sunitinib or Bevacizumab,COMPLETED,2008-09,2012-09,2015-05-20,INTERVENTIONAL,PHASE2,57.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Renal Cell Carcinoma,Pazopanib,DRUG,1,1,18 Years,,ALL,False,"SCRI Development Innovations, LLC",OTHER,1,17,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.060443010546419,medium,1,1,0,1,0,1,1,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT00100711,Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Refractory or Relapsed Disease,TERMINATED,2004-10,,2014-05-23,INTERVENTIONAL,PHASE2,27.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Motexafin Gadolinium,DRUG,1,3,18 Years,,ALL,False,Pharmacyclics LLC.,INDUSTRY,0,3,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,2,3.332204510175204,small,1,0,1,0,0,0,1,0,1,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,1,0
NCT00003151,Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma,A Phase II Clinical Trial of Anti-Helicobacter Pylori Treatment in Endoscopically Diagnosed Low-Grade Localized Gastric Lymphoma,COMPLETED,1997-09,,2012-07-02,INTERVENTIONAL,PHASE2,96.0,ESTIMATED,,,TREATMENT,,Lymphoma,bismuth subcitrate|amoxicillin|clarithromycin|metronidazole hydrochloride|omeprazole|tetracycline hydrochloride,DRUG|DIETARY_SUPPLEMENT,0,0,18 Years,,ALL,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,1,22,United Kingdom,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.574710978503383,medium,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,6,1,,,,,0,1,0
NCT05481151,"A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV","A Phase IIIb, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Polycythemia Vera (PV)",ACTIVE_NOT_RECRUITING,2022-10-26,2027-07-31,2025-08-13,INTERVENTIONAL,PHASE3,111.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Polycythemia Vera,P1101 (Ropeginterferon alfa-2b-njft)|Ropeginterferon alfa-2b-njft (P1101),DRUG,1,0,18 Years,,ALL,False,PharmaEssentia,INDUSTRY,0,23,Canada|United States,,0,0,1,0,0,3.0,0,0,0,0,1,4.718498871295094,medium,0,1,1,0,0,0,1,1,1,0,1,0,1,1,1,0,1,0,0,2,1,2022-10-26,2027-07-31,1739.0,2022.0,1,2,0
NCT02775851,Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery,A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM),ACTIVE_NOT_RECRUITING,2017-02-06,2026-05-15,2025-12-02,INTERVENTIONAL,PHASE2,57.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Desmoplastic Melanoma,Biopsy Procedure|Biospecimen Collection|Computed Tomography|Magnetic Resonance Elastography|Pembrolizumab|Positron Emission Tomography|Therapeutic Conventional Surgery,PROCEDURE|BIOLOGICAL,2,4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,281,United States,,0,1,0,0,0,2.0,1,0,0,0,1,4.060443010546419,medium,1,1,0,1,0,0,1,0,1,0,0,0,1,1,6,1,0,1,0,7,1,2017-02-06,2026-05-15,3385.0,2017.0,1,2,0
NCT00019929,Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer,Phase II Trial of Individualized Mutant p53 Peptide-Pulsed Cultured Autologous Dendritic Cells in the Adjuvant Treatment of Patients With Locally Advanced Non-Small Cell Lung Cancer After Standard Therapy,COMPLETED,2000-08,2005-12,2013-06-20,INTERVENTIONAL,PHASE2,,,,,TREATMENT,,Lung Cancer,mutant p53 peptide pulsed dendritic cell vaccine|adjuvant therapy,PROCEDURE|BIOLOGICAL,3,1,,,ALL,False,National Cancer Institute (NCI),NIH,0,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,0,0,0,1,0,0,1,0,1,0,0,0,1,0,4,1,0,1,0,2,1,,,,,0,1,0
NCT00070629,CPG 7909 Injection in Non-Small Cell Lung Cancer,"Promune™ (CPG 7909 Injection) In Combination With Chemotherapy In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer, A Randomized, Multi-Center, Controlled, Phase 2 Study",COMPLETED,2003-05,2007-07,2009-02-10,INTERVENTIONAL,PHASE2,116.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Carcinoma, Non-Small Cell Lung",CPG 7909|Chemotherapy|Chemotherapy,DRUG,2,4,18 Years,,ALL,False,Pfizer,INDUSTRY,0,24,Germany|Canada|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.762173934797756,medium,0,1,1,0,1,0,1,1,1,1,1,0,1,1,6,1,1,0,0,3,1,,,,,0,3,1
NCT06081829,A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation,"A Phase 2, Open-label, Multicenter Study of Orally Administered Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation",ACTIVE_NOT_RECRUITING,2023-10-10,2027-05,2025-12-09,INTERVENTIONAL,PHASE2,12.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cholangiocarcinoma Non-resectable|Cholangiocarcinoma Metastatic,Ivosidenib,DRUG,1,20,18 Years,,ALL,False,Servier,INDUSTRY,0,7,Japan,,0,1,0,0,0,2.0,1,0,0,0,2,2.5649493574615367,small,1,1,1,0,0,0,1,0,0,0,0,0,1,0,21,1,1,0,0,1,0,2023-10-10,,,2023.0,1,2,0
NCT01519102,Comparison of Closed-loop Operation After Morning Meal With and Without Carbohydrate Counting,"An Open-label, Randomized Two-way, Cross-over Study to Compare Meal-and-carbohydrate-announcement Strategy Versus Meal-announcement Strategy During Closed-loop Regulation of Glucose Levels in a Morning Meal in Adults With Type-1 Diabetes.",COMPLETED,2012-01,2012-11,2012-12-10,INTERVENTIONAL,PHASE2,12.0,,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Type-1 Diabetes,Dual Hormone closed-loop system,DEVICE,1,8,18 Years,65 Years,ALL,False,Institut de Recherches Cliniques de Montreal,OTHER,2,1,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.5649493574615367,small,1,0,0,1,0,1,0,0,0,0,1,0,1,0,9,1,0,0,1,1,0,,,,,0,1,0
NCT03996772,PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation,PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation (PRESTIGE-AF),COMPLETED,2019-06-03,2024-05-31,2025-01-13,INTERVENTIONAL,PHASE3,319.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Atrial Fibrillation|Intracerebral Hemorrhage,Apixaban Oral Tablet|Dabigatran|Edoxaban Tablets|Rivaroxaban,DRUG,2,13,18 Years,,ALL,False,Imperial College London,OTHER,14,64,United Kingdom|Austria|France|Spain|Germany|Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.768320995793772,large,0,1,0,1,0,1,1,1,0,1,1,0,0,1,15,1,1,0,0,4,1,2019-06-03,2024-05-31,1824.0,2019.0,1,4,1
NCT01954745,Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma,A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy,COMPLETED,2013-09,2016-06,2017-02-03,INTERVENTIONAL,PHASE2,19.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Bile Duct Cancer|Intrahepatic Cholangiocarcinoma|Cholangiocarcinoma of the Extrahepatic Bile Duct,Cabozantinib,DRUG,1,3,18 Years,,ALL,False,Massachusetts General Hospital,OTHER,1,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,2.995732273553991,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,1,0
NCT00628095,"Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate","A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF CE-224,535, AN ANTAGONIST OF THE P2X7 RECEPTOR, IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN SUBJECTS WHO ARE INADEQUATELY CONTROLLED ON METHOTREXATE",COMPLETED,2008-04-07,2009-02-04,2022-04-04,INTERVENTIONAL,PHASE2,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Arthritis, Rheumatoid","CE-224,535|Placebo",DRUG,1,12,18 Years,99 Years,ALL,False,Pfizer,INDUSTRY,0,27,Chile|United States|Spain|Czechia|Mexico|Poland|South Korea,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.61512051684126,medium,0,1,1,0,1,0,1,1,1,1,1,1,1,1,13,1,1,0,0,2,1,2008-04-07,2009-02-04,303.0,2008.0,0,3,1
NCT00089895,EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED),"Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS)",COMPLETED,2004-11-01,2008-11-01,2024-05-17,INTERVENTIONAL,PHASE3,9406.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Myocardial Ischemia|Acute Coronary Syndrome,Eptifibatide (Integrilin)|Placebo,DRUG,1,1,18 Years,,ALL,False,Organon and Co,INDUSTRY,1,0,,1.0,0,0,1,0,0,3.0,0,0,0,1,2,9.149209371971951,xlarge,0,1,1,0,0,1,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,2004-11-01,2008-11-01,1461.0,2004.0,0,2,0
NCT00687739,Prevention of Obesity in Women Via Estradiol Regulation,Estrogen Deficiency and Mechanisms of Fat Accumulation,COMPLETED,2008-05,2014-06,2025-04-01,INTERVENTIONAL,PHASE3,79.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Obesity,leuprolide acetate|Estradiol Transdermal|progressive resistance exercise training,DRUG|BEHAVIORAL,2,3,18 Years,49 Years,FEMALE,True,"University of Colorado, Denver",OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.382026634673881,medium,1,1,0,1,0,1,0,0,1,0,1,1,1,1,5,1,1,0,0,3,1,,,,,0,1,0
NCT02414139,"Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)","A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)",COMPLETED,2015-06-11,2023-05-16,2024-03-20,INTERVENTIONAL,PHASE2,373.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,"Carcinoma, Non-Small-Cell Lung",Capmatinib,DRUG,1,17,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,95,Austria|Argentina|Russia|Spain|Norway|Belgium|Italy|Israel|United States|Sweden|France|Lebanon|Singapore|South Korea|Netherlands|Germany|United Kingdom|Taiwan|Mexico|Japan,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.924255797414532,large,0,1,1,0,1,0,1,1,1,1,0,0,1,1,18,1,1,0,0,1,0,2015-06-11,2023-05-16,2896.0,2015.0,1,2,0
NCT04480775,Triamcinolone Versus Methylprednisolone in Transversus Abdominis Plane Block,Triamcinolone Versus Methylprednisolone in Ultrasound Guided Transversus Abdominis Plane Block in Major Open Abdominal Surgery,COMPLETED,2020-07-15,2020-12-15,2021-03-03,INTERVENTIONAL,PHASE2|PHASE3,84.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Major Abdominal Surgery,Triamcinolone|Methylprednisolone|bupivacaine,DRUG,1,1,20 Years,60 Years,ALL,False,ghada fouad,OTHER,0,1,Egypt,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.442651256490317,medium,1,1,0,1,0,0,0,0,0,0,1,1,0,1,2,1,1,0,0,3,1,2020-07-15,2020-12-15,153.0,2020.0,1,2,0
NCT00036075,Study Using CP-461 to Treat Advanced Prostate Cancer,,COMPLETED,2001-08,2005-12,2011-10-17,INTERVENTIONAL,PHASE2,25.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,CP-461,DRUG,0,0,18 Years,,MALE,False,Astellas Pharma Inc,INDUSTRY,2,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.258096538021482,small,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT00528775,Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages,A Phase II Study of Photodynamic Therapy (PDT) Using 2-[1-hexyloxyethyl]-2 Devinyl Pyropheophorbide-a (HPPH) for Treatment of Advanced Obstructing Endobronchial Lung Cancer,TERMINATED,2007-08,2014-03,2014-06-10,INTERVENTIONAL,PHASE2,6.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lung Cancer,HPPH|endoscopic procedure,DRUG|PROCEDURE,1,4,18 Years,,ALL,False,Roswell Park Cancer Institute,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,5,1,1,0,0,2,1,,,,,0,1,0
NCT00012012,Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer,A Two Part Phase I/II Study Of Extended Field External Irradiation And Intracavitary Brachytherapy Combined With Chemotherapy And Amifostine In Carcinoma Of The Cervix With Positive Para-Aortic Or High Common Iliac Lymph Nodes,COMPLETED,2001-08,2010-06,2015-01-07,INTERVENTIONAL,PHASE1|PHASE2,45.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Cervical Cancer|Radiation Toxicity,Amifostine trihydrate|Cisplatin|Intracavitary brachytherapy|External beam radiation therapy,DRUG|RADIATION,2,2,18 Years,,FEMALE,False,Radiation Therapy Oncology Group,NETWORK,1,17,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,2,3.828641396489095,small,1,1,0,0,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,4,1,,,,,0,3,1
NCT00434681,Paracetamol Oral Paediatric Suspension at 4.8% : Study of Acceptability and Safety.,"Multicentre, Open, Non-Comparative Study of the Acceptability and Safety of Paracetamol Oral Paediatric Suspension at 4.8%.",COMPLETED,2006-10,2007-04,2008-07-21,INTERVENTIONAL,PHASE3,48.0,,NON_RANDOMIZED,SINGLE_GROUP,,NONE,Fever|Pain,paracetamol 4.8% paediatric oral suspension,DRUG,2,1,1 Day,8 Years,ALL,False,Sanofi,INDUSTRY,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,2,3.8918202981106265,small,1,0,1,0,1,0,0,0,0,1,0,0,0,0,3,1,1,0,0,1,0,,,,,0,1,0
NCT01458119,Open-Label Phase 3 Long-Term Safety Study of Migalastat,An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease,TERMINATED,2011-10-14,2016-02-17,2018-10-02,INTERVENTIONAL,PHASE3,85.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Fabry Disease,migalastat hydrochloride,DRUG,1,1,16 Years,,ALL,False,Amicus Therapeutics,INDUSTRY,0,25,United Kingdom|Argentina|Turkey (Türkiye)|Denmark|Australia|United States|Canada|Brazil|France|Spain|Egypt|Belgium|Italy,0.0,0,0,1,0,0,3.0,0,0,0,0,1,4.454347296253507,medium,1,1,1,0,0,0,1,1,1,1,0,0,1,0,2,1,1,0,0,1,0,2011-10-14,2016-02-17,1587.0,2011.0,0,1,0
NCT00131430,An Eighteen Month Efficacy and Safety Study in Obese Patients (0364-020)(COMPLETED),"An 18-Month Study to Assess the Safety, Tolerability, and Efficacy of MK0364 in Obese Patients",COMPLETED,2005-08,2007-05,2016-06-07,INTERVENTIONAL,PHASE2|PHASE3,500.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Obesity and Obesity-related Medical Conditions,taranabant,DRUG,1,1,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,1,1,0,1,2.5,0,0,0,0,1,6.2166061010848646,large,0,1,1,0,1,0,0,0,0,0,1,1,1,1,2,1,1,0,0,1,0,,,,,0,1,0
NCT03707730,"A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease","A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Persons With Celiac Disease Age > 10 Years",COMPLETED,2019-10-29,2023-12-31,2024-03-06,INTERVENTIONAL,PHASE2,161.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Celiac Disease,AGY|placebo,OTHER|DIETARY_SUPPLEMENT,1,0,10 Years,65 Years,ALL,False,Igy Inc.,INDUSTRY,1,2,Canada,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.087596335232384,medium,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,2,1,2019-10-29,2023-12-31,1524.0,2019.0,1,1,0
NCT02231528,Interest of Ultrasound Coupled to a Guidance System (GPS) for Central Venous Catheters (CVC) Insertion.,Interest of Ultrasound Coupled to a Guidance System (GPS) for Central Venous Catheters (CVC) Insertion.,COMPLETED,2013-10,2014-09,2015-06-02,INTERVENTIONAL,PHASE3,100.0,ACTUAL,RANDOMIZED,PARALLEL,,SINGLE,Surgery,Use of ultrasound with active GPS|Use of ultrasound with inactive GPS,DEVICE,1,3,18 Years,,ALL,False,"University Hospital, Grenoble",OTHER,0,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.61512051684126,medium,0,1,0,1,0,0,0,0,0,1,1,0,0,1,4,1,0,0,1,2,1,,,,,0,1,0
NCT02760030,Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery,Phase II Trial of Primary Endocrine Therapy With Combination of Fulvestrant or an Aromatase Inhibitor and Palbociclib in Elderly Patients With Hormone Responsive Breast Cancer Who Have Inoperable Tumor Or Operable Tumor But Cannot Undergo Surgery Due to Frailty Or Who Refuse Surgery,COMPLETED,2017-02-16,2025-08-31,2025-12-19,INTERVENTIONAL,PHASE2,14.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Estrogen Receptor and/or Progesterone Receptor Positive|HER2/Neu Negative|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer,Fulvestrant|Laboratory Biomarker Analysis|Palbociclib|Questionnaire Administration|Aromatase Inhibitors,DRUG|OTHER,1,14,65 Years,,FEMALE,False,Ohio State University Comprehensive Cancer Center,OTHER,0,3,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,9,2.70805020110221,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,15,1,1,0,0,5,1,2017-02-16,2025-08-31,3118.0,2017.0,1,3,1
NCT05944965,Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea,Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea,COMPLETED,2023-12-01,2025-06-17,2025-12-17,INTERVENTIONAL,PHASE1|PHASE2,27.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,OSA,Atomoxetine 80 mg plus Oxybutynin 5 mg|Atomoxetine 80 MG|Placebo,DRUG,3,6,21 Years,70 Years,ALL,True,Brigham and Women's Hospital,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.332204510175204,small,1,1,0,1,0,0,0,0,1,0,1,1,1,0,9,1,1,0,0,3,1,2023-12-01,2025-06-17,564.0,2023.0,1,3,1
NCT01816165,"Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes","Role of Lipotoxicity in Insulin Resistance, Vascular, and Mitochondrial Dysfunction in Type 1 Diabetes",COMPLETED,2011-06,2015-06-24,2022-01-21,INTERVENTIONAL,PHASE3,28.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Type 1 Diabetes,Acipimox|Placebo,DRUG,4,13,25 Years,59 Years,ALL,True,"University of Colorado, Denver",OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.367295829986474,small,1,1,0,1,0,0,0,0,1,0,1,1,1,0,17,1,1,0,0,2,1,,2015-06-24,,,0,2,0
NCT00931567,Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing,Evaluation of the Efficiency of Autologous Platelet Gel (Platelet Rich Fibrin) Obtained From Own Patients' Blood Versus Vaselitulle in Dupuytren's Disease Postoperative Wound Healing,COMPLETED,2007-08,2010-02,2012-03-20,INTERVENTIONAL,PHASE2|PHASE3,80.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Dupuytren's Contracture,Autologous platelets gel|Vaselitulle,DEVICE|BIOLOGICAL,1,1,18 Years,,ALL,False,Centre Hospitalier Universitaire de Nice,OTHER,1,2,France,1.0,0,1,1,0,1,2.5,0,0,0,0,1,4.394449154672439,medium,1,1,0,1,0,1,1,0,0,1,1,0,1,1,2,1,0,1,1,2,1,,,,,0,2,0
NCT02395900,The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease,"The Effects of Flaxseed Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease",COMPLETED,2014-03,2015-01,2016-03-22,INTERVENTIONAL,PHASE2|PHASE3,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Non Alcoholic Steatohepatitis,Flaxseed|control,OTHER|DIETARY_SUPPLEMENT,2,1,18 Years,70 Years,ALL,False,National Nutrition and Food Technology Institute,OTHER,0,0,,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.9318256327243257,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,3,1,0,0,0,2,1,,,,,0,2,0
NCT00525707,Tezosentan in Acute Heart Failure,"Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Tezosentan in Patients With Acute Heart Failure.",COMPLETED,2003-04,2005-01,2018-07-10,INTERVENTIONAL,PHASE3,735.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Heart Failure|Acute Decompensation of Chronic Heart Failure|New Onset of Heart Failure,tezosentan,DRUG,1,1,18 Years,,ALL,False,Idorsia Pharmaceuticals Ltd.,INDUSTRY,0,35,United Kingdom|Denmark|United States|Poland|Austria|France|Switzerland|Germany|Greece|Israel,1.0,0,0,1,0,0,3.0,0,0,0,1,3,6.601230118728877,xlarge,0,1,1,0,0,0,1,1,1,1,1,1,1,1,2,1,1,0,0,1,0,,,,,0,2,0
NCT00989092,Darbepoetin Alfa and Anemia of Cancer,"A Randomized, Open-label, Comparative Study to Estimate the Effect of Darbepoetin Alfa on Hospital Days, Economic Outcomes, and Health-related Quality of Life in Subjects With Nonmyeloid Malignancies and Anemia of Cancer",TERMINATED,2002-05,2004-06,2014-01-29,INTERVENTIONAL,PHASE2,287.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Anemia|Anemia of Cancer|Cancer|Carcinoma|Neoplasms|Non-Myeloid Malignancies,darbepoetin alfa,BIOLOGICAL,3,11,18 Years,,ALL,False,Amgen,INDUSTRY,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,6,5.662960480135946,large,0,1,1,0,1,0,0,0,0,0,1,0,0,1,14,1,0,1,0,1,0,,,,,0,2,0
NCT00941811,Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment,"An Explorative, Single Center and Controlled Study to Analyze the Immune Escape Mechanisms of HPV-associated Lesions and to Evaluate the Efficiency and Mechanisms of Imiquimod Treatment of Vulvar Intraepithelial Neoplasias 2/3 (VIN) and Anogenital Warts",COMPLETED,2008-12,2010-05,2015-06-16,INTERVENTIONAL,PHASE2,5.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,HPV,Imiquimod,DRUG,1,1,18 Years,,FEMALE,True,Medical University of Vienna,OTHER,0,1,Austria,1.0,0,1,0,0,0,2.0,0,0,0,0,1,1.791759469228055,small,1,1,0,1,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT03442764,A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM),"A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction",COMPLETED,2018-03-30,2020-01-07,2022-08-09,INTERVENTIONAL,PHASE2,59.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Non-obstructive Hypertrophic Cardiomyopathy,mavacamten|Placebo,DRUG,2,0,18 Years,,ALL,False,"MyoKardia, Inc.",INDUSTRY,0,32,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.0943445622221,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,1,2,0,1,0,0,2,1,2018-03-30,2020-01-07,648.0,2018.0,1,1,0
NCT01055964,a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients,a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients,COMPLETED,2008-09,,2015-05-27,INTERVENTIONAL,PHASE3,80.0,ESTIMATED,RANDOMIZED,CROSSOVER,,NONE,Pharmacokinetics|Tacrolimus,Tacrolimus,DRUG,1,0,19 Years,65 Years,ALL,,Seoul National University Hospital,OTHER,0,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.394449154672439,medium,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,,,,,0,1,0
NCT02920164,Auricular Acupuncture for Exam Anxiety in Medical Students,Auricular Acupuncture for Exam Anxiety in Medical Students: A Randomized Crossover Investigation,COMPLETED,2012-04,2012-07,2016-09-30,INTERVENTIONAL,PHASE2,44.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Anxiety,Auricular acupuncture|Placebo acupuncture,DEVICE,1,2,19 Years,35 Years,ALL,True,University Medicine Greifswald,OTHER,0,1,Germany,1.0,0,1,0,0,0,2.0,0,0,1,0,1,3.8066624897703196,small,1,1,0,1,0,0,0,0,0,1,1,1,1,0,3,1,0,0,1,2,1,,,,,0,1,0
NCT01796964,Efficacy and Safety Study of ESBA1008 Versus EYLEA®,"A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA® in Subjects With Exudative Age-Related Macular Degeneration",COMPLETED,2013-03,2014-08,2016-02-09,INTERVENTIONAL,PHASE2,173.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Exudative Age-Related Macular Degeneration,ESBA1008 solution|Aflibercept,DRUG,1,8,50 Years,,ALL,False,Alcon Research,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.159055299214529,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,9,1,1,0,0,2,1,,,,,0,2,0
NCT01129544,"Gene Transfer for Severe Combined Immunodeficiency, X-linked (SCID-X1) Using a Self-inactivating (SIN) Gammaretroviral Vector",Multi-site Phase I/II Trial Evaluating the Treatment of SCID-X1 Patients With Retrovirus-mediated Gene Transfer,COMPLETED,2010-04,2023-03,2023-11-14,INTERVENTIONAL,PHASE1|PHASE2,8.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Severe Combined Immunodeficiency,Gene transfer,BIOLOGICAL,2,3,,,MALE,False,David Williams,OTHER,3,3,United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.1972245773362196,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,5,1,0,1,0,1,0,,,,,0,1,0
NCT02015234,12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients,"A 12-Month, Multicenter, Open-Label Extension Study (F202) to Evaluate the Long-term Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia",COMPLETED,2013-12,2015-08,2017-07-07,INTERVENTIONAL,PHASE3,158.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Primary Fibromyalgia,TNX-102 SL,DRUG,1,3,18 Years,65 Years,ALL,False,"Tonix Pharmaceuticals, Inc.",INDUSTRY,0,13,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.0689042022202315,medium,0,1,1,0,0,0,1,0,1,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT01001234,A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7),"A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents",COMPLETED,2009-11-30,2011-04-21,2024-05-07,INTERVENTIONAL,PHASE3,1382.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,"Migraine, Acute",rizatriptan|placebo|rizatriptan|placebo,DRUG,1,3,6 Years,17 Years,ALL,False,Organon and Co,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,1,0,1,7.232010331664759,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,1,1,4,1,1,0,0,4,1,2009-11-30,2011-04-21,507.0,2009.0,0,1,0
NCT00063934,Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer,A Phase 1/2 Study of Bcl-2 Antisense Oligonucleotide G3139 in Combination With Doxorubicin and Docetaxel in Metastatic and Locally Advanced Breast Cancer,TERMINATED,2003-05,2008-02,2019-03-05,INTERVENTIONAL,PHASE1|PHASE2,31.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Male Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer,oblimersen sodium|doxorubicin hydrochloride|docetaxel|filgrastim|pegfilgrastim|therapeutic conventional surgery|pharmacological study|laboratory biomarker analysis,DRUG|OTHER|PROCEDURE|BIOLOGICAL,2,2,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,1,United States,0.0,1,1,0,0,1,1.5,1,0,0,0,5,3.4657359027997265,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,4,1,1,1,0,8,1,,,,,0,3,1
NCT00664664,Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia,"A Randomized, Double-blind, Placebo-controlled Subjective Study to Assess the Efficacy of APD125 in Patients With Primary Insomnia Characterized by Difficulty Maintaining Sleep",COMPLETED,2008-04,2008-11,2020-12-24,INTERVENTIONAL,PHASE2,744.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Primary Insomnia,APD125|APD125|Placebo,DRUG,1,4,18 Years,65 Years,ALL,False,Arena Pharmaceuticals,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.61338421837956,xlarge,0,1,1,0,0,0,0,0,1,0,1,1,1,1,5,1,1,0,0,3,1,,,,,0,1,0
NCT01288664,Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis,,WITHDRAWN,2011-01,2012-12,2014-02-12,INTERVENTIONAL,PHASE3,0.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Lupus Nephritis,ADVAGRAF,DRUG,1,5,14 Years,65 Years,ALL,False,Sun Yat-sen University,OTHER,0,1,China,0.0,0,0,1,0,0,3.0,0,1,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,6,1,1,0,0,1,0,,,,,0,1,0
NCT01245764,GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046),Evaluation of Safety and Immunogenicity of GARDASIL™ in Healthy Females Between 9 and 26 Years of Age in SubSaharan Africa,COMPLETED,2011-03-21,2013-04-15,2018-11-14,INTERVENTIONAL,PHASE3,250.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Papillomavirus Infections,"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)|Placebo",BIOLOGICAL,7,4,9 Years,26 Years,FEMALE,True,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.5254529391317835,large,0,1,1,0,1,0,0,0,0,0,1,1,0,1,11,1,0,1,0,2,1,2011-03-21,2013-04-15,756.0,2011.0,0,2,0
NCT01774864,Efficacy and Safety Study of Udenafil to Treat Erectile Dysfunction,Phase 3 Study to Evaluate the Efficacy and Safety of Once-a-day Dosing of Udenafil in the Treatment of Erectile Dysfunction,COMPLETED,2011-04,2012-05,2013-01-24,INTERVENTIONAL,PHASE3,349.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Erectile Dysfunction,DA-8159 (Udenafil)|Placebo,DRUG,1,1,20 Years,,MALE,False,"Dong-A Pharmaceutical Co., Ltd.",INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.857933154483459,large,0,1,1,0,0,0,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT03003364,Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury,"A Phase I/IIa, Randomized, Double-blind, Single-dose, Placebo Controlled, Two-way Crossover Clinical Trial to Assess the Safety and to Obtain Efficacy Data in Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury",COMPLETED,2016-12-27,2020-02-11,2020-02-17,INTERVENTIONAL,PHASE1|PHASE2,10.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,"Spinal Cord Injury, Chronic",XCEL-UMC-BETA|Placebo,DRUG,1,14,18 Years,65 Years,ALL,False,Banc de Sang i Teixits,OTHER,3,1,Spain,1.0,1,1,0,0,1,1.5,0,0,0,0,1,2.3978952727983707,small,1,1,0,1,0,1,0,0,0,1,1,1,1,0,15,1,1,0,0,2,1,2016-12-27,2020-02-11,1141.0,2016.0,1,3,1
NCT04192266,Estrogen and Fear in PTSD,"A Randomized, Double-blind Placebo-controlled Multi-center Study of Identifying Neural Mechanisms of PTSD Symptom Reduction Induced by Combined Estrogen and Prolonged Exposure Therapy",COMPLETED,2020-06-24,2024-12-02,2026-01-09,INTERVENTIONAL,PHASE3,83.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,PTSD,Estradiol|Placebo oral tablet|Prolonged Exposure (PE) therapy,DRUG|BEHAVIORAL,4,5,18 Years,45 Years,FEMALE,False,"The University of Texas Health Science Center, Houston",OTHER,1,2,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.430816798843313,medium,1,1,0,1,0,1,1,0,1,0,1,1,1,1,9,1,1,0,0,3,1,2020-06-24,2024-12-02,1622.0,2020.0,1,2,0
NCT03727022,Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Bone Health of Multiple Injections of SM04690 Injected in the Target Knee of Moderately to Severely Symptomatic Osteoarthritis Subjects",COMPLETED,2018-11-28,2021-08-18,2026-01-12,INTERVENTIONAL,PHASE2,101.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Knee Osteoarthritis,Placebo|SM04690,DRUG,1,7,40 Years,80 Years,ALL,False,"Biosplice Therapeutics, Inc.",INDUSTRY,0,13,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,4.624972813284271,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,8,1,1,0,0,2,1,2018-11-28,2021-08-18,994.0,2018.0,1,2,0
NCT02433522,Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab,Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial,COMPLETED,2015-03-31,2018-08-16,2025-11-20,INTERVENTIONAL,PHASE3,97.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,ANCA-associated Vasculitides,rituximab|Placebo,DRUG,1,17,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,2,1,France,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.584967478670572,medium,1,1,0,1,0,1,0,0,0,1,1,1,1,1,18,1,1,0,0,2,1,2015-03-31,2018-08-16,1234.0,2015.0,1,2,0
NCT00363922,Rehabilitation After Coronary Bypass Grafting. Comparison of Different Types of Rehabilitation Programs,Rehabilitation After Coronary Bypass Grafting: Home Based Rehabilitation Versus Rehabilitation in Institution and Rehabilitation in Institution Versus Out-patient Rehabilitation at the Hospital,COMPLETED,2006-09,2008-06,2015-09-29,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Coronary Artery Disease,Rehabilitation in institution|Rehabilitation at home|Out-patient rehabilitation at the hospital,BEHAVIORAL,1,3,18 Years,,ALL,True,Norwegian University of Science and Technology,OTHER,1,1,Norway,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,4,1,0,0,0,3,1,,,,,0,1,0
NCT02427451,"Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia","Obinutuzumab, Ibrutinib, and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (CLL)",ACTIVE_NOT_RECRUITING,2015-08-03,2026-04-15,2026-01-27,INTERVENTIONAL,PHASE1|PHASE2,87.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia,Bcl-2 Inhibitor GDC-0199|Obinutuzumab|Ibrutinib|Pharmacological Study|Laboratory Biomarker Analysis|Quality-of-Life Assessment,DRUG|OTHER|BIOLOGICAL,2,17,18 Years,,ALL,False,Kerry Rogers,OTHER,0,1,United States,,1,1,0,0,1,1.5,1,0,0,0,2,4.477336814478207,medium,1,1,0,1,0,0,0,0,1,0,0,0,1,0,19,1,1,1,0,6,1,2015-08-03,2026-04-15,3908.0,2015.0,1,4,1
NCT03246529,"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)","A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma - The GENESIS Study",ACTIVE_NOT_RECRUITING,2018-03-23,2029-09-30,2026-01-15,INTERVENTIONAL,PHASE3,180.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Multiple Myeloma,BL-8040 1.25 mg/kg + G-CSF|Placebo +G-CSF,DRUG,1,8,18 Years,78 Years,ALL,False,"BioLineRx, Ltd.",INDUSTRY,0,18,United States|Hungary|Spain|Germany|Italy,,0,0,1,0,0,3.0,1,0,0,0,1,5.198497031265826,medium,0,1,1,0,0,0,1,1,1,1,1,1,1,1,9,1,1,0,0,2,1,2018-03-23,2029-09-30,4209.0,2018.0,1,3,1
NCT05421429,KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia,"An Open, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous (SC) Doses of KN057 in Subjects with Hemophilia a or B, with or Without Inhibitors",COMPLETED,2022-07-07,2024-01-17,2024-12-30,INTERVENTIONAL,PHASE2,24.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,PREVENTION,NONE,Hemophilia,KN057 doseⅠ|KN057 dose Ⅱ|KN057 dose Ⅲ,BIOLOGICAL,10,14,18 Years,70 Years,MALE,False,"Suzhou Alphamab Co., Ltd.",INDUSTRY,0,2,China,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.2188758248682006,small,1,1,1,0,0,0,1,0,0,0,0,0,0,0,24,1,0,1,0,3,1,2022-07-07,2024-01-17,559.0,2022.0,1,2,0
NCT00663429,Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma,A Phase II Open-Label Extension Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma,COMPLETED,2007-11,2010-03,2011-08-31,INTERVENTIONAL,PHASE2,10.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Neuroendocrine Carcinoma,Atiprimod,DRUG,2,1,18 Years,,ALL,False,Callisto Pharmaceuticals,INDUSTRY,0,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.3978952727983707,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT00135629,Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever,Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever: A Pilot Study. (Up-dosing Study),COMPLETED,2002-10,2008-10,2024-05-16,INTERVENTIONAL,PHASE3,18.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,"Rhinitis, Allergic, Seasonal",Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).|Placebo Injection|Venepuncture: 100ml blood sample taken on 12 separate visits,PROCEDURE|OTHER|BIOLOGICAL,2,1,18 Years,65 Years,ALL,False,Imperial College London,OTHER,1,1,United Kingdom,1.0,0,0,1,0,0,3.0,0,0,0,0,1,2.9444389791664403,small,1,1,0,1,0,1,0,0,0,1,1,0,1,1,3,1,0,1,0,3,1,,,,,0,1,0
NCT03306329,DNS-7801 vs. Placebo in Parkinson's Disease,"A Phase 2a, Double-Blind, Placebo-Controlled Two-Part Study To Investigate the Safety and Efficacy of Increasing Doses Of DNS-7801 In Parkinson's Disease (PD) Subjects With Motor Fluctuations",TERMINATED,2017-09-13,2017-12-31,2018-02-01,INTERVENTIONAL,PHASE2,5.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Parkinson's Disease,DNS-7801 (low-dose)|DNS-7801 (high dose)|Placebo,DRUG,2,10,30 Years,,ALL,False,"Dart NeuroScience, LLC",INDUSTRY,0,9,United States,0.0,0,1,0,0,0,2.0,0,0,1,0,1,1.791759469228055,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,12,1,1,0,0,3,1,2017-09-13,2017-12-31,109.0,2017.0,1,2,0
NCT01027429,Simplified Antibiotic Therapy for Sepsis in Young Infants,Simplified Antibiotic Regimens for the Management of Sepsis in Young Infants in First-level Facilities: Randomized Controlled Trial,COMPLETED,2009-12,2013-12,2015-06-29,INTERVENTIONAL,PHASE3,2543.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Neonatal Sepsis|Sepsis|Infection,"procaine penicillin and gentamicin|amoxicillin and gentamicin|procaine penicillin, gentamicin, amoxicillin",DRUG,1,0,,59 Days,ALL,False,Aga Khan University,OTHER,4,1,Pakistan,1.0,0,0,1,0,0,3.0,0,0,0,0,3,7.841492924460013,xlarge,0,1,0,1,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,3,1,,,,,0,2,0
NCT03227731,Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women,Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women An Open-Label Randomised Control Study,COMPLETED,2017-09-28,2021-12-30,2022-11-07,INTERVENTIONAL,PHASE2|PHASE3,540.0,ACTUAL,RANDOMIZED,PARALLEL,OTHER,NONE,HIV-1-infection,Truvada,DRUG,3,0,18 Years,50 Years,FEMALE,True,University of KwaZulu,OTHER,2,1,South Africa,1.0,0,1,1,0,1,2.5,0,0,0,0,1,6.293419278846481,xlarge,0,1,0,1,0,1,0,0,0,0,1,0,0,1,3,0,1,0,0,1,0,2017-09-28,2021-12-30,1554.0,2017.0,1,1,0
NCT00478231,"Multicenter, Safety Study Of Maraviroc","A Multicenter, Open Label, Non-Comparative Safety Study Of Maraviroc",COMPLETED,2007-07,2010-09,2011-09-09,INTERVENTIONAL,PHASE3,209.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Acquired Immunodeficiency Syndrome|HIV Infection,Maraviroc,DRUG,5,8,18 Years,,ALL,False,ViiV Healthcare,INDUSTRY,1,16,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,2,5.3471075307174685,large,0,1,1,0,0,1,1,0,0,0,0,0,1,0,13,1,1,0,0,1,0,,,,,0,2,0
NCT01204502,Suicide Gene Therapy Trial,Phase I/II Clinical Trial of T-cell Suicide Gene Therapy Following Haploidentical Stem Cell Transplantation,TERMINATED,2011-01,2013-01,2013-09-18,INTERVENTIONAL,PHASE1|PHASE2,2.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Haploidentical Stem Cell Transplantation,HSVTK retrovirally-transduced donor T lymphocytes,BIOLOGICAL,1,2,,16 Years,ALL,False,Great Ormond Street Hospital for Children NHS Foundation Trust,OTHER,0,1,United Kingdom,0.0,1,1,0,0,1,1.5,0,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,3,1,0,1,0,1,0,,,,,0,1,0
NCT00213837,Reconstruction Implant Bone After Removal Using Porous Titanium Prosthesis,Reconstruction Implant Bone (Anterior Mandibular Arch) After Removing Using Porous Titanium Prosthesis in ENT Surgery,COMPLETED,2003-10,2008-09,2025-12-22,INTERVENTIONAL,PHASE2,7.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,PREVENTION,NONE,Otorhinolaryngologic Diseases,Mandibular prosthesis made of a new highly biointegratable material,DEVICE,3,0,18 Years,,ALL,False,"University Hospital, Strasbourg, France",OTHER,0,1,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.0794415416798357,small,1,1,0,1,0,0,0,0,0,1,0,0,0,0,3,0,0,0,1,1,0,,,,,0,0,0
NCT05390645,A Study of MFA-370 in Patients with Metastatic Urothelial Cancer,"An Open-label, Multi-center, Phase I/II Study of MFA-370 in Patients with Metastatic Urothelial Cancer",WITHDRAWN,2024-12-01,2025-12-01,2024-09-26,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SEQUENTIAL,TREATMENT,NONE,Metastatic Urothelial Cancer,MFA-370,DRUG,3,8,18 Years,,ALL,False,Ectin Research AB,INDUSTRY,0,1,Sweden,0.0,1,1,0,0,1,1.5,1,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,0,0,0,0,1,0,11,1,1,0,0,1,0,2024-12-01,2025-12-01,365.0,2024.0,1,2,0
NCT00481572,Continuous Infusion of Terlipressin in Septic Shock,"Continuous Terlipressin Versus Vasopressin Infusion in Septic Shock. A Randomized, Controlled, Pilot Trial. ""THE TERLIVAP STUDY""",COMPLETED,2007-01,2007-12,2008-02-29,INTERVENTIONAL,PHASE2,45.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Septic Shock,Terlipressin|Vasopressin|Norepinephrine,DRUG,1,1,18 Years,,ALL,False,University of Roma La Sapienza,OTHER,0,1,Italy,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.828641396489095,small,1,1,0,1,0,0,0,0,0,1,1,1,1,1,2,1,1,0,0,3,1,,,,,0,1,0
NCT01660295,Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects,"An Open-label, Single Center, Parallel-group Study to Compare the Single- and Repeated-dose Pharmacokinetics of Stepwise Increasing Doses of Subcutaneous Certoparin (3000 IU o.d., 3000 IU b.i.d., 8000 IU o.d., and 8000 IU b.i.d.) in Subjects With Severe Renal Insufficiency and Healthy Subjects",COMPLETED,2011-12,,2012-08-08,INTERVENTIONAL,PHASE1|PHASE2,32.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Renal Insufficiency,"Certoparin 3,000 IU Once Daily|Certoparin 3,000 IU Twice a Day|Certoparin 8,000 IU Once Daily|Certoparin 8,000 IU Twice a Day",DRUG,4,0,21 Years,60 Years,ALL,True,Novartis Pharmaceuticals,INDUSTRY,0,1,Hungary,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.4965075614664802,small,1,1,1,0,1,0,0,0,0,0,0,0,1,1,4,0,1,0,0,4,1,,,,,0,2,0
NCT04364139,African American Study of Kidney Disease and Hypertension,African American Study of Kidney Disease and Hypertension,COMPLETED,1995-02-01,2007-06-30,2020-04-27,INTERVENTIONAL,PHASE3,1094.0,ACTUAL,RANDOMIZED,FACTORIAL,TREATMENT,DOUBLE,Hypertensive Nephrosclerosis|Chronic Renal Insufficiency,MAP goal less than or equal to 92 mm Hg|MAP goal 102-107 mm Hg|Ramipril|Amlodipine|Metoprolol,DRUG|OTHER,1,3,18 Years,70 Years,ALL,False,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),NIH,1,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.9985096422506015,xlarge,0,1,0,1,0,1,0,0,0,0,1,1,1,0,4,1,1,0,0,5,1,1995-02-01,2007-06-30,4532.0,1995.0,0,2,0
NCT00457639,Cholic Acid for Hepatic Steatosis in Lipodystrophy,Phase II Study of Cholic Acid for Hepatic Steatosis in Lipodystrophy Patients,COMPLETED,2006-04,2011-04,2025-08-06,INTERVENTIONAL,PHASE2,18.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Hepatic Steatosis,Cholic Acid,DRUG,1,1,6 Years,70 Years,ALL,False,University of Texas Southwestern Medical Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.9444389791664403,small,1,1,0,1,0,1,0,0,1,0,1,1,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT02558439,"Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain","A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging 24-Week Study to Evaluate the Safety and Efficacy of a Single Injection of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain",COMPLETED,2015-08,2017-02,2017-08-08,INTERVENTIONAL,PHASE2,175.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Osteoarthritis,CNTX-4975|Placebo,DRUG|OTHER,1,3,45 Years,80 Years,ALL,False,Centrexion Therapeutics,INDUSTRY,0,22,United States,1.0,0,1,0,0,0,2.0,0,1,0,0,1,5.170483995038151,medium,0,1,1,0,0,0,1,0,1,0,1,1,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT06597175,Evaluating Investigational Medical Device for Breast Tumor Diagnosis Using Diffusion Optical Spectroscopy,"A Multi-center, Open-label, Single Arm, Prospective Pivotal Medical Device Clinical Trial to Evaluate Efficacy and Safety of Study Device (ORIGO) That Provides Numerical Data by Measuring the Composition Within Breast Tissue Using Diffusion Optical Spectroscopy Imaging Technology to Assist in the Differential Diagnosis of Breast Tumors in Patients With Breast Lesions",COMPLETED,2024-04-16,2024-12-16,2025-08-13,INTERVENTIONAL,PHASE3,300.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,"Breast Cancer|Breast Tumor|Mammary Carcinoma, Human",ORIGO,DEVICE,1,0,19 Years,,FEMALE,False,Olive Healthcare,INDUSTRY,0,5,South Korea,1.0,0,0,1,0,0,3.0,1,0,0,0,3,5.707110264748875,large,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,2024-04-16,2024-12-16,244.0,2024.0,1,1,0
NCT00349557,Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer,Pilot Phase II Trial of Bevacizumab in Combination With Hormonal and Radiotherapy in Patients With High-Risk Prostate Cancer,COMPLETED,2006-04,,2014-07-16,INTERVENTIONAL,PHASE2,18.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,"bevacizumab, bicalutamide and goserelin|intensity modulated radiation therapy (IMRT)",DRUG|PROCEDURE,1,2,18 Years,,MALE,False,Benaroya Research Institute,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.9444389791664403,small,1,0,0,1,0,1,0,0,1,0,0,0,1,0,3,1,1,0,0,2,1,,,,,0,1,0
NCT01321957,Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer,FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study,COMPLETED,2011-05,2018-08-15,2018-10-25,INTERVENTIONAL,PHASE2,250.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Metastatic Colorectal Cancer,"Oxaliplatin, 5FU/LV, Bevacizumab|5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan",DRUG,1,6,18 Years,,ALL,True,Martin-Luther-Universität Halle-Wittenberg,OTHER,1,51,Germany,1.0,0,1,0,0,0,2.0,1,0,0,0,1,5.5254529391317835,large,0,1,0,1,0,1,1,0,0,1,1,0,1,1,7,1,1,0,0,2,1,,2018-08-15,,,0,2,0
NCT02139501,An Investigation of rhTPO With Different Frequencies in the Management of ITP,A Randomized Study to Evaluate the Efficacy and Safety of Different Doses and Frequencies of Recombinant Human Thrombopoietin (rhTPO) in the Management of Primary Immune Thrombocytopenia (ITP),COMPLETED,2014-05,2015-01,2016-04-20,INTERVENTIONAL,PHASE3,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Immune Thrombocytopenia,Recombinant Human Thrombopoietin (rhTPO),DRUG,1,1,18 Years,60 Years,ALL,False,Shandong University,OTHER,2,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.8918202981106265,small,1,1,0,1,0,1,0,0,0,0,1,0,1,1,2,1,1,0,0,1,0,,,,,0,0,0
NCT04359901,Sarilumab for Patients With Moderate COVID-19 Disease,Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design,COMPLETED,2020-04-10,2021-08-02,2023-12-06,INTERVENTIONAL,PHASE2,50.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,COVID,SARILUMAB,BIOLOGICAL,1,0,18 Years,,ALL,False,Westyn Branch-Elliman,FED,0,5,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.9318256327243257,small,1,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,0,1,0,2020-04-10,2021-08-02,479.0,2020.0,1,0,0
NCT02919501,Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder,"Interventional, Randomised, Double-blind, Parallel-group Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder",COMPLETED,2016-09-27,2017-04-27,2018-06-20,INTERVENTIONAL,PHASE2,55.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"Depressive Disorder, Major",Vortioxetine (IV)|Placebo (IV)|Vortioxetine (tablet),DRUG|OTHER,1,11,18 Years,65 Years,ALL,False,H. Lundbeck A/S,INDUSTRY,1,7,Estonia|Finland,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.02535169073515,medium,1,1,1,0,0,1,1,1,0,0,1,1,1,1,12,1,1,0,0,3,1,2016-09-27,2017-04-27,212.0,2016.0,1,3,1
NCT02484001,Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures,"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures: a Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Clinical Study - Open-label ESL Extension",COMPLETED,2016-03-01,2018-09-11,2018-10-16,INTERVENTIONAL,PHASE3,206.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Epilepsy,ESL 800 mg|ESL 1200 mg|ESL 1600 mg|ESL 400 mg,DRUG,1,1,18 Years,,ALL,False,Bial - Portela C S.A.,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,1,0,1,5.332718793265369,large,0,1,1,0,0,0,0,0,0,0,0,0,1,0,2,1,1,0,0,4,1,2016-03-01,2018-09-11,924.0,2016.0,1,1,0
NCT02203812,Effect of Probiotic Lozenge on Gingivitis and Periodontitis,The Effect of Probiotic Lozenge Administration on Gingivitis and on Mild & Moderate Periodontitis: A Randomized Controlled Clinical Trial.,COMPLETED,2015-01,2016-05,2016-07-27,INTERVENTIONAL,PHASE3,32.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Mild and Moderate Chronic Periodontitis,Probiotic Arm|Placebo Arm,DRUG,1,1,20 Years,50 Years,ALL,False,CD Pharma India Pvt. Ltd.,INDUSTRY,1,1,India,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.4965075614664802,small,1,1,1,0,0,1,0,0,0,0,1,1,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT00347581,A Randomized Trial of Base-in Prism Reading Glasses Convergence Insufficiency in Children,A Randomized Clinical Trial of the Effectiveness of Base-in Prism Reading Glasses Vs. Placebo Reading Glasses for Symptomatic Convergence Insufficiency in Children,COMPLETED,2003-05,2004-08,2006-07-04,INTERVENTIONAL,PHASE3,72.0,,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Convergence Insufficiency,Base-in prism glasses for reading|Placebo reading glasses,PROCEDURE,1,2,9 Years,18 Years,ALL,True,Pennsylvania College of Optometry,INDUSTRY,0,10,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.290459441148391,medium,1,0,1,0,0,0,1,0,1,0,1,1,1,0,3,1,0,0,0,2,1,,,,,0,1,0
NCT00002881,"Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer",PHASE III TRIAL OF ORCHIECTOMY/LHRH ANALOG + FLUTAMIDE + SURAMIN + HYDROCORTISONE VS ORCHIECTOMY/LHRH ANALOG + FLUTAMIDE IN PATIENTS WITH METASTATIC PROSTATE CANCER,COMPLETED,1996-10,,2010-11-09,INTERVENTIONAL,PHASE3,,,RANDOMIZED,,TREATMENT,,Prostate Cancer,flutamide|goserelin acetate|leuprolide acetate|suramin|therapeutic hydrocortisone|orchiectomy,DRUG|PROCEDURE,0,0,18 Years,,MALE,False,Eastern Cooperative Oncology Group,NETWORK,3,1,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,0.0,,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,6,1,,,,,0,1,0
NCT01016119,Efficacy of Folrex in the Superior Extremity Rehabilitation After Acute Stroke,Efficacy of Folrex in the Superior Extremity Rehabilitation After Acute Stroke,COMPLETED,2009-10,2010-03,2010-03-08,INTERVENTIONAL,PHASE3,40.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Stroke,Folrex|Placebo,DRUG,1,2,20 Years,90 Years,ALL,False,Catalysis SL,INDUSTRY,0,1,Cuba,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.713572066704308,small,1,0,1,0,0,0,0,0,0,0,1,1,1,1,3,1,1,0,0,2,1,,,,,0,1,0
NCT00109330,A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine,"A Phase III, Observer-blinded Randomised, Multi-centre Clinical Study of the Safety, Immunogenicity and Consistency of Three Manufacturing Lots of GSK Biologicals' Candidate Tdap Vaccine as Compared to a US-licensed Td Vaccine When Given as a Booster Dose to Healthy Adolescents (10-18 Years of Age)",COMPLETED,2002-11,2004-04,2016-09-09,INTERVENTIONAL,PHASE3,4116.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Diphtheria|Tetanus|Acellular Pertussis,"Combined diphtheria, tetanus, acellular pertussis vaccine",BIOLOGICAL,0,0,10 Years,18 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,44,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,3,8.322880021769905,xlarge,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,,,,,0,1,0
NCT05562830,A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A),A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants With PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A,ACTIVE_NOT_RECRUITING,2022-11-16,2028-06-20,2026-01-26,INTERVENTIONAL,PHASE1|PHASE2,48.0,ESTIMATED,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Urothelial Carcinoma,Zilovertamab vedotin|Pembrolizumab|MK-3120,BIOLOGICAL,4,2,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,25,United Kingdom|Chile|Denmark|Australia|United States|Spain|Italy|South Korea|Netherlands|Israel,,1,1,0,0,1,1.5,1,0,0,0,1,3.8918202981106265,small,1,0,1,0,1,0,1,1,1,1,0,0,1,1,6,1,0,1,0,3,1,2022-11-16,2028-06-20,2043.0,2022.0,1,4,1
NCT02036528,Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers,"A Phase I/II, Open Label, Controlled Study to Evaluate the Safety and Efficacy of AppliGel-G [Gentamicin Sulfate Topical Gel] for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers in Patients With Type 1 and Type 2 Diabetes",TERMINATED,2014-01,,2015-05-14,INTERVENTIONAL,PHASE1|PHASE2,9.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Diabetic Foot Ulcers,Gentamicin Topical Gel|Ciprofloxacin|Doxycycline,DRUG,1,3,18 Years,,ALL,False,"Royer Biomedical, Inc.",INDUSTRY,0,7,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,1,2.302585092994046,small,1,1,1,0,0,0,1,0,1,0,1,0,1,1,4,1,1,0,0,3,1,,,,,0,2,0
NCT06480565,A Phase 1/2 Trial of ADI-270 in ccRCC,A Phase 1/2 Trial of ADI-270 (Engineered γδ Chimeric Receptor [CAR] Vδ1 T Cells Targeting CD70) in Adults With Relapsed or Refractory (R/R) Clear Cell Renal Cell Carcinoma (ccRCC),ACTIVE_NOT_RECRUITING,2024-12-12,2027-06,2025-08-15,INTERVENTIONAL,PHASE1|PHASE2,60.0,ESTIMATED,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Clear Cell Renal Cell Carcinoma,ADI-270|Fludarabine|Cyclophosphamide,DRUG,2,0,18 Years,,ALL,False,Adicet Therapeutics,INDUSTRY,0,1,United States,,1,1,0,0,1,1.5,1,0,0,0,1,4.110873864173311,medium,1,0,1,0,0,0,0,0,1,0,0,0,1,0,2,0,1,0,0,3,1,2024-12-12,,,2024.0,1,2,0
NCT00003900,Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer,A Phase II Study of Irinotecan (CPT-11) and Docetaxel (Taxotere) in Patients With Recurrent Non-Small Cell Lung Cancer,COMPLETED,1999-10,2006-03,2016-07-06,INTERVENTIONAL,PHASE2,48.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lung Cancer,docetaxel|irinotecan hydrochloride,DRUG,1,1,18 Years,,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,1,19,Canada|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.8918202981106265,small,1,1,0,1,0,1,1,1,1,0,0,0,1,0,2,1,1,0,0,2,1,,,,,0,2,0
NCT01739400,"Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome","Long Term, Single-arm, Open-label Extension Study of Protocol AC-055-305 to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome",TERMINATED,2013-09-10,2018-01-12,2019-04-16,INTERVENTIONAL,PHASE3,217.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Pulmonary Arterial Hypertension,"Macitentan 10 mg tablet, once daily.",DRUG,4,0,12 Years,,ALL,False,Actelion,INDUSTRY,0,51,Austria|China|Russia|Bulgaria|Portugal|Spain|Romania|Chile|United States|Vietnam|France|Germany|Poland|Greece|United Kingdom|Malaysia|Philippines|Mexico|Serbia,0.0,0,0,1,0,0,3.0,0,0,0,1,1,5.384495062789089,large,0,1,1,0,0,0,1,1,1,1,0,0,1,0,4,0,1,0,0,1,0,2013-09-10,2018-01-12,1585.0,2013.0,0,1,0
NCT03827200,A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis,"A Phase II, Single-arm, Open-label Study to Characterise the Effect on Portal Pressure, the Effect on Renal Function and the Pharmacokinetic Profile of N-003 in Patients With Decompensated Cirrhosis",TERMINATED,2019-04-11,2021-01-21,2021-02-26,INTERVENTIONAL,PHASE2,19.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Cirrhosis|Portal Hypertension|Ascites,Ambrisentan,DRUG,1,10,18 Years,,ALL,False,Noorik Biopharmaceuticals AG,INDUSTRY,0,6,Spain,0.0,0,1,0,0,0,2.0,0,0,0,1,3,2.995732273553991,small,1,1,1,0,0,0,1,0,0,1,0,0,1,0,11,1,1,0,0,1,0,2019-04-11,2021-01-21,651.0,2019.0,1,2,0
NCT05116800,Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma,"A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Advanced Soft Tissue and Bone Sarcomas",WITHDRAWN,2022-03-01,2030-08,2021-12-07,INTERVENTIONAL,PHASE2,0.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Soft Tissue Sarcoma|Undifferentiated Pleomorphic Sarcoma|Myxofibrosarcoma|Leiomyosarcoma|Liposarcoma|Angiosarcoma|Synovial Sarcoma|Rhabdomyosarcoma|Spindle Cell Sarcoma|High Grade Sarcoma|Bone Sarcoma|Osteosarcoma|Ewing Sarcoma of Bone,Gemcitabine|9-ING-41|Docetaxel,DRUG,1,1,10 Years,,ALL,False,Brown University,OTHER,1,2,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,13,0.0,,1,1,0,1,0,1,1,0,1,0,0,0,1,1,2,1,1,0,0,3,1,2022-03-01,,,2022.0,1,2,0
NCT04655807,A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease,"A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Proof-of-Concept Clinical Study to Evaluate the Safety and Efficacy of JNJ-64304500 as Add-on Therapy to Standard of Care Biologic Therapy With Anti-Tumor Necrosis Factor Alpha or Anti-Interleukin 12/23 in Responder Not Remitter Participants With Active Crohn's Disease",WITHDRAWN,2021-03-03,2023-09-04,2025-04-27,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Crohn Disease,JNJ-64304500|Placebo|Adalimumab|Ustekinumab,DRUG,8,13,18 Years,65 Years,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,1,United States,0.0,0,1,0,0,0,2.0,0,1,0,0,1,0.0,,1,1,1,0,0,0,0,0,1,0,1,1,1,1,21,1,1,0,0,4,1,2021-03-03,2023-09-04,915.0,2021.0,1,2,0
NCT07229807,Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A,A Phase 3 Study of ZSP1273 in Otherwise Healthy Children 2-11 Years Old With Influenza A,ACTIVE_NOT_RECRUITING,2025-11-22,2025-12-31,2025-12-16,INTERVENTIONAL,PHASE3,119.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Influenza a,ZSP1273|Oseltamivir,DRUG,1,2,2 Years,11 Years,ALL,False,"Guangdong Raynovent Biotech Co., Ltd",INDUSTRY,0,1,China,,0,0,1,0,0,3.0,0,0,0,0,1,4.787491742782046,medium,0,0,1,0,0,0,0,0,0,0,1,1,1,1,3,1,1,0,0,2,1,2025-11-22,2025-12-31,39.0,2025.0,1,1,0
NCT03680092,Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation,A Randomized Phase II Trial Comparing a Calcineurin Inhibitor-free Graft-versus-host Disease Prophylaxis Regimen With Post-transplantation Cyclophosphamide and Abatacept to Standard of Care,COMPLETED,2019-11-26,2023-06-15,2025-10-02,INTERVENTIONAL,PHASE2,43.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,GVHD|Hematologic Neoplasms,Cyclophosphamide|abatacept|Methotrexate|Tacrolimus,DRUG,1,1,18 Years,,ALL,False,"Dimitrios Tzachanis, MD PhD",OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.784189633918261,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,2,1,1,0,0,4,1,2019-11-26,2023-06-15,1297.0,2019.0,1,2,0
NCT02796807,Correlation Between SUV on 68Ga-HBED-CC-PSMA and Gleason Score in Prostate Cancer,Correlation Between SUV on 68Ga-HBED-CC-PSMA and Gleason Score in Prostate Cancer,COMPLETED,2016-05,2017-12,2018-03-06,INTERVENTIONAL,PHASE2,88.0,ACTUAL,,SINGLE_GROUP,BASIC_SCIENCE,NONE,Prostate Cancer,68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT,DRUG,1,0,18 Years,120 Years,MALE,False,Sir Mortimer B. Davis - Jewish General Hospital,OTHER,0,1,Canada,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.48863636973214,medium,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT00844792,Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer,"A Randomized, Double-Blind Study of Combination Vitamin E, Selenium and Lycopene vs. Placebo in Men Undergoing Radical Prostatectomy for Prostate Cancer",COMPLETED,2008-10,2013-12,2017-10-26,INTERVENTIONAL,PHASE2,48.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Cancer of the Prostate|Prostate Cancer|Prostatic Neoplasms,"Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Placebo",DRUG|DIETARY_SUPPLEMENT,1,0,18 Years,,MALE,False,"University Health Network, Toronto",OTHER,0,1,Canada,1.0,0,1,0,0,0,2.0,1,0,0,0,3,3.8918202981106265,small,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,2,0
NCT01977911,Clinical Trial of Stem Cell Based Tissue Engineered Laryngeal Implants,Phase I/IIa Clinical Trial of Stem Cell Based Tissue Engineered Partial Laryngeal Implants in 10 Adult Patients With End-stage Laryngeal Stenosis With 24 Months Follow-up.,WITHDRAWN,2018-04,2018-05-25,2018-06-06,INTERVENTIONAL,PHASE1|PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Disorder of Upper Respiratory System|Laryngostenosis|Tracheal Stenosis,Stem cell based tissue engineered partial laryngeal implants,OTHER,1,1,18 Years,,ALL,False,"University College, London",OTHER,1,1,United Kingdom,0.0,1,1,0,0,1,1.5,0,0,0,0,3,0.0,,1,1,0,1,0,1,0,0,0,1,0,0,1,0,2,1,0,0,0,1,0,,2018-05-25,,,0,2,0
NCT00364611,Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer,"A Pilot, Phase II, Multicenter, Open-Label, Prospective Evaluation of Docetaxel and Bevacizumab ± Trastuzumab in the First-Line Treatment of Patients With Metastatic Breast Cancer",COMPLETED,2006-08,2012-04,2012-08-23,INTERVENTIONAL,PHASE2,73.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,Bevacizumab|Docetaxel|Trastuzumab,DRUG,2,5,18 Years,,FEMALE,False,Sanofi,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.30406509320417,medium,1,1,1,0,1,0,0,0,1,0,0,0,1,1,7,1,1,0,0,3,1,,,,,0,2,0
NCT01744444,Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis,,COMPLETED,2012-11,2013-07,2025-09-03,INTERVENTIONAL,PHASE2,10.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Pendular Nystagmus Patients With Multiple Sclerosis,Memantine|Gabapentin,DRUG,4,3,18 Years,,ALL,False,Hospices Civils de Lyon,OTHER,0,1,France,1.0,0,1,0,0,0,2.0,0,1,0,0,1,2.3978952727983707,small,1,1,0,1,0,0,0,0,0,1,1,0,1,0,7,1,1,0,0,2,1,,,,,0,2,0
NCT02720744,Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy,"A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects With Narcolepsy",COMPLETED,2016-11-17,2020-03-25,2022-03-22,INTERVENTIONAL,PHASE3,212.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Excessive Daytime Sleepiness|Cataplexy|Narcolepsy,FT218|Placebo,DRUG,3,0,16 Years,,ALL,False,Avadel,INDUSTRY,0,57,Australia|United States|Canada|France|Czechia|Germany,1.0,0,0,1,0,0,3.0,0,0,0,0,3,5.3612921657094255,large,0,1,1,0,0,0,1,1,1,1,1,1,1,1,3,0,1,0,0,2,1,2016-11-17,2020-03-25,1224.0,2016.0,1,3,1
NCT04728802,Proxalutamide Treatment for Hospitalized COVID-19 Patients,Proxalutamide Treatment for Hospitalized COVID-19 Patients,COMPLETED,2021-02-01,2021-04-15,2021-06-24,INTERVENTIONAL,PHASE3,645.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Covid19|SARS (Severe Acute Respiratory Syndrome),Proxalutamide|Placebo,DRUG,1,3,18 Years,,ALL,False,"Applied Biology, Inc.",INDUSTRY,0,8,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,2,6.470799503782602,xlarge,0,1,1,0,0,0,1,0,0,0,1,1,1,1,4,1,1,0,0,2,1,2021-02-01,2021-04-15,73.0,2021.0,1,2,0
NCT04701502,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,COMPLETED,2020-11-09,2021-02-15,2021-10-21,INTERVENTIONAL,PHASE2,60.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,NONE,Covid19|Respiratory Disease|Immune System|Immunomodulator|Antiseptic|Supportive Care,Viusid|Asbrip|Standard Care,DRUG|DIETARY_SUPPLEMENT,4,9,18 Years,,ALL,False,Catalysis SL,INDUSTRY,0,2,Bulgaria,1.0,0,1,0,0,0,2.0,0,0,0,0,6,4.110873864173311,medium,1,1,1,0,0,0,1,0,0,0,1,0,0,1,13,1,1,0,0,3,1,2020-11-09,2021-02-15,98.0,2020.0,1,3,1
NCT00654953,"Clinical Efficacy of Sertraline Augmented With Gabapentin in Depressed, Recently Abstinent Cocaine-dependent Humans",Sertraline Augmented With GABA Agents for Cocaine Dependence,COMPLETED,2006-01,2009-05,2011-04-25,INTERVENTIONAL,PHASE2,102.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Cocaine Dependence|Depressive Symptoms,sertraline|Placebo|gabapentin,DRUG,1,0,18 Years,65 Years,ALL,False,University of Arkansas,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,2,4.634728988229636,medium,0,1,0,1,0,1,0,0,1,0,1,1,1,1,1,0,1,0,0,3,1,,,,,0,2,0
NCT04584853,PreOperative Endocrine Therapy for Individualised Care With Abemaciclib,PreOperative Endocrine Therapy for Individualised Care With Abemaciclib,ACTIVE_NOT_RECRUITING,2020-12-23,2030-10,2026-01-14,INTERVENTIONAL,PHASE3,123.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer Female,"Abemaciclib|Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)",DRUG,1,7,18 Years,,FEMALE,False,"Institute of Cancer Research, United Kingdom",OTHER,0,62,United Kingdom,,0,0,1,0,0,3.0,1,0,0,0,1,4.820281565605037,medium,0,1,0,1,0,0,1,0,0,1,1,0,1,1,8,1,1,0,0,2,1,2020-12-23,,,2020.0,1,2,0
NCT01875653,Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma,"Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma",TERMINATED,2014-10,2016-01,2019-05-10,INTERVENTIONAL,PHASE3,4.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Stage IV Melanoma|Stage III Melanoma,Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|Autologous PBMCs in GM-CSF (MC),BIOLOGICAL,1,1,18 Years,,ALL,False,"Lisata Therapeutics, Inc.",INDUSTRY,0,18,United States,0.0,0,0,1,0,0,3.0,1,0,0,0,2,1.6094379124341003,small,1,1,1,0,0,0,1,0,1,0,1,1,1,1,2,1,0,1,0,2,1,,,,,0,2,0
NCT00215553,KL₄Surfactant Treatment in Patients With ARDS,"A Multicenter, Randomized, Controlled Trial Comparing the Safety and Effectiveness of SURFAXIN® (Lucinactant) Delivered Via Bronchopulmonary Segmental Lavage to Standard of Care in Patients With Acute Respiratory Distress Syndrome (ARDS).",TERMINATED,2001-05,2006-02,2018-08-09,INTERVENTIONAL,PHASE2,124.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Acute Respiratory Distress Syndrome,A.1 Lucinactant|B.3 SoC|A.2 Lucinactant|A.3 Lucinactant|A.4 Lucinactant|B.1 Lucinactant|B.2 Lucinactant,DRUG|OTHER,1,2,16 Years,75 Years,ALL,False,Windtree Therapeutics,INDUSTRY,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,4.8283137373023015,medium,0,1,1,0,0,0,0,0,1,0,1,0,1,1,3,1,1,0,0,7,1,,,,,0,1,0
NCT01252745,Efficacy of an Intranasal Testosterone Product,"An Open Label, Randomized, Balanced, Three Treatment, Parallel Design, Pharmacokinetic Study of Intranasal TBS-1 Administration to Hypogonadal Men",COMPLETED,2010-08,2010-12,2018-05-23,INTERVENTIONAL,PHASE2,22.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hypogonadism,"10.0 mg of Testosterone, 4.0% TID|13.5 mg of Testosterone, 4.5% B.I.D|11.25 mg of Testosterone, 4.5% T.I.D",DRUG,3,0,18 Years,80 Years,MALE,False,Acerus Pharmaceuticals Corporation,INDUSTRY,0,3,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.1354942159291497,small,1,1,1,0,0,0,1,0,1,0,1,0,1,1,3,0,1,0,0,3,1,,,,,0,1,0
NCT00896545,Early Childhood Prevention of Childhood Overweight,Development of an Early Intervention for the Prevention of Childhood Obesity,COMPLETED,2008-11,2011-05,2011-07-25,INTERVENTIONAL,PHASE3,100.0,ESTIMATED,RANDOMIZED,PARALLEL,PREVENTION,NONE,Overweight,5-keys counseling|Lifestyle counseling,BEHAVIORAL,1,1,2 Years,4 Years,ALL,True,Stanford University,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.61512051684126,medium,0,0,0,1,0,0,0,0,1,0,1,0,0,1,2,1,0,0,0,2,1,,,,,0,1,0
NCT03848845,"Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)",A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (DREAMM 4),COMPLETED,2019-03-14,2023-06-14,2024-04-09,INTERVENTIONAL,PHASE1|PHASE2,41.0,ACTUAL,NON_RANDOMIZED,SEQUENTIAL,TREATMENT,NONE,Multiple Myeloma,belantamab mafodotin|Pembrolizumab,DRUG,12,74,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,1,12,Germany|Canada|Spain|United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.7376696182833684,small,1,1,1,0,0,1,1,1,1,1,0,0,1,0,86,1,1,0,0,2,1,2019-03-14,2023-06-14,1553.0,2019.0,1,4,1
NCT04102995,A Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual Migraine,"An Exploratory Phase II, Randomised, Double-blind, Placebo-controlled, Parallel-group Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual Migraine",COMPLETED,2019-08-27,2021-05-15,2021-07-26,INTERVENTIONAL,PHASE2,86.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Menstrual Migraine,Sepranolone injection low dose|Sepranolone injection high dose|Placebo injection,DRUG,1,0,18 Years,48 Years,FEMALE,False,Asarina Pharma,INDUSTRY,1,7,Sweden|Finland,1.0,0,1,0,0,0,2.0,0,0,1,0,1,4.465908118654584,medium,1,1,1,0,0,1,1,1,0,0,1,1,0,1,1,0,1,0,0,3,1,2019-08-27,2021-05-15,627.0,2019.0,1,2,0
NCT02953639,A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics,"A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Basmisanil (RO5186582) as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia Treated With Antipsychotics",COMPLETED,2016-11-30,2019-12-12,2021-02-09,INTERVENTIONAL,PHASE2,214.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Schizophrenia,Basmisanil|Placebo,DRUG,1,14,18 Years,50 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,37,United States,1.0,0,1,0,0,0,2.0,0,0,1,0,1,5.3706380281276624,large,0,1,1,0,1,0,1,0,1,0,1,1,1,1,15,1,1,0,0,2,1,2016-11-30,2019-12-12,1107.0,2016.0,1,2,0
NCT03431077,A Study of LJPC-501 in Pediatric Patients With Hypotension,"An Open-Label, Multi-Center Study of LJPC-501 in Pediatric Patients Who Remain Hypotensive Despite Receiving Fluid Therapy and Vasopressor Therapy",COMPLETED,2018-02-11,2018-04-14,2018-08-07,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Catecholamine-resistant Hypotension (CRH)|Distributive Shock|High Output Shock|Sepsis,Angiotensin II,DRUG,2,12,2 Years,17 Years,ALL,False,La Jolla Pharmaceutical Company,INDUSTRY,0,3,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,4,1.0986122886681098,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,14,1,1,0,0,1,0,2018-02-11,2018-04-14,62.0,2018.0,1,2,0
NCT01399775,Evaluation of Ridge Dimensional Changes After Immediate Implantation and Efficacy of This Procedure,Evaluation of Implant Stability and Dimensional Changes in Alveolar Ridge Following Immediate Implantation,COMPLETED,2010-05,2011-02,2015-04-08,INTERVENTIONAL,PHASE1|PHASE2,24.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Atrophy of Edentulous Alveolar Ridge|Alveolar Ridge Augmentation,immediate implantation|Delayed implantation,PROCEDURE,1,1,,,ALL,True,Mashhad University of Medical Sciences,OTHER,0,1,Iran,1.0,1,1,0,0,1,1.5,0,0,0,0,2,3.2188758248682006,small,1,1,0,1,0,0,0,0,0,0,0,0,1,1,2,1,0,0,0,2,1,,,,,0,3,1
NCT05122975,Treatment of an Inherited Ventricular Arrhythmia,Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 (CPVT1),TERMINATED,2023-08-01,2024-04-01,2024-09-19,INTERVENTIONAL,PHASE2,8.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Catecholaminergic Polymorphic Ventricular Tachycardia Type 1,S48168 (ARM210)|Matching Placebo,DRUG,1,1,18 Years,65 Years,ALL,False,"RyCarma Therapeutics, Inc.",INDUSTRY,0,2,Netherlands|United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,2.1972245773362196,small,1,1,1,0,0,0,1,1,1,0,1,1,1,0,2,1,1,0,0,2,1,2023-08-01,2024-04-01,244.0,2023.0,1,2,0
NCT01050257,A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza,A Multicenter Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged Greater Than or Equal to 13 Years,COMPLETED,2010-01,2012-09,2013-11-01,INTERVENTIONAL,PHASE3,118.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Influenza,Oseltamivir IV|Oseltamivir Oral,DRUG,1,10,13 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,96,Denmark|United States|Lithuania|France|Spain|Hungary|Poland|Romania|Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.77912349311153,medium,0,1,1,0,1,0,1,1,1,1,1,1,1,1,11,1,1,0,0,2,1,,,,,0,3,1
NCT01654081,A Protocol of Irinotecan for Carcinoma of the Lung,"A Non-randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced ISG15-positive Non-small Cell Carcinoma of the Lung",WITHDRAWN,2013-10,2014-05,2014-05-30,INTERVENTIONAL,PHASE2,0.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lung Cancer,Irinotecan,DRUG,1,0,18 Years,,ALL,False,Susanne Arnold,OTHER,0,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT00718419,A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma,"An Open Label, Multicenter Phase 2 Study of Single-Agent Enzastaurin HCl in Previously Treated Waldenstrom's Macroglobulinemia or Multiple Myeloma",COMPLETED,2008-07,2012-08,2020-09-03,INTERVENTIONAL,PHASE2,56.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Waldenstrom's Macroglobulinemia|Multiple Myeloma,Enzastaurin,DRUG,1,3,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,4,France|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,4.04305126783455,medium,1,1,1,0,1,0,1,1,1,1,0,0,1,0,4,1,1,0,0,1,0,,,,,0,2,0
NCT00032630,Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass,CSP #517 - Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass,COMPLETED,2002-04,2008-04,2014-05-05,INTERVENTIONAL,PHASE3,2203.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Ischemic Heart Disease,Coronary artery bypass - on-pump|Coronary artery bypass - off-pump,PROCEDURE,2,0,,,ALL,False,US Department of Veterans Affairs,FED,0,17,United States,1.0,0,0,1,0,0,3.0,0,0,0,1,1,7.698029170272805,xlarge,0,1,0,0,0,0,1,0,1,0,1,0,1,1,2,0,0,0,0,2,1,,,,,0,1,0
NCT05968430,"Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension","An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension",ACTIVE_NOT_RECRUITING,2023-07-14,2026-12,2026-02-02,INTERVENTIONAL,PHASE3,1076.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hypertension,lorundrostat|Placebo,DRUG,2,0,18 Years,,ALL,False,Mineralys Therapeutics Inc.,INDUSTRY,0,177,United Kingdom|Australia|Bulgaria|United States|Canada|Puerto Rico|Poland|France|Spain|Germany|Netherlands|Romania|Italy,,0,0,1,0,0,3.0,0,0,0,1,1,6.981934677156389,xlarge,0,1,1,0,0,0,1,1,1,1,0,0,1,0,2,0,1,0,0,2,1,2023-07-14,,,2023.0,1,2,0
NCT03365765,mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer,Exploratory Study on the Efficacy and the Safety of mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer,COMPLETED,2018-02-12,2022-12-31,2023-02-14,INTERVENTIONAL,PHASE3,63.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Apatinib,Apatinib|Oxaliplatin|5-fluorouracil,DRUG,1,2,18 Years,70 Years,ALL,False,Huashan Hospital,OTHER,0,1,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.1588830833596715,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,1,3,1,1,0,0,3,1,2018-02-12,2022-12-31,1783.0,2018.0,1,1,0
NCT06545500,A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD,"A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD",COMPLETED,2024-08-16,2025-01-08,2025-04-02,INTERVENTIONAL,PHASE2,46.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,TRIPLE,Chronic Obstructive Pulmonary Disease,Glycopyrrolate (85 μg)|Glycopyrrolate (42.5 μg)|Glycopyrrolate (14 μg)|Placebo,DRUG,1,10,40 Years,80 Years,ALL,False,Verona Pharma plc,INDUSTRY,0,7,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.8501476017100584,small,1,1,1,0,0,0,1,0,1,0,1,1,1,0,11,1,1,0,0,4,1,2024-08-16,2025-01-08,145.0,2024.0,1,2,0
NCT00151307,Effects of Cerebral Oxygen Saturation on Neuropsychological Outcomes,The Effects of Monitoring and Maintaining Cerebral Oxygen Saturation on Neuropsychological Outcomes in Patients Undergoing Cardiac Surgery,TERMINATED,2001-02,2007-04,2008-06-06,INTERVENTIONAL,PHASE2|PHASE3,200.0,ESTIMATED,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Cardiovascular Diseases|Postoperative Complications,INVOS cerebral oximeter,DEVICE,6,3,18 Years,80 Years,ALL,False,Weill Medical College of Cornell University,OTHER,1,1,United States,0.0,0,1,1,0,1,2.5,0,0,0,1,2,5.303304908059076,medium,0,0,0,1,0,1,0,0,1,0,1,0,0,1,9,1,0,0,1,1,0,,,,,0,3,1
NCT00675792,Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774),"A Multi-center, Randomized, Parallel Group, Comparative, Active Controlled, Safety-assessor Blinded, Anesthesiologist-TOF-Watch® SX Blinded Trial Comparing T4/T1 Ratio at Time of Tracheal Extubation Using 4 mg/kg Sugammadex Administered at 1-2 PTCs or Better After the Last Dose of Rocuronium Bromide to 50 µg/kg Neostigmine Administered as Per Standard of Care in Adult Subjects Undergoing Elective Open Abdominal Procedures Requiring Neuromuscular Blockade Reversal",COMPLETED,2008-05,2008-09,2015-03-13,INTERVENTIONAL,PHASE3,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Anesthesia,Sugammadex|Neostigmine|Rocuronium,DRUG,1,5,18 Years,65 Years,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.61512051684126,medium,0,1,1,0,1,0,0,0,0,0,1,0,1,1,6,1,1,0,0,3,1,,,,,0,2,0
NCT03656536,A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma,"A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)",TERMINATED,2019-06-03,2025-07-07,2025-08-24,INTERVENTIONAL,PHASE3,167.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Unresectable Cholangiocarcinoma|Metastatic Cholangiocarcinoma,Pemigatinib|Gemcitabine|Cisplatin,DRUG,1,8,18 Years,,ALL,False,Incyte Corporation,INDUSTRY,0,215,Canada|Ireland|Austria|China|Spain|Norway|Belgium|Italy|Israel|Finland|United States|Sweden|France|Germany|Netherlands|United Kingdom|Denmark|Switzerland|Japan,0.0,0,0,1,0,0,3.0,1,0,0,0,2,5.123963979403259,medium,0,1,1,0,0,0,1,1,1,1,1,0,1,1,9,1,1,0,0,3,1,2019-06-03,2025-07-07,2226.0,2019.0,1,4,1
NCT00928811,Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant,One-year Exploratory Study to Evaluate the Safety of Partial Replacement of CNI With Chronic Administration of Simulect in de Novo Normal-risk Kidney Transplant Recipients Treated With MPA,TERMINATED,2009-05,2010-04,2015-02-10,INTERVENTIONAL,PHASE2|PHASE3,5.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,End Stage Renal Disease,basiliximab|basiliximab,DRUG,1,7,18 Years,75 Years,ALL,False,Drexel University College of Medicine,OTHER,1,1,United States,0.0,0,1,1,0,1,2.5,0,0,0,0,1,1.791759469228055,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,8,1,1,0,0,2,1,,,,,0,3,1
NCT01422811,"Unnecessary, Avoidable Lengths of Stay: a Strategy for Clinician Empowerment and Effectiveness Evaluation","Unnecessary, Avoidable Lengths of Stay: a Strategy for Clinician Empowerment and Effectiveness Evaluation",COMPLETED,2008-02,2010-02,2018-07-03,INTERVENTIONAL,PHASE3,3862.0,ACTUAL,RANDOMIZED,PARALLEL,HEALTH_SERVICES_RESEARCH,DOUBLE,Hospitalization|Length of Stay,Multicomponent strategy to reduce avoidable length of stay|No intervention,OTHER|BEHAVIORAL,1,1,,,ALL,False,Azienda Ospedaliero-Universitaria di Parma,OTHER,1,1,Italy,1.0,0,0,1,0,0,3.0,0,0,0,0,2,8.259199362666282,xlarge,0,1,0,1,0,1,0,0,0,1,1,1,0,1,2,1,0,0,0,2,1,,,,,0,2,0
NCT05017844,"[KSR-001-P02] Phase 2b/3 Study, Evaluate the Efficacy and Safety of KSR-001 in Patients With Dry Eye Syndrome","A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel Phase 2b/3 Study to Evaluate the Efficacy and Safety of KSR-001 in Patients With Dry Eye Syndrome",COMPLETED,2020-02-18,2021-06-22,2021-08-24,INTERVENTIONAL,PHASE2|PHASE3,222.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Dry Eye Syndromes,KSR-001-04|KSR-001-02|KSR-001-03,DRUG,1,5,19 Years,,ALL,False,Kukje Pharma,OTHER,1,1,South Korea,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.407171771460119,large,0,1,0,1,0,1,0,0,0,0,1,1,1,1,6,1,1,0,0,3,1,2020-02-18,2021-06-22,490.0,2020.0,1,3,1
NCT00390234,"Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma",A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas,COMPLETED,2006-09,2013-08,2015-12-07,INTERVENTIONAL,PHASE2,63.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Fallopian Tube Cancer|Female Reproductive Cancer|Ovarian Carcinosarcoma|Ovarian Sarcoma|Recurrent Ovarian Epithelial Cancer|Recurrent Uterine Sarcoma|Stage III Ovarian Epithelial Cancer|Stage III Uterine Sarcoma|Stage IV Ovarian Epithelial Cancer|Stage IV Uterine Sarcoma|Uterine Carcinosarcoma|Uterine Leiomyosarcoma,ziv-aflibercept,DRUG,3,2,18 Years,,FEMALE,False,National Cancer Institute (NCI),NIH,0,16,Canada|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,12,4.1588830833596715,medium,1,1,0,1,0,0,1,1,1,0,0,0,1,0,5,1,1,0,0,1,0,,,,,0,2,0
NCT06277934,A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of RGT001-075 Compared With Placebo in Adult Patients With Obesity or Overweight With Weight-Related Comorbidities",COMPLETED,2024-03-08,2024-08-13,2025-08-07,INTERVENTIONAL,PHASE2,73.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Obesity,RGT001-075|Placebo,DRUG,1,10,18 Years,75 Years,ALL,False,Regor Pharmaceuticals Inc.,INDUSTRY,0,10,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.30406509320417,medium,1,1,1,0,0,0,1,0,1,0,1,1,1,1,11,1,1,0,0,2,1,2024-03-08,2024-08-13,158.0,2024.0,1,2,0
NCT01783834,Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients,Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients With Advanced Non-small Cell Lung Cancer,COMPLETED,2008-02,2014-06,2016-02-11,INTERVENTIONAL,PHASE2,95.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Previous Treated Metastatic Non-small Cell Lung Cancer,Gefitinib|Pemetrexed,DRUG,1,1,18 Years,,ALL,False,Gachon University Gil Medical Center,OTHER,0,1,South Korea,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.564348191467836,medium,1,1,0,1,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,2,1,,,,,0,1,0
NCT00260234,Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients,A Single-Center Phase I/II Study Of Peg-Encapsulated Islet Allografts Implanted In Patients With Type I Diabetes,TERMINATED,2005-11,2007-12,2014-09-09,INTERVENTIONAL,PHASE1|PHASE2,12.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,"Diabetes Mellitus, Type 1",Allogeneic Cultured Islet Cells (human); Encapsulated,BIOLOGICAL,1,13,20 Years,,ALL,False,Novocell,INDUSTRY,2,2,United States,0.0,1,1,0,0,1,1.5,0,0,0,0,1,2.5649493574615367,small,1,0,1,0,0,1,1,0,1,0,0,0,1,0,14,1,0,1,0,1,0,,,,,0,2,0
NCT02301364,Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL),A Phase II Trial Of Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL),COMPLETED,2014-11-20,2016-10-11,2017-10-19,INTERVENTIONAL,PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lymphoma|Primary Central Nervous System Lymphoma|Recurrent/Refractory Secondary Central Nervous System Lymphoma,Buparlisib (BKM120),DRUG,1,3,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,4,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,1.6094379124341003,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2014-11-20,2016-10-11,691.0,2014.0,0,1,0
NCT00855764,Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer,Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer,COMPLETED,2005-10,2006-10,2010-02-04,INTERVENTIONAL,PHASE2,36.0,ESTIMATED,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Head and Neck Cancer,Paclitaxel,DRUG,1,2,20 Years,74 Years,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.6109179126442243,small,1,0,1,0,1,0,0,0,0,0,0,0,1,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT00789464,Probiotics for Girls With Recurring Urinary Tract Infections,H-23187: Probiotic Prophylaxis Against Recurrent Pediatric Urinary Tract Infection,WITHDRAWN,,,2020-08-18,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Recurrent Urinary Tract Infection,Lactobacillus reuteri DSM 17938|trimethoprim/sulfamethoxazole,DRUG|DIETARY_SUPPLEMENT,1,0,3 Months,17 Years,FEMALE,False,Baylor College of Medicine,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,2,1,,,,,0,1,0
NCT00321464,A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.,"A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer",COMPLETED,2006-04-01,2012-04-04,2022-11-08,INTERVENTIONAL,PHASE3,2049.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,TRIPLE,Bone Metastases,Denosumab|Zoledronic Acid,DRUG|BIOLOGICAL,1,2,18 Years,,ALL,False,Amgen,INDUSTRY,1,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.6255950721324535,xlarge,0,1,1,0,1,1,0,0,0,0,1,1,0,1,3,1,1,1,0,2,1,2006-04-01,2012-04-04,2195.0,2006.0,0,1,0
NCT02682264,"An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris","An Open-Label, Long-Term Extension Study to Evaluate the Safety of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice-Daily in Subjects With Acne Vulgaris",COMPLETED,2016-03-09,2018-08-31,2020-11-17,INTERVENTIONAL,PHASE3,609.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acne Vulgaris,"CB-03-01 cream, 1%",DRUG,1,0,9 Years,,ALL,False,Cassiopea SpA,INDUSTRY,0,74,Ukraine|Bulgaria|United States|Georgia|Romania|Poland|Serbia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.413458957167357,xlarge,0,1,1,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,2016-03-09,2018-08-31,905.0,2016.0,1,1,0
NCT02013609,"Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment","Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.",COMPLETED,2013-11,2014-10,2016-03-29,INTERVENTIONAL,PHASE3,48.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,MDD,Brexpiprazole,DRUG,1,19,18 Years,35 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,1,24,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.8918202981106265,small,1,1,1,0,0,1,1,0,1,0,0,0,1,0,20,1,1,0,0,1,0,,,,,0,1,0
NCT00296309,Comparing Efficacy & Safety of Tacrolimus & MMF With/Without Induction in the Elderly Following Kidney Transplantation.,"A Multicentre, Randomised, Open Clinical Study to Compare the Efficacy and Safety of a Combination of Tacrolimus and Mycophenolate Mofetil Based Regimen With or Without Induction in Elderly Recipients Undergoing Kidney Transplantation",COMPLETED,2004-10,2006-08,2014-09-01,INTERVENTIONAL,PHASE3,267.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,Kidney Transplantation,Tacrolimus,DRUG,1,1,60 Years,,ALL,False,Astellas Pharma Inc,INDUSTRY,1,33,United Kingdom|France|Spain|Switzerland|Germany|Netherlands|Belgium,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.5909869805108565,large,0,1,1,0,0,1,1,1,0,1,1,0,0,1,2,1,1,0,0,1,0,,,,,0,1,0
NCT02611609,A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome,A Phase 1/2 Study to Assess the Safety and Efficacy of MultiStem® Therapy in Subjects With Acute Respiratory Distress Syndrome,COMPLETED,2016-01,2019-07,2019-11-20,INTERVENTIONAL,PHASE1|PHASE2,36.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Acute Respiratory Distress Syndrome,MultiStem|MultiStem|Placebo,BIOLOGICAL,2,11,18 Years,90 Years,ALL,False,Healios K.K.,INDUSTRY,2,10,United Kingdom|United States,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.6109179126442243,small,1,1,1,0,0,1,1,1,1,1,1,1,1,1,13,1,0,1,0,3,1,,,,,0,4,1
NCT00785109,Vitamin K Supplement for Inhibition of the Progress in Aortic Valve Calcification,Vitamin K Containing Nutritional Supplement for Activation of Matrix-GIa-proteins (MGP) and Inhibition of Aortic Valve Calcification Process,COMPLETED,2010-01,2015-08,2017-04-21,INTERVENTIONAL,PHASE3,99.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Aortic Valve Calcification,Vitamin K supplementation,DIETARY_SUPPLEMENT,1,1,50 Years,,ALL,False,RWTH Aachen University,OTHER,0,1,Germany,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.605170185988092,medium,1,1,0,1,0,0,0,0,0,1,1,0,1,1,2,1,0,0,0,1,0,,,,,0,0,0
NCT02019472,A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis,"A Multicenter, Randomized, Double-blind, Parallel Group Study of Sirukumab Monotherapy Compared With HUMIRA® Monotherapy Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis",COMPLETED,2014-04-04,2016-08-17,2017-10-26,INTERVENTIONAL,PHASE3,559.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Arthritis, Rheumatoid",adalimumab 40 mg|sirukumab 100 mg|sirukumab 50 mg|Placebo,DRUG|BIOLOGICAL,2,2,18 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,1,107,Chile|Russia|Serbia|Mexico|Ukraine|Bulgaria|United States|Colombia|Hungary|Lithuania|South Africa|Spain|Germany|Poland|Romania|Moldova,1.0,0,0,1,0,0,3.0,0,1,0,0,1,6.327936783729195,xlarge,0,1,1,0,0,1,1,1,1,1,1,1,1,1,4,1,1,1,0,4,1,2014-04-04,2016-08-17,866.0,2014.0,0,2,0
NCT00429039,A Study to Accelerate Immune System Recovery Following Stem Cell Transplantation,LLME Treated Cellular Immunotherapy Following T-cell Depleted Allogeneic Heamtopoietic Stem Cell Transplantation for Acceleration of Immune Reconstitution,TERMINATED,2000-09,2009-08,2016-10-21,INTERVENTIONAL,PHASE2,21.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION,L-leucyl-L-leucine methyl ester (LLME),DRUG,0,0,16 Years,,ALL,False,Sidney Kimmel Cancer Center at Thomas Jefferson University,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.091042453358316,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT00562939,Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults,Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults,COMPLETED,2008-01,2009-01,2009-01-21,INTERVENTIONAL,PHASE1|PHASE2,97.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,HIV Infections,Pneumococcal vaccines + CPG 7909|Pneumococcal vaccines,BIOLOGICAL,1,7,18 Years,,ALL,False,University of Aarhus,OTHER,1,1,Denmark,1.0,1,1,0,0,1,1.5,0,0,0,0,1,4.584967478670572,medium,1,1,0,1,0,1,0,0,0,0,1,1,0,1,8,1,0,1,0,2,1,,,,,0,3,1
NCT01116739,Preventing Caries in Preschoolers: Testing a Unique Service Delivery Model in American Indian Head Start Programs,Preventing Caries in Preschoolers: Testing a Unique Service Delivery Model in American Indian Head Start Programs,COMPLETED,2011-04,2018-12,2021-06-10,INTERVENTIONAL,PHASE3,2060.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,SINGLE,Fluoride Varnish and Oral Health Promotion|Usual Care,Fluoride varnish|Oral health education|Dental services delivered by the Indian Health Service.,OTHER|BEHAVIORAL|DEVICE,4,4,3 Years,5 Years,ALL,True,"University of Colorado, Denver",OTHER,1,1,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,2,7.630946580890459,xlarge,0,1,0,1,0,1,0,0,1,0,1,0,0,1,8,1,0,0,1,3,1,,,,,0,3,1
NCT02582177,Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis,"Phase 3 Study, Randomized, Double-blind, Parallel to Evaluate Ketoconazole and Betamethasone Dipropionate(Candicort®) Compared to Clotrimazole and Dexamethasone Acetate(Baycuten N®) in Relief of Fungal Infections/Dermatophytosis Symptoms.",COMPLETED,2019-06-11,2020-03-24,2021-09-20,INTERVENTIONAL,PHASE3,125.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Tinea,Candicort®|Nizoral®|Baycuten N®|Canesten®,DRUG,1,5,18 Years,65 Years,ALL,False,Ache Laboratorios Farmaceuticos S.A.,INDUSTRY,0,9,Brazil,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.836281906951478,medium,0,1,1,0,0,0,1,0,0,0,1,1,1,1,6,1,1,0,0,4,1,2019-06-11,2020-03-24,287.0,2019.0,1,2,0
NCT04675177,Polidocanol Foam VS Artery Ligation in Hemorrhoidal Disease,Sclerotherapy With Polidocanol Foam Versus Hemorrhoidal Artery Ligation With Recto Anal Repair in the Treatment of Second and Third-grade Hemorrhoidal Disease: a Prospective Study,COMPLETED,2019-09-01,2020-03-25,2021-02-10,INTERVENTIONAL,PHASE2|PHASE3,45.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Hemorrhoids,Polidocanol foam sclerotherapy|Doppler-guided hemorrhoidal artery ligation,DRUG|PROCEDURE,2,4,18 Years,,ALL,False,Universidade do Porto,OTHER,0,1,Portugal,1.0,0,1,1,0,1,2.5,0,0,0,0,1,3.828641396489095,small,1,1,0,1,0,0,0,0,0,0,1,0,1,1,6,1,1,0,0,2,1,2019-09-01,2020-03-25,206.0,2019.0,1,3,1
NCT01507857,An Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine,"A Multicentered, Double - Blind, Randomized, and Placebo - Controlled Clinical Trial With Inactivated Enterovirus Type 71 (EV71) Vaccines",COMPLETED,2012-01,2013-03,2013-11-28,INTERVENTIONAL,PHASE3,10077.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,"Hand, Foot and Mouth Disease",400U /0.5ml EV71 vaccine|0/0.5ml placebo,BIOLOGICAL,1,4,6 Months,35 Months,ALL,True,"Sinovac Biotech Co., Ltd",INDUSTRY,0,3,China,1.0,0,0,1,0,0,3.0,0,0,0,0,1,9.218110109240543,,0,1,1,0,0,0,1,0,0,0,1,1,0,1,5,1,0,1,0,2,1,,,,,0,1,0
NCT00328757,Safety of Regular Diet as the First Meal in Patients Who Underwent Surgical Treatment for Gynecologic Cancer,Regular Versus Liquid Diet as the First Meal in Patients Undergoing Major Abdominal Gynecologic Cancer Operation: A Randomized Controlled Trial,WITHDRAWN,2006-05,2007-04,2011-06-28,INTERVENTIONAL,PHASE3,240.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Gynecologic Neoplasms,Regular diet as the first postoperative meal,BEHAVIORAL,1,5,18 Years,75 Years,FEMALE,False,Chiang Mai University,OTHER,0,1,Thailand,0.0,0,0,1,0,0,3.0,0,0,0,0,1,5.484796933490655,large,0,0,0,1,0,0,0,0,0,0,1,0,1,1,6,1,0,0,0,1,0,,,,,0,1,0
NCT01743157,Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma,A Phase I-II Study of Treatment of Metastatic Melanoma Using Induction Therapy With Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab (BBI),COMPLETED,2010-12,2013-05,2013-08-29,INTERVENTIONAL,PHASE1|PHASE2,24.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Metastatic Melanoma,Biochemo + bevacizumab then ipilimumab,DRUG,1,1,18 Years,,ALL,False,California Pacific Medical Center Research Institute,OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,3.2188758248682006,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,,,,,0,1,0
NCT00121901,Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis?,,COMPLETED,2004-10,2007-10,2007-10-18,INTERVENTIONAL,PHASE3,1600.0,ESTIMATED,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Pancreatitis,glyceryl nitrate,DRUG,1,3,18 Years,,ALL,False,Hvidovre University Hospital,OTHER,0,14,Sweden|France|Denmark|Norway,1.0,0,0,1,0,0,3.0,0,0,0,0,1,7.3783837129967145,xlarge,0,0,0,1,0,0,1,1,0,1,1,1,0,1,4,1,1,0,0,1,0,,,,,0,1,0
NCT00200512,Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months,"A Prospective, Randomized, Placebo-Controlled, Crossover Study of the Safety and Effectiveness of Subcutaneous Injections of Apomorphine in the Treatment of ""Off"" Episodes in Patients With ""On/Off"" or ""Wearing Off"" Effects Associated With Late Stage Parkinson's Disease",COMPLETED,1999-09,1999-11,2005-12-16,INTERVENTIONAL,PHASE2|PHASE3,16.0,,RANDOMIZED,CROSSOVER,TREATMENT,DOUBLE,Parkinson Disease,apomorphine HCl injection,DRUG,1,4,18 Years,,ALL,False,Mylan Bertek Pharmaceuticals,INDUSTRY,0,2,United Kingdom,1.0,0,1,1,0,1,2.5,0,0,1,0,1,2.833213344056216,small,1,0,1,0,0,0,1,0,0,1,1,1,1,0,5,1,1,0,0,1,0,,,,,0,1,0
NCT02535312,"Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin",Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin,ACTIVE_NOT_RECRUITING,2016-03-08,2026-10-15,2025-10-29,INTERVENTIONAL,PHASE1|PHASE2,30.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Advanced Malignant Solid Neoplasm|Advanced Peritoneal Malignant Mesothelioma|Advanced Pleural Malignant Mesothelioma|Recurrent Peritoneal Malignant Mesothelioma|Recurrent Pleural Malignant Mesothelioma|Refractory Malignant Solid Neoplasm|Unresectable Solid Neoplasm,Cisplatin|Methoxyamine|Pemetrexed Disodium,DRUG,3,2,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,14,United States,,1,1,0,0,1,1.5,0,0,0,0,7,3.4339872044851463,small,1,1,0,1,0,0,1,0,1,0,0,0,1,1,5,1,1,0,0,3,1,2016-03-08,2026-10-15,3873.0,2016.0,1,3,1
NCT00740181,"Decitabine, Cytarabine, GCSF for Refractory AML/MDS","A Phase II Study With Decitabine, Low Dose Cytarabine and G-CSF in High-risk Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia or Acute Myeloid Leukemia in Patients With Significant Co-morbidities.",TERMINATED,2008-08,2010-04,2022-01-14,INTERVENTIONAL,PHASE2,9.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Myelodysplasia|Leukemia,chemotherapy,DRUG,1,0,19 Years,,ALL,False,Brown University,OTHER,2,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,2,2.302585092994046,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,1,0
NCT02912312,Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer,Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): A Randomized Trial of Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer,ACTIVE_NOT_RECRUITING,2017-02-23,2031-02-28,2026-01-07,INTERVENTIONAL,PHASE2,805.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Invasive Breast Carcinoma|Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7,Hypofractionated Radiation Therapy|Laboratory Biomarker Analysis|Quality-of-Life Assessment|Questionnaire Administration|Radiation Therapy,OTHER|RADIATION,1,1,18 Years,,FEMALE,False,M.D. Anderson Cancer Center,OTHER,1,12,United States,,0,1,0,0,0,2.0,1,0,0,0,9,6.692083742506628,xlarge,0,1,0,1,0,1,1,0,1,0,1,0,1,1,2,1,0,0,0,5,1,2017-02-23,2031-02-28,5118.0,2017.0,1,2,0
NCT03719612,DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY,"A Phase III, Open-Label, Multicenter Trial to Evaluate Ejection Fraction, End-Diastolic and End-Systolic Volumes, by Unenhanced and DEFINITY®-Enhanced 2D-Echo and Magnetic Resonance Imaging",COMPLETED,2018-12-28,2020-01-09,2021-01-28,INTERVENTIONAL,PHASE3,160.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Cardiac Disease,DEFINITY®,DRUG,1,5,18 Years,,ALL,False,Lantheus Medical Imaging,INDUSTRY,1,15,United States,1.0,0,0,1,0,0,3.0,0,0,0,1,1,5.081404364984463,medium,0,1,1,0,0,1,1,0,1,0,0,0,0,0,6,1,1,0,0,1,0,2018-12-28,2020-01-09,377.0,2018.0,1,1,0
NCT01538381,Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck,Neoadjuvant Afatinib Based Treatment Strategies Followed by Surgery in Squamous Cell Carcinoma of the Head and Neck: an EORTC NOCI-HNCG Window Study.,COMPLETED,2012-07,2015-08,2018-07-09,INTERVENTIONAL,PHASE2,30.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,"Carcinoma, Squamous Cell of Head and Neck",Afatinib|Observation,DRUG|OTHER,1,1,18 Years,,ALL,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,1,4,Belgium|Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4339872044851463,small,1,1,0,0,0,1,1,1,0,1,1,0,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT00003119,Surgery in Treating Children With Neuroblastoma,Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study,COMPLETED,1998-03,2006-03,2017-03-13,INTERVENTIONAL,PHASE3,968.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Neuroblastoma,filgrastim|sargramostim|carboplatin|cyclophosphamide|doxorubicin hydrochloride|etoposide|adjuvant therapy|conventional surgery|radiation therapy,DRUG|RADIATION|PROCEDURE|BIOLOGICAL,1,0,,21 Years,ALL,False,Children's Oncology Group,NETWORK,1,235,Australia|United States|Puerto Rico|Canada|New Zealand|Switzerland|Netherlands,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.876264611890766,xlarge,0,1,0,0,0,1,1,1,1,0,0,0,1,0,1,0,1,1,0,9,1,,,,,0,2,0
NCT02724228,"A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)","A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia",ACTIVE_NOT_RECRUITING,2016-01-26,2028-02,2025-01-09,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Achondroplasia,BMN 111,DRUG,1,4,7 Years,,ALL,False,BioMarin Pharmaceutical,INDUSTRY,0,9,United Kingdom|France|Australia|United States,,0,1,0,0,0,2.0,0,0,0,0,1,3.4339872044851463,small,1,1,1,0,0,0,1,1,1,1,0,0,1,0,5,1,1,0,0,1,0,2016-01-26,,,2016.0,1,1,0
NCT04542330,Using BCG to Protect Senior Citizens During the COVID-19 Pandemic,Using BCG Vaccine to Enhance Non-specific Protection of Senior Citizens During the COVID-19 Pandemic. A Randomized Clinical Trial.,COMPLETED,2020-09-15,2023-01-11,2024-08-22,INTERVENTIONAL,PHASE3,1700.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Covid19|Non-specific Effects of Vaccines|Heterologous Immunity|Morbidity|Immunosenescence|Vaccine Preventable Disease,BCG-Denmark|Saline,BIOLOGICAL,1,3,65 Years,110 Years,ALL,True,Bandim Health Project,OTHER,3,1,Denmark,1.0,0,0,1,0,0,3.0,0,0,0,0,6,7.438971592395862,xlarge,0,1,0,1,0,1,0,0,0,0,1,1,0,1,4,1,0,1,0,2,1,2020-09-15,2023-01-11,848.0,2020.0,1,2,0
NCT00021567,"A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections","A Randomized, Double-Blinded, Placebo-Controlled, Phase II Study of the Safety and Efficacy of Inhaled Interferon Gamma-1b With Antimycobacterial in Previously Treated or Moderate to Severe Pulmonary Mycobacterium Avium Complex (MAC) Infection",COMPLETED,2001-07,2002-06,2008-03-04,INTERVENTIONAL,PHASE2,20.0,,,,TREATMENT,,Mycobacterium Avium-Intracellulare Infection,Interferon Gamma for Aerosol,DRUG,0,0,,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,0,0
NCT06342167,Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma,Efficacy and Safety of Concurrent Sintilimab and Radiotherapy With Immunonutrition Support in Esophageal Cancer: A Phase II Multicenter Clinical Trial,ACTIVE_NOT_RECRUITING,2024-03-14,2026-12-01,2024-06-11,INTERVENTIONAL,PHASE2,57.0,ESTIMATED,,SINGLE_GROUP,TREATMENT,NONE,Locally Advanced Esophageal Squamous Cell Carcinoma|Sintilimab|Radiotherapy|Concurrent Chemoradiotherapy|Immunonutrition,Radiotherapy|Programmed Cell Death Protein 1 Inhibitor|Immunonutrition support,DRUG|DIETARY_SUPPLEMENT|RADIATION,1,5,18 Years,80 Years,ALL,False,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",OTHER,0,9,China,,0,1,0,0,0,2.0,1,0,0,0,5,4.060443010546419,medium,1,0,0,1,0,0,1,0,0,0,0,0,1,0,6,1,1,0,0,3,1,2024-03-14,2026-12-01,992.0,2024.0,1,3,1
NCT00598507,Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma,Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma,COMPLETED,2007-05,2013-01,2013-12-11,INTERVENTIONAL,PHASE2,35.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Melanoma,ZK-EPO,DRUG,1,3,18 Years,,ALL,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.58351893845611,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT00103207,Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer,Phase II Study of C225 (Cetuximab) for the Treatment of Patients With Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma With BAC Features,COMPLETED,2005-10-13,2012-08,2023-06-28,INTERVENTIONAL,PHASE2,72.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lung Cancer,cetuximab,BIOLOGICAL,1,4,18 Years,,ALL,False,Eastern Cooperative Oncology Group,NETWORK,1,157,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.290459441148391,medium,1,1,0,0,0,1,1,0,1,0,0,0,1,0,5,1,0,1,0,1,0,2005-10-13,,,2005.0,0,0,0
NCT04345692,A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients,"A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients",TERMINATED,2020-03-26,2020-08-31,2020-11-17,INTERVENTIONAL,PHASE3,17.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,COVID-19,Hydroxychloroquine,DRUG,1,4,18 Years,95 Years,ALL,False,Queen's Medical Center,OTHER,0,1,United States,0.0,0,0,1,0,0,3.0,0,0,0,0,1,2.8903717578961645,small,1,1,0,1,0,0,0,0,1,0,1,0,1,1,5,1,1,0,0,1,0,2020-03-26,2020-08-31,158.0,2020.0,1,0,0
NCT01143792,Evaluation of Treatments for Homeless Youths,"Evaluation of Treatments for Homeless Youth: CRA, MET and Case Management",COMPLETED,2006-09,2012-06,2013-04-16,INTERVENTIONAL,PHASE2,270.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Substance Abuse,Community Reinforcement Approach (CRA) + HIV prevention|Case Management + HIV Prevention|Motivational Enhancement Therapy (MET) + HIV prevention,BEHAVIORAL,3,6,14 Years,20 Years,ALL,False,Ohio State University,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.602118820879701,large,0,1,0,1,0,1,0,0,1,0,1,0,1,1,9,1,0,0,0,3,1,,,,,0,2,0
NCT01765192,Roflumilast Plus Montelukast in Adults With Severe Asthma,"A Phase 2, Randomized, Double-Blind, 4-week Crossover Trial to Investigate the Effect of a Once-Daily Combination of 500 µg Roflumilast Plus 10 mg Montelukast vs 10 mg Montelukast Alone on Pulmonary Function, Asthma Symptoms, and Inflammatory Markers in Subjects With Severe Asthma Not Adequately Controlled With a Combination of at Least Medium Dose Inhaled Corticosteroids and Long-Acting Beta Agonists Maintenance Therapy",COMPLETED,2013-02,2013-10,2017-02-01,INTERVENTIONAL,PHASE2,64.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Asthma,Roflumilast|Roflumilast placebo|Montelukast,DRUG,1,6,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,13,Germany|Hungary|South Africa,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.174387269895637,medium,1,1,1,0,1,0,1,1,0,1,1,1,1,0,7,1,1,0,0,3,1,,,,,0,3,1
NCT04703192,"Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)","Single-arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects With Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)",ACTIVE_NOT_RECRUITING,2021-06-03,2027-02-19,2025-12-09,INTERVENTIONAL,PHASE2,155.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Relapsed/Refractory Peripheral T-Cell Lymphoma|Adult T Cell Leukemia/Lymphoma,Valemetostat Tosylate,DRUG,2,6,18 Years,,ALL,False,Daiichi Sankyo,INDUSTRY,0,60,United Kingdom|Australia|United States|Canada|Netherlands|South Korea|Taiwan|France|Spain|Germany|Japan|Italy,,0,1,0,0,0,2.0,1,0,0,0,2,5.049856007249537,medium,0,1,1,0,0,0,1,1,1,1,0,0,1,1,8,1,1,0,0,1,0,2021-06-03,2027-02-19,2087.0,2021.0,1,3,1
NCT00931736,Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness,A Randomized Clinical Trial of 4 Months of Rifampin vs. 9 Months of Isoniazid for Latent Tuberculosis Infection. Part 3 - Effectiveness,COMPLETED,2009-08,2017-04,2017-12-19,INTERVENTIONAL,PHASE3,6031.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Latent Tuberculosis Infection,Isoniazid|Rifampin,DRUG,1,5,18 Years,,ALL,False,McGill University,OTHER,1,12,Australia|Canada|Brazil|Ghana|Guinea|Benin|Saudi Arabia|South Korea|Indonesia,1.0,0,0,1,0,0,3.0,0,0,0,0,1,8.704833909687792,xlarge,0,1,0,1,0,1,1,1,0,0,1,0,1,1,6,1,1,0,0,2,1,,,,,0,3,1
NCT00988936,Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug,"A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug",COMPLETED,2009-09,2012-05,2012-08-22,INTERVENTIONAL,PHASE2,35.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,,NONE,Metastatic Breast Cancer|Metastatic Colon/Rectum Cancer|Non-squamous Non-small Cell Lung Cancer,[F-18]RGD-K5,DRUG,1,2,18 Years,,ALL,False,Siemens Molecular Imaging,INDUSTRY,0,8,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,3,3.58351893845611,small,1,1,1,0,0,0,1,0,1,0,0,0,0,0,3,1,1,0,0,1,0,,,,,0,1,0
NCT01591811,Prospective Trial of Two Prone Breast Radiotherapy Techniques With Randomization to Concurrent Versus Weekly Boost,Prospective Trial of Two Prone Breast Radiotherapy Techniques With Randomization to Concurrent Versus Weekly Boost,COMPLETED,2012-04-16,2015-04-30,2021-01-19,INTERVENTIONAL,PHASE3,433.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,Arm 1 Daily Boost of Radiation Therapy|Arm 2 Weekly Boost of Radiation Therapy,RADIATION,3,0,18 Years,,FEMALE,False,NYU Langone Health,OTHER,0,1,United States,1.0,0,0,1,0,0,3.0,1,0,0,0,1,6.073044534100405,large,0,1,0,1,0,0,0,0,1,0,1,0,1,1,3,0,0,0,0,2,1,2012-04-16,2015-04-30,1109.0,2012.0,0,1,0
NCT05304611,Anti-malaria MAb in Malian Children,"Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium Falciparum, in a Dose-Escalation Trial in Adults and Children and a Randomized, Double-Blind Trial of Children in Mali",COMPLETED,2022-03-18,2024-04-20,2025-07-10,INTERVENTIONAL,PHASE2,365.0,ACTUAL,RANDOMIZED,SEQUENTIAL,PREVENTION,TRIPLE,Plasmodium Falciparum Infection|Malaria,L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection|L9LS (VRC-MALMAB0114-00-AB) intravenous injection|Placebo,OTHER|BIOLOGICAL,12,7,6 Years,55 Years,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,6,2,Mali,1.0,0,1,0,0,0,2.0,0,0,0,0,2,5.902633333401366,large,0,1,0,1,0,1,1,0,0,0,1,1,0,0,19,1,0,1,0,3,1,2022-03-18,2024-04-20,764.0,2022.0,1,3,1
NCT01194271,Neoadjuvant Ipilimumab in Prostate Cancer,A Neoadjuvant Phase IIa Study of Ipilimumab {Formerly Known as MDX-010 (BMS-734016)} Plus Hormone Ablation in Men With Prostate Cancer Followed by Radical Prostatectomy.,COMPLETED,2010-09,2015-10,2024-06-06,INTERVENTIONAL,PHASE2,19.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,Leuprolide Acetate|Ipilimumab|Radical Prostatectomy,DRUG|PROCEDURE,1,0,18 Years,,MALE,False,M.D. Anderson Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.995732273553991,small,1,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,3,1,,,,,0,1,0
NCT03563144,QUILT-3.088: NANT Pancreatic Cancer Vaccine,QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients With Metastatic Pancreatic Cancer,WITHDRAWN,2018-08,2022-02-09,2025-02-21,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Metastatic Pancreatic Cancer,Gemcitabine|Nab-paclitaxel|Aldoxorubicin HCl|ALT-803|ETBX-011|ETBX-021|ETBX-051|ETBX-061|GI-4000|GI-6207|GI-6301|haNK|Avelumab|Bevacizumab|Capecitabine|Cyclophosphamide|5-Fluorouracil|Leucovorin|Oxaliplatin,DRUG|BIOLOGICAL,1,7,18 Years,,ALL,False,"ImmunityBio, Inc.",INDUSTRY,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,1,0,0,0,0,0,1,0,1,0,1,0,8,1,1,1,0,19,1,,2022-02-09,,,0,2,0
NCT04053634,Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations,"A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE)",COMPLETED,2019-08-26,2025-07-28,2025-08-19,INTERVENTIONAL,PHASE3,689.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Chronic Obstructive Pulmonary Disease,Benralizumab|Placebo,BIOLOGICAL,1,16,40 Years,85 Years,ALL,False,AstraZeneca,INDUSTRY,0,343,Canada|Austria|China|Hungary|Argentina|Australia|Bulgaria|Spain|Belgium|Italy|Chile|United States|Sweden|Colombia|Vietnam|Czechia|Germany|Greece|Netherlands|Poland|India|South Korea|United Kingdom|Turkey (Türkiye)|Denmark|Brazil|Philippines|New Zealand|Mexico|Japan,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.536691597591305,xlarge,0,1,1,0,1,0,1,1,1,1,1,1,1,1,17,1,0,1,0,2,1,2019-08-26,2025-07-28,2163.0,2019.0,1,3,1
NCT00544934,Multiple Dose Trial of Anti-glycation Agent GLY-230 in Healthy and Diabetic Subjects,"A Dose-ranging Study to Evaluate the Safety, Metabolism and Therapeutic Dosing of Three Multiple Dose Levels of GLY-230 in Healthy and Diabetic Subjects",COMPLETED,2007-02,2007-10,2016-02-10,INTERVENTIONAL,PHASE1|PHASE2,42.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Diabetic Nephropathy,GLY-230|Placebo,DRUG|OTHER,1,1,18 Years,55 Years,MALE,True,Glycadia,INDUSTRY,0,0,,1.0,1,1,0,0,1,1.5,0,0,0,0,1,3.7612001156935624,small,1,1,1,0,0,0,0,0,0,0,1,0,1,1,2,1,1,0,0,2,1,,,,,0,2,0
NCT02644057,Dobutamaine Versus Milrinone in Cardiorenal Syndrome,Comparison of Dobutamine Versus Milrinone for Renal Recovery in Patients With Cardiorenal Syndrome-A Prospective Cohort Study in Patients With Acute Decompensated Heart Failure,WITHDRAWN,2016-03,2016-09,2018-08-10,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Cardiorenal Syndrome,Milrinone|Dobutamine,DRUG,1,5,18 Years,95 Years,ALL,False,Maimonides Medical Center,OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,0.0,,1,1,0,1,0,0,0,0,1,0,1,0,1,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT00315757,Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma,"A Phase 2, Multi-Center, Open-Label, Randomized Study of Mapatumumab (TRM-1 [HGS1012], a Fully Human Monoclonal Antibody to TRAIL-R1) in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma",COMPLETED,2006-05,2010-10,2013-08-08,INTERVENTIONAL,PHASE2,105.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Multiple Myeloma,Mapatumumab|Mapatumumab|Bortezomib,DRUG|BIOLOGICAL,1,1,18 Years,,ALL,False,Human Genome Sciences Inc.,INDUSTRY,0,20,Canada|India|Australia|United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.663439094112067,medium,0,1,1,0,0,0,1,1,1,0,1,0,1,1,2,1,1,1,0,3,1,,,,,0,2,0
NCT00401401,Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer,"An Open-labeled Trial With a Dose-escalation Part and a Parallel Group Design(1) Investigating Zalutumumab, an Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation as First Line Treatment of Patients With Cancer of the Head and Neck (1) The Parallel Group Part Was Cancelled",TERMINATED,2006-12,2010-10,2011-12-23,INTERVENTIONAL,PHASE1|PHASE2,30.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,NONE,Head and Neck Cancer|Squamous Cell Cancer,zalutumumab|cisplatin|Radiotherapy,DRUG|PROCEDURE,1,3,18 Years,,ALL,False,Genmab,INDUSTRY,0,7,United States|Sweden|France|Netherlands|Belgium,0.0,1,1,0,0,1,1.5,1,0,0,0,2,3.4339872044851463,small,1,1,1,0,0,0,1,1,1,1,0,0,1,1,4,1,1,0,0,3,1,,,,,0,4,1
NCT00134212,Dopexamine and Norepinephrine Compared With Epinephrine Alone in Septic Shock,"Prospective, Randomized Study on Two Parallel Groups Comparing Dopexamine and Norepinephrine in Combination to Epinephrine Alone on Systemic and Pulmonary Hemodynamics, Gastric Mucosal Perfusion, and Oxidative Stress in Septic Shock",COMPLETED,2002-03,2004-06,2006-01-02,INTERVENTIONAL,PHASE2,20.0,,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Septic Shock,Dopexamine and norepinephrine|Epinephrine,DRUG,1,8,18 Years,,ALL,False,Rennes University Hospital,OTHER,0,1,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.044522437723423,small,1,0,0,1,0,0,0,0,0,1,1,0,1,1,9,1,1,0,0,2,1,,,,,0,2,0
NCT03042312,Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy,PSMA-directed endoRadiothErapy of Castration-reSISTant Prostate Cancer (RESIST-PC). A Phase II Clinical Trial,TERMINATED,2017-07-12,2020-01-15,2021-03-24,INTERVENTIONAL,PHASE2,71.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Metastatic Castration Resistant Prostate Cancer,177Lu-PSMA-617,DRUG,2,8,18 Years,,MALE,False,Endocyte,INDUSTRY,0,2,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,4.276666119016055,medium,1,1,1,0,0,0,1,0,1,0,0,0,1,0,10,1,1,0,0,1,0,2017-07-12,2020-01-15,917.0,2017.0,1,1,0
NCT00720512,Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab,"AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS BEVACIZUMAB.",TERMINATED,2008-06,2014-03,2015-03-11,INTERVENTIONAL,PHASE3,184.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Colorectal Cancer,bevacizumab|fluorouracil|irinotecan hydrochloride|leucovorin calcium|oxaliplatin,DRUG|BIOLOGICAL,1,3,18 Years,75 Years,ALL,False,Gruppo Oncologico del Nord-Ovest,OTHER,0,21,Italy,0.0,0,0,1,0,0,3.0,1,0,0,0,1,5.220355825078324,medium,0,1,0,1,0,0,1,0,0,1,1,0,1,1,4,1,1,1,0,5,1,,,,,0,1,0
NCT06586112,A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis,"A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis (ONWARD1)",ACTIVE_NOT_RECRUITING,2024-07-25,2025-12,2025-12-09,INTERVENTIONAL,PHASE3,840.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Plaque Psoriasis,ESK-001|Apremilast|Placebo,DRUG,1,10,18 Years,,ALL,False,Alumis Inc,INDUSTRY,0,158,Australia|Bulgaria|United States|Canada|Poland|Portugal|Czechia|Germany|Japan|South Korea,,0,0,1,0,0,3.0,0,1,0,0,1,6.734591659972948,xlarge,0,0,1,0,0,0,1,1,1,1,1,1,1,1,11,1,1,0,0,3,1,2024-07-25,,,2024.0,1,3,1
NCT03961919,Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant,Evaluation of Safety and Efficacy of Treosulfan-cytarabine-fludarabine (FLAT) Combination Prior to Autologous Stem Cell Transplant (HSCT) in Elderly Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),COMPLETED,2009-02-10,2021-12-31,2023-11-18,INTERVENTIONAL,PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Acute Myeloid Leukemia|Myelodysplastic Syndromes|Transplant-Related Hematologic Malignancy,Fludarabine|ARA-C|Treosulfan|Peripheral Blood Stem Cell Transplant,DRUG|PROCEDURE,1,0,65 Years,,ALL,False,Ciceri Fabio,OTHER,0,1,Italy,1.0,0,1,0,0,0,2.0,1,0,0,0,3,2.772588722239781,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,4,1,2009-02-10,2021-12-31,4707.0,2009.0,0,2,0
NCT02820519,"Tolerability and Analgesic Efficacy of Loxapine in Patients With Refractory, Chemotherapy-induced Neuropathic Pain","Tolerability and Analgesic Efficacy of Loxapine in Patients With Refractory, Chemotherapy-induced Neuropathic Pain",TERMINATED,2016-06-07,2017-05-04,2022-07-01,INTERVENTIONAL,PHASE2,4.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Neuropathic Pain,Loxapine,DRUG,1,12,18 Years,,ALL,False,University of Witten/Herdecke,OTHER,0,1,Germany,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.6094379124341003,small,1,1,0,1,0,0,0,0,0,1,0,0,1,0,13,1,1,0,0,1,0,2016-06-07,2017-05-04,331.0,2016.0,1,1,0
NCT02839330,"A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age","A Phase 3 Randomized, Observer-Blind, Multi-center, Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age",COMPLETED,2016-07-11,2017-10-04,2024-12-06,INTERVENTIONAL,PHASE3,3196.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Avian Influenza,aH5N1c|Placebo,BIOLOGICAL,5,7,18 Years,,ALL,True,Seqirus,INDUSTRY,1,26,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,8.069968149059841,xlarge,0,1,1,0,0,1,1,0,1,0,1,1,0,1,12,1,0,1,0,2,1,2016-07-11,2017-10-04,450.0,2016.0,1,2,0
NCT01096628,Chiropractic and Exercise for Low Back Pain in Adolescents,Chiropractic and Exercise for Low Back Pain in Adolescents,COMPLETED,2010-03,2013-12,2014-01-31,INTERVENTIONAL,PHASE2|PHASE3,185.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Low Back Pain,Chiropractic + Exercise|Exercise,OTHER,1,10,12 Years,18 Years,ALL,False,Northwestern Health Sciences University,OTHER,2,2,United States,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.225746673713202,medium,0,1,0,1,0,1,1,0,1,0,1,0,1,1,11,1,0,0,0,2,1,,,,,0,3,1
NCT05771428,"Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease","A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-552 in Participants With Mild Alzheimer's Disease",COMPLETED,2023-06-05,2024-09-12,2025-10-15,INTERVENTIONAL,PHASE2,263.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Alzheimer's Disease (AD),ABBV-552|Placebo for ABBV-552,DRUG,1,0,50 Years,90 Years,ALL,False,AbbVie,INDUSTRY,0,64,United Kingdom|Australia|United States|New Zealand|Spain|Germany|Japan,1.0,0,1,0,0,0,2.0,0,0,1,0,1,5.575949103146316,large,0,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,0,2,1,2023-06-05,2024-09-12,465.0,2023.0,1,2,0
NCT02096328,"Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia","A Phase II, Open-label, Multi-center Study to Assess Pharmacokinetics (PK), Safety and Efficacy of POL7080 Co-administered With Standard of Care (SoC) Treatment in Patients With Ventilator- Associated Pneumonia (VAP) Due to Suspected or Documented Pseudomonas Aeruginosa Infection.",COMPLETED,2013-10,2016-12,2017-11-28,INTERVENTIONAL,PHASE2,25.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Ventilator Associated Pneumonia|Lower Respiratory Infection,POL7080,DRUG,1,2,18 Years,,ALL,False,Polyphor Ltd.,INDUSTRY,0,10,Greece|Spain,1.0,0,1,0,0,0,2.0,0,0,0,0,2,3.258096538021482,small,1,1,1,0,0,0,1,1,0,1,0,0,1,0,3,1,1,0,0,1,0,,,,,0,2,0
NCT04741828,Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian,"Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian Adults, Adolescent, Children and Infants",COMPLETED,2021-05-03,2024-12-30,2025-06-03,INTERVENTIONAL,PHASE2|PHASE3,188.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Vaccine,Vi-DT Typhoid Conjugate Vaccine,DRUG,1,4,6 Months,40 Years,ALL,True,PT Bio Farma,INDUSTRY,1,2,Indonesia,1.0,0,1,1,0,1,2.5,0,0,0,0,1,5.241747015059643,medium,0,1,1,0,0,1,1,0,0,0,0,0,0,0,5,1,1,0,0,1,0,2021-05-03,2024-12-30,1337.0,2021.0,1,1,0
NCT00210028,Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer,"Open, Single-Arm Phase II Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer Expressing the Estrogen and/or Progesterone Receptor",TERMINATED,2003-08,2008-08,2006-11-14,INTERVENTIONAL,PHASE2,40.0,,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Breast Neoplasms,Tamoxifen|Zarnestra,DRUG,1,5,18 Years,,FEMALE,False,Institut Claudius Regaud,OTHER,1,3,France,0.0,0,1,0,0,0,2.0,0,0,0,0,1,3.713572066704308,small,1,0,0,1,0,1,1,0,0,1,0,0,1,0,6,1,1,0,0,2,1,,,,,0,2,0
NCT02596867,Neoadjuvant Propanolol in Breast Cancer,"Pilot ""Window of Opportunity"" Neoadjuvant Study of Propranolol in Breast Cancer",TERMINATED,2015-09-01,2017-05-01,2018-03-01,INTERVENTIONAL,PHASE2,2.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Breast Cancer,propanolol,DRUG,1,1,18 Years,65 Years,FEMALE,False,"Texas Tech University Health Sciences Center, El Paso",OTHER,0,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,0,1,1.0986122886681098,small,1,1,0,1,0,0,0,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2015-09-01,2017-05-01,608.0,2015.0,1,0,0
NCT03197467,Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer,Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer [NEOMUN],COMPLETED,2018-06-18,2023-05-05,2025-04-04,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Non-small Cell Lung Cancer (NSCLC),Pembrolizumab,DRUG,5,5,18 Years,,ALL,False,AIO-Studien-gGmbH,OTHER,1,1,Germany,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,1,0,0,0,1,0,0,1,0,10,1,1,0,0,1,0,2018-06-18,2023-05-05,1782.0,2018.0,1,1,0
NCT00286000,High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study,High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study,COMPLETED,2004-06,2005-12,2007-12-28,INTERVENTIONAL,PHASE2,106.0,,RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Advanced Colorectal Cancer,Administration of high dose simplified folfiri,DRUG,1,3,18 Years,69 Years,ALL,False,"University Hospital, Ghent",OTHER,0,1,Belgium,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.672828834461906,medium,0,0,0,1,0,0,0,0,0,0,1,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT00359892,Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma,"A Multi-Center, Open-Label Phase II Study of Single-Agent GX15-070MS Administered as a 24-Hour Infusion Every 2 Weeks to Patients With Relapsed or Refractory Hodgkin's Lymphoma",COMPLETED,2006-07,2008-11,2012-08-06,INTERVENTIONAL,PHASE2,13.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Hodgkin's Lymphoma,Obatoclax mesylate (GX15-070MS),DRUG,1,0,18 Years,,ALL,False,Gemin X,INDUSTRY,0,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,2.6390573296152584,small,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,,,,,0,0,0
NCT00106236,Efficacy of Exercise at a Fitness Club for Cardiovascular Risk Reduction,Sapporo Fitness Club Trial (SFCT): A Randomized Controlled Trial to Test the Efficacy of Exercise at a Fitness Club for the Reduction of Cardiovascular Risk Factors,COMPLETED,2003-04,2004-04,2009-07-14,INTERVENTIONAL,PHASE1|PHASE2,561.0,,RANDOMIZED,PARALLEL,,NONE,Diabetes Mellitus|Hypertension|Hyperlipidemia,exercise,BEHAVIORAL,3,12,45 Years,89 Years,ALL,False,Sapporo Health Promotion Foundation,OTHER,0,1,Japan,1.0,1,1,0,0,1,1.5,0,0,0,1,3,6.331501849893691,xlarge,0,0,0,1,0,0,0,0,0,0,1,0,0,1,15,1,0,0,0,1,0,,,,,0,3,1
NCT00366236,Study of Nitazoxanide in the Treatment of Amebiasis in Adults and Adolescents,"Multi-Center, Double-Blind, Placebo-Controlled Study of Nitazoxanide Tablets in the Treatment of Diarrhea Caused by Entamoeba Histolytica in Adults and Adolescents",COMPLETED,2004-02,2005-11,2006-08-21,INTERVENTIONAL,PHASE3,50.0,,RANDOMIZED,SINGLE_GROUP,TREATMENT,DOUBLE,Amebiasis,Nitazoxanide,DRUG,1,2,12 Years,,ALL,False,Romark Laboratories L.C.,INDUSTRY,0,2,Egypt,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.9318256327243257,small,1,0,1,0,0,0,1,0,0,0,1,1,1,0,3,1,1,0,0,1,0,,,,,0,0,0
NCT01968044,A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study),"A Multicenter,Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase IIIb Study to Evaluate the Safety and Efficacy After 12 Weeks Administration of Gemigliptin and Placebo in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment With an Additional 40 Weeks, Double-blind,Active-controlled, Double-dummy,Long-term Extension Study",COMPLETED,2013-10,2015-10,2016-03-23,INTERVENTIONAL,PHASE3,132.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Type 2 DM Patients With Moderate or Severe Renal Impairment,Gemigliptin|Placebo to Linagliptin,DRUG,1,9,19 Years,75 Years,ALL,False,LG Life Sciences,INDUSTRY,0,1,South Korea,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.890349128221754,medium,0,1,1,0,0,0,0,0,0,0,1,1,1,1,10,1,1,0,0,2,1,,,,,0,2,0
NCT04959344,Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V),Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V) Administered to Healthy Adults: A FTIH Phase I/II Randomized and Controlled Study,COMPLETED,2021-07-05,2022-09-26,2022-10-04,INTERVENTIONAL,PHASE1|PHASE2,166.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,TRIPLE,Klebsiella Pneumoniae Infection,Kleb4V target dose|Kleb4V target dose + AS03|Kleb4V low dose|Kleb4V low dose + AS03|Placebo,BIOLOGICAL,4,0,18 Years,70 Years,ALL,True,LimmaTech Biologics AG,INDUSTRY,1,2,Germany,1.0,1,1,0,0,1,1.5,0,0,0,0,1,5.117993812416755,medium,0,1,1,0,0,1,1,0,0,1,1,1,0,1,4,0,0,1,0,5,1,2021-07-05,2022-09-26,448.0,2021.0,1,2,0
NCT01190709,Study of Tibial Shaft Fracture Fixation: Intramedullary Nailing Comparing With Dynamic Compression Plate,Study of Surgical Methods for Treatment of Tibial Fractures,COMPLETED,2008-10,2009-03,2010-08-30,INTERVENTIONAL,PHASE2,100.0,ACTUAL,NON_RANDOMIZED,PARALLEL,TREATMENT,SINGLE,Tibial Shaft Fracture,Dynamic Compression Plate|Unreamed intramedullary nailing,PROCEDURE,1,3,,,ALL,True,Isfahan University of Medical Sciences,OTHER,0,1,Iran,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.61512051684126,medium,0,1,0,1,0,0,0,0,0,0,0,0,1,1,4,1,0,0,0,2,1,,,,,0,1,0
NCT03691909,Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis,A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis,COMPLETED,2018-09-25,2020-09-28,2025-09-26,INTERVENTIONAL,PHASE1|PHASE2,15.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Rheumatoid Arthritis,HB-adMSCs,BIOLOGICAL,1,5,18 Years,65 Years,ALL,False,Hope Biosciences LLC,INDUSTRY,0,1,United States,1.0,1,1,0,0,1,1.5,0,1,0,0,1,2.772588722239781,small,1,1,1,0,0,0,0,0,1,0,0,0,1,0,6,1,0,1,0,1,0,2018-09-25,2020-09-28,734.0,2018.0,1,2,0
NCT00721799,F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients,F-18 Fluorothymidine (FLT) PET Imaging for Early Evaluation of Response to Chemoradiation Therapy in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC),COMPLETED,2008-03-01,2014-12-31,2019-08-06,INTERVENTIONAL,PHASE2,33.0,ACTUAL,,SINGLE_GROUP,DIAGNOSTIC,NONE,Mouth Neoplasms|Oropharyngeal Neoplasms|Laryngeal Neoplasms|Head and Neck Neoplasms,18F-Fluorothymidine PET scan,DRUG,32,0,18 Years,,ALL,False,University of Iowa,OTHER,2,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,4,3.5263605246161616,small,1,1,0,1,0,1,0,0,1,0,0,0,0,0,32,0,1,0,0,1,0,2008-03-01,2014-12-31,2496.0,2008.0,0,2,0
NCT03391232,PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO),"Safety, Tolerability, Immunogenicity and Efficacy of Multiple PolyPEPI1018 Vaccinations as an Add-on Immunotherapy to the Standard-of-Care Maintenance Therapy in Subjects With Metastatic Colorectal Cancer",COMPLETED,2018-05-03,2019-07-17,2022-05-26,INTERVENTIONAL,PHASE1|PHASE2,11.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Colorectal Cancer,PolyPEPI1018 CRC Vaccine,BIOLOGICAL,1,2,18 Years,75 Years,ALL,False,Treos Bio Zrt,INDUSTRY,5,2,Italy|United States,1.0,1,1,0,0,1,1.5,1,0,0,0,1,2.4849066497880004,small,1,1,1,0,0,1,1,1,1,1,0,0,1,0,3,1,0,1,0,1,0,2018-05-03,2019-07-17,440.0,2018.0,1,2,0
NCT01624532,"A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109","A Phase 2 Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Administered in Multi Intramuscular Doses to Healthy Subjects",COMPLETED,2021-07-14,2022-12-19,2023-01-04,INTERVENTIONAL,PHASE2,240.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,Anthrax,GC1109 or Placebo of GC1109,BIOLOGICAL,2,8,19 Years,65 Years,ALL,True,Green Cross Corporation,INDUSTRY,1,1,South Korea,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.484796933490655,large,0,1,1,0,0,1,0,0,0,0,1,1,0,1,10,1,0,1,0,1,0,2021-07-14,2022-12-19,523.0,2021.0,1,1,0
NCT02132832,"Buspirone, Stress, and Attentional Bias to Marijuana Cues","Buspirone, Stress, and Attentional Bias to Marijuana Cues",COMPLETED,2013-06,2016-03,2017-06-02,INTERVENTIONAL,PHASE2,45.0,ACTUAL,RANDOMIZED,PARALLEL,BASIC_SCIENCE,TRIPLE,Cannabis Use Disorder,Buspirone|Placebo,DRUG,12,0,18 Years,45 Years,ALL,False,"The University of Texas Health Science Center, Houston",OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.828641396489095,small,1,1,0,1,0,1,0,0,1,0,1,1,0,1,12,0,1,0,0,2,1,,,,,0,2,0
NCT00097032,Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients,Differences in Cognitive Function Due to Acute Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Out-Patients.,COMPLETED,2004-10,2005-05,2011-05-24,INTERVENTIONAL,PHASE3,30.0,ACTUAL,RANDOMIZED,CROSSOVER,,DOUBLE,Bipolar Disorder,risperidone; quetiapine,DRUG,1,1,18 Years,45 Years,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,1,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.4339872044851463,small,1,1,1,0,0,1,0,0,0,0,1,1,0,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT02088632,Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia,"A Randomized, Double-Blind, Placebo-Controlled, Add-on Therapy Study of Xeomin (Incobotulinumtoxina) Versus Placebo in the Treatment of Trigeminal Neuralgia",TERMINATED,2014-03-14,2016-10-19,2023-06-28,INTERVENTIONAL,PHASE2,6.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,Trigeminal Neuralgia,Incobotulinumtoxina|Placebo Comparator,OTHER|BIOLOGICAL,1,1,18 Years,75 Years,ALL,False,Thomas Jefferson University,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,0,0,0,0,1,1.9459101490553132,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,2,1,0,1,0,2,1,2014-03-14,2016-10-19,950.0,2014.0,0,1,0
NCT01189032,Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye,Dose-Response Study of DE-089 Ophthalmic Solution in Patients With Dry Eye -Late Phase II Confirmatory Study-,COMPLETED,,,2014-08-13,INTERVENTIONAL,PHASE2,320.0,ACTUAL,,,,,Dry Eye,DE-089 ophthalmic solution|DE-089 ophthalmic solution|Placebo ophthalmic solution,DRUG,1,0,20 Years,,ALL,,"Santen Pharmaceutical Co., Ltd.",INDUSTRY,0,1,Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.771441123130016,large,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,3,1,,,,,0,1,0
NCT01224132,Effect of Probiotics in the Atopic Dermatitis,Effect of Probiotics in the Treatment of Children With Atopic Dermatitis,COMPLETED,2007-10,2008-04,2010-10-19,INTERVENTIONAL,PHASE3,40.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,DOUBLE,"Atopic Dermatitis, Probiotics",probiotic ® pur,DRUG,0,0,8 Weeks,8 Weeks,ALL,True,Yuzuncu Yil University,OTHER,0,0,,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.713572066704308,small,1,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,,,,,0,0,0
NCT01839032,Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy,A Phase II Study of Cisplatin With Intravenous and Oral Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemotherapy With Oral Vinorelbine and Cisplatine for Locally Advances Non-small Cell Lung Cancer,COMPLETED,2005-05,2008-10,2013-04-24,INTERVENTIONAL,PHASE2,70.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Lung Cancer,Vinorelbine cisplatin radiotherapy,DRUG,1,1,18 Years,75 Years,ALL,False,Pierre Fabre Medicament,INDUSTRY,0,1,France,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.2626798770413155,medium,1,1,1,0,0,0,0,0,0,1,0,0,1,0,2,1,1,0,0,1,0,,,,,0,0,0
NCT06409663,A Strain Change Study for SARS-CoV-2 rS Vaccines,"A Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of a JN.1 Subvariant SARS CoV-2 rS Vaccine",COMPLETED,2024-10-14,2025-04-17,2025-07-18,INTERVENTIONAL,PHASE3,60.0,ACTUAL,,SINGLE_GROUP,PREVENTION,NONE,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,NVX-CoV2705 Vaccine,BIOLOGICAL,3,6,18 Years,90 Years,ALL,True,Novavax,INDUSTRY,0,2,United States,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.110873864173311,medium,1,1,1,0,0,0,1,0,1,0,0,0,0,0,9,1,0,1,0,1,0,2024-10-14,2025-04-17,185.0,2024.0,1,1,0
NCT00974363,Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612,Persistence of Antibodies After Vaccination With GSK Biologicals' Meningococcal Vaccine GSK134612 in Adolescents and Young Adults,COMPLETED,2009-09,2013-05,2017-04-12,INTERVENTIONAL,PHASE3,697.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,NONE,"Infections, Meningococcal",Blood Sampling,PROCEDURE,4,4,11 Years,17 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,5,Philippines|India,1.0,0,0,1,0,0,3.0,0,0,0,0,1,6.548219102762372,xlarge,0,1,1,0,0,0,1,1,0,0,1,0,0,1,8,1,0,0,0,1,0,,,,,0,2,0
NCT02154763,The Use of Intraperitoneal Ropivacaine in Bariatric Bypass Surgery,"A Pilot Study to Assess the Feasibility of a Future Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Role of Intra-Peritoneal Ropivacaine in Gastric Bypass Surgery: INOPAIN Trial",COMPLETED,2014-07,2015-07,2019-03-19,INTERVENTIONAL,PHASE3,120.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Bariatric Surgery Candidate,Ropivacaine|Normal Saline,DRUG,11,43,18 Years,,ALL,False,Ottawa Hospital Research Institute,OTHER,0,1,Canada,1.0,0,0,1,0,0,3.0,0,0,0,0,1,4.795790545596741,medium,0,1,0,1,0,0,0,0,0,0,1,1,1,1,54,1,1,0,0,2,1,,,,,0,2,0
NCT02384187,Gabapentin Premedication and Adenotonsillectomy in Pediatric Patients,The Effects of Oral Gabapentin Premedication on Postoperative Nausea and Vomiting and Early Postoperative Recovery Profile in Pediatric Patients Undergoing Adenotonsillectomy,COMPLETED,2015-01,2015-08,2015-12-23,INTERVENTIONAL,PHASE3,140.0,ACTUAL,RANDOMIZED,PARALLEL,SUPPORTIVE_CARE,QUADRUPLE,Post Operative Nausea and Vomiting (PONV)|Adenotonsillectomy,Gabapentin as premedication|placebo,DRUG,1,6,3 Years,12 Years,ALL,False,Cairo University,OTHER,0,1,Egypt,1.0,0,0,1,0,0,3.0,0,0,0,0,2,4.948759890378168,medium,0,1,0,1,0,0,0,0,0,0,1,1,0,1,7,1,1,0,0,2,1,,,,,0,3,1
NCT00641693,Assess the Efficacy and Safety of Rhinocort Aqua,"A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Phase II Study to Assess the Efficacy and Safety of RHINOCORT AQUA (Budesonide) Nasal Spray 16mg, 32mg and 64mg Per Day Versus Placebo in Paediatric Subjects Ages 2-5 Years Old With Allergic Rhinitis.",COMPLETED,2004-04,2005-05,2011-01-24,INTERVENTIONAL,PHASE2,650.0,ESTIMATED,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Allergic Rhinitis,Budesonide|Budesonide|Budesonide|Placebo,DRUG,1,2,2 Years,5 Years,ALL,False,AstraZeneca,INDUSTRY,0,0,,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.478509642208569,xlarge,0,0,1,0,1,0,0,0,0,0,1,1,1,1,3,1,1,0,0,4,1,,,,,0,1,0
NCT05949021,OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer,OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple Negative Breast Cancer,ACTIVE_NOT_RECRUITING,2023-10-07,2027-09-30,2025-11-14,INTERVENTIONAL,PHASE2,30.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Triple Negative Breast Cancer (TNBC),Combination of liposomal doxorubicin,DRUG,1,1,,,FEMALE,False,"Mridula George, MD",OTHER,0,8,United States,,0,1,0,0,0,2.0,1,0,0,0,1,3.4339872044851463,small,1,1,0,1,0,0,1,0,1,0,0,0,1,0,2,1,1,0,0,1,0,2023-10-07,2027-09-30,1454.0,2023.0,1,0,0
NCT06385821,A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus,"Multicenter, Double-blind, Randomized, Parallel Group Study to Evaluate the Immunogenicity, Reactogenicity and Safety of the Grippol® Quadrivalent Vaccine in Children Aged 6 Months to 5 Years (Inclusive)",COMPLETED,2022-09-21,2023-10-09,2024-04-26,INTERVENTIONAL,PHASE3,824.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,"Influenza|Influenza A|Influenza, Human|Influenza Type B|Flu|Influenza A H3N2|Influenza A H1N1|Influenza Epidemic|Flu, Human|Acute Respiratory Infection|Vaccine Reaction",Grippol Quadrivalent|Grippol Plus,BIOLOGICAL,1,9,6 Months,5 Years,ALL,True,NPO Petrovax,INDUSTRY,0,14,Russia,1.0,0,0,1,0,0,3.0,0,0,0,0,11,6.715383386334681,xlarge,0,1,1,0,0,0,1,0,0,0,1,1,0,1,10,1,0,1,0,2,1,2022-09-21,2023-10-09,383.0,2022.0,1,3,1
NCT03861416,"""Unifuzol®"" in Patients With Peripheral Arterial Disease","A Multicentre, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Unifuzol® in Patients With Peripheral Arterial Disease",COMPLETED,2018-03-16,2019-10-26,2020-01-31,INTERVENTIONAL,PHASE2,360.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Peripheral Arterial Disease,L-arginine 1.4% 500 ml|L-arginine 1.4% 250 ml + placebo 250 ml|Placebo solution,DRUG,1,0,40 Years,79 Years,ALL,False,POLYSAN Scientific & Technological Pharmaceutical Company,INDUSTRY,0,19,Russia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.8888779583328805,large,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,3,1,2018-03-16,2019-10-26,589.0,2018.0,1,1,0
NCT00949806,Restless Legs Syndrome Treatment With Botulinum Toxin,"Phase II Non Comparative, Open Study to Assess the Efficacy and Safety of the Botulinum Toxin Type A in Patients With Restless Legs Syndrome (RLS)",COMPLETED,2009-08,2011-11,2012-07-19,INTERVENTIONAL,PHASE2,27.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Restless Legs Syndrome,BNT (intradermal injection),DRUG,1,3,18 Years,,ALL,False,"University Hospital, Bordeaux",OTHER,1,1,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,3.332204510175204,small,1,1,0,1,0,1,0,0,0,1,0,0,1,0,4,1,1,0,0,1,0,,,,,0,0,0
NCT02674204,STOP Heart Disease in Breast Cancer Survivors Trial,Statin Therapy Operates to Prevent (STOP) Heart Disease in Breast Cancer Survivors Trial,TERMINATED,2016-05-05,2018-05-25,2019-05-15,INTERVENTIONAL,PHASE2,2.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Breast Cancer|Heart Disease|Cardiotoxicity|Myocardial Dysfunction,Atorvastatin|Placebo,DRUG,1,14,18 Years,,FEMALE,False,Cedars-Sinai Medical Center,OTHER,1,1,United States,0.0,0,1,0,0,0,2.0,1,0,0,1,4,1.0986122886681098,small,1,1,0,1,0,1,0,0,1,0,1,1,1,1,15,1,1,0,0,2,1,2016-05-05,2018-05-25,750.0,2016.0,1,3,1
NCT02541604,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors","An Early-Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) In Pediatric and Young Adult Patients With Previously Treated Solid Tumors",TERMINATED,2015-11-30,2019-06-06,2020-02-25,INTERVENTIONAL,PHASE1|PHASE2,87.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Solid Tumor,Atezolizumab,DRUG,15,16,,30 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,30,United Kingdom|Denmark|United States|Canada|France|Spain|Italy|Switzerland|Germany|Netherlands|Israel,0.0,1,1,0,0,1,1.5,1,0,0,0,1,4.477336814478207,medium,1,1,1,0,1,0,1,1,1,1,0,0,1,0,31,1,1,0,0,1,0,2015-11-30,2019-06-06,1284.0,2015.0,1,3,1
NCT00386204,Side Effects of Q-Switched Ruby Laser for the Treatment of Lentigines in Light and Dark Skin Types,Efficacy and Side Effects of Q-Switched Ruby Laser Treatment of Solar Lentigines in Two Different Fitzpatrick Skin Types II and IV,COMPLETED,2005-11,2006-09,2008-06-04,INTERVENTIONAL,PHASE2,90.0,,RANDOMIZED,SINGLE_GROUP,TREATMENT,SINGLE,Solar Lentigines,Q-switched Ruby Laser,DEVICE,2,0,,80 Years,ALL,True,Shahid Beheshti University of Medical Sciences,OTHER,0,1,Iran,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.51085950651685,medium,1,0,0,1,0,0,0,0,0,0,1,0,1,0,2,0,0,0,1,1,0,,,,,0,0,0
NCT02341404,"A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer","An Open, Single Dose, Antitumour Effect Study of 2-hydroxy-flutamide as a Controlled Release Product (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer",COMPLETED,2012-05,2015-05,2016-03-11,INTERVENTIONAL,PHASE2,23.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Prostate Cancer,2-hydroxyflutamide (2-HOF),DRUG,3,7,50 Years,75 Years,MALE,False,Lidds AB,INDUSTRY,1,2,Sweden|Finland,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.1780538303479458,small,1,1,1,0,0,1,1,1,0,0,0,0,1,0,10,1,1,0,0,1,0,,,,,0,2,0
NCT00829933,Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation,A Randomized Dose-ranging Controlled Trial of DU-176b Versus Warfarin Potassium in Patients With Non-valvular Atrial Fibrillation,COMPLETED,2007-03,2008-09,2019-02-25,INTERVENTIONAL,PHASE2,536.0,ACTUAL,RANDOMIZED,PARALLEL,PREVENTION,QUADRUPLE,Atrial Fibrillation,DU-176b tablets|Warfarin potassium tablets,DRUG,1,5,20 Years,,ALL,False,"Daiichi Sankyo Co., Ltd.",INDUSTRY,0,1,Japan,1.0,0,1,0,0,0,2.0,0,0,0,0,1,6.285998094508865,xlarge,0,1,1,0,0,0,0,0,0,0,1,1,0,1,6,1,1,0,0,2,1,,,,,0,2,0
NCT01841333,PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant,A Phase 2 Study of PF-04449913 for the Treatment of Acute Myeloid Leukemia Patients With High Risk of Post-Allogeneic Stem Cell Transplantation Relapse,COMPLETED,2013-04-29,2020-02-04,2022-01-25,INTERVENTIONAL,PHASE2,31.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Adult Acute Myeloid Leukemia in Remission|Recurrent Adult Acute Myeloid Leukemia,PF-04449913,DRUG,1,3,18 Years,,ALL,False,"University of Colorado, Denver",OTHER,1,2,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,2,3.4657359027997265,small,1,1,0,1,0,1,1,0,1,0,0,0,1,0,4,1,1,0,0,1,0,2013-04-29,2020-02-04,2472.0,2013.0,0,1,0
NCT03805152,Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia,"A 48-Week Prospective, Double-Blinded, Randomized, Cross-over Design in Multicenter Study of 250 Unit of Dysport Versus 50 Unit of Neuronox Injection For Cervical Dystonia in Thai Patients",COMPLETED,2019-10-25,2021-01-31,2021-03-09,INTERVENTIONAL,PHASE3,52.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,QUADRUPLE,Cervical Dystonia,Neuronox(R)|Dysport (R),DRUG,2,4,18 Years,100 Years,ALL,False,Department of Medical Services Ministry of Public Health of Thailand,OTHER_GOV,0,4,Thailand,1.0,0,0,1,0,0,3.0,0,0,0,0,1,3.970291913552122,medium,1,1,0,1,0,0,1,0,0,0,1,1,1,0,6,1,1,0,0,2,1,2019-10-25,2021-01-31,464.0,2019.0,1,2,0
NCT01267552,Study of Axillary Lymphadenectomy Without Drainage for Breast Cancer,Randomized Clinical Trial of Axillary Lymphadenectomy Without Drainage for Breast Cancer Treatment,COMPLETED,2000-07,2007-12,2010-12-28,INTERVENTIONAL,PHASE2|PHASE3,240.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer|Complications|Seroma,Non drains will be placed during operation|Closed suction drainage,PROCEDURE,1,1,,,FEMALE,False,Universidade Federal de Goias,OTHER,1,2,Brazil,1.0,0,1,1,0,1,2.5,1,0,0,0,3,5.484796933490655,large,0,1,0,1,0,1,1,0,0,0,1,0,1,1,2,1,0,0,0,2,1,,,,,0,3,1
NCT03841747,Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer,"A Phase II, Randomized Study of Paclitaxel Weekly Plus Pembrolizumab Versus Paclitaxel Weekly in ER-positive, Luminal B Metastatic Breast Cancer",WITHDRAWN,2020-12,2025-06,2024-03-12,INTERVENTIONAL,PHASE2,0.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Breast Cancer,Pembrolizumab|Paclitaxel,DRUG,2,2,18 Years,,FEMALE,False,Queen Mary University of London,OTHER,2,0,,0.0,0,1,0,0,0,2.0,1,0,0,0,1,0.0,,1,1,0,1,0,1,0,0,0,0,1,0,1,1,4,1,1,0,0,2,1,,,,,0,1,0
NCT00021749,Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia,Phase I-II Multicenter Study of Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Advanced Chronic Lymphocytic Leukemia,COMPLETED,2001-01,,2009-11-13,INTERVENTIONAL,PHASE1|PHASE2,40.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Chronic Lymphocytic Leukemia|CLL,"Oblimerson sodium, G3139",DRUG,0,0,18 Years,,ALL,False,Genta Incorporated,INDUSTRY,0,3,United States,1.0,1,1,0,0,1,1.5,1,0,0,0,2,3.713572066704308,small,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,,,,,0,2,0
NCT00143130,Pregabalin In Partial Seizures Extension Study,"Pregabalin in Partial Seizures (PREPS) Extension Study: An 18-month Follow-on Open-label, International, Multicenter Add-on Therapy Trial",COMPLETED,2005-04,2007-09,2021-01-28,INTERVENTIONAL,PHASE3,227.0,ACTUAL,NON_RANDOMIZED,SINGLE_GROUP,TREATMENT,NONE,Seizures,Pregabalin,DRUG,1,3,18 Years,,ALL,False,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,INDUSTRY,0,47,Finland|Portugal|France|Switzerland|Poland|Belgium,1.0,0,0,1,0,0,3.0,0,0,0,0,1,5.429345628954441,large,0,1,1,0,1,0,1,1,0,1,0,0,1,0,4,1,1,0,0,1,0,,,,,0,1,0
NCT01450930,Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency,Pharmacokinetics of Hydrocortisone After Subcutaneous Administration Compared With Intramuscular Injection in Chronic Adrenal Insufficiency,COMPLETED,2011-11,2012-07,2012-08-01,INTERVENTIONAL,PHASE2,12.0,ACTUAL,RANDOMIZED,CROSSOVER,TREATMENT,NONE,Primary Adrenal Insufficiency,Hydrocortisone intramuscular first|Hydrocortisone subcutaneously first,DRUG,1,1,18 Years,64 Years,ALL,False,Bruno Allolio,OTHER,0,1,Germany,1.0,0,1,0,0,0,2.0,0,0,0,0,1,2.5649493574615367,small,1,1,0,1,0,0,0,0,0,1,1,0,1,0,2,1,1,0,0,2,1,,,,,0,1,0
NCT01796028,Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer,"A Multicentric, Randomized, Phase II Study Evaluating the Combination of METFORMIN With TAXOTERE®+Metformine Placebo Versus TAXOTERE®+Metformin for the Treatment of Metastatic Hormone-refractory Prostate Cancer.",COMPLETED,2013-01,2018-05-31,2018-06-06,INTERVENTIONAL,PHASE2,100.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,Prostatic Neoplasms,METFORMIN|Placebo|TAXOTERE®,DRUG,1,1,18 Years,,MALE,False,Centre Antoine Lacassagne,OTHER,0,1,France,1.0,0,1,0,0,0,2.0,0,0,0,0,1,4.61512051684126,medium,0,1,0,1,0,0,0,0,0,1,1,1,1,1,2,1,1,0,0,3,1,,2018-05-31,,,0,1,0
NCT00028665,Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma,Randomized Phase II Trial of B-Lymphocyte Purging of Autologous Peripheral Blood Progenitor Cells in Patients With B-Cell Non-Hodgkin's Lymphoma,COMPLETED,2000-06,,2010-06-10,INTERVENTIONAL,PHASE2,37.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,NONE,Lymphoma,filgrastim|rituximab|carmustine|cisplatin|cyclophosphamide|etoposide|bone marrow ablation with stem cell support|peripheral blood stem cell transplantation|radiation therapy,DRUG|RADIATION|PROCEDURE|BIOLOGICAL,4,0,12 Years,65 Years,ALL,False,Case Comprehensive Cancer Center,OTHER,1,1,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,3.6375861597263857,small,1,1,0,1,0,1,0,0,1,0,1,0,1,1,4,0,1,1,0,9,1,,,,,0,1,0
NCT02590965,A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer,"A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fruquintinib Plus Best Supportive Care in Patients With Advanced Non-squamous Non-small Cell Lung Cancer",COMPLETED,2014-05-29,2017-02-10,2020-02-13,INTERVENTIONAL,PHASE2,91.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,Non-small Cell Lung Cancer,Fruquintinib|Placebo,DRUG,1,4,18 Years,75 Years,ALL,False,Hutchison Medipharma Limited,INDUSTRY,1,12,China,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.5217885770490405,medium,1,1,1,0,0,1,1,0,0,0,1,1,1,1,5,1,1,0,0,2,1,2014-05-29,2017-02-10,988.0,2014.0,0,1,0
NCT02159365,Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients,A Phase 2 Single Arm Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients,COMPLETED,2014-03-08,2018-07-11,2019-07-16,INTERVENTIONAL,PHASE2,84.0,ACTUAL,,SINGLE_GROUP,TREATMENT,NONE,Multiple Myeloma,Elotuzumab|Lenalidomide|Dexamethasone,DRUG,1,1,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,29,United States,1.0,0,1,0,0,0,2.0,1,0,0,0,1,4.442651256490317,medium,1,1,1,0,1,0,1,0,1,0,0,0,1,0,2,1,1,0,0,3,1,2014-03-08,2018-07-11,1586.0,2014.0,0,1,0
NCT00581867,Memory and Insulin in Early Alzheimer's Disease,Intranasal Insulin and Memory in Early Alzheimer's Disease,COMPLETED,2007-10,2012-05,2015-07-14,INTERVENTIONAL,PHASE1|PHASE2,31.0,ACTUAL,RANDOMIZED,CROSSOVER,BASIC_SCIENCE,DOUBLE,Alzheimer's Disease,Insulin Aspart|Placebo,DRUG,1,1,60 Years,,ALL,True,"Jeff Burns, MD",OTHER,0,1,United States,1.0,1,1,0,0,1,1.5,0,0,1,0,1,3.4657359027997265,small,1,1,0,1,0,0,0,0,1,0,1,1,0,0,2,1,1,0,0,2,1,,,,,0,2,0
NCT00160667,A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia),"An Exploratory, Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Study, for the Assessment of Efficacy, Safety and Tolerability of Ucb 34714 50 mg Oral Capsules in b.i.d. Administration at the Doses of 200 mg/Day and 400 mg/Day, in Subjects (at Least 18 Years Old) Suffering From Post Herpetic Neuralgia (PHN)",COMPLETED,2004-10-11,2006-01-05,2019-01-31,INTERVENTIONAL,PHASE2,152.0,ACTUAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,"Neuralgia, Postherpetic",Placebo|Brivaracetam,DRUG,1,13,18 Years,,ALL,False,UCB Pharma,INDUSTRY,0,50,United Kingdom|Bulgaria|Slovakia|France|Spain|Czechia|Germany|Poland|Belgium|Serbia,1.0,0,1,0,0,0,2.0,0,0,0,0,1,5.030437921392435,medium,0,1,1,0,0,0,1,1,0,1,1,1,1,1,14,1,1,0,0,2,1,2004-10-11,2006-01-05,451.0,2004.0,0,3,1
